<SEC-DOCUMENT>0001628280-22-013439.txt : 20220510
<SEC-HEADER>0001628280-22-013439.hdr.sgml : 20220510
<ACCEPTANCE-DATETIME>20220510061050
ACCESSION NUMBER:		0001628280-22-013439
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		78
CONFORMED PERIOD OF REPORT:	20220331
FILED AS OF DATE:		20220510
DATE AS OF CHANGE:		20220510

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Aurinia Pharmaceuticals Inc.
		CENTRAL INDEX KEY:			0001600620
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			A0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36421
		FILM NUMBER:		22907225

	BUSINESS ADDRESS:	
		STREET 1:		#1203-4464 MARKHAM STREET
		CITY:			VICTORIA BC
		STATE:			A1
		ZIP:			V8Z 7X8
		BUSINESS PHONE:		250-708-4272

	MAIL ADDRESS:	
		STREET 1:		#1203-4464 MARKHAM STREET
		CITY:			VICTORIA BC
		STATE:			A1
		ZIP:			V8Z 7X8
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>auph-20220331.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:778f08dd-b92a-42f0-b4bb-a50ecfb6a537,g:a60fc6d8-f25a-4b7b-af6a-b9dcc6be1df4,d:2d3a8f7e52e84dcebfa935bec5ca9eb6--><html xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns="http://www.w3.org/1999/xhtml" xmlns:auph="http://www.auriniapharma.com/20220331" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>auph-20220331</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl80L2ZyYWc6ZDZlZGIyMDFmMWY3NDBjM2I2ZGZiNTVlZmYwNmMyYjYvdGFibGU6YzMzMjllZDFjZjU0NDJmOGJmMDcyOTIwN2QzMDg1M2MvdGFibGVyYW5nZTpjMzMyOWVkMWNmNTQ0MmY4YmYwNzI5MjA3ZDMwODUzY18yLTEtMS0xLTQ2ODkx_99dcea64-b3ee-4ed8-8b19-d471f574c000">false</ix:nonNumeric><ix:nonNumeric contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl80L2ZyYWc6ZDZlZGIyMDFmMWY3NDBjM2I2ZGZiNTVlZmYwNmMyYjYvdGFibGU6YzMzMjllZDFjZjU0NDJmOGJmMDcyOTIwN2QzMDg1M2MvdGFibGVyYW5nZTpjMzMyOWVkMWNmNTQ0MmY4YmYwNzI5MjA3ZDMwODUzY18zLTEtMS0xLTQ2ODkx_791fc350-3fbb-4f28-a771-cfe5056daa60">2022</ix:nonNumeric><ix:nonNumeric contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl80L2ZyYWc6ZDZlZGIyMDFmMWY3NDBjM2I2ZGZiNTVlZmYwNmMyYjYvdGFibGU6YzMzMjllZDFjZjU0NDJmOGJmMDcyOTIwN2QzMDg1M2MvdGFibGVyYW5nZTpjMzMyOWVkMWNmNTQ0MmY4YmYwNzI5MjA3ZDMwODUzY180LTEtMS0xLTQ2ODkx_949fddd1-86c6-4e37-a8f8-01d4b6893626">Q1</ix:nonNumeric><ix:nonNumeric contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl80L2ZyYWc6ZDZlZGIyMDFmMWY3NDBjM2I2ZGZiNTVlZmYwNmMyYjYvdGFibGU6YzMzMjllZDFjZjU0NDJmOGJmMDcyOTIwN2QzMDg1M2MvdGFibGVyYW5nZTpjMzMyOWVkMWNmNTQ0MmY4YmYwNzI5MjA3ZDMwODUzY181LTEtMS0xLTQ2ODkx_42726f00-cee0-4a11-ab06-f880a75c9836">0001600620</ix:nonNumeric><ix:nonNumeric contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331" name="dei:CurrentFiscalYearEndDate" format="ixt:date-month-day" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl80L2ZyYWc6ZDZlZGIyMDFmMWY3NDBjM2I2ZGZiNTVlZmYwNmMyYjYvdGFibGU6YzMzMjllZDFjZjU0NDJmOGJmMDcyOTIwN2QzMDg1M2MvdGFibGVyYW5nZTpjMzMyOWVkMWNmNTQ0MmY4YmYwNzI5MjA3ZDMwODUzY182LTEtMS0xLTQ2ODkx_e9e34f7e-1c9e-4ee7-8ffb-8752e4a0771e">12-31</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="auph-20220331.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibe0bdd3550be438099ca2e1dd9fc02ae_I20220509"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-05-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="id7882ae6aff54a3aacdef67ddf11a428_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i784f65549351439fa4b7bedf90ce7e3f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i34e7d6696f5d40019bbef585c942db1a_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i717bc91cf1504e20b9b5b1c709508591_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1d6565befaf14fa4b0f390573f13f8fc_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i25e47e5aca8445b7b6e872243cf6ab56_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i56599386fa47443a8975bb3f7a6a8c57_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i61d2ecb1315b47b48046b2cc2d26a3f4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibc985adebb4d4146be71a1355b404db9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4141e328567a4e2f84032e5f733bf3a6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieebe2ef8481d495ea52a69991654df61_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic38a142e678c4e85a1b730ee6415c5c0_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i76345d0397ef41589260147ade867835_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i33e38a2732764762b66982ec4717a1b2_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7f565b8d63fc448ba775e2bac6da89d9_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id1291b626776443495f8c67d0b44222b_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie8ed19e5e01745febb700f621d5350bd_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4bfaf26bef40473cbb8aa323aa9dbf99_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7607dc50eb3d4d29b612005eb9d96af6_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i83ebb56fc7614da58997add4fc4d898e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i52d7b06be2c943d9943aab7a9199636b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icd1c1d725ea74622ad8c60cbfb9c0470_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i14fc3af75b3846e58ef3a457eee1c040_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i52aa203b7e954d69b001129473620362_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id2b8ec5b433843479fee7e7d7ae9434b_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i980c28f6b4b34116a0110c4e8f58bea5_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idf2709893482407e9aa1a24504869283_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if37f87c2e8144a4ea775f7bcf996abdb_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ida3e66f3cb8a46fd8e7d2fa464feee4b_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icee959888619433fa3bbb75703c9942a_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic279a1a852fa4d1c8cfc697be1c04112_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0bdfb000085746f589116096f0a92b19_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0260d11b47b2403fbf3efe386b4d6b0f_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>auph:segment</xbrli:measure></xbrli:unit><xbrli:context id="ie14c65a2be5d40e1975aef5b5c3f0072_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">auph:SpecialtyPharmacyOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i5a87beff7e574242be649c7dbc5fa755_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">auph:SpecialtyPharmacyTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibaf8c62e96254608ab5682b00b33999f_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">auph:CashableGuaranteedInvestmentCertificatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i40b2265057054504ab60aa0aafba0f0e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">auph:CashableGuaranteedInvestmentCertificatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5235f32286c3431198c094116ea7192b_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">auph:ShortTermCorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iea26fc49428d4511a2fb37c1bb666a8b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">auph:ShortTermCorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3dfcd77b916a46af88c7474c6cb4ec1a_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id3450fe582114ff195b2b48f8c26afea_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iee34030c8c804c4a98def156ea552450_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i67d405ac9e79458eb8e91ab5d55e0df4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8018f58d25ea48ecbbc969caded6e2f5_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifa7bf46cccc44c9484be6b855b0a6f1c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iafe3ea51a2814a819363caa378a6a94a_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i24997e0475c34f689abd5af9a097e9c9_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8116ed39be8b477bb9e41a6b0e3aee53_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idb5a73ea0d9f46779238702423cc8e54_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2473f3d624824cfa9dc37ac978052ad5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1b3926824aa84496acd5d466e41d1cb4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i24b881bff2734aaa92863336ea94e41e_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i33ea857e82c542399286eb48ddbe86ef_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i92bd80a74b4b4c98b74a56c4941dbae8_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic252965e91864c4ca85c5288d34a489d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie8b21348dac34f0191509120fede5c4c_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9a37e52ecdc4461f971b3b1b848318b1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8774cc7bdb954684aaebe802c8d2b5ca_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ida382f7681f54ed38ba2838dbf0642cd_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib8a4d21008a14bdda5d40b91949726ff_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic45495e9bd3646529b0eba68d7729780_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5a90c58801134d6383b036247c03afa2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">auph:VictoriaBritishColumbiaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:context id="i9d7a2759ec7d41e3937bd48023be99f9_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">auph:VictoriaBritishColumbiaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6d2b9fee1c02434b9949db0279cfaf7f_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">auph:VictoriaBritishColumbiaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i495ff60b2f3b469a944a5922a5e9036d_I20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">auph:VictoriaBritishColumbiaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia4a97e4de8cb475abddcffdb81d0a5d1_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">auph:RockvilleMarylandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="extension_option"><xbrli:measure>auph:extension_option</xbrli:measure></xbrli:unit><xbrli:context id="i5aa97519cf354667a42c1e73e81155c5_D20200301-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">auph:RockvilleMarylandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0d45f33fe1934685a0328a1b8e0fb9fa_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">auph:RockvilleMarylandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaf32dde531a54bedaeee2771bb3cf07c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">auph:RockvilleMarylandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i26b07d59c782432196f10a8bbea26c86_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">auph:RockvilleMarylandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i32b726a815d044a59392431a6d822684_I20200312"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">auph:RockvilleMarylandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i46bd9d31980341bb91e4ebbab17839ed_D20210101-20210131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="chf"><xbrli:measure>iso4217:CHF</xbrli:measure></xbrli:unit><xbrli:context id="ie64f915dc5df48b09796dbc7d367824b_D20210201-20210228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-01</xbrli:startDate><xbrli:endDate>2021-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib637c27de79d47f58aea7f1e1b7c5885_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:DemandDepositsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie1195a2d281043b09ef29f66c38b70ce_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:DemandDepositsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9987c4f832174d15b1448eb73ba6f1e4_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:DemandDepositsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if5d8980b569c49318287bb43ff08a07e_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:DemandDepositsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib211792a2e6b4a88a6e391b311e94df4_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i074dc118299746aa9f97075509308a92_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3751e29f9e2148e9be8536444f9cac26_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icfd26c5e43f842a78369ad600a9bf8a6_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iecaeb1e9e3bc4350b03471a79a3ee234_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if7d17ebbb59b417ca9c046ea7c8aa94f_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id893926028184fda8d4b75b7a5667586_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ief379dc869194260b8c12ebe6e7e061a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:DemandDepositsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4888c5f13e9e4351a811914afa543777_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:DemandDepositsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i640e6485e7c84a2ab48d83257384aea7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:DemandDepositsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6146eb45aa0d48429dc434439051e0bc_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:DemandDepositsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if383a572500e4c839c8c398879a64567_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0cb7b13b98f9423daa95abadbd4c2281_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i23085f6e6a1046b1a8320d2f389c49cd_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7d77f002b76741e8b5071bbad8036827_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i84bcadfa5a52412e91d596d25121ad94_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia35491a16c814a76bd71423d10de8bd7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib03d0da6db22482c8918b1f6ab3b5e9b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6eea8e21df8b47b4892af7d314ff753b_D20210817-20210817"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">auph:RiptideBioscienceIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-17</xbrli:startDate><xbrli:endDate>2021-08-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i13c8ed2824064c1abec1d76ae28d9dd8_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">auph:RiptideBioscienceIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia4c126547bde44f3af61232c8aecf4ac_D20201217-20201217"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">auph:OtuskaPharmaceuticalCoLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-17</xbrli:startDate><xbrli:endDate>2020-12-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic3d998d2005a4d13bf8d4c76ad081c32_I20201217"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">auph:OtuskaPharmaceuticalCoLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if24948855cce4a1ab004e64a606f9fda_I20201217"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">auph:OtuskaPharmaceuticalCoLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4263b02edbdb433b9ce6580e359a81eb_I20201217"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">auph:OtuskaPharmaceuticalCoLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie2ed7292d01844ac989e99b1cafc7555_D20201201-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">auph:OtuskaPharmaceuticalCoLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibb901623e47548488a8a8d92817c020b_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">auph:OtuskaPharmaceuticalCoLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic3ca33ca8bfb4c8aac86d02183ad2fa2_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i105a1152b5c54760ad7380e7462cbfbf_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iae2da8378b4b45af98b0443b437184a5_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6384fea4599b405a9d8a4d0a174ba37c_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic530833cd3564851886dba86e0d1fbb6_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5d28d6c0f0d940f59d45551ddc72575a_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib81c30a26c6a41b69cf92282735549ea_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6ee10ba4e3a1477e80be6a7ae14a5733_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic967022eaed24a72b01d3974047a24dc_D20210601-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">auph:AmendedAndRestatedEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib997dd537ee44595bf4b5e42a02596ac_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib8ebe99a1b5a4e18b4d3a1b5a2e4806a_D20201023-20201023"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:OfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-23</xbrli:startDate><xbrli:endDate>2020-10-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6658318dd5b2443bbb61848fe5a802d9_D20210318-20210318"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:OfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-18</xbrli:startDate><xbrli:endDate>2021-03-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i16277210576f40e6b66abe8fff631587_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:OfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i756422f9e99948068788efa1b4d47e72_D20210806-20210806"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">auph:PerformanceShareSandRestrictedStockUnitsRSUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:OfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-06</xbrli:startDate><xbrli:endDate>2021-08-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i262fb9bddf114af5919be54955f6f018_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1bc38d71f54444c69c2a074dc7d8a2ce_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">auph:PerformanceShareSandRestrictedStockUnitsRSUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:OfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id05699051d2448519e6e9c2935d67b1f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">auph:PerformanceShareSandRestrictedStockUnitsRSUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:OfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8ae01a892dec40ae88dac42dfa1c30cb_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">auph:PerformanceShareSandRestrictedStockUnitsRSUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:OfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib9883d643a66472482b410bc95fa9f79_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">auph:PerformanceShareSandRestrictedStockUnitsRSUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:OfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie473ec9331e14abfac72e9b57746b74a_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:OfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifd9d5feb8f3b40e69374a5807ae20c1f_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i962d1c17149f4639be473baed960c8c3_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1b24f1f549b24893a1d6972293f410a2_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0680c2b94da240e9969e80a91c607742_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i40ed8df1852d4048bff930cdf8525c46_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InventoriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0424c4860c3e42b790b55eb7b0362418_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InventoriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if708ee56f3c0413dbeaf542b7c53ca83_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">auph:MilestonePaymentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">auph:ILJINMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if844161c2cc7421fb00cb10e05a3bda0_D20211001-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">auph:MilestonePaymentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">auph:ILJINMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i273a514c48a74a41b3aabc3abfd173d8_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">auph:ILJINMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic0ea34cae9704c0ba2c86c1759915479_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001600620</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">auph:ILJINMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i2d3a8f7e52e84dcebfa935bec5ca9eb6_1"></div><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">WASHINGTON, DC 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">_____________________________________________</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xL2ZyYWc6N2I4NGE0Mzg1ZmRjNDY1NWI2NzI3ZDdmMTY1ZjFkMjgvdGV4dHJlZ2lvbjo3Yjg0YTQzODVmZGM0NjU1YjY3MjdkN2YxNjVmMWQyOF8yMjg4_5ed3aac5-7792-4a52-b7d5-3158a76d8df4">10-Q</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">_____________________________________________</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.847%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.953%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331" name="dei:DocumentQuarterlyReport" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xL2ZyYWc6N2I4NGE0Mzg1ZmRjNDY1NWI2NzI3ZDdmMTY1ZjFkMjgvdGFibGU6MTM1MjhiMWZmOGQ2NGFjYmJlNTQ1NTliODA1Mzk1NGUvdGFibGVyYW5nZToxMzUyOGIxZmY4ZDY0YWNiYmU1NDU1OWI4MDUzOTU0ZV8wLTAtMS0xLTQ2ODkx_75b36544-f7b9-489e-ae9d-930f8f370ec0">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xL2ZyYWc6N2I4NGE0Mzg1ZmRjNDY1NWI2NzI3ZDdmMTY1ZjFkMjgvdGV4dHJlZ2lvbjo3Yjg0YTQzODVmZGM0NjU1YjY3MjdkN2YxNjVmMWQyOF8yMTI_03470018-9452-499c-b349-67497b014b40">March 31, 2022</ix:nonNumeric></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OR</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.847%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.953%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xL2ZyYWc6N2I4NGE0Mzg1ZmRjNDY1NWI2NzI3ZDdmMTY1ZjFkMjgvdGFibGU6ZTNhNzM5MTZlMzYyNGIwYzg0YTI3OTFkZTZlNTI1MjkvdGFibGVyYW5nZTplM2E3MzkxNmUzNjI0YjBjODRhMjc5MWRlNmU1MjUyOV8wLTAtMS0xLTQ2ODkx_5583402f-6f61-4788-98bc-7f97f3235868">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:7pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the transition period from_____________ to ________________</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission file number: <ix:nonNumeric contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xL2ZyYWc6N2I4NGE0Mzg1ZmRjNDY1NWI2NzI3ZDdmMTY1ZjFkMjgvdGV4dHJlZ2lvbjo3Yjg0YTQzODVmZGM0NjU1YjY3MjdkN2YxNjVmMWQyOF8yMjg5_d801de8a-cf02-472c-9758-67d71403a4b9">001-36421</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">__________________________________________</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xL2ZyYWc6N2I4NGE0Mzg1ZmRjNDY1NWI2NzI3ZDdmMTY1ZjFkMjgvdGV4dHJlZ2lvbjo3Yjg0YTQzODVmZGM0NjU1YjY3MjdkN2YxNjVmMWQyOF8yMjkw_aae5c906-cdc9-4c3a-98da-9521db393365">Aurinia Pharmaceuticals Inc.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Exact Name of Registrant as Specified in its Charter)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">__________________________________________</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Alberta, <ix:nonNumeric contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:edgarprovcountryen" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xL2ZyYWc6N2I4NGE0Mzg1ZmRjNDY1NWI2NzI3ZDdmMTY1ZjFkMjgvdGFibGU6NDVkMGEwMDk3NWEyNDE1Y2I1NjUyMzhhZmZhNjEzNTkvdGFibGVyYW5nZTo0NWQwYTAwOTc1YTI0MTVjYjU2NTIzOGFmZmE2MTM1OV8wLTAtMS0xLTQ2ODkxL3RleHRyZWdpb246NmRmOWRmZGU1ZWNjNGRjYmE4MDQ1NjNjNzczNmNhZjhfMTM_165ccc17-ae20-4d68-96b8-7dce1f57b004">Canada</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xL2ZyYWc6N2I4NGE0Mzg1ZmRjNDY1NWI2NzI3ZDdmMTY1ZjFkMjgvdGFibGU6NDVkMGEwMDk3NWEyNDE1Y2I1NjUyMzhhZmZhNjEzNTkvdGFibGVyYW5nZTo0NWQwYTAwOTc1YTI0MTVjYjU2NTIzOGFmZmE2MTM1OV8yLTAtMS0xLTQ2ODkxL3RleHRyZWdpb246YzExMjlkNjUwMDQ0NDkxNWE4YjIxYjQ2ZTZlZjFjNjFfNA_86aacf91-5e5a-41d8-950c-cfcfafd58d99">#1203-4464 Markham Street</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xL2ZyYWc6N2I4NGE0Mzg1ZmRjNDY1NWI2NzI3ZDdmMTY1ZjFkMjgvdGFibGU6NDVkMGEwMDk3NWEyNDE1Y2I1NjUyMzhhZmZhNjEzNTkvdGFibGVyYW5nZTo0NWQwYTAwOTc1YTI0MTVjYjU2NTIzOGFmZmE2MTM1OV8yLTAtMS0xLTQ2ODkxL3RleHRyZWdpb246YzExMjlkNjUwMDQ0NDkxNWE4YjIxYjQ2ZTZlZjFjNjFfNw_296ecdc2-41b8-4906-9031-9998671a26a5">Victoria</ix:nonNumeric>, <ix:nonNumeric contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xL2ZyYWc6N2I4NGE0Mzg1ZmRjNDY1NWI2NzI3ZDdmMTY1ZjFkMjgvdGFibGU6NDVkMGEwMDk3NWEyNDE1Y2I1NjUyMzhhZmZhNjEzNTkvdGFibGVyYW5nZTo0NWQwYTAwOTc1YTI0MTVjYjU2NTIzOGFmZmE2MTM1OV8yLTAtMS0xLTQ2ODkxL3RleHRyZWdpb246YzExMjlkNjUwMDQ0NDkxNWE4YjIxYjQ2ZTZlZjFjNjFfMTE_ca88ed60-86b3-4457-97d8-67be89277a58">British Columbia</ix:nonNumeric> <ix:nonNumeric contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xL2ZyYWc6N2I4NGE0Mzg1ZmRjNDY1NWI2NzI3ZDdmMTY1ZjFkMjgvdGFibGU6NDVkMGEwMDk3NWEyNDE1Y2I1NjUyMzhhZmZhNjEzNTkvdGFibGVyYW5nZTo0NWQwYTAwOTc1YTI0MTVjYjU2NTIzOGFmZmE2MTM1OV8yLTAtMS0xLTQ2ODkxL3RleHRyZWdpb246YzExMjlkNjUwMDQ0NDkxNWE4YjIxYjQ2ZTZlZjFjNjFfMTQ_b8334960-1069-4ce3-9a8b-79559ac1a7c0">V8Z 7X8</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xL2ZyYWc6N2I4NGE0Mzg1ZmRjNDY1NWI2NzI3ZDdmMTY1ZjFkMjgvdGFibGU6NDVkMGEwMDk3NWEyNDE1Y2I1NjUyMzhhZmZhNjEzNTkvdGFibGVyYW5nZTo0NWQwYTAwOTc1YTI0MTVjYjU2NTIzOGFmZmE2MTM1OV8yLTEtMS0xLTQ2ODkxL3RleHRyZWdpb246NzM4ZTg4YThkMzdiNDU4ZmFhZmQwNDc1NWMwYzczYWRfNA_2209c04d-df4e-4efb-ab72-d615daa7e1c2">98-1231763</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">(I.R.S. Employer<br/>Identification Number)</span></td></tr></table></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xL2ZyYWc6N2I4NGE0Mzg1ZmRjNDY1NWI2NzI3ZDdmMTY1ZjFkMjgvdGV4dHJlZ2lvbjo3Yjg0YTQzODVmZGM0NjU1YjY3MjdkN2YxNjVmMWQyOF8yMjkx_9de8421f-e4d3-4b74-9a3b-76d83a9a6441">(250)</ix:nonNumeric> <ix:nonNumeric contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xL2ZyYWc6N2I4NGE0Mzg1ZmRjNDY1NWI2NzI3ZDdmMTY1ZjFkMjgvdGV4dHJlZ2lvbjo3Yjg0YTQzODVmZGM0NjU1YjY3MjdkN2YxNjVmMWQyOF8yMjg0_a9b48124-c7a4-4c51-85fd-871eb36cbfbb">708-4272</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">Registrant&#8217;s telephone number, including area code</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">_____________________________________________</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. &#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xL2ZyYWc6N2I4NGE0Mzg1ZmRjNDY1NWI2NzI3ZDdmMTY1ZjFkMjgvdGV4dHJlZ2lvbjo3Yjg0YTQzODVmZGM0NjU1YjY3MjdkN2YxNjVmMWQyOF8yMjg1_af642d76-b161-4cdc-8366-18d59e3aa994">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xL2ZyYWc6N2I4NGE0Mzg1ZmRjNDY1NWI2NzI3ZDdmMTY1ZjFkMjgvdGV4dHJlZ2lvbjo3Yjg0YTQzODVmZGM0NjU1YjY3MjdkN2YxNjVmMWQyOF8yMjg2_f573ef0e-e43e-492e-85f6-bccb4dc2110e">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:20.537%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.577%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.069%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.537%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.580%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xL2ZyYWc6N2I4NGE0Mzg1ZmRjNDY1NWI2NzI3ZDdmMTY1ZjFkMjgvdGFibGU6ODVlNWY5YTA5NjJhNDI4ZjhlZTA2M2MxNGEyOTMzODYvdGFibGVyYW5nZTo4NWU1ZjlhMDk2MmE0MjhmOGVlMDYzYzE0YTI5MzM4Nl8wLTAtMS0xLTQ2ODkx_5e2d0bdf-5e86-4d8f-a805-a8610f8fb97e">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accelerated&#160;filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Smaller&#160;reporting&#160;company</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331" name="dei:EntitySmallBusiness" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xL2ZyYWc6N2I4NGE0Mzg1ZmRjNDY1NWI2NzI3ZDdmMTY1ZjFkMjgvdGFibGU6ODVlNWY5YTA5NjJhNDI4ZjhlZTA2M2MxNGEyOTMzODYvdGFibGVyYW5nZTo4NWU1ZjlhMDk2MmE0MjhmOGVlMDYzYzE0YTI5MzM4Nl8yLTQtMS0xLTQ2ODkx_089e2492-ef54-4970-9632-4b1b79cfdb34">&#9744;</ix:nonNumeric></span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xL2ZyYWc6N2I4NGE0Mzg1ZmRjNDY1NWI2NzI3ZDdmMTY1ZjFkMjgvdGFibGU6ODVlNWY5YTA5NjJhNDI4ZjhlZTA2M2MxNGEyOTMzODYvdGFibGVyYW5nZTo4NWU1ZjlhMDk2MmE0MjhmOGVlMDYzYzE0YTI5MzM4Nl80LTEtMS0xLTQ2ODkx_33c563a1-da88-4946-9df0-3d3c8fa35791">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:1pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#160;&#160;&#160;&#160;Yes&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">o</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331" name="dei:EntityShellCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xL2ZyYWc6N2I4NGE0Mzg1ZmRjNDY1NWI2NzI3ZDdmMTY1ZjFkMjgvdGV4dHJlZ2lvbjo3Yjg0YTQzODVmZGM0NjU1YjY3MjdkN2YxNjVmMWQyOF8yMjg3_ffac4596-3302-4221-a90d-43a93a2fbde6">x</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate the number of shares outstanding of each of the registrant's classes of common shares, as of the latest predictable date. As of May&#160;9, 2022, the registrant had <ix:nonFraction unitRef="shares" contextRef="ibe0bdd3550be438099ca2e1dd9fc02ae_I20220509" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xL2ZyYWc6N2I4NGE0Mzg1ZmRjNDY1NWI2NzI3ZDdmMTY1ZjFkMjgvdGV4dHJlZ2lvbjo3Yjg0YTQzODVmZGM0NjU1YjY3MjdkN2YxNjVmMWQyOF8yMTg5_105f8330-c940-444b-86f0-cdd3cdf570cb">141,741,580</ix:nonFraction> of common shares outstanding.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.297%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.685%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Trading Symbol</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Name of exchange on which registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xL2ZyYWc6N2I4NGE0Mzg1ZmRjNDY1NWI2NzI3ZDdmMTY1ZjFkMjgvdGFibGU6OGQwZTJjMjk1OWEyNDBkNGI3MTQ5OWQ2ZjFmZDk3OGIvdGFibGVyYW5nZTo4ZDBlMmMyOTU5YTI0MGQ0YjcxNDk5ZDZmMWZkOTc4Yl8xLTAtMS0xLTQ2ODkx_35f8bbfc-93c8-4ae8-bf44-f8250bb87fa4">Common shares, no par value</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xL2ZyYWc6N2I4NGE0Mzg1ZmRjNDY1NWI2NzI3ZDdmMTY1ZjFkMjgvdGFibGU6OGQwZTJjMjk1OWEyNDBkNGI3MTQ5OWQ2ZjFmZDk3OGIvdGFibGVyYW5nZTo4ZDBlMmMyOTU5YTI0MGQ0YjcxNDk5ZDZmMWZkOTc4Yl8xLTEtMS0xLTQ2ODkx_64bfa2bc-1aef-4547-8273-083752bb72f3">AUPH</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xL2ZyYWc6N2I4NGE0Mzg1ZmRjNDY1NWI2NzI3ZDdmMTY1ZjFkMjgvdGFibGU6OGQwZTJjMjk1OWEyNDBkNGI3MTQ5OWQ2ZjFmZDk3OGIvdGFibGVyYW5nZTo4ZDBlMmMyOTU5YTI0MGQ0YjcxNDk5ZDZmMWZkOTc4Yl8xLTItMS0xLTQ2ODkx_4823a0d6-a518-4b28-aa6d-503781298f5e">The Nasdaq Global Market LLC</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i2d3a8f7e52e84dcebfa935bec5ca9eb6_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AURINIA PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:81.356%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.358%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:none" href="#i2d3a8f7e52e84dcebfa935bec5ca9eb6_10">PART I.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2d3a8f7e52e84dcebfa935bec5ca9eb6_10">FINANCIAL INFORMATION</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2d3a8f7e52e84dcebfa935bec5ca9eb6_10">1</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2d3a8f7e52e84dcebfa935bec5ca9eb6_13">Item 1.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2d3a8f7e52e84dcebfa935bec5ca9eb6_13">Financial Statements (Unaudited)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2d3a8f7e52e84dcebfa935bec5ca9eb6_13">1</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2d3a8f7e52e84dcebfa935bec5ca9eb6_16">Condensed Consolidated Balance Sheets as of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2d3a8f7e52e84dcebfa935bec5ca9eb6_16">March 31, 2022</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2d3a8f7e52e84dcebfa935bec5ca9eb6_16"> (unaudited) and December 31, </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2d3a8f7e52e84dcebfa935bec5ca9eb6_16">2021</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2d3a8f7e52e84dcebfa935bec5ca9eb6_16">1</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2d3a8f7e52e84dcebfa935bec5ca9eb6_19">Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited) for the three </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2d3a8f7e52e84dcebfa935bec5ca9eb6_19">months ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2d3a8f7e52e84dcebfa935bec5ca9eb6_19">March 31, 2022</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2d3a8f7e52e84dcebfa935bec5ca9eb6_19"> and </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2d3a8f7e52e84dcebfa935bec5ca9eb6_19">March 31, 2021</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2d3a8f7e52e84dcebfa935bec5ca9eb6_19">2</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2d3a8f7e52e84dcebfa935bec5ca9eb6_22">Condensed Consolidated Statements of Shareholders&#8217; Equity (unaudited) for the three </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2d3a8f7e52e84dcebfa935bec5ca9eb6_22">months ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2d3a8f7e52e84dcebfa935bec5ca9eb6_22">March 31, 2022</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2d3a8f7e52e84dcebfa935bec5ca9eb6_22"> and </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2d3a8f7e52e84dcebfa935bec5ca9eb6_22">March 31, 2021</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2d3a8f7e52e84dcebfa935bec5ca9eb6_22">3</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2d3a8f7e52e84dcebfa935bec5ca9eb6_25">Condensed Consolidated Statements of Cash Flows (unaudited) for the </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2d3a8f7e52e84dcebfa935bec5ca9eb6_25">three</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2d3a8f7e52e84dcebfa935bec5ca9eb6_25"> months ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2d3a8f7e52e84dcebfa935bec5ca9eb6_25">March 31, 2022</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2d3a8f7e52e84dcebfa935bec5ca9eb6_25"> and </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2d3a8f7e52e84dcebfa935bec5ca9eb6_25">March 31, 2021</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2d3a8f7e52e84dcebfa935bec5ca9eb6_25">4</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2d3a8f7e52e84dcebfa935bec5ca9eb6_28">Notes to Unaudited Condensed Consolidated Financial Statements (unaudited)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2d3a8f7e52e84dcebfa935bec5ca9eb6_28">5</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2d3a8f7e52e84dcebfa935bec5ca9eb6_94">Item 2.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2d3a8f7e52e84dcebfa935bec5ca9eb6_94">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2d3a8f7e52e84dcebfa935bec5ca9eb6_94">17</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2d3a8f7e52e84dcebfa935bec5ca9eb6_112">Item 3.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2d3a8f7e52e84dcebfa935bec5ca9eb6_112">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2d3a8f7e52e84dcebfa935bec5ca9eb6_112">20</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2d3a8f7e52e84dcebfa935bec5ca9eb6_115">Item 4.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2d3a8f7e52e84dcebfa935bec5ca9eb6_115">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2d3a8f7e52e84dcebfa935bec5ca9eb6_115">21</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:none" href="#i2d3a8f7e52e84dcebfa935bec5ca9eb6_118">PART II.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2d3a8f7e52e84dcebfa935bec5ca9eb6_118">OTHER INFORMATION</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2d3a8f7e52e84dcebfa935bec5ca9eb6_118">23</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2d3a8f7e52e84dcebfa935bec5ca9eb6_121">Item 1.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2d3a8f7e52e84dcebfa935bec5ca9eb6_121">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2d3a8f7e52e84dcebfa935bec5ca9eb6_121">23</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2d3a8f7e52e84dcebfa935bec5ca9eb6_124">Item 1A.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2d3a8f7e52e84dcebfa935bec5ca9eb6_124">Risk Factors</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2d3a8f7e52e84dcebfa935bec5ca9eb6_124">23</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2d3a8f7e52e84dcebfa935bec5ca9eb6_127">Item 2.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2d3a8f7e52e84dcebfa935bec5ca9eb6_127">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2d3a8f7e52e84dcebfa935bec5ca9eb6_127">23</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2d3a8f7e52e84dcebfa935bec5ca9eb6_130">Item 3.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2d3a8f7e52e84dcebfa935bec5ca9eb6_130">Defaults Upon Senior Securities</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2d3a8f7e52e84dcebfa935bec5ca9eb6_130">23</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2d3a8f7e52e84dcebfa935bec5ca9eb6_133">Item 4.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2d3a8f7e52e84dcebfa935bec5ca9eb6_133">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2d3a8f7e52e84dcebfa935bec5ca9eb6_133">23</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2d3a8f7e52e84dcebfa935bec5ca9eb6_136">Item 5.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2d3a8f7e52e84dcebfa935bec5ca9eb6_136">Other Information</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2d3a8f7e52e84dcebfa935bec5ca9eb6_136">23</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2d3a8f7e52e84dcebfa935bec5ca9eb6_139">Item 6.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2d3a8f7e52e84dcebfa935bec5ca9eb6_139">Exhibits</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2d3a8f7e52e84dcebfa935bec5ca9eb6_139">23</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2d3a8f7e52e84dcebfa935bec5ca9eb6_142">Signatures</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2d3a8f7e52e84dcebfa935bec5ca9eb6_142">25</a></span></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><div id="i2d3a8f7e52e84dcebfa935bec5ca9eb6_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I&#8212;FINANCIAL INFORMATION</span></div><div id="i2d3a8f7e52e84dcebfa935bec5ca9eb6_13"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. Financial Statements</span></div><div id="i2d3a8f7e52e84dcebfa935bec5ca9eb6_16"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">AURINIA PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">CONDENSED CONSOLIDATED BALANCE SHEETS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">(in thousands)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.683%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.353%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7882ae6aff54a3aacdef67ddf11a428_I20220331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xNi9mcmFnOjljZDUxYTE0NzJmODQ5ZWViZmI0YzllYmNiOGRjNzdiL3RhYmxlOjBjZDY0ODYwODI3MzRmYTJhZDJiNWNiNDQzZGZhMDhjL3RhYmxlcmFuZ2U6MGNkNjQ4NjA4MjczNGZhMmFkMmI1Y2I0NDNkZmEwOGNfNC0yLTEtMS00Njg5MQ_8930a944-bcd1-47bd-a3a9-5fe3bae6e44c">132,542</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i784f65549351439fa4b7bedf90ce7e3f_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xNi9mcmFnOjljZDUxYTE0NzJmODQ5ZWViZmI0YzllYmNiOGRjNzdiL3RhYmxlOjBjZDY0ODYwODI3MzRmYTJhZDJiNWNiNDQzZGZhMDhjL3RhYmxlcmFuZ2U6MGNkNjQ4NjA4MjczNGZhMmFkMmI1Y2I0NDNkZmEwOGNfNC00LTEtMS00Njg5MQ_f022cd0a-8041-4871-88bc-ef2d96a21f6a">231,900</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7882ae6aff54a3aacdef67ddf11a428_I20220331" decimals="-3" name="us-gaap:DebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xNi9mcmFnOjljZDUxYTE0NzJmODQ5ZWViZmI0YzllYmNiOGRjNzdiL3RhYmxlOjBjZDY0ODYwODI3MzRmYTJhZDJiNWNiNDQzZGZhMDhjL3RhYmxlcmFuZ2U6MGNkNjQ4NjA4MjczNGZhMmFkMmI1Y2I0NDNkZmEwOGNfNS0yLTEtMS00Njg5MQ_1f119417-74f0-46a6-ada9-a6887a7dc948">286,210</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i784f65549351439fa4b7bedf90ce7e3f_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xNi9mcmFnOjljZDUxYTE0NzJmODQ5ZWViZmI0YzllYmNiOGRjNzdiL3RhYmxlOjBjZDY0ODYwODI3MzRmYTJhZDJiNWNiNDQzZGZhMDhjL3RhYmxlcmFuZ2U6MGNkNjQ4NjA4MjczNGZhMmFkMmI1Y2I0NDNkZmEwOGNfNS00LTEtMS00Njg5MQ_1b341612-041b-476c-a249-41cd97edc662">234,178</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7882ae6aff54a3aacdef67ddf11a428_I20220331" decimals="-3" name="us-gaap:AccountsAndOtherReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xNi9mcmFnOjljZDUxYTE0NzJmODQ5ZWViZmI0YzllYmNiOGRjNzdiL3RhYmxlOjBjZDY0ODYwODI3MzRmYTJhZDJiNWNiNDQzZGZhMDhjL3RhYmxlcmFuZ2U6MGNkNjQ4NjA4MjczNGZhMmFkMmI1Y2I0NDNkZmEwOGNfNi0yLTEtMS00Njg5MQ_e54664c5-2407-4b11-b6e7-2fae43735277">20,401</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i784f65549351439fa4b7bedf90ce7e3f_I20211231" decimals="-3" name="us-gaap:AccountsAndOtherReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xNi9mcmFnOjljZDUxYTE0NzJmODQ5ZWViZmI0YzllYmNiOGRjNzdiL3RhYmxlOjBjZDY0ODYwODI3MzRmYTJhZDJiNWNiNDQzZGZhMDhjL3RhYmxlcmFuZ2U6MGNkNjQ4NjA4MjczNGZhMmFkMmI1Y2I0NDNkZmEwOGNfNi00LTEtMS00Njg5MQ_e2f076b2-65ca-4cde-bd80-4c1b368a14b0">15,414</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7882ae6aff54a3aacdef67ddf11a428_I20220331" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xNi9mcmFnOjljZDUxYTE0NzJmODQ5ZWViZmI0YzllYmNiOGRjNzdiL3RhYmxlOjBjZDY0ODYwODI3MzRmYTJhZDJiNWNiNDQzZGZhMDhjL3RhYmxlcmFuZ2U6MGNkNjQ4NjA4MjczNGZhMmFkMmI1Y2I0NDNkZmEwOGNfNy0yLTEtMS00Njg5MQ_e161541b-8bd3-481f-8cd7-30be3a3bd074">26,266</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i784f65549351439fa4b7bedf90ce7e3f_I20211231" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xNi9mcmFnOjljZDUxYTE0NzJmODQ5ZWViZmI0YzllYmNiOGRjNzdiL3RhYmxlOjBjZDY0ODYwODI3MzRmYTJhZDJiNWNiNDQzZGZhMDhjL3RhYmxlcmFuZ2U6MGNkNjQ4NjA4MjczNGZhMmFkMmI1Y2I0NDNkZmEwOGNfNy00LTEtMS00Njg5MQ_960a5424-f637-4a41-8ed7-2647361bdcba">19,326</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7882ae6aff54a3aacdef67ddf11a428_I20220331" decimals="-3" name="us-gaap:PrepaidExpenseCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xNi9mcmFnOjljZDUxYTE0NzJmODQ5ZWViZmI0YzllYmNiOGRjNzdiL3RhYmxlOjBjZDY0ODYwODI3MzRmYTJhZDJiNWNiNDQzZGZhMDhjL3RhYmxlcmFuZ2U6MGNkNjQ4NjA4MjczNGZhMmFkMmI1Y2I0NDNkZmEwOGNfOC0yLTEtMS00Njg5MQ_29681420-c706-46c7-82d4-8d2d3a7219c2">12,199</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i784f65549351439fa4b7bedf90ce7e3f_I20211231" decimals="-3" name="us-gaap:PrepaidExpenseCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xNi9mcmFnOjljZDUxYTE0NzJmODQ5ZWViZmI0YzllYmNiOGRjNzdiL3RhYmxlOjBjZDY0ODYwODI3MzRmYTJhZDJiNWNiNDQzZGZhMDhjL3RhYmxlcmFuZ2U6MGNkNjQ4NjA4MjczNGZhMmFkMmI1Y2I0NDNkZmEwOGNfOC00LTEtMS00Njg5MQ_2731f796-3831-4487-863b-c6d07398bccf">12,506</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7882ae6aff54a3aacdef67ddf11a428_I20220331" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xNi9mcmFnOjljZDUxYTE0NzJmODQ5ZWViZmI0YzllYmNiOGRjNzdiL3RhYmxlOjBjZDY0ODYwODI3MzRmYTJhZDJiNWNiNDQzZGZhMDhjL3RhYmxlcmFuZ2U6MGNkNjQ4NjA4MjczNGZhMmFkMmI1Y2I0NDNkZmEwOGNfOS0yLTEtMS00Njg5MQ_754e5f2f-23db-412c-b918-98617cf7e453">477,618</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i784f65549351439fa4b7bedf90ce7e3f_I20211231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xNi9mcmFnOjljZDUxYTE0NzJmODQ5ZWViZmI0YzllYmNiOGRjNzdiL3RhYmxlOjBjZDY0ODYwODI3MzRmYTJhZDJiNWNiNDQzZGZhMDhjL3RhYmxlcmFuZ2U6MGNkNjQ4NjA4MjczNGZhMmFkMmI1Y2I0NDNkZmEwOGNfOS00LTEtMS00Njg5MQ_1b9a2bd2-0b5a-400a-b080-86792e3e6852">513,324</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7882ae6aff54a3aacdef67ddf11a428_I20220331" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xNi9mcmFnOjljZDUxYTE0NzJmODQ5ZWViZmI0YzllYmNiOGRjNzdiL3RhYmxlOjBjZDY0ODYwODI3MzRmYTJhZDJiNWNiNDQzZGZhMDhjL3RhYmxlcmFuZ2U6MGNkNjQ4NjA4MjczNGZhMmFkMmI1Y2I0NDNkZmEwOGNfMTMtMi0xLTEtNDY4OTE_c9eb3abd-8fb9-49b3-9ebf-397b0a4cee22">11,838</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i784f65549351439fa4b7bedf90ce7e3f_I20211231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xNi9mcmFnOjljZDUxYTE0NzJmODQ5ZWViZmI0YzllYmNiOGRjNzdiL3RhYmxlOjBjZDY0ODYwODI3MzRmYTJhZDJiNWNiNDQzZGZhMDhjL3RhYmxlcmFuZ2U6MGNkNjQ4NjA4MjczNGZhMmFkMmI1Y2I0NDNkZmEwOGNfMTMtNC0xLTEtNDY4OTE_7a9770a4-0550-4bc8-8fbc-bf9b37c0d2f8">11,838</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7882ae6aff54a3aacdef67ddf11a428_I20220331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xNi9mcmFnOjljZDUxYTE0NzJmODQ5ZWViZmI0YzllYmNiOGRjNzdiL3RhYmxlOjBjZDY0ODYwODI3MzRmYTJhZDJiNWNiNDQzZGZhMDhjL3RhYmxlcmFuZ2U6MGNkNjQ4NjA4MjczNGZhMmFkMmI1Y2I0NDNkZmEwOGNfMTQtMi0xLTEtNDY4OTE_b6486062-4cc1-400a-9f60-0137d27f41e7">4,332</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i784f65549351439fa4b7bedf90ce7e3f_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xNi9mcmFnOjljZDUxYTE0NzJmODQ5ZWViZmI0YzllYmNiOGRjNzdiL3RhYmxlOjBjZDY0ODYwODI3MzRmYTJhZDJiNWNiNDQzZGZhMDhjL3RhYmxlcmFuZ2U6MGNkNjQ4NjA4MjczNGZhMmFkMmI1Y2I0NDNkZmEwOGNfMTQtNC0xLTEtNDY4OTE_bc8de736-a591-4fa8-a86d-6cf1a9029c56">4,418</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired intellectual property and other intangible assets, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7882ae6aff54a3aacdef67ddf11a428_I20220331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xNi9mcmFnOjljZDUxYTE0NzJmODQ5ZWViZmI0YzllYmNiOGRjNzdiL3RhYmxlOjBjZDY0ODYwODI3MzRmYTJhZDJiNWNiNDQzZGZhMDhjL3RhYmxlcmFuZ2U6MGNkNjQ4NjA4MjczNGZhMmFkMmI1Y2I0NDNkZmEwOGNfMTUtMi0xLTEtNDY4OTE_91a836d0-6824-411d-840a-e9c63bb45be8">7,882</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i784f65549351439fa4b7bedf90ce7e3f_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xNi9mcmFnOjljZDUxYTE0NzJmODQ5ZWViZmI0YzllYmNiOGRjNzdiL3RhYmxlOjBjZDY0ODYwODI3MzRmYTJhZDJiNWNiNDQzZGZhMDhjL3RhYmxlcmFuZ2U6MGNkNjQ4NjA4MjczNGZhMmFkMmI1Y2I0NDNkZmEwOGNfMTUtNC0xLTEtNDY4OTE_995e007c-87fa-46b5-bc1c-c651c01988b3">8,404</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7882ae6aff54a3aacdef67ddf11a428_I20220331" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xNi9mcmFnOjljZDUxYTE0NzJmODQ5ZWViZmI0YzllYmNiOGRjNzdiL3RhYmxlOjBjZDY0ODYwODI3MzRmYTJhZDJiNWNiNDQzZGZhMDhjL3RhYmxlcmFuZ2U6MGNkNjQ4NjA4MjczNGZhMmFkMmI1Y2I0NDNkZmEwOGNfMTYtMi0xLTEtNDY4OTE_891acbd1-3620-4313-9cb6-2b80dfbea883">5,232</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i784f65549351439fa4b7bedf90ce7e3f_I20211231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xNi9mcmFnOjljZDUxYTE0NzJmODQ5ZWViZmI0YzllYmNiOGRjNzdiL3RhYmxlOjBjZDY0ODYwODI3MzRmYTJhZDJiNWNiNDQzZGZhMDhjL3RhYmxlcmFuZ2U6MGNkNjQ4NjA4MjczNGZhMmFkMmI1Y2I0NDNkZmEwOGNfMTYtNC0xLTEtNDY4OTE_421b0fe2-020e-428e-a6e2-16b21529c5c8">5,383</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7882ae6aff54a3aacdef67ddf11a428_I20220331" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xNi9mcmFnOjljZDUxYTE0NzJmODQ5ZWViZmI0YzllYmNiOGRjNzdiL3RhYmxlOjBjZDY0ODYwODI3MzRmYTJhZDJiNWNiNDQzZGZhMDhjL3RhYmxlcmFuZ2U6MGNkNjQ4NjA4MjczNGZhMmFkMmI1Y2I0NDNkZmEwOGNfMTctMi0xLTEtNDY4OTE_caa856d4-c6b6-4cf7-accb-c1e2e4c61927">506,902</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i784f65549351439fa4b7bedf90ce7e3f_I20211231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xNi9mcmFnOjljZDUxYTE0NzJmODQ5ZWViZmI0YzllYmNiOGRjNzdiL3RhYmxlOjBjZDY0ODYwODI3MzRmYTJhZDJiNWNiNDQzZGZhMDhjL3RhYmxlcmFuZ2U6MGNkNjQ4NjA4MjczNGZhMmFkMmI1Y2I0NDNkZmEwOGNfMTctNC0xLTEtNDY4OTE_99a65914-7693-4e5a-a1d1-1c9b609404f9">543,367</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LIABILITIES</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7882ae6aff54a3aacdef67ddf11a428_I20220331" decimals="-3" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xNi9mcmFnOjljZDUxYTE0NzJmODQ5ZWViZmI0YzllYmNiOGRjNzdiL3RhYmxlOjBjZDY0ODYwODI3MzRmYTJhZDJiNWNiNDQzZGZhMDhjL3RhYmxlcmFuZ2U6MGNkNjQ4NjA4MjczNGZhMmFkMmI1Y2I0NDNkZmEwOGNfMjEtMi0xLTEtNDY4OTE_cdd3de98-2939-4691-81f0-b660ee2809b8">32,327</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i784f65549351439fa4b7bedf90ce7e3f_I20211231" decimals="-3" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xNi9mcmFnOjljZDUxYTE0NzJmODQ5ZWViZmI0YzllYmNiOGRjNzdiL3RhYmxlOjBjZDY0ODYwODI3MzRmYTJhZDJiNWNiNDQzZGZhMDhjL3RhYmxlcmFuZ2U6MGNkNjQ4NjA4MjczNGZhMmFkMmI1Y2I0NDNkZmEwOGNfMjEtNC0xLTEtNDY4OTE_e017904a-9877-4965-8b9a-78ffd72d082b">34,947</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7882ae6aff54a3aacdef67ddf11a428_I20220331" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xNi9mcmFnOjljZDUxYTE0NzJmODQ5ZWViZmI0YzllYmNiOGRjNzdiL3RhYmxlOjBjZDY0ODYwODI3MzRmYTJhZDJiNWNiNDQzZGZhMDhjL3RhYmxlcmFuZ2U6MGNkNjQ4NjA4MjczNGZhMmFkMmI1Y2I0NDNkZmEwOGNfMjItMi0xLTEtNDY4OTE_88ede420-6590-43de-ab14-386d5e681b5f">502</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i784f65549351439fa4b7bedf90ce7e3f_I20211231" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xNi9mcmFnOjljZDUxYTE0NzJmODQ5ZWViZmI0YzllYmNiOGRjNzdiL3RhYmxlOjBjZDY0ODYwODI3MzRmYTJhZDJiNWNiNDQzZGZhMDhjL3RhYmxlcmFuZ2U6MGNkNjQ4NjA4MjczNGZhMmFkMmI1Y2I0NDNkZmEwOGNfMjItNC0xLTEtNDY4OTE_95fa483c-1382-48e5-b19f-45a2628158f4">4,640</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7882ae6aff54a3aacdef67ddf11a428_I20220331" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xNi9mcmFnOjljZDUxYTE0NzJmODQ5ZWViZmI0YzllYmNiOGRjNzdiL3RhYmxlOjBjZDY0ODYwODI3MzRmYTJhZDJiNWNiNDQzZGZhMDhjL3RhYmxlcmFuZ2U6MGNkNjQ4NjA4MjczNGZhMmFkMmI1Y2I0NDNkZmEwOGNfMjMtMi0xLTEtNDY4OTE_f7c9defa-1e47-45ce-bb64-0155deb67c7a">1,009</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i784f65549351439fa4b7bedf90ce7e3f_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xNi9mcmFnOjljZDUxYTE0NzJmODQ5ZWViZmI0YzllYmNiOGRjNzdiL3RhYmxlOjBjZDY0ODYwODI3MzRmYTJhZDJiNWNiNDQzZGZhMDhjL3RhYmxlcmFuZ2U6MGNkNjQ4NjA4MjczNGZhMmFkMmI1Y2I0NDNkZmEwOGNfMjMtNC0xLTEtNDY4OTE_fe059d7c-43df-4973-8cf3-b530d60a1893">1,059</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7882ae6aff54a3aacdef67ddf11a428_I20220331" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xNi9mcmFnOjljZDUxYTE0NzJmODQ5ZWViZmI0YzllYmNiOGRjNzdiL3RhYmxlOjBjZDY0ODYwODI3MzRmYTJhZDJiNWNiNDQzZGZhMDhjL3RhYmxlcmFuZ2U6MGNkNjQ4NjA4MjczNGZhMmFkMmI1Y2I0NDNkZmEwOGNfMjQtMi0xLTEtNDY4OTE_9fe2ecfc-2061-4975-a051-fadf7fddfbd9">33,838</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i784f65549351439fa4b7bedf90ce7e3f_I20211231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xNi9mcmFnOjljZDUxYTE0NzJmODQ5ZWViZmI0YzllYmNiOGRjNzdiL3RhYmxlOjBjZDY0ODYwODI3MzRmYTJhZDJiNWNiNDQzZGZhMDhjL3RhYmxlcmFuZ2U6MGNkNjQ4NjA4MjczNGZhMmFkMmI1Y2I0NDNkZmEwOGNfMjQtNC0xLTEtNDY4OTE_666119e9-bc76-4b34-976e-499cfc1822ae">40,646</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred compensation and other non-current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7882ae6aff54a3aacdef67ddf11a428_I20220331" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xNi9mcmFnOjljZDUxYTE0NzJmODQ5ZWViZmI0YzllYmNiOGRjNzdiL3RhYmxlOjBjZDY0ODYwODI3MzRmYTJhZDJiNWNiNDQzZGZhMDhjL3RhYmxlcmFuZ2U6MGNkNjQ4NjA4MjczNGZhMmFkMmI1Y2I0NDNkZmEwOGNfMjctMi0xLTEtNDY4OTE_41e7a447-47a3-4409-87de-b880e94ca448">17,379</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i784f65549351439fa4b7bedf90ce7e3f_I20211231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xNi9mcmFnOjljZDUxYTE0NzJmODQ5ZWViZmI0YzllYmNiOGRjNzdiL3RhYmxlOjBjZDY0ODYwODI3MzRmYTJhZDJiNWNiNDQzZGZhMDhjL3RhYmxlcmFuZ2U6MGNkNjQ4NjA4MjczNGZhMmFkMmI1Y2I0NDNkZmEwOGNfMjctNC0xLTEtNDY4OTE_a99416c5-aa0a-4acd-a348-bf995070f79c">15,950</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7882ae6aff54a3aacdef67ddf11a428_I20220331" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xNi9mcmFnOjljZDUxYTE0NzJmODQ5ZWViZmI0YzllYmNiOGRjNzdiL3RhYmxlOjBjZDY0ODYwODI3MzRmYTJhZDJiNWNiNDQzZGZhMDhjL3RhYmxlcmFuZ2U6MGNkNjQ4NjA4MjczNGZhMmFkMmI1Y2I0NDNkZmEwOGNfMjgtMi0xLTEtNDY4OTE_514bb88a-afd6-4e83-9efd-9243da723574">7,562</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i784f65549351439fa4b7bedf90ce7e3f_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xNi9mcmFnOjljZDUxYTE0NzJmODQ5ZWViZmI0YzllYmNiOGRjNzdiL3RhYmxlOjBjZDY0ODYwODI3MzRmYTJhZDJiNWNiNDQzZGZhMDhjL3RhYmxlcmFuZ2U6MGNkNjQ4NjA4MjczNGZhMmFkMmI1Y2I0NDNkZmEwOGNfMjgtNC0xLTEtNDY4OTE_1e0d38e6-eddb-40cc-b95c-c72186630479">7,680</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7882ae6aff54a3aacdef67ddf11a428_I20220331" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xNi9mcmFnOjljZDUxYTE0NzJmODQ5ZWViZmI0YzllYmNiOGRjNzdiL3RhYmxlOjBjZDY0ODYwODI3MzRmYTJhZDJiNWNiNDQzZGZhMDhjL3RhYmxlcmFuZ2U6MGNkNjQ4NjA4MjczNGZhMmFkMmI1Y2I0NDNkZmEwOGNfMjktMi0xLTEtNDY4OTE_c30057a6-2b04-4414-89d3-85d1b4615dad">58,779</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i784f65549351439fa4b7bedf90ce7e3f_I20211231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xNi9mcmFnOjljZDUxYTE0NzJmODQ5ZWViZmI0YzllYmNiOGRjNzdiL3RhYmxlOjBjZDY0ODYwODI3MzRmYTJhZDJiNWNiNDQzZGZhMDhjL3RhYmxlcmFuZ2U6MGNkNjQ4NjA4MjczNGZhMmFkMmI1Y2I0NDNkZmEwOGNfMjktNC0xLTEtNDY4OTE_6bd54b0f-685e-4550-b03b-6c855029eb3e">64,276</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and contingencies (Note 18)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="id7882ae6aff54a3aacdef67ddf11a428_I20220331" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xNi9mcmFnOjljZDUxYTE0NzJmODQ5ZWViZmI0YzllYmNiOGRjNzdiL3RhYmxlOjBjZDY0ODYwODI3MzRmYTJhZDJiNWNiNDQzZGZhMDhjL3RhYmxlcmFuZ2U6MGNkNjQ4NjA4MjczNGZhMmFkMmI1Y2I0NDNkZmEwOGNfMzAtMi0xLTEtNDY4OTE_264b2948-41a7-4ff1-9b4c-11aaf45ee63d"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i784f65549351439fa4b7bedf90ce7e3f_I20211231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xNi9mcmFnOjljZDUxYTE0NzJmODQ5ZWViZmI0YzllYmNiOGRjNzdiL3RhYmxlOjBjZDY0ODYwODI3MzRmYTJhZDJiNWNiNDQzZGZhMDhjL3RhYmxlcmFuZ2U6MGNkNjQ4NjA4MjczNGZhMmFkMmI1Y2I0NDNkZmEwOGNfMzAtNC0xLTEtNDY4OTE_a4c77908-6f11-4eda-a79f-c0089d7918df"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">SHAREHOLDER&#8217;S EQUITY</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common shares - no par value, unlimited shares authorized, <ix:nonFraction unitRef="shares" contextRef="id7882ae6aff54a3aacdef67ddf11a428_I20220331" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xNi9mcmFnOjljZDUxYTE0NzJmODQ5ZWViZmI0YzllYmNiOGRjNzdiL3RhYmxlOjBjZDY0ODYwODI3MzRmYTJhZDJiNWNiNDQzZGZhMDhjL3RhYmxlcmFuZ2U6MGNkNjQ4NjA4MjczNGZhMmFkMmI1Y2I0NDNkZmEwOGNfMzItMC0xLTEtNDY4OTEvdGV4dHJlZ2lvbjphOTA1NmUzYTA5ZTE0NGE2ODI0YzVkMzcwMDUzMDJhZV82Mw_7c03301b-bd7a-45cd-929c-646116f22f96"><ix:nonFraction unitRef="shares" contextRef="id7882ae6aff54a3aacdef67ddf11a428_I20220331" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xNi9mcmFnOjljZDUxYTE0NzJmODQ5ZWViZmI0YzllYmNiOGRjNzdiL3RhYmxlOjBjZDY0ODYwODI3MzRmYTJhZDJiNWNiNDQzZGZhMDhjL3RhYmxlcmFuZ2U6MGNkNjQ4NjA4MjczNGZhMmFkMmI1Y2I0NDNkZmEwOGNfMzItMC0xLTEtNDY4OTEvdGV4dHJlZ2lvbjphOTA1NmUzYTA5ZTE0NGE2ODI0YzVkMzcwMDUzMDJhZV82Mw_af017bc0-a057-4396-8eb4-cad062249461">141,742</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i784f65549351439fa4b7bedf90ce7e3f_I20211231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xNi9mcmFnOjljZDUxYTE0NzJmODQ5ZWViZmI0YzllYmNiOGRjNzdiL3RhYmxlOjBjZDY0ODYwODI3MzRmYTJhZDJiNWNiNDQzZGZhMDhjL3RhYmxlcmFuZ2U6MGNkNjQ4NjA4MjczNGZhMmFkMmI1Y2I0NDNkZmEwOGNfMzItMC0xLTEtNDY4OTEvdGV4dHJlZ2lvbjphOTA1NmUzYTA5ZTE0NGE2ODI0YzVkMzcwMDUzMDJhZV83MA_7141f9a4-296a-4ba3-a091-af1dc46ed667"><ix:nonFraction unitRef="shares" contextRef="i784f65549351439fa4b7bedf90ce7e3f_I20211231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xNi9mcmFnOjljZDUxYTE0NzJmODQ5ZWViZmI0YzllYmNiOGRjNzdiL3RhYmxlOjBjZDY0ODYwODI3MzRmYTJhZDJiNWNiNDQzZGZhMDhjL3RhYmxlcmFuZ2U6MGNkNjQ4NjA4MjczNGZhMmFkMmI1Y2I0NDNkZmEwOGNfMzItMC0xLTEtNDY4OTEvdGV4dHJlZ2lvbjphOTA1NmUzYTA5ZTE0NGE2ODI0YzVkMzcwMDUzMDJhZV83MA_bf7f1f85-74ff-4824-bed0-4b64a739fca7">141,600</ix:nonFraction></ix:nonFraction> shares issued and outstanding at March 31, 2022 and December 31, 2021, respectively</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7882ae6aff54a3aacdef67ddf11a428_I20220331" decimals="-3" name="us-gaap:CommonStockValueOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xNi9mcmFnOjljZDUxYTE0NzJmODQ5ZWViZmI0YzllYmNiOGRjNzdiL3RhYmxlOjBjZDY0ODYwODI3MzRmYTJhZDJiNWNiNDQzZGZhMDhjL3RhYmxlcmFuZ2U6MGNkNjQ4NjA4MjczNGZhMmFkMmI1Y2I0NDNkZmEwOGNfMzItMi0xLTEtNDY4OTE_a887c287-2465-4c73-b331-221d2a4beaf3">1,178,807</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i784f65549351439fa4b7bedf90ce7e3f_I20211231" decimals="-3" name="us-gaap:CommonStockValueOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xNi9mcmFnOjljZDUxYTE0NzJmODQ5ZWViZmI0YzllYmNiOGRjNzdiL3RhYmxlOjBjZDY0ODYwODI3MzRmYTJhZDJiNWNiNDQzZGZhMDhjL3RhYmxlcmFuZ2U6MGNkNjQ4NjA4MjczNGZhMmFkMmI1Y2I0NDNkZmEwOGNfMzItNC0xLTEtNDY4OTE_a7418a4f-86bc-4163-a596-ddb0a6e72f3a">1,177,051</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7882ae6aff54a3aacdef67ddf11a428_I20220331" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xNi9mcmFnOjljZDUxYTE0NzJmODQ5ZWViZmI0YzllYmNiOGRjNzdiL3RhYmxlOjBjZDY0ODYwODI3MzRmYTJhZDJiNWNiNDQzZGZhMDhjL3RhYmxlcmFuZ2U6MGNkNjQ4NjA4MjczNGZhMmFkMmI1Y2I0NDNkZmEwOGNfMzMtMi0xLTEtNDY4OTE_547f4476-81e5-4b3b-bf88-d7eb3d4d30c0">64,686</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i784f65549351439fa4b7bedf90ce7e3f_I20211231" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xNi9mcmFnOjljZDUxYTE0NzJmODQ5ZWViZmI0YzllYmNiOGRjNzdiL3RhYmxlOjBjZDY0ODYwODI3MzRmYTJhZDJiNWNiNDQzZGZhMDhjL3RhYmxlcmFuZ2U6MGNkNjQ4NjA4MjczNGZhMmFkMmI1Y2I0NDNkZmEwOGNfMzMtNC0xLTEtNDY4OTE_9aaa2942-cbb3-4a65-a83d-1b86aceac49c">59,014</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id7882ae6aff54a3aacdef67ddf11a428_I20220331" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xNi9mcmFnOjljZDUxYTE0NzJmODQ5ZWViZmI0YzllYmNiOGRjNzdiL3RhYmxlOjBjZDY0ODYwODI3MzRmYTJhZDJiNWNiNDQzZGZhMDhjL3RhYmxlcmFuZ2U6MGNkNjQ4NjA4MjczNGZhMmFkMmI1Y2I0NDNkZmEwOGNfMzQtMi0xLTEtNDY4OTE_12b5dfc9-35a1-4101-9e63-0152e58bbf6c">1,618</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i784f65549351439fa4b7bedf90ce7e3f_I20211231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xNi9mcmFnOjljZDUxYTE0NzJmODQ5ZWViZmI0YzllYmNiOGRjNzdiL3RhYmxlOjBjZDY0ODYwODI3MzRmYTJhZDJiNWNiNDQzZGZhMDhjL3RhYmxlcmFuZ2U6MGNkNjQ4NjA4MjczNGZhMmFkMmI1Y2I0NDNkZmEwOGNfMzQtNC0xLTEtNDY4OTE_ba2af9c9-1b73-46ce-9973-24d60d252c4a">852</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id7882ae6aff54a3aacdef67ddf11a428_I20220331" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xNi9mcmFnOjljZDUxYTE0NzJmODQ5ZWViZmI0YzllYmNiOGRjNzdiL3RhYmxlOjBjZDY0ODYwODI3MzRmYTJhZDJiNWNiNDQzZGZhMDhjL3RhYmxlcmFuZ2U6MGNkNjQ4NjA4MjczNGZhMmFkMmI1Y2I0NDNkZmEwOGNfMzUtMi0xLTEtNDY4OTE_0858511f-8d99-49df-9c0a-91ddf7b581a4">793,752</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i784f65549351439fa4b7bedf90ce7e3f_I20211231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xNi9mcmFnOjljZDUxYTE0NzJmODQ5ZWViZmI0YzllYmNiOGRjNzdiL3RhYmxlOjBjZDY0ODYwODI3MzRmYTJhZDJiNWNiNDQzZGZhMDhjL3RhYmxlcmFuZ2U6MGNkNjQ4NjA4MjczNGZhMmFkMmI1Y2I0NDNkZmEwOGNfMzUtNC0xLTEtNDY4OTE_7a56e2f7-841c-43c5-93eb-49c7b672662b">756,122</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total shareholders' equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7882ae6aff54a3aacdef67ddf11a428_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xNi9mcmFnOjljZDUxYTE0NzJmODQ5ZWViZmI0YzllYmNiOGRjNzdiL3RhYmxlOjBjZDY0ODYwODI3MzRmYTJhZDJiNWNiNDQzZGZhMDhjL3RhYmxlcmFuZ2U6MGNkNjQ4NjA4MjczNGZhMmFkMmI1Y2I0NDNkZmEwOGNfMzYtMi0xLTEtNDY4OTE_35adae84-cfea-4c61-8efd-fe211c87725d">448,123</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i784f65549351439fa4b7bedf90ce7e3f_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xNi9mcmFnOjljZDUxYTE0NzJmODQ5ZWViZmI0YzllYmNiOGRjNzdiL3RhYmxlOjBjZDY0ODYwODI3MzRmYTJhZDJiNWNiNDQzZGZhMDhjL3RhYmxlcmFuZ2U6MGNkNjQ4NjA4MjczNGZhMmFkMmI1Y2I0NDNkZmEwOGNfMzYtNC0xLTEtNDY4OTE_0aa8425b-f2be-4a08-a0c5-01d1b3e46669">479,091</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and shareholders&#8217; equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7882ae6aff54a3aacdef67ddf11a428_I20220331" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xNi9mcmFnOjljZDUxYTE0NzJmODQ5ZWViZmI0YzllYmNiOGRjNzdiL3RhYmxlOjBjZDY0ODYwODI3MzRmYTJhZDJiNWNiNDQzZGZhMDhjL3RhYmxlcmFuZ2U6MGNkNjQ4NjA4MjczNGZhMmFkMmI1Y2I0NDNkZmEwOGNfMzctMi0xLTEtNDY4OTE_a99d6340-d02c-4605-86a4-aabcf351429d">506,902</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i784f65549351439fa4b7bedf90ce7e3f_I20211231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xNi9mcmFnOjljZDUxYTE0NzJmODQ5ZWViZmI0YzllYmNiOGRjNzdiL3RhYmxlOjBjZDY0ODYwODI3MzRmYTJhZDJiNWNiNDQzZGZhMDhjL3RhYmxlcmFuZ2U6MGNkNjQ4NjA4MjczNGZhMmFkMmI1Y2I0NDNkZmEwOGNfMzctNC0xLTEtNDY4OTE_38a6c4f8-6d68-4a2e-aee9-c89d3fce0bd7">543,367</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:7pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><div id="i2d3a8f7e52e84dcebfa935bec5ca9eb6_19"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">AURINIA PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except per share data)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.291%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenue, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34e7d6696f5d40019bbef585c942db1a_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xOS9mcmFnOjA2ZWYwNzk4YTBlODRlMjRhODJiNTcxNWU1YmRmMjU1L3RhYmxlOmE4MWYwMGM4NmI2NDQyZTNiNGVlZDU5YjUyOWY2ODBlL3RhYmxlcmFuZ2U6YTgxZjAwYzg2YjY0NDJlM2I0ZWVkNTliNTI5ZjY4MGVfNS0yLTEtMS00Njg5MQ_32856bdd-a3a8-4f1e-b853-a24778262576">21,492</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i717bc91cf1504e20b9b5b1c709508591_D20210101-20210331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xOS9mcmFnOjA2ZWYwNzk4YTBlODRlMjRhODJiNTcxNWU1YmRmMjU1L3RhYmxlOmE4MWYwMGM4NmI2NDQyZTNiNGVlZDU5YjUyOWY2ODBlL3RhYmxlcmFuZ2U6YTgxZjAwYzg2YjY0NDJlM2I0ZWVkNTliNTI5ZjY4MGVfNS00LTEtMS00Njg5MQ_4c9c5cc2-3cf9-41a4-80eb-4c75874c850e">884</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License and collaboration revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d6565befaf14fa4b0f390573f13f8fc_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xOS9mcmFnOjA2ZWYwNzk4YTBlODRlMjRhODJiNTcxNWU1YmRmMjU1L3RhYmxlOmE4MWYwMGM4NmI2NDQyZTNiNGVlZDU5YjUyOWY2ODBlL3RhYmxlcmFuZ2U6YTgxZjAwYzg2YjY0NDJlM2I0ZWVkNTliNTI5ZjY4MGVfNi0yLTEtMS00Njg5MQ_acdb18d5-e1fc-486a-94f6-1721d209a1a0">133</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25e47e5aca8445b7b6e872243cf6ab56_D20210101-20210331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xOS9mcmFnOjA2ZWYwNzk4YTBlODRlMjRhODJiNTcxNWU1YmRmMjU1L3RhYmxlOmE4MWYwMGM4NmI2NDQyZTNiNGVlZDU5YjUyOWY2ODBlL3RhYmxlcmFuZ2U6YTgxZjAwYzg2YjY0NDJlM2I0ZWVkNTliNTI5ZjY4MGVfNi00LTEtMS00Njg5MQ_74da76bb-9d14-49c6-8883-a4baa9338e7f">30</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xOS9mcmFnOjA2ZWYwNzk4YTBlODRlMjRhODJiNTcxNWU1YmRmMjU1L3RhYmxlOmE4MWYwMGM4NmI2NDQyZTNiNGVlZDU5YjUyOWY2ODBlL3RhYmxlcmFuZ2U6YTgxZjAwYzg2YjY0NDJlM2I0ZWVkNTliNTI5ZjY4MGVfNy0yLTEtMS00Njg5MQ_2aa366e2-71d2-4463-b824-fbdf410cafd5">21,625</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56599386fa47443a8975bb3f7a6a8c57_D20210101-20210331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xOS9mcmFnOjA2ZWYwNzk4YTBlODRlMjRhODJiNTcxNWU1YmRmMjU1L3RhYmxlOmE4MWYwMGM4NmI2NDQyZTNiNGVlZDU5YjUyOWY2ODBlL3RhYmxlcmFuZ2U6YTgxZjAwYzg2YjY0NDJlM2I0ZWVkNTliNTI5ZjY4MGVfNy00LTEtMS00Njg5MQ_204187e2-8742-4409-8d9b-71743d0aa110">914</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331" decimals="-3" name="us-gaap:CostOfRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xOS9mcmFnOjA2ZWYwNzk4YTBlODRlMjRhODJiNTcxNWU1YmRmMjU1L3RhYmxlOmE4MWYwMGM4NmI2NDQyZTNiNGVlZDU5YjUyOWY2ODBlL3RhYmxlcmFuZ2U6YTgxZjAwYzg2YjY0NDJlM2I0ZWVkNTliNTI5ZjY4MGVfOS0yLTEtMS00Njg5MQ_17954d37-3abc-4a7c-9741-f9af54255ef6">256</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56599386fa47443a8975bb3f7a6a8c57_D20210101-20210331" decimals="-3" name="us-gaap:CostOfRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xOS9mcmFnOjA2ZWYwNzk4YTBlODRlMjRhODJiNTcxNWU1YmRmMjU1L3RhYmxlOmE4MWYwMGM4NmI2NDQyZTNiNGVlZDU5YjUyOWY2ODBlL3RhYmxlcmFuZ2U6YTgxZjAwYzg2YjY0NDJlM2I0ZWVkNTliNTI5ZjY4MGVfOS00LTEtMS00Njg5MQ_c61a2e02-d411-4604-8999-428b806a82ad">48</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xOS9mcmFnOjA2ZWYwNzk4YTBlODRlMjRhODJiNTcxNWU1YmRmMjU1L3RhYmxlOmE4MWYwMGM4NmI2NDQyZTNiNGVlZDU5YjUyOWY2ODBlL3RhYmxlcmFuZ2U6YTgxZjAwYzg2YjY0NDJlM2I0ZWVkNTliNTI5ZjY4MGVfMTAtMi0xLTEtNDY4OTE_7c363fef-e153-461c-90ab-6d185908f38f">45,197</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56599386fa47443a8975bb3f7a6a8c57_D20210101-20210331" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xOS9mcmFnOjA2ZWYwNzk4YTBlODRlMjRhODJiNTcxNWU1YmRmMjU1L3RhYmxlOmE4MWYwMGM4NmI2NDQyZTNiNGVlZDU5YjUyOWY2ODBlL3RhYmxlcmFuZ2U6YTgxZjAwYzg2YjY0NDJlM2I0ZWVkNTliNTI5ZjY4MGVfMTAtNC0xLTEtNDY4OTE_eebff4e8-cf1f-48a5-976a-e7860432a3d0">39,805</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xOS9mcmFnOjA2ZWYwNzk4YTBlODRlMjRhODJiNTcxNWU1YmRmMjU1L3RhYmxlOmE4MWYwMGM4NmI2NDQyZTNiNGVlZDU5YjUyOWY2ODBlL3RhYmxlcmFuZ2U6YTgxZjAwYzg2YjY0NDJlM2I0ZWVkNTliNTI5ZjY4MGVfMTEtMi0xLTEtNDY4OTE_cf9e60c4-5385-4e5c-8380-bbaa79c16e8c">12,620</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56599386fa47443a8975bb3f7a6a8c57_D20210101-20210331" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xOS9mcmFnOjA2ZWYwNzk4YTBlODRlMjRhODJiNTcxNWU1YmRmMjU1L3RhYmxlOmE4MWYwMGM4NmI2NDQyZTNiNGVlZDU5YjUyOWY2ODBlL3RhYmxlcmFuZ2U6YTgxZjAwYzg2YjY0NDJlM2I0ZWVkNTliNTI5ZjY4MGVfMTEtNC0xLTEtNDY4OTE_a07a4a03-8b1b-42d5-a1c9-e68717ad169c">9,833</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xOS9mcmFnOjA2ZWYwNzk4YTBlODRlMjRhODJiNTcxNWU1YmRmMjU1L3RhYmxlOmE4MWYwMGM4NmI2NDQyZTNiNGVlZDU5YjUyOWY2ODBlL3RhYmxlcmFuZ2U6YTgxZjAwYzg2YjY0NDJlM2I0ZWVkNTliNTI5ZjY4MGVfMTMtMi0xLTEtNDY4OTE_115e8791-5b2b-4f17-af04-af6ab0e4471a">1,434</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56599386fa47443a8975bb3f7a6a8c57_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xOS9mcmFnOjA2ZWYwNzk4YTBlODRlMjRhODJiNTcxNWU1YmRmMjU1L3RhYmxlOmE4MWYwMGM4NmI2NDQyZTNiNGVlZDU5YjUyOWY2ODBlL3RhYmxlcmFuZ2U6YTgxZjAwYzg2YjY0NDJlM2I0ZWVkNTliNTI5ZjY4MGVfMTMtNC0xLTEtNDY4OTE_347c7b23-851a-45bf-95f6-ca8b44687deb">1,771</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cost of sales and operating expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xOS9mcmFnOjA2ZWYwNzk4YTBlODRlMjRhODJiNTcxNWU1YmRmMjU1L3RhYmxlOmE4MWYwMGM4NmI2NDQyZTNiNGVlZDU5YjUyOWY2ODBlL3RhYmxlcmFuZ2U6YTgxZjAwYzg2YjY0NDJlM2I0ZWVkNTliNTI5ZjY4MGVfMTQtMi0xLTEtNDY4OTE_bc2f471e-5369-44c7-b6e5-c1ae35c972df">59,507</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56599386fa47443a8975bb3f7a6a8c57_D20210101-20210331" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xOS9mcmFnOjA2ZWYwNzk4YTBlODRlMjRhODJiNTcxNWU1YmRmMjU1L3RhYmxlOmE4MWYwMGM4NmI2NDQyZTNiNGVlZDU5YjUyOWY2ODBlL3RhYmxlcmFuZ2U6YTgxZjAwYzg2YjY0NDJlM2I0ZWVkNTliNTI5ZjY4MGVfMTQtNC0xLTEtNDY4OTE_dc5fa5f5-6b4b-4687-aa9c-fece878d22cb">51,457</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xOS9mcmFnOjA2ZWYwNzk4YTBlODRlMjRhODJiNTcxNWU1YmRmMjU1L3RhYmxlOmE4MWYwMGM4NmI2NDQyZTNiNGVlZDU5YjUyOWY2ODBlL3RhYmxlcmFuZ2U6YTgxZjAwYzg2YjY0NDJlM2I0ZWVkNTliNTI5ZjY4MGVfMTUtMi0xLTEtNDY4OTE_bdc20dce-d9c5-4c6c-a3ba-8c6b5de69b4e">37,882</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i56599386fa47443a8975bb3f7a6a8c57_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xOS9mcmFnOjA2ZWYwNzk4YTBlODRlMjRhODJiNTcxNWU1YmRmMjU1L3RhYmxlOmE4MWYwMGM4NmI2NDQyZTNiNGVlZDU5YjUyOWY2ODBlL3RhYmxlcmFuZ2U6YTgxZjAwYzg2YjY0NDJlM2I0ZWVkNTliNTI5ZjY4MGVfMTUtNC0xLTEtNDY4OTE_860fa46a-e426-4f94-b1ef-ce39dd5c53ec">50,543</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331" decimals="-3" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xOS9mcmFnOjA2ZWYwNzk4YTBlODRlMjRhODJiNTcxNWU1YmRmMjU1L3RhYmxlOmE4MWYwMGM4NmI2NDQyZTNiNGVlZDU5YjUyOWY2ODBlL3RhYmxlcmFuZ2U6YTgxZjAwYzg2YjY0NDJlM2I0ZWVkNTliNTI5ZjY4MGVfMTYtMi0xLTEtNDY4OTE_c5aa731f-4b02-46a2-83e8-7ed9f81f1b16">262</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56599386fa47443a8975bb3f7a6a8c57_D20210101-20210331" decimals="-3" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xOS9mcmFnOjA2ZWYwNzk4YTBlODRlMjRhODJiNTcxNWU1YmRmMjU1L3RhYmxlOmE4MWYwMGM4NmI2NDQyZTNiNGVlZDU5YjUyOWY2ODBlL3RhYmxlcmFuZ2U6YTgxZjAwYzg2YjY0NDJlM2I0ZWVkNTliNTI5ZjY4MGVfMTYtNC0xLTEtNDY4OTE_17a761eb-18c0-40a6-9f57-ce6ebb5175b0">172</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss before income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xOS9mcmFnOjA2ZWYwNzk4YTBlODRlMjRhODJiNTcxNWU1YmRmMjU1L3RhYmxlOmE4MWYwMGM4NmI2NDQyZTNiNGVlZDU5YjUyOWY2ODBlL3RhYmxlcmFuZ2U6YTgxZjAwYzg2YjY0NDJlM2I0ZWVkNTliNTI5ZjY4MGVfMTctMi0xLTEtNDY4OTE_d18c6200-3c45-4b11-8b4e-51ea3bce60c8">37,620</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i56599386fa47443a8975bb3f7a6a8c57_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xOS9mcmFnOjA2ZWYwNzk4YTBlODRlMjRhODJiNTcxNWU1YmRmMjU1L3RhYmxlOmE4MWYwMGM4NmI2NDQyZTNiNGVlZDU5YjUyOWY2ODBlL3RhYmxlcmFuZ2U6YTgxZjAwYzg2YjY0NDJlM2I0ZWVkNTliNTI5ZjY4MGVfMTctNC0xLTEtNDY4OTE_ce4af9c0-20a8-42e9-a5e8-a8f983917a69">50,371</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xOS9mcmFnOjA2ZWYwNzk4YTBlODRlMjRhODJiNTcxNWU1YmRmMjU1L3RhYmxlOmE4MWYwMGM4NmI2NDQyZTNiNGVlZDU5YjUyOWY2ODBlL3RhYmxlcmFuZ2U6YTgxZjAwYzg2YjY0NDJlM2I0ZWVkNTliNTI5ZjY4MGVfMTgtMi0xLTEtNDY4OTE_f39e9a53-8400-4ffc-8374-4994149debfc">10</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56599386fa47443a8975bb3f7a6a8c57_D20210101-20210331" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xOS9mcmFnOjA2ZWYwNzk4YTBlODRlMjRhODJiNTcxNWU1YmRmMjU1L3RhYmxlOmE4MWYwMGM4NmI2NDQyZTNiNGVlZDU5YjUyOWY2ODBlL3RhYmxlcmFuZ2U6YTgxZjAwYzg2YjY0NDJlM2I0ZWVkNTliNTI5ZjY4MGVfMTgtNC0xLTEtNDY4OTE_c7ffd45b-972c-42e0-923c-a5ef9a7da933">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xOS9mcmFnOjA2ZWYwNzk4YTBlODRlMjRhODJiNTcxNWU1YmRmMjU1L3RhYmxlOmE4MWYwMGM4NmI2NDQyZTNiNGVlZDU5YjUyOWY2ODBlL3RhYmxlcmFuZ2U6YTgxZjAwYzg2YjY0NDJlM2I0ZWVkNTliNTI5ZjY4MGVfMTktMi0xLTEtNDY4OTE_6ac9ab29-7f15-4343-8494-ecfbaffe82b1">37,630</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i56599386fa47443a8975bb3f7a6a8c57_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xOS9mcmFnOjA2ZWYwNzk4YTBlODRlMjRhODJiNTcxNWU1YmRmMjU1L3RhYmxlOmE4MWYwMGM4NmI2NDQyZTNiNGVlZDU5YjUyOWY2ODBlL3RhYmxlcmFuZ2U6YTgxZjAwYzg2YjY0NDJlM2I0ZWVkNTliNTI5ZjY4MGVfMTktNC0xLTEtNDY4OTE_0d63b369-faef-472b-80a7-2b877d7d527e">50,379</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized (loss) gain on available-for-sale securities, net of tax of <ix:nonFraction unitRef="usd" contextRef="i56599386fa47443a8975bb3f7a6a8c57_D20210101-20210331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xOS9mcmFnOjA2ZWYwNzk4YTBlODRlMjRhODJiNTcxNWU1YmRmMjU1L3RhYmxlOmE4MWYwMGM4NmI2NDQyZTNiNGVlZDU5YjUyOWY2ODBlL3RhYmxlcmFuZ2U6YTgxZjAwYzg2YjY0NDJlM2I0ZWVkNTliNTI5ZjY4MGVfMjEtMC0xLTEtNDY4OTEvdGV4dHJlZ2lvbjoxN2M4OTQzMjJmZjg0Mjc0OTNhYWQzZmQxOGU0MjJlN183NQ_1e3f377e-175e-4fcf-a1e9-e1052ec7698b"><ix:nonFraction unitRef="usd" contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xOS9mcmFnOjA2ZWYwNzk4YTBlODRlMjRhODJiNTcxNWU1YmRmMjU1L3RhYmxlOmE4MWYwMGM4NmI2NDQyZTNiNGVlZDU5YjUyOWY2ODBlL3RhYmxlcmFuZ2U6YTgxZjAwYzg2YjY0NDJlM2I0ZWVkNTliNTI5ZjY4MGVfMjEtMC0xLTEtNDY4OTEvdGV4dHJlZ2lvbjoxN2M4OTQzMjJmZjg0Mjc0OTNhYWQzZmQxOGU0MjJlN183NQ_d4682284-a245-41cd-9277-4d50df7fb4be">nil</ix:nonFraction></ix:nonFraction></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xOS9mcmFnOjA2ZWYwNzk4YTBlODRlMjRhODJiNTcxNWU1YmRmMjU1L3RhYmxlOmE4MWYwMGM4NmI2NDQyZTNiNGVlZDU5YjUyOWY2ODBlL3RhYmxlcmFuZ2U6YTgxZjAwYzg2YjY0NDJlM2I0ZWVkNTliNTI5ZjY4MGVfMjEtMi0xLTEtNDY4OTE_a78c72f4-16d8-470e-ad9a-0a1a3ff3e2bc">766</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56599386fa47443a8975bb3f7a6a8c57_D20210101-20210331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xOS9mcmFnOjA2ZWYwNzk4YTBlODRlMjRhODJiNTcxNWU1YmRmMjU1L3RhYmxlOmE4MWYwMGM4NmI2NDQyZTNiNGVlZDU5YjUyOWY2ODBlL3RhYmxlcmFuZ2U6YTgxZjAwYzg2YjY0NDJlM2I0ZWVkNTliNTI5ZjY4MGVfMjEtNC0xLTEtNDY4OTE_db2bc88f-fe82-4db7-b6b9-fb9a1f76579d">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xOS9mcmFnOjA2ZWYwNzk4YTBlODRlMjRhODJiNTcxNWU1YmRmMjU1L3RhYmxlOmE4MWYwMGM4NmI2NDQyZTNiNGVlZDU5YjUyOWY2ODBlL3RhYmxlcmFuZ2U6YTgxZjAwYzg2YjY0NDJlM2I0ZWVkNTliNTI5ZjY4MGVfMjItMi0xLTEtNDY4OTE_b8df8f16-00ec-4a31-b05d-d539fb46fe7f">38,396</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i56599386fa47443a8975bb3f7a6a8c57_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xOS9mcmFnOjA2ZWYwNzk4YTBlODRlMjRhODJiNTcxNWU1YmRmMjU1L3RhYmxlOmE4MWYwMGM4NmI2NDQyZTNiNGVlZDU5YjUyOWY2ODBlL3RhYmxlcmFuZ2U6YTgxZjAwYzg2YjY0NDJlM2I0ZWVkNTliNTI5ZjY4MGVfMjItNC0xLTEtNDY4OTE_5c6e3640-7e08-43fe-bccb-964847e12150">50,373</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted loss per share</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xOS9mcmFnOjA2ZWYwNzk4YTBlODRlMjRhODJiNTcxNWU1YmRmMjU1L3RhYmxlOmE4MWYwMGM4NmI2NDQyZTNiNGVlZDU5YjUyOWY2ODBlL3RhYmxlcmFuZ2U6YTgxZjAwYzg2YjY0NDJlM2I0ZWVkNTliNTI5ZjY4MGVfMjMtMi0xLTEtNDY4OTE_26db01ce-09b9-4be6-b2bb-72394cd25e91"><ix:nonFraction unitRef="usdPerShare" contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xOS9mcmFnOjA2ZWYwNzk4YTBlODRlMjRhODJiNTcxNWU1YmRmMjU1L3RhYmxlOmE4MWYwMGM4NmI2NDQyZTNiNGVlZDU5YjUyOWY2ODBlL3RhYmxlcmFuZ2U6YTgxZjAwYzg2YjY0NDJlM2I0ZWVkNTliNTI5ZjY4MGVfMjMtMi0xLTEtNDY4OTE_ee9c1b3b-7795-487a-ac85-fc59066ce615">0.27</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i56599386fa47443a8975bb3f7a6a8c57_D20210101-20210331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xOS9mcmFnOjA2ZWYwNzk4YTBlODRlMjRhODJiNTcxNWU1YmRmMjU1L3RhYmxlOmE4MWYwMGM4NmI2NDQyZTNiNGVlZDU5YjUyOWY2ODBlL3RhYmxlcmFuZ2U6YTgxZjAwYzg2YjY0NDJlM2I0ZWVkNTliNTI5ZjY4MGVfMjMtNC0xLTEtNDY4OTE_6a5c9688-627f-450e-b9dd-161ad682d9a8"><ix:nonFraction unitRef="usdPerShare" contextRef="i56599386fa47443a8975bb3f7a6a8c57_D20210101-20210331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xOS9mcmFnOjA2ZWYwNzk4YTBlODRlMjRhODJiNTcxNWU1YmRmMjU1L3RhYmxlOmE4MWYwMGM4NmI2NDQyZTNiNGVlZDU5YjUyOWY2ODBlL3RhYmxlcmFuZ2U6YTgxZjAwYzg2YjY0NDJlM2I0ZWVkNTliNTI5ZjY4MGVfMjMtNC0xLTEtNDY4OTE_e012714c-63bc-4814-872b-7e1def5e0d90">0.40</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding used in computation of basic and diluted loss per share</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xOS9mcmFnOjA2ZWYwNzk4YTBlODRlMjRhODJiNTcxNWU1YmRmMjU1L3RhYmxlOmE4MWYwMGM4NmI2NDQyZTNiNGVlZDU5YjUyOWY2ODBlL3RhYmxlcmFuZ2U6YTgxZjAwYzg2YjY0NDJlM2I0ZWVkNTliNTI5ZjY4MGVfMjQtMi0xLTEtNDY4OTE_342538a5-4abe-486e-97b8-17d9cf1d2bab"><ix:nonFraction unitRef="shares" contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xOS9mcmFnOjA2ZWYwNzk4YTBlODRlMjRhODJiNTcxNWU1YmRmMjU1L3RhYmxlOmE4MWYwMGM4NmI2NDQyZTNiNGVlZDU5YjUyOWY2ODBlL3RhYmxlcmFuZ2U6YTgxZjAwYzg2YjY0NDJlM2I0ZWVkNTliNTI5ZjY4MGVfMjQtMi0xLTEtNDY4OTE_6147aa37-f6b8-4a0d-aaea-2ec3d8b80492">141,675</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i56599386fa47443a8975bb3f7a6a8c57_D20210101-20210331" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xOS9mcmFnOjA2ZWYwNzk4YTBlODRlMjRhODJiNTcxNWU1YmRmMjU1L3RhYmxlOmE4MWYwMGM4NmI2NDQyZTNiNGVlZDU5YjUyOWY2ODBlL3RhYmxlcmFuZ2U6YTgxZjAwYzg2YjY0NDJlM2I0ZWVkNTliNTI5ZjY4MGVfMjQtNC0xLTEtNDY4OTE_608cff76-b0d9-4ef1-846a-ac66460ee841"><ix:nonFraction unitRef="shares" contextRef="i56599386fa47443a8975bb3f7a6a8c57_D20210101-20210331" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xOS9mcmFnOjA2ZWYwNzk4YTBlODRlMjRhODJiNTcxNWU1YmRmMjU1L3RhYmxlOmE4MWYwMGM4NmI2NDQyZTNiNGVlZDU5YjUyOWY2ODBlL3RhYmxlcmFuZ2U6YTgxZjAwYzg2YjY0NDJlM2I0ZWVkNTliNTI5ZjY4MGVfMjQtNC0xLTEtNDY4OTE_80803525-c7ec-4166-b3aa-da0462874adf">127,401</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:7pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="i2d3a8f7e52e84dcebfa935bec5ca9eb6_22"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">AURINIA PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:25.361%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.505%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Common Shares</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Additional<br/>paid in<br/>capital</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>(Loss) Income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total<br/>Shareholders'<br/>Equity</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i61d2ecb1315b47b48046b2cc2d26a3f4_I20211231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yMi9mcmFnOjYxMTdlMmQxMDAwYTQyNjRiZDM4ODA2OTRlY2IwNzJmL3RhYmxlOmYyNGY0YzM1ZjI4MDRjZWI4YWEwOTkxYjFlM2E3YWNmL3RhYmxlcmFuZ2U6ZjI0ZjRjMzVmMjgwNGNlYjhhYTA5OTFiMWUzYTdhY2ZfMi0yLTEtMS00Njg5MQ_72d88b53-9236-434b-b6a0-52b015c3a6ff">141,600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61d2ecb1315b47b48046b2cc2d26a3f4_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yMi9mcmFnOjYxMTdlMmQxMDAwYTQyNjRiZDM4ODA2OTRlY2IwNzJmL3RhYmxlOmYyNGY0YzM1ZjI4MDRjZWI4YWEwOTkxYjFlM2E3YWNmL3RhYmxlcmFuZ2U6ZjI0ZjRjMzVmMjgwNGNlYjhhYTA5OTFiMWUzYTdhY2ZfMi00LTEtMS00Njg5MQ_5aef5401-dca4-496d-98e6-90ec1fdfc611">1,177,051</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc985adebb4d4146be71a1355b404db9_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yMi9mcmFnOjYxMTdlMmQxMDAwYTQyNjRiZDM4ODA2OTRlY2IwNzJmL3RhYmxlOmYyNGY0YzM1ZjI4MDRjZWI4YWEwOTkxYjFlM2E3YWNmL3RhYmxlcmFuZ2U6ZjI0ZjRjMzVmMjgwNGNlYjhhYTA5OTFiMWUzYTdhY2ZfMi02LTEtMS00Njg5MQ_aaf2c995-24b6-456b-a8ba-32edbda8f6e8">59,014</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4141e328567a4e2f84032e5f733bf3a6_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yMi9mcmFnOjYxMTdlMmQxMDAwYTQyNjRiZDM4ODA2OTRlY2IwNzJmL3RhYmxlOmYyNGY0YzM1ZjI4MDRjZWI4YWEwOTkxYjFlM2E3YWNmL3RhYmxlcmFuZ2U6ZjI0ZjRjMzVmMjgwNGNlYjhhYTA5OTFiMWUzYTdhY2ZfMi04LTEtMS00Njg5MQ_2db4faf3-9dfe-4b67-b7aa-13a00b8023b9">852</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieebe2ef8481d495ea52a69991654df61_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yMi9mcmFnOjYxMTdlMmQxMDAwYTQyNjRiZDM4ODA2OTRlY2IwNzJmL3RhYmxlOmYyNGY0YzM1ZjI4MDRjZWI4YWEwOTkxYjFlM2E3YWNmL3RhYmxlcmFuZ2U6ZjI0ZjRjMzVmMjgwNGNlYjhhYTA5OTFiMWUzYTdhY2ZfMi0xMC0xLTEtNDY4OTE_426cf8c1-1998-4413-9fd1-05961d69c5e9">756,122</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i784f65549351439fa4b7bedf90ce7e3f_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yMi9mcmFnOjYxMTdlMmQxMDAwYTQyNjRiZDM4ODA2OTRlY2IwNzJmL3RhYmxlOmYyNGY0YzM1ZjI4MDRjZWI4YWEwOTkxYjFlM2E3YWNmL3RhYmxlcmFuZ2U6ZjI0ZjRjMzVmMjgwNGNlYjhhYTA5OTFiMWUzYTdhY2ZfMi0xMi0xLTEtNDY4OTE_91aa15f8-8576-46d1-898b-e233ccce3ed5">479,091</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares issued on exercise of stock options and vesting of performance awards</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic38a142e678c4e85a1b730ee6415c5c0_D20220101-20220331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yMi9mcmFnOjYxMTdlMmQxMDAwYTQyNjRiZDM4ODA2OTRlY2IwNzJmL3RhYmxlOmYyNGY0YzM1ZjI4MDRjZWI4YWEwOTkxYjFlM2E3YWNmL3RhYmxlcmFuZ2U6ZjI0ZjRjMzVmMjgwNGNlYjhhYTA5OTFiMWUzYTdhY2ZfMy0yLTEtMS00Njg5MQ_ebf8f39c-1ce9-45d9-bdc2-00d998198a0b">142</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic38a142e678c4e85a1b730ee6415c5c0_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yMi9mcmFnOjYxMTdlMmQxMDAwYTQyNjRiZDM4ODA2OTRlY2IwNzJmL3RhYmxlOmYyNGY0YzM1ZjI4MDRjZWI4YWEwOTkxYjFlM2E3YWNmL3RhYmxlcmFuZ2U6ZjI0ZjRjMzVmMjgwNGNlYjhhYTA5OTFiMWUzYTdhY2ZfMy00LTEtMS00Njg5MQ_6025514e-56bd-4b0c-af63-c2867b2ca6e4">1,756</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i76345d0397ef41589260147ade867835_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yMi9mcmFnOjYxMTdlMmQxMDAwYTQyNjRiZDM4ODA2OTRlY2IwNzJmL3RhYmxlOmYyNGY0YzM1ZjI4MDRjZWI4YWEwOTkxYjFlM2E3YWNmL3RhYmxlcmFuZ2U6ZjI0ZjRjMzVmMjgwNGNlYjhhYTA5OTFiMWUzYTdhY2ZfMy02LTEtMS00Njg5MQ_21cc72d0-09b3-4274-a42b-70468eea031f">1,351</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yMi9mcmFnOjYxMTdlMmQxMDAwYTQyNjRiZDM4ODA2OTRlY2IwNzJmL3RhYmxlOmYyNGY0YzM1ZjI4MDRjZWI4YWEwOTkxYjFlM2E3YWNmL3RhYmxlcmFuZ2U6ZjI0ZjRjMzVmMjgwNGNlYjhhYTA5OTFiMWUzYTdhY2ZfMy0xMi0xLTEtNDY4OTE_2095025c-236e-4f61-87fa-19e1b87d2de4">405</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Share-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76345d0397ef41589260147ade867835_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yMi9mcmFnOjYxMTdlMmQxMDAwYTQyNjRiZDM4ODA2OTRlY2IwNzJmL3RhYmxlOmYyNGY0YzM1ZjI4MDRjZWI4YWEwOTkxYjFlM2E3YWNmL3RhYmxlcmFuZ2U6ZjI0ZjRjMzVmMjgwNGNlYjhhYTA5OTFiMWUzYTdhY2ZfNC02LTEtMS00Njg5MQ_04c121f0-51b2-4bff-8d5a-71c362a16342">7,023</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yMi9mcmFnOjYxMTdlMmQxMDAwYTQyNjRiZDM4ODA2OTRlY2IwNzJmL3RhYmxlOmYyNGY0YzM1ZjI4MDRjZWI4YWEwOTkxYjFlM2E3YWNmL3RhYmxlcmFuZ2U6ZjI0ZjRjMzVmMjgwNGNlYjhhYTA5OTFiMWUzYTdhY2ZfNC0xMi0xLTEtNDY4OTE_ae94930f-279f-4eeb-8883-f8d6d57fe867">7,023</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized loss on available-for-sale securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i33e38a2732764762b66982ec4717a1b2_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yMi9mcmFnOjYxMTdlMmQxMDAwYTQyNjRiZDM4ODA2OTRlY2IwNzJmL3RhYmxlOmYyNGY0YzM1ZjI4MDRjZWI4YWEwOTkxYjFlM2E3YWNmL3RhYmxlcmFuZ2U6ZjI0ZjRjMzVmMjgwNGNlYjhhYTA5OTFiMWUzYTdhY2ZfNS04LTEtMS00Njg5MQ_c7f2d4a0-aa8a-40cd-84b6-68ed96f34944">766</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yMi9mcmFnOjYxMTdlMmQxMDAwYTQyNjRiZDM4ODA2OTRlY2IwNzJmL3RhYmxlOmYyNGY0YzM1ZjI4MDRjZWI4YWEwOTkxYjFlM2E3YWNmL3RhYmxlcmFuZ2U6ZjI0ZjRjMzVmMjgwNGNlYjhhYTA5OTFiMWUzYTdhY2ZfNS0xMi0xLTEtNDY4OTE_1fc2e9b5-5020-4e5c-a3ad-01e818384d71">766</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7f565b8d63fc448ba775e2bac6da89d9_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yMi9mcmFnOjYxMTdlMmQxMDAwYTQyNjRiZDM4ODA2OTRlY2IwNzJmL3RhYmxlOmYyNGY0YzM1ZjI4MDRjZWI4YWEwOTkxYjFlM2E3YWNmL3RhYmxlcmFuZ2U6ZjI0ZjRjMzVmMjgwNGNlYjhhYTA5OTFiMWUzYTdhY2ZfNy0xMC0xLTEtNDY4OTE_4530f302-ea4f-43f1-ae58-d7e727c8879f">37,630</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yMi9mcmFnOjYxMTdlMmQxMDAwYTQyNjRiZDM4ODA2OTRlY2IwNzJmL3RhYmxlOmYyNGY0YzM1ZjI4MDRjZWI4YWEwOTkxYjFlM2E3YWNmL3RhYmxlcmFuZ2U6ZjI0ZjRjMzVmMjgwNGNlYjhhYTA5OTFiMWUzYTdhY2ZfNy0xMi0xLTEtNDY4OTE_30fbe2af-1fc0-4c62-9dc6-c5887dd0dfae">37,630</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Balance at March 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id1291b626776443495f8c67d0b44222b_I20220331" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yMi9mcmFnOjYxMTdlMmQxMDAwYTQyNjRiZDM4ODA2OTRlY2IwNzJmL3RhYmxlOmYyNGY0YzM1ZjI4MDRjZWI4YWEwOTkxYjFlM2E3YWNmL3RhYmxlcmFuZ2U6ZjI0ZjRjMzVmMjgwNGNlYjhhYTA5OTFiMWUzYTdhY2ZfOC0yLTEtMS00Njg5MQ_54e91b3b-d336-4c75-b7ae-5e6f737a76db">141,742</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1291b626776443495f8c67d0b44222b_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yMi9mcmFnOjYxMTdlMmQxMDAwYTQyNjRiZDM4ODA2OTRlY2IwNzJmL3RhYmxlOmYyNGY0YzM1ZjI4MDRjZWI4YWEwOTkxYjFlM2E3YWNmL3RhYmxlcmFuZ2U6ZjI0ZjRjMzVmMjgwNGNlYjhhYTA5OTFiMWUzYTdhY2ZfOC00LTEtMS00Njg5MQ_5e01fde3-6829-46f1-bde1-cbb1dbf7d939">1,178,807</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8ed19e5e01745febb700f621d5350bd_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yMi9mcmFnOjYxMTdlMmQxMDAwYTQyNjRiZDM4ODA2OTRlY2IwNzJmL3RhYmxlOmYyNGY0YzM1ZjI4MDRjZWI4YWEwOTkxYjFlM2E3YWNmL3RhYmxlcmFuZ2U6ZjI0ZjRjMzVmMjgwNGNlYjhhYTA5OTFiMWUzYTdhY2ZfOC02LTEtMS00Njg5MQ_592264d0-a6ca-4b1f-a149-d4803efe930f">64,686</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4bfaf26bef40473cbb8aa323aa9dbf99_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yMi9mcmFnOjYxMTdlMmQxMDAwYTQyNjRiZDM4ODA2OTRlY2IwNzJmL3RhYmxlOmYyNGY0YzM1ZjI4MDRjZWI4YWEwOTkxYjFlM2E3YWNmL3RhYmxlcmFuZ2U6ZjI0ZjRjMzVmMjgwNGNlYjhhYTA5OTFiMWUzYTdhY2ZfOC04LTEtMS00Njg5MQ_f12590cb-e3ea-41d1-b00b-6511b41461b2">1,618</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7607dc50eb3d4d29b612005eb9d96af6_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yMi9mcmFnOjYxMTdlMmQxMDAwYTQyNjRiZDM4ODA2OTRlY2IwNzJmL3RhYmxlOmYyNGY0YzM1ZjI4MDRjZWI4YWEwOTkxYjFlM2E3YWNmL3RhYmxlcmFuZ2U6ZjI0ZjRjMzVmMjgwNGNlYjhhYTA5OTFiMWUzYTdhY2ZfOC0xMC0xLTEtNDY4OTE_4b576531-aae3-4580-836a-64da13ba8d67">793,752</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7882ae6aff54a3aacdef67ddf11a428_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yMi9mcmFnOjYxMTdlMmQxMDAwYTQyNjRiZDM4ODA2OTRlY2IwNzJmL3RhYmxlOmYyNGY0YzM1ZjI4MDRjZWI4YWEwOTkxYjFlM2E3YWNmL3RhYmxlcmFuZ2U6ZjI0ZjRjMzVmMjgwNGNlYjhhYTA5OTFiMWUzYTdhY2ZfOC0xMi0xLTEtNDY4OTE_2b0c817c-0b14-441c-bd71-467d9f8bd8f8">448,123</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Common Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Additional<br/>paid in<br/>capital</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>(Loss) Income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total<br/>Shareholders'<br/>Equity</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i83ebb56fc7614da58997add4fc4d898e_I20201231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yMi9mcmFnOjYxMTdlMmQxMDAwYTQyNjRiZDM4ODA2OTRlY2IwNzJmL3RhYmxlOmYyNGY0YzM1ZjI4MDRjZWI4YWEwOTkxYjFlM2E3YWNmL3RhYmxlcmFuZ2U6ZjI0ZjRjMzVmMjgwNGNlYjhhYTA5OTFiMWUzYTdhY2ZfMTItMi0xLTEtNDY4OTE_d9002037-d7f0-4e61-88dc-28a0a7421e29">126,725</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83ebb56fc7614da58997add4fc4d898e_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yMi9mcmFnOjYxMTdlMmQxMDAwYTQyNjRiZDM4ODA2OTRlY2IwNzJmL3RhYmxlOmYyNGY0YzM1ZjI4MDRjZWI4YWEwOTkxYjFlM2E3YWNmL3RhYmxlcmFuZ2U6ZjI0ZjRjMzVmMjgwNGNlYjhhYTA5OTFiMWUzYTdhY2ZfMTItNC0xLTEtNDY4OTE_ca19b015-759b-45e8-b1f1-af1a5c095072">944,328</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52d7b06be2c943d9943aab7a9199636b_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yMi9mcmFnOjYxMTdlMmQxMDAwYTQyNjRiZDM4ODA2OTRlY2IwNzJmL3RhYmxlOmYyNGY0YzM1ZjI4MDRjZWI4YWEwOTkxYjFlM2E3YWNmL3RhYmxlcmFuZ2U6ZjI0ZjRjMzVmMjgwNGNlYjhhYTA5OTFiMWUzYTdhY2ZfMTItNi0xLTEtNDY4OTE_a2526309-ff28-4fda-9678-b94304b455c5">39,383</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icd1c1d725ea74622ad8c60cbfb9c0470_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yMi9mcmFnOjYxMTdlMmQxMDAwYTQyNjRiZDM4ODA2OTRlY2IwNzJmL3RhYmxlOmYyNGY0YzM1ZjI4MDRjZWI4YWEwOTkxYjFlM2E3YWNmL3RhYmxlcmFuZ2U6ZjI0ZjRjMzVmMjgwNGNlYjhhYTA5OTFiMWUzYTdhY2ZfMTItOC0xLTEtNDY4OTE_90e91ca5-ba58-4e7b-a04e-f4c21dc1d422">805</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i14fc3af75b3846e58ef3a457eee1c040_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yMi9mcmFnOjYxMTdlMmQxMDAwYTQyNjRiZDM4ODA2OTRlY2IwNzJmL3RhYmxlOmYyNGY0YzM1ZjI4MDRjZWI4YWEwOTkxYjFlM2E3YWNmL3RhYmxlcmFuZ2U6ZjI0ZjRjMzVmMjgwNGNlYjhhYTA5OTFiMWUzYTdhY2ZfMTItMTAtMS0xLTQ2ODkx_bdd1cbf7-992f-477d-babe-ae55d4590a95">575,156</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52aa203b7e954d69b001129473620362_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yMi9mcmFnOjYxMTdlMmQxMDAwYTQyNjRiZDM4ODA2OTRlY2IwNzJmL3RhYmxlOmYyNGY0YzM1ZjI4MDRjZWI4YWEwOTkxYjFlM2E3YWNmL3RhYmxlcmFuZ2U6ZjI0ZjRjMzVmMjgwNGNlYjhhYTA5OTFiMWUzYTdhY2ZfMTItMTItMS0xLTQ2ODkx_01cbfeaa-a733-4e41-b07b-469735a50fcc">407,750</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares issued on exercise of stock options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id2b8ec5b433843479fee7e7d7ae9434b_D20210101-20210331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yMi9mcmFnOjYxMTdlMmQxMDAwYTQyNjRiZDM4ODA2OTRlY2IwNzJmL3RhYmxlOmYyNGY0YzM1ZjI4MDRjZWI4YWEwOTkxYjFlM2E3YWNmL3RhYmxlcmFuZ2U6ZjI0ZjRjMzVmMjgwNGNlYjhhYTA5OTFiMWUzYTdhY2ZfMTMtMi0xLTEtNDY4OTE_106b2396-3b9c-45e6-87f4-6b51c2da6d57">877</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2b8ec5b433843479fee7e7d7ae9434b_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yMi9mcmFnOjYxMTdlMmQxMDAwYTQyNjRiZDM4ODA2OTRlY2IwNzJmL3RhYmxlOmYyNGY0YzM1ZjI4MDRjZWI4YWEwOTkxYjFlM2E3YWNmL3RhYmxlcmFuZ2U6ZjI0ZjRjMzVmMjgwNGNlYjhhYTA5OTFiMWUzYTdhY2ZfMTMtNC0xLTEtNDY4OTE_afc2d889-c02d-42b9-9da6-f63e8ae25155">7,619</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i980c28f6b4b34116a0110c4e8f58bea5_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yMi9mcmFnOjYxMTdlMmQxMDAwYTQyNjRiZDM4ODA2OTRlY2IwNzJmL3RhYmxlOmYyNGY0YzM1ZjI4MDRjZWI4YWEwOTkxYjFlM2E3YWNmL3RhYmxlcmFuZ2U6ZjI0ZjRjMzVmMjgwNGNlYjhhYTA5OTFiMWUzYTdhY2ZfMTMtNi0xLTEtNDY4OTE_222cbe33-5615-4eec-bf4c-344fe79732d9">2,620</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56599386fa47443a8975bb3f7a6a8c57_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yMi9mcmFnOjYxMTdlMmQxMDAwYTQyNjRiZDM4ODA2OTRlY2IwNzJmL3RhYmxlOmYyNGY0YzM1ZjI4MDRjZWI4YWEwOTkxYjFlM2E3YWNmL3RhYmxlcmFuZ2U6ZjI0ZjRjMzVmMjgwNGNlYjhhYTA5OTFiMWUzYTdhY2ZfMTMtMTItMS0xLTQ2ODkx_e51bf58e-5034-49ef-96f4-a5171ecf9795">4,999</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercise of warrants</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id2b8ec5b433843479fee7e7d7ae9434b_D20210101-20210331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yMi9mcmFnOjYxMTdlMmQxMDAwYTQyNjRiZDM4ODA2OTRlY2IwNzJmL3RhYmxlOmYyNGY0YzM1ZjI4MDRjZWI4YWEwOTkxYjFlM2E3YWNmL3RhYmxlcmFuZ2U6ZjI0ZjRjMzVmMjgwNGNlYjhhYTA5OTFiMWUzYTdhY2ZfMTQtMi0xLTEtNDY4OTE_18895764-6130-409b-8fb4-80a0824ff7cc">519</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2b8ec5b433843479fee7e7d7ae9434b_D20210101-20210331" decimals="-3" name="us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yMi9mcmFnOjYxMTdlMmQxMDAwYTQyNjRiZDM4ODA2OTRlY2IwNzJmL3RhYmxlOmYyNGY0YzM1ZjI4MDRjZWI4YWEwOTkxYjFlM2E3YWNmL3RhYmxlcmFuZ2U6ZjI0ZjRjMzVmMjgwNGNlYjhhYTA5OTFiMWUzYTdhY2ZfMTQtNC0xLTEtNDY4OTE_f7aca47c-edd7-41ca-b18f-fca5605178c8">726</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i980c28f6b4b34116a0110c4e8f58bea5_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yMi9mcmFnOjYxMTdlMmQxMDAwYTQyNjRiZDM4ODA2OTRlY2IwNzJmL3RhYmxlOmYyNGY0YzM1ZjI4MDRjZWI4YWEwOTkxYjFlM2E3YWNmL3RhYmxlcmFuZ2U6ZjI0ZjRjMzVmMjgwNGNlYjhhYTA5OTFiMWUzYTdhY2ZfMTQtNi0xLTEtNDY4OTE_6094795b-fae5-4e7b-9100-add4eb5a3442">695</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56599386fa47443a8975bb3f7a6a8c57_D20210101-20210331" decimals="-3" name="us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yMi9mcmFnOjYxMTdlMmQxMDAwYTQyNjRiZDM4ODA2OTRlY2IwNzJmL3RhYmxlOmYyNGY0YzM1ZjI4MDRjZWI4YWEwOTkxYjFlM2E3YWNmL3RhYmxlcmFuZ2U6ZjI0ZjRjMzVmMjgwNGNlYjhhYTA5OTFiMWUzYTdhY2ZfMTQtMTItMS0xLTQ2ODkx_5899b5d5-2eff-4632-beb2-fa88caf81838">31</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shared-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i980c28f6b4b34116a0110c4e8f58bea5_D20210101-20210331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yMi9mcmFnOjYxMTdlMmQxMDAwYTQyNjRiZDM4ODA2OTRlY2IwNzJmL3RhYmxlOmYyNGY0YzM1ZjI4MDRjZWI4YWEwOTkxYjFlM2E3YWNmL3RhYmxlcmFuZ2U6ZjI0ZjRjMzVmMjgwNGNlYjhhYTA5OTFiMWUzYTdhY2ZfMTUtNi0xLTEtNDY4OTE_dfc95d69-e0bf-4d07-9106-b194acf646f9">7,821</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56599386fa47443a8975bb3f7a6a8c57_D20210101-20210331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yMi9mcmFnOjYxMTdlMmQxMDAwYTQyNjRiZDM4ODA2OTRlY2IwNzJmL3RhYmxlOmYyNGY0YzM1ZjI4MDRjZWI4YWEwOTkxYjFlM2E3YWNmL3RhYmxlcmFuZ2U6ZjI0ZjRjMzVmMjgwNGNlYjhhYTA5OTFiMWUzYTdhY2ZfMTUtMTItMS0xLTQ2ODkx_4e892362-8e66-4946-930c-a1a24d0050de">7,821</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gain on available-for-sale securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf2709893482407e9aa1a24504869283_D20210101-20210331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yMi9mcmFnOjYxMTdlMmQxMDAwYTQyNjRiZDM4ODA2OTRlY2IwNzJmL3RhYmxlOmYyNGY0YzM1ZjI4MDRjZWI4YWEwOTkxYjFlM2E3YWNmL3RhYmxlcmFuZ2U6ZjI0ZjRjMzVmMjgwNGNlYjhhYTA5OTFiMWUzYTdhY2ZfMTYtOC0xLTEtNDY4OTE_58c9d5f4-da81-4697-9fb3-8859a80023df">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56599386fa47443a8975bb3f7a6a8c57_D20210101-20210331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yMi9mcmFnOjYxMTdlMmQxMDAwYTQyNjRiZDM4ODA2OTRlY2IwNzJmL3RhYmxlOmYyNGY0YzM1ZjI4MDRjZWI4YWEwOTkxYjFlM2E3YWNmL3RhYmxlcmFuZ2U6ZjI0ZjRjMzVmMjgwNGNlYjhhYTA5OTFiMWUzYTdhY2ZfMTYtMTItMS0xLTQ2ODkx_552698c4-eaad-495d-8a36-1992951b8d43">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if37f87c2e8144a4ea775f7bcf996abdb_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yMi9mcmFnOjYxMTdlMmQxMDAwYTQyNjRiZDM4ODA2OTRlY2IwNzJmL3RhYmxlOmYyNGY0YzM1ZjI4MDRjZWI4YWEwOTkxYjFlM2E3YWNmL3RhYmxlcmFuZ2U6ZjI0ZjRjMzVmMjgwNGNlYjhhYTA5OTFiMWUzYTdhY2ZfMTctMTAtMS0xLTQ2ODkx_d3ee49b8-5d8e-4d60-bfcb-cae6eb334117">50,379</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i56599386fa47443a8975bb3f7a6a8c57_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yMi9mcmFnOjYxMTdlMmQxMDAwYTQyNjRiZDM4ODA2OTRlY2IwNzJmL3RhYmxlOmYyNGY0YzM1ZjI4MDRjZWI4YWEwOTkxYjFlM2E3YWNmL3RhYmxlcmFuZ2U6ZjI0ZjRjMzVmMjgwNGNlYjhhYTA5OTFiMWUzYTdhY2ZfMTctMTItMS0xLTQ2ODkx_e9ed88ec-956e-4f0c-b55f-e35942cba274">50,379</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at March 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ida3e66f3cb8a46fd8e7d2fa464feee4b_I20210331" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yMi9mcmFnOjYxMTdlMmQxMDAwYTQyNjRiZDM4ODA2OTRlY2IwNzJmL3RhYmxlOmYyNGY0YzM1ZjI4MDRjZWI4YWEwOTkxYjFlM2E3YWNmL3RhYmxlcmFuZ2U6ZjI0ZjRjMzVmMjgwNGNlYjhhYTA5OTFiMWUzYTdhY2ZfMTgtMi0xLTEtNDY4OTE_2d7f5bd6-8215-478a-af9a-11d53161c867">128,121</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida3e66f3cb8a46fd8e7d2fa464feee4b_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yMi9mcmFnOjYxMTdlMmQxMDAwYTQyNjRiZDM4ODA2OTRlY2IwNzJmL3RhYmxlOmYyNGY0YzM1ZjI4MDRjZWI4YWEwOTkxYjFlM2E3YWNmL3RhYmxlcmFuZ2U6ZjI0ZjRjMzVmMjgwNGNlYjhhYTA5OTFiMWUzYTdhY2ZfMTgtNC0xLTEtNDY4OTE_172eff61-cb29-46d6-bb41-48ddf3087aac">952,673</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icee959888619433fa3bbb75703c9942a_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yMi9mcmFnOjYxMTdlMmQxMDAwYTQyNjRiZDM4ODA2OTRlY2IwNzJmL3RhYmxlOmYyNGY0YzM1ZjI4MDRjZWI4YWEwOTkxYjFlM2E3YWNmL3RhYmxlcmFuZ2U6ZjI0ZjRjMzVmMjgwNGNlYjhhYTA5OTFiMWUzYTdhY2ZfMTgtNi0xLTEtNDY4OTE_f2b94762-61b6-4a0e-bd32-0a64b84be78b">43,889</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic279a1a852fa4d1c8cfc697be1c04112_I20210331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yMi9mcmFnOjYxMTdlMmQxMDAwYTQyNjRiZDM4ODA2OTRlY2IwNzJmL3RhYmxlOmYyNGY0YzM1ZjI4MDRjZWI4YWEwOTkxYjFlM2E3YWNmL3RhYmxlcmFuZ2U6ZjI0ZjRjMzVmMjgwNGNlYjhhYTA5OTFiMWUzYTdhY2ZfMTgtOC0xLTEtNDY4OTE_f60a28c6-b5c9-47d8-8530-c250a86d4693">799</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0bdfb000085746f589116096f0a92b19_I20210331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yMi9mcmFnOjYxMTdlMmQxMDAwYTQyNjRiZDM4ODA2OTRlY2IwNzJmL3RhYmxlOmYyNGY0YzM1ZjI4MDRjZWI4YWEwOTkxYjFlM2E3YWNmL3RhYmxlcmFuZ2U6ZjI0ZjRjMzVmMjgwNGNlYjhhYTA5OTFiMWUzYTdhY2ZfMTgtMTAtMS0xLTQ2ODkx_2888690c-d357-42cc-8fe3-899559df6a67">625,535</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0260d11b47b2403fbf3efe386b4d6b0f_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yMi9mcmFnOjYxMTdlMmQxMDAwYTQyNjRiZDM4ODA2OTRlY2IwNzJmL3RhYmxlOmYyNGY0YzM1ZjI4MDRjZWI4YWEwOTkxYjFlM2E3YWNmL3RhYmxlcmFuZ2U6ZjI0ZjRjMzVmMjgwNGNlYjhhYTA5OTFiMWUzYTdhY2ZfMTgtMTItMS0xLTQ2ODkx_8824b434-2ec7-4b8b-a375-2611849d28cb">370,228</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:7pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="i2d3a8f7e52e84dcebfa935bec5ca9eb6_25"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">AURINIA PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.523%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yNS9mcmFnOmZjZmRhMmQ4NmM2NTRiNjA5OTNkM2UxN2YzN2I0ZWE1L3RhYmxlOjlkMWYxMzljZjdjMzRiOGI5YzY3ODFmNWVmY2NhYmJjL3RhYmxlcmFuZ2U6OWQxZjEzOWNmN2MzNGI4YjljNjc4MWY1ZWZjY2FiYmNfNS0yLTEtMS00Njg5MQ_2c29e920-4e2a-4c45-a9eb-e8e17930730c">37,630</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i56599386fa47443a8975bb3f7a6a8c57_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yNS9mcmFnOmZjZmRhMmQ4NmM2NTRiNjA5OTNkM2UxN2YzN2I0ZWE1L3RhYmxlOjlkMWYxMzljZjdjMzRiOGI5YzY3ODFmNWVmY2NhYmJjL3RhYmxlcmFuZ2U6OWQxZjEzOWNmN2MzNGI4YjljNjc4MWY1ZWZjY2FiYmNfNS00LTEtMS00Njg5MQ_77ddcc9d-0356-442b-9b57-5c72891a16c8">50,379</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331" decimals="-3" name="us-gaap:Depreciation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yNS9mcmFnOmZjZmRhMmQ4NmM2NTRiNjA5OTNkM2UxN2YzN2I0ZWE1L3RhYmxlOjlkMWYxMzljZjdjMzRiOGI5YzY3ODFmNWVmY2NhYmJjL3RhYmxlcmFuZ2U6OWQxZjEzOWNmN2MzNGI4YjljNjc4MWY1ZWZjY2FiYmNfNy0yLTEtMS00Njg5MQ_221d84ea-7c0e-4638-a5fd-e5bcfbc6862d">687</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56599386fa47443a8975bb3f7a6a8c57_D20210101-20210331" decimals="-3" name="us-gaap:Depreciation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yNS9mcmFnOmZjZmRhMmQ4NmM2NTRiNjA5OTNkM2UxN2YzN2I0ZWE1L3RhYmxlOjlkMWYxMzljZjdjMzRiOGI5YzY3ODFmNWVmY2NhYmJjL3RhYmxlcmFuZ2U6OWQxZjEzOWNmN2MzNGI4YjljNjc4MWY1ZWZjY2FiYmNfNy00LTEtMS00Njg5MQ_59d77926-760c-4d7e-adce-b7f092bace8c">688</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of operating lease right-of-use assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yNS9mcmFnOmZjZmRhMmQ4NmM2NTRiNjA5OTNkM2UxN2YzN2I0ZWE1L3RhYmxlOjlkMWYxMzljZjdjMzRiOGI5YzY3ODFmNWVmY2NhYmJjL3RhYmxlcmFuZ2U6OWQxZjEzOWNmN2MzNGI4YjljNjc4MWY1ZWZjY2FiYmNfOC0yLTEtMS00Njg5MQ_444ac5e0-0255-4eba-9093-c01b6222186a">151</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i56599386fa47443a8975bb3f7a6a8c57_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yNS9mcmFnOmZjZmRhMmQ4NmM2NTRiNjA5OTNkM2UxN2YzN2I0ZWE1L3RhYmxlOjlkMWYxMzljZjdjMzRiOGI5YzY3ODFmNWVmY2NhYmJjL3RhYmxlcmFuZ2U6OWQxZjEzOWNmN2MzNGI4YjljNjc4MWY1ZWZjY2FiYmNfOC00LTEtMS00Njg5MQ_56658e62-b3f6-4b39-926e-e66d13185c2f">272</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yNS9mcmFnOmZjZmRhMmQ4NmM2NTRiNjA5OTNkM2UxN2YzN2I0ZWE1L3RhYmxlOjlkMWYxMzljZjdjMzRiOGI5YzY3ODFmNWVmY2NhYmJjL3RhYmxlcmFuZ2U6OWQxZjEzOWNmN2MzNGI4YjljNjc4MWY1ZWZjY2FiYmNfMTAtMi0xLTEtNDY4OTE_550a4c95-9cac-4388-89e3-81da6cd43d33">7,023</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56599386fa47443a8975bb3f7a6a8c57_D20210101-20210331" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yNS9mcmFnOmZjZmRhMmQ4NmM2NTRiNjA5OTNkM2UxN2YzN2I0ZWE1L3RhYmxlOjlkMWYxMzljZjdjMzRiOGI5YzY3ODFmNWVmY2NhYmJjL3RhYmxlcmFuZ2U6OWQxZjEzOWNmN2MzNGI4YjljNjc4MWY1ZWZjY2FiYmNfMTAtNC0xLTEtNDY4OTE_972a4c5a-7582-4298-b6e1-9560ac5e64b8">7,821</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherNoncashIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yNS9mcmFnOmZjZmRhMmQ4NmM2NTRiNjA5OTNkM2UxN2YzN2I0ZWE1L3RhYmxlOjlkMWYxMzljZjdjMzRiOGI5YzY3ODFmNWVmY2NhYmJjL3RhYmxlcmFuZ2U6OWQxZjEzOWNmN2MzNGI4YjljNjc4MWY1ZWZjY2FiYmNfMTEtMi0xLTEtNDY4OTE_55961320-4f81-495c-8c03-fc5dab3e8d37">1,514</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i56599386fa47443a8975bb3f7a6a8c57_D20210101-20210331" decimals="-3" name="us-gaap:OtherNoncashIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yNS9mcmFnOmZjZmRhMmQ4NmM2NTRiNjA5OTNkM2UxN2YzN2I0ZWE1L3RhYmxlOjlkMWYxMzljZjdjMzRiOGI5YzY3ODFmNWVmY2NhYmJjL3RhYmxlcmFuZ2U6OWQxZjEzOWNmN2MzNGI4YjljNjc4MWY1ZWZjY2FiYmNfMTEtNC0xLTEtNDY4OTE_e9f55c72-7fbf-4e41-8d81-8e4b6ff52271">2,111</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net changes in operating assets and liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 43pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331" decimals="-3" name="us-gaap:IncreaseDecreaseInReceivables" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yNS9mcmFnOmZjZmRhMmQ4NmM2NTRiNjA5OTNkM2UxN2YzN2I0ZWE1L3RhYmxlOjlkMWYxMzljZjdjMzRiOGI5YzY3ODFmNWVmY2NhYmJjL3RhYmxlcmFuZ2U6OWQxZjEzOWNmN2MzNGI4YjljNjc4MWY1ZWZjY2FiYmNfMTMtMi0xLTEtNDY4OTE_4d7f9b71-d7bc-4aa5-a29f-b5c728b9666c">4,986</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i56599386fa47443a8975bb3f7a6a8c57_D20210101-20210331" decimals="-3" name="us-gaap:IncreaseDecreaseInReceivables" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yNS9mcmFnOmZjZmRhMmQ4NmM2NTRiNjA5OTNkM2UxN2YzN2I0ZWE1L3RhYmxlOjlkMWYxMzljZjdjMzRiOGI5YzY3ODFmNWVmY2NhYmJjL3RhYmxlcmFuZ2U6OWQxZjEzOWNmN2MzNGI4YjljNjc4MWY1ZWZjY2FiYmNfMTMtNC0xLTEtNDY4OTE_3446d8a4-ab91-4775-b352-a450a56e47ff">1,187</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 43pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yNS9mcmFnOmZjZmRhMmQ4NmM2NTRiNjA5OTNkM2UxN2YzN2I0ZWE1L3RhYmxlOjlkMWYxMzljZjdjMzRiOGI5YzY3ODFmNWVmY2NhYmJjL3RhYmxlcmFuZ2U6OWQxZjEzOWNmN2MzNGI4YjljNjc4MWY1ZWZjY2FiYmNfMTQtMi0xLTEtNDY4OTE_8c2545a1-86d8-447f-a5e4-a91aec70041d">6,940</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i56599386fa47443a8975bb3f7a6a8c57_D20210101-20210331" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yNS9mcmFnOmZjZmRhMmQ4NmM2NTRiNjA5OTNkM2UxN2YzN2I0ZWE1L3RhYmxlOjlkMWYxMzljZjdjMzRiOGI5YzY3ODFmNWVmY2NhYmJjL3RhYmxlcmFuZ2U6OWQxZjEzOWNmN2MzNGI4YjljNjc4MWY1ZWZjY2FiYmNfMTQtNC0xLTEtNDY4OTE_bcbdcb84-e9a2-4883-8b89-75a4e10afc1a">2,009</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 43pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yNS9mcmFnOmZjZmRhMmQ4NmM2NTRiNjA5OTNkM2UxN2YzN2I0ZWE1L3RhYmxlOjlkMWYxMzljZjdjMzRiOGI5YzY3ODFmNWVmY2NhYmJjL3RhYmxlcmFuZ2U6OWQxZjEzOWNmN2MzNGI4YjljNjc4MWY1ZWZjY2FiYmNfMTUtMi0xLTEtNDY4OTE_8ba3b8c8-9d55-4396-999c-61acd7688322">307</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56599386fa47443a8975bb3f7a6a8c57_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yNS9mcmFnOmZjZmRhMmQ4NmM2NTRiNjA5OTNkM2UxN2YzN2I0ZWE1L3RhYmxlOjlkMWYxMzljZjdjMzRiOGI5YzY3ODFmNWVmY2NhYmJjL3RhYmxlcmFuZ2U6OWQxZjEzOWNmN2MzNGI4YjljNjc4MWY1ZWZjY2FiYmNfMTUtNC0xLTEtNDY4OTE_1a9f1bc0-1cf0-435b-bd83-2f0aa19dc2f4">308</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 52.75pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yNS9mcmFnOmZjZmRhMmQ4NmM2NTRiNjA5OTNkM2UxN2YzN2I0ZWE1L3RhYmxlOjlkMWYxMzljZjdjMzRiOGI5YzY3ODFmNWVmY2NhYmJjL3RhYmxlcmFuZ2U6OWQxZjEzOWNmN2MzNGI4YjljNjc4MWY1ZWZjY2FiYmNfMTYtMi0xLTEtNDY4OTE_239b7a88-c57b-4c37-956d-a1ad4dac3438">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56599386fa47443a8975bb3f7a6a8c57_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yNS9mcmFnOmZjZmRhMmQ4NmM2NTRiNjA5OTNkM2UxN2YzN2I0ZWE1L3RhYmxlOjlkMWYxMzljZjdjMzRiOGI5YzY3ODFmNWVmY2NhYmJjL3RhYmxlcmFuZ2U6OWQxZjEzOWNmN2MzNGI4YjljNjc4MWY1ZWZjY2FiYmNfMTYtNC0xLTEtNDY4OTE_332da4be-0002-48d0-a0e2-be18c8e0462a">229</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 43pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable, accrued and other liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yNS9mcmFnOmZjZmRhMmQ4NmM2NTRiNjA5OTNkM2UxN2YzN2I0ZWE1L3RhYmxlOjlkMWYxMzljZjdjMzRiOGI5YzY3ODFmNWVmY2NhYmJjL3RhYmxlcmFuZ2U6OWQxZjEzOWNmN2MzNGI4YjljNjc4MWY1ZWZjY2FiYmNfMTgtMi0xLTEtNDY4OTE_0ccd2e30-c093-4d82-a476-7e8311dbd800">6,704</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i56599386fa47443a8975bb3f7a6a8c57_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yNS9mcmFnOmZjZmRhMmQ4NmM2NTRiNjA5OTNkM2UxN2YzN2I0ZWE1L3RhYmxlOjlkMWYxMzljZjdjMzRiOGI5YzY3ODFmNWVmY2NhYmJjL3RhYmxlcmFuZ2U6OWQxZjEzOWNmN2MzNGI4YjljNjc4MWY1ZWZjY2FiYmNfMTgtNC0xLTEtNDY4OTE_502aa765-4da8-4937-9bfd-54da3c377982">7,103</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 43pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yNS9mcmFnOmZjZmRhMmQ4NmM2NTRiNjA5OTNkM2UxN2YzN2I0ZWE1L3RhYmxlOjlkMWYxMzljZjdjMzRiOGI5YzY3ODFmNWVmY2NhYmJjL3RhYmxlcmFuZ2U6OWQxZjEzOWNmN2MzNGI4YjljNjc4MWY1ZWZjY2FiYmNfMTktMi0xLTEtNDY4OTE_a303a984-9070-459d-93d6-e27f9aaf088d">168</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56599386fa47443a8975bb3f7a6a8c57_D20210101-20210331" decimals="-3" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yNS9mcmFnOmZjZmRhMmQ4NmM2NTRiNjA5OTNkM2UxN2YzN2I0ZWE1L3RhYmxlOjlkMWYxMzljZjdjMzRiOGI5YzY3ODFmNWVmY2NhYmJjL3RhYmxlcmFuZ2U6OWQxZjEzOWNmN2MzNGI4YjljNjc4MWY1ZWZjY2FiYmNfMTktNC0xLTEtNDY4OTE_929d7042-77d7-48d2-98e5-c834352a096c">474</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in operating activities </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yNS9mcmFnOmZjZmRhMmQ4NmM2NTRiNjA5OTNkM2UxN2YzN2I0ZWE1L3RhYmxlOjlkMWYxMzljZjdjMzRiOGI5YzY3ODFmNWVmY2NhYmJjL3RhYmxlcmFuZ2U6OWQxZjEzOWNmN2MzNGI4YjljNjc4MWY1ZWZjY2FiYmNfMjAtMi0xLTEtNDY4OTE_0e1bff7f-9673-45b4-bc18-6817cc4a2f84">46,746</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i56599386fa47443a8975bb3f7a6a8c57_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yNS9mcmFnOmZjZmRhMmQ4NmM2NTRiNjA5OTNkM2UxN2YzN2I0ZWE1L3RhYmxlOjlkMWYxMzljZjdjMzRiOGI5YzY3ODFmNWVmY2NhYmJjL3RhYmxlcmFuZ2U6OWQxZjEzOWNmN2MzNGI4YjljNjc4MWY1ZWZjY2FiYmNfMjAtNC0xLTEtNDY4OTE_afd3f199-588a-4587-8b7b-828ddfbf859d">53,541</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows used in investing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchase of investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331" decimals="-3" name="us-gaap:PaymentsToAcquireMarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yNS9mcmFnOmZjZmRhMmQ4NmM2NTRiNjA5OTNkM2UxN2YzN2I0ZWE1L3RhYmxlOjlkMWYxMzljZjdjMzRiOGI5YzY3ODFmNWVmY2NhYmJjL3RhYmxlcmFuZ2U6OWQxZjEzOWNmN2MzNGI4YjljNjc4MWY1ZWZjY2FiYmNfMjItMi0xLTEtNDY4OTE_72962182-0dc3-458d-8846-013b8fa15cc7">163,504</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i56599386fa47443a8975bb3f7a6a8c57_D20210101-20210331" decimals="-3" name="us-gaap:PaymentsToAcquireMarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yNS9mcmFnOmZjZmRhMmQ4NmM2NTRiNjA5OTNkM2UxN2YzN2I0ZWE1L3RhYmxlOjlkMWYxMzljZjdjMzRiOGI5YzY3ODFmNWVmY2NhYmJjL3RhYmxlcmFuZ2U6OWQxZjEzOWNmN2MzNGI4YjljNjc4MWY1ZWZjY2FiYmNfMjItNC0xLTEtNDY4OTE_ba226cef-56b3-483b-8e3c-a0e276976734">115,168</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yNS9mcmFnOmZjZmRhMmQ4NmM2NTRiNjA5OTNkM2UxN2YzN2I0ZWE1L3RhYmxlOjlkMWYxMzljZjdjMzRiOGI5YzY3ODFmNWVmY2NhYmJjL3RhYmxlcmFuZ2U6OWQxZjEzOWNmN2MzNGI4YjljNjc4MWY1ZWZjY2FiYmNfMjMtMi0xLTEtNDY4OTE_67478d3a-fc9f-49db-af00-5efa90c82116">110,566</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56599386fa47443a8975bb3f7a6a8c57_D20210101-20210331" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yNS9mcmFnOmZjZmRhMmQ4NmM2NTRiNjA5OTNkM2UxN2YzN2I0ZWE1L3RhYmxlOjlkMWYxMzljZjdjMzRiOGI5YzY3ODFmNWVmY2NhYmJjL3RhYmxlcmFuZ2U6OWQxZjEzOWNmN2MzNGI4YjljNjc4MWY1ZWZjY2FiYmNfMjMtNC0xLTEtNDY4OTE_dba1f52e-af0a-40ca-a01f-28943124420c">60,940</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 33.25pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Upfront lease payment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331" decimals="-3" name="us-gaap:PaymentsToAcquireLeaseReceivables" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yNS9mcmFnOmZjZmRhMmQ4NmM2NTRiNjA5OTNkM2UxN2YzN2I0ZWE1L3RhYmxlOjlkMWYxMzljZjdjMzRiOGI5YzY3ODFmNWVmY2NhYmJjL3RhYmxlcmFuZ2U6OWQxZjEzOWNmN2MzNGI4YjljNjc4MWY1ZWZjY2FiYmNfMjQtMi0xLTEtNDY4OTE_1584a79c-b214-4a1d-9493-3dd5680d4dfa">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i56599386fa47443a8975bb3f7a6a8c57_D20210101-20210331" decimals="-3" name="us-gaap:PaymentsToAcquireLeaseReceivables" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yNS9mcmFnOmZjZmRhMmQ4NmM2NTRiNjA5OTNkM2UxN2YzN2I0ZWE1L3RhYmxlOjlkMWYxMzljZjdjMzRiOGI5YzY3ODFmNWVmY2NhYmJjL3RhYmxlcmFuZ2U6OWQxZjEzOWNmN2MzNGI4YjljNjc4MWY1ZWZjY2FiYmNfMjQtNC0xLTEtNDY4OTE_68c594ed-41b8-4b7c-9915-36f10ddd967d">11,838</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 33.25pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchase of long-lived assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331" decimals="-3" name="us-gaap:PaymentsToAcquireOtherProductiveAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yNS9mcmFnOmZjZmRhMmQ4NmM2NTRiNjA5OTNkM2UxN2YzN2I0ZWE1L3RhYmxlOjlkMWYxMzljZjdjMzRiOGI5YzY3ODFmNWVmY2NhYmJjL3RhYmxlcmFuZ2U6OWQxZjEzOWNmN2MzNGI4YjljNjc4MWY1ZWZjY2FiYmNfMjYtMi0xLTEtNDY4OTE_ded4ce73-9912-49e6-81ef-3d8a572f469c">79</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i56599386fa47443a8975bb3f7a6a8c57_D20210101-20210331" decimals="-3" name="us-gaap:PaymentsToAcquireOtherProductiveAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yNS9mcmFnOmZjZmRhMmQ4NmM2NTRiNjA5OTNkM2UxN2YzN2I0ZWE1L3RhYmxlOjlkMWYxMzljZjdjMzRiOGI5YzY3ODFmNWVmY2NhYmJjL3RhYmxlcmFuZ2U6OWQxZjEzOWNmN2MzNGI4YjljNjc4MWY1ZWZjY2FiYmNfMjYtNC0xLTEtNDY4OTE_93ef979a-3589-434f-9932-e1e921b0c17e">136</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions to internal use-software implementation costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331" decimals="-3" name="us-gaap:PaymentsForSoftware" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yNS9mcmFnOmZjZmRhMmQ4NmM2NTRiNjA5OTNkM2UxN2YzN2I0ZWE1L3RhYmxlOjlkMWYxMzljZjdjMzRiOGI5YzY3ODFmNWVmY2NhYmJjL3RhYmxlcmFuZ2U6OWQxZjEzOWNmN2MzNGI4YjljNjc4MWY1ZWZjY2FiYmNfMjctMi0xLTEtNDY4OTE_582ac4b1-d8ac-4851-8c6a-c001f0cb9543">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i56599386fa47443a8975bb3f7a6a8c57_D20210101-20210331" decimals="-3" name="us-gaap:PaymentsForSoftware" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yNS9mcmFnOmZjZmRhMmQ4NmM2NTRiNjA5OTNkM2UxN2YzN2I0ZWE1L3RhYmxlOjlkMWYxMzljZjdjMzRiOGI5YzY3ODFmNWVmY2NhYmJjL3RhYmxlcmFuZ2U6OWQxZjEzOWNmN2MzNGI4YjljNjc4MWY1ZWZjY2FiYmNfMjctNC0xLTEtNDY4OTE_06d86959-7feb-476f-9028-4a43aaabf33c">1,039</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized patent costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331" decimals="-3" name="us-gaap:PaymentsToAcquireIntangibleAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yNS9mcmFnOmZjZmRhMmQ4NmM2NTRiNjA5OTNkM2UxN2YzN2I0ZWE1L3RhYmxlOjlkMWYxMzljZjdjMzRiOGI5YzY3ODFmNWVmY2NhYmJjL3RhYmxlcmFuZ2U6OWQxZjEzOWNmN2MzNGI4YjljNjc4MWY1ZWZjY2FiYmNfMjgtMi0xLTEtNDY4OTE_47a237b6-ee31-4048-afeb-4436f61b53ee">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i56599386fa47443a8975bb3f7a6a8c57_D20210101-20210331" decimals="-3" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yNS9mcmFnOmZjZmRhMmQ4NmM2NTRiNjA5OTNkM2UxN2YzN2I0ZWE1L3RhYmxlOjlkMWYxMzljZjdjMzRiOGI5YzY3ODFmNWVmY2NhYmJjL3RhYmxlcmFuZ2U6OWQxZjEzOWNmN2MzNGI4YjljNjc4MWY1ZWZjY2FiYmNfMjgtNC0xLTEtNDY4OTE_9b28044a-3c48-442e-bbee-454ef9903b61">6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in investing activities </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yNS9mcmFnOmZjZmRhMmQ4NmM2NTRiNjA5OTNkM2UxN2YzN2I0ZWE1L3RhYmxlOjlkMWYxMzljZjdjMzRiOGI5YzY3ODFmNWVmY2NhYmJjL3RhYmxlcmFuZ2U6OWQxZjEzOWNmN2MzNGI4YjljNjc4MWY1ZWZjY2FiYmNfMjktMi0xLTEtNDY4OTE_e09acc9a-6ddd-4ce1-8fc3-be376a06624e">53,017</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i56599386fa47443a8975bb3f7a6a8c57_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yNS9mcmFnOmZjZmRhMmQ4NmM2NTRiNjA5OTNkM2UxN2YzN2I0ZWE1L3RhYmxlOjlkMWYxMzljZjdjMzRiOGI5YzY3ODFmNWVmY2NhYmJjL3RhYmxlcmFuZ2U6OWQxZjEzOWNmN2MzNGI4YjljNjc4MWY1ZWZjY2FiYmNfMjktNC0xLTEtNDY4OTE_a690bca7-cbf1-43a9-a3e4-0d84b0b26f9e">67,247</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows from financing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from exercise of stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yNS9mcmFnOmZjZmRhMmQ4NmM2NTRiNjA5OTNkM2UxN2YzN2I0ZWE1L3RhYmxlOjlkMWYxMzljZjdjMzRiOGI5YzY3ODFmNWVmY2NhYmJjL3RhYmxlcmFuZ2U6OWQxZjEzOWNmN2MzNGI4YjljNjc4MWY1ZWZjY2FiYmNfMzEtMi0xLTEtNDY4OTE_7e5cacd2-bd54-4f35-ae02-728f9c0e3310">405</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56599386fa47443a8975bb3f7a6a8c57_D20210101-20210331" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yNS9mcmFnOmZjZmRhMmQ4NmM2NTRiNjA5OTNkM2UxN2YzN2I0ZWE1L3RhYmxlOjlkMWYxMzljZjdjMzRiOGI5YzY3ODFmNWVmY2NhYmJjL3RhYmxlcmFuZ2U6OWQxZjEzOWNmN2MzNGI4YjljNjc4MWY1ZWZjY2FiYmNfMzEtNC0xLTEtNDY4OTE_0ca0d223-29bb-45ad-b375-970e17daf043">4,999</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from exercise of warrants</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331" decimals="-3" name="us-gaap:ProceedsFromWarrantExercises" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yNS9mcmFnOmZjZmRhMmQ4NmM2NTRiNjA5OTNkM2UxN2YzN2I0ZWE1L3RhYmxlOjlkMWYxMzljZjdjMzRiOGI5YzY3ODFmNWVmY2NhYmJjL3RhYmxlcmFuZ2U6OWQxZjEzOWNmN2MzNGI4YjljNjc4MWY1ZWZjY2FiYmNfMzItMi0xLTEtNDY4OTE_aa86ef09-151c-438d-9239-3575a9d79f4c">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56599386fa47443a8975bb3f7a6a8c57_D20210101-20210331" decimals="-3" name="us-gaap:ProceedsFromWarrantExercises" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yNS9mcmFnOmZjZmRhMmQ4NmM2NTRiNjA5OTNkM2UxN2YzN2I0ZWE1L3RhYmxlOjlkMWYxMzljZjdjMzRiOGI5YzY3ODFmNWVmY2NhYmJjL3RhYmxlcmFuZ2U6OWQxZjEzOWNmN2MzNGI4YjljNjc4MWY1ZWZjY2FiYmNfMzItNC0xLTEtNDY4OTE_ba2f777a-9840-40c0-a478-894a3004fa5a">30</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash provided by financing activities </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yNS9mcmFnOmZjZmRhMmQ4NmM2NTRiNjA5OTNkM2UxN2YzN2I0ZWE1L3RhYmxlOjlkMWYxMzljZjdjMzRiOGI5YzY3ODFmNWVmY2NhYmJjL3RhYmxlcmFuZ2U6OWQxZjEzOWNmN2MzNGI4YjljNjc4MWY1ZWZjY2FiYmNfMzQtMi0xLTEtNDY4OTE_6626e449-c13e-49c1-b8ce-b482e297d620">405</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56599386fa47443a8975bb3f7a6a8c57_D20210101-20210331" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yNS9mcmFnOmZjZmRhMmQ4NmM2NTRiNjA5OTNkM2UxN2YzN2I0ZWE1L3RhYmxlOjlkMWYxMzljZjdjMzRiOGI5YzY3ODFmNWVmY2NhYmJjL3RhYmxlcmFuZ2U6OWQxZjEzOWNmN2MzNGI4YjljNjc4MWY1ZWZjY2FiYmNfMzQtNC0xLTEtNDY4OTE_b0b632b3-e878-4194-b8df-ad2f6c0969c6">5,029</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net decrease in cash, cash equivalents and restricted cash</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yNS9mcmFnOmZjZmRhMmQ4NmM2NTRiNjA5OTNkM2UxN2YzN2I0ZWE1L3RhYmxlOjlkMWYxMzljZjdjMzRiOGI5YzY3ODFmNWVmY2NhYmJjL3RhYmxlcmFuZ2U6OWQxZjEzOWNmN2MzNGI4YjljNjc4MWY1ZWZjY2FiYmNfMzUtMi0xLTEtNDY4OTE_3d400d43-12fc-49e1-bd34-2d9419099659">99,358</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i56599386fa47443a8975bb3f7a6a8c57_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yNS9mcmFnOmZjZmRhMmQ4NmM2NTRiNjA5OTNkM2UxN2YzN2I0ZWE1L3RhYmxlOjlkMWYxMzljZjdjMzRiOGI5YzY3ODFmNWVmY2NhYmJjL3RhYmxlcmFuZ2U6OWQxZjEzOWNmN2MzNGI4YjljNjc4MWY1ZWZjY2FiYmNfMzUtNC0xLTEtNDY4OTE_ea7ce96d-bf34-487d-947b-3f0e33c403ba">115,759</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash, beginning of period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i784f65549351439fa4b7bedf90ce7e3f_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yNS9mcmFnOmZjZmRhMmQ4NmM2NTRiNjA5OTNkM2UxN2YzN2I0ZWE1L3RhYmxlOjlkMWYxMzljZjdjMzRiOGI5YzY3ODFmNWVmY2NhYmJjL3RhYmxlcmFuZ2U6OWQxZjEzOWNmN2MzNGI4YjljNjc4MWY1ZWZjY2FiYmNfMzYtMi0xLTEtNDY4OTE_94b2659f-a7a3-4143-a824-301adc511e36">231,900</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52aa203b7e954d69b001129473620362_I20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yNS9mcmFnOmZjZmRhMmQ4NmM2NTRiNjA5OTNkM2UxN2YzN2I0ZWE1L3RhYmxlOjlkMWYxMzljZjdjMzRiOGI5YzY3ODFmNWVmY2NhYmJjL3RhYmxlcmFuZ2U6OWQxZjEzOWNmN2MzNGI4YjljNjc4MWY1ZWZjY2FiYmNfMzYtNC0xLTEtNDY4OTE_880f27a6-1ccc-401c-acfd-3499e3f95df7">272,350</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash, end of period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7882ae6aff54a3aacdef67ddf11a428_I20220331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yNS9mcmFnOmZjZmRhMmQ4NmM2NTRiNjA5OTNkM2UxN2YzN2I0ZWE1L3RhYmxlOjlkMWYxMzljZjdjMzRiOGI5YzY3ODFmNWVmY2NhYmJjL3RhYmxlcmFuZ2U6OWQxZjEzOWNmN2MzNGI4YjljNjc4MWY1ZWZjY2FiYmNfMzctMi0xLTEtNDY4OTE_c4f851be-8f63-4b51-98fb-b457a637dc3b">132,542</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0260d11b47b2403fbf3efe386b4d6b0f_I20210331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yNS9mcmFnOmZjZmRhMmQ4NmM2NTRiNjA5OTNkM2UxN2YzN2I0ZWE1L3RhYmxlOjlkMWYxMzljZjdjMzRiOGI5YzY3ODFmNWVmY2NhYmJjL3RhYmxlcmFuZ2U6OWQxZjEzOWNmN2MzNGI4YjljNjc4MWY1ZWZjY2FiYmNfMzctNC0xLTEtNDY4OTE_b70dbe69-ef20-4648-8e58-1ca76161ca95">156,591</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental cash flow information</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash received for interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331" decimals="-3" name="us-gaap:ProceedsFromInterestReceived" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yNS9mcmFnOmZjZmRhMmQ4NmM2NTRiNjA5OTNkM2UxN2YzN2I0ZWE1L3RhYmxlOjlkMWYxMzljZjdjMzRiOGI5YzY3ODFmNWVmY2NhYmJjL3RhYmxlcmFuZ2U6OWQxZjEzOWNmN2MzNGI4YjljNjc4MWY1ZWZjY2FiYmNfNDAtMi0xLTEtNDY4OTE_909cabab-3be1-45bf-83b8-06dcba65b6e5">13</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56599386fa47443a8975bb3f7a6a8c57_D20210101-20210331" decimals="-3" name="us-gaap:ProceedsFromInterestReceived" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yNS9mcmFnOmZjZmRhMmQ4NmM2NTRiNjA5OTNkM2UxN2YzN2I0ZWE1L3RhYmxlOjlkMWYxMzljZjdjMzRiOGI5YzY3ODFmNWVmY2NhYmJjL3RhYmxlcmFuZ2U6OWQxZjEzOWNmN2MzNGI4YjljNjc4MWY1ZWZjY2FiYmNfNDAtNC0xLTEtNDY4OTE_8fcb95de-6d5b-4157-99e5-7a826d2ae314">425</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10.75pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331" decimals="-3" name="us-gaap:CapitalLeaseObligationsIncurred" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yNS9mcmFnOmZjZmRhMmQ4NmM2NTRiNjA5OTNkM2UxN2YzN2I0ZWE1L3RhYmxlOjlkMWYxMzljZjdjMzRiOGI5YzY3ODFmNWVmY2NhYmJjL3RhYmxlcmFuZ2U6OWQxZjEzOWNmN2MzNGI4YjljNjc4MWY1ZWZjY2FiYmNfNDItMi0xLTEtNDY4OTE_0dba29aa-d8a4-4980-996b-720c5882e6a4">281</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i56599386fa47443a8975bb3f7a6a8c57_D20210101-20210331" decimals="-3" name="us-gaap:CapitalLeaseObligationsIncurred" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yNS9mcmFnOmZjZmRhMmQ4NmM2NTRiNjA5OTNkM2UxN2YzN2I0ZWE1L3RhYmxlOjlkMWYxMzljZjdjMzRiOGI5YzY3ODFmNWVmY2NhYmJjL3RhYmxlcmFuZ2U6OWQxZjEzOWNmN2MzNGI4YjljNjc4MWY1ZWZjY2FiYmNfNDItNC0xLTEtNDY4OTE_135c41ec-ab3b-4629-9663-afdc61975d0f">63</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental disclosure of noncash transactions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Initial recognition of operating lease right-of-use asset</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yNS9mcmFnOmZjZmRhMmQ4NmM2NTRiNjA5OTNkM2UxN2YzN2I0ZWE1L3RhYmxlOjlkMWYxMzljZjdjMzRiOGI5YzY3ODFmNWVmY2NhYmJjL3RhYmxlcmFuZ2U6OWQxZjEzOWNmN2MzNGI4YjljNjc4MWY1ZWZjY2FiYmNfNDQtMi0xLTEtNDY4OTE_3e14d862-7286-4b2c-bd96-4c231dfae361">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56599386fa47443a8975bb3f7a6a8c57_D20210101-20210331" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yNS9mcmFnOmZjZmRhMmQ4NmM2NTRiNjA5OTNkM2UxN2YzN2I0ZWE1L3RhYmxlOjlkMWYxMzljZjdjMzRiOGI5YzY3ODFmNWVmY2NhYmJjL3RhYmxlcmFuZ2U6OWQxZjEzOWNmN2MzNGI4YjljNjc4MWY1ZWZjY2FiYmNfNDQtNC0xLTEtNDY4OTE_3629d87e-2861-4ecd-8912-42d68416881e">5,804</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Reconciliation of cash, cash equivalents and restricted cash to the condensed consolidated balance sheets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7882ae6aff54a3aacdef67ddf11a428_I20220331" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yNS9mcmFnOmZjZmRhMmQ4NmM2NTRiNjA5OTNkM2UxN2YzN2I0ZWE1L3RhYmxlOjlkMWYxMzljZjdjMzRiOGI5YzY3ODFmNWVmY2NhYmJjL3RhYmxlcmFuZ2U6OWQxZjEzOWNmN2MzNGI4YjljNjc4MWY1ZWZjY2FiYmNfNDctMi0xLTEtNTQ3OTQ_0d252311-fd4f-4800-9940-df0c7daf4e23">131,636</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0260d11b47b2403fbf3efe386b4d6b0f_I20210331" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yNS9mcmFnOmZjZmRhMmQ4NmM2NTRiNjA5OTNkM2UxN2YzN2I0ZWE1L3RhYmxlOjlkMWYxMzljZjdjMzRiOGI5YzY3ODFmNWVmY2NhYmJjL3RhYmxlcmFuZ2U6OWQxZjEzOWNmN2MzNGI4YjljNjc4MWY1ZWZjY2FiYmNfNDctNC0xLTEtNTQ3OTQ_50591c50-94eb-4817-9cf6-81d382e1275e">156,591</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7882ae6aff54a3aacdef67ddf11a428_I20220331" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yNS9mcmFnOmZjZmRhMmQ4NmM2NTRiNjA5OTNkM2UxN2YzN2I0ZWE1L3RhYmxlOjlkMWYxMzljZjdjMzRiOGI5YzY3ODFmNWVmY2NhYmJjL3RhYmxlcmFuZ2U6OWQxZjEzOWNmN2MzNGI4YjljNjc4MWY1ZWZjY2FiYmNfNDgtMi0xLTEtNTQ3OTQ_a5ab9125-7b37-4922-8ad8-c17093086b42">906</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0260d11b47b2403fbf3efe386b4d6b0f_I20210331" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalents" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yNS9mcmFnOmZjZmRhMmQ4NmM2NTRiNjA5OTNkM2UxN2YzN2I0ZWE1L3RhYmxlOjlkMWYxMzljZjdjMzRiOGI5YzY3ODFmNWVmY2NhYmJjL3RhYmxlcmFuZ2U6OWQxZjEzOWNmN2MzNGI4YjljNjc4MWY1ZWZjY2FiYmNfNDgtNC0xLTEtNTQ3OTQ_ac9ba817-684f-4762-b10f-7a68d2c42752">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents and restricted cash</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7882ae6aff54a3aacdef67ddf11a428_I20220331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yNS9mcmFnOmZjZmRhMmQ4NmM2NTRiNjA5OTNkM2UxN2YzN2I0ZWE1L3RhYmxlOjlkMWYxMzljZjdjMzRiOGI5YzY3ODFmNWVmY2NhYmJjL3RhYmxlcmFuZ2U6OWQxZjEzOWNmN2MzNGI4YjljNjc4MWY1ZWZjY2FiYmNfNDktMi0xLTEtNTQ3OTQ_a0ebb017-2866-4949-bc76-506c4cfe0aad">132,542</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0260d11b47b2403fbf3efe386b4d6b0f_I20210331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yNS9mcmFnOmZjZmRhMmQ4NmM2NTRiNjA5OTNkM2UxN2YzN2I0ZWE1L3RhYmxlOjlkMWYxMzljZjdjMzRiOGI5YzY3ODFmNWVmY2NhYmJjL3RhYmxlcmFuZ2U6OWQxZjEzOWNmN2MzNGI4YjljNjc4MWY1ZWZjY2FiYmNfNDktNC0xLTEtNTQ3OTQ_9dcb81d6-b69d-4c0a-a1b2-2c2897aa8abb">156,591</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:7pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="i2d3a8f7e52e84dcebfa935bec5ca9eb6_28"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:10pt"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">AURINIA PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div id="i2d3a8f7e52e84dcebfa935bec5ca9eb6_31"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:28.5pt"><ix:nonNumeric contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8zMS9mcmFnOjI5NDExMmFjODQ1NzQ2OTk4MThjMTI5ZWIyNTZkNTI3L3RleHRyZWdpb246Mjk0MTEyYWM4NDU3NDY5OTgxOGMxMjllYjI1NmQ1MjdfMTc2MA_f76d1406-c51e-4fbd-8d9d-a12555b17025" continuedAt="id4da272f20ce4593910cc4bbed6be502" escape="true">Organization and Description of Business</ix:nonNumeric></span></div><ix:continuation id="id4da272f20ce4593910cc4bbed6be502" continuedAt="i6ce26052f412452997361076443e62c4"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Aurinia Pharmaceuticals Inc. (Aurinia or the Company) is a fully integrated biopharmaceutical company focused on delivering therapies to treat targeted patient populations that are impacted by serious diseases with a high unmet medical need. In January 2021, the Company introduced LUPKYNIS&#8482; (voclosporin), the first U.S. Food and Drug Administration (FDA) approved oral therapy for the treatment of adult patients with active LN and continues to conduct pre-clinical, clinical, and regulatory advancement to support the voclosporin development program. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 17, 2021, the Company announced the addition of two novel assets AUR200 and AUR300. AUR200 is currently undergoing pre-clinical development with projected submission of an Investigational New Drug Application (IND) to the FDA in 2023. The Company anticipates that an IND for AUR300 will also be submitted during 2023.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Aurinia's head office is located at #1203-4464 Markham Street, Victoria, British Columbia, Canada and its registered office is located at #201, 17873-106 A Avenue, Edmonton, Alberta. Aurinia also has a U.S. commercial office located at 77 Upper Rock Circle Suite 700, Rockville, Maryland, 20850 United States.</span></div></ix:continuation><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i6ce26052f412452997361076443e62c4">Aurinia is incorporated pursuant to the Business Corporations Act (Alberta). The Company&#8217;s common shares are traded on the Nasdaq Global Market (Nasdaq) under the symbol AUPH</ix:continuation>.</span></div><div id="i2d3a8f7e52e84dcebfa935bec5ca9eb6_34"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:28.5pt"><ix:nonNumeric contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331" name="us-gaap:BasisOfAccounting" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8zNC9mcmFnOmQwODBmYjU4YjRmNDQwMTRhYjFmN2Q4ZGJkNjRjODYwL3RleHRyZWdpb246ZDA4MGZiNThiNGY0NDAxNGFiMWY3ZDhkYmQ2NGM4NjBfMzIzNw_b28cea4c-e25a-44b5-9190-09112ceec5db" continuedAt="ic791cf9277b74a21928e380fc9842111" escape="true">Basis of Presentation</ix:nonNumeric></span></div><ix:continuation id="ic791cf9277b74a21928e380fc9842111"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States (U.S. GAAP) for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of normal recurring adjustments considered necessary for fair presentation in accordance with U.S. GAAP. The condensed consolidated balance sheet as of December&#160;31, 2021 was derived from audited annual consolidated financial statements but does not include all annual disclosures required by U.S. GAAP. These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements included in the Company's Annual Report on Form 10-K for the year ended December&#160;31, 2021. The results of operations for the three months ended March&#160;31, 2022 are not necessarily indicative of the results to be expected for the full year or any other future periods.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, Aurinia Pharma U.S., Inc. (Delaware incorporated) and Aurinia Pharma Limited (UK incorporated). All intercompany balances and transactions have been eliminated in consolidation and operate in <ix:nonFraction unitRef="segment" contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8zNC9mcmFnOmQwODBmYjU4YjRmNDQwMTRhYjFmN2Q4ZGJkNjRjODYwL3RleHRyZWdpb246ZDA4MGZiNThiNGY0NDAxNGFiMWY3ZDhkYmQ2NGM4NjBfMTY0OTI2NzQ0NTI3OA_6ae86e88-2a47-427e-8c29-1855d6f56c7d">one</ix:nonFraction> segment.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These unaudited condensed consolidated financial statements are presented in U.S. dollars which is the Company's functional currency therefore there is no currency translation adjustment upon consolidation as the remeasurement of gains or losses are recorded in the condensed consolidated statements of operations. All assets and liabilities denominated in a foreign currency are remeasured into U.S. dollars at the exchange rate on the balance sheet date. Revenues and expenses are remeasured at the average exchange rate during the period. Foreign exchange gains and losses arising on translation or settlement of a foreign currency denominated monetary item are included in the condensed consolidated statements of operations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is devoting the majority of our operational efforts and financial resources towards the commercialization and post approval commitments of our approved drug, LUPKYNIS. The Company is also expending efforts towards our newly acquired assets AUR200 and AUR300. Taking into consideration the Company's cash, cash equivalents, restricted cash and investments of $<ix:nonFraction unitRef="usd" contextRef="id7882ae6aff54a3aacdef67ddf11a428_I20220331" decimals="-5" name="auph:CashCashEquivalentsAndDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8zNC9mcmFnOmQwODBmYjU4YjRmNDQwMTRhYjFmN2Q4ZGJkNjRjODYwL3RleHRyZWdpb246ZDA4MGZiNThiNGY0NDAxNGFiMWY3ZDhkYmQ2NGM4NjBfMzA0MA_8e61c9d1-3e70-49a6-b31b-db77ac4de434">418.8</ix:nonFraction> million as of March&#160;31, 2022, the Company believes that it has sufficient resources to fund its operations for at least the next few years beyond the date that the unaudited condensed consolidated financial statements are issued.</span></div></ix:continuation><div id="i2d3a8f7e52e84dcebfa935bec5ca9eb6_37"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:28.5pt"><ix:nonNumeric contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8zNy9mcmFnOmNjZmQ3NmIxZTk2MDQ0ODBiYjcyOTBjYjUzMjdlYmQ0L3RleHRyZWdpb246Y2NmZDc2YjFlOTYwNDQ4MGJiNzI5MGNiNTMyN2ViZDRfMjA0MjU_ae2a0e2a-a3c2-41ac-a4a7-a9b846fb0c05" continuedAt="i5f8ad26343d548b89a2a7f7dc86c81fb" escape="true">Summary of Significant Accounting Policies</ix:nonNumeric></span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i5f8ad26343d548b89a2a7f7dc86c81fb" continuedAt="ic402bc66e3b843e584b744dbcedd4bd1">Other than as described below, the Company's significant accounting policies have not changed from those previously described in the Company's Annual Report on Form 10-K for the year ended December&#160;31, 2021.</ix:continuation></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ic402bc66e3b843e584b744dbcedd4bd1" continuedAt="i7771de349b674cd48e787276f2070730"><div style="margin-top:12pt;text-align:justify"><ix:nonNumeric contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8zNy9mcmFnOmNjZmQ3NmIxZTk2MDQ0ODBiYjcyOTBjYjUzMjdlYmQ0L3RleHRyZWdpb246Y2NmZDc2YjFlOTYwNDQ4MGJiNzI5MGNiNTMyN2ViZDRfMzI5ODUzNDk2MTA3MQ_14cd3394-592d-49f4-972b-28dff8024c03" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restricted cash</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: Restricted cash consists of the 2021 Employee Share Purchase Plan (2021 ESPP) deposits of $<ix:nonFraction unitRef="usd" contextRef="id7882ae6aff54a3aacdef67ddf11a428_I20220331" decimals="-5" name="us-gaap:RestrictedCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8zNy9mcmFnOmNjZmQ3NmIxZTk2MDQ0ODBiYjcyOTBjYjUzMjdlYmQ0L3RleHRyZWdpb246Y2NmZDc2YjFlOTYwNDQ4MGJiNzI5MGNiNTMyN2ViZDRfMzI5ODUzNDk2MTA0NA_1c4c033c-3864-47f8-8a76-96be045c517d">0.9</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i784f65549351439fa4b7bedf90ce7e3f_I20211231" decimals="-5" name="us-gaap:RestrictedCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8zNy9mcmFnOmNjZmQ3NmIxZTk2MDQ0ODBiYjcyOTBjYjUzMjdlYmQ0L3RleHRyZWdpb246Y2NmZDc2YjFlOTYwNDQ4MGJiNzI5MGNiNTMyN2ViZDRfMzI5ODUzNDk2MTA1OA_0a5f2576-a87b-4d48-aa2d-57f0c055551f">0.3</ix:nonFraction>&#160;million as of March&#160;31, 2022 and December&#160;31, 2021, respectively.</span></ix:nonNumeric></div><div style="margin-top:12pt;text-align:justify"><ix:nonNumeric contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331" name="us-gaap:ConcentrationRiskCreditRisk" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8zNy9mcmFnOmNjZmQ3NmIxZTk2MDQ0ODBiYjcyOTBjYjUzMjdlYmQ0L3RleHRyZWdpb246Y2NmZDc2YjFlOTYwNDQ4MGJiNzI5MGNiNTMyN2ViZDRfMjA0MjE_6cd516f7-249c-4f9b-988c-e1396ce0152e" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Major Customers:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company currently has two main customers for U.S. commercial sales of LUPKYNIS and one customer for sales of voclosporin in the European Union, Japan, as well as the United Kingdom, Russia, Switzerland, Norway, Belarus, Iceland, Liechtenstein and Ukraine. Revenues from two customers accounted for approximately <ix:nonFraction unitRef="number" contextRef="ie14c65a2be5d40e1975aef5b5c3f0072_D20220101-20220331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8zNy9mcmFnOmNjZmQ3NmIxZTk2MDQ0ODBiYjcyOTBjYjUzMjdlYmQ0L3RleHRyZWdpb246Y2NmZDc2YjFlOTYwNDQ4MGJiNzI5MGNiNTMyN2ViZDRfNDA3Mw_9a4af87a-0e2d-4835-be58-3687000e604f">54</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i5a87beff7e574242be649c7dbc5fa755_D20220101-20220331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8zNy9mcmFnOmNjZmQ3NmIxZTk2MDQ0ODBiYjcyOTBjYjUzMjdlYmQ0L3RleHRyZWdpb246Y2NmZDc2YjFlOTYwNDQ4MGJiNzI5MGNiNTMyN2ViZDRfNDA4MA_c9035910-95d0-41ee-9b0a-a4901af6e02e">45</ix:nonFraction>% respectively of the Company's total revenues for the three months ended March&#160;31, 2022. The Company monitors economic conditions, the creditworthiness of customers and government regulations and funding, both domestically and abroad. The Company regularly communicates with its customers regarding the status of receivable balances, including their payment plans and obtains positive confirmation of the validity of the receivables. Global economic conditions and customer specific factors may require the Company to periodically re-evaluate the collectability of its receivables and the Company could potentially incur credit losses.</span></ix:nonNumeric></div><div style="margin-top:12pt;text-align:justify"><ix:nonNumeric contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331" name="us-gaap:TradeAndOtherAccountsReceivablePolicy" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8zNy9mcmFnOmNjZmQ3NmIxZTk2MDQ0ODBiYjcyOTBjYjUzMjdlYmQ0L3RleHRyZWdpb246Y2NmZDc2YjFlOTYwNDQ4MGJiNzI5MGNiNTMyN2ViZDRfMjA0MTk_d8ad4885-14ab-4665-8e5d-8a04a0463471" continuedAt="ic8352411e1404b4388f3d1a41f94a882" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounts receivable, net:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Accounts receivable are stated at their net realizable value. As of March&#160;31, 2022 and December&#160;31, 2021, accounts receivable, net are $<ix:nonFraction unitRef="usd" contextRef="id7882ae6aff54a3aacdef67ddf11a428_I20220331" decimals="-5" name="us-gaap:AccountsAndOtherReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8zNy9mcmFnOmNjZmQ3NmIxZTk2MDQ0ODBiYjcyOTBjYjUzMjdlYmQ0L3RleHRyZWdpb246Y2NmZDc2YjFlOTYwNDQ4MGJiNzI5MGNiNTMyN2ViZDRfMTk2MzA_0262a4d8-8c9c-452d-9162-9d05fd5c5b5c">20.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i784f65549351439fa4b7bedf90ce7e3f_I20211231" decimals="-5" name="us-gaap:AccountsAndOtherReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8zNy9mcmFnOmNjZmQ3NmIxZTk2MDQ0ODBiYjcyOTBjYjUzMjdlYmQ0L3RleHRyZWdpb246Y2NmZDc2YjFlOTYwNDQ4MGJiNzI5MGNiNTMyN2ViZDRfMTA5OTUxMTcwNTU0OQ_76fb857b-0038-435d-b680-5fa86959bf58">15.4</ix:nonFraction> million. We estimate the allowance for doubtful accounts using current expected credit loss model, or CECL model. Under the CECL model, the allowance for doubtful accounts reflects the net amount expected to be collected from the account receivables. We evaluate the collectability of these cash flows based on the asset&#8217;s amortized cost, the risk of loss even when that risk is remote, losses over an asset&#8217;s contractual life, and other relevant information available to us. Accounts receivable balances are written off against the allowance when it is probable that</span></ix:nonNumeric></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ic8352411e1404b4388f3d1a41f94a882">the receivable will not be collected. The allowance for doubtful accounts was $<ix:nonFraction unitRef="usd" contextRef="id7882ae6aff54a3aacdef67ddf11a428_I20220331" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8zNy9mcmFnOmNjZmQ3NmIxZTk2MDQ0ODBiYjcyOTBjYjUzMjdlYmQ0L3RleHRyZWdpb246Y2NmZDc2YjFlOTYwNDQ4MGJiNzI5MGNiNTMyN2ViZDRfMTk4Nzg_2c9863bd-741b-4c7e-bd0e-920d266243d2"><ix:nonFraction unitRef="usd" contextRef="i784f65549351439fa4b7bedf90ce7e3f_I20211231" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8zNy9mcmFnOmNjZmQ3NmIxZTk2MDQ0ODBiYjcyOTBjYjUzMjdlYmQ0L3RleHRyZWdpb246Y2NmZDc2YjFlOTYwNDQ4MGJiNzI5MGNiNTMyN2ViZDRfMTk4Nzg_64150c8b-0ab4-43bd-853c-a2f244064536">nil</ix:nonFraction></ix:nonFraction> as of March&#160;31, 2022 and as of December&#160;31, 2021</ix:continuation>.</span></div><div style="margin-top:12pt;text-align:justify"><ix:nonNumeric contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8zNy9mcmFnOmNjZmQ3NmIxZTk2MDQ0ODBiYjcyOTBjYjUzMjdlYmQ0L3RleHRyZWdpb246Y2NmZDc2YjFlOTYwNDQ4MGJiNzI5MGNiNTMyN2ViZDRfMzI5ODUzNDkxODU5NQ_43ba0ab7-2115-49ae-a794-627e44f909b7" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Share-Based Compensation: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company follows ASC Topic 718, Compensation - Stock Compensation (ASC 718), which requires the measurement and recognition of compensation expense, based on estimated fair values, for all share-based awards made to employees and directors. The Company records compensation expense based on the fair value on the grant date using the graded accelerated vesting method for all share-based payments related to stock options, performance awards (PAs), restricted stock units (RSUs) and purchases under the Company's 2021 ESPP. For stock options, forfeitures are estimated based on historical experience at the time of grant and revised in subsequent periods if actual forfeitures differ from those estimates. For RSUs and PAs, forfeitures are accounted for as they occur.</span></ix:nonNumeric></div></ix:continuation><div id="i2d3a8f7e52e84dcebfa935bec5ca9eb6_40"></div><ix:continuation id="i7771de349b674cd48e787276f2070730"><ix:nonNumeric contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl80MC9mcmFnOjE5Y2RlOTg2NGRmYzQwZmRiYWM4MzU3ZjhhZTM5OTllL3RleHRyZWdpb246MTljZGU5ODY0ZGZjNDBmZGJhYzgzNTdmOGFlMzk5OWVfNDkyMA_1a778848-d3a3-4b3e-9671-3d5fae08ce00" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently adopted accounting pronouncements</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued ASU 2019-12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Topic 740): Simplifying the Accounting for Income Taxes, which clarifies and simplifies certain aspects of the accounting for income taxes. The standard is effective for years beginning after December 15, 2020, and interim periods within annual periods beginning after December 15, 2020. The Company adopted the ASU effective January 1, 2021, with no material impact on the condensed consolidated financial statements.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2021, the FASB issued ASU No. 2021-10, Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance, which requires business entities to make annual disclosures about transactions with a government (including government assistance) by analogizing to a grant or contribution accounting model. The required disclosures include the nature of the transaction, the entity's related accounting policy, the financial statement line items affected and the amounts reflected in the current period financial statements, as well as any significant terms and conditions. The guidance is effective for financial statements issued for annual periods beginning after December 15, 2021. The Company adopted the ASU effective January 1, 2022, with no material impact on the condensed consolidated financial statements.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><div id="i2d3a8f7e52e84dcebfa935bec5ca9eb6_43"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl80My9mcmFnOjQ3ZjgwM2VmY2QyNTRiNjFiNzI0MGU2ZDk1M2IxODllL3RleHRyZWdpb246NDdmODAzZWZjZDI1NGI2MWI3MjQwZTZkOTUzYjE4OWVfMTMwMw_fe4305a8-91db-4d2e-928b-272fd7bf68bd" continuedAt="i77eeae45935f4a2f9762b7055219938f" escape="true">Investments</ix:nonNumeric></span></div><ix:continuation id="i77eeae45935f4a2f9762b7055219938f" continuedAt="if23dd7962fba4b61a5a9cff268f7179d"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March&#160;31, 2022 and December&#160;31, 2021, the Company had $<ix:nonFraction unitRef="usd" contextRef="id7882ae6aff54a3aacdef67ddf11a428_I20220331" decimals="-5" name="us-gaap:DebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl80My9mcmFnOjQ3ZjgwM2VmY2QyNTRiNjFiNzI0MGU2ZDk1M2IxODllL3RleHRyZWdpb246NDdmODAzZWZjZDI1NGI2MWI3MjQwZTZkOTUzYjE4OWVfNTM_f4188e32-f751-491a-b3b6-6b8005803173">286.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i784f65549351439fa4b7bedf90ce7e3f_I20211231" decimals="-5" name="us-gaap:DebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl80My9mcmFnOjQ3ZjgwM2VmY2QyNTRiNjFiNzI0MGU2ZDk1M2IxODllL3RleHRyZWdpb246NDdmODAzZWZjZDI1NGI2MWI3MjQwZTZkOTUzYjE4OWVfNjg_8ef9c19a-79ec-45ba-a8a0-b89fdb5ca98e">234.2</ix:nonFraction> million of short-term investments, respectively, mainly consisting of commercial paper and bonds as summarized below. As of March&#160;31, 2022, $<ix:nonFraction unitRef="usd" contextRef="id7882ae6aff54a3aacdef67ddf11a428_I20220331" decimals="-5" name="us-gaap:HeldToMaturitySecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl80My9mcmFnOjQ3ZjgwM2VmY2QyNTRiNjFiNzI0MGU2ZDk1M2IxODllL3RleHRyZWdpb246NDdmODAzZWZjZDI1NGI2MWI3MjQwZTZkOTUzYjE4OWVfMjc0_ace439e1-84af-40b2-9e83-45fac4e2bfce">8.8</ix:nonFraction> million are held to maturity debt securities which are carried at amortized cost and are approximately equal to fair market value. As of March&#160;31, 2022, $<ix:nonFraction unitRef="usd" contextRef="id7882ae6aff54a3aacdef67ddf11a428_I20220331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl80My9mcmFnOjQ3ZjgwM2VmY2QyNTRiNjFiNzI0MGU2ZDk1M2IxODllL3RleHRyZWdpb246NDdmODAzZWZjZDI1NGI2MWI3MjQwZTZkOTUzYjE4OWVfNDEw_ea18a798-7ba4-4831-8ea6-7b827e96b602">277.4</ix:nonFraction> million are available-for-sale debt securities which are carried at fair market value. As of December&#160;31, 2021, $<ix:nonFraction unitRef="usd" contextRef="i784f65549351439fa4b7bedf90ce7e3f_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl80My9mcmFnOjQ3ZjgwM2VmY2QyNTRiNjFiNzI0MGU2ZDk1M2IxODllL3RleHRyZWdpb246NDdmODAzZWZjZDI1NGI2MWI3MjQwZTZkOTUzYjE4OWVfMTA5OTUxMTYyOTM4Ng_f0be5335-c6b5-4bb6-9b73-88e497db7609">215.0</ix:nonFraction> million were classified as available-for-sale and $<ix:nonFraction unitRef="usd" contextRef="i784f65549351439fa4b7bedf90ce7e3f_I20211231" decimals="-5" name="us-gaap:HeldToMaturitySecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl80My9mcmFnOjQ3ZjgwM2VmY2QyNTRiNjFiNzI0MGU2ZDk1M2IxODllL3RleHRyZWdpb246NDdmODAzZWZjZDI1NGI2MWI3MjQwZTZkOTUzYjE4OWVfMTA5OTUxMTYyOTM3MA_168f33f8-39e3-4a50-90f6-3d8e4a074cb5">19.2</ix:nonFraction> million were held-to-maturity. </span></div><div style="text-align:justify"><ix:nonNumeric contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331" name="us-gaap:MarketableSecuritiesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl80My9mcmFnOjQ3ZjgwM2VmY2QyNTRiNjFiNzI0MGU2ZDk1M2IxODllL3RleHRyZWdpb246NDdmODAzZWZjZDI1NGI2MWI3MjQwZTZkOTUzYjE4OWVfMTMwNA_6e45e5cc-c7c7-43cc-96b5-fbc6efaeffd1" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.347%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cashable Guaranteed Investment Certificate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibaf8c62e96254608ab5682b00b33999f_I20220331" decimals="-3" name="us-gaap:DebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl80My9mcmFnOjQ3ZjgwM2VmY2QyNTRiNjFiNzI0MGU2ZDk1M2IxODllL3RhYmxlOmI0NGZiZWQ5NDBhNDQ2MWM5OGY2NTA1YTVmNDM2NjE5L3RhYmxlcmFuZ2U6YjQ0ZmJlZDk0MGE0NDYxYzk4ZjY1MDVhNWY0MzY2MTlfMS0yLTEtMS00Njg5MQ_6dac04f5-2aaf-4727-ae54-0792b50eb658">3,128</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40b2265057054504ab60aa0aafba0f0e_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl80My9mcmFnOjQ3ZjgwM2VmY2QyNTRiNjFiNzI0MGU2ZDk1M2IxODllL3RhYmxlOmI0NGZiZWQ5NDBhNDQ2MWM5OGY2NTA1YTVmNDM2NjE5L3RhYmxlcmFuZ2U6YjQ0ZmJlZDk0MGE0NDYxYzk4ZjY1MDVhNWY0MzY2MTlfMS00LTEtMS00Njg5MQ_df36d4a8-3b6f-4751-b96d-dfd7a31cf730">3,140</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate Bond</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5235f32286c3431198c094116ea7192b_I20220331" decimals="-3" name="us-gaap:DebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl80My9mcmFnOjQ3ZjgwM2VmY2QyNTRiNjFiNzI0MGU2ZDk1M2IxODllL3RhYmxlOmI0NGZiZWQ5NDBhNDQ2MWM5OGY2NTA1YTVmNDM2NjE5L3RhYmxlcmFuZ2U6YjQ0ZmJlZDk0MGE0NDYxYzk4ZjY1MDVhNWY0MzY2MTlfMi0yLTEtMS00Njg5MQ_f3e7463a-351a-45e3-8a36-5bf7092650b5">60,390</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea26fc49428d4511a2fb37c1bb666a8b_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl80My9mcmFnOjQ3ZjgwM2VmY2QyNTRiNjFiNzI0MGU2ZDk1M2IxODllL3RhYmxlOmI0NGZiZWQ5NDBhNDQ2MWM5OGY2NTA1YTVmNDM2NjE5L3RhYmxlcmFuZ2U6YjQ0ZmJlZDk0MGE0NDYxYzk4ZjY1MDVhNWY0MzY2MTlfMi00LTEtMS00Njg5MQ_73a73b1f-bd9d-4cc6-ad13-9911995563a9">21,820</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial Paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dfcd77b916a46af88c7474c6cb4ec1a_I20220331" decimals="-3" name="us-gaap:DebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl80My9mcmFnOjQ3ZjgwM2VmY2QyNTRiNjFiNzI0MGU2ZDk1M2IxODllL3RhYmxlOmI0NGZiZWQ5NDBhNDQ2MWM5OGY2NTA1YTVmNDM2NjE5L3RhYmxlcmFuZ2U6YjQ0ZmJlZDk0MGE0NDYxYzk4ZjY1MDVhNWY0MzY2MTlfMy0yLTEtMS00Njg5MQ_de6f521d-a4f2-4f0c-8990-e646ab3d5d7d">152,295</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3450fe582114ff195b2b48f8c26afea_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl80My9mcmFnOjQ3ZjgwM2VmY2QyNTRiNjFiNzI0MGU2ZDk1M2IxODllL3RhYmxlOmI0NGZiZWQ5NDBhNDQ2MWM5OGY2NTA1YTVmNDM2NjE5L3RhYmxlcmFuZ2U6YjQ0ZmJlZDk0MGE0NDYxYzk4ZjY1MDVhNWY0MzY2MTlfMy00LTEtMS00Njg5MQ_9eeb33a1-8a19-4005-8521-a2819ce1ba59">206,724</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treasury Bill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee34030c8c804c4a98def156ea552450_I20220331" decimals="-3" name="us-gaap:DebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl80My9mcmFnOjQ3ZjgwM2VmY2QyNTRiNjFiNzI0MGU2ZDk1M2IxODllL3RhYmxlOmI0NGZiZWQ5NDBhNDQ2MWM5OGY2NTA1YTVmNDM2NjE5L3RhYmxlcmFuZ2U6YjQ0ZmJlZDk0MGE0NDYxYzk4ZjY1MDVhNWY0MzY2MTlfNC0yLTEtMS00Njg5MQ_2042a4cc-a033-4ac4-8028-4c056de98211">19,530</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67d405ac9e79458eb8e91ab5d55e0df4_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl80My9mcmFnOjQ3ZjgwM2VmY2QyNTRiNjFiNzI0MGU2ZDk1M2IxODllL3RhYmxlOmI0NGZiZWQ5NDBhNDQ2MWM5OGY2NTA1YTVmNDM2NjE5L3RhYmxlcmFuZ2U6YjQ0ZmJlZDk0MGE0NDYxYzk4ZjY1MDVhNWY0MzY2MTlfNC00LTEtMS00Njg5MQ_e8d081e7-4701-4f4d-bfaf-80e9b5eb10c6">2,494</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treasury Bond</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8018f58d25ea48ecbbc969caded6e2f5_I20220331" decimals="-3" name="us-gaap:DebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl80My9mcmFnOjQ3ZjgwM2VmY2QyNTRiNjFiNzI0MGU2ZDk1M2IxODllL3RhYmxlOmI0NGZiZWQ5NDBhNDQ2MWM5OGY2NTA1YTVmNDM2NjE5L3RhYmxlcmFuZ2U6YjQ0ZmJlZDk0MGE0NDYxYzk4ZjY1MDVhNWY0MzY2MTlfNS0yLTEtMS00Njg5MQ_56ab8fb4-ea3e-4baf-9f31-64706d7afcac">50,867</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa7bf46cccc44c9484be6b855b0a6f1c_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl80My9mcmFnOjQ3ZjgwM2VmY2QyNTRiNjFiNzI0MGU2ZDk1M2IxODllL3RhYmxlOmI0NGZiZWQ5NDBhNDQ2MWM5OGY2NTA1YTVmNDM2NjE5L3RhYmxlcmFuZ2U6YjQ0ZmJlZDk0MGE0NDYxYzk4ZjY1MDVhNWY0MzY2MTlfNS00LTEtMS00Njg5MQ_e507cd23-e306-465a-8e6b-900a41a6ec4e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7882ae6aff54a3aacdef67ddf11a428_I20220331" decimals="-3" name="us-gaap:DebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl80My9mcmFnOjQ3ZjgwM2VmY2QyNTRiNjFiNzI0MGU2ZDk1M2IxODllL3RhYmxlOmI0NGZiZWQ5NDBhNDQ2MWM5OGY2NTA1YTVmNDM2NjE5L3RhYmxlcmFuZ2U6YjQ0ZmJlZDk0MGE0NDYxYzk4ZjY1MDVhNWY0MzY2MTlfNy0yLTEtMS00Njg5MQ_9bad803c-0f6a-4e03-800f-2eedf8cb7053">286,210</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i784f65549351439fa4b7bedf90ce7e3f_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl80My9mcmFnOjQ3ZjgwM2VmY2QyNTRiNjFiNzI0MGU2ZDk1M2IxODllL3RhYmxlOmI0NGZiZWQ5NDBhNDQ2MWM5OGY2NTA1YTVmNDM2NjE5L3RhYmxlcmFuZ2U6YjQ0ZmJlZDk0MGE0NDYxYzk4ZjY1MDVhNWY0MzY2MTlfNy00LTEtMS00Njg5MQ_45f446ee-fc1e-4da1-9331-88fd3bd8ff06">234,178</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:nonNumeric></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="if23dd7962fba4b61a5a9cff268f7179d">Currently, the Company does not intend to sell investments and has the ability and intent to hold these investments until maturity in order to collect interest payments over the life of the investments. As of March&#160;31, 2022 and December&#160;31, 2021, accrued interest receivable from the investments were $<ix:nonFraction unitRef="usd" contextRef="id7882ae6aff54a3aacdef67ddf11a428_I20220331" decimals="-5" name="us-gaap:InterestReceivable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl80My9mcmFnOjQ3ZjgwM2VmY2QyNTRiNjFiNzI0MGU2ZDk1M2IxODllL3RleHRyZWdpb246NDdmODAzZWZjZDI1NGI2MWI3MjQwZTZkOTUzYjE4OWVfOTM4_e0ec7b50-2292-4c34-a3c2-23979428fde9">0.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i784f65549351439fa4b7bedf90ce7e3f_I20211231" decimals="-5" name="us-gaap:InterestReceivable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl80My9mcmFnOjQ3ZjgwM2VmY2QyNTRiNjFiNzI0MGU2ZDk1M2IxODllL3RleHRyZWdpb246NDdmODAzZWZjZDI1NGI2MWI3MjQwZTZkOTUzYjE4OWVfOTQ1_339378a8-e1dc-4718-b1c8-5f7d451d4de5">0.1</ix:nonFraction> million, respectively. During the three months ended March&#160;31, 2022 and 2021, the Company had $<ix:nonFraction unitRef="usd" contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl80My9mcmFnOjQ3ZjgwM2VmY2QyNTRiNjFiNzI0MGU2ZDk1M2IxODllL3RleHRyZWdpb246NDdmODAzZWZjZDI1NGI2MWI3MjQwZTZkOTUzYjE4OWVfMTAyNw_ec5d6ef2-4527-4d30-bc5c-410700e82378">766</ix:nonFraction> thousand and $<ix:nonFraction unitRef="usd" contextRef="i56599386fa47443a8975bb3f7a6a8c57_D20210101-20210331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl80My9mcmFnOjQ3ZjgwM2VmY2QyNTRiNjFiNzI0MGU2ZDk1M2IxODllL3RleHRyZWdpb246NDdmODAzZWZjZDI1NGI2MWI3MjQwZTZkOTUzYjE4OWVfMTA5OTUxMTYyOTU2Ng_58238264-c0c6-4a68-8277-3831bcf829d3">6</ix:nonFraction> thousand unrealized losses on available-for-sale securities, net of tax, respectively, which are included as a component of comprehensive loss on the consolidated statements of operations. The Company's investments as of March&#160;31, 2022 mature at various dates through January 2023.</ix:continuation> </span></div><div style="text-align:justify"><span><br/></span></div><div id="i2d3a8f7e52e84dcebfa935bec5ca9eb6_49"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331" name="us-gaap:InventoryDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl80OS9mcmFnOjc3NzgxNmZhNmQ0ZDQwYmRhYmQ0YzNjZTZiOThiYTk1L3RleHRyZWdpb246Nzc3ODE2ZmE2ZDRkNDBiZGFiZDRjM2NlNmI5OGJhOTVfOTQy_2357ab93-c982-4df9-b785-7f1c5f38b32f" continuedAt="i29da815a6125446caec2ac39167b8c05" escape="true">Inventories</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i29da815a6125446caec2ac39167b8c05"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories are valued under a standard costing methodology on a first-in, first-out basis and are stated at the lower of cost or net realizable value. The Company capitalizes inventory costs related to products to be sold in the ordinary course of business. The Company makes a determination of capitalizing inventory costs for a product based on, among other factors, status of regulatory approval, information regarding safety, efficacy and expectations relating to commercial sales and recoverability of costs. Capitalized costs of inventories for LUPKYNIS mainly include third party manufacturing costs, transportation, storage, insurance, depreciation and allocated internal labor.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assesses recoverability of inventory each reporting period to determine any write down to net realizable value resulting from excess or obsolete inventories.</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl80OS9mcmFnOjc3NzgxNmZhNmQ0ZDQwYmRhYmQ0YzNjZTZiOThiYTk1L3RleHRyZWdpb246Nzc3ODE2ZmE2ZDRkNDBiZGFiZDRjM2NlNmI5OGJhOTVfOTQz_09cdd4e7-e2c5-4ebd-8444-f0baccf8fcce" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of inventory are as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.347%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7882ae6aff54a3aacdef67ddf11a428_I20220331" decimals="-3" name="us-gaap:InventoryRawMaterialsNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl80OS9mcmFnOjc3NzgxNmZhNmQ0ZDQwYmRhYmQ0YzNjZTZiOThiYTk1L3RhYmxlOjgxOGE2MGM0MTVhNzQzYmViMGQwNGJkODhjZTFlN2MyL3RhYmxlcmFuZ2U6ODE4YTYwYzQxNWE3NDNiZWIwZDA0YmQ4OGNlMWU3YzJfMS0yLTEtMS00Njg5MQ_128b742b-562c-47fd-a5ca-cc93a5824e32">2,217</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i784f65549351439fa4b7bedf90ce7e3f_I20211231" decimals="-3" name="us-gaap:InventoryRawMaterialsNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl80OS9mcmFnOjc3NzgxNmZhNmQ0ZDQwYmRhYmQ0YzNjZTZiOThiYTk1L3RhYmxlOjgxOGE2MGM0MTVhNzQzYmViMGQwNGJkODhjZTFlN2MyL3RhYmxlcmFuZ2U6ODE4YTYwYzQxNWE3NDNiZWIwZDA0YmQ4OGNlMWU3YzJfMS00LTEtMS00Njg5MQ_a33fed47-7863-4ea1-8e6f-b868c926dc23">2,217</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7882ae6aff54a3aacdef67ddf11a428_I20220331" decimals="-3" name="us-gaap:InventoryWorkInProcessNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl80OS9mcmFnOjc3NzgxNmZhNmQ0ZDQwYmRhYmQ0YzNjZTZiOThiYTk1L3RhYmxlOjgxOGE2MGM0MTVhNzQzYmViMGQwNGJkODhjZTFlN2MyL3RhYmxlcmFuZ2U6ODE4YTYwYzQxNWE3NDNiZWIwZDA0YmQ4OGNlMWU3YzJfMi0yLTEtMS00Njg5MQ_d8b7b0c9-8330-4638-bbe2-8e9190591701">19,713</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i784f65549351439fa4b7bedf90ce7e3f_I20211231" decimals="-3" name="us-gaap:InventoryWorkInProcessNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl80OS9mcmFnOjc3NzgxNmZhNmQ0ZDQwYmRhYmQ0YzNjZTZiOThiYTk1L3RhYmxlOjgxOGE2MGM0MTVhNzQzYmViMGQwNGJkODhjZTFlN2MyL3RhYmxlcmFuZ2U6ODE4YTYwYzQxNWE3NDNiZWIwZDA0YmQ4OGNlMWU3YzJfMi00LTEtMS00Njg5MQ_23612fe1-1584-42a5-b020-bbea8ebf207a">12,566</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7882ae6aff54a3aacdef67ddf11a428_I20220331" decimals="-3" name="us-gaap:InventoryFinishedGoodsNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl80OS9mcmFnOjc3NzgxNmZhNmQ0ZDQwYmRhYmQ0YzNjZTZiOThiYTk1L3RhYmxlOjgxOGE2MGM0MTVhNzQzYmViMGQwNGJkODhjZTFlN2MyL3RhYmxlcmFuZ2U6ODE4YTYwYzQxNWE3NDNiZWIwZDA0YmQ4OGNlMWU3YzJfMy0yLTEtMS00Njg5MQ_52d3826b-6d1b-42c6-9326-a7429568d9fb">4,336</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i784f65549351439fa4b7bedf90ce7e3f_I20211231" decimals="-3" name="us-gaap:InventoryFinishedGoodsNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl80OS9mcmFnOjc3NzgxNmZhNmQ0ZDQwYmRhYmQ0YzNjZTZiOThiYTk1L3RhYmxlOjgxOGE2MGM0MTVhNzQzYmViMGQwNGJkODhjZTFlN2MyL3RhYmxlcmFuZ2U6ODE4YTYwYzQxNWE3NDNiZWIwZDA0YmQ4OGNlMWU3YzJfMy00LTEtMS00Njg5MQ_9cd7d049-b1e8-4525-9e3e-daf3dbb8d8bd">4,543</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventories</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7882ae6aff54a3aacdef67ddf11a428_I20220331" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl80OS9mcmFnOjc3NzgxNmZhNmQ0ZDQwYmRhYmQ0YzNjZTZiOThiYTk1L3RhYmxlOjgxOGE2MGM0MTVhNzQzYmViMGQwNGJkODhjZTFlN2MyL3RhYmxlcmFuZ2U6ODE4YTYwYzQxNWE3NDNiZWIwZDA0YmQ4OGNlMWU3YzJfNC0yLTEtMS00Njg5MQ_cedc5c58-2671-4e89-950d-84a6b3a6e450">26,266</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i784f65549351439fa4b7bedf90ce7e3f_I20211231" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl80OS9mcmFnOjc3NzgxNmZhNmQ0ZDQwYmRhYmQ0YzNjZTZiOThiYTk1L3RhYmxlOjgxOGE2MGM0MTVhNzQzYmViMGQwNGJkODhjZTFlN2MyL3RhYmxlcmFuZ2U6ODE4YTYwYzQxNWE3NDNiZWIwZDA0YmQ4OGNlMWU3YzJfNC00LTEtMS00Njg5MQ_3659594e-20cc-4cf8-ad80-c9c6dacc603f">19,326</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><div id="i2d3a8f7e52e84dcebfa935bec5ca9eb6_52"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:28.5pt"><ix:nonNumeric contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331" name="us-gaap:OtherCurrentAssetsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl81Mi9mcmFnOjQ4NTI5N2U4ZWNiMzRlZGM4ZWVhNzU5MWUyZWE4ZTRhL3RleHRyZWdpb246NDg1Mjk3ZThlY2IzNGVkYzhlZWE3NTkxZTJlYThlNGFfMTI0_3c5bd595-9ca2-471f-ab8f-780a93b1dfe3" continuedAt="i1c85ab8c97f54fe6a2f86b630c0096c8" escape="true">Prepaid Expenses and Other Current Assets</ix:nonNumeric></span></div><ix:continuation id="i1c85ab8c97f54fe6a2f86b630c0096c8"><ix:nonNumeric contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331" name="us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl81Mi9mcmFnOjQ4NTI5N2U4ZWNiMzRlZGM4ZWVhNzU5MWUyZWE4ZTRhL3RleHRyZWdpb246NDg1Mjk3ZThlY2IzNGVkYzhlZWE3NTkxZTJlYThlNGFfMTI1_6ce74ef0-aa94-4bbc-aa87-4930a2c35d85" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets are as follows:</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.347%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7882ae6aff54a3aacdef67ddf11a428_I20220331" decimals="-3" name="auph:PrepaidAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl81Mi9mcmFnOjQ4NTI5N2U4ZWNiMzRlZGM4ZWVhNzU5MWUyZWE4ZTRhL3RhYmxlOmE5YTY3OWJkMWExYjQ4MjJiZTk2M2M2NjZmZmI1MWEwL3RhYmxlcmFuZ2U6YTlhNjc5YmQxYTFiNDgyMmJlOTYzYzY2NmZmYjUxYTBfMS0yLTEtMS00Njg5MQ_699d61ec-1e81-47e0-aae8-914f5732401a">6,351</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i784f65549351439fa4b7bedf90ce7e3f_I20211231" decimals="-3" name="auph:PrepaidAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl81Mi9mcmFnOjQ4NTI5N2U4ZWNiMzRlZGM4ZWVhNzU5MWUyZWE4ZTRhL3RhYmxlOmE5YTY3OWJkMWExYjQ4MjJiZTk2M2M2NjZmZmI1MWEwL3RhYmxlcmFuZ2U6YTlhNjc5YmQxYTFiNDgyMmJlOTYzYzY2NmZmYjUxYTBfMS00LTEtMS00Njg5MQ_1e592ca8-40ef-45dc-8db9-209d52b86d2a">5,316</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid insurance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7882ae6aff54a3aacdef67ddf11a428_I20220331" decimals="-3" name="us-gaap:PrepaidInsurance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl81Mi9mcmFnOjQ4NTI5N2U4ZWNiMzRlZGM4ZWVhNzU5MWUyZWE4ZTRhL3RhYmxlOmE5YTY3OWJkMWExYjQ4MjJiZTk2M2M2NjZmZmI1MWEwL3RhYmxlcmFuZ2U6YTlhNjc5YmQxYTFiNDgyMmJlOTYzYzY2NmZmYjUxYTBfMi0yLTEtMS00Njg5MQ_089c1f72-bf49-4e8e-ab6d-421a6c253ecd">682</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i784f65549351439fa4b7bedf90ce7e3f_I20211231" decimals="-3" name="us-gaap:PrepaidInsurance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl81Mi9mcmFnOjQ4NTI5N2U4ZWNiMzRlZGM4ZWVhNzU5MWUyZWE4ZTRhL3RhYmxlOmE5YTY3OWJkMWExYjQ4MjJiZTk2M2M2NjZmZmI1MWEwL3RhYmxlcmFuZ2U6YTlhNjc5YmQxYTFiNDgyMmJlOTYzYzY2NmZmYjUxYTBfMi00LTEtMS00Njg5MQ_4a865a83-26d3-4a80-8ada-0ccebe18e1bf">1,632</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7882ae6aff54a3aacdef67ddf11a428_I20220331" decimals="-3" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl81Mi9mcmFnOjQ4NTI5N2U4ZWNiMzRlZGM4ZWVhNzU5MWUyZWE4ZTRhL3RhYmxlOmE5YTY3OWJkMWExYjQ4MjJiZTk2M2M2NjZmZmI1MWEwL3RhYmxlcmFuZ2U6YTlhNjc5YmQxYTFiNDgyMmJlOTYzYzY2NmZmYjUxYTBfMy0yLTEtMS00Njg5MQ_1cf3cdc1-cfa1-494c-adfb-dc11f7311175">3,966</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i784f65549351439fa4b7bedf90ce7e3f_I20211231" decimals="-3" name="us-gaap:OtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl81Mi9mcmFnOjQ4NTI5N2U4ZWNiMzRlZGM4ZWVhNzU5MWUyZWE4ZTRhL3RhYmxlOmE5YTY3OWJkMWExYjQ4MjJiZTk2M2M2NjZmZmI1MWEwL3RhYmxlcmFuZ2U6YTlhNjc5YmQxYTFiNDgyMmJlOTYzYzY2NmZmYjUxYTBfMy00LTEtMS00Njg5MQ_2bcffd19-de4a-462f-a745-9ddb4cf6732a">796</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid deposits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7882ae6aff54a3aacdef67ddf11a428_I20220331" decimals="-3" name="auph:PrepaidRentAndPrepaidContinuingStudies" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl81Mi9mcmFnOjQ4NTI5N2U4ZWNiMzRlZGM4ZWVhNzU5MWUyZWE4ZTRhL3RhYmxlOmE5YTY3OWJkMWExYjQ4MjJiZTk2M2M2NjZmZmI1MWEwL3RhYmxlcmFuZ2U6YTlhNjc5YmQxYTFiNDgyMmJlOTYzYzY2NmZmYjUxYTBfNC0yLTEtMS00Njg5MQ_991c899d-66c0-4168-9681-d06fca0e45a8">1,200</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i784f65549351439fa4b7bedf90ce7e3f_I20211231" decimals="-3" name="auph:PrepaidRentAndPrepaidContinuingStudies" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl81Mi9mcmFnOjQ4NTI5N2U4ZWNiMzRlZGM4ZWVhNzU5MWUyZWE4ZTRhL3RhYmxlOmE5YTY3OWJkMWExYjQ4MjJiZTk2M2M2NjZmZmI1MWEwL3RhYmxlcmFuZ2U6YTlhNjc5YmQxYTFiNDgyMmJlOTYzYzY2NmZmYjUxYTBfNC00LTEtMS00Njg5MQ_306337f1-0add-456b-a5fd-349456d748f2">4,762</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7882ae6aff54a3aacdef67ddf11a428_I20220331" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl81Mi9mcmFnOjQ4NTI5N2U4ZWNiMzRlZGM4ZWVhNzU5MWUyZWE4ZTRhL3RhYmxlOmE5YTY3OWJkMWExYjQ4MjJiZTk2M2M2NjZmZmI1MWEwL3RhYmxlcmFuZ2U6YTlhNjc5YmQxYTFiNDgyMmJlOTYzYzY2NmZmYjUxYTBfNS0yLTEtMS00Njg5MQ_a1194edf-da66-425c-a1a7-28ed38ef54ec">12,199</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i784f65549351439fa4b7bedf90ce7e3f_I20211231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl81Mi9mcmFnOjQ4NTI5N2U4ZWNiMzRlZGM4ZWVhNzU5MWUyZWE4ZTRhL3RhYmxlOmE5YTY3OWJkMWExYjQ4MjJiZTk2M2M2NjZmZmI1MWEwL3RhYmxlcmFuZ2U6YTlhNjc5YmQxYTFiNDgyMmJlOTYzYzY2NmZmYjUxYTBfNS00LTEtMS00Njg5MQ_be266423-6202-4aed-86d0-8f8c8016beb4">12,506</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div id="i2d3a8f7e52e84dcebfa935bec5ca9eb6_55"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:28.5pt"><ix:nonNumeric contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331" name="us-gaap:IntangibleAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl81NS9mcmFnOmYxNjVmMjIyM2VmNzRkMTdhY2Q0MGJmMGU5ZTJlMzNiL3RleHRyZWdpb246ZjE2NWYyMjIzZWY3NGQxN2FjZDQwYmYwZTllMmUzM2JfMjg3_9ab06955-ae2e-4922-8cb6-e4ccf734f099" continuedAt="i081663952875424f9bbf3b3123903030" escape="true">Intangible Assets</ix:nonNumeric></span></div><ix:continuation id="i081663952875424f9bbf3b3123903030" continuedAt="i4ab5cbfe05c447338a57cebd6d0a9ed5"><ix:nonNumeric contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl81NS9mcmFnOmYxNjVmMjIyM2VmNzRkMTdhY2Q0MGJmMGU5ZTJlMzNiL3RleHRyZWdpb246ZjE2NWYyMjIzZWY3NGQxN2FjZDQwYmYwZTllMmUzM2JfMjg4_dc4d6a40-820d-4866-95a5-b10bf44c83e8" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the carrying amount of intangible assets, net of accumulated amortization. </span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.584%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.424%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Carrying<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Carrying<br/>Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iafe3ea51a2814a819363caa378a6a94a_I20220331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl81NS9mcmFnOmYxNjVmMjIyM2VmNzRkMTdhY2Q0MGJmMGU5ZTJlMzNiL3RhYmxlOjY2Zjg4N2I0Njc5ZDQzNDdhMWIyODliNzc0ZDE3OGY0L3RhYmxlcmFuZ2U6NjZmODg3YjQ2NzlkNDM0N2ExYjI4OWI3NzRkMTc4ZjRfMi0yLTEtMS00Njg5MQ_e7f3fe2c-ed51-4b2b-b95d-4f49a3b20fa1">1,471</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iafe3ea51a2814a819363caa378a6a94a_I20220331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl81NS9mcmFnOmYxNjVmMjIyM2VmNzRkMTdhY2Q0MGJmMGU5ZTJlMzNiL3RhYmxlOjY2Zjg4N2I0Njc5ZDQzNDdhMWIyODliNzc0ZDE3OGY0L3RhYmxlcmFuZ2U6NjZmODg3YjQ2NzlkNDM0N2ExYjI4OWI3NzRkMTc4ZjRfMi00LTEtMS00Njg5MQ_d0b10162-272a-4aac-93ae-d547738e2acc">1,200</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iafe3ea51a2814a819363caa378a6a94a_I20220331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl81NS9mcmFnOmYxNjVmMjIyM2VmNzRkMTdhY2Q0MGJmMGU5ZTJlMzNiL3RhYmxlOjY2Zjg4N2I0Njc5ZDQzNDdhMWIyODliNzc0ZDE3OGY0L3RhYmxlcmFuZ2U6NjZmODg3YjQ2NzlkNDM0N2ExYjI4OWI3NzRkMTc4ZjRfMi02LTEtMS00Njg5MQ_d50e2f08-5b21-4a48-8396-10de49ef0c3a">271</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired intellectual property and reacquired rights</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24997e0475c34f689abd5af9a097e9c9_I20220331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl81NS9mcmFnOmYxNjVmMjIyM2VmNzRkMTdhY2Q0MGJmMGU5ZTJlMzNiL3RhYmxlOjY2Zjg4N2I0Njc5ZDQzNDdhMWIyODliNzc0ZDE3OGY0L3RhYmxlcmFuZ2U6NjZmODg3YjQ2NzlkNDM0N2ExYjI4OWI3NzRkMTc4ZjRfMy0yLTEtMS00Njg5MQ_cf14ecb4-b476-4b10-ae86-6b5dece898c2">15,126</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i24997e0475c34f689abd5af9a097e9c9_I20220331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl81NS9mcmFnOmYxNjVmMjIyM2VmNzRkMTdhY2Q0MGJmMGU5ZTJlMzNiL3RhYmxlOjY2Zjg4N2I0Njc5ZDQzNDdhMWIyODliNzc0ZDE3OGY0L3RhYmxlcmFuZ2U6NjZmODg3YjQ2NzlkNDM0N2ExYjI4OWI3NzRkMTc4ZjRfMy00LTEtMS00Njg5MQ_7ec1e670-e807-479f-b5b0-bf92e390cb25">9,063</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24997e0475c34f689abd5af9a097e9c9_I20220331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl81NS9mcmFnOmYxNjVmMjIyM2VmNzRkMTdhY2Q0MGJmMGU5ZTJlMzNiL3RhYmxlOjY2Zjg4N2I0Njc5ZDQzNDdhMWIyODliNzc0ZDE3OGY0L3RhYmxlcmFuZ2U6NjZmODg3YjQ2NzlkNDM0N2ExYjI4OWI3NzRkMTc4ZjRfMy02LTEtMS00Njg5MQ_484f16d7-9e3f-41d2-a1bc-fbea6c0b677f">6,063</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Internal-use software implementation costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8116ed39be8b477bb9e41a6b0e3aee53_I20220331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl81NS9mcmFnOmYxNjVmMjIyM2VmNzRkMTdhY2Q0MGJmMGU5ZTJlMzNiL3RhYmxlOjY2Zjg4N2I0Njc5ZDQzNDdhMWIyODliNzc0ZDE3OGY0L3RhYmxlcmFuZ2U6NjZmODg3YjQ2NzlkNDM0N2ExYjI4OWI3NzRkMTc4ZjRfNC0yLTEtMS00Njg5MQ_285ade06-e556-471f-a7ff-2c1e3e8ff662">2,873</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8116ed39be8b477bb9e41a6b0e3aee53_I20220331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl81NS9mcmFnOmYxNjVmMjIyM2VmNzRkMTdhY2Q0MGJmMGU5ZTJlMzNiL3RhYmxlOjY2Zjg4N2I0Njc5ZDQzNDdhMWIyODliNzc0ZDE3OGY0L3RhYmxlcmFuZ2U6NjZmODg3YjQ2NzlkNDM0N2ExYjI4OWI3NzRkMTc4ZjRfNC00LTEtMS00Njg5MQ_b4066554-1bb5-4bb6-b060-caa4e79df78e">1,325</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8116ed39be8b477bb9e41a6b0e3aee53_I20220331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl81NS9mcmFnOmYxNjVmMjIyM2VmNzRkMTdhY2Q0MGJmMGU5ZTJlMzNiL3RhYmxlOjY2Zjg4N2I0Njc5ZDQzNDdhMWIyODliNzc0ZDE3OGY0L3RhYmxlcmFuZ2U6NjZmODg3YjQ2NzlkNDM0N2ExYjI4OWI3NzRkMTc4ZjRfNC02LTEtMS00Njg5MQ_64981f8a-cefb-4942-bfa6-a2097d7d38db">1,548</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7882ae6aff54a3aacdef67ddf11a428_I20220331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl81NS9mcmFnOmYxNjVmMjIyM2VmNzRkMTdhY2Q0MGJmMGU5ZTJlMzNiL3RhYmxlOjY2Zjg4N2I0Njc5ZDQzNDdhMWIyODliNzc0ZDE3OGY0L3RhYmxlcmFuZ2U6NjZmODg3YjQ2NzlkNDM0N2ExYjI4OWI3NzRkMTc4ZjRfNS0yLTEtMS00Njg5MQ_4934b60a-ddea-40af-b24f-7094ea6add75">19,470</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id7882ae6aff54a3aacdef67ddf11a428_I20220331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl81NS9mcmFnOmYxNjVmMjIyM2VmNzRkMTdhY2Q0MGJmMGU5ZTJlMzNiL3RhYmxlOjY2Zjg4N2I0Njc5ZDQzNDdhMWIyODliNzc0ZDE3OGY0L3RhYmxlcmFuZ2U6NjZmODg3YjQ2NzlkNDM0N2ExYjI4OWI3NzRkMTc4ZjRfNS00LTEtMS00Njg5MQ_ba6511ec-41f1-4bd3-aea2-9024a44b26ec">11,588</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7882ae6aff54a3aacdef67ddf11a428_I20220331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl81NS9mcmFnOmYxNjVmMjIyM2VmNzRkMTdhY2Q0MGJmMGU5ZTJlMzNiL3RhYmxlOjY2Zjg4N2I0Njc5ZDQzNDdhMWIyODliNzc0ZDE3OGY0L3RhYmxlcmFuZ2U6NjZmODg3YjQ2NzlkNDM0N2ExYjI4OWI3NzRkMTc4ZjRfNS02LTEtMS00Njg5MQ_831c25d9-2035-489d-84bb-c584b8d63015">7,882</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:7pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.584%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.424%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Carrying<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Carrying<br/>Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb5a73ea0d9f46779238702423cc8e54_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl81NS9mcmFnOmYxNjVmMjIyM2VmNzRkMTdhY2Q0MGJmMGU5ZTJlMzNiL3RhYmxlOjE0YWM4NmU1OWM3MDQ5ZjdiZDA0YTMzZmY5OTdmZmRlL3RhYmxlcmFuZ2U6MTRhYzg2ZTU5YzcwNDlmN2JkMDRhMzNmZjk5N2ZmZGVfMi0yLTEtMS00Njg5MQ_0f45958a-59e0-4091-9a42-410c2328aa94">1,471</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb5a73ea0d9f46779238702423cc8e54_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl81NS9mcmFnOmYxNjVmMjIyM2VmNzRkMTdhY2Q0MGJmMGU5ZTJlMzNiL3RhYmxlOjE0YWM4NmU1OWM3MDQ5ZjdiZDA0YTMzZmY5OTdmZmRlL3RhYmxlcmFuZ2U6MTRhYzg2ZTU5YzcwNDlmN2JkMDRhMzNmZjk5N2ZmZGVfMi00LTEtMS00Njg5MQ_987e879a-8961-4692-b22a-8ac3b4b90c43">1,176</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb5a73ea0d9f46779238702423cc8e54_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl81NS9mcmFnOmYxNjVmMjIyM2VmNzRkMTdhY2Q0MGJmMGU5ZTJlMzNiL3RhYmxlOjE0YWM4NmU1OWM3MDQ5ZjdiZDA0YTMzZmY5OTdmZmRlL3RhYmxlcmFuZ2U6MTRhYzg2ZTU5YzcwNDlmN2JkMDRhMzNmZjk5N2ZmZGVfMi02LTEtMS00Njg5MQ_d65f4900-79ce-4f00-bfd6-7bbcb6f66295">295</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired intellectual property and reacquired rights</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2473f3d624824cfa9dc37ac978052ad5_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl81NS9mcmFnOmYxNjVmMjIyM2VmNzRkMTdhY2Q0MGJmMGU5ZTJlMzNiL3RhYmxlOjE0YWM4NmU1OWM3MDQ5ZjdiZDA0YTMzZmY5OTdmZmRlL3RhYmxlcmFuZ2U6MTRhYzg2ZTU5YzcwNDlmN2JkMDRhMzNmZjk5N2ZmZGVfMy0yLTEtMS00Njg5MQ_57ac1b7f-2ee4-4480-acfd-d9730baf70bc">15,126</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2473f3d624824cfa9dc37ac978052ad5_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl81NS9mcmFnOmYxNjVmMjIyM2VmNzRkMTdhY2Q0MGJmMGU5ZTJlMzNiL3RhYmxlOjE0YWM4NmU1OWM3MDQ5ZjdiZDA0YTMzZmY5OTdmZmRlL3RhYmxlcmFuZ2U6MTRhYzg2ZTU5YzcwNDlmN2JkMDRhMzNmZjk5N2ZmZGVfMy00LTEtMS00Njg5MQ_1e74cc1e-426e-41a2-9430-69b1b2fcb079">8,804</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2473f3d624824cfa9dc37ac978052ad5_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl81NS9mcmFnOmYxNjVmMjIyM2VmNzRkMTdhY2Q0MGJmMGU5ZTJlMzNiL3RhYmxlOjE0YWM4NmU1OWM3MDQ5ZjdiZDA0YTMzZmY5OTdmZmRlL3RhYmxlcmFuZ2U6MTRhYzg2ZTU5YzcwNDlmN2JkMDRhMzNmZjk5N2ZmZGVfMy02LTEtMS00Njg5MQ_d66c17f5-d632-4e2f-b1f8-5a5b6890eb5d">6,322</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Internal-use software implementation costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b3926824aa84496acd5d466e41d1cb4_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl81NS9mcmFnOmYxNjVmMjIyM2VmNzRkMTdhY2Q0MGJmMGU5ZTJlMzNiL3RhYmxlOjE0YWM4NmU1OWM3MDQ5ZjdiZDA0YTMzZmY5OTdmZmRlL3RhYmxlcmFuZ2U6MTRhYzg2ZTU5YzcwNDlmN2JkMDRhMzNmZjk5N2ZmZGVfNC0yLTEtMS00Njg5MQ_27688142-e91a-4587-9751-f0343b947ae9">2,873</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1b3926824aa84496acd5d466e41d1cb4_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl81NS9mcmFnOmYxNjVmMjIyM2VmNzRkMTdhY2Q0MGJmMGU5ZTJlMzNiL3RhYmxlOjE0YWM4NmU1OWM3MDQ5ZjdiZDA0YTMzZmY5OTdmZmRlL3RhYmxlcmFuZ2U6MTRhYzg2ZTU5YzcwNDlmN2JkMDRhMzNmZjk5N2ZmZGVfNC00LTEtMS00Njg5MQ_c9a60279-e1f3-426f-924c-290f7ef7ce53">1,086</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b3926824aa84496acd5d466e41d1cb4_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl81NS9mcmFnOmYxNjVmMjIyM2VmNzRkMTdhY2Q0MGJmMGU5ZTJlMzNiL3RhYmxlOjE0YWM4NmU1OWM3MDQ5ZjdiZDA0YTMzZmY5OTdmZmRlL3RhYmxlcmFuZ2U6MTRhYzg2ZTU5YzcwNDlmN2JkMDRhMzNmZjk5N2ZmZGVfNC02LTEtMS00Njg5MQ_8869a134-cb30-407a-897a-a9c65c463f89">1,787</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i784f65549351439fa4b7bedf90ce7e3f_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl81NS9mcmFnOmYxNjVmMjIyM2VmNzRkMTdhY2Q0MGJmMGU5ZTJlMzNiL3RhYmxlOjE0YWM4NmU1OWM3MDQ5ZjdiZDA0YTMzZmY5OTdmZmRlL3RhYmxlcmFuZ2U6MTRhYzg2ZTU5YzcwNDlmN2JkMDRhMzNmZjk5N2ZmZGVfNS0yLTEtMS00Njg5MQ_1d54d1e1-0966-49b8-9eed-30dfcadd930d">19,470</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i784f65549351439fa4b7bedf90ce7e3f_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl81NS9mcmFnOmYxNjVmMjIyM2VmNzRkMTdhY2Q0MGJmMGU5ZTJlMzNiL3RhYmxlOjE0YWM4NmU1OWM3MDQ5ZjdiZDA0YTMzZmY5OTdmZmRlL3RhYmxlcmFuZ2U6MTRhYzg2ZTU5YzcwNDlmN2JkMDRhMzNmZjk5N2ZmZGVfNS00LTEtMS00Njg5MQ_bdec8dec-8550-4b83-a4c9-b2d05edcd0e0">11,066</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i784f65549351439fa4b7bedf90ce7e3f_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl81NS9mcmFnOmYxNjVmMjIyM2VmNzRkMTdhY2Q0MGJmMGU5ZTJlMzNiL3RhYmxlOjE0YWM4NmU1OWM3MDQ5ZjdiZDA0YTMzZmY5OTdmZmRlL3RhYmxlcmFuZ2U6MTRhYzg2ZTU5YzcwNDlmN2JkMDRhMzNmZjk5N2ZmZGVfNS02LTEtMS00Njg5MQ_e4b0c3d5-ea67-499c-88b5-ec74edeb710d">8,404</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i4ab5cbfe05c447338a57cebd6d0a9ed5">Amortization expense for the three months ended March&#160;31, 2022 and 2021 was $<ix:nonFraction unitRef="usd" contextRef="i56599386fa47443a8975bb3f7a6a8c57_D20210101-20210331" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl81NS9mcmFnOmYxNjVmMjIyM2VmNzRkMTdhY2Q0MGJmMGU5ZTJlMzNiL3RleHRyZWdpb246ZjE2NWYyMjIzZWY3NGQxN2FjZDQwYmYwZTllMmUzM2JfMTk2_08c9e462-5bc8-49d4-9408-971fc001b56b"><ix:nonFraction unitRef="usd" contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl81NS9mcmFnOmYxNjVmMjIyM2VmNzRkMTdhY2Q0MGJmMGU5ZTJlMzNiL3RleHRyZWdpb246ZjE2NWYyMjIzZWY3NGQxN2FjZDQwYmYwZTllMmUzM2JfMTk2_74d839ed-76d4-4785-bbff-b8d9d557397f">0.5</ix:nonFraction></ix:nonFraction> million for both periods.</ix:continuation> </span></div><div style="margin-top:2pt;text-align:justify"><span><br/></span></div><div id="i2d3a8f7e52e84dcebfa935bec5ca9eb6_58"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl81OC9mcmFnOmJhZmFkMmZjZGQ5OTRkMmE4ZmQxMTg4M2Y0NjcxMjNmL3RleHRyZWdpb246YmFmYWQyZmNkZDk5NGQyYThmZDExODgzZjQ2NzEyM2ZfMzMx_5f216d3d-af9d-446c-887c-f09893b38b7a" continuedAt="i17965cbd73a94141a1b80f397bc250c6" escape="true">Property and Equipment, net</ix:nonNumeric></span></div><ix:continuation id="i17965cbd73a94141a1b80f397bc250c6"><ix:nonNumeric contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl81OC9mcmFnOmJhZmFkMmZjZGQ5OTRkMmE4ZmQxMTg4M2Y0NjcxMjNmL3RleHRyZWdpb246YmFmYWQyZmNkZDk5NGQyYThmZDExODgzZjQ2NzEyM2ZfMzMy_3c6c8a7f-5ec9-490c-880f-f09b7e34d518" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net are as follows: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.347%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24b881bff2734aaa92863336ea94e41e_I20220331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl81OC9mcmFnOmJhZmFkMmZjZGQ5OTRkMmE4ZmQxMTg4M2Y0NjcxMjNmL3RhYmxlOmJiYWM2MmRmZTQwMzQ5ZDI5MDJhYzNjOWVlZTA4YmRjL3RhYmxlcmFuZ2U6YmJhYzYyZGZlNDAzNDlkMjkwMmFjM2M5ZWVlMDhiZGNfMS0yLTEtMS00Njg5MQ_1678b718-440b-426f-9518-2225de11f32c">472</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33ea857e82c542399286eb48ddbe86ef_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl81OC9mcmFnOmJhZmFkMmZjZGQ5OTRkMmE4ZmQxMTg4M2Y0NjcxMjNmL3RhYmxlOmJiYWM2MmRmZTQwMzQ5ZDI5MDJhYzNjOWVlZTA4YmRjL3RhYmxlcmFuZ2U6YmJhYzYyZGZlNDAzNDlkMjkwMmFjM2M5ZWVlMDhiZGNfMS00LTEtMS00Njg5MQ_60e1ccea-46de-49a1-af8b-3b364382cdc7">393</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92bd80a74b4b4c98b74a56c4941dbae8_I20220331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl81OC9mcmFnOmJhZmFkMmZjZGQ5OTRkMmE4ZmQxMTg4M2Y0NjcxMjNmL3RhYmxlOmJiYWM2MmRmZTQwMzQ5ZDI5MDJhYzNjOWVlZTA4YmRjL3RhYmxlcmFuZ2U6YmJhYzYyZGZlNDAzNDlkMjkwMmFjM2M5ZWVlMDhiZGNfMi0yLTEtMS00Njg5MQ_cf03e423-c6f0-46da-9206-74b842c66a88">2,978</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic252965e91864c4ca85c5288d34a489d_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl81OC9mcmFnOmJhZmFkMmZjZGQ5OTRkMmE4ZmQxMTg4M2Y0NjcxMjNmL3RhYmxlOmJiYWM2MmRmZTQwMzQ5ZDI5MDJhYzNjOWVlZTA4YmRjL3RhYmxlcmFuZ2U6YmJhYzYyZGZlNDAzNDlkMjkwMmFjM2M5ZWVlMDhiZGNfMi00LTEtMS00Njg5MQ_c465fdd1-e066-404f-bcbd-578c7be17907">2,978</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8b21348dac34f0191509120fede5c4c_I20220331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl81OC9mcmFnOmJhZmFkMmZjZGQ5OTRkMmE4ZmQxMTg4M2Y0NjcxMjNmL3RhYmxlOmJiYWM2MmRmZTQwMzQ5ZDI5MDJhYzNjOWVlZTA4YmRjL3RhYmxlcmFuZ2U6YmJhYzYyZGZlNDAzNDlkMjkwMmFjM2M5ZWVlMDhiZGNfMy0yLTEtMS00Njg5MQ_c63dd669-fa7e-4115-9532-454d41d560ec">645</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a37e52ecdc4461f971b3b1b848318b1_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl81OC9mcmFnOmJhZmFkMmZjZGQ5OTRkMmE4ZmQxMTg4M2Y0NjcxMjNmL3RhYmxlOmJiYWM2MmRmZTQwMzQ5ZDI5MDJhYzNjOWVlZTA4YmRjL3RhYmxlcmFuZ2U6YmJhYzYyZGZlNDAzNDlkMjkwMmFjM2M5ZWVlMDhiZGNfMy00LTEtMS00Njg5MQ_04ae6f9c-8716-4c40-a4e1-6399f27ecbb8">645</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8774cc7bdb954684aaebe802c8d2b5ca_I20220331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl81OC9mcmFnOmJhZmFkMmZjZGQ5OTRkMmE4ZmQxMTg4M2Y0NjcxMjNmL3RhYmxlOmJiYWM2MmRmZTQwMzQ5ZDI5MDJhYzNjOWVlZTA4YmRjL3RhYmxlcmFuZ2U6YmJhYzYyZGZlNDAzNDlkMjkwMmFjM2M5ZWVlMDhiZGNfNC0yLTEtMS01MTI2NQ_370a8a2e-1586-4e99-92b0-266dff6820de">976</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida382f7681f54ed38ba2838dbf0642cd_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl81OC9mcmFnOmJhZmFkMmZjZGQ5OTRkMmE4ZmQxMTg4M2Y0NjcxMjNmL3RhYmxlOmJiYWM2MmRmZTQwMzQ5ZDI5MDJhYzNjOWVlZTA4YmRjL3RhYmxlcmFuZ2U6YmJhYzYyZGZlNDAzNDlkMjkwMmFjM2M5ZWVlMDhiZGNfNC00LTEtMS01MTI2NQ_d7cb67db-3e79-45bb-bb83-90237570289f">976</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8a4d21008a14bdda5d40b91949726ff_I20220331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl81OC9mcmFnOmJhZmFkMmZjZGQ5OTRkMmE4ZmQxMTg4M2Y0NjcxMjNmL3RhYmxlOmJiYWM2MmRmZTQwMzQ5ZDI5MDJhYzNjOWVlZTA4YmRjL3RhYmxlcmFuZ2U6YmJhYzYyZGZlNDAzNDlkMjkwMmFjM2M5ZWVlMDhiZGNfNC0yLTEtMS00Njg5MQ_5c91b82e-5382-4d24-9afd-c6209cd746d1">260</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic45495e9bd3646529b0eba68d7729780_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl81OC9mcmFnOmJhZmFkMmZjZGQ5OTRkMmE4ZmQxMTg4M2Y0NjcxMjNmL3RhYmxlOmJiYWM2MmRmZTQwMzQ5ZDI5MDJhYzNjOWVlZTA4YmRjL3RhYmxlcmFuZ2U6YmJhYzYyZGZlNDAzNDlkMjkwMmFjM2M5ZWVlMDhiZGNfNC00LTEtMS00Njg5MQ_ec45be7e-963d-49e9-8522-b65d3aab8d6d">262</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7882ae6aff54a3aacdef67ddf11a428_I20220331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl81OC9mcmFnOmJhZmFkMmZjZGQ5OTRkMmE4ZmQxMTg4M2Y0NjcxMjNmL3RhYmxlOmJiYWM2MmRmZTQwMzQ5ZDI5MDJhYzNjOWVlZTA4YmRjL3RhYmxlcmFuZ2U6YmJhYzYyZGZlNDAzNDlkMjkwMmFjM2M5ZWVlMDhiZGNfNS0yLTEtMS00Njg5MQ_4aa40ac3-0bb2-4905-8f01-120d758218b4">5,331</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i784f65549351439fa4b7bedf90ce7e3f_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl81OC9mcmFnOmJhZmFkMmZjZGQ5OTRkMmE4ZmQxMTg4M2Y0NjcxMjNmL3RhYmxlOmJiYWM2MmRmZTQwMzQ5ZDI5MDJhYzNjOWVlZTA4YmRjL3RhYmxlcmFuZ2U6YmJhYzYyZGZlNDAzNDlkMjkwMmFjM2M5ZWVlMDhiZGNfNS00LTEtMS00Njg5MQ_61a3a265-ee2b-4718-a676-3ad579131915">5,254</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated depreciation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id7882ae6aff54a3aacdef67ddf11a428_I20220331" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl81OC9mcmFnOmJhZmFkMmZjZGQ5OTRkMmE4ZmQxMTg4M2Y0NjcxMjNmL3RhYmxlOmJiYWM2MmRmZTQwMzQ5ZDI5MDJhYzNjOWVlZTA4YmRjL3RhYmxlcmFuZ2U6YmJhYzYyZGZlNDAzNDlkMjkwMmFjM2M5ZWVlMDhiZGNfNi0yLTEtMS00Njg5MQ_e5f32d74-f30e-43b2-b857-9879ec05d607">999</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i784f65549351439fa4b7bedf90ce7e3f_I20211231" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl81OC9mcmFnOmJhZmFkMmZjZGQ5OTRkMmE4ZmQxMTg4M2Y0NjcxMjNmL3RhYmxlOmJiYWM2MmRmZTQwMzQ5ZDI5MDJhYzNjOWVlZTA4YmRjL3RhYmxlcmFuZ2U6YmJhYzYyZGZlNDAzNDlkMjkwMmFjM2M5ZWVlMDhiZGNfNi00LTEtMS00Njg5MQ_ac024879-d553-4aac-8cb7-d49c92dd5e62">836</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7882ae6aff54a3aacdef67ddf11a428_I20220331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl81OC9mcmFnOmJhZmFkMmZjZGQ5OTRkMmE4ZmQxMTg4M2Y0NjcxMjNmL3RhYmxlOmJiYWM2MmRmZTQwMzQ5ZDI5MDJhYzNjOWVlZTA4YmRjL3RhYmxlcmFuZ2U6YmJhYzYyZGZlNDAzNDlkMjkwMmFjM2M5ZWVlMDhiZGNfNy0yLTEtMS00Njg5MQ_981bf617-2e87-4115-ad11-4cf98a8a9f32">4,332</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i784f65549351439fa4b7bedf90ce7e3f_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl81OC9mcmFnOmJhZmFkMmZjZGQ5OTRkMmE4ZmQxMTg4M2Y0NjcxMjNmL3RhYmxlOmJiYWM2MmRmZTQwMzQ5ZDI5MDJhYzNjOWVlZTA4YmRjL3RhYmxlcmFuZ2U6YmJhYzYyZGZlNDAzNDlkMjkwMmFjM2M5ZWVlMDhiZGNfNy00LTEtMS00Njg5MQ_09096ec0-532b-471e-976f-3b1741a7b96a">4,418</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><div id="i2d3a8f7e52e84dcebfa935bec5ca9eb6_61"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl82MS9mcmFnOjhhNTE5MDJjNjUzMDQ2NWQ5MWE2MWM4NGJmMTVjYjJiL3RleHRyZWdpb246OGE1MTkwMmM2NTMwNDY1ZDkxYTYxYzg0YmYxNWNiMmJfNDgwNQ_368b1db0-9676-4b8d-99b4-21bd70d9eb91" continuedAt="i7450f1bc6e144c93910d8c437bf9abca" escape="true">Lease Obligations</ix:nonNumeric></span></div><ix:continuation id="i7450f1bc6e144c93910d8c437bf9abca" continuedAt="i78d50910ac384c9c9ae07eacf45ba372"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has the following lease obligations:</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Victoria, British Columbia</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the fourth quarter of 2020, the Company entered into facility and furniture leases for its head office located in Victoria, British Columbia for a total space of <ix:nonFraction unitRef="sqft" contextRef="i5a90c58801134d6383b036247c03afa2_I20201231" decimals="0" name="us-gaap:AreaOfRealEstateProperty" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl82MS9mcmFnOjhhNTE5MDJjNjUzMDQ2NWQ5MWE2MWM4NGJmMTVjYjJiL3RleHRyZWdpb246OGE1MTkwMmM2NTMwNDY1ZDkxYTYxYzg0YmYxNWNiMmJfNDgwOA_64a89957-8178-4a78-a9f5-56fc81472874">13,206</ix:nonFraction> square feet of office space for the facility lease. The lease terms commenced on January 1, 2021 for the facility and furniture leases. As of March&#160;31, 2022, the Company had $<ix:nonFraction unitRef="usd" contextRef="i9d7a2759ec7d41e3937bd48023be99f9_I20220331" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl82MS9mcmFnOjhhNTE5MDJjNjUzMDQ2NWQ5MWE2MWM4NGJmMTVjYjJiL3RleHRyZWdpb246OGE1MTkwMmM2NTMwNDY1ZDkxYTYxYzg0YmYxNWNiMmJfNDM2_f1da340e-f7a7-48f7-981b-952c8c162292">0.1</ix:nonFraction> million right-of-use assets (ROU assets) and $<ix:nonFraction unitRef="usd" contextRef="i9d7a2759ec7d41e3937bd48023be99f9_I20220331" decimals="-5" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl82MS9mcmFnOjhhNTE5MDJjNjUzMDQ2NWQ5MWE2MWM4NGJmMTVjYjJiL3RleHRyZWdpb246OGE1MTkwMmM2NTMwNDY1ZDkxYTYxYzg0YmYxNWNiMmJfNDgwMQ_926baa62-2c82-4fbe-b338-96b4acd0ca3d">0.1</ix:nonFraction> million lease liabilities related to the leases. The Company recognized operating lease costs that are included in SG&amp;A expenses in the condensed consolidated statements of operations. The incremental borrowing rate applied to the lease liabilities on January 1, 2021 was <ix:nonFraction unitRef="number" contextRef="i6d2b9fee1c02434b9949db0279cfaf7f_I20210101" decimals="4" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl82MS9mcmFnOjhhNTE5MDJjNjUzMDQ2NWQ5MWE2MWM4NGJmMTVjYjJiL3RleHRyZWdpb246OGE1MTkwMmM2NTMwNDY1ZDkxYTYxYzg0YmYxNWNiMmJfNzIy_909de453-1e79-49f3-a0c9-ee936f4628ef">4.08</ix:nonFraction>% based on financial position of the Company, geographical region and terms of lease.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During August 2020, the Company signed a lease for commercial office space in Victoria, British Columbia. The present value of the expected minimum lease payments for this lease are $<ix:nonFraction unitRef="usd" contextRef="i495ff60b2f3b469a944a5922a5e9036d_I20200831" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl82MS9mcmFnOjhhNTE5MDJjNjUzMDQ2NWQ5MWE2MWM4NGJmMTVjYjJiL3RleHRyZWdpb246OGE1MTkwMmM2NTMwNDY1ZDkxYTYxYzg0YmYxNWNiMmJfMTAxMw_54c338b3-b17a-458e-874b-0e34156fc7fd">2.3</ix:nonFraction>&#160;million. As of March&#160;31, 2022, the lease has not commenced and as a result, there has been no accounting recognition associated with the lease.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Rockville, Maryland</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During March 2020, the Company entered into a lease for its U.S. commercial office in Rockville, Maryland for a total of <ix:nonFraction unitRef="sqft" contextRef="ia4a97e4de8cb475abddcffdb81d0a5d1_I20200331" decimals="0" name="us-gaap:AreaOfRealEstateProperty" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl82MS9mcmFnOjhhNTE5MDJjNjUzMDQ2NWQ5MWE2MWM4NGJmMTVjYjJiL3RleHRyZWdpb246OGE1MTkwMmM2NTMwNDY1ZDkxYTYxYzg0YmYxNWNiMmJfMzI5ODUzNDg4OTQ1MA_b24e4d09-5002-408f-bb86-da1447ec221e">30,531</ix:nonFraction> square feet of office space. The lease has a remaining term of approximately <ix:nonNumeric contextRef="ia4a97e4de8cb475abddcffdb81d0a5d1_I20200331" name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl82MS9mcmFnOjhhNTE5MDJjNjUzMDQ2NWQ5MWE2MWM4NGJmMTVjYjJiL3RleHRyZWdpb246OGE1MTkwMmM2NTMwNDY1ZDkxYTYxYzg0YmYxNWNiMmJfMTMwOQ_2bd19f30-e2f6-416d-b445-36e4ce07ad4e">9</ix:nonNumeric> years and has an option to extend for <ix:nonFraction unitRef="extension_option" contextRef="ia4a97e4de8cb475abddcffdb81d0a5d1_I20200331" decimals="INF" name="auph:LesseeOperatingLeaseNumberOfExtensionOptions" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl82MS9mcmFnOjhhNTE5MDJjNjUzMDQ2NWQ5MWE2MWM4NGJmMTVjYjJiL3RleHRyZWdpb246OGE1MTkwMmM2NTMwNDY1ZDkxYTYxYzg0YmYxNWNiMmJfMTM0NA_f516fb95-b270-4ed7-b751-356ba856ba2a">two</ix:nonFraction> <ix:nonNumeric contextRef="ia4a97e4de8cb475abddcffdb81d0a5d1_I20200331" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl82MS9mcmFnOjhhNTE5MDJjNjUzMDQ2NWQ5MWE2MWM4NGJmMTVjYjJiL3RleHRyZWdpb246OGE1MTkwMmM2NTMwNDY1ZDkxYTYxYzg0YmYxNWNiMmJfNDgwMw_3d985f07-0690-41ad-9d3b-17d6a45afe2a">five-year</ix:nonNumeric> periods after the initial term of <ix:nonNumeric contextRef="ia4a97e4de8cb475abddcffdb81d0a5d1_I20200331" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl82MS9mcmFnOjhhNTE5MDJjNjUzMDQ2NWQ5MWE2MWM4NGJmMTVjYjJiL3RleHRyZWdpb246OGE1MTkwMmM2NTMwNDY1ZDkxYTYxYzg0YmYxNWNiMmJfMTM3Mw_455fafcc-b2cb-471a-878c-705eea37b5b3">11</ix:nonNumeric> years has elapsed and has an option to terminate after <ix:nonNumeric contextRef="i5aa97519cf354667a42c1e73e81155c5_D20200301-20200331" name="auph:LesseeOperatingLeaseLeaseTerminationTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl82MS9mcmFnOjhhNTE5MDJjNjUzMDQ2NWQ5MWE2MWM4NGJmMTVjYjJiL3RleHRyZWdpb246OGE1MTkwMmM2NTMwNDY1ZDkxYTYxYzg0YmYxNWNiMmJfMTQyNQ_e3c1d73a-934f-4c4b-adda-119a009956d5">seven years</ix:nonNumeric>. As of March&#160;31, 2022, the Company had a right-of-use asset of $<ix:nonFraction unitRef="usd" contextRef="i0d45f33fe1934685a0328a1b8e0fb9fa_I20220331" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl82MS9mcmFnOjhhNTE5MDJjNjUzMDQ2NWQ5MWE2MWM4NGJmMTVjYjJiL3RleHRyZWdpb246OGE1MTkwMmM2NTMwNDY1ZDkxYTYxYzg0YmYxNWNiMmJfMTQ3OQ_b1fa2da1-0e77-448b-a1f2-43aa5897be48">5.1</ix:nonFraction> million and lease liability of $<ix:nonFraction unitRef="usd" contextRef="i0d45f33fe1934685a0328a1b8e0fb9fa_I20220331" decimals="-5" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl82MS9mcmFnOjhhNTE5MDJjNjUzMDQ2NWQ5MWE2MWM4NGJmMTVjYjJiL3RleHRyZWdpb246OGE1MTkwMmM2NTMwNDY1ZDkxYTYxYzg0YmYxNWNiMmJfMTUwNQ_1a7b9ac4-d7fe-40f0-bf89-2f7ba2319398">8.5</ix:nonFraction> million included in the condensed consolidated balance sheets. As of December&#160;31, 2021, the Company had a right of use asset of $<ix:nonFraction unitRef="usd" contextRef="iaf32dde531a54bedaeee2771bb3cf07c_I20211231" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl82MS9mcmFnOjhhNTE5MDJjNjUzMDQ2NWQ5MWE2MWM4NGJmMTVjYjJiL3RleHRyZWdpb246OGE1MTkwMmM2NTMwNDY1ZDkxYTYxYzg0YmYxNWNiMmJfMTYxMw_49955f62-bd5c-4ee1-bfd6-79d26d2261c9">5.2</ix:nonFraction> million and lease liability of $<ix:nonFraction unitRef="usd" contextRef="iaf32dde531a54bedaeee2771bb3cf07c_I20211231" decimals="-5" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl82MS9mcmFnOjhhNTE5MDJjNjUzMDQ2NWQ5MWE2MWM4NGJmMTVjYjJiL3RleHRyZWdpb246OGE1MTkwMmM2NTMwNDY1ZDkxYTYxYzg0YmYxNWNiMmJfMTYzOQ_1d535375-13dd-405b-acf5-b478d17f3c60">8.6</ix:nonFraction> million included in the condensed consolidated balance sheets. The Company recorded leasehold improvement incentives in the amount of $<ix:nonFraction unitRef="usd" contextRef="i26b07d59c782432196f10a8bbea26c86_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:PaymentsForProceedsFromTenantAllowance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl82MS9mcmFnOjhhNTE5MDJjNjUzMDQ2NWQ5MWE2MWM4NGJmMTVjYjJiL3RleHRyZWdpb246OGE1MTkwMmM2NTMwNDY1ZDkxYTYxYzg0YmYxNWNiMmJfMzI5ODUzNDg5NTA5NA_a557682c-3ade-477e-8874-7c6de4bc75e4">2.3</ix:nonFraction>&#160;million as additions to the lease liability. The lease term commenced on March 12, 2020. When measuring the lease liability, the Company discounted lease payments using its incremental borrowing rate at March 12, 2020. The incremental borrowing rate applied to the lease liability on March 12, 2020 was <ix:nonFraction unitRef="number" contextRef="i32b726a815d044a59392431a6d822684_I20200312" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl82MS9mcmFnOjhhNTE5MDJjNjUzMDQ2NWQ5MWE2MWM4NGJmMTVjYjJiL3RleHRyZWdpb246OGE1MTkwMmM2NTMwNDY1ZDkxYTYxYzg0YmYxNWNiMmJfMjE5NQ_7cab6834-b849-476e-b828-955c33f4c8a7">5.2</ix:nonFraction>% based on the financial position of the Company, geographical region and term of lease.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Edmonton, Alberta</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized the lease premises in Edmonton, Alberta as a short-term lease in which expenses are incurred in SG&amp;A. The lease is not material to the Company's financial position.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning January 1, 2021, the Company began to incur variable lease costs under the existing Victoria and Rockville leases. These costs include operation and maintenance costs included in SG&amp;A and are expensed as incurred. The variable leases costs are not material to the Company's financial position.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The operating lease costs for the three months ended March&#160;31, 2022 and March&#160;31, 2021 are $<ix:nonFraction unitRef="usd" contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331" decimals="-5" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl82MS9mcmFnOjhhNTE5MDJjNjUzMDQ2NWQ5MWE2MWM4NGJmMTVjYjJiL3RleHRyZWdpb246OGE1MTkwMmM2NTMwNDY1ZDkxYTYxYzg0YmYxNWNiMmJfMzI5ODUzNDg5NTEwOA_0826e651-a62d-49ff-9b53-9dea7002994f"><ix:nonFraction unitRef="usd" contextRef="i56599386fa47443a8975bb3f7a6a8c57_D20210101-20210331" decimals="-5" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl82MS9mcmFnOjhhNTE5MDJjNjUzMDQ2NWQ5MWE2MWM4NGJmMTVjYjJiL3RleHRyZWdpb246OGE1MTkwMmM2NTMwNDY1ZDkxYTYxYzg0YmYxNWNiMmJfMzI5ODUzNDg5NTEwOA_ba81a244-a17d-4bf9-bea5-da2e56a5067c">0.3</ix:nonFraction></ix:nonFraction>&#160;million for both periods.</span></div><ix:nonNumeric contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331" name="auph:AssetsAndLiabilitiesLesseeTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl82MS9mcmFnOjhhNTE5MDJjNjUzMDQ2NWQ5MWE2MWM4NGJmMTVjYjJiL3RleHRyZWdpb246OGE1MTkwMmM2NTMwNDY1ZDkxYTYxYzg0YmYxNWNiMmJfNDc5OA_5c9b716f-6669-40d9-a944-3b0a71c293d6" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides supplemental balance sheet information related to the operating lease ROU assets and lease liabilities:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.087%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.747%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.297%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.717%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance Sheet Classification</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right of-use assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7882ae6aff54a3aacdef67ddf11a428_I20220331" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl82MS9mcmFnOjhhNTE5MDJjNjUzMDQ2NWQ5MWE2MWM4NGJmMTVjYjJiL3RhYmxlOmRmODBmMzRmZGYyMTRiZmRhNDU0YTQ2ZjQ0ODVkZTQyL3RhYmxlcmFuZ2U6ZGY4MGYzNGZkZjIxNGJmZGE0NTRhNDZmNDQ4NWRlNDJfMi00LTEtMS00Njg5MQ_be7e4dc2-461d-4405-875f-4e141a65d2c1">5,232</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i784f65549351439fa4b7bedf90ce7e3f_I20211231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl82MS9mcmFnOjhhNTE5MDJjNjUzMDQ2NWQ5MWE2MWM4NGJmMTVjYjJiL3RhYmxlOmRmODBmMzRmZGYyMTRiZmRhNDU0YTQ2ZjQ0ODVkZTQyL3RhYmxlcmFuZ2U6ZGY4MGYzNGZkZjIxNGJmZGE0NTRhNDZmNDQ4NWRlNDJfMi02LTEtMS00Njg5MQ_b905961e-621b-46c6-ab3d-b3db6662f58b">5,383</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7882ae6aff54a3aacdef67ddf11a428_I20220331" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl82MS9mcmFnOjhhNTE5MDJjNjUzMDQ2NWQ5MWE2MWM4NGJmMTVjYjJiL3RhYmxlOmRmODBmMzRmZGYyMTRiZmRhNDU0YTQ2ZjQ0ODVkZTQyL3RhYmxlcmFuZ2U6ZGY4MGYzNGZkZjIxNGJmZGE0NTRhNDZmNDQ4NWRlNDJfNS00LTEtMS00Njg5MQ_4782767e-6791-4668-b3da-179f41e5ac7f">1,009</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i784f65549351439fa4b7bedf90ce7e3f_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl82MS9mcmFnOjhhNTE5MDJjNjUzMDQ2NWQ5MWE2MWM4NGJmMTVjYjJiL3RhYmxlOmRmODBmMzRmZGYyMTRiZmRhNDU0YTQ2ZjQ0ODVkZTQyL3RhYmxlcmFuZ2U6ZGY4MGYzNGZkZjIxNGJmZGE0NTRhNDZmNDQ4NWRlNDJfNS02LTEtMS00Njg5MQ_ef4bd689-2dd0-449e-b3ae-99fe697051e9">1,059</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7882ae6aff54a3aacdef67ddf11a428_I20220331" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl82MS9mcmFnOjhhNTE5MDJjNjUzMDQ2NWQ5MWE2MWM4NGJmMTVjYjJiL3RhYmxlOmRmODBmMzRmZGYyMTRiZmRhNDU0YTQ2ZjQ0ODVkZTQyL3RhYmxlcmFuZ2U6ZGY4MGYzNGZkZjIxNGJmZGE0NTRhNDZmNDQ4NWRlNDJfNi00LTEtMS00Njg5MQ_76dbbd9c-fc2c-410d-8997-437074a6f77e">7,562</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i784f65549351439fa4b7bedf90ce7e3f_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl82MS9mcmFnOjhhNTE5MDJjNjUzMDQ2NWQ5MWE2MWM4NGJmMTVjYjJiL3RhYmxlOmRmODBmMzRmZGYyMTRiZmRhNDU0YTQ2ZjQ0ODVkZTQyL3RhYmxlcmFuZ2U6ZGY4MGYzNGZkZjIxNGJmZGE0NTRhNDZmNDQ4NWRlNDJfNi02LTEtMS00Njg5MQ_e281467a-cf43-4012-8b25-b9fe174a62f7">7,680</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7882ae6aff54a3aacdef67ddf11a428_I20220331" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl82MS9mcmFnOjhhNTE5MDJjNjUzMDQ2NWQ5MWE2MWM4NGJmMTVjYjJiL3RhYmxlOmRmODBmMzRmZGYyMTRiZmRhNDU0YTQ2ZjQ0ODVkZTQyL3RhYmxlcmFuZ2U6ZGY4MGYzNGZkZjIxNGJmZGE0NTRhNDZmNDQ4NWRlNDJfNy00LTEtMS00Njg5MQ_1eabbfe2-e0e4-4ceb-972f-f41e19493f50">8,571</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i784f65549351439fa4b7bedf90ce7e3f_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl82MS9mcmFnOjhhNTE5MDJjNjUzMDQ2NWQ5MWE2MWM4NGJmMTVjYjJiL3RhYmxlOmRmODBmMzRmZGYyMTRiZmRhNDU0YTQ2ZjQ0ODVkZTQyL3RhYmxlcmFuZ2U6ZGY4MGYzNGZkZjIxNGJmZGE0NTRhNDZmNDQ4NWRlNDJfNy02LTEtMS00Njg5MQ_3d87a440-61b4-42a8-afcc-b16c61dc57b9">8,739</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i78d50910ac384c9c9ae07eacf45ba372" continuedAt="i696c97d2309949708ca5f48703182b2a"><ix:nonNumeric contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331" name="us-gaap:LeaseCostTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl82MS9mcmFnOjhhNTE5MDJjNjUzMDQ2NWQ5MWE2MWM4NGJmMTVjYjJiL3RleHRyZWdpb246OGE1MTkwMmM2NTMwNDY1ZDkxYTYxYzg0YmYxNWNiMmJfNDgwMg_6dce3039-5cc5-4f50-8f0f-93c89e584cca" escape="true"><div style="margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents the weighted-average remaining lease term and discount rate as of March&#160;31, 2022:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.347%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of March 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Remaining Lease Term (years)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Discount Rate</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id7882ae6aff54a3aacdef67ddf11a428_I20220331" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl82MS9mcmFnOjhhNTE5MDJjNjUzMDQ2NWQ5MWE2MWM4NGJmMTVjYjJiL3RhYmxlOjdhMmJiNmYxNWNjYzRjNGY5NzA4YjA1YjdiOTBlYTZjL3RhYmxlcmFuZ2U6N2EyYmI2ZjE1Y2NjNGM0Zjk3MDhiMDViN2I5MGVhNmNfMi0yLTEtMS00Njg5MQ_b7204339-fd43-44c7-b060-c49fa1a42ef4">9.30</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id7882ae6aff54a3aacdef67ddf11a428_I20220331" decimals="4" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl82MS9mcmFnOjhhNTE5MDJjNjUzMDQ2NWQ5MWE2MWM4NGJmMTVjYjJiL3RhYmxlOjdhMmJiNmYxNWNjYzRjNGY5NzA4YjA1YjdiOTBlYTZjL3RhYmxlcmFuZ2U6N2EyYmI2ZjE1Y2NjNGM0Zjk3MDhiMDViN2I5MGVhNmNfMi00LTEtMS00Njg5MQ_9e4fcc56-f665-4030-a14d-3f0720157b58">5.20</ix:nonFraction>%</span></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl82MS9mcmFnOjhhNTE5MDJjNjUzMDQ2NWQ5MWE2MWM4NGJmMTVjYjJiL3RleHRyZWdpb246OGE1MTkwMmM2NTMwNDY1ZDkxYTYxYzg0YmYxNWNiMmJfNDgwNA_12e3a2f8-4d20-4f69-806f-5041db38558a" escape="true"><div style="margin-top:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a summary of operating lease liabilities payments for the next five years and thereafter:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:78.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.346%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating Lease Payments</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7882ae6aff54a3aacdef67ddf11a428_I20220331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl82MS9mcmFnOjhhNTE5MDJjNjUzMDQ2NWQ5MWE2MWM4NGJmMTVjYjJiL3RhYmxlOjFlODcxN2VhYzJjMzRlOWViZmIyZGY3MjI2MjIzNDc5L3RhYmxlcmFuZ2U6MWU4NzE3ZWFjMmMzNGU5ZWJmYjJkZjcyMjYyMjM0NzlfMS0yLTEtMS00Njg5MQ_655aa437-a854-463e-9278-29ee92ffa4aa">863</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7882ae6aff54a3aacdef67ddf11a428_I20220331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl82MS9mcmFnOjhhNTE5MDJjNjUzMDQ2NWQ5MWE2MWM4NGJmMTVjYjJiL3RhYmxlOjFlODcxN2VhYzJjMzRlOWViZmIyZGY3MjI2MjIzNDc5L3RhYmxlcmFuZ2U6MWU4NzE3ZWFjMmMzNGU5ZWJmYjJkZjcyMjYyMjM0NzlfMi0yLTEtMS00Njg5MQ_17f81313-0ba6-4521-8df7-e4e4533a69c3">1,061</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7882ae6aff54a3aacdef67ddf11a428_I20220331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl82MS9mcmFnOjhhNTE5MDJjNjUzMDQ2NWQ5MWE2MWM4NGJmMTVjYjJiL3RhYmxlOjFlODcxN2VhYzJjMzRlOWViZmIyZGY3MjI2MjIzNDc5L3RhYmxlcmFuZ2U6MWU4NzE3ZWFjMmMzNGU5ZWJmYjJkZjcyMjYyMjM0NzlfMy0yLTEtMS00Njg5MQ_720af77d-ba55-4d7f-9668-3f5b0df339b6">1,085</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7882ae6aff54a3aacdef67ddf11a428_I20220331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl82MS9mcmFnOjhhNTE5MDJjNjUzMDQ2NWQ5MWE2MWM4NGJmMTVjYjJiL3RhYmxlOjFlODcxN2VhYzJjMzRlOWViZmIyZGY3MjI2MjIzNDc5L3RhYmxlcmFuZ2U6MWU4NzE3ZWFjMmMzNGU5ZWJmYjJkZjcyMjYyMjM0NzlfNC0yLTEtMS00Njg5MQ_70300c78-6327-40eb-bf37-e4e1a2a08188">1,110</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7882ae6aff54a3aacdef67ddf11a428_I20220331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl82MS9mcmFnOjhhNTE5MDJjNjUzMDQ2NWQ5MWE2MWM4NGJmMTVjYjJiL3RhYmxlOjFlODcxN2VhYzJjMzRlOWViZmIyZGY3MjI2MjIzNDc5L3RhYmxlcmFuZ2U6MWU4NzE3ZWFjMmMzNGU5ZWJmYjJkZjcyMjYyMjM0NzlfNS0yLTEtMS00Njg5MQ_b86ba297-b3fc-4ac2-978b-d6cc581e47e7">1,135</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7882ae6aff54a3aacdef67ddf11a428_I20220331" decimals="-3" name="auph:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl82MS9mcmFnOjhhNTE5MDJjNjUzMDQ2NWQ5MWE2MWM4NGJmMTVjYjJiL3RhYmxlOjFlODcxN2VhYzJjMzRlOWViZmIyZGY3MjI2MjIzNDc5L3RhYmxlcmFuZ2U6MWU4NzE3ZWFjMmMzNGU5ZWJmYjJkZjcyMjYyMjM0NzlfNi0yLTEtMS00Njg5MQ_b95b4ba0-51b4-439e-9330-6ebb1a1a69d9">5,638</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total future minimum lease payments </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7882ae6aff54a3aacdef67ddf11a428_I20220331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl82MS9mcmFnOjhhNTE5MDJjNjUzMDQ2NWQ5MWE2MWM4NGJmMTVjYjJiL3RhYmxlOjFlODcxN2VhYzJjMzRlOWViZmIyZGY3MjI2MjIzNDc5L3RhYmxlcmFuZ2U6MWU4NzE3ZWFjMmMzNGU5ZWJmYjJkZjcyMjYyMjM0NzlfNy0yLTEtMS00Njg5MQ_616a26b5-b112-4b59-b14b-56e470b8343f">10,892</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: lease imputed interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id7882ae6aff54a3aacdef67ddf11a428_I20220331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl82MS9mcmFnOjhhNTE5MDJjNjUzMDQ2NWQ5MWE2MWM4NGJmMTVjYjJiL3RhYmxlOjFlODcxN2VhYzJjMzRlOWViZmIyZGY3MjI2MjIzNDc5L3RhYmxlcmFuZ2U6MWU4NzE3ZWFjMmMzNGU5ZWJmYjJkZjcyMjYyMjM0NzlfOC0yLTEtMS00Njg5MQ_1b179c12-843d-4f85-8a31-5e3d1833b9ff">2,321</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total future minimum lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7882ae6aff54a3aacdef67ddf11a428_I20220331" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl82MS9mcmFnOjhhNTE5MDJjNjUzMDQ2NWQ5MWE2MWM4NGJmMTVjYjJiL3RhYmxlOjFlODcxN2VhYzJjMzRlOWViZmIyZGY3MjI2MjIzNDc5L3RhYmxlcmFuZ2U6MWU4NzE3ZWFjMmMzNGU5ZWJmYjJkZjcyMjYyMjM0NzlfOS0yLTEtMS00Njg5MQ_26e13d47-096d-4e0f-a34c-918fd71341b5">8,571</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 15, 2020, the Company entered into a collaborative agreement with Lonza to build a dedicated manufacturing facility within Lonza&#8217;s existing small molecule facility in Visp, Switzerland. The dedicated facility (also referred to as "monoplant") will be equipped with state-of-the-art manufacturing equipment to provide cost and production efficiency for the manufacture of voclosporin, while expanding existing capacity and providing supply security to meet future commercial demand.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following U.S. regulatory approval of LUPKYNIS in January 2021, the Company has commenced a capital expenditure payment program for the monoplant totaling approximately CHF <ix:nonFraction unitRef="chf" contextRef="i46bd9d31980341bb91e4ebbab17839ed_D20210101-20210131" decimals="-5" name="us-gaap:PaymentsForCapitalImprovements" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl82MS9mcmFnOjhhNTE5MDJjNjUzMDQ2NWQ5MWE2MWM4NGJmMTVjYjJiL3RleHRyZWdpb246OGE1MTkwMmM2NTMwNDY1ZDkxYTYxYzg0YmYxNWNiMmJfMzI5ODUzNDg4OTQzNg_52ce8015-c879-48b0-b908-c106082464df">21.0</ix:nonFraction>&#160;million. The first capital expenditure payment was made in February 2021 of $<ix:nonFraction unitRef="usd" contextRef="ie64f915dc5df48b09796dbc7d367824b_D20210201-20210228" decimals="-5" name="us-gaap:FinanceLeasePrincipalPayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl82MS9mcmFnOjhhNTE5MDJjNjUzMDQ2NWQ5MWE2MWM4NGJmMTVjYjJiL3RleHRyZWdpb246OGE1MTkwMmM2NTMwNDY1ZDkxYTYxYzg0YmYxNWNiMmJfMTA5OTUxMTYzMzk3NQ_bfd4f149-9ec9-434c-bfed-5aeacf30990a">11.8</ix:nonFraction>&#160;million and was treated as an upfront lease payment and recorded under other non-current assets on the condensed consolidated balance sheets. The second payment is not due until the facility fulfills the required operational qualifications which is estimated to be during 2023. Upon completion of the monoplant, the Company will have the right to maintain sole dedicated use of the monoplant by paying a quarterly fixed facility fee. The Company expects to account for the arrangement as a finance lease under ASC 842. The present value of the minimum lease payments total approximately $<ix:nonFraction unitRef="usd" contextRef="id7882ae6aff54a3aacdef67ddf11a428_I20220331" decimals="-5" name="us-gaap:FinanceLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl82MS9mcmFnOjhhNTE5MDJjNjUzMDQ2NWQ5MWE2MWM4NGJmMTVjYjJiL3RleHRyZWdpb246OGE1MTkwMmM2NTMwNDY1ZDkxYTYxYzg0YmYxNWNiMmJfNDcxMg_773d3793-b5e6-4b6a-9527-01994944846c">78.0</ix:nonFraction>&#160;million, beginning April 2023 and expiring in 2030, and are not included in the above table.</span></div></ix:continuation><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i696c97d2309949708ca5f48703182b2a">The Company has entered into an equipment and facility finance lease for a backup manufacturing encapsulation site that has not yet commenced and is therefore, not included in the above table. As part of the agreement, the Company expects to make approximately $<ix:nonFraction unitRef="usd" contextRef="id7882ae6aff54a3aacdef67ddf11a428_I20220331" decimals="-3" name="auph:LesseeOperatingLeaseLeaseNotYetCommencedPaymentsPriorToCommencementOfLease" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl82MS9mcmFnOjhhNTE5MDJjNjUzMDQ2NWQ5MWE2MWM4NGJmMTVjYjJiL3RleHRyZWdpb246OGE1MTkwMmM2NTMwNDY1ZDkxYTYxYzg0YmYxNWNiMmJfMTA5OTUxMTYzNzQ0OQ_7c3a1dfb-2534-49d0-a000-065dbb9b7f6a">885</ix:nonFraction>&#160;thousand of payments prior to lease commencement and the future value of minimum lease payments will total approximately $<ix:nonFraction unitRef="usd" contextRef="id7882ae6aff54a3aacdef67ddf11a428_I20220331" decimals="-3" name="auph:LesseeOperatingLeaseLeaseNotYetCommencedLiabilityToBePaid" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl82MS9mcmFnOjhhNTE5MDJjNjUzMDQ2NWQ5MWE2MWM4NGJmMTVjYjJiL3RleHRyZWdpb246OGE1MTkwMmM2NTMwNDY1ZDkxYTYxYzg0YmYxNWNiMmJfMTA5OTUxMTYzNzQ2NA_c79e5a10-92ce-4fd2-b983-570c9e91ff13">120</ix:nonFraction>&#160;thousand.</ix:continuation> </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><div id="i2d3a8f7e52e84dcebfa935bec5ca9eb6_64"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:23.5pt"><ix:nonNumeric contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl82NC9mcmFnOmZjMjUxNmJhNDU3ZTQzM2VhY2U4NTFkODVhYTU2Yjc2L3RleHRyZWdpb246ZmMyNTE2YmE0NTdlNDMzZWFjZTg1MWQ4NWFhNTZiNzZfMTM2_3403c3bb-80e5-461d-ae73-e8659786d9a5" continuedAt="ibf386398317b4980bdcf3f9533968de6" escape="true">Accounts Payable and Accrued Liabilities</ix:nonNumeric></span></div><ix:continuation id="ibf386398317b4980bdcf3f9533968de6"><ix:nonNumeric contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl82NC9mcmFnOmZjMjUxNmJhNDU3ZTQzM2VhY2U4NTFkODVhYTU2Yjc2L3RleHRyZWdpb246ZmMyNTE2YmE0NTdlNDMzZWFjZTg1MWQ4NWFhNTZiNzZfMTM3_c1583cf5-b2ca-4b2a-93f3-9a70edb8ec19" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable and accrued liabilities are as follows:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.642%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.447%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7882ae6aff54a3aacdef67ddf11a428_I20220331" decimals="-3" name="us-gaap:AccountsPayableTradeCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl82NC9mcmFnOmZjMjUxNmJhNDU3ZTQzM2VhY2U4NTFkODVhYTU2Yjc2L3RhYmxlOjA0OWQ0OTU3YzJkYTQ0NzM4MTA0YzhiMzdiNjFiMjBjL3RhYmxlcmFuZ2U6MDQ5ZDQ5NTdjMmRhNDQ3MzgxMDRjOGIzN2I2MWIyMGNfMS0yLTEtMS00Njg5MQ_a2e5b14b-b616-4569-bb5b-73c0967b5f08">3,267</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i784f65549351439fa4b7bedf90ce7e3f_I20211231" decimals="-3" name="us-gaap:AccountsPayableTradeCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl82NC9mcmFnOmZjMjUxNmJhNDU3ZTQzM2VhY2U4NTFkODVhYTU2Yjc2L3RhYmxlOjA0OWQ0OTU3YzJkYTQ0NzM4MTA0YzhiMzdiNjFiMjBjL3RhYmxlcmFuZ2U6MDQ5ZDQ5NTdjMmRhNDQ3MzgxMDRjOGIzN2I2MWIyMGNfMS00LTEtMS00Njg5MQ_59861f6f-223c-45ae-ac56-dbbaf4b37a77">3,879</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7882ae6aff54a3aacdef67ddf11a428_I20220331" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl82NC9mcmFnOmZjMjUxNmJhNDU3ZTQzM2VhY2U4NTFkODVhYTU2Yjc2L3RhYmxlOjA0OWQ0OTU3YzJkYTQ0NzM4MTA0YzhiMzdiNjFiMjBjL3RhYmxlcmFuZ2U6MDQ5ZDQ5NTdjMmRhNDQ3MzgxMDRjOGIzN2I2MWIyMGNfMi0yLTEtMS00Njg5MQ_9bdc8115-50b8-422d-92c5-d40fa94c165e">7,289</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i784f65549351439fa4b7bedf90ce7e3f_I20211231" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl82NC9mcmFnOmZjMjUxNmJhNDU3ZTQzM2VhY2U4NTFkODVhYTU2Yjc2L3RhYmxlOjA0OWQ0OTU3YzJkYTQ0NzM4MTA0YzhiMzdiNjFiMjBjL3RhYmxlcmFuZ2U6MDQ5ZDQ5NTdjMmRhNDQ3MzgxMDRjOGIzN2I2MWIyMGNfMi00LTEtMS00Njg5MQ_dedf610a-89d1-4d79-a96f-bfb5d0e83d8e">3,428</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued R&amp;D projects</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7882ae6aff54a3aacdef67ddf11a428_I20220331" decimals="-3" name="auph:AccruedResearchCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl82NC9mcmFnOmZjMjUxNmJhNDU3ZTQzM2VhY2U4NTFkODVhYTU2Yjc2L3RhYmxlOjA0OWQ0OTU3YzJkYTQ0NzM4MTA0YzhiMzdiNjFiMjBjL3RhYmxlcmFuZ2U6MDQ5ZDQ5NTdjMmRhNDQ3MzgxMDRjOGIzN2I2MWIyMGNfMy0yLTEtMS00Njg5MQ_1af6dc62-8da5-4b9f-8ce0-b2815fd4ef30">5,409</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i784f65549351439fa4b7bedf90ce7e3f_I20211231" decimals="-3" name="auph:AccruedResearchCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl82NC9mcmFnOmZjMjUxNmJhNDU3ZTQzM2VhY2U4NTFkODVhYTU2Yjc2L3RhYmxlOjA0OWQ0OTU3YzJkYTQ0NzM4MTA0YzhiMzdiNjFiMjBjL3RhYmxlcmFuZ2U6MDQ5ZDQ5NTdjMmRhNDQ3MzgxMDRjOGIzN2I2MWIyMGNfMy00LTEtMS00Njg5MQ_5e074b03-c5f4-44c5-b60e-ae30d9144cd0">4,383</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee accruals</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7882ae6aff54a3aacdef67ddf11a428_I20220331" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl82NC9mcmFnOmZjMjUxNmJhNDU3ZTQzM2VhY2U4NTFkODVhYTU2Yjc2L3RhYmxlOjA0OWQ0OTU3YzJkYTQ0NzM4MTA0YzhiMzdiNjFiMjBjL3RhYmxlcmFuZ2U6MDQ5ZDQ5NTdjMmRhNDQ3MzgxMDRjOGIzN2I2MWIyMGNfNC0yLTEtMS00Njg5MQ_70bc6692-01fd-49b2-86d7-e856eb8d5d25">9,609</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i784f65549351439fa4b7bedf90ce7e3f_I20211231" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl82NC9mcmFnOmZjMjUxNmJhNDU3ZTQzM2VhY2U4NTFkODVhYTU2Yjc2L3RhYmxlOjA0OWQ0OTU3YzJkYTQ0NzM4MTA0YzhiMzdiNjFiMjBjL3RhYmxlcmFuZ2U6MDQ5ZDQ5NTdjMmRhNDQ3MzgxMDRjOGIzN2I2MWIyMGNfNC00LTEtMS00Njg5MQ_46e7ad5f-89bb-4952-9f7f-bb858dafdc5e">18,242</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial accruals</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7882ae6aff54a3aacdef67ddf11a428_I20220331" decimals="-3" name="auph:CommercialRelatedAccrualsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl82NC9mcmFnOmZjMjUxNmJhNDU3ZTQzM2VhY2U4NTFkODVhYTU2Yjc2L3RhYmxlOjA0OWQ0OTU3YzJkYTQ0NzM4MTA0YzhiMzdiNjFiMjBjL3RhYmxlcmFuZ2U6MDQ5ZDQ5NTdjMmRhNDQ3MzgxMDRjOGIzN2I2MWIyMGNfNS0yLTEtMS01NTc1MA_a7f860d7-dbca-4794-98b6-fbce5cce5a77">6,753</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i784f65549351439fa4b7bedf90ce7e3f_I20211231" decimals="-3" name="auph:CommercialRelatedAccrualsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl82NC9mcmFnOmZjMjUxNmJhNDU3ZTQzM2VhY2U4NTFkODVhYTU2Yjc2L3RhYmxlOjA0OWQ0OTU3YzJkYTQ0NzM4MTA0YzhiMzdiNjFiMjBjL3RhYmxlcmFuZ2U6MDQ5ZDQ5NTdjMmRhNDQ3MzgxMDRjOGIzN2I2MWIyMGNfNS00LTEtMS01NTc1MA_34e5a14b-7427-47a8-b9bf-2ecd62f5716b">5,015</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accounts payable and accrued liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7882ae6aff54a3aacdef67ddf11a428_I20220331" decimals="-3" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl82NC9mcmFnOmZjMjUxNmJhNDU3ZTQzM2VhY2U4NTFkODVhYTU2Yjc2L3RhYmxlOjA0OWQ0OTU3YzJkYTQ0NzM4MTA0YzhiMzdiNjFiMjBjL3RhYmxlcmFuZ2U6MDQ5ZDQ5NTdjMmRhNDQ3MzgxMDRjOGIzN2I2MWIyMGNfNS0yLTEtMS00Njg5MQ_9969d3f2-92ae-4944-a6d7-7b1f00b222de">32,327</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i784f65549351439fa4b7bedf90ce7e3f_I20211231" decimals="-3" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl82NC9mcmFnOmZjMjUxNmJhNDU3ZTQzM2VhY2U4NTFkODVhYTU2Yjc2L3RhYmxlOjA0OWQ0OTU3YzJkYTQ0NzM4MTA0YzhiMzdiNjFiMjBjL3RhYmxlcmFuZ2U6MDQ5ZDQ5NTdjMmRhNDQ3MzgxMDRjOGIzN2I2MWIyMGNfNS00LTEtMS00Njg5MQ_36703dbe-549a-4724-b7ac-f62b5375a928">34,947</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div><span><br/></span></div><div id="i2d3a8f7e52e84dcebfa935bec5ca9eb6_67"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:23.5pt"><ix:nonNumeric contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331" name="us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureNoncurrentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl82Ny9mcmFnOjZjZjc3NGY1MjJhMTQ2ZTRhYTRhYmI0N2FkOGMxYWIzL3RleHRyZWdpb246NmNmNzc0ZjUyMmExNDZlNGFhNGFiYjQ3YWQ4YzFhYjNfNTM5_5560bdfa-2e42-4e8c-9e86-5abaea322af5" continuedAt="i83e5410caa824baba018cb3db996c24a" escape="true">Deferred Compensation and Other Non-current Liabilities</ix:nonNumeric></span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i83e5410caa824baba018cb3db996c24a">The Company recorded other non-current liabilities of $<ix:nonFraction unitRef="usd" contextRef="id7882ae6aff54a3aacdef67ddf11a428_I20220331" decimals="-5" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl82Ny9mcmFnOjZjZjc3NGY1MjJhMTQ2ZTRhYTRhYmI0N2FkOGMxYWIzL3RleHRyZWdpb246NmNmNzc0ZjUyMmExNDZlNGFhNGFiYjQ3YWQ4YzFhYjNfODQ_ae94998f-b69f-462a-9ced-b95b719fd667">17.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i784f65549351439fa4b7bedf90ce7e3f_I20211231" decimals="-5" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl82Ny9mcmFnOjZjZjc3NGY1MjJhMTQ2ZTRhYTRhYmI0N2FkOGMxYWIzL3RleHRyZWdpb246NmNmNzc0ZjUyMmExNDZlNGFhNGFiYjQ3YWQ4YzFhYjNfOTE_7ada42b0-46a5-4863-b5c4-c7647ab6e071">16.0</ix:nonFraction> million as of March&#160;31, 2022 and December&#160;31, 2021, respectively. The balance as of March&#160;31, 2022 and December&#160;31, 2021 primarily included deferred compensation arrangements whereby certain executive officers as of March 8, 2012 were provided with future potential employee benefit obligations for remaining with the Company, for a certain period of time. These obligations were also contingent on the occurrence of uncertain future events. Other non-current liabilities also include milestone payments deemed probable to be paid in the future.</ix:continuation></span></div><div id="i2d3a8f7e52e84dcebfa935bec5ca9eb6_70"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:23.5pt"><ix:nonNumeric contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83MC9mcmFnOjZiNDI0YTgyMzM0NzQzOWFhNmU4NjZiZmNmMGVjMDAxL3RleHRyZWdpb246NmI0MjRhODIzMzQ3NDM5YWE2ZTg2NmJmY2YwZWMwMDFfMjE4MQ_1c440ff5-9e62-430c-a00f-25d925e23c12" continuedAt="i4706a5bf2a6f4f74a90e0380fb16f410" escape="true">Fair Value Measurements</ix:nonNumeric></span></div><ix:continuation id="i4706a5bf2a6f4f74a90e0380fb16f410" continuedAt="i1e7ce19b84164d8ca90a8ac73b90a403"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's financial instruments consist primarily of cash and cash equivalents, investments, accounts receivable, accounts payable and accrued liabilities. The carrying value of accounts receivable, accounts payable and accrued liabilities approximate their fair value because of their short-term nature. Estimated fair values of held to maturity and available-for-sale debt securities are generally based on prices obtained from commercial pricing services.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with measuring the fair value of its assets and liabilities, the Company seeks to maximize the use of observable inputs (market data obtained from sources independent from the Company) and to minimize the use of unobservable inputs (the Company&#8217;s assumptions about how market participants would price assets and liabilities). As a basis for considering such assumptions, a three-tier fair value hierarchy has been established, which prioritizes the inputs used in measuring fair value as follows:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Level 1 - Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities.</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Level 2 - Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Level 3 - Unobservable inputs that reflect the reporting entity&#8217;s own assumptions.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's Level 1 instruments include deposits held with banks and short-term investments that are valued using quoted market prices. Level 2 instruments include the Company's short-term investments that are valued through third-party pricing services that use verifiable observable market data. The Company has no Level 3 instruments as of March&#160;31, 2022 and December&#160;31, 2021.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i1e7ce19b84164d8ca90a8ac73b90a403"><ix:nonNumeric contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83MC9mcmFnOjZiNDI0YTgyMzM0NzQzOWFhNmU4NjZiZmNmMGVjMDAxL3RleHRyZWdpb246NmI0MjRhODIzMzQ3NDM5YWE2ZTg2NmJmY2YwZWMwMDFfMjE4MA_9d461440-02dd-47be-a785-d6d8d5bbd802" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present the financial assets measured at fair value on a recurring basis:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.777%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deposits held with banks</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib637c27de79d47f58aea7f1e1b7c5885_I20220331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83MC9mcmFnOjZiNDI0YTgyMzM0NzQzOWFhNmU4NjZiZmNmMGVjMDAxL3RhYmxlOjNiYzg4Mjg2NDAyZTQ2NTU4Mzk5NzQ0OWI0NGU3ZmEzL3RhYmxlcmFuZ2U6M2JjODgyODY0MDJlNDY1NTgzOTk3NDQ5YjQ0ZTdmYTNfNC0yLTEtMS00Njg5MQ_b730d006-d5d0-4624-9fa0-4bb1298ec6d1">113,268</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1195a2d281043b09ef29f66c38b70ce_I20220331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83MC9mcmFnOjZiNDI0YTgyMzM0NzQzOWFhNmU4NjZiZmNmMGVjMDAxL3RhYmxlOjNiYzg4Mjg2NDAyZTQ2NTU4Mzk5NzQ0OWI0NGU3ZmEzL3RhYmxlcmFuZ2U6M2JjODgyODY0MDJlNDY1NTgzOTk3NDQ5YjQ0ZTdmYTNfNC00LTEtMS00Njg5MQ_798b8c8b-cf3d-4360-8a40-c4c7d27a3a40">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9987c4f832174d15b1448eb73ba6f1e4_I20220331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83MC9mcmFnOjZiNDI0YTgyMzM0NzQzOWFhNmU4NjZiZmNmMGVjMDAxL3RhYmxlOjNiYzg4Mjg2NDAyZTQ2NTU4Mzk5NzQ0OWI0NGU3ZmEzL3RhYmxlcmFuZ2U6M2JjODgyODY0MDJlNDY1NTgzOTk3NDQ5YjQ0ZTdmYTNfNC02LTEtMS00Njg5MQ_23c57b18-9340-4bd6-84cd-4e03ea555f47">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5d8980b569c49318287bb43ff08a07e_I20220331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83MC9mcmFnOjZiNDI0YTgyMzM0NzQzOWFhNmU4NjZiZmNmMGVjMDAxL3RhYmxlOjNiYzg4Mjg2NDAyZTQ2NTU4Mzk5NzQ0OWI0NGU3ZmEzL3RhYmxlcmFuZ2U6M2JjODgyODY0MDJlNDY1NTgzOTk3NDQ5YjQ0ZTdmYTNfNC04LTEtMS00Njg5MQ_e20e6aaf-7f0f-49b4-a4ef-85129704a5cf">113,268</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term highly liquid investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib211792a2e6b4a88a6e391b311e94df4_I20220331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83MC9mcmFnOjZiNDI0YTgyMzM0NzQzOWFhNmU4NjZiZmNmMGVjMDAxL3RhYmxlOjNiYzg4Mjg2NDAyZTQ2NTU4Mzk5NzQ0OWI0NGU3ZmEzL3RhYmxlcmFuZ2U6M2JjODgyODY0MDJlNDY1NTgzOTk3NDQ5YjQ0ZTdmYTNfNS0yLTEtMS00Njg5MQ_d73fc93e-aa82-494f-b423-99f824dc5ed6">19,274</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i074dc118299746aa9f97075509308a92_I20220331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83MC9mcmFnOjZiNDI0YTgyMzM0NzQzOWFhNmU4NjZiZmNmMGVjMDAxL3RhYmxlOjNiYzg4Mjg2NDAyZTQ2NTU4Mzk5NzQ0OWI0NGU3ZmEzL3RhYmxlcmFuZ2U6M2JjODgyODY0MDJlNDY1NTgzOTk3NDQ5YjQ0ZTdmYTNfNS00LTEtMS00Njg5MQ_53f2dd4d-7a9d-4c6b-b402-03a17c2c2813">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3751e29f9e2148e9be8536444f9cac26_I20220331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83MC9mcmFnOjZiNDI0YTgyMzM0NzQzOWFhNmU4NjZiZmNmMGVjMDAxL3RhYmxlOjNiYzg4Mjg2NDAyZTQ2NTU4Mzk5NzQ0OWI0NGU3ZmEzL3RhYmxlcmFuZ2U6M2JjODgyODY0MDJlNDY1NTgzOTk3NDQ5YjQ0ZTdmYTNfNS02LTEtMS00Njg5MQ_3b35e00b-6a6b-48b1-9b93-061784d5f7f6">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfd26c5e43f842a78369ad600a9bf8a6_I20220331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83MC9mcmFnOjZiNDI0YTgyMzM0NzQzOWFhNmU4NjZiZmNmMGVjMDAxL3RhYmxlOjNiYzg4Mjg2NDAyZTQ2NTU4Mzk5NzQ0OWI0NGU3ZmEzL3RhYmxlcmFuZ2U6M2JjODgyODY0MDJlNDY1NTgzOTk3NDQ5YjQ0ZTdmYTNfNS04LTEtMS00Njg5MQ_6c35eb69-556b-4721-855d-95eb77c61558">19,274</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecaeb1e9e3bc4350b03471a79a3ee234_I20220331" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83MC9mcmFnOjZiNDI0YTgyMzM0NzQzOWFhNmU4NjZiZmNmMGVjMDAxL3RhYmxlOjNiYzg4Mjg2NDAyZTQ2NTU4Mzk5NzQ0OWI0NGU3ZmEzL3RhYmxlcmFuZ2U6M2JjODgyODY0MDJlNDY1NTgzOTk3NDQ5YjQ0ZTdmYTNfNi0yLTEtMS00Njg5MQ_e8430eb0-57ad-48e3-9357-e44fa0c743c2">152,295</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7d17ebbb59b417ca9c046ea7c8aa94f_I20220331" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83MC9mcmFnOjZiNDI0YTgyMzM0NzQzOWFhNmU4NjZiZmNmMGVjMDAxL3RhYmxlOjNiYzg4Mjg2NDAyZTQ2NTU4Mzk5NzQ0OWI0NGU3ZmEzL3RhYmxlcmFuZ2U6M2JjODgyODY0MDJlNDY1NTgzOTk3NDQ5YjQ0ZTdmYTNfNi00LTEtMS00Njg5MQ_4a39445c-a419-478a-8a6a-1cd4cc3ff623">133,915</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id893926028184fda8d4b75b7a5667586_I20220331" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83MC9mcmFnOjZiNDI0YTgyMzM0NzQzOWFhNmU4NjZiZmNmMGVjMDAxL3RhYmxlOjNiYzg4Mjg2NDAyZTQ2NTU4Mzk5NzQ0OWI0NGU3ZmEzL3RhYmxlcmFuZ2U6M2JjODgyODY0MDJlNDY1NTgzOTk3NDQ5YjQ0ZTdmYTNfNi02LTEtMS00Njg5MQ_4cde465c-763e-42c6-b152-f6a50c9e6856">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7882ae6aff54a3aacdef67ddf11a428_I20220331" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83MC9mcmFnOjZiNDI0YTgyMzM0NzQzOWFhNmU4NjZiZmNmMGVjMDAxL3RhYmxlOjNiYzg4Mjg2NDAyZTQ2NTU4Mzk5NzQ0OWI0NGU3ZmEzL3RhYmxlcmFuZ2U6M2JjODgyODY0MDJlNDY1NTgzOTk3NDQ5YjQ0ZTdmYTNfNi04LTEtMS00Njg5MQ_95cb4821-34ac-4550-899a-00b90486b455">286,210</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecaeb1e9e3bc4350b03471a79a3ee234_I20220331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83MC9mcmFnOjZiNDI0YTgyMzM0NzQzOWFhNmU4NjZiZmNmMGVjMDAxL3RhYmxlOjNiYzg4Mjg2NDAyZTQ2NTU4Mzk5NzQ0OWI0NGU3ZmEzL3RhYmxlcmFuZ2U6M2JjODgyODY0MDJlNDY1NTgzOTk3NDQ5YjQ0ZTdmYTNfNy0yLTEtMS00Njg5MQ_97e033d2-a53b-46b9-97c7-054ced005212">284,837</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7d17ebbb59b417ca9c046ea7c8aa94f_I20220331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83MC9mcmFnOjZiNDI0YTgyMzM0NzQzOWFhNmU4NjZiZmNmMGVjMDAxL3RhYmxlOjNiYzg4Mjg2NDAyZTQ2NTU4Mzk5NzQ0OWI0NGU3ZmEzL3RhYmxlcmFuZ2U6M2JjODgyODY0MDJlNDY1NTgzOTk3NDQ5YjQ0ZTdmYTNfNy00LTEtMS00Njg5MQ_cf8d4de0-a6c2-4108-901c-4386bca146a1">133,915</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id893926028184fda8d4b75b7a5667586_I20220331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83MC9mcmFnOjZiNDI0YTgyMzM0NzQzOWFhNmU4NjZiZmNmMGVjMDAxL3RhYmxlOjNiYzg4Mjg2NDAyZTQ2NTU4Mzk5NzQ0OWI0NGU3ZmEzL3RhYmxlcmFuZ2U6M2JjODgyODY0MDJlNDY1NTgzOTk3NDQ5YjQ0ZTdmYTNfNy02LTEtMS00Njg5MQ_b64cf1d8-b9e9-4472-8223-6c0dbbef7168">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7882ae6aff54a3aacdef67ddf11a428_I20220331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83MC9mcmFnOjZiNDI0YTgyMzM0NzQzOWFhNmU4NjZiZmNmMGVjMDAxL3RhYmxlOjNiYzg4Mjg2NDAyZTQ2NTU4Mzk5NzQ0OWI0NGU3ZmEzL3RhYmxlcmFuZ2U6M2JjODgyODY0MDJlNDY1NTgzOTk3NDQ5YjQ0ZTdmYTNfNy04LTEtMS00Njg5MQ_6cc5ca04-88ad-4cce-8013-e2605a072495">418,752</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:7pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.777%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deposits held with banks</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief379dc869194260b8c12ebe6e7e061a_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83MC9mcmFnOjZiNDI0YTgyMzM0NzQzOWFhNmU4NjZiZmNmMGVjMDAxL3RhYmxlOmNlNTBjY2Q4ZjEzYTQwOWFiNTU3ZGUwOWQ2NWFhNmIzL3RhYmxlcmFuZ2U6Y2U1MGNjZDhmMTNhNDA5YWI1NTdkZTA5ZDY1YWE2YjNfNC0yLTEtMS00Njg5MQ_c6a5bad8-8044-493c-85b5-23534fde5c36">214,702</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4888c5f13e9e4351a811914afa543777_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83MC9mcmFnOjZiNDI0YTgyMzM0NzQzOWFhNmU4NjZiZmNmMGVjMDAxL3RhYmxlOmNlNTBjY2Q4ZjEzYTQwOWFiNTU3ZGUwOWQ2NWFhNmIzL3RhYmxlcmFuZ2U6Y2U1MGNjZDhmMTNhNDA5YWI1NTdkZTA5ZDY1YWE2YjNfNC00LTEtMS00Njg5MQ_75eb7b0b-f156-44aa-8a61-6b1bea9c91c3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i640e6485e7c84a2ab48d83257384aea7_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83MC9mcmFnOjZiNDI0YTgyMzM0NzQzOWFhNmU4NjZiZmNmMGVjMDAxL3RhYmxlOmNlNTBjY2Q4ZjEzYTQwOWFiNTU3ZGUwOWQ2NWFhNmIzL3RhYmxlcmFuZ2U6Y2U1MGNjZDhmMTNhNDA5YWI1NTdkZTA5ZDY1YWE2YjNfNC02LTEtMS00Njg5MQ_13bdfdcc-7f21-4979-8640-cd7a0f3cc919">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6146eb45aa0d48429dc434439051e0bc_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83MC9mcmFnOjZiNDI0YTgyMzM0NzQzOWFhNmU4NjZiZmNmMGVjMDAxL3RhYmxlOmNlNTBjY2Q4ZjEzYTQwOWFiNTU3ZGUwOWQ2NWFhNmIzL3RhYmxlcmFuZ2U6Y2U1MGNjZDhmMTNhNDA5YWI1NTdkZTA5ZDY1YWE2YjNfNC04LTEtMS00Njg5MQ_5574db62-6d7b-48bc-ad63-223712bef7a5">214,702</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term highly liquid investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if383a572500e4c839c8c398879a64567_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83MC9mcmFnOjZiNDI0YTgyMzM0NzQzOWFhNmU4NjZiZmNmMGVjMDAxL3RhYmxlOmNlNTBjY2Q4ZjEzYTQwOWFiNTU3ZGUwOWQ2NWFhNmIzL3RhYmxlcmFuZ2U6Y2U1MGNjZDhmMTNhNDA5YWI1NTdkZTA5ZDY1YWE2YjNfNS0yLTEtMS00Njg5MQ_9e47bc73-a1cc-41cc-af15-9faa9017617b">17,198</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cb7b13b98f9423daa95abadbd4c2281_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83MC9mcmFnOjZiNDI0YTgyMzM0NzQzOWFhNmU4NjZiZmNmMGVjMDAxL3RhYmxlOmNlNTBjY2Q4ZjEzYTQwOWFiNTU3ZGUwOWQ2NWFhNmIzL3RhYmxlcmFuZ2U6Y2U1MGNjZDhmMTNhNDA5YWI1NTdkZTA5ZDY1YWE2YjNfNS00LTEtMS00Njg5MQ_99bcd4d4-589e-466b-98a4-a3c9ee758838">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23085f6e6a1046b1a8320d2f389c49cd_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83MC9mcmFnOjZiNDI0YTgyMzM0NzQzOWFhNmU4NjZiZmNmMGVjMDAxL3RhYmxlOmNlNTBjY2Q4ZjEzYTQwOWFiNTU3ZGUwOWQ2NWFhNmIzL3RhYmxlcmFuZ2U6Y2U1MGNjZDhmMTNhNDA5YWI1NTdkZTA5ZDY1YWE2YjNfNS02LTEtMS00Njg5MQ_b93a0643-ea94-4367-836c-94aea0a608b6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d77f002b76741e8b5071bbad8036827_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83MC9mcmFnOjZiNDI0YTgyMzM0NzQzOWFhNmU4NjZiZmNmMGVjMDAxL3RhYmxlOmNlNTBjY2Q4ZjEzYTQwOWFiNTU3ZGUwOWQ2NWFhNmIzL3RhYmxlcmFuZ2U6Y2U1MGNjZDhmMTNhNDA5YWI1NTdkZTA5ZDY1YWE2YjNfNS04LTEtMS00Njg5MQ_897af133-4c72-4585-9531-414c784a4153">17,198</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84bcadfa5a52412e91d596d25121ad94_I20211231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83MC9mcmFnOjZiNDI0YTgyMzM0NzQzOWFhNmU4NjZiZmNmMGVjMDAxL3RhYmxlOmNlNTBjY2Q4ZjEzYTQwOWFiNTU3ZGUwOWQ2NWFhNmIzL3RhYmxlcmFuZ2U6Y2U1MGNjZDhmMTNhNDA5YWI1NTdkZTA5ZDY1YWE2YjNfNi0yLTEtMS00Njg5MQ_46486d7b-93d8-49b7-a2aa-a1d5e069f4ef">206,724</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia35491a16c814a76bd71423d10de8bd7_I20211231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83MC9mcmFnOjZiNDI0YTgyMzM0NzQzOWFhNmU4NjZiZmNmMGVjMDAxL3RhYmxlOmNlNTBjY2Q4ZjEzYTQwOWFiNTU3ZGUwOWQ2NWFhNmIzL3RhYmxlcmFuZ2U6Y2U1MGNjZDhmMTNhNDA5YWI1NTdkZTA5ZDY1YWE2YjNfNi00LTEtMS00Njg5MQ_32452a7d-c740-4775-afa3-2faa8790461b">27,454</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib03d0da6db22482c8918b1f6ab3b5e9b_I20211231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83MC9mcmFnOjZiNDI0YTgyMzM0NzQzOWFhNmU4NjZiZmNmMGVjMDAxL3RhYmxlOmNlNTBjY2Q4ZjEzYTQwOWFiNTU3ZGUwOWQ2NWFhNmIzL3RhYmxlcmFuZ2U6Y2U1MGNjZDhmMTNhNDA5YWI1NTdkZTA5ZDY1YWE2YjNfNi02LTEtMS00Njg5MQ_d7e0d35b-2f4d-4938-b62c-9fb59078d173">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i784f65549351439fa4b7bedf90ce7e3f_I20211231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83MC9mcmFnOjZiNDI0YTgyMzM0NzQzOWFhNmU4NjZiZmNmMGVjMDAxL3RhYmxlOmNlNTBjY2Q4ZjEzYTQwOWFiNTU3ZGUwOWQ2NWFhNmIzL3RhYmxlcmFuZ2U6Y2U1MGNjZDhmMTNhNDA5YWI1NTdkZTA5ZDY1YWE2YjNfNi04LTEtMS00Njg5MQ_59d02411-5197-45bc-b484-20bb6b403c9a">234,178</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84bcadfa5a52412e91d596d25121ad94_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83MC9mcmFnOjZiNDI0YTgyMzM0NzQzOWFhNmU4NjZiZmNmMGVjMDAxL3RhYmxlOmNlNTBjY2Q4ZjEzYTQwOWFiNTU3ZGUwOWQ2NWFhNmIzL3RhYmxlcmFuZ2U6Y2U1MGNjZDhmMTNhNDA5YWI1NTdkZTA5ZDY1YWE2YjNfNy0yLTEtMS00Njg5MQ_9fa98d29-3376-4133-b070-4a9bb8ea2844">438,624</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia35491a16c814a76bd71423d10de8bd7_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83MC9mcmFnOjZiNDI0YTgyMzM0NzQzOWFhNmU4NjZiZmNmMGVjMDAxL3RhYmxlOmNlNTBjY2Q4ZjEzYTQwOWFiNTU3ZGUwOWQ2NWFhNmIzL3RhYmxlcmFuZ2U6Y2U1MGNjZDhmMTNhNDA5YWI1NTdkZTA5ZDY1YWE2YjNfNy00LTEtMS00Njg5MQ_0bf292c2-5d05-42cc-976c-69500d8c0d1d">27,454</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib03d0da6db22482c8918b1f6ab3b5e9b_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83MC9mcmFnOjZiNDI0YTgyMzM0NzQzOWFhNmU4NjZiZmNmMGVjMDAxL3RhYmxlOmNlNTBjY2Q4ZjEzYTQwOWFiNTU3ZGUwOWQ2NWFhNmIzL3RhYmxlcmFuZ2U6Y2U1MGNjZDhmMTNhNDA5YWI1NTdkZTA5ZDY1YWE2YjNfNy02LTEtMS00Njg5MQ_8571c14b-f28e-45eb-ac0f-e70dccbf3a3b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i784f65549351439fa4b7bedf90ce7e3f_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83MC9mcmFnOjZiNDI0YTgyMzM0NzQzOWFhNmU4NjZiZmNmMGVjMDAxL3RhYmxlOmNlNTBjY2Q4ZjEzYTQwOWFiNTU3ZGUwOWQ2NWFhNmIzL3RhYmxlcmFuZ2U6Y2U1MGNjZDhmMTNhNDA5YWI1NTdkZTA5ZDY1YWE2YjNfNy04LTEtMS00Njg5MQ_6e4df82f-2e06-4f2a-b1fd-9481bc6f892c">466,078</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note 4, &#8220;Investments,&#8221; for the carrying amount and related unrealized gains (losses) by type of investment.</span></div></ix:continuation><div id="i2d3a8f7e52e84dcebfa935bec5ca9eb6_73"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:23.5pt"><ix:nonNumeric contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83My9mcmFnOjBmMDFlMDBlNmZmZDRjZmQ5ZjlmZWVlNzM3NmVlODFmL3RleHRyZWdpb246MGYwMWUwMGU2ZmZkNGNmZDlmOWZlZWU3Mzc2ZWU4MWZfMzIwMA_f5447370-a5de-4c60-bb8d-d5898bea2373" continuedAt="i23a40570afba4122931978cec856ebcf" escape="true">License and Collaboration Agreements</ix:nonNumeric></span></div><ix:continuation id="i23a40570afba4122931978cec856ebcf" continuedAt="ifdacd66ff8374b028ec84afb4659c948"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Riptide License</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 17, 2021, AUR300 (M2 macrophage modulation via CD206 binding) was secured through a global licensing and research agreement with Riptide Bioscience, Inc. (Riptide), a private company. As part of the agreement, in 2021 the Company paid Riptide an upfront license fee of $<ix:nonFraction unitRef="usd" contextRef="i6eea8e21df8b47b4892af7d314ff753b_D20210817-20210817" decimals="-5" name="us-gaap:PaymentsToAcquireProductiveAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83My9mcmFnOjBmMDFlMDBlNmZmZDRjZmQ5ZjlmZWVlNzM3NmVlODFmL3RleHRyZWdpb246MGYwMWUwMGU2ZmZkNGNmZDlmOWZlZWU3Mzc2ZWU4MWZfMzI5_fc1c625d-e0d6-43e6-9481-cddae7aad6bb">6.0</ix:nonFraction>&#160;million which was expensed as research and development on the condensed consolidated statements of operations. During the first quarter of 2022, Aurinia paid $<ix:nonFraction unitRef="usd" contextRef="i13c8ed2824064c1abec1d76ae28d9dd8_D20220101-20220331" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83My9mcmFnOjBmMDFlMDBlNmZmZDRjZmQ5ZjlmZWVlNzM3NmVlODFmL3RleHRyZWdpb246MGYwMWUwMGU2ZmZkNGNmZDlmOWZlZWU3Mzc2ZWU4MWZfMTA5OTUxMTYzMTg2OQ_7912c7a1-c464-46f1-a1b4-cf46ac2f7576">4.0</ix:nonFraction>&#160;million for the achievement of a one-time milestone. Additional payments are due upon certain development, clinical and regulatory milestones, and royalties will be payable upon commercialization. It is anticipated that clinical development for AUR300 will commence during 2023.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Otsuka Contract</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 17, 2020, the Company entered into a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. (Otsuka) for the development and commercialization of oral LUPKYNIS in the EU, Japan, as well as the United Kingdom, Russia, Switzerland, Norway, Belarus, Iceland, Liechtenstein and Ukraine.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the agreement, Aurinia received an upfront cash payment of $<ix:nonFraction unitRef="usd" contextRef="ia4c126547bde44f3af61232c8aecf4ac_D20201217-20201217" decimals="-5" name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83My9mcmFnOjBmMDFlMDBlNmZmZDRjZmQ5ZjlmZWVlNzM3NmVlODFmL3RleHRyZWdpb246MGYwMWUwMGU2ZmZkNGNmZDlmOWZlZWU3Mzc2ZWU4MWZfMTEzNA_df50944d-c4f9-4004-87ce-71d1ca181fe9">50.0</ix:nonFraction>&#160;million for the license agreement and has the potential to receive up to $<ix:nonFraction unitRef="usd" contextRef="ic3d998d2005a4d13bf8d4c76ad081c32_I20201217" decimals="-5" name="auph:ResearchAndDevelopmentArrangementContractToPerformForOthersPerformanceObligationPotentialRevenueAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83My9mcmFnOjBmMDFlMDBlNmZmZDRjZmQ5ZjlmZWVlNzM3NmVlODFmL3RleHRyZWdpb246MGYwMWUwMGU2ZmZkNGNmZDlmOWZlZWU3Mzc2ZWU4MWZfMTIwMg_3f8aafdf-38cd-4f39-ad9a-b5aec6287167">50.0</ix:nonFraction>&#160;million in regulatory milestones. Aurinia will receive tiered royalties on future sales ranging from <ix:nonFraction unitRef="number" contextRef="if24948855cce4a1ab004e64a606f9fda_I20201217" decimals="INF" name="auph:ResearchAndDevelopmentArrangementContractToPerformForOthersTieredRoyaltyPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83My9mcmFnOjBmMDFlMDBlNmZmZDRjZmQ5ZjlmZWVlNzM3NmVlODFmL3RleHRyZWdpb246MGYwMWUwMGU2ZmZkNGNmZDlmOWZlZWU3Mzc2ZWU4MWZfMTI5OA_933661f6-e355-4182-8162-53f69f79569f">10</ix:nonFraction> to <ix:nonFraction unitRef="number" contextRef="i4263b02edbdb433b9ce6580e359a81eb_I20201217" decimals="INF" name="auph:ResearchAndDevelopmentArrangementContractToPerformForOthersTieredRoyaltyPercent" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83My9mcmFnOjBmMDFlMDBlNmZmZDRjZmQ5ZjlmZWVlNzM3NmVlODFmL3RleHRyZWdpb246MGYwMWUwMGU2ZmZkNGNmZDlmOWZlZWU3Mzc2ZWU4MWZfMTMwNA_f7646f86-9c95-4648-8a36-caddffa4d31f">20</ix:nonFraction> percent (dependent on achievement of sale thresholds) on net sales upon commercialization, along with additional milestone payments based on the attainment of certain annual sales by Otsuka. In addition, certain manufacturing services are provided to Otsuka on a cost-plus basis.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the Otsuka Agreement under ASC 606. Based on that evaluation, the license transferred was determined to be functional IP that has significant standalone functionality. That is, the treatment of LN and other diseases provides significant benefit to Otsuka at the point of transfer, and it is not expected that the utility of the IP will substantively change as a result of any remaining clinical trials or ongoing activities of Aurinia. The Company determined the upfront fee of $<ix:nonFraction unitRef="usd" contextRef="ie2ed7292d01844ac989e99b1cafc7555_D20201201-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83My9mcmFnOjBmMDFlMDBlNmZmZDRjZmQ5ZjlmZWVlNzM3NmVlODFmL3RleHRyZWdpb246MGYwMWUwMGU2ZmZkNGNmZDlmOWZlZWU3Mzc2ZWU4MWZfMjA3OQ_ceae9ddc-aa48-444c-a42c-06dd44e262cb">50.0</ix:nonFraction>&#160;million was fixed consideration for the transfer of the license and was recognized upon transfer of the license in December 2020.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The remaining forms of consideration are variable because they are dependent on achieving milestones or are based on aggregate future net sales for the regions. None of the regulatory milestones have been included in the transaction price, as all milestone amounts were fully constrained. As part of its evaluation of the constraint, the Company considered numerous </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ifdacd66ff8374b028ec84afb4659c948" continuedAt="i2d28cbd3ef0b484ab716119df1895c36">factors, including the magnitude of a potential reversal of revenue, uncertainty about if or when the milestone related performance obligations might be achieved, and that receipt of the milestones are outside the control of the Company since they are dependent on efforts to be undertaken by Otsuka and regulatory approval by various foreign government agencies. Any consideration related to sales-based royalties (and sales-based thresholds) will be recognized when the related sales occur.</ix:continuation></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i2d28cbd3ef0b484ab716119df1895c36">As of March&#160;31, 2022, the Company recorded $<ix:nonFraction unitRef="usd" contextRef="ibb901623e47548488a8a8d92817c020b_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83My9mcmFnOjBmMDFlMDBlNmZmZDRjZmQ5ZjlmZWVlNzM3NmVlODFmL3RleHRyZWdpb246MGYwMWUwMGU2ZmZkNGNmZDlmOWZlZWU3Mzc2ZWU4MWZfMTA5OTUxMTYzMTg5OA_03ed36e1-ebef-414f-9351-853947670c73">104</ix:nonFraction>&#160;thousand of collaboration revenue related to manufacturing services provided under the Otsuka contract</ix:continuation>.</span></div><div id="i2d3a8f7e52e84dcebfa935bec5ca9eb6_76"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">14.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:23.5pt"><ix:nonNumeric contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83Ni9mcmFnOjU1YjBkMDU4NTU2MDRhNjE4NGI4ZTgyYjNmMjQxMjM0L3RleHRyZWdpb246NTViMGQwNTg1NTYwNGE2MTg0YjhlODJiM2YyNDEyMzRfNDc5_1a9359e8-4af3-46cf-a90d-3264b3549689" continuedAt="i1771b798e07240a7ad8fd4608589e948" escape="true">Net Loss per Common Share</ix:nonNumeric></span></div><ix:continuation id="i1771b798e07240a7ad8fd4608589e948"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted net loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding. Since the Company was in a loss position for all periods presented, diluted net loss per share is the same as basic net loss per share. <ix:nonNumeric contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83Ni9mcmFnOjU1YjBkMDU4NTU2MDRhNjE4NGI4ZTgyYjNmMjQxMjM0L3RleHRyZWdpb246NTViMGQwNTg1NTYwNGE2MTg0YjhlODJiM2YyNDEyMzRfNDgw_5de1f9a7-d558-47dd-9fe7-907055a89007" continuedAt="i2afe8fc0cf1d402c98e3c81ced19f55e" escape="true">The numerator and denominator used in the calculation of basic and diluted net loss per common share are as follows:</ix:nonNumeric></span></div><ix:continuation id="i2afe8fc0cf1d402c98e3c81ced19f55e"><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:72.135%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.388%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.694%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.388%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.695%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended<br/>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands, except per share data)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83Ni9mcmFnOjU1YjBkMDU4NTU2MDRhNjE4NGI4ZTgyYjNmMjQxMjM0L3RhYmxlOjI4YmEwZmI0OTNlMDQxZjk5MTU5MWM5ZWFmNzlmNTRjL3RhYmxlcmFuZ2U6MjhiYTBmYjQ5M2UwNDFmOTkxNTkxYzllYWY3OWY1NGNfMi0yLTEtMS00Njg5MQ_6ac9ab29-7f15-4343-8494-ecfbaffe82b1">37,630</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i56599386fa47443a8975bb3f7a6a8c57_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83Ni9mcmFnOjU1YjBkMDU4NTU2MDRhNjE4NGI4ZTgyYjNmMjQxMjM0L3RhYmxlOjI4YmEwZmI0OTNlMDQxZjk5MTU5MWM5ZWFmNzlmNTRjL3RhYmxlcmFuZ2U6MjhiYTBmYjQ5M2UwNDFmOTkxNTkxYzllYWY3OWY1NGNfMi00LTEtMS00Njg5MQ_0d63b369-faef-472b-80a7-2b877d7d527e">50,379</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83Ni9mcmFnOjU1YjBkMDU4NTU2MDRhNjE4NGI4ZTgyYjNmMjQxMjM0L3RhYmxlOjI4YmEwZmI0OTNlMDQxZjk5MTU5MWM5ZWFmNzlmNTRjL3RhYmxlcmFuZ2U6MjhiYTBmYjQ5M2UwNDFmOTkxNTkxYzllYWY3OWY1NGNfMy0yLTEtMS00Njg5MQ_342538a5-4abe-486e-97b8-17d9cf1d2bab"><ix:nonFraction unitRef="shares" contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83Ni9mcmFnOjU1YjBkMDU4NTU2MDRhNjE4NGI4ZTgyYjNmMjQxMjM0L3RhYmxlOjI4YmEwZmI0OTNlMDQxZjk5MTU5MWM5ZWFmNzlmNTRjL3RhYmxlcmFuZ2U6MjhiYTBmYjQ5M2UwNDFmOTkxNTkxYzllYWY3OWY1NGNfMy0yLTEtMS00Njg5MQ_6147aa37-f6b8-4a0d-aaea-2ec3d8b80492">141,675</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i56599386fa47443a8975bb3f7a6a8c57_D20210101-20210331" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83Ni9mcmFnOjU1YjBkMDU4NTU2MDRhNjE4NGI4ZTgyYjNmMjQxMjM0L3RhYmxlOjI4YmEwZmI0OTNlMDQxZjk5MTU5MWM5ZWFmNzlmNTRjL3RhYmxlcmFuZ2U6MjhiYTBmYjQ5M2UwNDFmOTkxNTkxYzllYWY3OWY1NGNfMy00LTEtMS00Njg5MQ_608cff76-b0d9-4ef1-846a-ac66460ee841"><ix:nonFraction unitRef="shares" contextRef="i56599386fa47443a8975bb3f7a6a8c57_D20210101-20210331" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83Ni9mcmFnOjU1YjBkMDU4NTU2MDRhNjE4NGI4ZTgyYjNmMjQxMjM0L3RhYmxlOjI4YmEwZmI0OTNlMDQxZjk5MTU5MWM5ZWFmNzlmNTRjL3RhYmxlcmFuZ2U6MjhiYTBmYjQ5M2UwNDFmOTkxNTkxYzllYWY3OWY1NGNfMy00LTEtMS00Njg5MQ_80803525-c7ec-4166-b3aa-da0462874adf">127,401</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per common share (expressed in $ per share)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83Ni9mcmFnOjU1YjBkMDU4NTU2MDRhNjE4NGI4ZTgyYjNmMjQxMjM0L3RhYmxlOjI4YmEwZmI0OTNlMDQxZjk5MTU5MWM5ZWFmNzlmNTRjL3RhYmxlcmFuZ2U6MjhiYTBmYjQ5M2UwNDFmOTkxNTkxYzllYWY3OWY1NGNfNC0yLTEtMS00Njg5MQ_26db01ce-09b9-4be6-b2bb-72394cd25e91"><ix:nonFraction unitRef="usdPerShare" contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83Ni9mcmFnOjU1YjBkMDU4NTU2MDRhNjE4NGI4ZTgyYjNmMjQxMjM0L3RhYmxlOjI4YmEwZmI0OTNlMDQxZjk5MTU5MWM5ZWFmNzlmNTRjL3RhYmxlcmFuZ2U6MjhiYTBmYjQ5M2UwNDFmOTkxNTkxYzllYWY3OWY1NGNfNC0yLTEtMS00Njg5MQ_ee9c1b3b-7795-487a-ac85-fc59066ce615">0.27</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i56599386fa47443a8975bb3f7a6a8c57_D20210101-20210331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83Ni9mcmFnOjU1YjBkMDU4NTU2MDRhNjE4NGI4ZTgyYjNmMjQxMjM0L3RhYmxlOjI4YmEwZmI0OTNlMDQxZjk5MTU5MWM5ZWFmNzlmNTRjL3RhYmxlcmFuZ2U6MjhiYTBmYjQ5M2UwNDFmOTkxNTkxYzllYWY3OWY1NGNfNC00LTEtMS00Njg5MQ_6a5c9688-627f-450e-b9dd-161ad682d9a8"><ix:nonFraction unitRef="usdPerShare" contextRef="i56599386fa47443a8975bb3f7a6a8c57_D20210101-20210331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83Ni9mcmFnOjU1YjBkMDU4NTU2MDRhNjE4NGI4ZTgyYjNmMjQxMjM0L3RhYmxlOjI4YmEwZmI0OTNlMDQxZjk5MTU5MWM5ZWFmNzlmNTRjL3RhYmxlcmFuZ2U6MjhiYTBmYjQ5M2UwNDFmOTkxNTkxYzllYWY3OWY1NGNfNC00LTEtMS00Njg5MQ_e012714c-63bc-4814-872b-7e1def5e0d90">0.40</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company did not include the securities in the following table in the computation of the net loss per common share because the effect would have been anti-dilutive during each period:</span></div></ix:continuation><div><span><br/></span></div><div style="margin-top:12pt;text-align:justify"><ix:nonNumeric contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83Ni9mcmFnOjU1YjBkMDU4NTU2MDRhNjE4NGI4ZTgyYjNmMjQxMjM0L3RleHRyZWdpb246NTViMGQwNTg1NTYwNGE2MTg0YjhlODJiM2YyNDEyMzRfNDgx_3c997a36-8c8b-4b7b-8bb0-7e1064210164" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.145%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic3ca33ca8bfb4c8aac86d02183ad2fa2_D20220101-20220331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83Ni9mcmFnOjU1YjBkMDU4NTU2MDRhNjE4NGI4ZTgyYjNmMjQxMjM0L3RhYmxlOjcyZjMwYThiNzE3NzRiMGNiYzJiODU1NGI0MmRkOGQ4L3RhYmxlcmFuZ2U6NzJmMzBhOGI3MTc3NGIwY2JjMmI4NTU0YjQyZGQ4ZDhfMi0yLTEtMS00Njg5MQ_28366fd9-30e8-47eb-b26b-c5980a9cd7c1">14,649</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i105a1152b5c54760ad7380e7462cbfbf_D20210101-20210331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83Ni9mcmFnOjU1YjBkMDU4NTU2MDRhNjE4NGI4ZTgyYjNmMjQxMjM0L3RhYmxlOjcyZjMwYThiNzE3NzRiMGNiYzJiODU1NGI0MmRkOGQ4L3RhYmxlcmFuZ2U6NzJmMzBhOGI3MTc3NGIwY2JjMmI4NTU0YjQyZGQ4ZDhfMi00LTEtMS00Njg5MQ_1ce5f89a-a9a2-4ee1-abab-0d9c23fe3300">14,332</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested performance awards</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iae2da8378b4b45af98b0443b437184a5_D20220101-20220331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83Ni9mcmFnOjU1YjBkMDU4NTU2MDRhNjE4NGI4ZTgyYjNmMjQxMjM0L3RhYmxlOjcyZjMwYThiNzE3NzRiMGNiYzJiODU1NGI0MmRkOGQ4L3RhYmxlcmFuZ2U6NzJmMzBhOGI3MTc3NGIwY2JjMmI4NTU0YjQyZGQ4ZDhfMy0yLTEtMS00Njg5MQ_bc86eb90-9e7a-4521-aec2-83d8e87120e9">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6384fea4599b405a9d8a4d0a174ba37c_D20210101-20210331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83Ni9mcmFnOjU1YjBkMDU4NTU2MDRhNjE4NGI4ZTgyYjNmMjQxMjM0L3RhYmxlOjcyZjMwYThiNzE3NzRiMGNiYzJiODU1NGI0MmRkOGQ4L3RhYmxlcmFuZ2U6NzJmMzBhOGI3MTc3NGIwY2JjMmI4NTU0YjQyZGQ4ZDhfMy00LTEtMS00Njg5MQ_28e6c093-a99b-44c7-bb42-1a0e6c2954c1">439</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested restricted units</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic530833cd3564851886dba86e0d1fbb6_D20220101-20220331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83Ni9mcmFnOjU1YjBkMDU4NTU2MDRhNjE4NGI4ZTgyYjNmMjQxMjM0L3RhYmxlOjcyZjMwYThiNzE3NzRiMGNiYzJiODU1NGI0MmRkOGQ4L3RhYmxlcmFuZ2U6NzJmMzBhOGI3MTc3NGIwY2JjMmI4NTU0YjQyZGQ4ZDhfNC0yLTEtMS00Njg5MQ_2cfdc8b9-462a-4aac-8266-8a14107b3857">1,952</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5d28d6c0f0d940f59d45551ddc72575a_D20210101-20210331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83Ni9mcmFnOjU1YjBkMDU4NTU2MDRhNjE4NGI4ZTgyYjNmMjQxMjM0L3RhYmxlOjcyZjMwYThiNzE3NzRiMGNiYzJiODU1NGI0MmRkOGQ4L3RhYmxlcmFuZ2U6NzJmMzBhOGI3MTc3NGIwY2JjMmI4NTU0YjQyZGQ4ZDhfNC00LTEtMS00Njg5MQ_f68bb30c-b094-46da-abd2-7db5b27e6145">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib81c30a26c6a41b69cf92282735549ea_D20220101-20220331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83Ni9mcmFnOjU1YjBkMDU4NTU2MDRhNjE4NGI4ZTgyYjNmMjQxMjM0L3RhYmxlOjcyZjMwYThiNzE3NzRiMGNiYzJiODU1NGI0MmRkOGQ4L3RhYmxlcmFuZ2U6NzJmMzBhOGI3MTc3NGIwY2JjMmI4NTU0YjQyZGQ4ZDhfNS0yLTEtMS00Njg5MQ_bc356448-8c38-47b1-8dad-f58c08b686e7">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6ee10ba4e3a1477e80be6a7ae14a5733_D20210101-20210331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83Ni9mcmFnOjU1YjBkMDU4NTU2MDRhNjE4NGI4ZTgyYjNmMjQxMjM0L3RhYmxlOjcyZjMwYThiNzE3NzRiMGNiYzJiODU1NGI0MmRkOGQ4L3RhYmxlcmFuZ2U6NzJmMzBhOGI3MTc3NGIwY2JjMmI4NTU0YjQyZGQ4ZDhfNS00LTEtMS00Njg5MQ_858d1896-ea8f-4690-bc85-6aa7bf2cbe8b">1,014</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83Ni9mcmFnOjU1YjBkMDU4NTU2MDRhNjE4NGI4ZTgyYjNmMjQxMjM0L3RhYmxlOjcyZjMwYThiNzE3NzRiMGNiYzJiODU1NGI0MmRkOGQ4L3RhYmxlcmFuZ2U6NzJmMzBhOGI3MTc3NGIwY2JjMmI4NTU0YjQyZGQ4ZDhfNi0yLTEtMS00Njg5MQ_6f7c433a-fe91-4570-91e7-4e38f05b34f7">16,601</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i56599386fa47443a8975bb3f7a6a8c57_D20210101-20210331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83Ni9mcmFnOjU1YjBkMDU4NTU2MDRhNjE4NGI4ZTgyYjNmMjQxMjM0L3RhYmxlOjcyZjMwYThiNzE3NzRiMGNiYzJiODU1NGI0MmRkOGQ4L3RhYmxlcmFuZ2U6NzJmMzBhOGI3MTc3NGIwY2JjMmI4NTU0YjQyZGQ4ZDhfNi00LTEtMS00Njg5MQ_e2696b1d-c3de-4145-a674-7f2259449e35">15,785</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div></ix:continuation><div><span><br/></span></div><div id="i2d3a8f7e52e84dcebfa935bec5ca9eb6_79"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">15.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:23.5pt"><ix:nonNumeric contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83OS9mcmFnOmJmMGVkNmYyMzkyYzQyZDJiNWQxNjkzN2ZmMjQzOTU5L3RleHRyZWdpb246YmYwZWQ2ZjIzOTJjNDJkMmI1ZDE2OTM3ZmYyNDM5NTlfMzc1Mg_b96726ef-f30c-447c-988d-a762c8e64f34" continuedAt="i62ef6dc797fe4c9aba1e50db09896044" escape="true">Share-based Compensation</ix:nonNumeric></span></div><ix:continuation id="i62ef6dc797fe4c9aba1e50db09896044" continuedAt="i3bfce1b0d8c949478a71343fd08d4863"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's Amended and Restated Equity Incentive Plan (the Plan), which was adopted and approved by the Company's shareholders in June 2021, allows for an issuance of up to an aggregate of <ix:nonFraction unitRef="shares" contextRef="ic967022eaed24a72b01d3974047a24dc_D20210601-20210630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83OS9mcmFnOmJmMGVkNmYyMzkyYzQyZDJiNWQxNjkzN2ZmMjQzOTU5L3RleHRyZWdpb246YmYwZWQ2ZjIzOTJjNDJkMmI1ZDE2OTM3ZmYyNDM5NTlfMjIy_2ad29544-571b-4c92-a108-9ca2acc1330d">23.8</ix:nonFraction> million shares (inclusive of outstanding awards) and provides for grants of stock options, performance awards, restricted stock and restricted stock units that may be settled in cash and stock. Also in June 2021, the Company's shareholders adopted and approved the Company's 2021 ESPP, which allows for the issuance of up to <ix:nonFraction unitRef="shares" contextRef="ib997dd537ee44595bf4b5e42a02596ac_I20210630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83OS9mcmFnOmJmMGVkNmYyMzkyYzQyZDJiNWQxNjkzN2ZmMjQzOTU5L3RleHRyZWdpb246YmYwZWQ2ZjIzOTJjNDJkMmI1ZDE2OTM3ZmYyNDM5NTlfNDI5_728391be-2859-4ddc-8d14-0a89e143db2d">2.5</ix:nonFraction> million shares. The 2021 ESPP is intended to qualify as an &#8220;employee stock purchase plan&#8221; under Section 423 of the Internal Revenue Code (the &#8220;Code&#8221;) but also permits the Company to include the employees, including non-United States employees, in offerings not intended to qualify under Section 423. The purpose of the 2021 ESPP is to provide eligible employees with opportunities to purchase the Company&#8217;s common shares at a discounted price. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Plan requires the exercise price of each option not to be less than the closing market price of the Company&#8217;s common shares on the day immediately prior to the date of grant. The board of directors approves the vesting criteria and periods at its discretion. The options issued under the plan are accounted for as equity-settled share-based payments. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company used the Black-Scholes option pricing model to estimate the fair value of the options granted. The Company considers historical volatility of its common shares in estimating its future stock price volatility. The risk-free interest rate for the expected life of the options was based on the yield available on government benchmark bonds with an approximate </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i3bfce1b0d8c949478a71343fd08d4863" continuedAt="id4824b41a3cc4fd88c20e6f108fff4a9"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">equivalent remaining term at the time of the grant. The expected life is based upon the contractual term, taking into account expected employee exercise and expected post-vesting employment termination behavior. </span></div><ix:nonNumeric contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83OS9mcmFnOmJmMGVkNmYyMzkyYzQyZDJiNWQxNjkzN2ZmMjQzOTU5L3RleHRyZWdpb246YmYwZWQ2ZjIzOTJjNDJkMmI1ZDE2OTM3ZmYyNDM5NTlfMzc1Mw_e5748198-907d-4522-80df-cd29edda5be1" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following weighted average assumptions were used to estimate the fair value of the options granted during the three months ended March&#160;31, 2022 and March&#160;31, 2021:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.642%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.447%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Annualized volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83OS9mcmFnOmJmMGVkNmYyMzkyYzQyZDJiNWQxNjkzN2ZmMjQzOTU5L3RhYmxlOjA0OTJiZjU1NzZiNDRlNTFiYjU1MzZkYTZhODIyN2I2L3RhYmxlcmFuZ2U6MDQ5MmJmNTU3NmI0NGU1MWJiNTUzNmRhNmE4MjI3YjZfMS0yLTEtMS00Njg5MQ_51dc1472-ace3-48a0-9936-fc0d228bd517">70</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i56599386fa47443a8975bb3f7a6a8c57_D20210101-20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83OS9mcmFnOmJmMGVkNmYyMzkyYzQyZDJiNWQxNjkzN2ZmMjQzOTU5L3RhYmxlOjA0OTJiZjU1NzZiNDRlNTFiYjU1MzZkYTZhODIyN2I2L3RhYmxlcmFuZ2U6MDQ5MmJmNTU3NmI0NGU1MWJiNTUzNmRhNmE4MjI3YjZfMS00LTEtMS00Njg5MQ_202fb2f9-113b-462e-98d7-a67d78502fa9">66</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83OS9mcmFnOmJmMGVkNmYyMzkyYzQyZDJiNWQxNjkzN2ZmMjQzOTU5L3RhYmxlOjA0OTJiZjU1NzZiNDRlNTFiYjU1MzZkYTZhODIyN2I2L3RhYmxlcmFuZ2U6MDQ5MmJmNTU3NmI0NGU1MWJiNTUzNmRhNmE4MjI3YjZfMi0yLTEtMS00Njg5MQ_c95384f0-4f44-4f36-a9d9-8188adc3d0ee">1.73</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i56599386fa47443a8975bb3f7a6a8c57_D20210101-20210331" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83OS9mcmFnOmJmMGVkNmYyMzkyYzQyZDJiNWQxNjkzN2ZmMjQzOTU5L3RhYmxlOjA0OTJiZjU1NzZiNDRlNTFiYjU1MzZkYTZhODIyN2I2L3RhYmxlcmFuZ2U6MDQ5MmJmNTU3NmI0NGU1MWJiNTUzNmRhNmE4MjI3YjZfMi00LTEtMS00Njg5MQ_8bef1eae-651e-4b9c-b4b2-e77a6d803924">0.28</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life of options in years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83OS9mcmFnOmJmMGVkNmYyMzkyYzQyZDJiNWQxNjkzN2ZmMjQzOTU5L3RhYmxlOjA0OTJiZjU1NzZiNDRlNTFiYjU1MzZkYTZhODIyN2I2L3RhYmxlcmFuZ2U6MDQ5MmJmNTU3NmI0NGU1MWJiNTUzNmRhNmE4MjI3YjZfMy0yLTEtMS00Njg5MQ_78993305-acc4-4fe9-91c2-0378b84878f2">5.0</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i56599386fa47443a8975bb3f7a6a8c57_D20210101-20210331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83OS9mcmFnOmJmMGVkNmYyMzkyYzQyZDJiNWQxNjkzN2ZmMjQzOTU5L3RhYmxlOjA0OTJiZjU1NzZiNDRlNTFiYjU1MzZkYTZhODIyN2I2L3RhYmxlcmFuZ2U6MDQ5MmJmNTU3NmI0NGU1MWJiNTUzNmRhNmE4MjI3YjZfMy00LTEtMS00Njg5MQ_4aed2215-21cb-4a9b-8bff-932de444596c">4.0</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated forfeiture rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331" decimals="4" name="auph:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83OS9mcmFnOmJmMGVkNmYyMzkyYzQyZDJiNWQxNjkzN2ZmMjQzOTU5L3RhYmxlOjA0OTJiZjU1NzZiNDRlNTFiYjU1MzZkYTZhODIyN2I2L3RhYmxlcmFuZ2U6MDQ5MmJmNTU3NmI0NGU1MWJiNTUzNmRhNmE4MjI3YjZfNC0yLTEtMS00Njg5MQ_b7227811-78f8-4258-870d-227a27c417ee">11.6</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i56599386fa47443a8975bb3f7a6a8c57_D20210101-20210331" decimals="4" name="auph:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83OS9mcmFnOmJmMGVkNmYyMzkyYzQyZDJiNWQxNjkzN2ZmMjQzOTU5L3RhYmxlOjA0OTJiZjU1NzZiNDRlNTFiYjU1MzZkYTZhODIyN2I2L3RhYmxlcmFuZ2U6MDQ5MmJmNTU3NmI0NGU1MWJiNTUzNmRhNmE4MjI3YjZfNC00LTEtMS00Njg5MQ_61662d0f-8761-4d11-a3b2-5d30ac2027d3">8.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83OS9mcmFnOmJmMGVkNmYyMzkyYzQyZDJiNWQxNjkzN2ZmMjQzOTU5L3RhYmxlOjA0OTJiZjU1NzZiNDRlNTFiYjU1MzZkYTZhODIyN2I2L3RhYmxlcmFuZ2U6MDQ5MmJmNTU3NmI0NGU1MWJiNTUzNmRhNmE4MjI3YjZfNS0yLTEtMS00Njg5MQ_f3836eb0-c10e-4efc-ae7a-ed37c586ec13">0.0</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56599386fa47443a8975bb3f7a6a8c57_D20210101-20210331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83OS9mcmFnOmJmMGVkNmYyMzkyYzQyZDJiNWQxNjkzN2ZmMjQzOTU5L3RhYmxlOjA0OTJiZjU1NzZiNDRlNTFiYjU1MzZkYTZhODIyN2I2L3RhYmxlcmFuZ2U6MDQ5MmJmNTU3NmI0NGU1MWJiNTUzNmRhNmE4MjI3YjZfNS00LTEtMS00Njg5MQ_d92e28c5-3a01-409b-9635-25333c99ff60">0.0</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value per common share option</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83OS9mcmFnOmJmMGVkNmYyMzkyYzQyZDJiNWQxNjkzN2ZmMjQzOTU5L3RhYmxlOjA0OTJiZjU1NzZiNDRlNTFiYjU1MzZkYTZhODIyN2I2L3RhYmxlcmFuZ2U6MDQ5MmJmNTU3NmI0NGU1MWJiNTUzNmRhNmE4MjI3YjZfNi0yLTEtMS00Njg5MQ_bd5578f6-55f3-4e2a-954c-2aba40e71e91">7.02</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i56599386fa47443a8975bb3f7a6a8c57_D20210101-20210331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83OS9mcmFnOmJmMGVkNmYyMzkyYzQyZDJiNWQxNjkzN2ZmMjQzOTU5L3RhYmxlOjA0OTJiZjU1NzZiNDRlNTFiYjU1MzZkYTZhODIyN2I2L3RhYmxlcmFuZ2U6MDQ5MmJmNTU3NmI0NGU1MWJiNTUzNmRhNmE4MjI3YjZfNi00LTEtMS00Njg5MQ_8bac8f52-0342-45d1-8255-bbe2e041e2e4">6.72</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83OS9mcmFnOmJmMGVkNmYyMzkyYzQyZDJiNWQxNjkzN2ZmMjQzOTU5L3RleHRyZWdpb246YmYwZWQ2ZjIzOTJjNDJkMmI1ZDE2OTM3ZmYyNDM5NTlfMzI5ODUzNDg4NzU1MA_1a03b8d3-c6e7-441e-9a0c-96af39bdf1af" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the option award activity during the three months ended March&#160;31, 2022:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.642%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.447%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of shares (in thousands)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted average exercise price $</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding - Beginning of Period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i784f65549351439fa4b7bedf90ce7e3f_I20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83OS9mcmFnOmJmMGVkNmYyMzkyYzQyZDJiNWQxNjkzN2ZmMjQzOTU5L3RhYmxlOjQ0NjcxM2RjYzhiZjQ5MjNiMWI1NWNhMDZiZjYzMWUwL3RhYmxlcmFuZ2U6NDQ2NzEzZGNjOGJmNDkyM2IxYjU1Y2EwNmJmNjMxZTBfMi0yLTEtMS00Njg5MQ_dcdb1193-f0ff-45e4-9f02-9284dc172754">12,074</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i784f65549351439fa4b7bedf90ce7e3f_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83OS9mcmFnOmJmMGVkNmYyMzkyYzQyZDJiNWQxNjkzN2ZmMjQzOTU5L3RhYmxlOjQ0NjcxM2RjYzhiZjQ5MjNiMWI1NWNhMDZiZjYzMWUwL3RhYmxlcmFuZ2U6NDQ2NzEzZGNjOGJmNDkyM2IxYjU1Y2EwNmJmNjMxZTBfMi00LTEtMS00Njg5MQ_e93eeee4-e785-4b90-bd5c-adeb74751961">12.84</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83OS9mcmFnOmJmMGVkNmYyMzkyYzQyZDJiNWQxNjkzN2ZmMjQzOTU5L3RhYmxlOjQ0NjcxM2RjYzhiZjQ5MjNiMWI1NWNhMDZiZjYzMWUwL3RhYmxlcmFuZ2U6NDQ2NzEzZGNjOGJmNDkyM2IxYjU1Y2EwNmJmNjMxZTBfMy0yLTEtMS00Njg5MQ_5f2af206-a86d-4821-9133-7062d4c05fc6">2,800</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83OS9mcmFnOmJmMGVkNmYyMzkyYzQyZDJiNWQxNjkzN2ZmMjQzOTU5L3RhYmxlOjQ0NjcxM2RjYzhiZjQ5MjNiMWI1NWNhMDZiZjYzMWUwL3RhYmxlcmFuZ2U6NDQ2NzEzZGNjOGJmNDkyM2IxYjU1Y2EwNmJmNjMxZTBfMy00LTEtMS00Njg5MQ_e102a642-ba2e-4d22-9d33-969f5b36c766">12.00</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83OS9mcmFnOmJmMGVkNmYyMzkyYzQyZDJiNWQxNjkzN2ZmMjQzOTU5L3RhYmxlOjQ0NjcxM2RjYzhiZjQ5MjNiMWI1NWNhMDZiZjYzMWUwL3RhYmxlcmFuZ2U6NDQ2NzEzZGNjOGJmNDkyM2IxYjU1Y2EwNmJmNjMxZTBfNC0yLTEtMS00Njg5MQ_2e398c43-450c-4c96-85d6-b6c7e4a3e241">54</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83OS9mcmFnOmJmMGVkNmYyMzkyYzQyZDJiNWQxNjkzN2ZmMjQzOTU5L3RhYmxlOjQ0NjcxM2RjYzhiZjQ5MjNiMWI1NWNhMDZiZjYzMWUwL3RhYmxlcmFuZ2U6NDQ2NzEzZGNjOGJmNDkyM2IxYjU1Y2EwNmJmNjMxZTBfNC00LTEtMS00Njg5MQ_0446072f-92af-48ff-9974-ad60a2b35fad">7.57</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83OS9mcmFnOmJmMGVkNmYyMzkyYzQyZDJiNWQxNjkzN2ZmMjQzOTU5L3RhYmxlOjQ0NjcxM2RjYzhiZjQ5MjNiMWI1NWNhMDZiZjYzMWUwL3RhYmxlcmFuZ2U6NDQ2NzEzZGNjOGJmNDkyM2IxYjU1Y2EwNmJmNjMxZTBfNS0yLTEtMS00Njg5MQ_b8a4b60d-9f9e-483e-8380-d2f52c17c880">171</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83OS9mcmFnOmJmMGVkNmYyMzkyYzQyZDJiNWQxNjkzN2ZmMjQzOTU5L3RhYmxlOjQ0NjcxM2RjYzhiZjQ5MjNiMWI1NWNhMDZiZjYzMWUwL3RhYmxlcmFuZ2U6NDQ2NzEzZGNjOGJmNDkyM2IxYjU1Y2EwNmJmNjMxZTBfNS00LTEtMS00Njg5MQ_87312974-f14f-47b5-a1ec-ef56b3228771">16.27</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding - End of Period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id7882ae6aff54a3aacdef67ddf11a428_I20220331" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83OS9mcmFnOmJmMGVkNmYyMzkyYzQyZDJiNWQxNjkzN2ZmMjQzOTU5L3RhYmxlOjQ0NjcxM2RjYzhiZjQ5MjNiMWI1NWNhMDZiZjYzMWUwL3RhYmxlcmFuZ2U6NDQ2NzEzZGNjOGJmNDkyM2IxYjU1Y2EwNmJmNjMxZTBfNi0yLTEtMS00Njg5MQ_af564570-38a3-4f90-bfc7-5b4a4b196edb">14,649</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id7882ae6aff54a3aacdef67ddf11a428_I20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83OS9mcmFnOmJmMGVkNmYyMzkyYzQyZDJiNWQxNjkzN2ZmMjQzOTU5L3RhYmxlOjQ0NjcxM2RjYzhiZjQ5MjNiMWI1NWNhMDZiZjYzMWUwL3RhYmxlcmFuZ2U6NDQ2NzEzZGNjOGJmNDkyM2IxYjU1Y2EwNmJmNjMxZTBfNi00LTEtMS00Njg5MQ_68002c04-0e98-4608-9699-e4df4aa95a8d">12.66</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Performance Awards and Restricted Stock Units</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 23, 2020, the Company issued <ix:nonFraction unitRef="shares" contextRef="ib8ebe99a1b5a4e18b4d3a1b5a2e4806a_D20201023-20201023" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83OS9mcmFnOmJmMGVkNmYyMzkyYzQyZDJiNWQxNjkzN2ZmMjQzOTU5L3RleHRyZWdpb246YmYwZWQ2ZjIzOTJjNDJkMmI1ZDE2OTM3ZmYyNDM5NTlfMjIyNQ_dc1f2919-9ee3-43ff-b720-f7e35692e858">439,000</ix:nonFraction> performance awards (PAs) to executive management of the Company whose vesting is contingent upon meeting specific performance metrics based on the results for the year ended December 31, 2021. Each PA which vests entitles the participant to receive common shares on the basis of the performance metrics set. On March 18, 2021 performance metrics were set and formally communicated. Therefore, March 18, 2021 was the grant date and the fair value on the grant date was $<ix:nonFraction unitRef="usdPerShare" contextRef="i6658318dd5b2443bbb61848fe5a802d9_D20210318-20210318" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83OS9mcmFnOmJmMGVkNmYyMzkyYzQyZDJiNWQxNjkzN2ZmMjQzOTU5L3RleHRyZWdpb246YmYwZWQ2ZjIzOTJjNDJkMmI1ZDE2OTM3ZmYyNDM5NTlfMjY4MQ_3df76d40-78dd-4794-80bb-9fdbd2843901">13.56</ix:nonFraction>. As of March&#160;31, 2022, approximately <ix:nonFraction unitRef="shares" contextRef="i16277210576f40e6b66abe8fff631587_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83OS9mcmFnOmJmMGVkNmYyMzkyYzQyZDJiNWQxNjkzN2ZmMjQzOTU5L3RleHRyZWdpb246YmYwZWQ2ZjIzOTJjNDJkMmI1ZDE2OTM3ZmYyNDM5NTlfMTA5OTUxMTYzMzM0OA_06ed27ec-d09d-439c-aa2e-4a07cc29ee2c">88,000</ix:nonFraction> PAs vested based on performance metrics achieved and <ix:nonFraction unitRef="shares" contextRef="i16277210576f40e6b66abe8fff631587_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83OS9mcmFnOmJmMGVkNmYyMzkyYzQyZDJiNWQxNjkzN2ZmMjQzOTU5L3RleHRyZWdpb246YmYwZWQ2ZjIzOTJjNDJkMmI1ZDE2OTM3ZmYyNDM5NTlfMTA5OTUxMTYzMzMzOQ_296fb877-afaf-48cb-89bb-e150a611273f">351,000</ix:nonFraction> were canceled as of December&#160;31, 2021 as performance metrics were not met.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 6, 2021, the Company granted approximately <ix:nonFraction unitRef="shares" contextRef="i756422f9e99948068788efa1b4d47e72_D20210806-20210806" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83OS9mcmFnOmJmMGVkNmYyMzkyYzQyZDJiNWQxNjkzN2ZmMjQzOTU5L3RleHRyZWdpb246YmYwZWQ2ZjIzOTJjNDJkMmI1ZDE2OTM3ZmYyNDM5NTlfMjczOA_0accfc5f-e824-48f6-9f93-4f1f02792109">619,000</ix:nonFraction> PAs and restricted stock units (RSUs). The grant date for the PAs and RSUs was August 6, 2021 and the fair value on the grant date was $<ix:nonFraction unitRef="usdPerShare" contextRef="i756422f9e99948068788efa1b4d47e72_D20210806-20210806" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83OS9mcmFnOmJmMGVkNmYyMzkyYzQyZDJiNWQxNjkzN2ZmMjQzOTU5L3RleHRyZWdpb246YmYwZWQ2ZjIzOTJjNDJkMmI1ZDE2OTM3ZmYyNDM5NTlfMjg3Ng_4336137a-588e-4456-9e77-cb6c69b6f5ba">14.42</ix:nonFraction> as this was the date performance measures were set and communicated to employees. The PAs vest on the employee's first anniversary of the grant date and the employee must achieve at least one of the performance metrics to obtain the portion of the award associated with the metric. The RSUs have no performance metrics and will vest on the <ix:nonNumeric contextRef="i262fb9bddf114af5919be54955f6f018_D20220101-20220331" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83OS9mcmFnOmJmMGVkNmYyMzkyYzQyZDJiNWQxNjkzN2ZmMjQzOTU5L3RleHRyZWdpb246YmYwZWQ2ZjIzOTJjNDJkMmI1ZDE2OTM3ZmYyNDM5NTlfMzI5ODUzNDg4OTU2Nw_9578cedb-4cde-4d5c-97cb-4f3f8b26f320">one year</ix:nonNumeric> anniversary of the grant. As of December&#160;31, 2021, approximately <ix:nonFraction unitRef="shares" contextRef="i1bc38d71f54444c69c2a074dc7d8a2ce_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83OS9mcmFnOmJmMGVkNmYyMzkyYzQyZDJiNWQxNjkzN2ZmMjQzOTU5L3RleHRyZWdpb246YmYwZWQ2ZjIzOTJjNDJkMmI1ZDE2OTM3ZmYyNDM5NTlfMTA5OTUxMTYzMzM1Ng_6d56c6f9-7bd2-4aa2-9199-c5d48e4fb385">375,000</ix:nonFraction> PAs and RSUs were canceled or forfeited.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the quarter, the Company has granted RSUs and intends to grant RSUs throughout the year under the Plan. The RSUs are fair valued based on the market price of our common stock on the date of the grant.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331" name="us-gaap:ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83OS9mcmFnOmJmMGVkNmYyMzkyYzQyZDJiNWQxNjkzN2ZmMjQzOTU5L3RleHRyZWdpb246YmYwZWQ2ZjIzOTJjNDJkMmI1ZDE2OTM3ZmYyNDM5NTlfMzc1NA_49b204e5-f162-4dc7-8bdf-075200508e05" continuedAt="i749bfe48566345ac90b43feed10c3405" escape="true">The following table summarizes the PAs and RSU activity for the three months ended March&#160;31, 2022:</ix:nonNumeric></span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="id4824b41a3cc4fd88c20e6f108fff4a9"><div style="margin-top:12pt;text-align:justify"><ix:continuation id="i749bfe48566345ac90b43feed10c3405"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.642%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.447%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of shares (in thousands)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted average exercise price $</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding - Beginning of Period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id05699051d2448519e6e9c2935d67b1f_I20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83OS9mcmFnOmJmMGVkNmYyMzkyYzQyZDJiNWQxNjkzN2ZmMjQzOTU5L3RhYmxlOmNiZTA5ZDUzNzIyNDRiOWNhMjc0NWYwYjNiMzNmNmEzL3RhYmxlcmFuZ2U6Y2JlMDlkNTM3MjI0NGI5Y2EyNzQ1ZjBiM2IzM2Y2YTNfMi0yLTEtMS01MzQ3Ng_3380a24c-a159-47b5-8ce8-3fc26f8076c8">347</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id05699051d2448519e6e9c2935d67b1f_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83OS9mcmFnOmJmMGVkNmYyMzkyYzQyZDJiNWQxNjkzN2ZmMjQzOTU5L3RhYmxlOmNiZTA5ZDUzNzIyNDRiOWNhMjc0NWYwYjNiMzNmNmEzL3RhYmxlcmFuZ2U6Y2JlMDlkNTM3MjI0NGI5Y2EyNzQ1ZjBiM2IzM2Y2YTNfMi00LTEtMS01MzQ3Ng_a51f6fc9-1b95-4d1c-8e6c-627d3c2d8391">13.33</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8ae01a892dec40ae88dac42dfa1c30cb_D20220101-20220331" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83OS9mcmFnOmJmMGVkNmYyMzkyYzQyZDJiNWQxNjkzN2ZmMjQzOTU5L3RhYmxlOmNiZTA5ZDUzNzIyNDRiOWNhMjc0NWYwYjNiMzNmNmEzL3RhYmxlcmFuZ2U6Y2JlMDlkNTM3MjI0NGI5Y2EyNzQ1ZjBiM2IzM2Y2YTNfMy0yLTEtMS01MzQ3Ng_f40f25c6-3796-4184-8fb5-fcab97799656">1,708</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8ae01a892dec40ae88dac42dfa1c30cb_D20220101-20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83OS9mcmFnOmJmMGVkNmYyMzkyYzQyZDJiNWQxNjkzN2ZmMjQzOTU5L3RhYmxlOmNiZTA5ZDUzNzIyNDRiOWNhMjc0NWYwYjNiMzNmNmEzL3RhYmxlcmFuZ2U6Y2JlMDlkNTM3MjI0NGI5Y2EyNzQ1ZjBiM2IzM2Y2YTNfMy00LTEtMS01MzQ3Ng_a5566e4a-36d8-46e8-8073-cbea0569c692">12.01</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i8ae01a892dec40ae88dac42dfa1c30cb_D20220101-20220331" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83OS9mcmFnOmJmMGVkNmYyMzkyYzQyZDJiNWQxNjkzN2ZmMjQzOTU5L3RhYmxlOmNiZTA5ZDUzNzIyNDRiOWNhMjc0NWYwYjNiMzNmNmEzL3RhYmxlcmFuZ2U6Y2JlMDlkNTM3MjI0NGI5Y2EyNzQ1ZjBiM2IzM2Y2YTNfNC0yLTEtMS01MzQ3Ng_a0c4b9ab-feac-488f-8e4b-5fe0e0d2e064">88</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8ae01a892dec40ae88dac42dfa1c30cb_D20220101-20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83OS9mcmFnOmJmMGVkNmYyMzkyYzQyZDJiNWQxNjkzN2ZmMjQzOTU5L3RhYmxlOmNiZTA5ZDUzNzIyNDRiOWNhMjc0NWYwYjNiMzNmNmEzL3RhYmxlcmFuZ2U6Y2JlMDlkNTM3MjI0NGI5Y2EyNzQ1ZjBiM2IzM2Y2YTNfNC00LTEtMS01MzQ3Ng_58445c16-aef0-4c4b-afe4-fd02486bb52b">13.56</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i8ae01a892dec40ae88dac42dfa1c30cb_D20220101-20220331" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83OS9mcmFnOmJmMGVkNmYyMzkyYzQyZDJiNWQxNjkzN2ZmMjQzOTU5L3RhYmxlOmNiZTA5ZDUzNzIyNDRiOWNhMjc0NWYwYjNiMzNmNmEzL3RhYmxlcmFuZ2U6Y2JlMDlkNTM3MjI0NGI5Y2EyNzQ1ZjBiM2IzM2Y2YTNfNS0yLTEtMS01MzQ3Ng_c34c02f1-ee4c-43d6-ae03-23ef96f53be3">15</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8ae01a892dec40ae88dac42dfa1c30cb_D20220101-20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83OS9mcmFnOmJmMGVkNmYyMzkyYzQyZDJiNWQxNjkzN2ZmMjQzOTU5L3RhYmxlOmNiZTA5ZDUzNzIyNDRiOWNhMjc0NWYwYjNiMzNmNmEzL3RhYmxlcmFuZ2U6Y2JlMDlkNTM3MjI0NGI5Y2EyNzQ1ZjBiM2IzM2Y2YTNfNS00LTEtMS01MzQ3Ng_73cfaded-9fce-43ab-9f47-5150ea34de03">13.85</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding - End of Period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib9883d643a66472482b410bc95fa9f79_I20220331" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83OS9mcmFnOmJmMGVkNmYyMzkyYzQyZDJiNWQxNjkzN2ZmMjQzOTU5L3RhYmxlOmNiZTA5ZDUzNzIyNDRiOWNhMjc0NWYwYjNiMzNmNmEzL3RhYmxlcmFuZ2U6Y2JlMDlkNTM3MjI0NGI5Y2EyNzQ1ZjBiM2IzM2Y2YTNfNi0yLTEtMS01MzQ3Ng_eeedf98f-40d0-4b42-a52c-14eafff8fd1f">1,952</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib9883d643a66472482b410bc95fa9f79_I20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83OS9mcmFnOmJmMGVkNmYyMzkyYzQyZDJiNWQxNjkzN2ZmMjQzOTU5L3RhYmxlOmNiZTA5ZDUzNzIyNDRiOWNhMjc0NWYwYjNiMzNmNmEzL3RhYmxlcmFuZ2U6Y2JlMDlkNTM3MjI0NGI5Y2EyNzQ1ZjBiM2IzM2Y2YTNfNi00LTEtMS01MzQ3Ng_188c59be-594d-4d9d-b884-f40c8c2bf85c">12.16</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded approximately $<ix:nonFraction unitRef="usd" contextRef="ie473ec9331e14abfac72e9b57746b74a_D20220101-20220331" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83OS9mcmFnOmJmMGVkNmYyMzkyYzQyZDJiNWQxNjkzN2ZmMjQzOTU5L3RleHRyZWdpb246YmYwZWQ2ZjIzOTJjNDJkMmI1ZDE2OTM3ZmYyNDM5NTlfMzI5Ng_6756f7e9-79a0-46b1-9898-9c0ef9d4241c">1.9</ix:nonFraction> million of share-based compensation expense related to PAs and RSUs during the three months ended March&#160;31, 2022.</span></div><div style="margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Compensation Expense</span></div><ix:nonNumeric contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331" name="us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83OS9mcmFnOmJmMGVkNmYyMzkyYzQyZDJiNWQxNjkzN2ZmMjQzOTU5L3RleHRyZWdpb246YmYwZWQ2ZjIzOTJjNDJkMmI1ZDE2OTM3ZmYyNDM5NTlfMzc1NQ_f1077dca-b5fc-47de-b472-2539a6e99d5e" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized share-based compensation expense for the three months ended March&#160;31, 2022 and March&#160;31, 2021 as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.642%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.447%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd9d5feb8f3b40e69374a5807ae20c1f_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83OS9mcmFnOmJmMGVkNmYyMzkyYzQyZDJiNWQxNjkzN2ZmMjQzOTU5L3RhYmxlOjg2NGYxZTIxY2NkMzRlYTI4Mjc3MWJmYTk5MGU3Y2E0L3RhYmxlcmFuZ2U6ODY0ZjFlMjFjY2QzNGVhMjgyNzcxYmZhOTkwZTdjYTRfMi0yLTEtMS00Njg5MQ_b4561f0b-7037-414c-8cb9-5868a25f2479">976</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i962d1c17149f4639be473baed960c8c3_D20210101-20210331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83OS9mcmFnOmJmMGVkNmYyMzkyYzQyZDJiNWQxNjkzN2ZmMjQzOTU5L3RhYmxlOjg2NGYxZTIxY2NkMzRlYTI4Mjc3MWJmYTk5MGU3Y2E0L3RhYmxlcmFuZ2U6ODY0ZjFlMjFjY2QzNGVhMjgyNzcxYmZhOTkwZTdjYTRfMi00LTEtMS00Njg5MQ_8c1b061d-11f5-4fad-9013-165b3f5c9e20">1,074</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b24f1f549b24893a1d6972293f410a2_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83OS9mcmFnOmJmMGVkNmYyMzkyYzQyZDJiNWQxNjkzN2ZmMjQzOTU5L3RhYmxlOjg2NGYxZTIxY2NkMzRlYTI4Mjc3MWJmYTk5MGU3Y2E0L3RhYmxlcmFuZ2U6ODY0ZjFlMjFjY2QzNGVhMjgyNzcxYmZhOTkwZTdjYTRfMy0yLTEtMS00Njg5MQ_bbfde43c-7c46-48f6-b1a9-a221b72cad6e">5,972</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0680c2b94da240e9969e80a91c607742_D20210101-20210331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83OS9mcmFnOmJmMGVkNmYyMzkyYzQyZDJiNWQxNjkzN2ZmMjQzOTU5L3RhYmxlOjg2NGYxZTIxY2NkMzRlYTI4Mjc3MWJmYTk5MGU3Y2E0L3RhYmxlcmFuZ2U6ODY0ZjFlMjFjY2QzNGVhMjgyNzcxYmZhOTkwZTdjYTRfMy00LTEtMS00Njg5MQ_d7a10594-1550-4d86-870f-5379dd385993">6,641</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized under inventories</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40ed8df1852d4048bff930cdf8525c46_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83OS9mcmFnOmJmMGVkNmYyMzkyYzQyZDJiNWQxNjkzN2ZmMjQzOTU5L3RhYmxlOjg2NGYxZTIxY2NkMzRlYTI4Mjc3MWJmYTk5MGU3Y2E0L3RhYmxlcmFuZ2U6ODY0ZjFlMjFjY2QzNGVhMjgyNzcxYmZhOTkwZTdjYTRfNC0yLTEtMS00Njg5MQ_8f30d175-76d8-4076-a3fc-3f9f972f20bb">75</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0424c4860c3e42b790b55eb7b0362418_D20210101-20210331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83OS9mcmFnOmJmMGVkNmYyMzkyYzQyZDJiNWQxNjkzN2ZmMjQzOTU5L3RhYmxlOjg2NGYxZTIxY2NkMzRlYTI4Mjc3MWJmYTk5MGU3Y2E0L3RhYmxlcmFuZ2U6ODY0ZjFlMjFjY2QzNGVhMjgyNzcxYmZhOTkwZTdjYTRfNC00LTEtMS00Njg5MQ_35a295e7-6857-49db-9335-d28bbd74bd5a">106</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83OS9mcmFnOmJmMGVkNmYyMzkyYzQyZDJiNWQxNjkzN2ZmMjQzOTU5L3RhYmxlOjg2NGYxZTIxY2NkMzRlYTI4Mjc3MWJmYTk5MGU3Y2E0L3RhYmxlcmFuZ2U6ODY0ZjFlMjFjY2QzNGVhMjgyNzcxYmZhOTkwZTdjYTRfNS0yLTEtMS00Njg5MQ_46cec457-be66-4037-9776-de2ab182385e">7,023</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56599386fa47443a8975bb3f7a6a8c57_D20210101-20210331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83OS9mcmFnOmJmMGVkNmYyMzkyYzQyZDJiNWQxNjkzN2ZmMjQzOTU5L3RhYmxlOjg2NGYxZTIxY2NkMzRlYTI4Mjc3MWJmYTk5MGU3Y2E0L3RhYmxlcmFuZ2U6ODY0ZjFlMjFjY2QzNGVhMjgyNzcxYmZhOTkwZTdjYTRfNS00LTEtMS00Njg5MQ_7c046dd0-a887-44f1-8d86-f1812befeb5c">7,821</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of March&#160;31, 2022, there was $<ix:nonFraction unitRef="usd" contextRef="id7882ae6aff54a3aacdef67ddf11a428_I20220331" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83OS9mcmFnOmJmMGVkNmYyMzkyYzQyZDJiNWQxNjkzN2ZmMjQzOTU5L3RleHRyZWdpb246YmYwZWQ2ZjIzOTJjNDJkMmI1ZDE2OTM3ZmYyNDM5NTlfMzU3Mw_99749182-36f3-4db8-a196-8e7b7076cada">48.3</ix:nonFraction>&#160;million of unrecognized share-based compensation expense related to unvested awards granted which is expected to be recognized over a weighted-average period of approximately <ix:nonNumeric contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83OS9mcmFnOmJmMGVkNmYyMzkyYzQyZDJiNWQxNjkzN2ZmMjQzOTU5L3RleHRyZWdpb246YmYwZWQ2ZjIzOTJjNDJkMmI1ZDE2OTM3ZmYyNDM5NTlfMzc0Mw_5bb3f9b9-3982-4667-b1ec-095a06b4f455">1.6</ix:nonNumeric> years.</span></div></ix:continuation><div style="margin-top:7pt;text-align:justify"><span><br/></span></div><div id="i2d3a8f7e52e84dcebfa935bec5ca9eb6_82"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">16.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:23.5pt"><ix:nonNumeric contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl84Mi9mcmFnOjU2MjBkYjlmMzJhMzQzNjg5ODU1ZTM4M2JjYmI4MWYyL3RleHRyZWdpb246NTYyMGRiOWYzMmEzNDM2ODk4NTVlMzgzYmNiYjgxZjJfMTE4NA_4d7921f2-8c85-4094-8c6b-2c9a07fb9edb" continuedAt="id0171d5ac02c498aab1098ccfdec13e6" escape="true">Income Taxes</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="id0171d5ac02c498aab1098ccfdec13e6"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective tax rates for the three months ended March&#160;31, 2022 and March&#160;31, 2021 differed from the federal statutory rate applied to losses before income taxes primarily as a result of the mix of income, losses and valuation allowances. The Company recognized an income tax expense of $<ix:nonFraction unitRef="usd" contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl84Mi9mcmFnOjU2MjBkYjlmMzJhMzQzNjg5ODU1ZTM4M2JjYmI4MWYyL3RleHRyZWdpb246NTYyMGRiOWYzMmEzNDM2ODk4NTVlMzgzYmNiYjgxZjJfMjgx_f39e9a53-8400-4ffc-8374-4994149debfc">10</ix:nonFraction> thousand and $<ix:nonFraction unitRef="usd" contextRef="i56599386fa47443a8975bb3f7a6a8c57_D20210101-20210331" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl84Mi9mcmFnOjU2MjBkYjlmMzJhMzQzNjg5ODU1ZTM4M2JjYmI4MWYyL3RleHRyZWdpb246NTYyMGRiOWYzMmEzNDM2ODk4NTVlMzgzYmNiYjgxZjJfMTA5OTUxMTYyOTMwMA_c7ffd45b-972c-42e0-923c-a5ef9a7da933">8</ix:nonFraction> thousand for the three months ended March&#160;31, 2022 and 2021, respectively. The expense recognized for these periods is a result of income in certain jurisdictions. This tax expense is not offset by a tax benefit as the Company has losses which are fully offset by a valuation allowance in its significant jurisdictions.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Uncertain Tax Positions</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company was under examination by the Canadian Revenue Agency for years 2017 and 2018. In March 2022, the Company was notified by the Canadian Revenue Agency the examination is now complete and there were no findings and as a result, there is no additional tax expense or benefit recognized in regards to the audit. There are no outstanding tax audits ongoing at March 31, 2022.</span></div></ix:continuation><div id="i2d3a8f7e52e84dcebfa935bec5ca9eb6_85"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">17.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:23.5pt"><ix:nonNumeric contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl84NS9mcmFnOjFhZGE0M2I2MTIxMDQ3ZDk4N2JjNWVmODY2N2M0OTA3L3RleHRyZWdpb246MWFkYTQzYjYxMjEwNDdkOTg3YmM1ZWY4NjY3YzQ5MDdfMTIwNA_a205a278-2dfd-4156-ad78-78b52fb8aae1" continuedAt="ib1bf96471e554e8d8db915472083f3e8" escape="true">Related Party Transactions</ix:nonNumeric></span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ib1bf96471e554e8d8db915472083f3e8">ILJIN SNT Co., Ltd (ILJIN) was considered to be a related party due to their equity ownership of over 5% as per their public filing. The outstanding related party amount payable to ILJIN was the result of a settlement completed on September 20, 2013 between ILJIN and the Company. During the first quarter of 2021, Aurinia paid $<ix:nonFraction unitRef="usd" contextRef="if708ee56f3c0413dbeaf542b7c53ca83_D20210101-20210331" decimals="-5" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl84NS9mcmFnOjFhZGE0M2I2MTIxMDQ3ZDk4N2JjNWVmODY2N2M0OTA3L3RleHRyZWdpb246MWFkYTQzYjYxMjEwNDdkOTg3YmM1ZWY4NjY3YzQ5MDdfMzEw_5b712aab-53dc-48ee-8b10-83817f618b53">4.0</ix:nonFraction>&#160;million upon achievement of specific milestones. The final $<ix:nonFraction unitRef="usd" contextRef="if844161c2cc7421fb00cb10e05a3bda0_D20211001-20211231" decimals="-5" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl84NS9mcmFnOjFhZGE0M2I2MTIxMDQ3ZDk4N2JjNWVmODY2N2M0OTA3L3RleHRyZWdpb246MWFkYTQzYjYxMjEwNDdkOTg3YmM1ZWY4NjY3YzQ5MDdfMTA5OTUxMTYzMDMxMw_dbcb8283-8a38-444e-8908-efde14dedcb0">2.0</ix:nonFraction>&#160;million outstanding amount payable was paid during the fourth quarter 2021. The amount payable to ILJIN is <ix:nonFraction unitRef="usd" contextRef="i273a514c48a74a41b3aabc3abfd173d8_I20220331" decimals="-5" name="us-gaap:DueToRelatedPartiesCurrentAndNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl84NS9mcmFnOjFhZGE0M2I2MTIxMDQ3ZDk4N2JjNWVmODY2N2M0OTA3L3RleHRyZWdpb246MWFkYTQzYjYxMjEwNDdkOTg3YmM1ZWY4NjY3YzQ5MDdfMzg1_0e93d6e9-2c12-422e-bbc1-4eb7a018a4d9"><ix:nonFraction unitRef="usd" contextRef="ic0ea34cae9704c0ba2c86c1759915479_I20211231" decimals="-5" name="us-gaap:DueToRelatedPartiesCurrentAndNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl84NS9mcmFnOjFhZGE0M2I2MTIxMDQ3ZDk4N2JjNWVmODY2N2M0OTA3L3RleHRyZWdpb246MWFkYTQzYjYxMjEwNDdkOTg3YmM1ZWY4NjY3YzQ5MDdfMzg1_708ad859-55f4-4175-aa49-9b5cbc18f970">nil</ix:nonFraction></ix:nonFraction> as of March&#160;31, 2022 and December&#160;31, 2021.</ix:continuation></span></div><div id="i2d3a8f7e52e84dcebfa935bec5ca9eb6_88"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:23.5pt"><ix:nonNumeric contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl84OC9mcmFnOjhiOWJiOTYyMzFmNzRjOWE4MzUyOTM5ZTc3YjhmNzE2L3RleHRyZWdpb246OGI5YmI5NjIzMWY3NGM5YTgzNTI5MzllNzdiOGY3MTZfMTE3Ng_1e76a4a6-e400-4cfa-8665-4308ee388683" continuedAt="i69ebc733fa714764a983e37155fa0e68" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i69ebc733fa714764a983e37155fa0e68" continuedAt="i9623ad5f315c466e8691883631c19ce1">The Company may, from time to time, be subject to claims and legal proceedings brought against it in the normal course of business. Such matters are subject to many uncertainties. Management believes the ultimate resolution of such contingencies will not have a material adverse effect on the consolidated financial position of the Company. The Company's material </ix:continuation></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i9623ad5f315c466e8691883631c19ce1"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">commitments and contingencies have not changed in any material manner from those previously described in the Company's Annual Report on Form 10-K for the year ended December&#160;31, 2021 except as described below.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 15, 2022, a purported shareholder class action complaint, Ortmann v. Aurinia Pharmaceuticals, Inc. et al., case no. 1:22-cv-02185, was filed in the United States District Court for the Eastern District of New York, naming Aurinia and certain of the Company's officers as defendants. The lawsuit alleges that Aurinia made materially false and misleading statements regarding the financial guidance and commercial prospects in violation of certain federal securities laws. The plaintiff seeks unspecified monetary damages on behalf of the putative class and an award of costs and expenses, including reasonable attorneys&#8217; fees. The defendants intend to vigorously defend this lawsuit. The Company has not, however, filed a response to the complaint and does not anticipate doing so until after the court appoints a lead plaintiff and that lead plaintiff files an operative complaint.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Funding Commitments</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, the Company enters into agreements with contract research organizations, contract manufacturing organizations and other third parties for services to be provided to the Company. Generally, these agreements provide for termination upon notice, with specified amounts due upon termination based on the timing of termination and the terms of the agreement. The actual amounts and timing of payments under these agreements are uncertain and contingent upon the initiation and completion of services to be provided to the Company.</span></div></ix:continuation><div style="margin-top:12pt;text-align:justify"><span><br/></span></div><div style="margin-top:12pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><div id="i2d3a8f7e52e84dcebfa935bec5ca9eb6_94"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:10pt"><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our unaudited condensed consolidated financial statements and related notes included in this Quarterly Report. The information in this discussion contains &#8220;forward-looking statements&#8221; within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Exchange Act, which are subject to the &#8220;safe harbor&#8221; created by those sections, as well as &#8220;forward-looking information&#8221; as defined in applicable Canadian securities laws. Forward-looking statements are based on our management&#8217;s beliefs and assumptions and on information currently available to our management. These forward-looking statements include, but are not limited to, statements concerning our strategy, future operations, future financial position, future revenues, projected costs, prospects and plans; objectives of management; the key potential benefits of LUPKYNIS; our belief that we have sufficient financial resources to fund our current plans for at least the next few years; and our potential to receive certain payments and royalties under our agreement with Otsuka; and that an IND is expected to be submitted for AUR200 and AUR300 in 2023. In some cases, you can identify forward-looking statements by terms such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;could,&#8221; &#8220;would,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;project,&#8221; &#8220;predict,&#8221; &#8220;propose,&#8221; &#8220;intend,&#8221; &#8220;continue,&#8221; &#8220;potential,&#8221; &#8220;possible,&#8221; &#8220;foreseeable,&#8221; &#8220;likely,&#8221; &#8220;unforeseen&#8221; and similar expressions intended to identify forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance, time frames or achievements to be materially different from any future results, performance, time frames or achievements expressed or implied by the forward-looking statements. We have made numerous assumptions about the forward-looking statements and information contained herein, including among other things, assumptions about: the accuracy of reported data from third party studies and reports; that our IP rights are valid and do not infringe the IP rights of third parties; our assumptions relating to the capital required to fund operations for the next 12 months; the assumption that our current good relationships with our suppliers, service providers and other third parties will be maintained; assumptions relating to the burn rate of our cash for operations; assumptions relating to the capital required to fund operations for the next few years; assumptions relating to the progress of our pre-clinical activities that our third party service providers will comply with their contractual obligations. Even though management believes that the assumptions made, and the expectations represented by such statements or information are reasonable, there can be no assurance that the forward-looking information will prove to be accurate. We discuss many of these risks, uncertainties and other factors in greater detail under the heading &#8220;Risk Factors&#8221; in Part I, Item 1A of our 2021 Annual Report on Form 10-K, as filed with the U.S. Securities and Exchange Commission on February 28, 2022 and with applicable Canadian securities regulatory authorities. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements. Also, these forward-looking statements represent our estimates and assumptions only as of the date of this filing. You should read this discussion completely and with the understanding that our actual future results may be materially different from what we expect. We hereby qualify our forward-looking statements by our cautionary statements. Except as required by law, we assume no obligation to update our forward-looking statements publicly, or to update the reasons that actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.</span></div><div id="i2d3a8f7e52e84dcebfa935bec5ca9eb6_97"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Aurinia is a fully integrated biopharmaceutical company focused on delivering therapies to treat targeted patient populations that are impacted by serious diseases with a high unmet medical need. In January 2021, we introduced LUPKYNIS&#8482; (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active LN and continue to conduct pre-clinical, clinical, and regulatory advancement to support the voclosporin development program as well as our other assets. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">LUPKYNIS is an orally administered CNI immunosuppressant that has the potential to improve near and long-term outcomes in LN when used in combination with mycophenolate mofetil (MMF) (although MMF is not currently approved as such) and steroids. By inhibiting calcineurin, LUPKYNIS reduces cytokine activation and blocks interleukin IL-2 expression and T-cell mediated immune responses. LUPKYNIS also potentially stabilizes podocytes, which can protect against proteinuria. Voclosporin, the active ingredient in LUPKYNIS, is made by a modification of a single amino acid of the cyclosporine molecule. The mechanism of action of LUPKYNIS has been validated with certain earlier generation CNIs for the prevention of rejection in patients undergoing solid organ transplants and in several autoimmune indications, including uveitis, keratoconjunctivitis sicca, psoriasis, rheumatoid arthritis, and for LN in Japan. We believe that LUPKYNIS possesses pharmacologic properties with the potential to demonstrate best-in-class differentiation.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Aurinia announced during the fourth quarter of 2021 the initiation of ENLIGHT-LN, a U.S. based prospective, observational registry of adult patients with LN treated with LUPKYNIS. The registry is intended to support the interests of patients, clinicians, regulatory bodies, payers and industry by obtaining longitudinal data on LUPKYNIS. During the first quarter of 2022 we began actively enrolling patients.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><div id="i2d3a8f7e52e84dcebfa935bec5ca9eb6_100"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:10pt"><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Significant Judgments and Estimates</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material changes to the Company&#8217;s critical accounting policies and significant judgments and estimates as described in our Annual Report on Form 10-K for the year ended December&#160;31, 2021.</span></div><div id="i2d3a8f7e52e84dcebfa935bec5ca9eb6_103"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Three Months ended March&#160;31, 2022 compared to Three Months ended March&#160;31, 2021</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth our results of operations for the three months ended March&#160;31, 2022 and March&#160;31, 2021.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.676%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenue, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">21,492</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">884&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,608&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License and collaboration revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">133</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">21,625</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">914&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,711&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">256</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">45,197</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,805&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,392&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12,620</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,833&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,787&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,434</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,771&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(337)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cost of sales and operating expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">59,507</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,457&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,050&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(37,882)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50,543)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,661&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">262</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss before income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(37,620)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50,371)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,751&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(37,630)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50,379)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,749&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenues</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total net revenue was $21.6 million and $914 thousand for the three months ended March&#160;31, 2022 and March&#160;31, 2021, respectively. Our net revenues primarily consisted of product revenue, net of adjustments, for LUPKYNIS following FDA approval in late January 2021. Quarter over quarter revenue growth is attributed to further progress in the launch of LUPKYNIS, driven predominantly by further penetration in the lupus nephritis market. No product sales commenced and no product marketing was permitted prior to January 22, 2021.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of Sales</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of sales were $256 thousand and $48 thousand for the three months ended March&#160;31, 2022 and March&#160;31, 2021, respectively. The increase was primarily due to the growth of LUPKYNIS sales as no product sales commenced prior to January 22, 2021 and gross margin remains reasonably consistent with prior periods. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross margin for the three months ended March&#160;31, 2022 and March&#160;31, 2021 was approximately 99% and 95% respectively. The fluctuation in gross margin is driven primarily by fixed specialty pharmacy costs in the first quarter of 2021, as a percentage of overall cost of sales.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:10pt"><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling, General and Administrative Expenses</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SG&amp;A expenses increased to $45.2 million for the three months ended March&#160;31, 2022 compared to $39.8 million for the three months ended March&#160;31, 2021. SG&amp;A expenses consisted of the following:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.999%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.768%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salaries, incentive pay and employee benefits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">22,523</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,194&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional fees and services</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10,898</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,717&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,972</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,641&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other corporate costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,628</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,805&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Travel, trade shows and sponsorships</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,176</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,448&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">45,197</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,805&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The primary drivers for the increase for the three months ended March&#160;31, 2022 as compared to the same periods ended </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">were an increase in employee related expenses, professional fees related to various corporate matters, pharmacovigilance costs and consulting related expenses tied to the increased investment in back office infrastructure to support the commercialization of LUPKYNIS.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">R&amp;D expenses were $12.6 million and $9.8 million for the three months ended March&#160;31, 2022 and March&#160;31, 2021, respectively. R&amp;D expenses consisted of the following:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.999%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.768%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract research organizations (CRO) and developmental expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,727</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,632&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical supply and distribution</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,562</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,232&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salaries, incentive pay and employee benefits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,273</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,024&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">976</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,074&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Travel, insurance, patent annuity fees, legal fees and other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">82</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(129)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12,620</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,833&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The primary driver for the increase for the three months ended March&#160;31, 2022 as compared to the same period of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was due to an increase in CRO and developmental expenses related to AUR200 and AUR300 partially offset by a decrease in expenses related to the AURORA 2 continuation study, which was completed during the fourth quarter of 2021 but had wind down activities ongoing in the quarter ended March&#160;31, 2022.</span></div><div id="i2d3a8f7e52e84dcebfa935bec5ca9eb6_106"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2022, we had cash, cash equivalents and restricted cash and investments of $418.8 million compared to cash, cash equivalents and restricted cash and investments of $466.1 million at December&#160;31, 2021. The decrease in cash, cash equivalents and restricted cash and investments is primarily related to the continued investment in commercialization activities, payments made for our ongoing post approval obligations and advancement of our pipeline, payments associated with inventory purchases to ensure adequate supply to meet forecasted demand and a payment for the achievement of a one-time milestone, partially offset by an increase in cash receipts from sales of LUPKYNIS. Cash, cash equivalents and restricted cash and investments are primarily held in U.S. dollars. As of March&#160;31, 2022 and December&#160;31, 2021, we had working capital of $443.8 million and $472.7 million, respectively.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are devoting the majority of our operational efforts and financial resources towards the commercialization and post approval commitments of our approved drug, LUPKYNIS. We are also expending efforts towards our AUR200 and AUR300 assets. Taking into consideration the cash and cash equivalents and investments as of March&#160;31, 2022, we believe that our cash </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:10pt"><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">position is sufficient to fund our current plans which include funding commercial activities, including our FDA related post approval commitments, manufacturing commercial drug supply, funding our supporting commercial infrastructure, conducting our planned R&amp;D programs, investing in our pipeline and funding our supporting corporate and working capital for at least the next few years.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash Flow Summary</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our cash flows for the three months ended March&#160;31, 2022 and March&#160;31, 2021:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.964%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.783%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.785%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash (used in) provided by:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(46,746)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53,541)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(53,017)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(67,247)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">405</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,029&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net decrease in cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(99,358)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(115,759)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:7pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities was $46.7 million for the three months ended March&#160;31, 2022 compared to $53.5 million for the three months ended March&#160;31, 2021. For the three months ended March&#160;31, 2022, cash used in operating activities was primarily related to the continued investment in commercialization activities, payments made for our ongoing post approval obligations and advancement of our pipeline, payments associated with inventory purchases to ensure adequate supply to meet forecasted demand and a payment for the achievement of a one-time milestone, partially offset by an increase in cash receipts from sales of LUPKYNIS. For the three months ended March&#160;31, 2021 cash used in operating activities of $53.5 million was due to the continued support of commercialization efforts in addition to a one-time payment to a related party upon achievement of specific milestones.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash used in investing activities during the three months ended March&#160;31, 2022 was $53.0 million compared to cash used in investing activities of $67.2 million during the three months ended March&#160;31, 2021. Investing activities during the three months ended March&#160;31, 2022 consisted primarily of $163.5 million for purchases of investments offset by $110.6 million of proceeds of maturities of investments. Cash used in investing activities of $67.2 million for the three months ended March&#160;31, 2021 was primarily attributable to $115.2 million for purchases of short-term investments and $11.8 million for an upfront lease payment offset by $60.9 million of proceeds of maturities of investments.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash provided by financing activities during the three months ended March&#160;31, 2022 was $0.4 million compared to cash provided by financing activities of $5.0 million during the three months ended March&#160;31, 2021. The decrease was primarily due to less proceeds from the exercise of stock options.</span></div><div id="i2d3a8f7e52e84dcebfa935bec5ca9eb6_109"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Off&#8209;Balance Sheet Arrangements</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the periods presented, we did not have, nor do we currently have, any off&#8209;balance sheet arrangements as such term is defined in Item 303(a)(4)(ii) of Regulation S-K under the Securities Act.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contractual Obligations</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material changes outside the ordinary course of business to our contractual obligations and commitments as described in &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; in our Annual Report on Form 10-K for the year ended December&#160;31, 2021.</span></div><div id="i2d3a8f7e52e84dcebfa935bec5ca9eb6_112"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Quantitative and Qualitative Disclosures About Market Risks</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our activities can expose us to market risks which include interest rate risk, foreign currency risk, inflation risk and credit risk. Risk management is carried out by management under policies approved by our Board of Directors, with oversight provided by </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:10pt"><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the Audit Committee of our Board of Directors. Our overall risk management program seeks to minimize adverse effects on our financial performance.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Rate Risk</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial assets and financial liabilities with variable interest rates expose us to cash flow interest rate risk. We manage our interest rate risk by maximizing the interest income earned on excess funds while maintaining the liquidity necessary to conduct</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">operations on a day-to-day basis. As of March&#160;31, 2022 our investment portfolio includes cash, cash equivalents, restricted cash and investments of $418.8 million that earn interest at market rates. Our investment portfolio is maintained in accordance with our investment policy, which defines allowable investments, specifies credit quality standards and limits the credit exposure of any single issuer. Our investments held during the year were comprised of instruments such as certificates of deposits, money market instruments, obligations issued by the U.S. government and U.S. government agencies as well as corporate debt securities. As of March&#160;31, 2022, these instruments have a maturity of less than a year.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2022 a decrease of 100 basis points on our interest rates of our investments would result in a $1.2 million loss on the fair market value of our portfolio and would be realized at the maturity of our investments.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable, accounts payable and accrued liabilities bear no interest. We do not believe that the results of operations or cash flows would be affected to any significant degree by a sudden change in market interest rates relative to our investment portfolio.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Risk</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to financial risk related to the fluctuation of foreign currency exchange rates. Foreign currency risk for the Company is the risk variations in exchange rates between the U.S. dollar and foreign currencies, primarily with the Canadian dollar, Swiss Franc and Great British Pound, which could affect our operating and financial results. As of March&#160;31, 2022, a 10% increase of the Canadian dollar would have increased the net loss by $0.5 million assuming all other variables remained constant. An assumed 10% weakening of the Canadian dollar would have had an equal but opposite effect to the amounts shown above, on the basis all other variables remain constant. There were no other foreign currency fluctuations that would have had a material impact on our financial condition or results of operations as of March&#160;31, 2022.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inflation Risk</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inflation may generally affect us by increasing our cost of labor, commercial support, manufacturing and clinical trial expenditures. Inflation has not had a material effect on our business, financial condition or results of operations as of March&#160;31, 2022.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Credit Risk</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our exposure to credit risk generally consists of cash and cash equivalents, investments and accounts receivable. We place our cash and cash equivalents with what we believe to be highly rated financial institutions and invest the excess cash in highly rated investments. Our investment policy limits investments to certain types of debt and money market instruments issued by institutions primarily with investment grade credit ratings and places restriction on maturities and concentrations by asset class and issuer.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to credit risk in connection with our accounts receivable due from our two customers which accounted for 99% of our net trade accounts receivable balances as of March&#160;31, 2022. We monitor economic conditions, the creditworthiness of our customers and government regulations and funding, both domestically and abroad. We regularly communicate with our customers regarding the status of receivable balances, including their payment plans and obtain positive confirmation of the validity of the receivables. During the quarter ended March&#160;31, 2022, we did not recognize any allowance for doubtful accounts receivable related to credit risk for our customers.</span></div><div id="i2d3a8f7e52e84dcebfa935bec5ca9eb6_115"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. Controls and Procedures.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our principal executive officer and principal financial officer, after evaluating the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act) as of&#160;March&#160;31, 2022, have concluded that, based on such evaluation, our disclosure controls and procedures were effective to ensure that information required to be </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:10pt"><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">disclosed by us in the reports we file or submit under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the rules and forms of the SEC, and is accumulated and communicated to our management, including our principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in Internal Control over Financial Reporting</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There has been no change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act) that occurred during the quarter ended March&#160;31, 2022 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><div id="i2d3a8f7e52e84dcebfa935bec5ca9eb6_118"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:10pt"><span><br/></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II&#8212;OTHER INFORMATION</span></div><div id="i2d3a8f7e52e84dcebfa935bec5ca9eb6_121"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. Legal Proceedings.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may be involved in various claims and legal proceedings relating to claims arising out of our operations. Regardless of outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are no material developments to report in respect of the litigation described in the Company's Annual Report on Form 10-K for the year ended December&#160;31, 2021.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 15, 2022, a purported shareholder class action complaint, Ortmann v. Aurinia Pharmaceuticals, Inc. et al., case no. 1:22-cv-02185, was filed in the United States District Court for the Eastern District of New York, naming us and certain of our officers as defendants. The lawsuit alleges that we made materially false and misleading statements regarding our financial guidance and commercial prospects in violation of certain federal securities laws. The plaintiff seeks unspecified monetary damages on behalf of the putative class and an award of costs and expenses, including reasonable attorneys&#8217; fees. The defendants intend to vigorously defend this lawsuit. We have not, however, filed a response to the complaint and does not anticipate doing so until after the court appoints a lead plaintiff and that lead plaintiff files an operative complaint.</span></div><div id="i2d3a8f7e52e84dcebfa935bec5ca9eb6_124"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1A. Risk Factors.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under Item 1A of our Annual Report on Form 10-K for the year ended December&#160;31, 2021 we identified important factors that could affect our financial performance and could cause our actual results for future periods to differ materially from our anticipated results or other expectations, including those expressed in any forward-looking statements made in this Quarterly Report. There has been no material change in our risk factors subsequent to the filing of our prior reports referenced above. However, the risks described in our reports are not the only risks we face. Additional risks and uncertainties that we currently deem to be immaterial or not currently known to us, as well as other risks reported from time to time in our reports to the SEC, also could cause our actual results to differ materially from our anticipated results or other expectations.</span></div><div id="i2d3a8f7e52e84dcebfa935bec5ca9eb6_127"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i2d3a8f7e52e84dcebfa935bec5ca9eb6_130"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Defaults Upon Senior Securities.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i2d3a8f7e52e84dcebfa935bec5ca9eb6_133"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. Mine Safety Disclosures.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i2d3a8f7e52e84dcebfa935bec5ca9eb6_136"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 5. Other Information.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i2d3a8f7e52e84dcebfa935bec5ca9eb6_139"></div><div style="-sec-extract:summary;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 6. Exhibits.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following exhibits are filed as part of this report:</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:10pt"><span><br/></span></div></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.521%"></td><td style="width:0.1%"></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit<br/>Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1600620/000162828021003060/exhibit31articlesofamalgam.htm">Articles of Amalgamation, as amended, as currently in effect (filed as Exhibit 3.1 to the Company's Annual Report on Form 10-K with the SEC on February 24, 2021 and incorporated herein by reference)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1600620/000162828021007736/exhibit32amendedandrestate.htm">Amended and Restated By-Law No. 2 amended as of April 23, 2021 (filed as Exhibit 3.2 to the Company's Current Report on Form 8-K filed with the SEC on April 27, 2021 and incorporated herein by reference)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="auph-2022q1exx311.htm">Certification of Principal Executive Officer pursuant to Rules 13a-14(a) or 15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="auph-2022q1exx312.htm">Certification of Principal Financial Officer pursuant to Rules 13a-14(a) or 15d-14(a) under the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="auph-2022q1exx321.htm">Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.2**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="auph-2022q1exx322.htm">Certification of Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema Document</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Label Linkbase Document</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="margin-top:2pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.521%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filed herewith.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furnished herewith. Exhibits 32.1 and 32.2 are being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liability of that section, nor shall such exhibit be deemed to be incorporated by reference in any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise specifically stated in such filing.</span></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><div id="i2d3a8f7e52e84dcebfa935bec5ca9eb6_142"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:10pt"><span><br/></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.338%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.432%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.930%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">AURINIA PHARMACEUTICALS INC.</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 9, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;Peter Greenleaf</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Peter Greenleaf</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Chief Executive Officer, Director<br/>(Principal Executive Officer)</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 9, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;Joseph Miller</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Joseph Miller</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Chief Financial Officer<br/>(Principal Financial and Accounting Officer)</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>auph-2022q1exx311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i3e79122a660042f196aabca6c8ba6dfe_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="margin-top:12pt;text-align:center;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO EXCHANGE RULES 13a-14(a) AND 15d-14(a), AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Peter Greenleaf, certify that&#58;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this quarterly report on Form 10-Q of Aurinia Pharmaceuticals Inc.&#59;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and</font></div><div style="margin-top:12pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.988%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.226%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.088%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 9, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Peter Greenleaf</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Peter Greenleaf</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Chief Executive Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">(Principal Executive Officer)</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>auph-2022q1exx312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="iadda0d8c46e44151b42af2bf75a53cf8_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO RULES 13a-14(a) AND 15d-14(a),</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Joseph Miller, certify that&#58;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this quarterly report on Form 10-Q of Aurinia Pharmaceuticals Inc..&#59;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and</font></div><div style="margin-top:12pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.228%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.226%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 9, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Joseph Miller</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Joseph Miller</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">(Principal Financial and Accounting Officer)</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>auph-2022q1exx321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i027879b3a5ef4fc894f65a7c217760a8_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Quarterly Report of Aurinia Pharmaceuticals Inc. (the &#8220;Company&#8221;) on Form 10-Q for the period ending March&#160;31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Peter Greenleaf, Chief Executive Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, that&#58;</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.747%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.759%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.847%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.247%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 9, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Peter Greenleaf</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Peter Greenleaf</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Chief Executive Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Principal Executive Officer)</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>auph-2022q1exx322.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i5f1cac29a2ef4566baf8f699ab59666e_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.2</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Quarterly Report of Aurinia Pharmaceuticals Inc. (the &#8220;Company&#8221;) on Form 10-Q for the period ending March&#160;31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Joseph Miller, Chief Financial Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, that&#58;</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.747%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.882%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.847%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.124%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 9, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Joseph Miller</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Joseph Miller</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Principal Financial and Accounting Officer)</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>auph-20220331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:778f08dd-b92a-42f0-b4bb-a50ecfb6a537,g:a60fc6d8-f25a-4b7b-af6a-b9dcc6be1df4-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:auph="http://www.auriniapharma.com/20220331" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.auriniapharma.com/20220331">
  <xs:import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2021q4" schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="auph-20220331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="auph-20220331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="auph-20220331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="auph-20220331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.auriniapharma.com/role/CoverPage">
        <link:definition>0001001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheets" roleURI="http://www.auriniapharma.com/role/CondensedConsolidatedBalanceSheets">
        <link:definition>1001002 - Statement - Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.auriniapharma.com/role/ConsolidatedBalanceSheetsParenthetical">
        <link:definition>1002003 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" roleURI="http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss">
        <link:definition>1003004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofOperationsandComprehensiveLossParenthetical" roleURI="http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossParenthetical">
        <link:definition>1004005 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofShareholdersEquity" roleURI="http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofShareholdersEquity">
        <link:definition>1005006 - Statement - Condensed Consolidated Statements of Shareholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofCashFlows" roleURI="http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows">
        <link:definition>1006007 - Statement - Condensed Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandDescriptionofBusiness" roleURI="http://www.auriniapharma.com/role/OrganizationandDescriptionofBusiness">
        <link:definition>2101101 - Disclosure - Organization and Description of Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentation" roleURI="http://www.auriniapharma.com/role/BasisofPresentation">
        <link:definition>2102102 - Disclosure - Basis of Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationDetails" roleURI="http://www.auriniapharma.com/role/BasisofPresentationDetails">
        <link:definition>2403401 - Disclosure - Basis of Presentation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://www.auriniapharma.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>2104103 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>2205201 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesNarrativeDetails" roleURI="http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails">
        <link:definition>2406402 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Investments" roleURI="http://www.auriniapharma.com/role/Investments">
        <link:definition>2107104 - Disclosure - Investments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsTables" roleURI="http://www.auriniapharma.com/role/InvestmentsTables">
        <link:definition>2308301 - Disclosure - Investments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsDetails" roleURI="http://www.auriniapharma.com/role/InvestmentsDetails">
        <link:definition>2409403 - Disclosure - Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Inventories" roleURI="http://www.auriniapharma.com/role/Inventories">
        <link:definition>2110105 - Disclosure - Inventories</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesTables" roleURI="http://www.auriniapharma.com/role/InventoriesTables">
        <link:definition>2311302 - Disclosure - Inventories (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesDetails" roleURI="http://www.auriniapharma.com/role/InventoriesDetails">
        <link:definition>2412404 - Disclosure - Inventories (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PrepaidExpensesandOtherCurrentAssets" roleURI="http://www.auriniapharma.com/role/PrepaidExpensesandOtherCurrentAssets">
        <link:definition>2113106 - Disclosure - Prepaid Expenses and Other Current Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PrepaidExpensesandOtherCurrentAssetsTables" roleURI="http://www.auriniapharma.com/role/PrepaidExpensesandOtherCurrentAssetsTables">
        <link:definition>2314303 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PrepaidExpensesandOtherCurrentAssetsDetails" roleURI="http://www.auriniapharma.com/role/PrepaidExpensesandOtherCurrentAssetsDetails">
        <link:definition>2415405 - Disclosure - Prepaid Expenses and Other Current Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssets" roleURI="http://www.auriniapharma.com/role/IntangibleAssets">
        <link:definition>2116107 - Disclosure - Intangible Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsTables" roleURI="http://www.auriniapharma.com/role/IntangibleAssetsTables">
        <link:definition>2317304 - Disclosure - Intangible Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsScheduleofIntangibleAssetsDetails" roleURI="http://www.auriniapharma.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails">
        <link:definition>2418406 - Disclosure - Intangible Assets - Schedule of Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsNarrativeDetails" roleURI="http://www.auriniapharma.com/role/IntangibleAssetsNarrativeDetails">
        <link:definition>2419407 - Disclosure - Intangible Assets - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantandEquipmentnet" roleURI="http://www.auriniapharma.com/role/PropertyPlantandEquipmentnet">
        <link:definition>2120108 - Disclosure - Property, Plant and Equipment, net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantandEquipmentnetTables" roleURI="http://www.auriniapharma.com/role/PropertyPlantandEquipmentnetTables">
        <link:definition>2321305 - Disclosure - Property, Plant and Equipment, net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantandEquipmentnetDetails" roleURI="http://www.auriniapharma.com/role/PropertyPlantandEquipmentnetDetails">
        <link:definition>2422408 - Disclosure - Property, Plant and Equipment, net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeaseObligations" roleURI="http://www.auriniapharma.com/role/LeaseObligations">
        <link:definition>2123109 - Disclosure - Lease Obligations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeaseObligationsTables" roleURI="http://www.auriniapharma.com/role/LeaseObligationsTables">
        <link:definition>2324306 - Disclosure - Lease Obligations (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeaseObligationsNarrativeDetails" roleURI="http://www.auriniapharma.com/role/LeaseObligationsNarrativeDetails">
        <link:definition>2425409 - Disclosure - Lease Obligations - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeaseObligationsSupplementalBalanceSheetInformationDetails" roleURI="http://www.auriniapharma.com/role/LeaseObligationsSupplementalBalanceSheetInformationDetails">
        <link:definition>2426410 - Disclosure - Lease Obligations - Supplemental Balance Sheet Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeaseObligationsSummaryofComponentsofLeasingCostsandRentDetails" roleURI="http://www.auriniapharma.com/role/LeaseObligationsSummaryofComponentsofLeasingCostsandRentDetails">
        <link:definition>2427411 - Disclosure - Lease Obligations - Summary of Components of Leasing Costs and Rent (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails" roleURI="http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails">
        <link:definition>2428412 - Disclosure - Lease Obligations - Schedule of Maturities of Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails_1" roleURI="http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails_1">
        <link:definition>2428412 - Disclosure - Lease Obligations - Schedule of Maturities of Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccountsPayableandAccruedLiabilities" roleURI="http://www.auriniapharma.com/role/AccountsPayableandAccruedLiabilities">
        <link:definition>2129110 - Disclosure - Accounts Payable and Accrued Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccountsPayableandAccruedLiabilitiesTables" roleURI="http://www.auriniapharma.com/role/AccountsPayableandAccruedLiabilitiesTables">
        <link:definition>2330307 - Disclosure - Accounts Payable and Accrued Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccountsPayableandAccruedLiabilitiesDetails" roleURI="http://www.auriniapharma.com/role/AccountsPayableandAccruedLiabilitiesDetails">
        <link:definition>2431413 - Disclosure - Accounts Payable and Accrued Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DeferredCompensationandOtherNoncurrentLiabilities" roleURI="http://www.auriniapharma.com/role/DeferredCompensationandOtherNoncurrentLiabilities">
        <link:definition>2132111 - Disclosure - Deferred Compensation and Other Non-current Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DeferredCompensationandOtherNoncurrentLiabilitiesDetails" roleURI="http://www.auriniapharma.com/role/DeferredCompensationandOtherNoncurrentLiabilitiesDetails">
        <link:definition>2433414 - Disclosure - Deferred Compensation and Other Non-current Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.auriniapharma.com/role/FairValueMeasurements">
        <link:definition>2134112 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.auriniapharma.com/role/FairValueMeasurementsTables">
        <link:definition>2335308 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" roleURI="http://www.auriniapharma.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonaRecurringBasisDetails">
        <link:definition>2436415 - Disclosure - Fair Value Measurements - Assets and Liabilities Measured on a Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LicenseandCollaborationAgreement" roleURI="http://www.auriniapharma.com/role/LicenseandCollaborationAgreement">
        <link:definition>2137113 - Disclosure - License and Collaboration Agreement</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LicenseandCollaborationAgreementDetails" roleURI="http://www.auriniapharma.com/role/LicenseandCollaborationAgreementDetails">
        <link:definition>2438416 - Disclosure - License and Collaboration Agreement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossperCommonShare" roleURI="http://www.auriniapharma.com/role/NetLossperCommonShare">
        <link:definition>2139114 - Disclosure - Net Loss per Common Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossperCommonShareTables" roleURI="http://www.auriniapharma.com/role/NetLossperCommonShareTables">
        <link:definition>2340309 - Disclosure - Net Loss per Common Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossperCommonShareDetails" roleURI="http://www.auriniapharma.com/role/NetLossperCommonShareDetails">
        <link:definition>2441417 - Disclosure - Net Loss per Common Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossperCommonShareAntiDilutiveSecuritiesDetails" roleURI="http://www.auriniapharma.com/role/NetLossperCommonShareAntiDilutiveSecuritiesDetails">
        <link:definition>2442418 - Disclosure - Net Loss per Common Share - Anti-Dilutive Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SharebasedCompensation" roleURI="http://www.auriniapharma.com/role/SharebasedCompensation">
        <link:definition>2143115 - Disclosure - Share-based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SharebasedCompensationTables" roleURI="http://www.auriniapharma.com/role/SharebasedCompensationTables">
        <link:definition>2344310 - Disclosure - Share-based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SharebasedCompensationNarrativeDetails" roleURI="http://www.auriniapharma.com/role/SharebasedCompensationNarrativeDetails">
        <link:definition>2445419 - Disclosure - Share-based Compensation - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationWeightedAverageAssumptionsDetails" roleURI="http://www.auriniapharma.com/role/ShareBasedCompensationWeightedAverageAssumptionsDetails">
        <link:definition>2446420 - Disclosure - Share-Based Compensation - Weighted Average Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationStockOptionActivityDetails" roleURI="http://www.auriniapharma.com/role/ShareBasedCompensationStockOptionActivityDetails">
        <link:definition>2447421 - Disclosure - Share-Based Compensation - Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationPerformanceAwardsandRestrictedStockUnitsActivityDetails" roleURI="http://www.auriniapharma.com/role/ShareBasedCompensationPerformanceAwardsandRestrictedStockUnitsActivityDetails">
        <link:definition>2448422 - Disclosure - Share-Based Compensation - Performance Awards and Restricted Stock Units Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationAllocatedShareBasedCompensationExpenseDetails" roleURI="http://www.auriniapharma.com/role/ShareBasedCompensationAllocatedShareBasedCompensationExpenseDetails">
        <link:definition>2449423 - Disclosure - Share-Based Compensation - Allocated Share-Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.auriniapharma.com/role/IncomeTaxes">
        <link:definition>2150116 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesNarrativeDetails" roleURI="http://www.auriniapharma.com/role/IncomeTaxesNarrativeDetails">
        <link:definition>2451424 - Disclosure - Income Taxes - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactions" roleURI="http://www.auriniapharma.com/role/RelatedPartyTransactions">
        <link:definition>2152117 - Disclosure - Related-Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactionsDetails" roleURI="http://www.auriniapharma.com/role/RelatedPartyTransactionsDetails">
        <link:definition>2453425 - Disclosure - Related-Party Transactions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentandContingencies" roleURI="http://www.auriniapharma.com/role/CommitmentandContingencies">
        <link:definition>2154118 - Disclosure - Commitment and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="auph_VictoriaBritishColumbiaMember" abstract="true" name="VictoriaBritishColumbiaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="auph_CommercialRelatedAccrualsCurrent" abstract="false" name="CommercialRelatedAccrualsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="auph_ILJINMember" abstract="true" name="ILJINMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="auph_PerformanceShareSandRestrictedStockUnitsRSUsMember" abstract="true" name="PerformanceShareSandRestrictedStockUnitsRSUsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="auph_SpecialtyPharmacyTwoMember" abstract="true" name="SpecialtyPharmacyTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="auph_ResearchAndDevelopmentArrangementContractToPerformForOthersTieredRoyaltyPercent" abstract="false" name="ResearchAndDevelopmentArrangementContractToPerformForOthersTieredRoyaltyPercent" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="auph_PrepaidAssetsCurrent" abstract="false" name="PrepaidAssetsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="auph_PrepaidRentAndPrepaidContinuingStudies" abstract="false" name="PrepaidRentAndPrepaidContinuingStudies" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="auph_SpecialtyPharmacyOneMember" abstract="true" name="SpecialtyPharmacyOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="auph_OperatingLeaseAssetsAndLiabilitiesLiabilitiesNoncurrentLesseeAbstract" abstract="true" name="OperatingLeaseAssetsAndLiabilitiesLiabilitiesNoncurrentLesseeAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="auph_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" abstract="false" name="LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="auph_OperatingLeaseAssetsAndLiabilitiesLiabilitiesCurrentLesseeAbstract" abstract="true" name="OperatingLeaseAssetsAndLiabilitiesLiabilitiesCurrentLesseeAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="auph_MilestonePaymentMember" abstract="true" name="MilestonePaymentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="auph_OtuskaPharmaceuticalCoLtdMember" abstract="true" name="OtuskaPharmaceuticalCoLtdMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="auph_LesseeOperatingLeaseLeaseNotYetCommencedPaymentsPriorToCommencementOfLease" abstract="false" name="LesseeOperatingLeaseLeaseNotYetCommencedPaymentsPriorToCommencementOfLease" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="auph_CashableGuaranteedInvestmentCertificatesMember" abstract="true" name="CashableGuaranteedInvestmentCertificatesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="auph_LesseeOperatingLeaseLeaseTerminationTerm" abstract="false" name="LesseeOperatingLeaseLeaseTerminationTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="auph_AmendedAndRestatedEquityIncentivePlanMember" abstract="true" name="AmendedAndRestatedEquityIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="auph_CashCashEquivalentsAndDebtSecuritiesCurrent" abstract="false" name="CashCashEquivalentsAndDebtSecuritiesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="auph_ShortTermCorporateDebtSecuritiesMember" abstract="true" name="ShortTermCorporateDebtSecuritiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="auph_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="auph_AccruedResearchCurrent" abstract="false" name="AccruedResearchCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="auph_OperatingLeaseAssetsAndLiabilitiesAssetsLesseeAbstract" abstract="true" name="OperatingLeaseAssetsAndLiabilitiesAssetsLesseeAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="auph_RockvilleMarylandMember" abstract="true" name="RockvilleMarylandMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="auph_ResearchAndDevelopmentArrangementContractToPerformForOthersPerformanceObligationPotentialRevenueAmount" abstract="false" name="ResearchAndDevelopmentArrangementContractToPerformForOthersPerformanceObligationPotentialRevenueAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="auph_LesseeOperatingLeaseNumberOfExtensionOptions" abstract="false" name="LesseeOperatingLeaseNumberOfExtensionOptions" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="auph_AssetsAndLiabilitiesLesseeTableTextBlock" abstract="false" name="AssetsAndLiabilitiesLesseeTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="auph_LesseeOperatingLeaseLeaseNotYetCommencedLiabilityToBePaid" abstract="false" name="LesseeOperatingLeaseLeaseNotYetCommencedLiabilityToBePaid" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="auph_RiptideBioscienceIncMember" abstract="true" name="RiptideBioscienceIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>auph-20220331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:778f08dd-b92a-42f0-b4bb-a50ecfb6a537,g:a60fc6d8-f25a-4b7b-af6a-b9dcc6be1df4-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.auriniapharma.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="auph-20220331.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.auriniapharma.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_db2d004c-5d40-414a-ab17-997f04bc6470" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_0709eaf0-77c0-4534-9119-fdfe91547181" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_db2d004c-5d40-414a-ab17-997f04bc6470" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_0709eaf0-77c0-4534-9119-fdfe91547181" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_c603e7cb-b478-4e63-a89b-f66399cb211b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_db2d004c-5d40-414a-ab17-997f04bc6470" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_c603e7cb-b478-4e63-a89b-f66399cb211b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_04ca6a72-ac2a-4b5d-bb1e-aa45c59cbfe6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_db2d004c-5d40-414a-ab17-997f04bc6470" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_04ca6a72-ac2a-4b5d-bb1e-aa45c59cbfe6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_50f1600e-d67e-4024-a12b-cb5c831e27bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValueOutstanding_80fb9d51-215e-4046-ad60-320475334112" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValueOutstanding"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_50f1600e-d67e-4024-a12b-cb5c831e27bc" xlink:to="loc_us-gaap_CommonStockValueOutstanding_80fb9d51-215e-4046-ad60-320475334112" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_d8bd27ef-f03a-404a-82b0-5f92bdeee470" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_50f1600e-d67e-4024-a12b-cb5c831e27bc" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_d8bd27ef-f03a-404a-82b0-5f92bdeee470" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_0389894f-72f5-4f2c-86aa-11e417aedb4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_50f1600e-d67e-4024-a12b-cb5c831e27bc" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_0389894f-72f5-4f2c-86aa-11e417aedb4a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_99ba65a4-b11e-4a8e-a7c4-79eabd541a93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_50f1600e-d67e-4024-a12b-cb5c831e27bc" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_99ba65a4-b11e-4a8e-a7c4-79eabd541a93" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_82a7313a-4d2e-43c5-8dec-2fbd9935ecac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_870134ea-9172-43e3-9e53-9dc07b1671ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_82a7313a-4d2e-43c5-8dec-2fbd9935ecac" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_870134ea-9172-43e3-9e53-9dc07b1671ad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_2efe84e1-5c5f-4490-a7ad-00ae99d6292f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_82a7313a-4d2e-43c5-8dec-2fbd9935ecac" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_2efe84e1-5c5f-4490-a7ad-00ae99d6292f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_d1715bc6-0671-42b5-ac85-b88b70a1b775" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_82a7313a-4d2e-43c5-8dec-2fbd9935ecac" xlink:to="loc_us-gaap_AssetsCurrent_d1715bc6-0671-42b5-ac85-b88b70a1b775" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_0027fae9-9d7e-4144-a48e-392da93e82ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_82a7313a-4d2e-43c5-8dec-2fbd9935ecac" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_0027fae9-9d7e-4144-a48e-392da93e82ec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_4c8bf2d9-f543-46e9-bcb2-8329c5e1ebb3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_82a7313a-4d2e-43c5-8dec-2fbd9935ecac" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_4c8bf2d9-f543-46e9-bcb2-8329c5e1ebb3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_63004cc7-4b31-4c24-9dfc-78ceb85ea8db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_bc5bc505-0d80-41f8-ba86-a2200f7d918a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_63004cc7-4b31-4c24-9dfc-78ceb85ea8db" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_bc5bc505-0d80-41f8-ba86-a2200f7d918a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_3c993048-ac55-42bc-b296-1464e440e0b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_63004cc7-4b31-4c24-9dfc-78ceb85ea8db" xlink:to="loc_us-gaap_LiabilitiesCurrent_3c993048-ac55-42bc-b296-1464e440e0b1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_ecb2939d-a066-4566-92e9-3ded57f44857" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_63004cc7-4b31-4c24-9dfc-78ceb85ea8db" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_ecb2939d-a066-4566-92e9-3ded57f44857" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_979a9cce-cd16-4e55-b272-1655743d064f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_ea49b786-fff6-42d0-aef6-2b3145df5b7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_979a9cce-cd16-4e55-b272-1655743d064f" xlink:to="loc_us-gaap_Liabilities_ea49b786-fff6-42d0-aef6-2b3145df5b7a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_8895e95e-510d-4eef-885a-40594e623326" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_979a9cce-cd16-4e55-b272-1655743d064f" xlink:to="loc_us-gaap_CommitmentsAndContingencies_8895e95e-510d-4eef-885a-40594e623326" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_f66037e9-015e-4a35-a8d3-508d88bc4c92" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_979a9cce-cd16-4e55-b272-1655743d064f" xlink:to="loc_us-gaap_StockholdersEquity_f66037e9-015e-4a35-a8d3-508d88bc4c92" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_23445149-9f79-4871-b590-a021d6bc64dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsAndOtherReceivablesNetCurrent_9b2cdcab-0533-45c9-bfbc-fcc6f41d35e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_23445149-9f79-4871-b590-a021d6bc64dc" xlink:to="loc_us-gaap_AccountsAndOtherReceivablesNetCurrent_9b2cdcab-0533-45c9-bfbc-fcc6f41d35e7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_73fc5565-b897-4fc9-821c-39a19d87bb62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_23445149-9f79-4871-b590-a021d6bc64dc" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_73fc5565-b897-4fc9-821c-39a19d87bb62" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_df8077bd-4fa2-40b4-ab0f-815e79506864" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_23445149-9f79-4871-b590-a021d6bc64dc" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_df8077bd-4fa2-40b4-ab0f-815e79506864" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_67cb592a-d5ed-4f66-a9fc-e8452d79a967" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_23445149-9f79-4871-b590-a021d6bc64dc" xlink:to="loc_us-gaap_InventoryNet_67cb592a-d5ed-4f66-a9fc-e8452d79a967" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesCurrent_dcfa4859-4341-4f1e-a28b-5bd7a0d40a05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_23445149-9f79-4871-b590-a021d6bc64dc" xlink:to="loc_us-gaap_DebtSecuritiesCurrent_dcfa4859-4341-4f1e-a28b-5bd7a0d40a05" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="auph-20220331.xsd#CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"/>
  <link:calculationLink xlink:role="http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_bc7f3fdb-b659-417b-8240-695495c9c7aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_c7da71ed-0963-4171-bc3f-349397899ea6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_bc7f3fdb-b659-417b-8240-695495c9c7aa" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_c7da71ed-0963-4171-bc3f-349397899ea6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_748da925-3c89-49ac-ab9c-62a43157b74b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_bc7f3fdb-b659-417b-8240-695495c9c7aa" xlink:to="loc_us-gaap_NetIncomeLoss_748da925-3c89-49ac-ab9c-62a43157b74b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_258f3606-8014-4a2b-bbf3-85391e7cd4cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_75786eea-ed90-4a0d-8abb-fd2145a6a687" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_258f3606-8014-4a2b-bbf3-85391e7cd4cd" xlink:to="loc_us-gaap_CostsAndExpenses_75786eea-ed90-4a0d-8abb-fd2145a6a687" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_219cb989-2783-4913-ad5b-0a4722b9afb1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_258f3606-8014-4a2b-bbf3-85391e7cd4cd" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_219cb989-2783-4913-ad5b-0a4722b9afb1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_3c48cc56-386d-4a37-bccd-1728251b649b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_e576e49b-7728-4243-af09-a96591e01a68" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_3c48cc56-386d-4a37-bccd-1728251b649b" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_e576e49b-7728-4243-af09-a96591e01a68" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_b61117ce-40db-4cf3-b6f5-b6adb1a1f18b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_3c48cc56-386d-4a37-bccd-1728251b649b" xlink:to="loc_us-gaap_OperatingIncomeLoss_b61117ce-40db-4cf3-b6f5-b6adb1a1f18b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_5d9e7d6e-d047-4409-b811-8c1026882d08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_ea83416a-2db3-4304-8e03-51d31adf57bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_5d9e7d6e-d047-4409-b811-8c1026882d08" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_ea83416a-2db3-4304-8e03-51d31adf57bc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_a8087676-2d80-488a-a391-e487699fe2ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_5d9e7d6e-d047-4409-b811-8c1026882d08" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_a8087676-2d80-488a-a391-e487699fe2ae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_39e0a17d-93d0-4b0a-9c63-e1e63546c293" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_b013b1cd-b895-4697-a1da-40111765a7a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_39e0a17d-93d0-4b0a-9c63-e1e63546c293" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_b013b1cd-b895-4697-a1da-40111765a7a9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_4730e848-c01d-41c7-b0d7-9277229a5918" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_39e0a17d-93d0-4b0a-9c63-e1e63546c293" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_4730e848-c01d-41c7-b0d7-9277229a5918" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_b06770e6-442d-4f18-b285-554ef76f308d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_39e0a17d-93d0-4b0a-9c63-e1e63546c293" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_b06770e6-442d-4f18-b285-554ef76f308d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue_7f99d4ff-9711-4f6d-bf55-5c0e548396c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfRevenue"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_39e0a17d-93d0-4b0a-9c63-e1e63546c293" xlink:to="loc_us-gaap_CostOfRevenue_7f99d4ff-9711-4f6d-bf55-5c0e548396c3" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="auph-20220331.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_bc498293-ea90-4982-8d7e-dd9b9530f554" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d80e837b-b3d7-40a3-9987-0441ccee963d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_bc498293-ea90-4982-8d7e-dd9b9530f554" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d80e837b-b3d7-40a3-9987-0441ccee963d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_9945ed35-554a-4cfd-bf61-5ed6065256b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_bc498293-ea90-4982-8d7e-dd9b9530f554" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_9945ed35-554a-4cfd-bf61-5ed6065256b8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_86b746b0-ba86-4082-94a9-d4d1da44a226" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_bc498293-ea90-4982-8d7e-dd9b9530f554" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_86b746b0-ba86-4082-94a9-d4d1da44a226" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_70a1f24e-d58e-48d3-8e98-cd3b5daabbe0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_46364b5b-0a3c-483e-bdc6-ae8eaf5708ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_70a1f24e-d58e-48d3-8e98-cd3b5daabbe0" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_46364b5b-0a3c-483e-bdc6-ae8eaf5708ed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_3d4893b0-9551-4380-aac6-323e26b2644c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_70a1f24e-d58e-48d3-8e98-cd3b5daabbe0" xlink:to="loc_us-gaap_Depreciation_3d4893b0-9551-4380-aac6-323e26b2644c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_16768f2b-d6c3-44b1-9314-628282515285" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_70a1f24e-d58e-48d3-8e98-cd3b5daabbe0" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_16768f2b-d6c3-44b1-9314-628282515285" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_a829fa52-7a9d-4e93-ae38-0c2371c99b38" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_70a1f24e-d58e-48d3-8e98-cd3b5daabbe0" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_a829fa52-7a9d-4e93-ae38-0c2371c99b38" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_b6a5a935-88b4-4d19-bdba-60752b1494c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_70a1f24e-d58e-48d3-8e98-cd3b5daabbe0" xlink:to="loc_us-gaap_ShareBasedCompensation_b6a5a935-88b4-4d19-bdba-60752b1494c1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_cdaf1f87-99e8-4df7-bbff-0c239bf7df1d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_70a1f24e-d58e-48d3-8e98-cd3b5daabbe0" xlink:to="loc_us-gaap_NetIncomeLoss_cdaf1f87-99e8-4df7-bbff-0c239bf7df1d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_1bb9680a-2f81-48b0-a933-e87b90e87607" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_70a1f24e-d58e-48d3-8e98-cd3b5daabbe0" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_1bb9680a-2f81-48b0-a933-e87b90e87607" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_d49f8692-a350-478b-925e-f270119a702b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_70a1f24e-d58e-48d3-8e98-cd3b5daabbe0" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_d49f8692-a350-478b-925e-f270119a702b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInReceivables_eb8468fe-5878-43f4-a3fd-287c3880cf1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInReceivables"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_70a1f24e-d58e-48d3-8e98-cd3b5daabbe0" xlink:to="loc_us-gaap_IncreaseDecreaseInReceivables_eb8468fe-5878-43f4-a3fd-287c3880cf1c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_d9bdfd67-79d1-444c-bfc0-9be7b944a4fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_70a1f24e-d58e-48d3-8e98-cd3b5daabbe0" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_d9bdfd67-79d1-444c-bfc0-9be7b944a4fc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_e5e3a5b7-ca57-45e9-a570-1084360e9469" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_70a1f24e-d58e-48d3-8e98-cd3b5daabbe0" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_e5e3a5b7-ca57-45e9-a570-1084360e9469" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_bb1be50e-1fe7-46c3-862a-e7ef20818b28" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForSoftware_f99784c7-b0e4-4c3a-ac4c-c117eeb7d70f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForSoftware"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_bb1be50e-1fe7-46c3-862a-e7ef20818b28" xlink:to="loc_us-gaap_PaymentsForSoftware_f99784c7-b0e4-4c3a-ac4c-c117eeb7d70f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_a562de62-6335-4d2e-9298-b7b81f25d8ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_bb1be50e-1fe7-46c3-862a-e7ef20818b28" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_a562de62-6335-4d2e-9298-b7b81f25d8ed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_c5b886d6-73fc-4f91-a673-77daf3fad169" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_bb1be50e-1fe7-46c3-862a-e7ef20818b28" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_c5b886d6-73fc-4f91-a673-77daf3fad169" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_4e7ab433-e531-4566-bbdc-6040bdfab48b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_bb1be50e-1fe7-46c3-862a-e7ef20818b28" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_4e7ab433-e531-4566-bbdc-6040bdfab48b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireLeaseReceivables_cdfd1742-2dca-474d-a2b9-efdca33bace3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireLeaseReceivables"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_bb1be50e-1fe7-46c3-862a-e7ef20818b28" xlink:to="loc_us-gaap_PaymentsToAcquireLeaseReceivables_cdfd1742-2dca-474d-a2b9-efdca33bace3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets_792ddb91-ddd2-4b09-affb-301fe307b843" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireOtherProductiveAssets"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_bb1be50e-1fe7-46c3-862a-e7ef20818b28" xlink:to="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets_792ddb91-ddd2-4b09-affb-301fe307b843" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_e4a54888-b342-4015-ad9e-752efc6c65a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_e3cb5b63-147a-492d-88ad-4352fefa4d65" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_e4a54888-b342-4015-ad9e-752efc6c65a1" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_e3cb5b63-147a-492d-88ad-4352fefa4d65" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_fe04c005-af90-4d1f-882b-d81fbbc77481" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_e4a54888-b342-4015-ad9e-752efc6c65a1" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_fe04c005-af90-4d1f-882b-d81fbbc77481" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_28066f81-9d6c-4a39-993a-51f779c10092" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_b8cee856-40f9-4f62-af08-ec7f668281bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_28066f81-9d6c-4a39-993a-51f779c10092" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalents_b8cee856-40f9-4f62-af08-ec7f668281bf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_a7fd399f-01cc-4582-91ce-8c59a901af66" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_28066f81-9d6c-4a39-993a-51f779c10092" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_a7fd399f-01cc-4582-91ce-8c59a901af66" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.auriniapharma.com/role/InventoriesDetails" xlink:type="simple" xlink:href="auph-20220331.xsd#InventoriesDetails"/>
  <link:calculationLink xlink:role="http://www.auriniapharma.com/role/InventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_10dd6d0a-e398-4b08-9e34-344910f97697" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_874c67ed-9ef9-45be-8daf-751531e9998a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_10dd6d0a-e398-4b08-9e34-344910f97697" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_874c67ed-9ef9-45be-8daf-751531e9998a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_0db080e8-afad-431c-9796-6700c2a5b43e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_10dd6d0a-e398-4b08-9e34-344910f97697" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_0db080e8-afad-431c-9796-6700c2a5b43e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_07307a7a-2265-422f-baef-c8efce21dd49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_10dd6d0a-e398-4b08-9e34-344910f97697" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_07307a7a-2265-422f-baef-c8efce21dd49" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.auriniapharma.com/role/PrepaidExpensesandOtherCurrentAssetsDetails" xlink:type="simple" xlink:href="auph-20220331.xsd#PrepaidExpensesandOtherCurrentAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.auriniapharma.com/role/PrepaidExpensesandOtherCurrentAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_70284f28-db13-4040-aaf6-6c7fb294e1e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidInsurance_c8350768-82b5-457a-85b9-1c569b643957" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidInsurance"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_70284f28-db13-4040-aaf6-6c7fb294e1e6" xlink:to="loc_us-gaap_PrepaidInsurance_c8350768-82b5-457a-85b9-1c569b643957" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_auph_PrepaidAssetsCurrent_2d664277-73b6-4b19-8fe9-07767e06d627" xlink:href="auph-20220331.xsd#auph_PrepaidAssetsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_70284f28-db13-4040-aaf6-6c7fb294e1e6" xlink:to="loc_auph_PrepaidAssetsCurrent_2d664277-73b6-4b19-8fe9-07767e06d627" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_auph_PrepaidRentAndPrepaidContinuingStudies_504cbe3a-6ba2-4637-a2db-19268879c976" xlink:href="auph-20220331.xsd#auph_PrepaidRentAndPrepaidContinuingStudies"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_70284f28-db13-4040-aaf6-6c7fb294e1e6" xlink:to="loc_auph_PrepaidRentAndPrepaidContinuingStudies_504cbe3a-6ba2-4637-a2db-19268879c976" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_a63474ba-047e-4edc-aa23-2a8dcf29e936" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_70284f28-db13-4040-aaf6-6c7fb294e1e6" xlink:to="loc_us-gaap_OtherAssetsCurrent_a63474ba-047e-4edc-aa23-2a8dcf29e936" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.auriniapharma.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails" xlink:type="simple" xlink:href="auph-20220331.xsd#IntangibleAssetsScheduleofIntangibleAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.auriniapharma.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_fe40b871-e100-40d3-931c-ebcfc739a6ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_5f0658a1-d056-4ee2-a138-227df6e2c356" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_fe40b871-e100-40d3-931c-ebcfc739a6ef" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_5f0658a1-d056-4ee2-a138-227df6e2c356" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_b00654b0-8aa0-4c5e-8d96-7b04a3687514" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_fe40b871-e100-40d3-931c-ebcfc739a6ef" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_b00654b0-8aa0-4c5e-8d96-7b04a3687514" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.auriniapharma.com/role/PropertyPlantandEquipmentnetDetails" xlink:type="simple" xlink:href="auph-20220331.xsd#PropertyPlantandEquipmentnetDetails"/>
  <link:calculationLink xlink:role="http://www.auriniapharma.com/role/PropertyPlantandEquipmentnetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_a75865d4-0a2b-40ff-9fcf-d01ff62c8781" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_35ee0a3f-a66d-48f2-995c-b4b7651717b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_a75865d4-0a2b-40ff-9fcf-d01ff62c8781" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_35ee0a3f-a66d-48f2-995c-b4b7651717b8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_97c16ae3-464f-400f-ab4b-504cd6560e8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_a75865d4-0a2b-40ff-9fcf-d01ff62c8781" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_97c16ae3-464f-400f-ab4b-504cd6560e8f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.auriniapharma.com/role/LeaseObligationsSupplementalBalanceSheetInformationDetails" xlink:type="simple" xlink:href="auph-20220331.xsd#LeaseObligationsSupplementalBalanceSheetInformationDetails"/>
  <link:calculationLink xlink:role="http://www.auriniapharma.com/role/LeaseObligationsSupplementalBalanceSheetInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_a22dbd33-0f2b-4054-b61c-59af6d0fbf9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_c139f6e9-ac49-41f4-8dfe-44deb8c7a84e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_a22dbd33-0f2b-4054-b61c-59af6d0fbf9c" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_c139f6e9-ac49-41f4-8dfe-44deb8c7a84e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_b06cc687-c065-4e2d-aa1b-6987c25e34b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_a22dbd33-0f2b-4054-b61c-59af6d0fbf9c" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_b06cc687-c065-4e2d-aa1b-6987c25e34b2" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="auph-20220331.xsd#LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_ecea3708-cbd9-407e-8710-6a14cfd837b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_cac51a50-3ff0-453e-b4aa-888acd5698da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_ecea3708-cbd9-407e-8710-6a14cfd837b2" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_cac51a50-3ff0-453e-b4aa-888acd5698da" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_2e35f2d5-8149-4a57-8acb-3508be98a05b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_ecea3708-cbd9-407e-8710-6a14cfd837b2" xlink:to="loc_us-gaap_OperatingLeaseLiability_2e35f2d5-8149-4a57-8acb-3508be98a05b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails_1" xlink:type="simple" xlink:href="auph-20220331.xsd#LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails_1"/>
  <link:calculationLink xlink:role="http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_c25deba1-a9b5-4014-a7ce-5c0121e21061" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_auph_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_5b9e7cad-2af1-42f6-bc63-3abc906aa4fa" xlink:href="auph-20220331.xsd#auph_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_c25deba1-a9b5-4014-a7ce-5c0121e21061" xlink:to="loc_auph_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_5b9e7cad-2af1-42f6-bc63-3abc906aa4fa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_a67b95ae-f168-486d-907c-98ef74d57313" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_c25deba1-a9b5-4014-a7ce-5c0121e21061" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_a67b95ae-f168-486d-907c-98ef74d57313" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_6929843e-f752-4d2e-8c08-4af263e54fc5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_c25deba1-a9b5-4014-a7ce-5c0121e21061" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_6929843e-f752-4d2e-8c08-4af263e54fc5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_568946c9-7abc-4fc5-89b5-f35d739d04d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_c25deba1-a9b5-4014-a7ce-5c0121e21061" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_568946c9-7abc-4fc5-89b5-f35d739d04d6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_9f15ab8f-e2e9-4d28-815a-a4af2f45d1ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_c25deba1-a9b5-4014-a7ce-5c0121e21061" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_9f15ab8f-e2e9-4d28-815a-a4af2f45d1ab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_49f82fcd-5e1f-4951-9a57-922c2f4d2f8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_c25deba1-a9b5-4014-a7ce-5c0121e21061" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_49f82fcd-5e1f-4951-9a57-922c2f4d2f8f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.auriniapharma.com/role/AccountsPayableandAccruedLiabilitiesDetails" xlink:type="simple" xlink:href="auph-20220331.xsd#AccountsPayableandAccruedLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.auriniapharma.com/role/AccountsPayableandAccruedLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_a19ae7a1-528a-4e80-8368-5964a211caad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_fa04d6b6-f205-43bb-bced-8bd1fcc92d2c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_a19ae7a1-528a-4e80-8368-5964a211caad" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_fa04d6b6-f205-43bb-bced-8bd1fcc92d2c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_296cec22-c261-4751-a7cf-27ece6b4de8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_a19ae7a1-528a-4e80-8368-5964a211caad" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_296cec22-c261-4751-a7cf-27ece6b4de8a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableTradeCurrent_25b02ca4-4f41-4a7e-b331-605f5e9b3c9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableTradeCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_a19ae7a1-528a-4e80-8368-5964a211caad" xlink:to="loc_us-gaap_AccountsPayableTradeCurrent_25b02ca4-4f41-4a7e-b331-605f5e9b3c9d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_auph_AccruedResearchCurrent_e26bb3df-086f-478d-b066-42eff0b1eb5d" xlink:href="auph-20220331.xsd#auph_AccruedResearchCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_a19ae7a1-528a-4e80-8368-5964a211caad" xlink:to="loc_auph_AccruedResearchCurrent_e26bb3df-086f-478d-b066-42eff0b1eb5d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_auph_CommercialRelatedAccrualsCurrent_adabefa1-c37f-4537-ab9e-7610eb6f2bc3" xlink:href="auph-20220331.xsd#auph_CommercialRelatedAccrualsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_a19ae7a1-528a-4e80-8368-5964a211caad" xlink:to="loc_auph_CommercialRelatedAccrualsCurrent_adabefa1-c37f-4537-ab9e-7610eb6f2bc3" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.auriniapharma.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" xlink:type="simple" xlink:href="auph-20220331.xsd#FairValueMeasurementsAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"/>
  <link:calculationLink xlink:role="http://www.auriniapharma.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_cab76308-4cf4-4918-9a28-69d63d7b7a94" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_9fb51220-84ad-40f3-899e-2573f6350360" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_cab76308-4cf4-4918-9a28-69d63d7b7a94" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_9fb51220-84ad-40f3-899e-2573f6350360" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_e05d7ea2-ad8a-4d1d-9712-8dc95cd9a820" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_cab76308-4cf4-4918-9a28-69d63d7b7a94" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_e05d7ea2-ad8a-4d1d-9712-8dc95cd9a820" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.auriniapharma.com/role/NetLossperCommonShareDetails" xlink:type="simple" xlink:href="auph-20220331.xsd#NetLossperCommonShareDetails"/>
  <link:calculationLink xlink:role="http://www.auriniapharma.com/role/NetLossperCommonShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_8eae4729-5b2e-483f-8308-8fcfb00f06e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_8e1f1741-5b2e-42df-a51d-1f5a8dfb9efd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EarningsPerShareDiluted_8eae4729-5b2e-483f-8308-8fcfb00f06e6" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_8e1f1741-5b2e-42df-a51d-1f5a8dfb9efd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_e498a21a-2dca-4cb9-9d3a-0a513e5876df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EarningsPerShareDiluted_8eae4729-5b2e-483f-8308-8fcfb00f06e6" xlink:to="loc_us-gaap_NetIncomeLoss_e498a21a-2dca-4cb9-9d3a-0a513e5876df" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_71c0b1a0-1e4b-44cb-a092-51fee3098fc4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2a272c6f-f9e5-455d-8dc3-9997c60e196a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EarningsPerShareBasic_71c0b1a0-1e4b-44cb-a092-51fee3098fc4" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2a272c6f-f9e5-455d-8dc3-9997c60e196a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_00ae1ec3-1bc0-402e-837e-c9950580afc4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EarningsPerShareBasic_71c0b1a0-1e4b-44cb-a092-51fee3098fc4" xlink:to="loc_us-gaap_NetIncomeLoss_00ae1ec3-1bc0-402e-837e-c9950580afc4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_e94e792b-3397-4e2d-ba32-f130740406ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EarningsPerShareBasic_71c0b1a0-1e4b-44cb-a092-51fee3098fc4" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_e94e792b-3397-4e2d-ba32-f130740406ca" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>auph-20220331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:778f08dd-b92a-42f0-b4bb-a50ecfb6a537,g:a60fc6d8-f25a-4b7b-af6a-b9dcc6be1df4-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="auph-20220331.xsd#CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"/>
  <link:definitionLink xlink:role="http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="extended" id="id8093c8d2dd54427b34d412cca32c277_CondensedConsolidatedStatementsofOperationsandComprehensiveLoss">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_e483c03c-6130-47e5-88da-fbf22344fda8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_f37e3682-2941-4043-8d81-952bc8821696" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e483c03c-6130-47e5-88da-fbf22344fda8" xlink:to="loc_us-gaap_RevenuesAbstract_f37e3682-2941-4043-8d81-952bc8821696" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_a522ee77-a439-465e-bdd4-59553bddcb50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_f37e3682-2941-4043-8d81-952bc8821696" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_a522ee77-a439-465e-bdd4-59553bddcb50" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_701c8a37-6fa2-4131-8dcd-b50149abd4b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e483c03c-6130-47e5-88da-fbf22344fda8" xlink:to="loc_us-gaap_OperatingExpensesAbstract_701c8a37-6fa2-4131-8dcd-b50149abd4b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue_86ea7bb3-9cf1-4cda-8682-236eedcb551b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_701c8a37-6fa2-4131-8dcd-b50149abd4b7" xlink:to="loc_us-gaap_CostOfRevenue_86ea7bb3-9cf1-4cda-8682-236eedcb551b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_d74fd3de-a897-4cd2-9a5e-f8f4277ba518" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_701c8a37-6fa2-4131-8dcd-b50149abd4b7" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_d74fd3de-a897-4cd2-9a5e-f8f4277ba518" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_ad21ad44-bf57-4110-bb46-7223ff0e5715" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_701c8a37-6fa2-4131-8dcd-b50149abd4b7" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_ad21ad44-bf57-4110-bb46-7223ff0e5715" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_7ef90984-0275-4a05-aa5f-2d660a4d2c05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_701c8a37-6fa2-4131-8dcd-b50149abd4b7" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_7ef90984-0275-4a05-aa5f-2d660a4d2c05" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_c782bcbe-efe5-49d5-b880-bc558a39d670" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_701c8a37-6fa2-4131-8dcd-b50149abd4b7" xlink:to="loc_us-gaap_CostsAndExpenses_c782bcbe-efe5-49d5-b880-bc558a39d670" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_cc6959c3-a894-4b49-96c1-6e0c2adcdd5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e483c03c-6130-47e5-88da-fbf22344fda8" xlink:to="loc_us-gaap_OperatingIncomeLoss_cc6959c3-a894-4b49-96c1-6e0c2adcdd5d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_e5aeb6f5-5449-44d8-8bed-60456c02b010" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e483c03c-6130-47e5-88da-fbf22344fda8" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_e5aeb6f5-5449-44d8-8bed-60456c02b010" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_53b4e593-7eba-4d57-b3cb-6ccd12d5a942" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e483c03c-6130-47e5-88da-fbf22344fda8" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_53b4e593-7eba-4d57-b3cb-6ccd12d5a942" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_e2660f87-d73d-4a1b-85cd-bf6539136104" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e483c03c-6130-47e5-88da-fbf22344fda8" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_e2660f87-d73d-4a1b-85cd-bf6539136104" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_b35c4c12-c21f-42e3-a7ab-8745e9a23489" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e483c03c-6130-47e5-88da-fbf22344fda8" xlink:to="loc_us-gaap_NetIncomeLoss_b35c4c12-c21f-42e3-a7ab-8745e9a23489" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_b762c2f7-f19e-4c2f-99b3-b11993966e1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e483c03c-6130-47e5-88da-fbf22344fda8" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_b762c2f7-f19e-4c2f-99b3-b11993966e1b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_e6fcede2-8158-46e9-b4db-1acaff20bd0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_b762c2f7-f19e-4c2f-99b3-b11993966e1b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_e6fcede2-8158-46e9-b4db-1acaff20bd0d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_40ae67a5-838c-4a40-b459-36bb630ac3c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e483c03c-6130-47e5-88da-fbf22344fda8" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_40ae67a5-838c-4a40-b459-36bb630ac3c6" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_e2929133-1cd4-43ce-81a8-08ebfe91662a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e483c03c-6130-47e5-88da-fbf22344fda8" xlink:to="loc_us-gaap_EarningsPerShareBasic_e2929133-1cd4-43ce-81a8-08ebfe91662a" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_ba537017-2ceb-4e67-978a-dc3529b0a939" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e483c03c-6130-47e5-88da-fbf22344fda8" xlink:to="loc_us-gaap_EarningsPerShareDiluted_ba537017-2ceb-4e67-978a-dc3529b0a939" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_3a8cb0f0-c7a9-43d6-b2c1-9174dae7ab36" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e483c03c-6130-47e5-88da-fbf22344fda8" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_3a8cb0f0-c7a9-43d6-b2c1-9174dae7ab36" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_c9c89c69-4c05-4e81-bf34-27d52c13a38b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e483c03c-6130-47e5-88da-fbf22344fda8" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_c9c89c69-4c05-4e81-bf34-27d52c13a38b" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_d543e310-9705-48e3-aa84-ccbe40dc5c7e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_e483c03c-6130-47e5-88da-fbf22344fda8" xlink:to="loc_us-gaap_StatementTable_d543e310-9705-48e3-aa84-ccbe40dc5c7e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_29346e3e-6765-4e7d-929d-f5f5349e5787" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_d543e310-9705-48e3-aa84-ccbe40dc5c7e" xlink:to="loc_srt_ProductOrServiceAxis_29346e3e-6765-4e7d-929d-f5f5349e5787" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_29346e3e-6765-4e7d-929d-f5f5349e5787_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_29346e3e-6765-4e7d-929d-f5f5349e5787" xlink:to="loc_srt_ProductsAndServicesDomain_29346e3e-6765-4e7d-929d-f5f5349e5787_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_776c6203-f202-474c-81ad-311780ada52b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_29346e3e-6765-4e7d-929d-f5f5349e5787" xlink:to="loc_srt_ProductsAndServicesDomain_776c6203-f202-474c-81ad-311780ada52b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_fa854be9-2739-4725-9fe8-8a59086e17cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_776c6203-f202-474c-81ad-311780ada52b" xlink:to="loc_us-gaap_ProductMember_fa854be9-2739-4725-9fe8-8a59086e17cd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_7b2cee62-f66e-4dac-ba0d-1eadb289b438" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_776c6203-f202-474c-81ad-311780ada52b" xlink:to="loc_us-gaap_LicenseMember_7b2cee62-f66e-4dac-ba0d-1eadb289b438" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofShareholdersEquity" xlink:type="simple" xlink:href="auph-20220331.xsd#CondensedConsolidatedStatementsofShareholdersEquity"/>
  <link:definitionLink xlink:role="http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofShareholdersEquity" xlink:type="extended" id="i7c39576e2d284fa4b0536fa395de12d0_CondensedConsolidatedStatementsofShareholdersEquity">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_3cc433bc-d64c-4a6e-beb1-3c1e7258e20a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f9085b1e-a6eb-4a74-a3a5-89de3504f461" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3cc433bc-d64c-4a6e-beb1-3c1e7258e20a" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f9085b1e-a6eb-4a74-a3a5-89de3504f461" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_96f62425-d0f6-4908-be0b-55e50dbb19e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f9085b1e-a6eb-4a74-a3a5-89de3504f461" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_96f62425-d0f6-4908-be0b-55e50dbb19e2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_4392463c-da0b-4940-b80e-1f06db0d9ab4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f9085b1e-a6eb-4a74-a3a5-89de3504f461" xlink:to="loc_us-gaap_StockholdersEquity_4392463c-da0b-4940-b80e-1f06db0d9ab4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_48095abc-c515-422e-88cc-50377e4a811d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f9085b1e-a6eb-4a74-a3a5-89de3504f461" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_48095abc-c515-422e-88cc-50377e4a811d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_b2b397d5-2dc4-41a8-be07-0dfcc274929c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f9085b1e-a6eb-4a74-a3a5-89de3504f461" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_b2b397d5-2dc4-41a8-be07-0dfcc274929c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_45d76d75-f625-46e9-8328-cd5cc7cc8a9a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f9085b1e-a6eb-4a74-a3a5-89de3504f461" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_45d76d75-f625-46e9-8328-cd5cc7cc8a9a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_b8c5b47b-7204-4b40-af14-b4e98e2d0937" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f9085b1e-a6eb-4a74-a3a5-89de3504f461" xlink:to="loc_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_b8c5b47b-7204-4b40-af14-b4e98e2d0937" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_5b1abf2d-cf13-4324-b5d7-8d42775f185b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f9085b1e-a6eb-4a74-a3a5-89de3504f461" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_5b1abf2d-cf13-4324-b5d7-8d42775f185b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_2ac6cc4e-d5c5-4d13-837f-92f0f07c7fe6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f9085b1e-a6eb-4a74-a3a5-89de3504f461" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_2ac6cc4e-d5c5-4d13-837f-92f0f07c7fe6" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_354fb5ce-f661-4616-9e71-bc744fa62576" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f9085b1e-a6eb-4a74-a3a5-89de3504f461" xlink:to="loc_us-gaap_NetIncomeLoss_354fb5ce-f661-4616-9e71-bc744fa62576" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_3d69a950-dbbb-44a8-a067-149077f94141" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_dd1ed54c-2d10-482b-80a7-7c3ef2a033c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_85b7970e-ff7c-4bc5-9291-d64f325cc6cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_3cc433bc-d64c-4a6e-beb1-3c1e7258e20a" xlink:to="loc_us-gaap_StatementTable_85b7970e-ff7c-4bc5-9291-d64f325cc6cd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_0f8b30a8-7854-475f-bab4-10ef0820e84c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_85b7970e-ff7c-4bc5-9291-d64f325cc6cd" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_0f8b30a8-7854-475f-bab4-10ef0820e84c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_0f8b30a8-7854-475f-bab4-10ef0820e84c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_0f8b30a8-7854-475f-bab4-10ef0820e84c" xlink:to="loc_us-gaap_EquityComponentDomain_0f8b30a8-7854-475f-bab4-10ef0820e84c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_085982ed-6249-43e1-9910-aacffb351956" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_0f8b30a8-7854-475f-bab4-10ef0820e84c" xlink:to="loc_us-gaap_EquityComponentDomain_085982ed-6249-43e1-9910-aacffb351956" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_a22b2734-9282-4b0d-b8fe-bb1840fd386f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_085982ed-6249-43e1-9910-aacffb351956" xlink:to="loc_us-gaap_CommonStockMember_a22b2734-9282-4b0d-b8fe-bb1840fd386f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_c8a16097-09db-4352-b851-3b3bf7d1cc21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_085982ed-6249-43e1-9910-aacffb351956" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_c8a16097-09db-4352-b851-3b3bf7d1cc21" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_a139a5e4-9a9a-41cf-b177-9c35191caf22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_085982ed-6249-43e1-9910-aacffb351956" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_a139a5e4-9a9a-41cf-b177-9c35191caf22" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_735f73ad-e0f5-4084-8a65-11c94f9e0cc2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_085982ed-6249-43e1-9910-aacffb351956" xlink:to="loc_us-gaap_RetainedEarningsMember_735f73ad-e0f5-4084-8a65-11c94f9e0cc2" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="auph-20220331.xsd#SummaryofSignificantAccountingPoliciesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended" id="ia6f936c155424612ab8bb2a68535e6d0_SummaryofSignificantAccountingPoliciesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_974a2341-d1b3-4e58-87b3-158e275b2350" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_39088d05-cfbc-4083-8842-612546872daa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_974a2341-d1b3-4e58-87b3-158e275b2350" xlink:to="loc_us-gaap_RestrictedCash_39088d05-cfbc-4083-8842-612546872daa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_819d3499-5195-470a-ac80-e8dc44bd4c88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_974a2341-d1b3-4e58-87b3-158e275b2350" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_819d3499-5195-470a-ac80-e8dc44bd4c88" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsAndOtherReceivablesNetCurrent_d433e677-4e41-470c-b715-6b0a0c23dbae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_974a2341-d1b3-4e58-87b3-158e275b2350" xlink:to="loc_us-gaap_AccountsAndOtherReceivablesNetCurrent_d433e677-4e41-470c-b715-6b0a0c23dbae" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_cea6fdbc-7021-4752-a9a4-acaeb0334abe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_974a2341-d1b3-4e58-87b3-158e275b2350" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_cea6fdbc-7021-4752-a9a4-acaeb0334abe" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_e128c5fb-a7a3-4472-bb0b-b2bd83c6fb04" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_974a2341-d1b3-4e58-87b3-158e275b2350" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_e128c5fb-a7a3-4472-bb0b-b2bd83c6fb04" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_8b3e252b-c231-42af-bcf0-4bfaf220c4de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_e128c5fb-a7a3-4472-bb0b-b2bd83c6fb04" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_8b3e252b-c231-42af-bcf0-4bfaf220c4de" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_8b3e252b-c231-42af-bcf0-4bfaf220c4de_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_8b3e252b-c231-42af-bcf0-4bfaf220c4de" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_8b3e252b-c231-42af-bcf0-4bfaf220c4de_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_83b7b3f0-8550-45a9-8d02-41fc3cc5b424" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_8b3e252b-c231-42af-bcf0-4bfaf220c4de" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_83b7b3f0-8550-45a9-8d02-41fc3cc5b424" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_6d737722-132f-4c7a-a67d-f0dc1ccd4a76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_83b7b3f0-8550-45a9-8d02-41fc3cc5b424" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_6d737722-132f-4c7a-a67d-f0dc1ccd4a76" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_5fc13dd8-df72-4838-b17c-24ca2219b5f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_e128c5fb-a7a3-4472-bb0b-b2bd83c6fb04" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_5fc13dd8-df72-4838-b17c-24ca2219b5f8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_5fc13dd8-df72-4838-b17c-24ca2219b5f8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_5fc13dd8-df72-4838-b17c-24ca2219b5f8" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_5fc13dd8-df72-4838-b17c-24ca2219b5f8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_9fcea0c5-613e-4393-8cef-83817a892213" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_5fc13dd8-df72-4838-b17c-24ca2219b5f8" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_9fcea0c5-613e-4393-8cef-83817a892213" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_a4b55f9f-f6af-4ab6-a014-22e9bb99730a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_9fcea0c5-613e-4393-8cef-83817a892213" xlink:to="loc_us-gaap_SalesRevenueNetMember_a4b55f9f-f6af-4ab6-a014-22e9bb99730a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_dfc5c6c6-f508-4534-8b70-188dbbaf692c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_e128c5fb-a7a3-4472-bb0b-b2bd83c6fb04" xlink:to="loc_srt_MajorCustomersAxis_dfc5c6c6-f508-4534-8b70-188dbbaf692c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_dfc5c6c6-f508-4534-8b70-188dbbaf692c_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_dfc5c6c6-f508-4534-8b70-188dbbaf692c" xlink:to="loc_srt_NameOfMajorCustomerDomain_dfc5c6c6-f508-4534-8b70-188dbbaf692c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_21fc246f-e1d4-438c-b1d5-afb863696733" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_dfc5c6c6-f508-4534-8b70-188dbbaf692c" xlink:to="loc_srt_NameOfMajorCustomerDomain_21fc246f-e1d4-438c-b1d5-afb863696733" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_auph_SpecialtyPharmacyOneMember_1cc7ed0f-aa84-42e0-bfe4-f0dab53429cd" xlink:href="auph-20220331.xsd#auph_SpecialtyPharmacyOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_21fc246f-e1d4-438c-b1d5-afb863696733" xlink:to="loc_auph_SpecialtyPharmacyOneMember_1cc7ed0f-aa84-42e0-bfe4-f0dab53429cd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_auph_SpecialtyPharmacyTwoMember_3a2aa5ec-7a84-4172-bfd9-d11c8c3fa691" xlink:href="auph-20220331.xsd#auph_SpecialtyPharmacyTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_21fc246f-e1d4-438c-b1d5-afb863696733" xlink:to="loc_auph_SpecialtyPharmacyTwoMember_3a2aa5ec-7a84-4172-bfd9-d11c8c3fa691" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.auriniapharma.com/role/InvestmentsDetails" xlink:type="simple" xlink:href="auph-20220331.xsd#InvestmentsDetails"/>
  <link:definitionLink xlink:role="http://www.auriniapharma.com/role/InvestmentsDetails" xlink:type="extended" id="i300269ddedfb44c0a3d7ff01f89cf701_InvestmentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesLineItems_8ae86dea-0aca-423b-98c8-22e8d4e8c744" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesCurrent_68cc9919-5b24-4ea7-9ef3-788dfb6cf07d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_8ae86dea-0aca-423b-98c8-22e8d4e8c744" xlink:to="loc_us-gaap_DebtSecuritiesCurrent_68cc9919-5b24-4ea7-9ef3-788dfb6cf07d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecurities_010f2e5f-e09a-4ba2-8e33-ac8c6c3f005a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HeldToMaturitySecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_8ae86dea-0aca-423b-98c8-22e8d4e8c744" xlink:to="loc_us-gaap_HeldToMaturitySecurities_010f2e5f-e09a-4ba2-8e33-ac8c6c3f005a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_f03ed3f5-f377-4562-a607-aad8d09c90fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_8ae86dea-0aca-423b-98c8-22e8d4e8c744" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_f03ed3f5-f377-4562-a607-aad8d09c90fe" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestReceivable_7728bab5-623c-41f2-a466-830bb8b6cded" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_8ae86dea-0aca-423b-98c8-22e8d4e8c744" xlink:to="loc_us-gaap_InterestReceivable_7728bab5-623c-41f2-a466-830bb8b6cded" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss_625e7018-d50c-4efa-b2ec-6ab683f4c06f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_8ae86dea-0aca-423b-98c8-22e8d4e8c744" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss_625e7018-d50c-4efa-b2ec-6ab683f4c06f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesTable_9fdf46e6-e41c-4037-927a-58e02e4f70d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_8ae86dea-0aca-423b-98c8-22e8d4e8c744" xlink:to="loc_us-gaap_MarketableSecuritiesTable_9fdf46e6-e41c-4037-927a-58e02e4f70d1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_fb48e6de-64b3-4aed-b80f-d6816d7cb89b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_MarketableSecuritiesTable_9fdf46e6-e41c-4037-927a-58e02e4f70d1" xlink:to="loc_us-gaap_FinancialInstrumentAxis_fb48e6de-64b3-4aed-b80f-d6816d7cb89b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_fb48e6de-64b3-4aed-b80f-d6816d7cb89b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_fb48e6de-64b3-4aed-b80f-d6816d7cb89b" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_fb48e6de-64b3-4aed-b80f-d6816d7cb89b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_16b7dd2f-7005-47ac-8c6b-7dfc1b2ad0ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_fb48e6de-64b3-4aed-b80f-d6816d7cb89b" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_16b7dd2f-7005-47ac-8c6b-7dfc1b2ad0ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_auph_CashableGuaranteedInvestmentCertificatesMember_620fea9a-07af-4316-8499-644807e43f7d" xlink:href="auph-20220331.xsd#auph_CashableGuaranteedInvestmentCertificatesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_16b7dd2f-7005-47ac-8c6b-7dfc1b2ad0ca" xlink:to="loc_auph_CashableGuaranteedInvestmentCertificatesMember_620fea9a-07af-4316-8499-644807e43f7d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_auph_ShortTermCorporateDebtSecuritiesMember_f1b9467f-9308-45d9-89ea-ace0fc8f4a1c" xlink:href="auph-20220331.xsd#auph_ShortTermCorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_16b7dd2f-7005-47ac-8c6b-7dfc1b2ad0ca" xlink:to="loc_auph_ShortTermCorporateDebtSecuritiesMember_f1b9467f-9308-45d9-89ea-ace0fc8f4a1c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_7acce8ba-21ef-47bd-a938-295a72c84501" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_16b7dd2f-7005-47ac-8c6b-7dfc1b2ad0ca" xlink:to="loc_us-gaap_CommercialPaperMember_7acce8ba-21ef-47bd-a938-295a72c84501" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryBillSecuritiesMember_cb4699ab-514c-4be4-90a5-99d8a25dc93f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasuryBillSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_16b7dd2f-7005-47ac-8c6b-7dfc1b2ad0ca" xlink:to="loc_us-gaap_USTreasuryBillSecuritiesMember_cb4699ab-514c-4be4-90a5-99d8a25dc93f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryBondSecuritiesMember_329980d5-7cc2-4ba1-a9fb-6a31f48b36dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasuryBondSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_16b7dd2f-7005-47ac-8c6b-7dfc1b2ad0ca" xlink:to="loc_us-gaap_USTreasuryBondSecuritiesMember_329980d5-7cc2-4ba1-a9fb-6a31f48b36dd" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.auriniapharma.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails" xlink:type="simple" xlink:href="auph-20220331.xsd#IntangibleAssetsScheduleofIntangibleAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.auriniapharma.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails" xlink:type="extended" id="i498910f4b94743699562d4d7fd5b45d3_IntangibleAssetsScheduleofIntangibleAssetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_bb63c5de-9d27-469a-b238-c4764f98d4ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_081e1c22-5b33-4b5e-a33c-801c63ec85e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_bb63c5de-9d27-469a-b238-c4764f98d4ec" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_081e1c22-5b33-4b5e-a33c-801c63ec85e9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_88dcf613-6f06-46c4-a7d9-227cfabe6cc0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_bb63c5de-9d27-469a-b238-c4764f98d4ec" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_88dcf613-6f06-46c4-a7d9-227cfabe6cc0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_009eb639-809e-47f6-af57-671dbb8bcf03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_bb63c5de-9d27-469a-b238-c4764f98d4ec" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_009eb639-809e-47f6-af57-671dbb8bcf03" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_b207b071-519e-484a-88ef-6bb062ee5cdb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_bb63c5de-9d27-469a-b238-c4764f98d4ec" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_b207b071-519e-484a-88ef-6bb062ee5cdb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_f3d9e65f-53b9-47c3-ac16-73e020620551" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_b207b071-519e-484a-88ef-6bb062ee5cdb" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_f3d9e65f-53b9-47c3-ac16-73e020620551" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f3d9e65f-53b9-47c3-ac16-73e020620551_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_f3d9e65f-53b9-47c3-ac16-73e020620551" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f3d9e65f-53b9-47c3-ac16-73e020620551_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_e3de5129-be2e-4657-a75d-396d2089f1d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_f3d9e65f-53b9-47c3-ac16-73e020620551" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_e3de5129-be2e-4657-a75d-396d2089f1d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PatentsMember_08f420ce-4434-4068-b0f5-7b0c2ef50fb3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PatentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_e3de5129-be2e-4657-a75d-396d2089f1d3" xlink:to="loc_us-gaap_PatentsMember_08f420ce-4434-4068-b0f5-7b0c2ef50fb3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntellectualPropertyMember_f40af0d3-4e07-4a25-94cc-b6340ab5083a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntellectualPropertyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_e3de5129-be2e-4657-a75d-396d2089f1d3" xlink:to="loc_us-gaap_IntellectualPropertyMember_f40af0d3-4e07-4a25-94cc-b6340ab5083a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_1f2310ec-a2ea-4730-91cb-ce05cfa16ff1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_e3de5129-be2e-4657-a75d-396d2089f1d3" xlink:to="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_1f2310ec-a2ea-4730-91cb-ce05cfa16ff1" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.auriniapharma.com/role/PropertyPlantandEquipmentnetDetails" xlink:type="simple" xlink:href="auph-20220331.xsd#PropertyPlantandEquipmentnetDetails"/>
  <link:definitionLink xlink:role="http://www.auriniapharma.com/role/PropertyPlantandEquipmentnetDetails" xlink:type="extended" id="i2e168b103e1342f6921cc33560e3f9f8_PropertyPlantandEquipmentnetDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_844cc1c4-ac2d-49c3-a911-4dad03d4068f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_c734b5e4-f2ce-4277-9bc3-7da61fc0f7fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_844cc1c4-ac2d-49c3-a911-4dad03d4068f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_c734b5e4-f2ce-4277-9bc3-7da61fc0f7fa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_562ffd3e-52bf-488a-9916-f314842ae9b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_844cc1c4-ac2d-49c3-a911-4dad03d4068f" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_562ffd3e-52bf-488a-9916-f314842ae9b6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_40344d44-9af1-4ed2-95d5-4d0df896ba19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_844cc1c4-ac2d-49c3-a911-4dad03d4068f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_40344d44-9af1-4ed2-95d5-4d0df896ba19" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_59e52894-1c71-4c6f-b734-9430838c7a57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_844cc1c4-ac2d-49c3-a911-4dad03d4068f" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_59e52894-1c71-4c6f-b734-9430838c7a57" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_29417945-a29e-4f06-a809-14b70762eee1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_59e52894-1c71-4c6f-b734-9430838c7a57" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_29417945-a29e-4f06-a809-14b70762eee1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_29417945-a29e-4f06-a809-14b70762eee1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_29417945-a29e-4f06-a809-14b70762eee1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_29417945-a29e-4f06-a809-14b70762eee1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_59a5908e-d2ed-455d-9615-ecd329287c09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_29417945-a29e-4f06-a809-14b70762eee1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_59a5908e-d2ed-455d-9615-ecd329287c09" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_25c81e47-8bec-4943-9470-3c5f6ac2fd9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_59a5908e-d2ed-455d-9615-ecd329287c09" xlink:to="loc_us-gaap_ConstructionInProgressMember_25c81e47-8bec-4943-9470-3c5f6ac2fd9c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_64b59d6c-81dd-4855-9552-cf38c3ae0183" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_59a5908e-d2ed-455d-9615-ecd329287c09" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_64b59d6c-81dd-4855-9552-cf38c3ae0183" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_73c0249a-a505-4a04-bdbd-870ad3c66480" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_59a5908e-d2ed-455d-9615-ecd329287c09" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_73c0249a-a505-4a04-bdbd-870ad3c66480" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OfficeEquipmentMember_4c29560e-d658-4a24-b09b-b4fc733df19a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OfficeEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_59a5908e-d2ed-455d-9615-ecd329287c09" xlink:to="loc_us-gaap_OfficeEquipmentMember_4c29560e-d658-4a24-b09b-b4fc733df19a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_3c0a4384-3ed8-4f69-9285-64b62c7fa0b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_59a5908e-d2ed-455d-9615-ecd329287c09" xlink:to="loc_us-gaap_ComputerEquipmentMember_3c0a4384-3ed8-4f69-9285-64b62c7fa0b2" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.auriniapharma.com/role/LeaseObligationsNarrativeDetails" xlink:type="simple" xlink:href="auph-20220331.xsd#LeaseObligationsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.auriniapharma.com/role/LeaseObligationsNarrativeDetails" xlink:type="extended" id="ie2fc016bcaec424c91c55fe6bcac17ba_LeaseObligationsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_66417155-b3c3-4a94-a70a-099605f68d16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfRealEstateProperty_76bf5ecf-fc4a-47e6-bbd5-21db791d06de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AreaOfRealEstateProperty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_66417155-b3c3-4a94-a70a-099605f68d16" xlink:to="loc_us-gaap_AreaOfRealEstateProperty_76bf5ecf-fc4a-47e6-bbd5-21db791d06de" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_daf87e91-057c-4498-8a81-4fa7da2d1329" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_66417155-b3c3-4a94-a70a-099605f68d16" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_daf87e91-057c-4498-8a81-4fa7da2d1329" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_3b5d00d4-2808-43ed-84aa-e3ee3720d8bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_66417155-b3c3-4a94-a70a-099605f68d16" xlink:to="loc_us-gaap_OperatingLeaseLiability_3b5d00d4-2808-43ed-84aa-e3ee3720d8bc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_2982c7cf-9ccb-466b-ae2a-14da25131c49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_66417155-b3c3-4a94-a70a-099605f68d16" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_2982c7cf-9ccb-466b-ae2a-14da25131c49" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_397c3b2c-7073-444f-8935-e8d31ff6f0c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_66417155-b3c3-4a94-a70a-099605f68d16" xlink:to="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_397c3b2c-7073-444f-8935-e8d31ff6f0c2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_auph_LesseeOperatingLeaseNumberOfExtensionOptions_99137d0d-17f6-418e-b48a-a9db41cc61b4" xlink:href="auph-20220331.xsd#auph_LesseeOperatingLeaseNumberOfExtensionOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_66417155-b3c3-4a94-a70a-099605f68d16" xlink:to="loc_auph_LesseeOperatingLeaseNumberOfExtensionOptions_99137d0d-17f6-418e-b48a-a9db41cc61b4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_407b55cc-08b1-4d65-a18a-08f6fac2730f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_66417155-b3c3-4a94-a70a-099605f68d16" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_407b55cc-08b1-4d65-a18a-08f6fac2730f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_110f900f-966e-42b3-82ba-40c3c65dabc7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_66417155-b3c3-4a94-a70a-099605f68d16" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_110f900f-966e-42b3-82ba-40c3c65dabc7" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_auph_LesseeOperatingLeaseLeaseTerminationTerm_c2b5c8b5-b658-4a3f-8549-bfc9d35fd774" xlink:href="auph-20220331.xsd#auph_LesseeOperatingLeaseLeaseTerminationTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_66417155-b3c3-4a94-a70a-099605f68d16" xlink:to="loc_auph_LesseeOperatingLeaseLeaseTerminationTerm_c2b5c8b5-b658-4a3f-8549-bfc9d35fd774" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_88496248-76cd-47ca-b554-b37b350dc66c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_66417155-b3c3-4a94-a70a-099605f68d16" xlink:to="loc_us-gaap_OperatingLeaseCost_88496248-76cd-47ca-b554-b37b350dc66c" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForCapitalImprovements_37a86e61-192d-449a-bf6c-b70fd04274dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForCapitalImprovements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_66417155-b3c3-4a94-a70a-099605f68d16" xlink:to="loc_us-gaap_PaymentsForCapitalImprovements_37a86e61-192d-449a-bf6c-b70fd04274dd" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_56a0bb47-9b43-49bf-b897-ff7a745e92b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_66417155-b3c3-4a94-a70a-099605f68d16" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_56a0bb47-9b43-49bf-b897-ff7a745e92b4" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_15c4265b-4fba-4e5e-a786-8e2a5e15161d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_66417155-b3c3-4a94-a70a-099605f68d16" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_15c4265b-4fba-4e5e-a786-8e2a5e15161d" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f6ee829f-f93b-4946-9d67-4587bd596a11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_66417155-b3c3-4a94-a70a-099605f68d16" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f6ee829f-f93b-4946-9d67-4587bd596a11" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_auph_LesseeOperatingLeaseLeaseNotYetCommencedPaymentsPriorToCommencementOfLease_1b05c6d7-03d1-4931-b4a2-2005402a180d" xlink:href="auph-20220331.xsd#auph_LesseeOperatingLeaseLeaseNotYetCommencedPaymentsPriorToCommencementOfLease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_66417155-b3c3-4a94-a70a-099605f68d16" xlink:to="loc_auph_LesseeOperatingLeaseLeaseNotYetCommencedPaymentsPriorToCommencementOfLease_1b05c6d7-03d1-4931-b4a2-2005402a180d" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_auph_LesseeOperatingLeaseLeaseNotYetCommencedLiabilityToBePaid_55cdc34a-e7f0-4e4a-b6a3-6c8b9ba9e347" xlink:href="auph-20220331.xsd#auph_LesseeOperatingLeaseLeaseNotYetCommencedLiabilityToBePaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_66417155-b3c3-4a94-a70a-099605f68d16" xlink:to="loc_auph_LesseeOperatingLeaseLeaseNotYetCommencedLiabilityToBePaid_55cdc34a-e7f0-4e4a-b6a3-6c8b9ba9e347" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromTenantAllowance_536d5526-f422-476a-ae20-4d91f5fb0159" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForProceedsFromTenantAllowance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_66417155-b3c3-4a94-a70a-099605f68d16" xlink:to="loc_us-gaap_PaymentsForProceedsFromTenantAllowance_536d5526-f422-476a-ae20-4d91f5fb0159" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_9fb3c853-5b42-4882-bba4-3cdc5a463d95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_66417155-b3c3-4a94-a70a-099605f68d16" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_9fb3c853-5b42-4882-bba4-3cdc5a463d95" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_4de6b454-7cab-4257-8e23-2ae4877afd6b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_9fb3c853-5b42-4882-bba4-3cdc5a463d95" xlink:to="loc_srt_StatementGeographicalAxis_4de6b454-7cab-4257-8e23-2ae4877afd6b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_4de6b454-7cab-4257-8e23-2ae4877afd6b_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_4de6b454-7cab-4257-8e23-2ae4877afd6b" xlink:to="loc_srt_SegmentGeographicalDomain_4de6b454-7cab-4257-8e23-2ae4877afd6b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_4559f741-5280-4ecd-8330-6c8ab6e6e7d2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_4de6b454-7cab-4257-8e23-2ae4877afd6b" xlink:to="loc_srt_SegmentGeographicalDomain_4559f741-5280-4ecd-8330-6c8ab6e6e7d2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_auph_VictoriaBritishColumbiaMember_e70e93fb-586c-4433-97c3-45b064e04700" xlink:href="auph-20220331.xsd#auph_VictoriaBritishColumbiaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_4559f741-5280-4ecd-8330-6c8ab6e6e7d2" xlink:to="loc_auph_VictoriaBritishColumbiaMember_e70e93fb-586c-4433-97c3-45b064e04700" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_auph_RockvilleMarylandMember_fdb8b375-e69b-4dd8-a816-cfe3909a5fc4" xlink:href="auph-20220331.xsd#auph_RockvilleMarylandMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_4559f741-5280-4ecd-8330-6c8ab6e6e7d2" xlink:to="loc_auph_RockvilleMarylandMember_fdb8b375-e69b-4dd8-a816-cfe3909a5fc4" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.auriniapharma.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" xlink:type="simple" xlink:href="auph-20220331.xsd#FairValueMeasurementsAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://www.auriniapharma.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" xlink:type="extended" id="ieaf79079eac849fa8a0d9fd5ba200ce4_FairValueMeasurementsAssetsandLiabilitiesMeasuredonaRecurringBasisDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_79d12700-b08d-4bbe-9ae3-20eddfe0252c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_585eb930-f103-49de-b26f-950f53b4b902" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_79d12700-b08d-4bbe-9ae3-20eddfe0252c" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_585eb930-f103-49de-b26f-950f53b4b902" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_f74844ea-efb2-4e9f-a7af-e4ecf81871f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_585eb930-f103-49de-b26f-950f53b4b902" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_f74844ea-efb2-4e9f-a7af-e4ecf81871f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_2544b1df-2520-4888-8582-c9223dcf7c2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_585eb930-f103-49de-b26f-950f53b4b902" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_2544b1df-2520-4888-8582-c9223dcf7c2d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_f8526464-1a83-4de7-958a-26291442f2ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_585eb930-f103-49de-b26f-950f53b4b902" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_f8526464-1a83-4de7-958a-26291442f2ee" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_10daaa2e-e2b9-4ae0-acce-203dcbd6316c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_79d12700-b08d-4bbe-9ae3-20eddfe0252c" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_10daaa2e-e2b9-4ae0-acce-203dcbd6316c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_307b774d-05da-462a-b210-250625755cf6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_10daaa2e-e2b9-4ae0-acce-203dcbd6316c" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_307b774d-05da-462a-b210-250625755cf6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_307b774d-05da-462a-b210-250625755cf6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_307b774d-05da-462a-b210-250625755cf6" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_307b774d-05da-462a-b210-250625755cf6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f8302e24-ba62-45a9-b04d-d35fa93a6709" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_307b774d-05da-462a-b210-250625755cf6" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f8302e24-ba62-45a9-b04d-d35fa93a6709" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_18a085fd-0179-4cbc-b92c-cb86c45ed312" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f8302e24-ba62-45a9-b04d-d35fa93a6709" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_18a085fd-0179-4cbc-b92c-cb86c45ed312" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_f2537789-14e4-4acb-9a37-604085aa6a22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f8302e24-ba62-45a9-b04d-d35fa93a6709" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_f2537789-14e4-4acb-9a37-604085aa6a22" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_9a93a1d3-3a83-4aaa-9b23-d276c152ee81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f8302e24-ba62-45a9-b04d-d35fa93a6709" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_9a93a1d3-3a83-4aaa-9b23-d276c152ee81" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_5e211338-e99b-4d6e-89f1-e9d27a150e05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_10daaa2e-e2b9-4ae0-acce-203dcbd6316c" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_5e211338-e99b-4d6e-89f1-e9d27a150e05" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_5e211338-e99b-4d6e-89f1-e9d27a150e05_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_5e211338-e99b-4d6e-89f1-e9d27a150e05" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_5e211338-e99b-4d6e-89f1-e9d27a150e05_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_ed632c0d-0bd3-4370-88e9-1827f9162f52" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_5e211338-e99b-4d6e-89f1-e9d27a150e05" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_ed632c0d-0bd3-4370-88e9-1827f9162f52" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DemandDepositsMember_690daa18-33d3-4596-acf1-51037667921b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DemandDepositsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_ed632c0d-0bd3-4370-88e9-1827f9162f52" xlink:to="loc_us-gaap_DemandDepositsMember_690daa18-33d3-4596-acf1-51037667921b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_43c383c6-ed58-481d-ae3e-87c7573e891d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_ed632c0d-0bd3-4370-88e9-1827f9162f52" xlink:to="loc_us-gaap_MoneyMarketFundsMember_43c383c6-ed58-481d-ae3e-87c7573e891d" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.auriniapharma.com/role/LicenseandCollaborationAgreementDetails" xlink:type="simple" xlink:href="auph-20220331.xsd#LicenseandCollaborationAgreementDetails"/>
  <link:definitionLink xlink:role="http://www.auriniapharma.com/role/LicenseandCollaborationAgreementDetails" xlink:type="extended" id="i35af4de1247b46fd879d3ba0f5a3d550_LicenseandCollaborationAgreementDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_2a015a32-b392-4d50-ae17-c0c102946797" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets_84505fae-1e89-4bca-912f-aa3494a38e03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_2a015a32-b392-4d50-ae17-c0c102946797" xlink:to="loc_us-gaap_PaymentsToAcquireProductiveAssets_84505fae-1e89-4bca-912f-aa3494a38e03" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_4510425a-0d84-4e03-b4da-1e174c92b072" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_2a015a32-b392-4d50-ae17-c0c102946797" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_4510425a-0d84-4e03-b4da-1e174c92b072" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_6770873f-8b3f-47e7-8ba9-b5ec827dd4c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_2a015a32-b392-4d50-ae17-c0c102946797" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_6770873f-8b3f-47e7-8ba9-b5ec827dd4c9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_auph_ResearchAndDevelopmentArrangementContractToPerformForOthersPerformanceObligationPotentialRevenueAmount_4b9aabb0-742d-447b-ab9a-129b8bfe4c74" xlink:href="auph-20220331.xsd#auph_ResearchAndDevelopmentArrangementContractToPerformForOthersPerformanceObligationPotentialRevenueAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_2a015a32-b392-4d50-ae17-c0c102946797" xlink:to="loc_auph_ResearchAndDevelopmentArrangementContractToPerformForOthersPerformanceObligationPotentialRevenueAmount_4b9aabb0-742d-447b-ab9a-129b8bfe4c74" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_auph_ResearchAndDevelopmentArrangementContractToPerformForOthersTieredRoyaltyPercent_0e44f509-9637-431f-8109-a072ddbc8077" xlink:href="auph-20220331.xsd#auph_ResearchAndDevelopmentArrangementContractToPerformForOthersTieredRoyaltyPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_2a015a32-b392-4d50-ae17-c0c102946797" xlink:to="loc_auph_ResearchAndDevelopmentArrangementContractToPerformForOthersTieredRoyaltyPercent_0e44f509-9637-431f-8109-a072ddbc8077" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_70c3711b-1e51-4fb3-bb94-7fae9e83caa0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_2a015a32-b392-4d50-ae17-c0c102946797" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_70c3711b-1e51-4fb3-bb94-7fae9e83caa0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_d5a87416-b874-45e1-a768-bb2cf420dcd4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_2a015a32-b392-4d50-ae17-c0c102946797" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_d5a87416-b874-45e1-a768-bb2cf420dcd4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_d99bc36f-7cc0-4d2b-8591-3a623b795131" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_d5a87416-b874-45e1-a768-bb2cf420dcd4" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_d99bc36f-7cc0-4d2b-8591-3a623b795131" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_d99bc36f-7cc0-4d2b-8591-3a623b795131_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_d99bc36f-7cc0-4d2b-8591-3a623b795131" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_d99bc36f-7cc0-4d2b-8591-3a623b795131_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_32869e34-2a10-4e06-bf61-9e4b2ed367c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_d99bc36f-7cc0-4d2b-8591-3a623b795131" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_32869e34-2a10-4e06-bf61-9e4b2ed367c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseAgreementTermsMember_3aa790bb-8b69-4d86-8ec1-2af9c75a9624" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseAgreementTermsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_32869e34-2a10-4e06-bf61-9e4b2ed367c6" xlink:to="loc_us-gaap_LicenseAgreementTermsMember_3aa790bb-8b69-4d86-8ec1-2af9c75a9624" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_c390af95-552b-4629-b6aa-bf99ba36ed91" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_d5a87416-b874-45e1-a768-bb2cf420dcd4" xlink:to="loc_srt_CounterpartyNameAxis_c390af95-552b-4629-b6aa-bf99ba36ed91" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c390af95-552b-4629-b6aa-bf99ba36ed91_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_c390af95-552b-4629-b6aa-bf99ba36ed91" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c390af95-552b-4629-b6aa-bf99ba36ed91_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b52ca46f-02ac-45b8-9d46-d3de21544122" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_c390af95-552b-4629-b6aa-bf99ba36ed91" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b52ca46f-02ac-45b8-9d46-d3de21544122" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_auph_OtuskaPharmaceuticalCoLtdMember_ec425b42-2236-4a5a-99b3-f2b9e66df9d0" xlink:href="auph-20220331.xsd#auph_OtuskaPharmaceuticalCoLtdMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b52ca46f-02ac-45b8-9d46-d3de21544122" xlink:to="loc_auph_OtuskaPharmaceuticalCoLtdMember_ec425b42-2236-4a5a-99b3-f2b9e66df9d0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_auph_RiptideBioscienceIncMember_65b6b640-3224-414e-b627-20a51152813a" xlink:href="auph-20220331.xsd#auph_RiptideBioscienceIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b52ca46f-02ac-45b8-9d46-d3de21544122" xlink:to="loc_auph_RiptideBioscienceIncMember_65b6b640-3224-414e-b627-20a51152813a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_3e315c7f-ef00-41e2-af74-dcb4e731c1ac" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_d5a87416-b874-45e1-a768-bb2cf420dcd4" xlink:to="loc_srt_RangeAxis_3e315c7f-ef00-41e2-af74-dcb4e731c1ac" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_3e315c7f-ef00-41e2-af74-dcb4e731c1ac_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_3e315c7f-ef00-41e2-af74-dcb4e731c1ac" xlink:to="loc_srt_RangeMember_3e315c7f-ef00-41e2-af74-dcb4e731c1ac_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_1ba18113-b457-442f-a14d-2668a000ecf2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_3e315c7f-ef00-41e2-af74-dcb4e731c1ac" xlink:to="loc_srt_RangeMember_1ba18113-b457-442f-a14d-2668a000ecf2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_eb093709-1b27-4442-af7c-2883e29edefc" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1ba18113-b457-442f-a14d-2668a000ecf2" xlink:to="loc_srt_MinimumMember_eb093709-1b27-4442-af7c-2883e29edefc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_4d71087c-abe5-439e-bd1f-5ab5c6fe1509" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1ba18113-b457-442f-a14d-2668a000ecf2" xlink:to="loc_srt_MaximumMember_4d71087c-abe5-439e-bd1f-5ab5c6fe1509" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.auriniapharma.com/role/NetLossperCommonShareAntiDilutiveSecuritiesDetails" xlink:type="simple" xlink:href="auph-20220331.xsd#NetLossperCommonShareAntiDilutiveSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://www.auriniapharma.com/role/NetLossperCommonShareAntiDilutiveSecuritiesDetails" xlink:type="extended" id="i7aa6d1453f6c47c99aea36185a719ebb_NetLossperCommonShareAntiDilutiveSecuritiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_81d266a8-e1a8-4c0e-8864-21a433385759" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_4f0f7798-1737-4dd0-81fe-9173ccb298ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_81d266a8-e1a8-4c0e-8864-21a433385759" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_4f0f7798-1737-4dd0-81fe-9173ccb298ee" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_86e13817-6b79-46a7-86ca-9affdc1f7044" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_81d266a8-e1a8-4c0e-8864-21a433385759" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_86e13817-6b79-46a7-86ca-9affdc1f7044" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_22dcd0ed-d035-4a3a-9f6c-b86e845dbedb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_86e13817-6b79-46a7-86ca-9affdc1f7044" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_22dcd0ed-d035-4a3a-9f6c-b86e845dbedb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_22dcd0ed-d035-4a3a-9f6c-b86e845dbedb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_22dcd0ed-d035-4a3a-9f6c-b86e845dbedb" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_22dcd0ed-d035-4a3a-9f6c-b86e845dbedb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_9d8cc07d-be6f-458c-967f-98210917ce22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_22dcd0ed-d035-4a3a-9f6c-b86e845dbedb" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_9d8cc07d-be6f-458c-967f-98210917ce22" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_9cb03ee3-0e01-4bea-81ab-87defff0673e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_9d8cc07d-be6f-458c-967f-98210917ce22" xlink:to="loc_us-gaap_EmployeeStockOptionMember_9cb03ee3-0e01-4bea-81ab-87defff0673e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_d620fe00-a629-4f78-8683-28bfbfe9476c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_9d8cc07d-be6f-458c-967f-98210917ce22" xlink:to="loc_us-gaap_PerformanceSharesMember_d620fe00-a629-4f78-8683-28bfbfe9476c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_e87add96-dd13-4876-980f-0bd78b4d16ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_9d8cc07d-be6f-458c-967f-98210917ce22" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_e87add96-dd13-4876-980f-0bd78b4d16ac" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_cacb5027-a964-4ecf-869f-13d5976f64a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_9d8cc07d-be6f-458c-967f-98210917ce22" xlink:to="loc_us-gaap_WarrantMember_cacb5027-a964-4ecf-869f-13d5976f64a1" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.auriniapharma.com/role/SharebasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="auph-20220331.xsd#SharebasedCompensationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.auriniapharma.com/role/SharebasedCompensationNarrativeDetails" xlink:type="extended" id="i19f50e0417dc430086dbc66b899b29a6_SharebasedCompensationNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_73b37fd4-6c78-4238-9e18-14a952507971" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_9245b7e3-879e-4409-803d-9346d949194d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_73b37fd4-6c78-4238-9e18-14a952507971" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_9245b7e3-879e-4409-803d-9346d949194d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_0a9002fe-3363-4680-b919-1aa9e22f91e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_73b37fd4-6c78-4238-9e18-14a952507971" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_0a9002fe-3363-4680-b919-1aa9e22f91e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_568bc2e4-d4d9-459c-9365-89aedd3a879f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_73b37fd4-6c78-4238-9e18-14a952507971" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_568bc2e4-d4d9-459c-9365-89aedd3a879f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_83b3e036-e205-487f-957c-bab50c45bbcf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_73b37fd4-6c78-4238-9e18-14a952507971" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_83b3e036-e205-487f-957c-bab50c45bbcf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_c9b1f5b7-c947-436c-ba0b-33a987e3ab0f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_73b37fd4-6c78-4238-9e18-14a952507971" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_c9b1f5b7-c947-436c-ba0b-33a987e3ab0f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_b5ff2644-6d07-4d44-bc5a-4cfcd4c14366" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_73b37fd4-6c78-4238-9e18-14a952507971" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_b5ff2644-6d07-4d44-bc5a-4cfcd4c14366" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_8dbd6331-fa8c-442b-a8b9-71015a4f8a8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_73b37fd4-6c78-4238-9e18-14a952507971" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_8dbd6331-fa8c-442b-a8b9-71015a4f8a8b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_d2692cfb-9bac-42ef-a394-12be67be6e43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_73b37fd4-6c78-4238-9e18-14a952507971" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_d2692cfb-9bac-42ef-a394-12be67be6e43" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_760ff13e-b05d-4a80-861c-99d0c841a88d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_73b37fd4-6c78-4238-9e18-14a952507971" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_760ff13e-b05d-4a80-861c-99d0c841a88d" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_8e6d3e21-609c-4b3e-916e-7db3d253e3b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_73b37fd4-6c78-4238-9e18-14a952507971" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_8e6d3e21-609c-4b3e-916e-7db3d253e3b5" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a0d42b69-50d0-4b5a-9416-b8f93ca678ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_73b37fd4-6c78-4238-9e18-14a952507971" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a0d42b69-50d0-4b5a-9416-b8f93ca678ee" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_ac593ad8-2ff8-406a-bd89-a4c4b8b49f23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a0d42b69-50d0-4b5a-9416-b8f93ca678ee" xlink:to="loc_us-gaap_AwardTypeAxis_ac593ad8-2ff8-406a-bd89-a4c4b8b49f23" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ac593ad8-2ff8-406a-bd89-a4c4b8b49f23_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_ac593ad8-2ff8-406a-bd89-a4c4b8b49f23" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ac593ad8-2ff8-406a-bd89-a4c4b8b49f23_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_76654134-d2d7-452c-a1ee-12516e6d4660" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_ac593ad8-2ff8-406a-bd89-a4c4b8b49f23" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_76654134-d2d7-452c-a1ee-12516e6d4660" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_2891f358-3cae-4a77-a3e5-88c131255ca9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_76654134-d2d7-452c-a1ee-12516e6d4660" xlink:to="loc_us-gaap_PerformanceSharesMember_2891f358-3cae-4a77-a3e5-88c131255ca9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_00fa4d97-fa98-46f1-8438-e0b247650aa3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_76654134-d2d7-452c-a1ee-12516e6d4660" xlink:to="loc_us-gaap_EmployeeStockMember_00fa4d97-fa98-46f1-8438-e0b247650aa3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_auph_PerformanceShareSandRestrictedStockUnitsRSUsMember_832d389d-4bac-4887-af5f-318f37284c04" xlink:href="auph-20220331.xsd#auph_PerformanceShareSandRestrictedStockUnitsRSUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_76654134-d2d7-452c-a1ee-12516e6d4660" xlink:to="loc_auph_PerformanceShareSandRestrictedStockUnitsRSUsMember_832d389d-4bac-4887-af5f-318f37284c04" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_2c59999c-e722-4e1c-bea9-3f74ddf9ee2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_76654134-d2d7-452c-a1ee-12516e6d4660" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_2c59999c-e722-4e1c-bea9-3f74ddf9ee2d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_c3272c59-cb48-4965-8d87-9fd8ca93bce8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a0d42b69-50d0-4b5a-9416-b8f93ca678ee" xlink:to="loc_srt_TitleOfIndividualAxis_c3272c59-cb48-4965-8d87-9fd8ca93bce8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_c3272c59-cb48-4965-8d87-9fd8ca93bce8_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_c3272c59-cb48-4965-8d87-9fd8ca93bce8" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_c3272c59-cb48-4965-8d87-9fd8ca93bce8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_d5d49d1e-f620-4335-a0f4-f9dc4fbdad11" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_c3272c59-cb48-4965-8d87-9fd8ca93bce8" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_d5d49d1e-f620-4335-a0f4-f9dc4fbdad11" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OfficerMember_761cb252-7251-4e2d-81ab-6214ae234439" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OfficerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_d5d49d1e-f620-4335-a0f4-f9dc4fbdad11" xlink:to="loc_srt_OfficerMember_761cb252-7251-4e2d-81ab-6214ae234439" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_0f958d1b-92de-4d3b-b824-cf391cd2fa08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a0d42b69-50d0-4b5a-9416-b8f93ca678ee" xlink:to="loc_us-gaap_PlanNameAxis_0f958d1b-92de-4d3b-b824-cf391cd2fa08" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_0f958d1b-92de-4d3b-b824-cf391cd2fa08_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_0f958d1b-92de-4d3b-b824-cf391cd2fa08" xlink:to="loc_us-gaap_PlanNameDomain_0f958d1b-92de-4d3b-b824-cf391cd2fa08_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_b2e727ef-1008-4d98-be7b-c820a4d1ae54" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_0f958d1b-92de-4d3b-b824-cf391cd2fa08" xlink:to="loc_us-gaap_PlanNameDomain_b2e727ef-1008-4d98-be7b-c820a4d1ae54" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_auph_AmendedAndRestatedEquityIncentivePlanMember_adde1a23-0b87-4c0d-8f36-25899972916b" xlink:href="auph-20220331.xsd#auph_AmendedAndRestatedEquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_b2e727ef-1008-4d98-be7b-c820a4d1ae54" xlink:to="loc_auph_AmendedAndRestatedEquityIncentivePlanMember_adde1a23-0b87-4c0d-8f36-25899972916b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.auriniapharma.com/role/ShareBasedCompensationPerformanceAwardsandRestrictedStockUnitsActivityDetails" xlink:type="simple" xlink:href="auph-20220331.xsd#ShareBasedCompensationPerformanceAwardsandRestrictedStockUnitsActivityDetails"/>
  <link:definitionLink xlink:role="http://www.auriniapharma.com/role/ShareBasedCompensationPerformanceAwardsandRestrictedStockUnitsActivityDetails" xlink:type="extended" id="i9f6c72ec45264c519d3206ea81e43b64_ShareBasedCompensationPerformanceAwardsandRestrictedStockUnitsActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_763f838a-ce64-4d4e-b920-3fdecd175427" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_2dcfee1e-3db4-42b4-8cf5-ca63035e30e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_763f838a-ce64-4d4e-b920-3fdecd175427" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_2dcfee1e-3db4-42b4-8cf5-ca63035e30e7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_18854ead-9ceb-4375-8d4c-d6a62d0823a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_2dcfee1e-3db4-42b4-8cf5-ca63035e30e7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_18854ead-9ceb-4375-8d4c-d6a62d0823a2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_73938566-9a6d-447c-b434-69435020549e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_2dcfee1e-3db4-42b4-8cf5-ca63035e30e7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_73938566-9a6d-447c-b434-69435020549e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_f616e09b-bdce-4180-8305-7bc7b6c3b933" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_2dcfee1e-3db4-42b4-8cf5-ca63035e30e7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_f616e09b-bdce-4180-8305-7bc7b6c3b933" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_de8f1e51-9427-4558-8e2e-9e32f161860f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_2dcfee1e-3db4-42b4-8cf5-ca63035e30e7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_de8f1e51-9427-4558-8e2e-9e32f161860f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_d15cb675-15ee-409a-baaf-9217de8c8342" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e9dc50e7-6675-4e89-a58e-e1d40aee4414" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_763f838a-ce64-4d4e-b920-3fdecd175427" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e9dc50e7-6675-4e89-a58e-e1d40aee4414" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_076bfdb5-07f1-417b-900b-c5ac6d66032e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e9dc50e7-6675-4e89-a58e-e1d40aee4414" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_076bfdb5-07f1-417b-900b-c5ac6d66032e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2a22225d-497a-48ff-b3b0-6ca788a2e4e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e9dc50e7-6675-4e89-a58e-e1d40aee4414" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2a22225d-497a-48ff-b3b0-6ca788a2e4e3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_23e9e7b6-32be-4629-add4-66e74e8076cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e9dc50e7-6675-4e89-a58e-e1d40aee4414" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_23e9e7b6-32be-4629-add4-66e74e8076cc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c70f56de-f59c-4821-bb1e-faf8d53f45d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e9dc50e7-6675-4e89-a58e-e1d40aee4414" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c70f56de-f59c-4821-bb1e-faf8d53f45d5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_9cca6e0c-bdb8-41d6-8949-01167dcf60de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a4f213af-e9ce-48da-8251-400d4e7267c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_763f838a-ce64-4d4e-b920-3fdecd175427" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a4f213af-e9ce-48da-8251-400d4e7267c4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_a49bb3a6-f902-4e5d-bcd5-fd381b127eb5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a4f213af-e9ce-48da-8251-400d4e7267c4" xlink:to="loc_us-gaap_AwardTypeAxis_a49bb3a6-f902-4e5d-bcd5-fd381b127eb5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a49bb3a6-f902-4e5d-bcd5-fd381b127eb5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_a49bb3a6-f902-4e5d-bcd5-fd381b127eb5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a49bb3a6-f902-4e5d-bcd5-fd381b127eb5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1bc3e917-76c5-46e6-9529-9fecac0ad064" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_a49bb3a6-f902-4e5d-bcd5-fd381b127eb5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1bc3e917-76c5-46e6-9529-9fecac0ad064" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_auph_PerformanceShareSandRestrictedStockUnitsRSUsMember_08353e3f-f847-426c-b4c5-4399095c38d9" xlink:href="auph-20220331.xsd#auph_PerformanceShareSandRestrictedStockUnitsRSUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1bc3e917-76c5-46e6-9529-9fecac0ad064" xlink:to="loc_auph_PerformanceShareSandRestrictedStockUnitsRSUsMember_08353e3f-f847-426c-b4c5-4399095c38d9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_b974942a-deca-4282-aaf6-cdb8c1f94ef8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a4f213af-e9ce-48da-8251-400d4e7267c4" xlink:to="loc_srt_TitleOfIndividualAxis_b974942a-deca-4282-aaf6-cdb8c1f94ef8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_b974942a-deca-4282-aaf6-cdb8c1f94ef8_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_b974942a-deca-4282-aaf6-cdb8c1f94ef8" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_b974942a-deca-4282-aaf6-cdb8c1f94ef8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_a123bf5e-3be8-4f12-a222-6923a2d16838" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_b974942a-deca-4282-aaf6-cdb8c1f94ef8" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_a123bf5e-3be8-4f12-a222-6923a2d16838" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OfficerMember_9852309b-4dd8-46fe-b178-ebd28b52105f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OfficerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_a123bf5e-3be8-4f12-a222-6923a2d16838" xlink:to="loc_srt_OfficerMember_9852309b-4dd8-46fe-b178-ebd28b52105f" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.auriniapharma.com/role/ShareBasedCompensationAllocatedShareBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="auph-20220331.xsd#ShareBasedCompensationAllocatedShareBasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.auriniapharma.com/role/ShareBasedCompensationAllocatedShareBasedCompensationExpenseDetails" xlink:type="extended" id="i93f2607f52cb4b429d61df7dc413b191_ShareBasedCompensationAllocatedShareBasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_114491dc-f6bf-4e24-a466-674741e1dabd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_5efb3ec0-2736-4ee6-95df-b1a1fc076767" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_114491dc-f6bf-4e24-a466-674741e1dabd" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_5efb3ec0-2736-4ee6-95df-b1a1fc076767" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_02621d7d-0365-47e4-8ba2-9ac1913e2fa2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_114491dc-f6bf-4e24-a466-674741e1dabd" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_02621d7d-0365-47e4-8ba2-9ac1913e2fa2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_8548542c-b0dd-4d2f-812a-0e0ccefe615a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_02621d7d-0365-47e4-8ba2-9ac1913e2fa2" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_8548542c-b0dd-4d2f-812a-0e0ccefe615a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_8548542c-b0dd-4d2f-812a-0e0ccefe615a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_8548542c-b0dd-4d2f-812a-0e0ccefe615a" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_8548542c-b0dd-4d2f-812a-0e0ccefe615a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_695581a8-5a1a-4beb-aafc-6336ccddaae5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_8548542c-b0dd-4d2f-812a-0e0ccefe615a" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_695581a8-5a1a-4beb-aafc-6336ccddaae5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_fcb2f372-a407-4b69-8e50-9d64e99f8cfa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_695581a8-5a1a-4beb-aafc-6336ccddaae5" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_fcb2f372-a407-4b69-8e50-9d64e99f8cfa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_0b7a3a30-01e9-4774-8c13-3d3b8f13a00f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_695581a8-5a1a-4beb-aafc-6336ccddaae5" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_0b7a3a30-01e9-4774-8c13-3d3b8f13a00f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoriesMember_1ddbc1c0-f784-4b9d-9c4c-efbf00c673cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoriesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_695581a8-5a1a-4beb-aafc-6336ccddaae5" xlink:to="loc_us-gaap_InventoriesMember_1ddbc1c0-f784-4b9d-9c4c-efbf00c673cf" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.auriniapharma.com/role/RelatedPartyTransactionsDetails" xlink:type="simple" xlink:href="auph-20220331.xsd#RelatedPartyTransactionsDetails"/>
  <link:definitionLink xlink:role="http://www.auriniapharma.com/role/RelatedPartyTransactionsDetails" xlink:type="extended" id="i633ec634e8fc4779b5ed32af3ce75cb2_RelatedPartyTransactionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_9758139d-1367-4758-9f7b-f679685370a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_77151655-8d98-4a7a-9c27-519e36f3f252" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_9758139d-1367-4758-9f7b-f679685370a8" xlink:to="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_77151655-8d98-4a7a-9c27-519e36f3f252" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_a326ccaa-e9ab-4c9b-893f-dbb3ff17dd07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_9758139d-1367-4758-9f7b-f679685370a8" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_a326ccaa-e9ab-4c9b-893f-dbb3ff17dd07" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_3bffa521-82fc-4098-90c6-4a38908b21e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_9758139d-1367-4758-9f7b-f679685370a8" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_3bffa521-82fc-4098-90c6-4a38908b21e8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_9c1bcd0b-20ec-4dba-bbc7-d24643fa7782" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_3bffa521-82fc-4098-90c6-4a38908b21e8" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_9c1bcd0b-20ec-4dba-bbc7-d24643fa7782" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_9c1bcd0b-20ec-4dba-bbc7-d24643fa7782_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_9c1bcd0b-20ec-4dba-bbc7-d24643fa7782" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_9c1bcd0b-20ec-4dba-bbc7-d24643fa7782_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_e87e6523-7451-4281-89ca-73a0396b9997" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_9c1bcd0b-20ec-4dba-bbc7-d24643fa7782" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_e87e6523-7451-4281-89ca-73a0396b9997" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_auph_MilestonePaymentMember_3bf98e2f-7db2-415c-b7ec-37f71fabdc8b" xlink:href="auph-20220331.xsd#auph_MilestonePaymentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_e87e6523-7451-4281-89ca-73a0396b9997" xlink:to="loc_auph_MilestonePaymentMember_3bf98e2f-7db2-415c-b7ec-37f71fabdc8b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_7db4dd8b-e7ab-421d-8fad-a6eba83c2c38" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_3bffa521-82fc-4098-90c6-4a38908b21e8" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_7db4dd8b-e7ab-421d-8fad-a6eba83c2c38" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_7db4dd8b-e7ab-421d-8fad-a6eba83c2c38_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_7db4dd8b-e7ab-421d-8fad-a6eba83c2c38" xlink:to="loc_us-gaap_RelatedPartyDomain_7db4dd8b-e7ab-421d-8fad-a6eba83c2c38_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_4c92ce95-3ce1-4bd7-be50-6e5429f59006" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_7db4dd8b-e7ab-421d-8fad-a6eba83c2c38" xlink:to="loc_us-gaap_RelatedPartyDomain_4c92ce95-3ce1-4bd7-be50-6e5429f59006" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember_edbb3ab3-8aba-460d-90ce-bd443da94595" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_AffiliatedEntityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_4c92ce95-3ce1-4bd7-be50-6e5429f59006" xlink:to="loc_srt_AffiliatedEntityMember_edbb3ab3-8aba-460d-90ce-bd443da94595" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_b631caae-c520-4a72-8b22-3f3e2bbec892" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_3bffa521-82fc-4098-90c6-4a38908b21e8" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_b631caae-c520-4a72-8b22-3f3e2bbec892" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_b631caae-c520-4a72-8b22-3f3e2bbec892_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_b631caae-c520-4a72-8b22-3f3e2bbec892" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_b631caae-c520-4a72-8b22-3f3e2bbec892_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_ab0a223f-191e-4cdb-9d5d-41e762c14346" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_b631caae-c520-4a72-8b22-3f3e2bbec892" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_ab0a223f-191e-4cdb-9d5d-41e762c14346" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_60b6da3a-b524-4725-a367-6449d25e6c1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_ab0a223f-191e-4cdb-9d5d-41e762c14346" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_60b6da3a-b524-4725-a367-6449d25e6c1c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_549720d2-fd9c-40ee-8ac1-eec1c004a290" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_3bffa521-82fc-4098-90c6-4a38908b21e8" xlink:to="loc_srt_CounterpartyNameAxis_549720d2-fd9c-40ee-8ac1-eec1c004a290" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_549720d2-fd9c-40ee-8ac1-eec1c004a290_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_549720d2-fd9c-40ee-8ac1-eec1c004a290" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_549720d2-fd9c-40ee-8ac1-eec1c004a290_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_fa37543c-4ac1-44de-a3cc-3deb09f3557b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_549720d2-fd9c-40ee-8ac1-eec1c004a290" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_fa37543c-4ac1-44de-a3cc-3deb09f3557b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_auph_ILJINMember_8f62635a-75e5-42cb-ae4e-190089f15eaf" xlink:href="auph-20220331.xsd#auph_ILJINMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_fa37543c-4ac1-44de-a3cc-3deb09f3557b" xlink:to="loc_auph_ILJINMember_8f62635a-75e5-42cb-ae4e-190089f15eaf" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>auph-20220331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:778f08dd-b92a-42f0-b4bb-a50ecfb6a537,g:a60fc6d8-f25a-4b7b-af6a-b9dcc6be1df4-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_ProceedsFromWarrantExercises_a1d65020-1df4-4872-aea1-9eb04d3328b5_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from exercise of warrants</link:label>
    <link:label id="lab_us-gaap_ProceedsFromWarrantExercises_label_en-US" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Warrant Exercises</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromWarrantExercises" xlink:to="lab_us-gaap_ProceedsFromWarrantExercises" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_a41d958b-7db7-47b9-a507-3ea0e7ec0679_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental cash flow information:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_dcdb45ab-ccb3-4fad-9be7-f0d10b4b6c39_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_auph_OperatingLeaseAssetsAndLiabilitiesAssetsLesseeAbstract_451b5106-f666-4d8e-a382-db70cc35ffe4_terseLabel_en-US" xlink:label="lab_auph_OperatingLeaseAssetsAndLiabilitiesAssetsLesseeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_auph_OperatingLeaseAssetsAndLiabilitiesAssetsLesseeAbstract_label_en-US" xlink:label="lab_auph_OperatingLeaseAssetsAndLiabilitiesAssetsLesseeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Assets And Liabilities, Assets, Lessee [Abstract]</link:label>
    <link:label id="lab_auph_OperatingLeaseAssetsAndLiabilitiesAssetsLesseeAbstract_documentation_en-US" xlink:label="lab_auph_OperatingLeaseAssetsAndLiabilitiesAssetsLesseeAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Assets And Liabilities, Assets, Lessee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_auph_OperatingLeaseAssetsAndLiabilitiesAssetsLesseeAbstract" xlink:href="auph-20220331.xsd#auph_OperatingLeaseAssetsAndLiabilitiesAssetsLesseeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_auph_OperatingLeaseAssetsAndLiabilitiesAssetsLesseeAbstract" xlink:to="lab_auph_OperatingLeaseAssetsAndLiabilitiesAssetsLesseeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_a4d8d804-e498-4bc1-9100-b18fa9cd4f7c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance shares vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_1d342f9a-afe0-4a3b-bf38-12172ccec10b_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance shares vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0e459eca-9761-4a1e-ba40-b578560e6d7d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_a06935f0-b904-4fcf-b8ab-3c546d68862e_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_084c1567-20ae-411b-b6f5-60601cc21145_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_08b36400-9dac-4bc6-b52b-e0c576323dc6_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_440d4d05-85dc-4ca1-a3be-b8061b7ce6b3_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_c3bc6672-c34d-4f05-9cb9-e9f1fcd4c947_terseLabel_en-US" xlink:label="lab_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of warrants</link:label>
    <link:label id="lab_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_label_en-US" xlink:label="lab_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock and Warrants Issued During Period, Value, Preferred Stock and Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:to="lab_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_77b18bb1-2e44-401e-bbc5-fbf749aa7369_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee accruals</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_dc32af6b-2544-435f-b725-1e5e3fe0a2c1_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_auph_ResearchAndDevelopmentArrangementContractToPerformForOthersTieredRoyaltyPercent_8c7949d5-eb70-4b3c-b379-5fd6970d5223_terseLabel_en-US" xlink:label="lab_auph_ResearchAndDevelopmentArrangementContractToPerformForOthersTieredRoyaltyPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tiered royalty percentages on future sales</link:label>
    <link:label id="lab_auph_ResearchAndDevelopmentArrangementContractToPerformForOthersTieredRoyaltyPercent_label_en-US" xlink:label="lab_auph_ResearchAndDevelopmentArrangementContractToPerformForOthersTieredRoyaltyPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Arrangement, Contract To Perform For Others, Tiered Royalty, Percent</link:label>
    <link:label id="lab_auph_ResearchAndDevelopmentArrangementContractToPerformForOthersTieredRoyaltyPercent_documentation_en-US" xlink:label="lab_auph_ResearchAndDevelopmentArrangementContractToPerformForOthersTieredRoyaltyPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Arrangement, Contract To Perform For Others, Tiered Royalty, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_auph_ResearchAndDevelopmentArrangementContractToPerformForOthersTieredRoyaltyPercent" xlink:href="auph-20220331.xsd#auph_ResearchAndDevelopmentArrangementContractToPerformForOthersTieredRoyaltyPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_auph_ResearchAndDevelopmentArrangementContractToPerformForOthersTieredRoyaltyPercent" xlink:to="lab_auph_ResearchAndDevelopmentArrangementContractToPerformForOthersTieredRoyaltyPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_1f80193f-6e52-487b-86ff-ab325c16f693_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_1c653a8a-c969-4445-ad8b-48102f1fb951_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_2ff603c8-0c62-4614-b704-a25758f9d922_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_78a5a863-2f4b-48f3-9c7c-22c17dc95e61_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_358986b0-9e5b-40f8-babd-ed72f18e5983_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance share forfeited, Weighted average exercise price (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_365ea6ca-df53-48b8-8a70-3c0618bf68f8_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_d9729904-8b83-4bcb-be37-3dcb562dd58c_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining lease term - operating leases (in years)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_ad2ed5d7-9674-4979-9384-7c5bee22e19d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c47f5158-720a-4e6b-a8a5-d221d9d25631_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_d21c7311-536a-4e76-95f3-1191712b0003_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net decrease in cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoriesMember_f1ede14f-071c-40e8-b6ef-09458a916ef4_terseLabel_en-US" xlink:label="lab_us-gaap_InventoriesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized under inventories</link:label>
    <link:label id="lab_us-gaap_InventoriesMember_label_en-US" xlink:label="lab_us-gaap_InventoriesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoriesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoriesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoriesMember" xlink:to="lab_us-gaap_InventoriesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_681cd9fa-18cf-4ab6-941c-7587457f37f7_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_c5f6d8a9-bee9-4042-9771-81e504472cfb_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shared-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_d1859183-2251-4b5f-9563-fbec846efd2b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_auph_CommercialRelatedAccrualsCurrent_e40b8056-cc02-4442-9460-5d65f6f77fe4_terseLabel_en-US" xlink:label="lab_auph_CommercialRelatedAccrualsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial accruals</link:label>
    <link:label id="lab_auph_CommercialRelatedAccrualsCurrent_label_en-US" xlink:label="lab_auph_CommercialRelatedAccrualsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Related Accruals, Current</link:label>
    <link:label id="lab_auph_CommercialRelatedAccrualsCurrent_documentation_en-US" xlink:label="lab_auph_CommercialRelatedAccrualsCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Related Accruals, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_auph_CommercialRelatedAccrualsCurrent" xlink:href="auph-20220331.xsd#auph_CommercialRelatedAccrualsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_auph_CommercialRelatedAccrualsCurrent" xlink:to="lab_auph_CommercialRelatedAccrualsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_13fdbcb5-e2a8-4499-b1c3-b3d37ca3f0f8_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_261e46c0-64c3-4ca5-a84b-5a77ea2ced63_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of intangible assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_f0a9e65e-59da-4007-8689-0a9cd01797d3_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive securities excluded from computation of earnings per share (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_cb9ada2c-57e0-4640-b334-2fd1b4e31742_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental borrowing rate</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_6673d5c0-e273-426b-8185-252a408e55e6_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average discount rate - operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_5b590ae3-36bf-49bb-8915-03026e2cb731_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_2a500d13-623f-4739-a47e-f5de1e7fffa4_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_047376de-0c38-4f03-a804-a543da83390b_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_dccaa9ff-889c-42fc-aa47-116bb6e864c9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted, Weighted average exercise price (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_f5f32fce-372c-4960-83f2-54d0a4babbc1_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance shares awards, Weighted average grant date fair value (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock_b6634676-9671-4d55-b9a8-1a54535b34d7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Performance Shares Activity</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Performance Shares, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock" xlink:to="lab_us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_7d9a5612-bb5a-4f6d-822a-0a872a38eefa_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_label_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax_f61add65-4f8b-424f-97b9-dace929c4710_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain on available-for-sale securities, tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_55abbcb0-4788-4dcb-a599-4b5f77b3ed0c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_02f19029-8fa8-469f-b2f5-05f769312d37_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_ec50f56a-62f8-46f9-ada7-f90eecedd1fe_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_96085791-3164-425e-badf-7777612c003d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_ba82cb94-f304-4b42-bd71-5c0c43beb2df_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_9a812382-650e-4ec6-be6f-3e8fc356c66b_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_657c914f-84e9-4418-89de-f8ca6c4f8aa9_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3c8f1121-c29d-45f5-aef7-858fb17100c7_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_8aa2728d-391d-43b0-99a8-3060bdad375c_verboseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AreaOfRealEstateProperty_d7cd2385-c1f5-4f2f-9737-17dd335deb7e_terseLabel_en-US" xlink:label="lab_us-gaap_AreaOfRealEstateProperty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Area of property (in sqft)</link:label>
    <link:label id="lab_us-gaap_AreaOfRealEstateProperty_label_en-US" xlink:label="lab_us-gaap_AreaOfRealEstateProperty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Area of Real Estate Property</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfRealEstateProperty" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AreaOfRealEstateProperty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AreaOfRealEstateProperty" xlink:to="lab_us-gaap_AreaOfRealEstateProperty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_d6edcbf9-07a1-497c-90b2-6daad1c5301f_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Noncurrent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_06f79967-a03c-4d46-994e-fe9c6526b9e3_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_ec887f87-5929-403b-9566-ded05e55b65f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_0d6bb9e5-d365-4f30-acf3-83e6f4ba40f3_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront payments received</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Compensation Earned</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_bba54ef8-09cc-4b74-962e-2435e42441ef_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_48439abd-40cc-4a49-8e22-01730e647c86_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial recognition of operating lease right-of-use asset</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_d841c70a-454f-49ad-86cf-ea21c8f59dfb_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_4a53a9bc-aa9e-4231-88fa-add442f5c104_terseLabel_en-US" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due to related parties</link:label>
    <link:label id="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due to Related Parties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:to="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_9bfe9ab9-c545-49ce-9863-04ef7f29a7d5_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital expenditure payments</link:label>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_label_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Principal Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:to="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_38181ddb-255a-499d-8c9d-e5be8ad764cf_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_e886bceb-5ac0-49a8-a000-89114f2e96e4_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic loss per share (expressed in $ per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_77c51a25-dcf6-4f30-92a5-446832e0f4ef_totalLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic loss per share (expressed in $ per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_c0d4126e-b77e-4026-8260-e9c1583f3703_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_0e912242-82b5-40d3-92b5-b8c0c8105dfa_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License and Collaboration Agreement</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_fbb4c290-5a8d-42e4-b3eb-6a525e943c7e_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding - Beginning of Period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_da7ab03f-6876-402c-86bc-b3c020ae90a9_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding - End of Period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_89f12a64-29e5-40bf-ab2c-ee35711764e0_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseCurrent" xlink:to="lab_us-gaap_PrepaidExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsAndOtherReceivablesNetCurrent_7c4e02a3-93af-4270-9a26-2612bf196044_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsAndOtherReceivablesNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts and Other Receivables, Net, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:to="lab_us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_69f59703-017c-4ec8-aaaf-d65a61d0579e_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_f435fab7-ba7d-4b23-8211-042ab5a7c2ce_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares authorized</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_e12b3cb2-9dd7-418b-976c-a41991026d9c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalents_0767a3c6-e982-4814-a2a6-8ba94f52b28d_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalents_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalents" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_auph_LesseeOperatingLeaseLeaseNotYetCommencedPaymentsPriorToCommencementOfLease_09424670-cf29-4b9d-ba24-b4c73e7f2539_terseLabel_en-US" xlink:label="lab_auph_LesseeOperatingLeaseLeaseNotYetCommencedPaymentsPriorToCommencementOfLease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected payments prior to commencement of lease</link:label>
    <link:label id="lab_auph_LesseeOperatingLeaseLeaseNotYetCommencedPaymentsPriorToCommencementOfLease_label_en-US" xlink:label="lab_auph_LesseeOperatingLeaseLeaseNotYetCommencedPaymentsPriorToCommencementOfLease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Lease Not yet Commenced, Payments Prior To Commencement Of Lease</link:label>
    <link:label id="lab_auph_LesseeOperatingLeaseLeaseNotYetCommencedPaymentsPriorToCommencementOfLease_documentation_en-US" xlink:label="lab_auph_LesseeOperatingLeaseLeaseNotYetCommencedPaymentsPriorToCommencementOfLease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Lease Not yet Commenced, Payments Prior To Commencement Of Lease</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_auph_LesseeOperatingLeaseLeaseNotYetCommencedPaymentsPriorToCommencementOfLease" xlink:href="auph-20220331.xsd#auph_LesseeOperatingLeaseLeaseNotYetCommencedPaymentsPriorToCommencementOfLease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_auph_LesseeOperatingLeaseLeaseNotYetCommencedPaymentsPriorToCommencementOfLease" xlink:to="lab_auph_LesseeOperatingLeaseLeaseNotYetCommencedPaymentsPriorToCommencementOfLease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_eb46c242-010f-4cb8-bd50-5137115abe77_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_ae6f4453-73f6-4f69-b922-80b4626077c3_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets:</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_fa831d8a-8396-4152-9f1c-9418d782c223_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_12519770-3d83-4ed0-9ef0-6cf63dfa69e0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_97d3c968-f651-4502-aae1-5708fb4de135_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_1828222e-f9e2-4ada-ab95-2faddb4b161f_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_bbb140c4-7960-4e99-87c0-b895298fc760_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and shareholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_8815b063-25ca-432e-9aba-853ec494e0b7_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other accrued liabilities</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend_d8fe5fcf-b3ca-4af4-8aa5-6b8f450529a2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Expected Dividend</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForCapitalImprovements_82dedb27-4a24-4979-a602-7a07f45ba071_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForCapitalImprovements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for capital improvements</link:label>
    <link:label id="lab_us-gaap_PaymentsForCapitalImprovements_label_en-US" xlink:label="lab_us-gaap_PaymentsForCapitalImprovements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Capital Improvements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForCapitalImprovements" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForCapitalImprovements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForCapitalImprovements" xlink:to="lab_us-gaap_PaymentsForCapitalImprovements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireOtherProductiveAssets_d7fa8fe3-9f7a-4b85-a974-fe2dc78cbe7d_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireOtherProductiveAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of long-lived assets</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireOtherProductiveAssets_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireOtherProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Other Productive Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireOtherProductiveAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets" xlink:to="lab_us-gaap_PaymentsToAcquireOtherProductiveAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_2d1b7e32-b376-4e70-abff-3db5b77193fb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCash_a9388358-3d3b-473c-9bd7-b81e4abd80b4_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCash_label_en-US" xlink:label="lab_us-gaap_RestrictedCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCash" xlink:to="lab_us-gaap_RestrictedCash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_c9d1570c-ea6e-41ce-afaa-4a722322bc02_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_77a4ee85-37f6-49ba-b208-06c56041ebfb_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Shareholders' Equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_eed76b26-521b-4528-8d5d-25f5994c0833_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_b3a87ef0-f861-43c1-8f76-c5a55abe12cb_totalLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total accounts payable and accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_auph_MilestonePaymentMember_918fd952-2439-43f1-8ed4-5971927ac145_terseLabel_en-US" xlink:label="lab_auph_MilestonePaymentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payment</link:label>
    <link:label id="lab_auph_MilestonePaymentMember_label_en-US" xlink:label="lab_auph_MilestonePaymentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payment [Member]</link:label>
    <link:label id="lab_auph_MilestonePaymentMember_documentation_en-US" xlink:label="lab_auph_MilestonePaymentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_auph_MilestonePaymentMember" xlink:href="auph-20220331.xsd#auph_MilestonePaymentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_auph_MilestonePaymentMember" xlink:to="lab_auph_MilestonePaymentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_7367711d-b214-4c27-917f-66ec3bf277b9_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows used in operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_ed8b7b2f-5976-4545-be5c-4115b239bb1b_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss per Common Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_auph_OperatingLeaseAssetsAndLiabilitiesLiabilitiesCurrentLesseeAbstract_c795e384-6ad5-4e84-9090-a6e1bc287ffe_terseLabel_en-US" xlink:label="lab_auph_OperatingLeaseAssetsAndLiabilitiesLiabilitiesCurrentLesseeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current</link:label>
    <link:label id="lab_auph_OperatingLeaseAssetsAndLiabilitiesLiabilitiesCurrentLesseeAbstract_label_en-US" xlink:label="lab_auph_OperatingLeaseAssetsAndLiabilitiesLiabilitiesCurrentLesseeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Assets And Liabilities, Liabilities, Current, Lessee [Abstract]</link:label>
    <link:label id="lab_auph_OperatingLeaseAssetsAndLiabilitiesLiabilitiesCurrentLesseeAbstract_documentation_en-US" xlink:label="lab_auph_OperatingLeaseAssetsAndLiabilitiesLiabilitiesCurrentLesseeAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Assets And Liabilities, Liabilities, Current, Lessee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_auph_OperatingLeaseAssetsAndLiabilitiesLiabilitiesCurrentLesseeAbstract" xlink:href="auph-20220331.xsd#auph_OperatingLeaseAssetsAndLiabilitiesLiabilitiesCurrentLesseeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_auph_OperatingLeaseAssetsAndLiabilitiesLiabilitiesCurrentLesseeAbstract" xlink:to="lab_auph_OperatingLeaseAssetsAndLiabilitiesLiabilitiesCurrentLesseeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_287e678c-f2a5-4cd3-8e56-71637814cec0_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureNoncurrentTextBlock_5201c35b-e1a4-424e-9fb3-0db94c5b23e2_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureNoncurrentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Compensation and Other Non-current Liabilities</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureNoncurrentTextBlock_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureNoncurrentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Noncurrent [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureNoncurrentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureNoncurrentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureNoncurrentTextBlock" xlink:to="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureNoncurrentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_833c6548-ec8f-4881-9007-fb7a8fa4fb2f_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_22a01bab-d751-4535-af49-1966abf9675f_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_8962eb11-3020-4a13-afa3-b7a59ff24344_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued on exercise of stock options and vesting of performance awards</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_c8febc8c-d179-4888-bb45-e78cf13a9b7b_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_55bef7a4-f207-4e13-94aa-47bc6794a904_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization and Description of Business</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_auph_ResearchAndDevelopmentArrangementContractToPerformForOthersPerformanceObligationPotentialRevenueAmount_7965782c-ddb2-4d6e-81dd-49f86277e124_terseLabel_en-US" xlink:label="lab_auph_ResearchAndDevelopmentArrangementContractToPerformForOthersPerformanceObligationPotentialRevenueAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential regulatory milestone revenue</link:label>
    <link:label id="lab_auph_ResearchAndDevelopmentArrangementContractToPerformForOthersPerformanceObligationPotentialRevenueAmount_label_en-US" xlink:label="lab_auph_ResearchAndDevelopmentArrangementContractToPerformForOthersPerformanceObligationPotentialRevenueAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Arrangement, Contract To Perform For Others, Performance Obligation, Potential Revenue Amount</link:label>
    <link:label id="lab_auph_ResearchAndDevelopmentArrangementContractToPerformForOthersPerformanceObligationPotentialRevenueAmount_documentation_en-US" xlink:label="lab_auph_ResearchAndDevelopmentArrangementContractToPerformForOthersPerformanceObligationPotentialRevenueAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Arrangement, Contract To Perform For Others, Performance Obligation, Potential Revenue Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_auph_ResearchAndDevelopmentArrangementContractToPerformForOthersPerformanceObligationPotentialRevenueAmount" xlink:href="auph-20220331.xsd#auph_ResearchAndDevelopmentArrangementContractToPerformForOthersPerformanceObligationPotentialRevenueAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_auph_ResearchAndDevelopmentArrangementContractToPerformForOthersPerformanceObligationPotentialRevenueAmount" xlink:to="lab_auph_ResearchAndDevelopmentArrangementContractToPerformForOthersPerformanceObligationPotentialRevenueAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_AffiliatedEntityMember_30783dd7-912e-446e-b71a-3cb4fb34f3e0_terseLabel_en-US" xlink:label="lab_srt_AffiliatedEntityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliated Shareholder</link:label>
    <link:label id="lab_srt_AffiliatedEntityMember_label_en-US" xlink:label="lab_srt_AffiliatedEntityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliated Entity [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_AffiliatedEntityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_AffiliatedEntityMember" xlink:to="lab_srt_AffiliatedEntityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_d9a66798-f0ac-4980-9b27-18ccb0a82bbe_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_329d24d1-fe36-464a-a295-d53f14379e62_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_bee7e03b-5753-4b52-b33a-de6cbed4d9c5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_0cea4178-e496-48af-8d46-c7ee8b87b154_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive loss:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_eba1b36a-d344-4c91-930e-4df11a30f17e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annualized volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_edda469d-5e04-488c-82b3-0cc401d41b61_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_ee0f10dd-af89-4af4-80f5-d33a41c7d957_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromInterestReceived_1110c8ad-c4e5-40fc-9bc3-4165a674b531_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromInterestReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash received for interest</link:label>
    <link:label id="lab_us-gaap_ProceedsFromInterestReceived_label_en-US" xlink:label="lab_us-gaap_ProceedsFromInterestReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Interest Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromInterestReceived" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromInterestReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromInterestReceived" xlink:to="lab_us-gaap_ProceedsFromInterestReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_caa1ad22-c9f2-4a99-a9c9-76cc11712c7b_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_006b3f17-93fa-4541-91b6-0a26c59c9ba5_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireLeaseReceivables_2d29ced0-dfb1-44cc-a241-d4fdde0c7a6c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireLeaseReceivables" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront lease payment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireLeaseReceivables_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireLeaseReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Lease Receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireLeaseReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireLeaseReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireLeaseReceivables" xlink:to="lab_us-gaap_PaymentsToAcquireLeaseReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_38518287-a816-4e79-b7ce-436de5561cba_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_36627fa6-75ab-4a85-84e4-b216469f278e_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_bb34b9a2-cb82-4e39-99b9-34f3be9fd3c2_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_3851833c-5b78-427b-9f9c-b36a1548690a_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_auph_SpecialtyPharmacyOneMember_4e048e39-789c-4146-b7e8-706f6b132daa_terseLabel_en-US" xlink:label="lab_auph_SpecialtyPharmacyOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Specialty Pharmacy One</link:label>
    <link:label id="lab_auph_SpecialtyPharmacyOneMember_label_en-US" xlink:label="lab_auph_SpecialtyPharmacyOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Specialty Pharmacy One [Member]</link:label>
    <link:label id="lab_auph_SpecialtyPharmacyOneMember_documentation_en-US" xlink:label="lab_auph_SpecialtyPharmacyOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Specialty Pharmacy One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_auph_SpecialtyPharmacyOneMember" xlink:href="auph-20220331.xsd#auph_SpecialtyPharmacyOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_auph_SpecialtyPharmacyOneMember" xlink:to="lab_auph_SpecialtyPharmacyOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_auph_ILJINMember_1a477749-5a25-49f6-a4aa-506448d9de6c_terseLabel_en-US" xlink:label="lab_auph_ILJINMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ILJIN</link:label>
    <link:label id="lab_auph_ILJINMember_label_en-US" xlink:label="lab_auph_ILJINMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ILJIN [Member]</link:label>
    <link:label id="lab_auph_ILJINMember_documentation_en-US" xlink:label="lab_auph_ILJINMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ILJIN</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_auph_ILJINMember" xlink:href="auph-20220331.xsd#auph_ILJINMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_auph_ILJINMember" xlink:to="lab_auph_ILJINMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_b964c540-4a4e-463a-b560-cb618e153e03_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_581937f6-e888-4225-9d42-fa2b34a0a77f_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_1f8d961b-8971-4af1-a1ea-86b5bc18a4b8_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total future minimum lease payments</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_d4687812-8d18-4391-85bb-b29269c34bbc_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_e131c299-6a20-4a97-92ab-81c3a773b8c3_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized share-based compensation expense weighted average recognition period</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_be521b70-989d-4cf7-a6fa-68c2b00d65fa_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, Weighted average exercise price - Beginning of Period (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_0359b6a7-04b5-4364-8b09-994a445f16b9_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, Weighted average exercise price - End of Period (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_eaaabcd2-bea4-4ee6-b1cc-78f13a7cd0c8_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PerformanceSharesMember_0ee8c9f5-cafe-42b7-b2b9-fd1c02f82fff_terseLabel_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested performance awards</link:label>
    <link:label id="lab_us-gaap_PerformanceSharesMember_label_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Shares [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PerformanceSharesMember" xlink:to="lab_us-gaap_PerformanceSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_b5a4d596-a8bb-4797-b71c-aac0a2135915_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies (Note 18)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_b5ce4b7f-bfa8-4018-9176-3fad69f80cd6_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Obligations</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_04d960b4-ced5-42f0-9374-67fc75ab59c2_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_e67b8d23-1220-4d74-b122-4765f2dd1d40_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_d08ef3c4-1a7c-43b0-9555-38aa219d5c6e_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remainder of 2022</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_9a5574de-fe4d-4877-bc70-4389e9a9915b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award Valuation Assumptions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_2c361f4d-a168-40f5-9ba2-e5e1141ba393_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_3c237ecb-4d05-4a3e-b41e-b342f670ccc5_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasuryBondSecuritiesMember_9e9a85df-c87a-49b5-b8a8-779e89220b9c_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasuryBondSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Bond</link:label>
    <link:label id="lab_us-gaap_USTreasuryBondSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USTreasuryBondSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury Bond Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryBondSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasuryBondSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasuryBondSecuritiesMember" xlink:to="lab_us-gaap_USTreasuryBondSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_6746c3ab-faec-4649-9043-35029cddbed0_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cost of sales and operating expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_53375ff2-a8e1-420c-86c8-c817f0ad4e94_negatedLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: lease imputed interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_78d3b55e-39f0-481c-8173-8a73aa048f47_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Work in process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Work in Process, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireProductiveAssets_36c81c27-eaf8-41b0-8a9f-bd4bffad7af0_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront license fee</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireProductiveAssets_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Productive Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireProductiveAssets" xlink:to="lab_us-gaap_PaymentsToAcquireProductiveAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_82f70f68-3f23-4565-b3a2-6c35c0320bd0_totalLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_af60e793-cdf9-4541-83f4-0f09912c0a21_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_da9000f7-027d-4f8b-a8b2-cdfba94de2d8_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_433edfef-a4df-40fe-b34b-23d3470f8b2f_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_auph_OtuskaPharmaceuticalCoLtdMember_df852521-c2e3-45fc-bfad-a639bb9ca0bc_terseLabel_en-US" xlink:label="lab_auph_OtuskaPharmaceuticalCoLtdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Otuska</link:label>
    <link:label id="lab_auph_OtuskaPharmaceuticalCoLtdMember_label_en-US" xlink:label="lab_auph_OtuskaPharmaceuticalCoLtdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Otuska Pharmaceutical Co., Ltd. [Member]</link:label>
    <link:label id="lab_auph_OtuskaPharmaceuticalCoLtdMember_documentation_en-US" xlink:label="lab_auph_OtuskaPharmaceuticalCoLtdMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Otuska Pharmaceutical Co., Ltd.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_auph_OtuskaPharmaceuticalCoLtdMember" xlink:href="auph-20220331.xsd#auph_OtuskaPharmaceuticalCoLtdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_auph_OtuskaPharmaceuticalCoLtdMember" xlink:to="lab_auph_OtuskaPharmaceuticalCoLtdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OfficeEquipmentMember_faef1980-ca35-4736-8847-0b4e2c864f54_terseLabel_en-US" xlink:label="lab_us-gaap_OfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office equipment</link:label>
    <link:label id="lab_us-gaap_OfficeEquipmentMember_label_en-US" xlink:label="lab_us-gaap_OfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OfficeEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OfficeEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OfficeEquipmentMember" xlink:to="lab_us-gaap_OfficeEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_auph_PrepaidRentAndPrepaidContinuingStudies_253bff30-a0b3-4c0a-91af-5e4ff3c2aa6a_terseLabel_en-US" xlink:label="lab_auph_PrepaidRentAndPrepaidContinuingStudies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid deposits</link:label>
    <link:label id="lab_auph_PrepaidRentAndPrepaidContinuingStudies_label_en-US" xlink:label="lab_auph_PrepaidRentAndPrepaidContinuingStudies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Rent and Prepaid Continuing Studies</link:label>
    <link:label id="lab_auph_PrepaidRentAndPrepaidContinuingStudies_documentation_en-US" xlink:label="lab_auph_PrepaidRentAndPrepaidContinuingStudies" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Rent and Prepaid Continuing Studies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_auph_PrepaidRentAndPrepaidContinuingStudies" xlink:href="auph-20220331.xsd#auph_PrepaidRentAndPrepaidContinuingStudies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_auph_PrepaidRentAndPrepaidContinuingStudies" xlink:to="lab_auph_PrepaidRentAndPrepaidContinuingStudies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_a0f44db8-b57f-4f21-8c50-34d2b8107981_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_6cdb98a4-bb53-4d0d-bf43-62c4d3c10f34_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidExpense_2b519721-13d5-4a89-89e8-eff4cf37d11f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidExpense_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_fc38bb89-03ef-4fb0-b266-5afac82a62c2_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_5a84fa8b-9c08-4c0f-bc09-9ea95dc2c89a_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_60b49cad-b5d7-4024-910d-e3593be59d4e_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Shares</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_a68e294b-9190-4217-a365-fce33413729b_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1b8213ec-2770-418e-a7ea-5de8f9779d97_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_d432839e-4b7e-4f1d-960c-9ddc0d1ebd38_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_83e9721a-0591-45c4-b61a-33dd06a9578a_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_auph_LesseeOperatingLeaseNumberOfExtensionOptions_404b927b-0e14-4a26-aa36-304b52d01aa3_terseLabel_en-US" xlink:label="lab_auph_LesseeOperatingLeaseNumberOfExtensionOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of extension options</link:label>
    <link:label id="lab_auph_LesseeOperatingLeaseNumberOfExtensionOptions_label_en-US" xlink:label="lab_auph_LesseeOperatingLeaseNumberOfExtensionOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Number of Extension Options</link:label>
    <link:label id="lab_auph_LesseeOperatingLeaseNumberOfExtensionOptions_documentation_en-US" xlink:label="lab_auph_LesseeOperatingLeaseNumberOfExtensionOptions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Number of Extension Options</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_auph_LesseeOperatingLeaseNumberOfExtensionOptions" xlink:href="auph-20220331.xsd#auph_LesseeOperatingLeaseNumberOfExtensionOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_auph_LesseeOperatingLeaseNumberOfExtensionOptions" xlink:to="lab_auph_LesseeOperatingLeaseNumberOfExtensionOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b362c749-8230-46c2-bd0e-559eac5ce238_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_9c44a8fc-fdb4-4e75-8697-ca2d95212c8c_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_88afb5d9-f9db-412a-9965-3a9288148792_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_0c54ee0a-4585-4aab-82cd-2c3140e8c74d_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_d2cd85e2-fe59-41d9-b306-a0210d5eb10c_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_72d6e0ca-4ab2-4bd9-b236-d0719a783efd_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction_8a89eb84-5c91-40fd-be66-32673f614a7f_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to related party</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Amounts of Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:to="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_auph_LesseeOperatingLeaseLeaseTerminationTerm_5b3f9777-b792-474f-b3cd-a7d1251463be_terseLabel_en-US" xlink:label="lab_auph_LesseeOperatingLeaseLeaseTerminationTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease termination option term</link:label>
    <link:label id="lab_auph_LesseeOperatingLeaseLeaseTerminationTerm_label_en-US" xlink:label="lab_auph_LesseeOperatingLeaseLeaseTerminationTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Lease Termination Term</link:label>
    <link:label id="lab_auph_LesseeOperatingLeaseLeaseTerminationTerm_documentation_en-US" xlink:label="lab_auph_LesseeOperatingLeaseLeaseTerminationTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Lease Termination Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_auph_LesseeOperatingLeaseLeaseTerminationTerm" xlink:href="auph-20220331.xsd#auph_LesseeOperatingLeaseLeaseTerminationTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_auph_LesseeOperatingLeaseLeaseTerminationTerm" xlink:to="lab_auph_LesseeOperatingLeaseLeaseTerminationTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidInsurance_99cbdbfa-8c8e-4181-804a-4628694be592_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidInsurance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid insurance</link:label>
    <link:label id="lab_us-gaap_PrepaidInsurance_label_en-US" xlink:label="lab_us-gaap_PrepaidInsurance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Insurance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidInsurance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidInsurance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidInsurance" xlink:to="lab_us-gaap_PrepaidInsurance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_b04916cd-ed24-4ecf-87cd-4371ceec016b_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_1b397755-dc57-4f8d-92a4-eede132cfa85_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_da09d001-c301-4ae6-84c6-812f88513888_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_0f8ea485-3047-4b6b-ac76-e792311cd895_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Raw Materials, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:to="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_0cf1139b-229e-4142-acd0-ecabfe867bd8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInReceivables_58b8ca52-0c58-44c6-b9fc-5b8082cae2d2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInReceivables" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInReceivables_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInReceivables" xlink:to="lab_us-gaap_IncreaseDecreaseInReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_36f5e675-a390-4567-8e88-8fcd94ebb9d5_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_f24f3cb5-df2b-481b-8ae9-7bd0a332eb8a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_dbbfb124-bc5c-491a-ab58-52a3bdd511cb_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_c7ebed8b-d3fb-4f90-98b8-e6b930001d4b_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total shareholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_51f659cb-6a45-48b2-9634-f50101c32910_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_b0d612c7-9bef-4d7f-9e11-cd7eb787d834_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_auph_AmendedAndRestatedEquityIncentivePlanMember_c1858f6e-8de0-4284-a7db-f7a56d381d92_terseLabel_en-US" xlink:label="lab_auph_AmendedAndRestatedEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended and Restated Equity Incentive Plan</link:label>
    <link:label id="lab_auph_AmendedAndRestatedEquityIncentivePlanMember_label_en-US" xlink:label="lab_auph_AmendedAndRestatedEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended and Restated Equity Incentive Plan [Member]</link:label>
    <link:label id="lab_auph_AmendedAndRestatedEquityIncentivePlanMember_documentation_en-US" xlink:label="lab_auph_AmendedAndRestatedEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended and Restated Equity Incentive Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_auph_AmendedAndRestatedEquityIncentivePlanMember" xlink:href="auph-20220331.xsd#auph_AmendedAndRestatedEquityIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_auph_AmendedAndRestatedEquityIncentivePlanMember" xlink:to="lab_auph_AmendedAndRestatedEquityIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_54f208e3-c720-446c-b67c-cd075e1f88da_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, issued (shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_a3c59d50-2985-44da-a71c-288cfeef1cb2_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_1b94daac-8821-4a6d-863e-fe659067fff0_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable, accrued and other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_auph_AssetsAndLiabilitiesLesseeTableTextBlock_df7662e7-c2c9-4f79-84b8-6e12e79160c6_terseLabel_en-US" xlink:label="lab_auph_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Balance Sheet Information</link:label>
    <link:label id="lab_auph_AssetsAndLiabilitiesLesseeTableTextBlock_label_en-US" xlink:label="lab_auph_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets And Liabilities, Lessee [Table Text Block]</link:label>
    <link:label id="lab_auph_AssetsAndLiabilitiesLesseeTableTextBlock_documentation_en-US" xlink:label="lab_auph_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets And Liabilities, Lessee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_auph_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:href="auph-20220331.xsd#auph_AssetsAndLiabilitiesLesseeTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_auph_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:to="lab_auph_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_e75f2982-8848-4625-93ca-d19109532fcf_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_5647d7c5-c6b2-4476-b33b-4752d7189217_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_6ebf2ba6-4f95-49fb-b55d-3a652c31de62_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_06c9ab09-416b-43c5-9e23-e0a338f42f1b_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Major Customers</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_9f59714a-6d4a-4dfd-b2a6-c01bf09e4989_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_a5466f88-c7c6-4e82-a263-7d839f8bfa4f_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_34b1d753-126e-457a-a129-dc9ed74b76b7_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue_9ed444dd-2ded-434d-a126-4c7ac1f78a52_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum finance lease liability payments due</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Payment, Due</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_auph_CashableGuaranteedInvestmentCertificatesMember_9d1a4346-ac9c-422a-b31e-7c78831cdbf8_terseLabel_en-US" xlink:label="lab_auph_CashableGuaranteedInvestmentCertificatesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cashable Guaranteed Investment Certificate</link:label>
    <link:label id="lab_auph_CashableGuaranteedInvestmentCertificatesMember_label_en-US" xlink:label="lab_auph_CashableGuaranteedInvestmentCertificatesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cashable Guaranteed Investment Certificates [Member]</link:label>
    <link:label id="lab_auph_CashableGuaranteedInvestmentCertificatesMember_documentation_en-US" xlink:label="lab_auph_CashableGuaranteedInvestmentCertificatesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cashable Guaranteed Investment Certificates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_auph_CashableGuaranteedInvestmentCertificatesMember" xlink:href="auph-20220331.xsd#auph_CashableGuaranteedInvestmentCertificatesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_auph_CashableGuaranteedInvestmentCertificatesMember" xlink:to="lab_auph_CashableGuaranteedInvestmentCertificatesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsNoncurrentAbstract_79bbc678-5b2b-47f1-9f73-5679b89bc908_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Noncurrent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract" xlink:to="lab_us-gaap_AssetsNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_auph_RiptideBioscienceIncMember_236f4351-ac19-4cef-86db-2aab88c583b9_terseLabel_en-US" xlink:label="lab_auph_RiptideBioscienceIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Riptide Bioscience, Inc.</link:label>
    <link:label id="lab_auph_RiptideBioscienceIncMember_label_en-US" xlink:label="lab_auph_RiptideBioscienceIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Riptide Bioscience, Inc. [Member]</link:label>
    <link:label id="lab_auph_RiptideBioscienceIncMember_documentation_en-US" xlink:label="lab_auph_RiptideBioscienceIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Riptide Bioscience, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_auph_RiptideBioscienceIncMember" xlink:href="auph-20220331.xsd#auph_RiptideBioscienceIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_auph_RiptideBioscienceIncMember" xlink:to="lab_auph_RiptideBioscienceIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_auph_PrepaidAssetsCurrent_eb852c06-39e2-4529-be6c-23fbe16c5402_terseLabel_en-US" xlink:label="lab_auph_PrepaidAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid assets</link:label>
    <link:label id="lab_auph_PrepaidAssetsCurrent_label_en-US" xlink:label="lab_auph_PrepaidAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Assets, Current</link:label>
    <link:label id="lab_auph_PrepaidAssetsCurrent_documentation_en-US" xlink:label="lab_auph_PrepaidAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_auph_PrepaidAssetsCurrent" xlink:href="auph-20220331.xsd#auph_PrepaidAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_auph_PrepaidAssetsCurrent" xlink:to="lab_auph_PrepaidAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_43c6e656-a81f-47c0-aa7e-2f129415d7e5_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_63802258-6419-4603-a842-2dac7ce986ff_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_5faf5060-887c-4278-9cc3-c8d6438f4183_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested restricted units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasuryBillSecuritiesMember_7197c05a-7129-459a-b374-764ce9e3cf04_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasuryBillSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Bill</link:label>
    <link:label id="lab_us-gaap_USTreasuryBillSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USTreasuryBillSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury Bill Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryBillSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasuryBillSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasuryBillSecuritiesMember" xlink:to="lab_us-gaap_USTreasuryBillSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_f92ff4ff-6361-4d7a-a196-b67302f35cfc_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_78cdf67e-9e8f-4c47-9d0b-d2e2e6ca76e3_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining lease term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_4a3ca4bc-974e-4c42-8d01-1910fe179fda_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_78c16fff-d981-4f17-aded-15219b71392d_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract" xlink:to="lab_us-gaap_InventoryDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_b9084690-17e0-455a-aa5c-0a1090d115fc_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from exercise of stock options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_55e1d66d-4792-418d-a0b5-cb8dd038a88d_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a7c74895-78e6-476d-9764-6ab0d568e497_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_18d0c808-3457-4a30-b03c-39975989bc2b_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_3389f5f7-c9bf-4698-863f-ae49fa06091e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax (benefit) expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_444d0fe7-e042-4e4d-9b0c-cf6800caab54_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_3f420c76-6908-4436-a943-b54d8b7b001d_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_40c14e71-430d-4249-948f-70e070d239e4_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_cd636a96-b69b-43fd-8a57-06fd538a9bff_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_5342e533-67ab-4815-902c-5ba77d81997a_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_6edc3c4d-e9c9-4584-ad47-8235764122ba_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntellectualPropertyMember_4a886d3e-2b8d-400b-8dd4-b30aeeb699f4_terseLabel_en-US" xlink:label="lab_us-gaap_IntellectualPropertyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired intellectual property and reacquired rights</link:label>
    <link:label id="lab_us-gaap_IntellectualPropertyMember_label_en-US" xlink:label="lab_us-gaap_IntellectualPropertyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intellectual Property [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntellectualPropertyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntellectualPropertyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntellectualPropertyMember" xlink:to="lab_us-gaap_IntellectualPropertyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_787a5dd8-c2d0-4811-8e08-d58653ef0d28_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_a62ddb55-b635-458c-87a0-cdef66f933a1_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_0bc3cdc5-23de-4595-8081-829c8036bdf0_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_f1fb496f-e1f4-4da1-abb3-be6992f8af9e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares forfeited/canceled (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_766a3847-558b-4f46-a8e2-db793fa22759_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance shares forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_d118e05c-68dc-4f31-a4c3-c5f3061eff63_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories, net</link:label>
    <link:label id="lab_us-gaap_InventoryNet_c2724224-9a9e-48ef-96d7-770a974e9adc_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_88180edd-0037-4f2b-899d-c02e77309c37_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_e7ba3375-529b-4805-80a7-95a497b4f541_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_9623191b-c43b-4303-a1b4-3f53b6705adb_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_d4dbe02b-2ab7-43f5-88de-c5f3bdfaa028_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_7318db01-1daf-4860-8dd0-5fae4db48de5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_label_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_6c1aa87d-8eb1-4f8a-bf56-49abd58e3cd7_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccounting_174e4c41-6d5b-400d-b748-ffeeba90cfa6_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccounting" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccounting_label_en-US" xlink:label="lab_us-gaap_BasisOfAccounting" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccounting" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccounting"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccounting" xlink:to="lab_us-gaap_BasisOfAccounting" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_e339d196-8fe1-446b-9f86-e1079440f0eb_terseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Benchmark</link:label>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_label_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueNetMember" xlink:to="lab_us-gaap_SalesRevenueNetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_e56decb1-0679-41db-805e-40e56181c172_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value per common share option (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_0bab89d7-20f1-428b-9ebc-a3469da9e6b2_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss_3d2aa513-1b1e-4805-a82e-a8a7aa550e67_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gains on available-for-sale securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_cbe8c8b2-c899-47e6-9ead-175fa926347a_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_184fb74e-e3b4-40e5-af86-f6bfa1ed2522_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_fa064f91-1545-4f70-9a67-69df57a0e7d7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_26a7b04d-88ee-45cc-ae7b-fffcc65f3a49_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_ac33a832-ca7d-4183-a195-69f1649e26c1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_384a4afc-0a46-4394-a95d-4f5d6b28d9fc_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_auph_AccruedResearchCurrent_562553a4-d13a-4c62-835f-599739b29acf_terseLabel_en-US" xlink:label="lab_auph_AccruedResearchCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued R&amp;D projects</link:label>
    <link:label id="lab_auph_AccruedResearchCurrent_label_en-US" xlink:label="lab_auph_AccruedResearchCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Research, Current</link:label>
    <link:label id="lab_auph_AccruedResearchCurrent_documentation_en-US" xlink:label="lab_auph_AccruedResearchCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Research, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_auph_AccruedResearchCurrent" xlink:href="auph-20220331.xsd#auph_AccruedResearchCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_auph_AccruedResearchCurrent" xlink:to="lab_auph_AccruedResearchCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_96136e1d-ff03-47b1-86be-633d80a4538e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allocation of Share-Based Payments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Cost by Plan [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_7b179539-e0c4-4ebc-894b-b967e7ae6651_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale debt securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_13ca0bc1-0bd2-4e5b-a1ff-448aa99eebb4_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_5f60cde2-3f88-41f4-9c91-b0f9fe149748_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_09720e54-89d6-4c5d-bef6-50497d0fabbc_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_523a19bb-5204-4169-ae5c-cbcfa40bd7a1_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_89c5a8f2-f4e8-49af-a4fd-13050652f87b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_e3f5fc25-5638-4fdd-b72c-14ca62d3b773_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_af2cc610-8c4b-4535-a903-f07472c6b26e_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_58a4de73-ac85-479b-88e2-c6411c396911_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_9e923613-a850-4e69-8650-67fff3af091c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_auph_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_19eca60a-2d89-4241-a9cc-fac14f88b5c5_terseLabel_en-US" xlink:label="lab_auph_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_auph_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_label_en-US" xlink:label="lab_auph_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, After Year Four</link:label>
    <link:label id="lab_auph_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_documentation_en-US" xlink:label="lab_auph_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, After Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_auph_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:href="auph-20220331.xsd#auph_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_auph_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:to="lab_auph_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_2e1d60da-27d3-4c88-b0ef-cbb7e4b21ff2_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_b652dc00-5964-4346-9474-187ddb88ec8f_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_de2e4828-cfa5-4075-b614-cc6818038c83_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_74a2244a-7dae-40db-bebb-451c12c5408a_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualAxis_07913a88-627b-40d5-9756-1809f6f0ae3f_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:label id="lab_srt_TitleOfIndividualAxis_label_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis" xlink:to="lab_srt_TitleOfIndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_3c06ae22-7afe-4ce5-a447-e0aa79354a0f_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_3cd42ff4-9635-429f-a379-ea9ab82c5dba_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_6c230dea-8323-4537-868a-4fe625e4bb6b_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_cbad08c8-b6b3-4030-9e93-e3316471d78d_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease extension term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_auph_SpecialtyPharmacyTwoMember_f6d92b4e-f3e9-49a3-8bdf-3d1606a9a8e2_terseLabel_en-US" xlink:label="lab_auph_SpecialtyPharmacyTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Specialty Pharmacy Two</link:label>
    <link:label id="lab_auph_SpecialtyPharmacyTwoMember_label_en-US" xlink:label="lab_auph_SpecialtyPharmacyTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Specialty Pharmacy Two [Member]</link:label>
    <link:label id="lab_auph_SpecialtyPharmacyTwoMember_documentation_en-US" xlink:label="lab_auph_SpecialtyPharmacyTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Specialty Pharmacy Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_auph_SpecialtyPharmacyTwoMember" xlink:href="auph-20220331.xsd#auph_SpecialtyPharmacyTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_auph_SpecialtyPharmacyTwoMember" xlink:to="lab_auph_SpecialtyPharmacyTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_506ed8e2-a2eb-4986-83d3-ac4c923fa478_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_64a25775-313c-4dcb-a5c0-c889a8e72447_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_ff329ac9-882c-4c11-b5b4-39826dac067f_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_04e7013d-118a-4eea-9cd6-ed4e63a669b0_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_eb333b5d-3249-487c-9202-e2eed0e91c7d_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_e187d59d-aa00-49fd-8c9e-7d034b2d1963_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_294a3046-e72b-4edd-a0de-417ed774ea52_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common shares outstanding used in computation of basic loss per share</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_b228edef-ce99-4f4c-a258-9478a8dff37e_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted loss per share (expressed in $ per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_8c29250c-3b0e-434e-8102-bdbc68b22d06_totalLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted loss per share (expressed in $ per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_3db9ee2d-4af4-4e43-b7e3-de1f496855b8_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of intangible assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Amortization Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductMember_c1829bbd-dd14-4ada-9b07-4d4ee9969b59_terseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product revenue, net</link:label>
    <link:label id="lab_us-gaap_ProductMember_label_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember" xlink:to="lab_us-gaap_ProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_f4d12b56-75b6-494f-83a9-6e848c4ddd6c_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfRevenue_f6cfcece-6be0-490b-a2ee-abed6e733080_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of sales</link:label>
    <link:label id="lab_us-gaap_CostOfRevenue_label_en-US" xlink:label="lab_us-gaap_CostOfRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfRevenue" xlink:to="lab_us-gaap_CostOfRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_3ac9275c-8ecc-4926-bce9-301b75bb9ef9_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_1a319fbf-5144-4810-80ab-9666b92305b4_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_00afe0a2-aaf6-4007-9d82-ed8cc1e2cde7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesCurrent_8d15628c-e0bf-4da9-9f74-a9ef3dfe498d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesCurrent" xlink:to="lab_us-gaap_DebtSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_32568f6a-c003-4d1c-b367-cb8f37532ea7_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of warrants (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_204eb41c-ea42-45ac-8cfd-b716e6e40432_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_eb2fc1e1-6915-4e73-bd22-6b4beb09fff0_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_b5d97dba-9edd-496a-9f67-a1038267414b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_c32c681a-8a55-41cb-bf7b-033ed0a0645e_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive (Loss) Income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_52523786-73b6-4df6-8f30-39b34b5386c7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesTable_b8a50317-411a-4db6-a6bd-bfc4bea8e620_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities [Table]</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesTable_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesTable" xlink:to="lab_us-gaap_MarketableSecuritiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_345b1f57-aec5-44ba-9aac-526b0d6bbab3_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, outstanding (shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_75f1c1eb-7515-4860-9324-c202d427511e_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_1fe78920-c425-44a4-a190-e9b03737ef76_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherOperatingIncomeExpenseNet_067ade36-1964-45c0-89f1-5a94e14ee8c9_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseNet" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other expense, net</link:label>
    <link:label id="lab_us-gaap_OtherOperatingIncomeExpenseNet_label_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Operating Income (Expense), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherOperatingIncomeExpenseNet" xlink:to="lab_us-gaap_OtherOperatingIncomeExpenseNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_bf17a6e7-038a-4c6f-8739-3165ca115fe8_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_e16b6d4a-34f3-4165-8fe9-bf73fad0a95e_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net revenue:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComputerSoftwareIntangibleAssetMember_a337ce52-de99-4310-9968-c5251a9d9cda_terseLabel_en-US" xlink:label="lab_us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cloud computing arrangements</link:label>
    <link:label id="lab_us-gaap_ComputerSoftwareIntangibleAssetMember_label_en-US" xlink:label="lab_us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Software, Intangible Asset [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:to="lab_us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_5e3e3bf4-b58f-4e9d-8bd6-a3b554ca8d92_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_68859a2d-81c9-47e1-a87a-a803f61ad648_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized patent costs</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_824abe1e-173b-44aa-aa74-2f512970025d_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_0e355bb7-c161-48d1-914f-42aa093d48d8_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_9fc1b193-5c5a-4f4c-8ceb-32bb4c677d8f_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_70b9acba-aafe-4b83-b835-528514e77f51_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Shares (in thousands)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_5a782cc1-04cb-4399-9a7c-e4886daf4887_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows used in investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_3725b94b-05f8-4f6d-8a0d-71e24044bc9a_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_ed2c3ef4-b917-4264-92c3-aaa658c82114_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromTenantAllowance_cfe99644-aef0-4f9a-9b42-3f5aff1206ea_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromTenantAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from tenant improvements</link:label>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromTenantAllowance_label_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromTenantAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for (Proceeds from) Tenant Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromTenantAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForProceedsFromTenantAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForProceedsFromTenantAllowance" xlink:to="lab_us-gaap_PaymentsForProceedsFromTenantAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_11486103-4584-4470-93f1-8b0374132811_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SHAREHOLDER&#8217;S EQUITY</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_3ae7ca7e-2725-47f2-b922-031ee8b1fc2f_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsFairValueDisclosure" xlink:to="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_af3b8868-5ef8-439e-acdf-f7387b36288a_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure of noncash transactions</link:label>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_4272e5d7-2a0b-4bae-8ea9-b7187e62b83d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of additional shares authorized</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_auph_ShortTermCorporateDebtSecuritiesMember_2d20b59d-9a79-4166-a803-e8bc11ae4f0c_terseLabel_en-US" xlink:label="lab_auph_ShortTermCorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Bond</link:label>
    <link:label id="lab_auph_ShortTermCorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_auph_ShortTermCorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term Corporate Debt Securities [Member]</link:label>
    <link:label id="lab_auph_ShortTermCorporateDebtSecuritiesMember_documentation_en-US" xlink:label="lab_auph_ShortTermCorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term Corporate Debt Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_auph_ShortTermCorporateDebtSecuritiesMember" xlink:href="auph-20220331.xsd#auph_ShortTermCorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_auph_ShortTermCorporateDebtSecuritiesMember" xlink:to="lab_auph_ShortTermCorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestReceivable_3d05ab6a-08ef-42e5-bd74-2748c43cd892_terseLabel_en-US" xlink:label="lab_us-gaap_InterestReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest receivable</link:label>
    <link:label id="lab_us-gaap_InterestReceivable_label_en-US" xlink:label="lab_us-gaap_InterestReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestReceivable" xlink:to="lab_us-gaap_InterestReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_d67e0fd8-40d3-45c6-8dda-67e413734a2b_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_97c819be-2358-403c-8632-ac5bd2bdafbc_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_caaedfd5-76cf-443f-948b-b9352347f097_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_08a5445e-55be-4bc0-af12-93f88ff32ea4_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred compensation and other non-current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_bdf86fa1-33c8-4d99-bd59-6a0a82b6c066_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_f6dfa92e-54f9-4ffe-846d-a6bbdd3447fb_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_005e317d-4724-4e5c-a10d-b013a6926cc0_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment, gross</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_3635c693-fd18-429f-aa7a-2ffd1ef1cb00_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_8a8d494a-3ccd-427a-af7f-f323c9f1a78e_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for doubtful accounts</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_auph_CashCashEquivalentsAndDebtSecuritiesCurrent_fd224efd-aece-4939-bfd0-b12fba800788_terseLabel_en-US" xlink:label="lab_auph_CashCashEquivalentsAndDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents and investments</link:label>
    <link:label id="lab_auph_CashCashEquivalentsAndDebtSecuritiesCurrent_label_en-US" xlink:label="lab_auph_CashCashEquivalentsAndDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents and Debt Securities, Current</link:label>
    <link:label id="lab_auph_CashCashEquivalentsAndDebtSecuritiesCurrent_documentation_en-US" xlink:label="lab_auph_CashCashEquivalentsAndDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents and Debt Securities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_auph_CashCashEquivalentsAndDebtSecuritiesCurrent" xlink:href="auph-20220331.xsd#auph_CashCashEquivalentsAndDebtSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_auph_CashCashEquivalentsAndDebtSecuritiesCurrent" xlink:to="lab_auph_CashCashEquivalentsAndDebtSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_b66dff44-a9cb-4cbe-8f07-4c0aed783e51_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain" xlink:to="lab_us-gaap_RelatedPartyTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesMember_b3c65447-824d-4be2-a1e6-718c38afd046_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Current Liabilities</link:label>
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Current Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentLiabilitiesMember" xlink:to="lab_us-gaap_OtherCurrentLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_auph_RockvilleMarylandMember_fd46e486-ff66-40b7-8f28-126da00ed96a_terseLabel_en-US" xlink:label="lab_auph_RockvilleMarylandMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rockville, Maryland</link:label>
    <link:label id="lab_auph_RockvilleMarylandMember_label_en-US" xlink:label="lab_auph_RockvilleMarylandMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rockville, Maryland [Member]</link:label>
    <link:label id="lab_auph_RockvilleMarylandMember_documentation_en-US" xlink:label="lab_auph_RockvilleMarylandMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rockville, Maryland</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_auph_RockvilleMarylandMember" xlink:href="auph-20220331.xsd#auph_RockvilleMarylandMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_auph_RockvilleMarylandMember" xlink:to="lab_auph_RockvilleMarylandMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_081430fb-5759-44b9-b090-7af1fb808d2c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_b7ec14be-d2b5-46aa-bcf8-81d5d79a234b_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantMember_99fc5be4-0664-4375-9860-bfd46893d14b_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants</link:label>
    <link:label id="lab_us-gaap_WarrantMember_label_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember" xlink:to="lab_us-gaap_WarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PatentsMember_febcd403-4e80-45db-b3e4-ceba06d3c3c8_terseLabel_en-US" xlink:label="lab_us-gaap_PatentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patents</link:label>
    <link:label id="lab_us-gaap_PatentsMember_label_en-US" xlink:label="lab_us-gaap_PatentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patents [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PatentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PatentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PatentsMember" xlink:to="lab_us-gaap_PatentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_0e9643c6-44fe-41a4-a96a-c90e11d82845_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_e7a65ca0-9a97-41e3-8c20-e76ec8466ea2_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalCashFlowElementsSummationsAbstract_f4ff0ea5-5164-45c5-bca1-cc5bdb760164_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalCashFlowElementsSummationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of cash, cash equivalents and restricted cash to the condensed consolidated balance sheets</link:label>
    <link:label id="lab_us-gaap_AdditionalCashFlowElementsSummationsAbstract_label_en-US" xlink:label="lab_us-gaap_AdditionalCashFlowElementsSummationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Cash Flow Elements, Summations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalCashFlowElementsSummationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalCashFlowElementsSummationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalCashFlowElementsSummationsAbstract" xlink:to="lab_us-gaap_AdditionalCashFlowElementsSummationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_auph_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate_2f75e67a-a272-44c7-9ade-aeaa9efe6030_terseLabel_en-US" xlink:label="lab_auph_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated forfeiture rate</link:label>
    <link:label id="lab_auph_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate_label_en-US" xlink:label="lab_auph_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Forfeiture Rate</link:label>
    <link:label id="lab_auph_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate_documentation_en-US" xlink:label="lab_auph_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Forfeiture Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_auph_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate" xlink:href="auph-20220331.xsd#auph_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_auph_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate" xlink:to="lab_auph_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_130d4c7e-5f9b-4ec8-bd34-233cbb6099d3_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_c9ffec38-d3b2-4ab1-927c-9b9f489c539a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price $</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_auph_OperatingLeaseAssetsAndLiabilitiesLiabilitiesNoncurrentLesseeAbstract_bb778579-4d2f-49cd-a46c-2fdaf76c3dbf_terseLabel_en-US" xlink:label="lab_auph_OperatingLeaseAssetsAndLiabilitiesLiabilitiesNoncurrentLesseeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current</link:label>
    <link:label id="lab_auph_OperatingLeaseAssetsAndLiabilitiesLiabilitiesNoncurrentLesseeAbstract_label_en-US" xlink:label="lab_auph_OperatingLeaseAssetsAndLiabilitiesLiabilitiesNoncurrentLesseeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Assets And Liabilities, Liabilities, Noncurrent, Lessee [Abstract]</link:label>
    <link:label id="lab_auph_OperatingLeaseAssetsAndLiabilitiesLiabilitiesNoncurrentLesseeAbstract_documentation_en-US" xlink:label="lab_auph_OperatingLeaseAssetsAndLiabilitiesLiabilitiesNoncurrentLesseeAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Assets And Liabilities, Liabilities, Noncurrent, Lessee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_auph_OperatingLeaseAssetsAndLiabilitiesLiabilitiesNoncurrentLesseeAbstract" xlink:href="auph-20220331.xsd#auph_OperatingLeaseAssetsAndLiabilitiesLiabilitiesNoncurrentLesseeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_auph_OperatingLeaseAssetsAndLiabilitiesLiabilitiesNoncurrentLesseeAbstract" xlink:to="lab_auph_OperatingLeaseAssetsAndLiabilitiesLiabilitiesNoncurrentLesseeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_bf270736-da2c-4614-944a-039fb74e5114_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_483d6f42-a19e-4cfc-84f2-c64283c6f66c_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale and Maturity of Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_label_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_eef5ea6e-3561-412f-a6a8-9fb176ef7406_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in progress</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in Progress [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressMember" xlink:to="lab_us-gaap_ConstructionInProgressMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ea6ef9a5-51f2-4f9b-b326-670d6f522a5f_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8b4a7496-3ef9-4d16-bb7e-cbf45fbc10a9_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash, beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f67373a2-ad1f-4346-bc65-cd99a4fdbc46_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash, end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_12f4f611-df04-42c6-9968-4659cfa2113d_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_89448783-8923-4533-b911-fe9a5062507d_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_e5668095-01cd-4bd7-97c6-fc0eccfebc1a_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others [Line Items]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_0b7ef670-84d3-4f44-bced-376f99ad70ce_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Carrying Value</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_ee1cabe9-dda6-4a4b-b32b-053155c69b9b_terseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_label_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income (Expense), Nonoperating, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:to="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_7753f9d1-7207-49d9-9a4c-62c02c37d318_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Intangible Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_34b17446-a5d8-4aa9-a87e-5542ef11b955_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents:</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_e79d5b14-e56d-4a7d-8755-eda0a512173c_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_559ee450-2ea8-4c78-9833-c045abf43089_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued on exercise of stock options and vesting of performance awards (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_c56fe6d3-3eaa-41bf-88a5-22a379e64350_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_33b78554-69e4-4d1e-ba85-106806b7b2f3_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common shares outstanding used in computation of diluted loss per share</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_6f5963ae-a5ff-4fc3-ba6e-c2cd460f351b_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain (loss) on available-for-sale securities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_8f7e5bc4-0a16-4100-ad95-0642a90fea58_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_52c56db5-d63e-4e0d-9741-1b03a92d7687_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_7b3125ad-50cd-41df-bc53-21ffe0c7ea8f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Option Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DemandDepositsMember_3bdd8cb5-07d9-467c-ad08-e28f701faa77_terseLabel_en-US" xlink:label="lab_us-gaap_DemandDepositsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deposits held with banks</link:label>
    <link:label id="lab_us-gaap_DemandDepositsMember_label_en-US" xlink:label="lab_us-gaap_DemandDepositsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Demand Deposits [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DemandDepositsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DemandDepositsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DemandDepositsMember" xlink:to="lab_us-gaap_DemandDepositsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_auph_VictoriaBritishColumbiaMember_2ee28987-2899-4ecd-8da4-8f0e2092778b_terseLabel_en-US" xlink:label="lab_auph_VictoriaBritishColumbiaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Victoria, British Columbia</link:label>
    <link:label id="lab_auph_VictoriaBritishColumbiaMember_label_en-US" xlink:label="lab_auph_VictoriaBritishColumbiaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Victoria, British Columbia [Member]</link:label>
    <link:label id="lab_auph_VictoriaBritishColumbiaMember_documentation_en-US" xlink:label="lab_auph_VictoriaBritishColumbiaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Victoria, British Columbia</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_auph_VictoriaBritishColumbiaMember" xlink:href="auph-20220331.xsd#auph_VictoriaBritishColumbiaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_auph_VictoriaBritishColumbiaMember" xlink:to="lab_auph_VictoriaBritishColumbiaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicenseAgreementTermsMember_05599833-a906-4525-832a-a49a073e843e_terseLabel_en-US" xlink:label="lab_us-gaap_LicenseAgreementTermsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement Terms</link:label>
    <link:label id="lab_us-gaap_LicenseAgreementTermsMember_label_en-US" xlink:label="lab_us-gaap_LicenseAgreementTermsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement Terms [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseAgreementTermsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseAgreementTermsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicenseAgreementTermsMember" xlink:to="lab_us-gaap_LicenseAgreementTermsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_468a8ffa-0132-4b87-8331-28643c2ac410_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCurrentAssetsTextBlock_f344eaa9-1460-490f-ba80-65e8ac2386b6_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentAssetsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expenses and Other Current Assets</link:label>
    <link:label id="lab_us-gaap_OtherCurrentAssetsTextBlock_label_en-US" xlink:label="lab_us-gaap_OtherCurrentAssetsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Current Assets [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentAssetsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCurrentAssetsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentAssetsTextBlock" xlink:to="lab_us-gaap_OtherCurrentAssetsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OfficerMember_ddabe0f2-1b61-4205-993b-df72d3084013_terseLabel_en-US" xlink:label="lab_srt_OfficerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Officer</link:label>
    <link:label id="lab_srt_OfficerMember_label_en-US" xlink:label="lab_srt_OfficerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Officer [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OfficerMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OfficerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OfficerMember" xlink:to="lab_srt_OfficerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_67170112-7ca7-4be2-974e-383a722239e0_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_742e9c58-dbb8-4e35-82cf-391e3ed2d4cf_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_10670b87-c291-49ff-b9a4-296d58b885fa_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a7575e81-9002-47a6-b974-2f0def6a250a_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net changes in operating assets and liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_9cdc05ca-85e4-4900-9766-8ead774eee09_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesLineItems_d3d38391-79a1-49aa-b9f4-423e264b1698_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities [Line Items]</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems" xlink:to="lab_us-gaap_MarketableSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_2ffece2c-afb8-4877-a147-36e115076120_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized (loss) gain on available-for-sale securities, net of tax of nil</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_c2113b79-afa8-416a-a7ca-968dcea19dc9_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure</link:label>
    <link:label id="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HeldToMaturitySecurities_d612ca95-d41a-426b-9569-eddc3cde912f_terseLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Held-to-maturity debt securities</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecurities_label_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-Maturity, Amortized Cost, before Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HeldToMaturitySecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecurities" xlink:to="lab_us-gaap_HeldToMaturitySecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_6901235e-3428-4a38-ae73-ba8c3e6e5c6a_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance shares vested, Weighted average grant date fair value (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_2780852f-2466-47cf-922c-1f85696a03d8_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_793a4d30-28f4-4c64-ab54-b76c17beaab4_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_6f825f5a-f714-40b5-be5e-f7331eb8d9f6_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected life of options in years</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_c93fbc35-3c8a-4472-a228-824dc4d68d9d_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockMember_97100dae-ce61-415e-8d7a-c852ed306640_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember" xlink:to="lab_us-gaap_EmployeeStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalLeaseObligationsIncurred_b365d827-a5cb-4742-8fde-7cdd2f1b2834_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_CapitalLeaseObligationsIncurred" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for amounts included in the measurement of lease liabilities</link:label>
    <link:label id="lab_us-gaap_CapitalLeaseObligationsIncurred_label_en-US" xlink:label="lab_us-gaap_CapitalLeaseObligationsIncurred" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Obligation Incurred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalLeaseObligationsIncurred" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalLeaseObligationsIncurred"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalLeaseObligationsIncurred" xlink:to="lab_us-gaap_CapitalLeaseObligationsIncurred" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_42355268-cd59-4d97-8b3e-8fde0aef1473_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term highly liquid investments</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableTradeCurrent_5398a6cd-3cbf-4c2a-b2ac-3b9d54d0e068_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableTradeCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableTradeCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableTradeCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Trade, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableTradeCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableTradeCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableTradeCurrent" xlink:to="lab_us-gaap_AccountsPayableTradeCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_e7e09408-2cec-4750-9ec9-7284259a55b7_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesTextBlock_20fd64c2-019f-40eb-95e3-b39e70f0e844_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesTextBlock_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesTextBlock" xlink:to="lab_us-gaap_MarketableSecuritiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_c2e0976b-c0e7-40d6-bd5c-82013841fdc2_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_3749ff3f-17ba-4529-bab9-21afc177bb75_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_88e9b27b-5ea0-4f30-b135-aa12e0295414_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares (in thousands)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_29807d4a-367b-4b83-a740-938dbe9cdf55_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recently adopted accounting pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_97cc7f1f-1ac4-4c7b-ac17-1ef5c869f5ed_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_4cb51fe3-3d9a-4aaa-b828-71bacea03c00_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForSoftware_62d947c7-7bd6-4913-be47-abf8a055be93_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForSoftware" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions to internal use-software implementation costs</link:label>
    <link:label id="lab_us-gaap_PaymentsForSoftware_label_en-US" xlink:label="lab_us-gaap_PaymentsForSoftware" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Software</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForSoftware" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForSoftware"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForSoftware" xlink:to="lab_us-gaap_PaymentsForSoftware" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_615374b6-0f98-4be8-967f-9cfdfba89607_terseLabel_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_label_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_703811e3-234b-4c94-b6cb-5be83957d87f_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired intellectual property and other intangible assets, net</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_3728f2fb-400d-4b83-a696-6ea175c240d4_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Carrying Amount</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_auph_LesseeOperatingLeaseLeaseNotYetCommencedLiabilityToBePaid_a7026bc5-aa4e-44b4-a55f-66e8ebe0af12_terseLabel_en-US" xlink:label="lab_auph_LesseeOperatingLeaseLeaseNotYetCommencedLiabilityToBePaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future value of minimum lease payments of leases not yet commenced</link:label>
    <link:label id="lab_auph_LesseeOperatingLeaseLeaseNotYetCommencedLiabilityToBePaid_label_en-US" xlink:label="lab_auph_LesseeOperatingLeaseLeaseNotYetCommencedLiabilityToBePaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Lease Not yet Commenced, Liability, to be Paid</link:label>
    <link:label id="lab_auph_LesseeOperatingLeaseLeaseNotYetCommencedLiabilityToBePaid_documentation_en-US" xlink:label="lab_auph_LesseeOperatingLeaseLeaseNotYetCommencedLiabilityToBePaid" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Lease Not yet Commenced, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_auph_LesseeOperatingLeaseLeaseNotYetCommencedLiabilityToBePaid" xlink:href="auph-20220331.xsd#auph_LesseeOperatingLeaseLeaseNotYetCommencedLiabilityToBePaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_auph_LesseeOperatingLeaseLeaseNotYetCommencedLiabilityToBePaid" xlink:to="lab_auph_LesseeOperatingLeaseLeaseNotYetCommencedLiabilityToBePaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicenseMember_f3750b3b-742e-4fbb-b366-aea863b1b45b_terseLabel_en-US" xlink:label="lab_us-gaap_LicenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License and collaboration revenue</link:label>
    <link:label id="lab_us-gaap_LicenseMember_label_en-US" xlink:label="lab_us-gaap_LicenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicenseMember" xlink:to="lab_us-gaap_LicenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_auph_PerformanceShareSandRestrictedStockUnitsRSUsMember_7c2d9c4d-7b82-4993-9a18-fa2c9367a5ef_terseLabel_en-US" xlink:label="lab_auph_PerformanceShareSandRestrictedStockUnitsRSUsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Share sand Restricted Stock Units (RSUs)</link:label>
    <link:label id="lab_auph_PerformanceShareSandRestrictedStockUnitsRSUsMember_label_en-US" xlink:label="lab_auph_PerformanceShareSandRestrictedStockUnitsRSUsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Share sand Restricted Stock Units (RSUs) [Member]</link:label>
    <link:label id="lab_auph_PerformanceShareSandRestrictedStockUnitsRSUsMember_documentation_en-US" xlink:label="lab_auph_PerformanceShareSandRestrictedStockUnitsRSUsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Share sand Restricted Stock Units (RSUs)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_auph_PerformanceShareSandRestrictedStockUnitsRSUsMember" xlink:href="auph-20220331.xsd#auph_PerformanceShareSandRestrictedStockUnitsRSUsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_auph_PerformanceShareSandRestrictedStockUnitsRSUsMember" xlink:to="lab_auph_PerformanceShareSandRestrictedStockUnitsRSUsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_84db8589-d075-4847-b5f3-175eb528c434_verboseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValueOutstanding_00e3bdbc-86fe-4532-bd82-17669fd21c52_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common shares - no par value, unlimited shares authorized, 141,742 and 141,600 shares issued and outstanding at March 31, 2022 and December 31, 2021, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValueOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValueOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValueOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValueOutstanding" xlink:to="lab_us-gaap_CommonStockValueOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_64050cb8-8dcb-4e63-b1aa-a3e08132c55b_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease costs</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_915d77a0-ce31-4261-89e4-a08ad3b63cea_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:to="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_d9f497d9-1101-48dc-9c36-dacc549ee677_terseLabel_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer equipment</link:label>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_label_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerEquipmentMember" xlink:to="lab_us-gaap_ComputerEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_c6f00a1d-48f4-441b-93ad-c189eafdd3f6_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related-Party Transactions</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_6c91d443-7bca-4ae0-815c-4d8d7aefa3aa_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_dfd48a8e-c921-4c19-a656-35399e03b483_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>auph-20220331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:778f08dd-b92a-42f0-b4bb-a50ecfb6a537,g:a60fc6d8-f25a-4b7b-af6a-b9dcc6be1df4-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.auriniapharma.com/role/CoverPage" xlink:type="simple" xlink:href="auph-20220331.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.auriniapharma.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_f8127d48-9d9e-4a77-b245-7f7387fee016" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_87743031-5e21-4d09-8419-95a7f77dd6dc" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f8127d48-9d9e-4a77-b245-7f7387fee016" xlink:to="loc_dei_DocumentType_87743031-5e21-4d09-8419-95a7f77dd6dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_bccf087d-8a0d-44b0-823c-1aae1baf8a5d" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f8127d48-9d9e-4a77-b245-7f7387fee016" xlink:to="loc_dei_DocumentQuarterlyReport_bccf087d-8a0d-44b0-823c-1aae1baf8a5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_ab5304ed-73ae-45ab-93ab-5f18a9255b96" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f8127d48-9d9e-4a77-b245-7f7387fee016" xlink:to="loc_dei_DocumentPeriodEndDate_ab5304ed-73ae-45ab-93ab-5f18a9255b96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_51ee4683-5c04-4560-93f3-c041262c6133" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f8127d48-9d9e-4a77-b245-7f7387fee016" xlink:to="loc_dei_DocumentTransitionReport_51ee4683-5c04-4560-93f3-c041262c6133" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_78351aae-50cb-40f3-97cb-2e068e9798d4" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f8127d48-9d9e-4a77-b245-7f7387fee016" xlink:to="loc_dei_EntityFileNumber_78351aae-50cb-40f3-97cb-2e068e9798d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_4a774118-4520-45e8-855b-085c66cd8bca" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f8127d48-9d9e-4a77-b245-7f7387fee016" xlink:to="loc_dei_EntityRegistrantName_4a774118-4520-45e8-855b-085c66cd8bca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_308bec94-2a24-4e42-8688-e5665a9de0dc" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f8127d48-9d9e-4a77-b245-7f7387fee016" xlink:to="loc_dei_EntityIncorporationStateCountryCode_308bec94-2a24-4e42-8688-e5665a9de0dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_347c5b7d-c5e5-4da7-9705-83bce2e6d2c2" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f8127d48-9d9e-4a77-b245-7f7387fee016" xlink:to="loc_dei_EntityTaxIdentificationNumber_347c5b7d-c5e5-4da7-9705-83bce2e6d2c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_adb44adb-8fa8-4ca4-b867-6064bf17c2fe" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f8127d48-9d9e-4a77-b245-7f7387fee016" xlink:to="loc_dei_EntityAddressAddressLine1_adb44adb-8fa8-4ca4-b867-6064bf17c2fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_f680d242-2021-4706-bee6-04218a862639" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f8127d48-9d9e-4a77-b245-7f7387fee016" xlink:to="loc_dei_EntityAddressCityOrTown_f680d242-2021-4706-bee6-04218a862639" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_38179c06-67c2-4f35-8dbe-e4ac50c078e7" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f8127d48-9d9e-4a77-b245-7f7387fee016" xlink:to="loc_dei_EntityAddressStateOrProvince_38179c06-67c2-4f35-8dbe-e4ac50c078e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_376e10e3-a9e9-416b-a252-a2f6c3d5c352" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f8127d48-9d9e-4a77-b245-7f7387fee016" xlink:to="loc_dei_EntityAddressPostalZipCode_376e10e3-a9e9-416b-a252-a2f6c3d5c352" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_701d9074-581c-48db-9e0d-802c1524606b" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f8127d48-9d9e-4a77-b245-7f7387fee016" xlink:to="loc_dei_CityAreaCode_701d9074-581c-48db-9e0d-802c1524606b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_27739afe-c800-4e78-8b4d-3e10ae22854e" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f8127d48-9d9e-4a77-b245-7f7387fee016" xlink:to="loc_dei_LocalPhoneNumber_27739afe-c800-4e78-8b4d-3e10ae22854e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_c3534f4f-a6e1-4def-b680-9bf317717b11" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f8127d48-9d9e-4a77-b245-7f7387fee016" xlink:to="loc_dei_EntityCurrentReportingStatus_c3534f4f-a6e1-4def-b680-9bf317717b11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_d2e8b158-61e6-4a29-a741-eddc9e157789" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f8127d48-9d9e-4a77-b245-7f7387fee016" xlink:to="loc_dei_EntityInteractiveDataCurrent_d2e8b158-61e6-4a29-a741-eddc9e157789" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_afbd77b4-4f20-4e6b-a146-401c69b34049" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f8127d48-9d9e-4a77-b245-7f7387fee016" xlink:to="loc_dei_EntityFilerCategory_afbd77b4-4f20-4e6b-a146-401c69b34049" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_13896a54-128e-4995-9eef-3e30054c4a74" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f8127d48-9d9e-4a77-b245-7f7387fee016" xlink:to="loc_dei_EntitySmallBusiness_13896a54-128e-4995-9eef-3e30054c4a74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_3e45dd4d-eae4-41d9-8c39-febb901a058e" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f8127d48-9d9e-4a77-b245-7f7387fee016" xlink:to="loc_dei_EntityEmergingGrowthCompany_3e45dd4d-eae4-41d9-8c39-febb901a058e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_78d9f4cd-7f37-45c2-82e4-4a666f6b92c9" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f8127d48-9d9e-4a77-b245-7f7387fee016" xlink:to="loc_dei_EntityShellCompany_78d9f4cd-7f37-45c2-82e4-4a666f6b92c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_d02bb69f-dc52-4561-b0d0-43c4d53d21df" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f8127d48-9d9e-4a77-b245-7f7387fee016" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_d02bb69f-dc52-4561-b0d0-43c4d53d21df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_08936a8b-20da-4fa6-8c53-05bee18b6ac8" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f8127d48-9d9e-4a77-b245-7f7387fee016" xlink:to="loc_dei_Security12bTitle_08936a8b-20da-4fa6-8c53-05bee18b6ac8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_b27eb921-0809-4a50-bbbe-2ca70ee49713" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f8127d48-9d9e-4a77-b245-7f7387fee016" xlink:to="loc_dei_TradingSymbol_b27eb921-0809-4a50-bbbe-2ca70ee49713" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_243abee6-ecc6-4fc3-a421-a1e167c1137f" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f8127d48-9d9e-4a77-b245-7f7387fee016" xlink:to="loc_dei_SecurityExchangeName_243abee6-ecc6-4fc3-a421-a1e167c1137f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_2914a73d-7319-4bcd-b4ae-0fb630cde7ff" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f8127d48-9d9e-4a77-b245-7f7387fee016" xlink:to="loc_dei_AmendmentFlag_2914a73d-7319-4bcd-b4ae-0fb630cde7ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_fc232f0b-30b7-49e6-90e0-6de4131159d1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f8127d48-9d9e-4a77-b245-7f7387fee016" xlink:to="loc_dei_DocumentFiscalYearFocus_fc232f0b-30b7-49e6-90e0-6de4131159d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_cbaa5abe-797e-491c-8455-52eec90f5f95" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f8127d48-9d9e-4a77-b245-7f7387fee016" xlink:to="loc_dei_DocumentFiscalPeriodFocus_cbaa5abe-797e-491c-8455-52eec90f5f95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_0d0df456-a4f9-4b79-a84d-f98d53a03456" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f8127d48-9d9e-4a77-b245-7f7387fee016" xlink:to="loc_dei_EntityCentralIndexKey_0d0df456-a4f9-4b79-a84d-f98d53a03456" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_b0b8835d-f36c-480a-ade0-d4e340dd08d4" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f8127d48-9d9e-4a77-b245-7f7387fee016" xlink:to="loc_dei_CurrentFiscalYearEndDate_b0b8835d-f36c-480a-ade0-d4e340dd08d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.auriniapharma.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="auph-20220331.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.auriniapharma.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_e7d9b8de-83cc-48cd-be25-15c626a33d45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_97aafe5c-ce03-4359-82cb-28952ae3a037" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_e7d9b8de-83cc-48cd-be25-15c626a33d45" xlink:to="loc_us-gaap_AssetsAbstract_97aafe5c-ce03-4359-82cb-28952ae3a037" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_838a0b8e-f9f2-427f-9488-550e5e15a3e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_97aafe5c-ce03-4359-82cb-28952ae3a037" xlink:to="loc_us-gaap_AssetsCurrentAbstract_838a0b8e-f9f2-427f-9488-550e5e15a3e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_254274d7-582a-406e-b017-2060a9e2d6ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_838a0b8e-f9f2-427f-9488-550e5e15a3e3" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_254274d7-582a-406e-b017-2060a9e2d6ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesCurrent_68ce5ee2-f69a-4f11-91ef-a0e85a1e4869" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_838a0b8e-f9f2-427f-9488-550e5e15a3e3" xlink:to="loc_us-gaap_DebtSecuritiesCurrent_68ce5ee2-f69a-4f11-91ef-a0e85a1e4869" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsAndOtherReceivablesNetCurrent_b81686df-3c94-49e4-b7e2-2f1fdc21594c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_838a0b8e-f9f2-427f-9488-550e5e15a3e3" xlink:to="loc_us-gaap_AccountsAndOtherReceivablesNetCurrent_b81686df-3c94-49e4-b7e2-2f1fdc21594c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_6c1d0e29-9f73-48d1-b0be-66b31e84cb4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_838a0b8e-f9f2-427f-9488-550e5e15a3e3" xlink:to="loc_us-gaap_InventoryNet_6c1d0e29-9f73-48d1-b0be-66b31e84cb4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_0bfd4488-11bb-4c05-a140-5378fb6f398a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_838a0b8e-f9f2-427f-9488-550e5e15a3e3" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_0bfd4488-11bb-4c05-a140-5378fb6f398a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_5d285f0d-a1f9-4a66-9715-c7c7ed6f837a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_838a0b8e-f9f2-427f-9488-550e5e15a3e3" xlink:to="loc_us-gaap_AssetsCurrent_5d285f0d-a1f9-4a66-9715-c7c7ed6f837a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrentAbstract_d816ff0d-7125-4ffd-af34-a0add07869e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsNoncurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_97aafe5c-ce03-4359-82cb-28952ae3a037" xlink:to="loc_us-gaap_AssetsNoncurrentAbstract_d816ff0d-7125-4ffd-af34-a0add07869e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_16e47d2e-53bc-4653-848c-cf7f36e7f781" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_d816ff0d-7125-4ffd-af34-a0add07869e3" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_16e47d2e-53bc-4653-848c-cf7f36e7f781" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_6b3c00ec-bfb9-435b-bb30-ee4d73cb9030" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_d816ff0d-7125-4ffd-af34-a0add07869e3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_6b3c00ec-bfb9-435b-bb30-ee4d73cb9030" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_b1178e1d-e0a7-4af6-bbfa-b293e7b24591" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_d816ff0d-7125-4ffd-af34-a0add07869e3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_b1178e1d-e0a7-4af6-bbfa-b293e7b24591" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_ed5a7de3-e0b3-4841-9c40-f498cf3482b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_d816ff0d-7125-4ffd-af34-a0add07869e3" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_ed5a7de3-e0b3-4841-9c40-f498cf3482b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_2449ccd3-fdf8-40a3-854b-5194906f806a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_d816ff0d-7125-4ffd-af34-a0add07869e3" xlink:to="loc_us-gaap_Assets_2449ccd3-fdf8-40a3-854b-5194906f806a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_62fdf76e-3ffe-40b0-9d3f-ac3d8c8c7b33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_e7d9b8de-83cc-48cd-be25-15c626a33d45" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_62fdf76e-3ffe-40b0-9d3f-ac3d8c8c7b33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_584a4591-5957-4b4f-968d-dfa4795fad45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_62fdf76e-3ffe-40b0-9d3f-ac3d8c8c7b33" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_584a4591-5957-4b4f-968d-dfa4795fad45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_d52b4abe-ccdb-450c-a320-f86117deeea7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_584a4591-5957-4b4f-968d-dfa4795fad45" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_d52b4abe-ccdb-450c-a320-f86117deeea7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_6dae7f3f-2996-4c06-bfb2-a781c21a9288" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_584a4591-5957-4b4f-968d-dfa4795fad45" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_6dae7f3f-2996-4c06-bfb2-a781c21a9288" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_99a147ee-b7a1-413b-a806-94a57e4d84b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_584a4591-5957-4b4f-968d-dfa4795fad45" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_99a147ee-b7a1-413b-a806-94a57e4d84b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_3dc0821b-a305-4808-9b06-96d097115cd2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_62fdf76e-3ffe-40b0-9d3f-ac3d8c8c7b33" xlink:to="loc_us-gaap_LiabilitiesCurrent_3dc0821b-a305-4808-9b06-96d097115cd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_689a6662-83f5-4765-9273-67e5c74fc3b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_62fdf76e-3ffe-40b0-9d3f-ac3d8c8c7b33" xlink:to="loc_us-gaap_LiabilitiesNoncurrentAbstract_689a6662-83f5-4765-9273-67e5c74fc3b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_7f999496-2a19-4081-accf-4a00f67fd620" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_689a6662-83f5-4765-9273-67e5c74fc3b0" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_7f999496-2a19-4081-accf-4a00f67fd620" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_479d6896-0769-4bda-9b95-e8a03d1d062f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_689a6662-83f5-4765-9273-67e5c74fc3b0" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_479d6896-0769-4bda-9b95-e8a03d1d062f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_5fba62ca-04d5-484a-a2a8-b2015ec18914" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_62fdf76e-3ffe-40b0-9d3f-ac3d8c8c7b33" xlink:to="loc_us-gaap_Liabilities_5fba62ca-04d5-484a-a2a8-b2015ec18914" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_8b0fd651-e3a6-4ec5-9341-9541070836f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_62fdf76e-3ffe-40b0-9d3f-ac3d8c8c7b33" xlink:to="loc_us-gaap_CommitmentsAndContingencies_8b0fd651-e3a6-4ec5-9341-9541070836f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_bf5aa312-2d5f-4be0-be40-1312d936196b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_62fdf76e-3ffe-40b0-9d3f-ac3d8c8c7b33" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_bf5aa312-2d5f-4be0-be40-1312d936196b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValueOutstanding_38508703-7771-40ab-93b8-ab51f8d5c274" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValueOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_bf5aa312-2d5f-4be0-be40-1312d936196b" xlink:to="loc_us-gaap_CommonStockValueOutstanding_38508703-7771-40ab-93b8-ab51f8d5c274" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_88e5fb5f-f16f-4574-8108-941dfe35641d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_bf5aa312-2d5f-4be0-be40-1312d936196b" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_88e5fb5f-f16f-4574-8108-941dfe35641d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_4f19a4e1-c119-4765-b9ea-624edcbdd5b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_bf5aa312-2d5f-4be0-be40-1312d936196b" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_4f19a4e1-c119-4765-b9ea-624edcbdd5b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_4f45017b-6aad-43eb-9172-88de89f6acfb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_bf5aa312-2d5f-4be0-be40-1312d936196b" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_4f45017b-6aad-43eb-9172-88de89f6acfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_0aba2b9e-8d51-4902-b00f-6c9e5b8efff9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_bf5aa312-2d5f-4be0-be40-1312d936196b" xlink:to="loc_us-gaap_StockholdersEquity_0aba2b9e-8d51-4902-b00f-6c9e5b8efff9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_39ca748b-efd1-4ab9-bb4b-56de07f45eef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_62fdf76e-3ffe-40b0-9d3f-ac3d8c8c7b33" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_39ca748b-efd1-4ab9-bb4b-56de07f45eef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.auriniapharma.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="auph-20220331.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.auriniapharma.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_96ff440b-9ffc-4015-884e-6cc288dd4be3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_eecfb05f-ef02-4344-95a0-55035a6d6c97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_96ff440b-9ffc-4015-884e-6cc288dd4be3" xlink:to="loc_us-gaap_CommonStockSharesIssued_eecfb05f-ef02-4344-95a0-55035a6d6c97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_abe092a0-ddeb-4b24-b82a-70858c6495c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_96ff440b-9ffc-4015-884e-6cc288dd4be3" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_abe092a0-ddeb-4b24-b82a-70858c6495c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="auph-20220331.xsd#CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"/>
  <link:presentationLink xlink:role="http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_fd7e1c50-0185-458e-99cb-6303f59dfe02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_d543e310-9705-48e3-aa84-ccbe40dc5c7e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_fd7e1c50-0185-458e-99cb-6303f59dfe02" xlink:to="loc_us-gaap_StatementTable_d543e310-9705-48e3-aa84-ccbe40dc5c7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_29346e3e-6765-4e7d-929d-f5f5349e5787" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_d543e310-9705-48e3-aa84-ccbe40dc5c7e" xlink:to="loc_srt_ProductOrServiceAxis_29346e3e-6765-4e7d-929d-f5f5349e5787" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_776c6203-f202-474c-81ad-311780ada52b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_29346e3e-6765-4e7d-929d-f5f5349e5787" xlink:to="loc_srt_ProductsAndServicesDomain_776c6203-f202-474c-81ad-311780ada52b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_fa854be9-2739-4725-9fe8-8a59086e17cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_776c6203-f202-474c-81ad-311780ada52b" xlink:to="loc_us-gaap_ProductMember_fa854be9-2739-4725-9fe8-8a59086e17cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_7b2cee62-f66e-4dac-ba0d-1eadb289b438" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_776c6203-f202-474c-81ad-311780ada52b" xlink:to="loc_us-gaap_LicenseMember_7b2cee62-f66e-4dac-ba0d-1eadb289b438" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_e483c03c-6130-47e5-88da-fbf22344fda8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_d543e310-9705-48e3-aa84-ccbe40dc5c7e" xlink:to="loc_us-gaap_StatementLineItems_e483c03c-6130-47e5-88da-fbf22344fda8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_f37e3682-2941-4043-8d81-952bc8821696" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e483c03c-6130-47e5-88da-fbf22344fda8" xlink:to="loc_us-gaap_RevenuesAbstract_f37e3682-2941-4043-8d81-952bc8821696" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_a522ee77-a439-465e-bdd4-59553bddcb50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_f37e3682-2941-4043-8d81-952bc8821696" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_a522ee77-a439-465e-bdd4-59553bddcb50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_701c8a37-6fa2-4131-8dcd-b50149abd4b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e483c03c-6130-47e5-88da-fbf22344fda8" xlink:to="loc_us-gaap_OperatingExpensesAbstract_701c8a37-6fa2-4131-8dcd-b50149abd4b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue_86ea7bb3-9cf1-4cda-8682-236eedcb551b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfRevenue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_701c8a37-6fa2-4131-8dcd-b50149abd4b7" xlink:to="loc_us-gaap_CostOfRevenue_86ea7bb3-9cf1-4cda-8682-236eedcb551b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_d74fd3de-a897-4cd2-9a5e-f8f4277ba518" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_701c8a37-6fa2-4131-8dcd-b50149abd4b7" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_d74fd3de-a897-4cd2-9a5e-f8f4277ba518" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_ad21ad44-bf57-4110-bb46-7223ff0e5715" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_701c8a37-6fa2-4131-8dcd-b50149abd4b7" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_ad21ad44-bf57-4110-bb46-7223ff0e5715" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_7ef90984-0275-4a05-aa5f-2d660a4d2c05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_701c8a37-6fa2-4131-8dcd-b50149abd4b7" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_7ef90984-0275-4a05-aa5f-2d660a4d2c05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_c782bcbe-efe5-49d5-b880-bc558a39d670" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_701c8a37-6fa2-4131-8dcd-b50149abd4b7" xlink:to="loc_us-gaap_CostsAndExpenses_c782bcbe-efe5-49d5-b880-bc558a39d670" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_cc6959c3-a894-4b49-96c1-6e0c2adcdd5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e483c03c-6130-47e5-88da-fbf22344fda8" xlink:to="loc_us-gaap_OperatingIncomeLoss_cc6959c3-a894-4b49-96c1-6e0c2adcdd5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_e5aeb6f5-5449-44d8-8bed-60456c02b010" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e483c03c-6130-47e5-88da-fbf22344fda8" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_e5aeb6f5-5449-44d8-8bed-60456c02b010" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_53b4e593-7eba-4d57-b3cb-6ccd12d5a942" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e483c03c-6130-47e5-88da-fbf22344fda8" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_53b4e593-7eba-4d57-b3cb-6ccd12d5a942" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_e2660f87-d73d-4a1b-85cd-bf6539136104" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e483c03c-6130-47e5-88da-fbf22344fda8" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_e2660f87-d73d-4a1b-85cd-bf6539136104" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_b35c4c12-c21f-42e3-a7ab-8745e9a23489" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e483c03c-6130-47e5-88da-fbf22344fda8" xlink:to="loc_us-gaap_NetIncomeLoss_b35c4c12-c21f-42e3-a7ab-8745e9a23489" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_b762c2f7-f19e-4c2f-99b3-b11993966e1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e483c03c-6130-47e5-88da-fbf22344fda8" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_b762c2f7-f19e-4c2f-99b3-b11993966e1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_e6fcede2-8158-46e9-b4db-1acaff20bd0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_b762c2f7-f19e-4c2f-99b3-b11993966e1b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_e6fcede2-8158-46e9-b4db-1acaff20bd0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_40ae67a5-838c-4a40-b459-36bb630ac3c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e483c03c-6130-47e5-88da-fbf22344fda8" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_40ae67a5-838c-4a40-b459-36bb630ac3c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_e2929133-1cd4-43ce-81a8-08ebfe91662a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e483c03c-6130-47e5-88da-fbf22344fda8" xlink:to="loc_us-gaap_EarningsPerShareBasic_e2929133-1cd4-43ce-81a8-08ebfe91662a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_ba537017-2ceb-4e67-978a-dc3529b0a939" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e483c03c-6130-47e5-88da-fbf22344fda8" xlink:to="loc_us-gaap_EarningsPerShareDiluted_ba537017-2ceb-4e67-978a-dc3529b0a939" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_3a8cb0f0-c7a9-43d6-b2c1-9174dae7ab36" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e483c03c-6130-47e5-88da-fbf22344fda8" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_3a8cb0f0-c7a9-43d6-b2c1-9174dae7ab36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_c9c89c69-4c05-4e81-bf34-27d52c13a38b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e483c03c-6130-47e5-88da-fbf22344fda8" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_c9c89c69-4c05-4e81-bf34-27d52c13a38b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossParenthetical" xlink:type="simple" xlink:href="auph-20220331.xsd#CondensedConsolidatedStatementsofOperationsandComprehensiveLossParenthetical"/>
  <link:presentationLink xlink:role="http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_af57be87-2da2-47ab-9196-5f0689a3bef2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax_81e503e3-39e4-4174-9cd7-cb4e91a0752c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_af57be87-2da2-47ab-9196-5f0689a3bef2" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax_81e503e3-39e4-4174-9cd7-cb4e91a0752c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofShareholdersEquity" xlink:type="simple" xlink:href="auph-20220331.xsd#CondensedConsolidatedStatementsofShareholdersEquity"/>
  <link:presentationLink xlink:role="http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofShareholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_801ccaf0-07c7-403f-aed5-064160a4dfc8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_85b7970e-ff7c-4bc5-9291-d64f325cc6cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_801ccaf0-07c7-403f-aed5-064160a4dfc8" xlink:to="loc_us-gaap_StatementTable_85b7970e-ff7c-4bc5-9291-d64f325cc6cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_0f8b30a8-7854-475f-bab4-10ef0820e84c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_85b7970e-ff7c-4bc5-9291-d64f325cc6cd" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_0f8b30a8-7854-475f-bab4-10ef0820e84c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_085982ed-6249-43e1-9910-aacffb351956" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_0f8b30a8-7854-475f-bab4-10ef0820e84c" xlink:to="loc_us-gaap_EquityComponentDomain_085982ed-6249-43e1-9910-aacffb351956" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_a22b2734-9282-4b0d-b8fe-bb1840fd386f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_085982ed-6249-43e1-9910-aacffb351956" xlink:to="loc_us-gaap_CommonStockMember_a22b2734-9282-4b0d-b8fe-bb1840fd386f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_c8a16097-09db-4352-b851-3b3bf7d1cc21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_085982ed-6249-43e1-9910-aacffb351956" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_c8a16097-09db-4352-b851-3b3bf7d1cc21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_a139a5e4-9a9a-41cf-b177-9c35191caf22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_085982ed-6249-43e1-9910-aacffb351956" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_a139a5e4-9a9a-41cf-b177-9c35191caf22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_735f73ad-e0f5-4084-8a65-11c94f9e0cc2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_085982ed-6249-43e1-9910-aacffb351956" xlink:to="loc_us-gaap_RetainedEarningsMember_735f73ad-e0f5-4084-8a65-11c94f9e0cc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_3cc433bc-d64c-4a6e-beb1-3c1e7258e20a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_85b7970e-ff7c-4bc5-9291-d64f325cc6cd" xlink:to="loc_us-gaap_StatementLineItems_3cc433bc-d64c-4a6e-beb1-3c1e7258e20a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f9085b1e-a6eb-4a74-a3a5-89de3504f461" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3cc433bc-d64c-4a6e-beb1-3c1e7258e20a" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f9085b1e-a6eb-4a74-a3a5-89de3504f461" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_96f62425-d0f6-4908-be0b-55e50dbb19e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f9085b1e-a6eb-4a74-a3a5-89de3504f461" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_96f62425-d0f6-4908-be0b-55e50dbb19e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_4392463c-da0b-4940-b80e-1f06db0d9ab4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f9085b1e-a6eb-4a74-a3a5-89de3504f461" xlink:to="loc_us-gaap_StockholdersEquity_4392463c-da0b-4940-b80e-1f06db0d9ab4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_48095abc-c515-422e-88cc-50377e4a811d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f9085b1e-a6eb-4a74-a3a5-89de3504f461" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_48095abc-c515-422e-88cc-50377e4a811d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_b2b397d5-2dc4-41a8-be07-0dfcc274929c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f9085b1e-a6eb-4a74-a3a5-89de3504f461" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_b2b397d5-2dc4-41a8-be07-0dfcc274929c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_45d76d75-f625-46e9-8328-cd5cc7cc8a9a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f9085b1e-a6eb-4a74-a3a5-89de3504f461" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_45d76d75-f625-46e9-8328-cd5cc7cc8a9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_b8c5b47b-7204-4b40-af14-b4e98e2d0937" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f9085b1e-a6eb-4a74-a3a5-89de3504f461" xlink:to="loc_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_b8c5b47b-7204-4b40-af14-b4e98e2d0937" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_5b1abf2d-cf13-4324-b5d7-8d42775f185b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f9085b1e-a6eb-4a74-a3a5-89de3504f461" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_5b1abf2d-cf13-4324-b5d7-8d42775f185b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_2ac6cc4e-d5c5-4d13-837f-92f0f07c7fe6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f9085b1e-a6eb-4a74-a3a5-89de3504f461" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_2ac6cc4e-d5c5-4d13-837f-92f0f07c7fe6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_354fb5ce-f661-4616-9e71-bc744fa62576" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f9085b1e-a6eb-4a74-a3a5-89de3504f461" xlink:to="loc_us-gaap_NetIncomeLoss_354fb5ce-f661-4616-9e71-bc744fa62576" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_3d69a950-dbbb-44a8-a067-149077f94141" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f9085b1e-a6eb-4a74-a3a5-89de3504f461" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_3d69a950-dbbb-44a8-a067-149077f94141" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_dd1ed54c-2d10-482b-80a7-7c3ef2a033c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f9085b1e-a6eb-4a74-a3a5-89de3504f461" xlink:to="loc_us-gaap_StockholdersEquity_dd1ed54c-2d10-482b-80a7-7c3ef2a033c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="auph-20220331.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_d25b589f-0c78-4cf9-bdec-380642e0f7e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_309542ac-f965-4ed8-8de3-0dac1d5e0435" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_d25b589f-0c78-4cf9-bdec-380642e0f7e8" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_309542ac-f965-4ed8-8de3-0dac1d5e0435" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_01a3d54a-4b3b-4b69-96ff-4e3f92880a14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_309542ac-f965-4ed8-8de3-0dac1d5e0435" xlink:to="loc_us-gaap_NetIncomeLoss_01a3d54a-4b3b-4b69-96ff-4e3f92880a14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_59c55a1d-a8bd-4d57-8c8c-ac1bbbb06497" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_309542ac-f965-4ed8-8de3-0dac1d5e0435" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_59c55a1d-a8bd-4d57-8c8c-ac1bbbb06497" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_e0a0a0bc-18a3-4e41-a65d-17d3a2946415" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_59c55a1d-a8bd-4d57-8c8c-ac1bbbb06497" xlink:to="loc_us-gaap_Depreciation_e0a0a0bc-18a3-4e41-a65d-17d3a2946415" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_ac969c67-aba0-4683-8554-91634c9e693a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_59c55a1d-a8bd-4d57-8c8c-ac1bbbb06497" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_ac969c67-aba0-4683-8554-91634c9e693a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_1c0cb0c0-e94c-4bce-bd89-55e9c896f5f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_59c55a1d-a8bd-4d57-8c8c-ac1bbbb06497" xlink:to="loc_us-gaap_ShareBasedCompensation_1c0cb0c0-e94c-4bce-bd89-55e9c896f5f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_87582a6a-725f-4983-98b7-76278a5ab60a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_59c55a1d-a8bd-4d57-8c8c-ac1bbbb06497" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_87582a6a-725f-4983-98b7-76278a5ab60a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_290fab13-5db9-4cac-9efa-8f099962c6ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_59c55a1d-a8bd-4d57-8c8c-ac1bbbb06497" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_290fab13-5db9-4cac-9efa-8f099962c6ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInReceivables_dd21662d-303f-459c-a1bd-38c79613c9f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInReceivables"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_290fab13-5db9-4cac-9efa-8f099962c6ca" xlink:to="loc_us-gaap_IncreaseDecreaseInReceivables_dd21662d-303f-459c-a1bd-38c79613c9f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_ea6999e3-68b7-48d8-b27f-688c504a4021" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_290fab13-5db9-4cac-9efa-8f099962c6ca" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_ea6999e3-68b7-48d8-b27f-688c504a4021" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_5d25d933-d2df-4ad1-ac6b-c16a9439799e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_290fab13-5db9-4cac-9efa-8f099962c6ca" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_5d25d933-d2df-4ad1-ac6b-c16a9439799e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_ca5d9d58-34b2-4aa8-93e5-17b2db4899c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_290fab13-5db9-4cac-9efa-8f099962c6ca" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_ca5d9d58-34b2-4aa8-93e5-17b2db4899c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_ace0bc1b-6034-4b77-8566-d91b96dd5800" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_290fab13-5db9-4cac-9efa-8f099962c6ca" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_ace0bc1b-6034-4b77-8566-d91b96dd5800" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_c76922ad-8018-4b38-9445-252d2fb258e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_290fab13-5db9-4cac-9efa-8f099962c6ca" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_c76922ad-8018-4b38-9445-252d2fb258e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_00dd9156-1f1a-477b-b75c-e128a7f12c0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_309542ac-f965-4ed8-8de3-0dac1d5e0435" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_00dd9156-1f1a-477b-b75c-e128a7f12c0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_325b3d94-dfd0-4943-b2d2-3c79ff22ece2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_d25b589f-0c78-4cf9-bdec-380642e0f7e8" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_325b3d94-dfd0-4943-b2d2-3c79ff22ece2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_374dfb37-dd47-4c46-9049-17b9a34a7402" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_325b3d94-dfd0-4943-b2d2-3c79ff22ece2" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_374dfb37-dd47-4c46-9049-17b9a34a7402" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_4e1db702-8dfb-4f8b-b55c-42ee41bfcabb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_325b3d94-dfd0-4943-b2d2-3c79ff22ece2" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_4e1db702-8dfb-4f8b-b55c-42ee41bfcabb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireLeaseReceivables_10ccc06e-ea77-4637-ad42-797567c67702" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireLeaseReceivables"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_325b3d94-dfd0-4943-b2d2-3c79ff22ece2" xlink:to="loc_us-gaap_PaymentsToAcquireLeaseReceivables_10ccc06e-ea77-4637-ad42-797567c67702" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets_40338153-7585-4252-aa45-2ccfe48ff80c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireOtherProductiveAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_325b3d94-dfd0-4943-b2d2-3c79ff22ece2" xlink:to="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets_40338153-7585-4252-aa45-2ccfe48ff80c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForSoftware_3cd04250-9773-4d64-8cef-d62631db5988" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForSoftware"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_325b3d94-dfd0-4943-b2d2-3c79ff22ece2" xlink:to="loc_us-gaap_PaymentsForSoftware_3cd04250-9773-4d64-8cef-d62631db5988" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_0b640466-0f79-4e0c-bfc2-c25d25315259" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_325b3d94-dfd0-4943-b2d2-3c79ff22ece2" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_0b640466-0f79-4e0c-bfc2-c25d25315259" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f8c50314-a518-4f9b-b9fe-59f57e66d951" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_325b3d94-dfd0-4943-b2d2-3c79ff22ece2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f8c50314-a518-4f9b-b9fe-59f57e66d951" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_95618fd3-ef29-455c-b846-9d08d15bbc3b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_d25b589f-0c78-4cf9-bdec-380642e0f7e8" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_95618fd3-ef29-455c-b846-9d08d15bbc3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_137b8ea4-7b5b-46e5-b265-fbfca5459391" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_95618fd3-ef29-455c-b846-9d08d15bbc3b" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_137b8ea4-7b5b-46e5-b265-fbfca5459391" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_0801ecc1-98c3-48dc-980c-add0ed55c0fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_95618fd3-ef29-455c-b846-9d08d15bbc3b" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_0801ecc1-98c3-48dc-980c-add0ed55c0fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_bb8fe425-2fac-4a94-a182-f68664715898" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_95618fd3-ef29-455c-b846-9d08d15bbc3b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_bb8fe425-2fac-4a94-a182-f68664715898" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2e79d316-0eb2-4619-a010-13531f819b47" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_d25b589f-0c78-4cf9-bdec-380642e0f7e8" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2e79d316-0eb2-4619-a010-13531f819b47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7ab66070-b8e6-440b-b0e8-53f8fbc9521a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_d25b589f-0c78-4cf9-bdec-380642e0f7e8" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7ab66070-b8e6-440b-b0e8-53f8fbc9521a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6ebf9388-be6b-4c36-8e78-179a10d1fe28" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_d25b589f-0c78-4cf9-bdec-380642e0f7e8" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6ebf9388-be6b-4c36-8e78-179a10d1fe28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_c099172d-bf6a-4aa5-91c2-7f74156fd6e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_d25b589f-0c78-4cf9-bdec-380642e0f7e8" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_c099172d-bf6a-4aa5-91c2-7f74156fd6e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromInterestReceived_836144bd-ebb2-476b-bacc-95ef75da1ff6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromInterestReceived"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_c099172d-bf6a-4aa5-91c2-7f74156fd6e1" xlink:to="loc_us-gaap_ProceedsFromInterestReceived_836144bd-ebb2-476b-bacc-95ef75da1ff6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalLeaseObligationsIncurred_c9a0ab82-92e5-49a4-9968-7521e15764dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalLeaseObligationsIncurred"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_c099172d-bf6a-4aa5-91c2-7f74156fd6e1" xlink:to="loc_us-gaap_CapitalLeaseObligationsIncurred_c9a0ab82-92e5-49a4-9968-7521e15764dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_adb125ef-f4a9-4e27-854b-7a1aca78e3c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_d25b589f-0c78-4cf9-bdec-380642e0f7e8" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_adb125ef-f4a9-4e27-854b-7a1aca78e3c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_6ff558fa-ba3c-4f18-8e60-9c6cd62b8b19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_adb125ef-f4a9-4e27-854b-7a1aca78e3c2" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_6ff558fa-ba3c-4f18-8e60-9c6cd62b8b19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalCashFlowElementsSummationsAbstract_e8e71fae-b920-44e1-bebe-e47cacd5deee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalCashFlowElementsSummationsAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_d25b589f-0c78-4cf9-bdec-380642e0f7e8" xlink:to="loc_us-gaap_AdditionalCashFlowElementsSummationsAbstract_e8e71fae-b920-44e1-bebe-e47cacd5deee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_df6d12ec-1d62-429e-aaa9-e890900b796e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdditionalCashFlowElementsSummationsAbstract_e8e71fae-b920-44e1-bebe-e47cacd5deee" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_df6d12ec-1d62-429e-aaa9-e890900b796e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_9ab239cc-1b59-4086-8aa6-40276fc80add" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdditionalCashFlowElementsSummationsAbstract_e8e71fae-b920-44e1-bebe-e47cacd5deee" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalents_9ab239cc-1b59-4086-8aa6-40276fc80add" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9c022e89-a90b-4cf8-b982-68449c3fc516" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdditionalCashFlowElementsSummationsAbstract_e8e71fae-b920-44e1-bebe-e47cacd5deee" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9c022e89-a90b-4cf8-b982-68449c3fc516" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.auriniapharma.com/role/OrganizationandDescriptionofBusiness" xlink:type="simple" xlink:href="auph-20220331.xsd#OrganizationandDescriptionofBusiness"/>
  <link:presentationLink xlink:role="http://www.auriniapharma.com/role/OrganizationandDescriptionofBusiness" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9a650848-a85d-4bb5-8769-8a7f644a1ca4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_1707221b-9aba-494a-8293-4bac96f5c0c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9a650848-a85d-4bb5-8769-8a7f644a1ca4" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_1707221b-9aba-494a-8293-4bac96f5c0c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.auriniapharma.com/role/BasisofPresentation" xlink:type="simple" xlink:href="auph-20220331.xsd#BasisofPresentation"/>
  <link:presentationLink xlink:role="http://www.auriniapharma.com/role/BasisofPresentation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4bdc09a6-0adf-42e2-a39d-ff402bc7de69" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccounting_f9a61431-6b4d-4b40-aa71-ba210a3d1ea2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccounting"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4bdc09a6-0adf-42e2-a39d-ff402bc7de69" xlink:to="loc_us-gaap_BasisOfAccounting_f9a61431-6b4d-4b40-aa71-ba210a3d1ea2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.auriniapharma.com/role/BasisofPresentationDetails" xlink:type="simple" xlink:href="auph-20220331.xsd#BasisofPresentationDetails"/>
  <link:presentationLink xlink:role="http://www.auriniapharma.com/role/BasisofPresentationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_bdaf9b02-1969-4bce-b455-291c581b0a03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_c36f959c-8eb9-4fdf-92bc-872154166407" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_bdaf9b02-1969-4bce-b455-291c581b0a03" xlink:to="loc_us-gaap_NumberOfOperatingSegments_c36f959c-8eb9-4fdf-92bc-872154166407" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_auph_CashCashEquivalentsAndDebtSecuritiesCurrent_6d2d17dd-8c4d-4407-af53-b13cc27632bb" xlink:href="auph-20220331.xsd#auph_CashCashEquivalentsAndDebtSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_bdaf9b02-1969-4bce-b455-291c581b0a03" xlink:to="loc_auph_CashCashEquivalentsAndDebtSecuritiesCurrent_6d2d17dd-8c4d-4407-af53-b13cc27632bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.auriniapharma.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="auph-20220331.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.auriniapharma.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_ebe83a0e-4ab8-4cb8-8622-16a606872cf8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_caf64c96-370f-4595-9fb5-fe66c685098a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ebe83a0e-4ab8-4cb8-8622-16a606872cf8" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_caf64c96-370f-4595-9fb5-fe66c685098a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="auph-20220331.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0ac17123-1df7-457f-a316-98047796a129" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_e00e9aa0-20d8-4d66-9726-1683c8ac1423" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0ac17123-1df7-457f-a316-98047796a129" xlink:to="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_e00e9aa0-20d8-4d66-9726-1683c8ac1423" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_40b4f085-a93c-4428-8f8a-60ffbe52ba15" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0ac17123-1df7-457f-a316-98047796a129" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_40b4f085-a93c-4428-8f8a-60ffbe52ba15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_897b956e-5513-4f49-a648-419f04b13662" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0ac17123-1df7-457f-a316-98047796a129" xlink:to="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_897b956e-5513-4f49-a648-419f04b13662" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_8e74288d-60ff-4f9c-8fe9-546543e5bcae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0ac17123-1df7-457f-a316-98047796a129" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_8e74288d-60ff-4f9c-8fe9-546543e5bcae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_ab58ad0b-9f56-48ed-ac38-1f450f6f94f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0ac17123-1df7-457f-a316-98047796a129" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_ab58ad0b-9f56-48ed-ac38-1f450f6f94f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="auph-20220331.xsd#SummaryofSignificantAccountingPoliciesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_119e2a33-948c-45c3-8ed5-966cf5c4145f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_e128c5fb-a7a3-4472-bb0b-b2bd83c6fb04" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_119e2a33-948c-45c3-8ed5-966cf5c4145f" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_e128c5fb-a7a3-4472-bb0b-b2bd83c6fb04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_8b3e252b-c231-42af-bcf0-4bfaf220c4de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_e128c5fb-a7a3-4472-bb0b-b2bd83c6fb04" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_8b3e252b-c231-42af-bcf0-4bfaf220c4de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_83b7b3f0-8550-45a9-8d02-41fc3cc5b424" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_8b3e252b-c231-42af-bcf0-4bfaf220c4de" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_83b7b3f0-8550-45a9-8d02-41fc3cc5b424" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_6d737722-132f-4c7a-a67d-f0dc1ccd4a76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_83b7b3f0-8550-45a9-8d02-41fc3cc5b424" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_6d737722-132f-4c7a-a67d-f0dc1ccd4a76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_5fc13dd8-df72-4838-b17c-24ca2219b5f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_e128c5fb-a7a3-4472-bb0b-b2bd83c6fb04" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_5fc13dd8-df72-4838-b17c-24ca2219b5f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_9fcea0c5-613e-4393-8cef-83817a892213" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_5fc13dd8-df72-4838-b17c-24ca2219b5f8" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_9fcea0c5-613e-4393-8cef-83817a892213" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_a4b55f9f-f6af-4ab6-a014-22e9bb99730a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_9fcea0c5-613e-4393-8cef-83817a892213" xlink:to="loc_us-gaap_SalesRevenueNetMember_a4b55f9f-f6af-4ab6-a014-22e9bb99730a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_dfc5c6c6-f508-4534-8b70-188dbbaf692c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_e128c5fb-a7a3-4472-bb0b-b2bd83c6fb04" xlink:to="loc_srt_MajorCustomersAxis_dfc5c6c6-f508-4534-8b70-188dbbaf692c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_21fc246f-e1d4-438c-b1d5-afb863696733" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_dfc5c6c6-f508-4534-8b70-188dbbaf692c" xlink:to="loc_srt_NameOfMajorCustomerDomain_21fc246f-e1d4-438c-b1d5-afb863696733" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_auph_SpecialtyPharmacyOneMember_1cc7ed0f-aa84-42e0-bfe4-f0dab53429cd" xlink:href="auph-20220331.xsd#auph_SpecialtyPharmacyOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_21fc246f-e1d4-438c-b1d5-afb863696733" xlink:to="loc_auph_SpecialtyPharmacyOneMember_1cc7ed0f-aa84-42e0-bfe4-f0dab53429cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_auph_SpecialtyPharmacyTwoMember_3a2aa5ec-7a84-4172-bfd9-d11c8c3fa691" xlink:href="auph-20220331.xsd#auph_SpecialtyPharmacyTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_21fc246f-e1d4-438c-b1d5-afb863696733" xlink:to="loc_auph_SpecialtyPharmacyTwoMember_3a2aa5ec-7a84-4172-bfd9-d11c8c3fa691" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_974a2341-d1b3-4e58-87b3-158e275b2350" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_e128c5fb-a7a3-4472-bb0b-b2bd83c6fb04" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_974a2341-d1b3-4e58-87b3-158e275b2350" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_39088d05-cfbc-4083-8842-612546872daa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCash"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_974a2341-d1b3-4e58-87b3-158e275b2350" xlink:to="loc_us-gaap_RestrictedCash_39088d05-cfbc-4083-8842-612546872daa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_819d3499-5195-470a-ac80-e8dc44bd4c88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_974a2341-d1b3-4e58-87b3-158e275b2350" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_819d3499-5195-470a-ac80-e8dc44bd4c88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsAndOtherReceivablesNetCurrent_d433e677-4e41-470c-b715-6b0a0c23dbae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_974a2341-d1b3-4e58-87b3-158e275b2350" xlink:to="loc_us-gaap_AccountsAndOtherReceivablesNetCurrent_d433e677-4e41-470c-b715-6b0a0c23dbae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_cea6fdbc-7021-4752-a9a4-acaeb0334abe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_974a2341-d1b3-4e58-87b3-158e275b2350" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_cea6fdbc-7021-4752-a9a4-acaeb0334abe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.auriniapharma.com/role/Investments" xlink:type="simple" xlink:href="auph-20220331.xsd#Investments"/>
  <link:presentationLink xlink:role="http://www.auriniapharma.com/role/Investments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_b61858ba-d197-4107-b1c1-f3af8ceae61d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_d03ed29b-257c-4545-bb40-84e768aedfec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_b61858ba-d197-4107-b1c1-f3af8ceae61d" xlink:to="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_d03ed29b-257c-4545-bb40-84e768aedfec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.auriniapharma.com/role/InvestmentsTables" xlink:type="simple" xlink:href="auph-20220331.xsd#InvestmentsTables"/>
  <link:presentationLink xlink:role="http://www.auriniapharma.com/role/InvestmentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_7a9d224a-13ac-45c7-98d9-1bf12e30def5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesTextBlock_de015382-0df1-44e9-8a1b-b5615ee63f35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_7a9d224a-13ac-45c7-98d9-1bf12e30def5" xlink:to="loc_us-gaap_MarketableSecuritiesTextBlock_de015382-0df1-44e9-8a1b-b5615ee63f35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.auriniapharma.com/role/InvestmentsDetails" xlink:type="simple" xlink:href="auph-20220331.xsd#InvestmentsDetails"/>
  <link:presentationLink xlink:role="http://www.auriniapharma.com/role/InvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_06473885-8e95-42ce-b4b1-1640eeac3aeb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesTable_9fdf46e6-e41c-4037-927a-58e02e4f70d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_06473885-8e95-42ce-b4b1-1640eeac3aeb" xlink:to="loc_us-gaap_MarketableSecuritiesTable_9fdf46e6-e41c-4037-927a-58e02e4f70d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_fb48e6de-64b3-4aed-b80f-d6816d7cb89b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketableSecuritiesTable_9fdf46e6-e41c-4037-927a-58e02e4f70d1" xlink:to="loc_us-gaap_FinancialInstrumentAxis_fb48e6de-64b3-4aed-b80f-d6816d7cb89b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_16b7dd2f-7005-47ac-8c6b-7dfc1b2ad0ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_fb48e6de-64b3-4aed-b80f-d6816d7cb89b" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_16b7dd2f-7005-47ac-8c6b-7dfc1b2ad0ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_auph_CashableGuaranteedInvestmentCertificatesMember_620fea9a-07af-4316-8499-644807e43f7d" xlink:href="auph-20220331.xsd#auph_CashableGuaranteedInvestmentCertificatesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_16b7dd2f-7005-47ac-8c6b-7dfc1b2ad0ca" xlink:to="loc_auph_CashableGuaranteedInvestmentCertificatesMember_620fea9a-07af-4316-8499-644807e43f7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_auph_ShortTermCorporateDebtSecuritiesMember_f1b9467f-9308-45d9-89ea-ace0fc8f4a1c" xlink:href="auph-20220331.xsd#auph_ShortTermCorporateDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_16b7dd2f-7005-47ac-8c6b-7dfc1b2ad0ca" xlink:to="loc_auph_ShortTermCorporateDebtSecuritiesMember_f1b9467f-9308-45d9-89ea-ace0fc8f4a1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_7acce8ba-21ef-47bd-a938-295a72c84501" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_16b7dd2f-7005-47ac-8c6b-7dfc1b2ad0ca" xlink:to="loc_us-gaap_CommercialPaperMember_7acce8ba-21ef-47bd-a938-295a72c84501" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryBillSecuritiesMember_cb4699ab-514c-4be4-90a5-99d8a25dc93f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasuryBillSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_16b7dd2f-7005-47ac-8c6b-7dfc1b2ad0ca" xlink:to="loc_us-gaap_USTreasuryBillSecuritiesMember_cb4699ab-514c-4be4-90a5-99d8a25dc93f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryBondSecuritiesMember_329980d5-7cc2-4ba1-a9fb-6a31f48b36dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasuryBondSecuritiesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_16b7dd2f-7005-47ac-8c6b-7dfc1b2ad0ca" xlink:to="loc_us-gaap_USTreasuryBondSecuritiesMember_329980d5-7cc2-4ba1-a9fb-6a31f48b36dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesLineItems_8ae86dea-0aca-423b-98c8-22e8d4e8c744" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketableSecuritiesTable_9fdf46e6-e41c-4037-927a-58e02e4f70d1" xlink:to="loc_us-gaap_MarketableSecuritiesLineItems_8ae86dea-0aca-423b-98c8-22e8d4e8c744" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesCurrent_68cc9919-5b24-4ea7-9ef3-788dfb6cf07d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_8ae86dea-0aca-423b-98c8-22e8d4e8c744" xlink:to="loc_us-gaap_DebtSecuritiesCurrent_68cc9919-5b24-4ea7-9ef3-788dfb6cf07d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecurities_010f2e5f-e09a-4ba2-8e33-ac8c6c3f005a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HeldToMaturitySecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_8ae86dea-0aca-423b-98c8-22e8d4e8c744" xlink:to="loc_us-gaap_HeldToMaturitySecurities_010f2e5f-e09a-4ba2-8e33-ac8c6c3f005a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_f03ed3f5-f377-4562-a607-aad8d09c90fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_8ae86dea-0aca-423b-98c8-22e8d4e8c744" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_f03ed3f5-f377-4562-a607-aad8d09c90fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestReceivable_7728bab5-623c-41f2-a466-830bb8b6cded" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestReceivable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_8ae86dea-0aca-423b-98c8-22e8d4e8c744" xlink:to="loc_us-gaap_InterestReceivable_7728bab5-623c-41f2-a466-830bb8b6cded" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss_625e7018-d50c-4efa-b2ec-6ab683f4c06f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_8ae86dea-0aca-423b-98c8-22e8d4e8c744" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss_625e7018-d50c-4efa-b2ec-6ab683f4c06f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.auriniapharma.com/role/Inventories" xlink:type="simple" xlink:href="auph-20220331.xsd#Inventories"/>
  <link:presentationLink xlink:role="http://www.auriniapharma.com/role/Inventories" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_0f74c124-c5f7-4b42-9dc7-cd8b434fc52d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_73c973da-be30-4c6f-887a-ab1c9ce81dd0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_0f74c124-c5f7-4b42-9dc7-cd8b434fc52d" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_73c973da-be30-4c6f-887a-ab1c9ce81dd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.auriniapharma.com/role/InventoriesTables" xlink:type="simple" xlink:href="auph-20220331.xsd#InventoriesTables"/>
  <link:presentationLink xlink:role="http://www.auriniapharma.com/role/InventoriesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_244216f2-dca3-43cc-88c5-6233c47a9613" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_5e0b8a69-61fc-47cd-ad89-136134b5951b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_244216f2-dca3-43cc-88c5-6233c47a9613" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_5e0b8a69-61fc-47cd-ad89-136134b5951b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.auriniapharma.com/role/InventoriesDetails" xlink:type="simple" xlink:href="auph-20220331.xsd#InventoriesDetails"/>
  <link:presentationLink xlink:role="http://www.auriniapharma.com/role/InventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_5aece738-ca34-45d4-a042-6a12d20adfea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_ad0d0bef-4951-4eea-9e47-0f71c1e0f8be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_5aece738-ca34-45d4-a042-6a12d20adfea" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_ad0d0bef-4951-4eea-9e47-0f71c1e0f8be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_ca65b85c-e7df-4f5f-bebe-686763e58228" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_5aece738-ca34-45d4-a042-6a12d20adfea" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_ca65b85c-e7df-4f5f-bebe-686763e58228" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_806567c7-6adb-44aa-a796-751ce11f75bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_5aece738-ca34-45d4-a042-6a12d20adfea" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_806567c7-6adb-44aa-a796-751ce11f75bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_0424e218-93c9-4019-ad30-2450c10ffabb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_5aece738-ca34-45d4-a042-6a12d20adfea" xlink:to="loc_us-gaap_InventoryNet_0424e218-93c9-4019-ad30-2450c10ffabb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.auriniapharma.com/role/PrepaidExpensesandOtherCurrentAssets" xlink:type="simple" xlink:href="auph-20220331.xsd#PrepaidExpensesandOtherCurrentAssets"/>
  <link:presentationLink xlink:role="http://www.auriniapharma.com/role/PrepaidExpensesandOtherCurrentAssets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_cdf32eb6-d330-45a9-b917-b5234cd7b5ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentAssetsTextBlock_77402814-85b6-411a-bf01-ded6984a92c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCurrentAssetsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_cdf32eb6-d330-45a9-b917-b5234cd7b5ff" xlink:to="loc_us-gaap_OtherCurrentAssetsTextBlock_77402814-85b6-411a-bf01-ded6984a92c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.auriniapharma.com/role/PrepaidExpensesandOtherCurrentAssetsTables" xlink:type="simple" xlink:href="auph-20220331.xsd#PrepaidExpensesandOtherCurrentAssetsTables"/>
  <link:presentationLink xlink:role="http://www.auriniapharma.com/role/PrepaidExpensesandOtherCurrentAssetsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_ea3959b4-83a9-4a85-95d3-41c8f284f91c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_f5415c85-f8e3-4112-b48d-c4649a85c0a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_ea3959b4-83a9-4a85-95d3-41c8f284f91c" xlink:to="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_f5415c85-f8e3-4112-b48d-c4649a85c0a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.auriniapharma.com/role/PrepaidExpensesandOtherCurrentAssetsDetails" xlink:type="simple" xlink:href="auph-20220331.xsd#PrepaidExpensesandOtherCurrentAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.auriniapharma.com/role/PrepaidExpensesandOtherCurrentAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_3e0707d9-bb29-46a2-b400-a96e353fb5b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_auph_PrepaidAssetsCurrent_2486ce06-e6fc-4077-b17c-10a73bc21909" xlink:href="auph-20220331.xsd#auph_PrepaidAssetsCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_3e0707d9-bb29-46a2-b400-a96e353fb5b5" xlink:to="loc_auph_PrepaidAssetsCurrent_2486ce06-e6fc-4077-b17c-10a73bc21909" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidInsurance_8300a9a3-ec9b-4a56-bdd1-2dc58438788c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidInsurance"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_3e0707d9-bb29-46a2-b400-a96e353fb5b5" xlink:to="loc_us-gaap_PrepaidInsurance_8300a9a3-ec9b-4a56-bdd1-2dc58438788c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_7459b62a-301e-4867-9db9-8a3555068a95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_3e0707d9-bb29-46a2-b400-a96e353fb5b5" xlink:to="loc_us-gaap_OtherAssetsCurrent_7459b62a-301e-4867-9db9-8a3555068a95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_auph_PrepaidRentAndPrepaidContinuingStudies_0fa2655b-a885-4327-a1cc-b5b0f114ee2d" xlink:href="auph-20220331.xsd#auph_PrepaidRentAndPrepaidContinuingStudies"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_3e0707d9-bb29-46a2-b400-a96e353fb5b5" xlink:to="loc_auph_PrepaidRentAndPrepaidContinuingStudies_0fa2655b-a885-4327-a1cc-b5b0f114ee2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_556e943f-1f07-4805-b3a8-ffbccad6e474" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_3e0707d9-bb29-46a2-b400-a96e353fb5b5" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_556e943f-1f07-4805-b3a8-ffbccad6e474" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.auriniapharma.com/role/IntangibleAssets" xlink:type="simple" xlink:href="auph-20220331.xsd#IntangibleAssets"/>
  <link:presentationLink xlink:role="http://www.auriniapharma.com/role/IntangibleAssets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_173af280-9a33-4614-b0d6-11306d4c8054" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_e2d9877f-82c6-4a5d-9dcd-5bc15cace9d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_173af280-9a33-4614-b0d6-11306d4c8054" xlink:to="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_e2d9877f-82c6-4a5d-9dcd-5bc15cace9d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.auriniapharma.com/role/IntangibleAssetsTables" xlink:type="simple" xlink:href="auph-20220331.xsd#IntangibleAssetsTables"/>
  <link:presentationLink xlink:role="http://www.auriniapharma.com/role/IntangibleAssetsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_9c47d3b1-dadb-4ee6-904a-a8dfadb98f16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_ce44904c-bce9-4d41-9c2f-f587e1d27c9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_9c47d3b1-dadb-4ee6-904a-a8dfadb98f16" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_ce44904c-bce9-4d41-9c2f-f587e1d27c9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.auriniapharma.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails" xlink:type="simple" xlink:href="auph-20220331.xsd#IntangibleAssetsScheduleofIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.auriniapharma.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_7653fae3-cdd3-4079-9907-3cf3924d9ca2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_b207b071-519e-484a-88ef-6bb062ee5cdb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_7653fae3-cdd3-4079-9907-3cf3924d9ca2" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_b207b071-519e-484a-88ef-6bb062ee5cdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_f3d9e65f-53b9-47c3-ac16-73e020620551" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_b207b071-519e-484a-88ef-6bb062ee5cdb" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_f3d9e65f-53b9-47c3-ac16-73e020620551" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_e3de5129-be2e-4657-a75d-396d2089f1d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_f3d9e65f-53b9-47c3-ac16-73e020620551" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_e3de5129-be2e-4657-a75d-396d2089f1d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PatentsMember_08f420ce-4434-4068-b0f5-7b0c2ef50fb3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PatentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_e3de5129-be2e-4657-a75d-396d2089f1d3" xlink:to="loc_us-gaap_PatentsMember_08f420ce-4434-4068-b0f5-7b0c2ef50fb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntellectualPropertyMember_f40af0d3-4e07-4a25-94cc-b6340ab5083a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntellectualPropertyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_e3de5129-be2e-4657-a75d-396d2089f1d3" xlink:to="loc_us-gaap_IntellectualPropertyMember_f40af0d3-4e07-4a25-94cc-b6340ab5083a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_1f2310ec-a2ea-4730-91cb-ce05cfa16ff1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_e3de5129-be2e-4657-a75d-396d2089f1d3" xlink:to="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_1f2310ec-a2ea-4730-91cb-ce05cfa16ff1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_bb63c5de-9d27-469a-b238-c4764f98d4ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_b207b071-519e-484a-88ef-6bb062ee5cdb" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_bb63c5de-9d27-469a-b238-c4764f98d4ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_081e1c22-5b33-4b5e-a33c-801c63ec85e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_bb63c5de-9d27-469a-b238-c4764f98d4ec" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_081e1c22-5b33-4b5e-a33c-801c63ec85e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_88dcf613-6f06-46c4-a7d9-227cfabe6cc0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_bb63c5de-9d27-469a-b238-c4764f98d4ec" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_88dcf613-6f06-46c4-a7d9-227cfabe6cc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_009eb639-809e-47f6-af57-671dbb8bcf03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_bb63c5de-9d27-469a-b238-c4764f98d4ec" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_009eb639-809e-47f6-af57-671dbb8bcf03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.auriniapharma.com/role/IntangibleAssetsNarrativeDetails" xlink:type="simple" xlink:href="auph-20220331.xsd#IntangibleAssetsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.auriniapharma.com/role/IntangibleAssetsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_3f98cd8c-c91b-47bd-a392-ad014abb0833" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_f8f04cf2-a63a-48a5-85e8-95f1d3b42016" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_3f98cd8c-c91b-47bd-a392-ad014abb0833" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_f8f04cf2-a63a-48a5-85e8-95f1d3b42016" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.auriniapharma.com/role/PropertyPlantandEquipmentnet" xlink:type="simple" xlink:href="auph-20220331.xsd#PropertyPlantandEquipmentnet"/>
  <link:presentationLink xlink:role="http://www.auriniapharma.com/role/PropertyPlantandEquipmentnet" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_31786c67-bdfb-41a4-adca-5cbbaee138ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_acf89d7f-ca2c-40c8-ab45-99425ca50871" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_31786c67-bdfb-41a4-adca-5cbbaee138ef" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_acf89d7f-ca2c-40c8-ab45-99425ca50871" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.auriniapharma.com/role/PropertyPlantandEquipmentnetTables" xlink:type="simple" xlink:href="auph-20220331.xsd#PropertyPlantandEquipmentnetTables"/>
  <link:presentationLink xlink:role="http://www.auriniapharma.com/role/PropertyPlantandEquipmentnetTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_794525a8-4434-426a-bdd0-59f55e526269" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_dc29adda-96b8-4054-9cf2-54a372278014" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_794525a8-4434-426a-bdd0-59f55e526269" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_dc29adda-96b8-4054-9cf2-54a372278014" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.auriniapharma.com/role/PropertyPlantandEquipmentnetDetails" xlink:type="simple" xlink:href="auph-20220331.xsd#PropertyPlantandEquipmentnetDetails"/>
  <link:presentationLink xlink:role="http://www.auriniapharma.com/role/PropertyPlantandEquipmentnetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_b93f8589-4499-4cae-b562-d75c891c0494" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_59e52894-1c71-4c6f-b734-9430838c7a57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_b93f8589-4499-4cae-b562-d75c891c0494" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_59e52894-1c71-4c6f-b734-9430838c7a57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_29417945-a29e-4f06-a809-14b70762eee1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_59e52894-1c71-4c6f-b734-9430838c7a57" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_29417945-a29e-4f06-a809-14b70762eee1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_59a5908e-d2ed-455d-9615-ecd329287c09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_29417945-a29e-4f06-a809-14b70762eee1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_59a5908e-d2ed-455d-9615-ecd329287c09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_25c81e47-8bec-4943-9470-3c5f6ac2fd9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_59a5908e-d2ed-455d-9615-ecd329287c09" xlink:to="loc_us-gaap_ConstructionInProgressMember_25c81e47-8bec-4943-9470-3c5f6ac2fd9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_64b59d6c-81dd-4855-9552-cf38c3ae0183" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_59a5908e-d2ed-455d-9615-ecd329287c09" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_64b59d6c-81dd-4855-9552-cf38c3ae0183" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_73c0249a-a505-4a04-bdbd-870ad3c66480" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_59a5908e-d2ed-455d-9615-ecd329287c09" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_73c0249a-a505-4a04-bdbd-870ad3c66480" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OfficeEquipmentMember_4c29560e-d658-4a24-b09b-b4fc733df19a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OfficeEquipmentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_59a5908e-d2ed-455d-9615-ecd329287c09" xlink:to="loc_us-gaap_OfficeEquipmentMember_4c29560e-d658-4a24-b09b-b4fc733df19a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_3c0a4384-3ed8-4f69-9285-64b62c7fa0b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_59a5908e-d2ed-455d-9615-ecd329287c09" xlink:to="loc_us-gaap_ComputerEquipmentMember_3c0a4384-3ed8-4f69-9285-64b62c7fa0b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_844cc1c4-ac2d-49c3-a911-4dad03d4068f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_59e52894-1c71-4c6f-b734-9430838c7a57" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_844cc1c4-ac2d-49c3-a911-4dad03d4068f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_c734b5e4-f2ce-4277-9bc3-7da61fc0f7fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_844cc1c4-ac2d-49c3-a911-4dad03d4068f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_c734b5e4-f2ce-4277-9bc3-7da61fc0f7fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_562ffd3e-52bf-488a-9916-f314842ae9b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_844cc1c4-ac2d-49c3-a911-4dad03d4068f" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_562ffd3e-52bf-488a-9916-f314842ae9b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_40344d44-9af1-4ed2-95d5-4d0df896ba19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_844cc1c4-ac2d-49c3-a911-4dad03d4068f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_40344d44-9af1-4ed2-95d5-4d0df896ba19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.auriniapharma.com/role/LeaseObligations" xlink:type="simple" xlink:href="auph-20220331.xsd#LeaseObligations"/>
  <link:presentationLink xlink:role="http://www.auriniapharma.com/role/LeaseObligations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_782d9348-0416-47a9-a264-c544cc91c0a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_44e4379a-c087-470c-b511-4074c6aad55e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_782d9348-0416-47a9-a264-c544cc91c0a5" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_44e4379a-c087-470c-b511-4074c6aad55e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.auriniapharma.com/role/LeaseObligationsTables" xlink:type="simple" xlink:href="auph-20220331.xsd#LeaseObligationsTables"/>
  <link:presentationLink xlink:role="http://www.auriniapharma.com/role/LeaseObligationsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_3f34e85b-e95e-4a45-b563-96f7cad431fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_auph_AssetsAndLiabilitiesLesseeTableTextBlock_2d4f7817-6261-4542-a999-37ea9ab9f979" xlink:href="auph-20220331.xsd#auph_AssetsAndLiabilitiesLesseeTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3f34e85b-e95e-4a45-b563-96f7cad431fb" xlink:to="loc_auph_AssetsAndLiabilitiesLesseeTableTextBlock_2d4f7817-6261-4542-a999-37ea9ab9f979" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_98e94bcc-3eb9-4172-bb20-cd6049cd1d89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3f34e85b-e95e-4a45-b563-96f7cad431fb" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_98e94bcc-3eb9-4172-bb20-cd6049cd1d89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_0f26a065-071f-474b-b00a-9719762a8e7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3f34e85b-e95e-4a45-b563-96f7cad431fb" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_0f26a065-071f-474b-b00a-9719762a8e7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.auriniapharma.com/role/LeaseObligationsNarrativeDetails" xlink:type="simple" xlink:href="auph-20220331.xsd#LeaseObligationsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.auriniapharma.com/role/LeaseObligationsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_42deee2d-0590-4a71-92fd-cfb1d5194187" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_9fb3c853-5b42-4882-bba4-3cdc5a463d95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_42deee2d-0590-4a71-92fd-cfb1d5194187" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_9fb3c853-5b42-4882-bba4-3cdc5a463d95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_4de6b454-7cab-4257-8e23-2ae4877afd6b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_9fb3c853-5b42-4882-bba4-3cdc5a463d95" xlink:to="loc_srt_StatementGeographicalAxis_4de6b454-7cab-4257-8e23-2ae4877afd6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_4559f741-5280-4ecd-8330-6c8ab6e6e7d2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_4de6b454-7cab-4257-8e23-2ae4877afd6b" xlink:to="loc_srt_SegmentGeographicalDomain_4559f741-5280-4ecd-8330-6c8ab6e6e7d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_auph_VictoriaBritishColumbiaMember_e70e93fb-586c-4433-97c3-45b064e04700" xlink:href="auph-20220331.xsd#auph_VictoriaBritishColumbiaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_4559f741-5280-4ecd-8330-6c8ab6e6e7d2" xlink:to="loc_auph_VictoriaBritishColumbiaMember_e70e93fb-586c-4433-97c3-45b064e04700" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_auph_RockvilleMarylandMember_fdb8b375-e69b-4dd8-a816-cfe3909a5fc4" xlink:href="auph-20220331.xsd#auph_RockvilleMarylandMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_4559f741-5280-4ecd-8330-6c8ab6e6e7d2" xlink:to="loc_auph_RockvilleMarylandMember_fdb8b375-e69b-4dd8-a816-cfe3909a5fc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_66417155-b3c3-4a94-a70a-099605f68d16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_9fb3c853-5b42-4882-bba4-3cdc5a463d95" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_66417155-b3c3-4a94-a70a-099605f68d16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfRealEstateProperty_76bf5ecf-fc4a-47e6-bbd5-21db791d06de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AreaOfRealEstateProperty"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_66417155-b3c3-4a94-a70a-099605f68d16" xlink:to="loc_us-gaap_AreaOfRealEstateProperty_76bf5ecf-fc4a-47e6-bbd5-21db791d06de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_daf87e91-057c-4498-8a81-4fa7da2d1329" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_66417155-b3c3-4a94-a70a-099605f68d16" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_daf87e91-057c-4498-8a81-4fa7da2d1329" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_3b5d00d4-2808-43ed-84aa-e3ee3720d8bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_66417155-b3c3-4a94-a70a-099605f68d16" xlink:to="loc_us-gaap_OperatingLeaseLiability_3b5d00d4-2808-43ed-84aa-e3ee3720d8bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_2982c7cf-9ccb-466b-ae2a-14da25131c49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_66417155-b3c3-4a94-a70a-099605f68d16" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_2982c7cf-9ccb-466b-ae2a-14da25131c49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_397c3b2c-7073-444f-8935-e8d31ff6f0c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_66417155-b3c3-4a94-a70a-099605f68d16" xlink:to="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_397c3b2c-7073-444f-8935-e8d31ff6f0c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_auph_LesseeOperatingLeaseNumberOfExtensionOptions_99137d0d-17f6-418e-b48a-a9db41cc61b4" xlink:href="auph-20220331.xsd#auph_LesseeOperatingLeaseNumberOfExtensionOptions"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_66417155-b3c3-4a94-a70a-099605f68d16" xlink:to="loc_auph_LesseeOperatingLeaseNumberOfExtensionOptions_99137d0d-17f6-418e-b48a-a9db41cc61b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_407b55cc-08b1-4d65-a18a-08f6fac2730f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_66417155-b3c3-4a94-a70a-099605f68d16" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_407b55cc-08b1-4d65-a18a-08f6fac2730f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_110f900f-966e-42b3-82ba-40c3c65dabc7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_66417155-b3c3-4a94-a70a-099605f68d16" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_110f900f-966e-42b3-82ba-40c3c65dabc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_auph_LesseeOperatingLeaseLeaseTerminationTerm_c2b5c8b5-b658-4a3f-8549-bfc9d35fd774" xlink:href="auph-20220331.xsd#auph_LesseeOperatingLeaseLeaseTerminationTerm"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_66417155-b3c3-4a94-a70a-099605f68d16" xlink:to="loc_auph_LesseeOperatingLeaseLeaseTerminationTerm_c2b5c8b5-b658-4a3f-8549-bfc9d35fd774" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_88496248-76cd-47ca-b554-b37b350dc66c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_66417155-b3c3-4a94-a70a-099605f68d16" xlink:to="loc_us-gaap_OperatingLeaseCost_88496248-76cd-47ca-b554-b37b350dc66c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForCapitalImprovements_37a86e61-192d-449a-bf6c-b70fd04274dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForCapitalImprovements"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_66417155-b3c3-4a94-a70a-099605f68d16" xlink:to="loc_us-gaap_PaymentsForCapitalImprovements_37a86e61-192d-449a-bf6c-b70fd04274dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_56a0bb47-9b43-49bf-b897-ff7a745e92b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_66417155-b3c3-4a94-a70a-099605f68d16" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_56a0bb47-9b43-49bf-b897-ff7a745e92b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_15c4265b-4fba-4e5e-a786-8e2a5e15161d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_66417155-b3c3-4a94-a70a-099605f68d16" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_15c4265b-4fba-4e5e-a786-8e2a5e15161d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f6ee829f-f93b-4946-9d67-4587bd596a11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_66417155-b3c3-4a94-a70a-099605f68d16" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f6ee829f-f93b-4946-9d67-4587bd596a11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_auph_LesseeOperatingLeaseLeaseNotYetCommencedPaymentsPriorToCommencementOfLease_1b05c6d7-03d1-4931-b4a2-2005402a180d" xlink:href="auph-20220331.xsd#auph_LesseeOperatingLeaseLeaseNotYetCommencedPaymentsPriorToCommencementOfLease"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_66417155-b3c3-4a94-a70a-099605f68d16" xlink:to="loc_auph_LesseeOperatingLeaseLeaseNotYetCommencedPaymentsPriorToCommencementOfLease_1b05c6d7-03d1-4931-b4a2-2005402a180d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_auph_LesseeOperatingLeaseLeaseNotYetCommencedLiabilityToBePaid_55cdc34a-e7f0-4e4a-b6a3-6c8b9ba9e347" xlink:href="auph-20220331.xsd#auph_LesseeOperatingLeaseLeaseNotYetCommencedLiabilityToBePaid"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_66417155-b3c3-4a94-a70a-099605f68d16" xlink:to="loc_auph_LesseeOperatingLeaseLeaseNotYetCommencedLiabilityToBePaid_55cdc34a-e7f0-4e4a-b6a3-6c8b9ba9e347" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromTenantAllowance_536d5526-f422-476a-ae20-4d91f5fb0159" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForProceedsFromTenantAllowance"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_66417155-b3c3-4a94-a70a-099605f68d16" xlink:to="loc_us-gaap_PaymentsForProceedsFromTenantAllowance_536d5526-f422-476a-ae20-4d91f5fb0159" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.auriniapharma.com/role/LeaseObligationsSupplementalBalanceSheetInformationDetails" xlink:type="simple" xlink:href="auph-20220331.xsd#LeaseObligationsSupplementalBalanceSheetInformationDetails"/>
  <link:presentationLink xlink:role="http://www.auriniapharma.com/role/LeaseObligationsSupplementalBalanceSheetInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_35a1ed7a-05bf-4e9d-9391-1f4a6b85e560" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_auph_OperatingLeaseAssetsAndLiabilitiesAssetsLesseeAbstract_99d2c42c-4183-444f-b0db-6203fc59fe01" xlink:href="auph-20220331.xsd#auph_OperatingLeaseAssetsAndLiabilitiesAssetsLesseeAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_35a1ed7a-05bf-4e9d-9391-1f4a6b85e560" xlink:to="loc_auph_OperatingLeaseAssetsAndLiabilitiesAssetsLesseeAbstract_99d2c42c-4183-444f-b0db-6203fc59fe01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_92119f5f-ff1b-4662-a9b8-88497fea3edb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_auph_OperatingLeaseAssetsAndLiabilitiesAssetsLesseeAbstract_99d2c42c-4183-444f-b0db-6203fc59fe01" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_92119f5f-ff1b-4662-a9b8-88497fea3edb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_auph_OperatingLeaseAssetsAndLiabilitiesLiabilitiesCurrentLesseeAbstract_7217aac6-649f-4e69-a2e8-2604c637bc81" xlink:href="auph-20220331.xsd#auph_OperatingLeaseAssetsAndLiabilitiesLiabilitiesCurrentLesseeAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_35a1ed7a-05bf-4e9d-9391-1f4a6b85e560" xlink:to="loc_auph_OperatingLeaseAssetsAndLiabilitiesLiabilitiesCurrentLesseeAbstract_7217aac6-649f-4e69-a2e8-2604c637bc81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_c9d99039-61e3-4c31-9237-966d967081d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_auph_OperatingLeaseAssetsAndLiabilitiesLiabilitiesCurrentLesseeAbstract_7217aac6-649f-4e69-a2e8-2604c637bc81" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_c9d99039-61e3-4c31-9237-966d967081d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_auph_OperatingLeaseAssetsAndLiabilitiesLiabilitiesNoncurrentLesseeAbstract_4de08afc-1280-4b0c-a4eb-b73bfb6d31ff" xlink:href="auph-20220331.xsd#auph_OperatingLeaseAssetsAndLiabilitiesLiabilitiesNoncurrentLesseeAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_35a1ed7a-05bf-4e9d-9391-1f4a6b85e560" xlink:to="loc_auph_OperatingLeaseAssetsAndLiabilitiesLiabilitiesNoncurrentLesseeAbstract_4de08afc-1280-4b0c-a4eb-b73bfb6d31ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_5f6a63ba-20f3-49f2-8bad-7c0077d98d9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_auph_OperatingLeaseAssetsAndLiabilitiesLiabilitiesNoncurrentLesseeAbstract_4de08afc-1280-4b0c-a4eb-b73bfb6d31ff" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_5f6a63ba-20f3-49f2-8bad-7c0077d98d9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_1126d443-607c-49da-93c3-26ae9d9cf6c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_35a1ed7a-05bf-4e9d-9391-1f4a6b85e560" xlink:to="loc_us-gaap_OperatingLeaseLiability_1126d443-607c-49da-93c3-26ae9d9cf6c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.auriniapharma.com/role/LeaseObligationsSummaryofComponentsofLeasingCostsandRentDetails" xlink:type="simple" xlink:href="auph-20220331.xsd#LeaseObligationsSummaryofComponentsofLeasingCostsandRentDetails"/>
  <link:presentationLink xlink:role="http://www.auriniapharma.com/role/LeaseObligationsSummaryofComponentsofLeasingCostsandRentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_e2510dd4-447f-49ed-9958-c4ddf32e5883" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_7a1eab0a-2876-404c-a20a-2a57a08bc68c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_e2510dd4-447f-49ed-9958-c4ddf32e5883" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_7a1eab0a-2876-404c-a20a-2a57a08bc68c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_759952a1-c060-4fb8-b136-349fdcb57064" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_e2510dd4-447f-49ed-9958-c4ddf32e5883" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_759952a1-c060-4fb8-b136-349fdcb57064" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="auph-20220331.xsd#LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_aa43a902-ff13-4d56-a231-c593378fb11e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_d986f407-a44f-4a53-9d46-ac8762e86081" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_aa43a902-ff13-4d56-a231-c593378fb11e" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_d986f407-a44f-4a53-9d46-ac8762e86081" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_c0aa5446-9759-4b7e-93e4-6e1c12de4762" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_aa43a902-ff13-4d56-a231-c593378fb11e" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_c0aa5446-9759-4b7e-93e4-6e1c12de4762" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_20952f1e-9a68-4328-a210-8c02d8e3b69d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_aa43a902-ff13-4d56-a231-c593378fb11e" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_20952f1e-9a68-4328-a210-8c02d8e3b69d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_3a7e31ba-cb17-4d8d-84b9-0e7f2d22f01c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_aa43a902-ff13-4d56-a231-c593378fb11e" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_3a7e31ba-cb17-4d8d-84b9-0e7f2d22f01c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_54d7342f-6995-4440-b56b-0ea0ec5fcbeb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_aa43a902-ff13-4d56-a231-c593378fb11e" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_54d7342f-6995-4440-b56b-0ea0ec5fcbeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_auph_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_b7d90a79-22f7-4dc2-8dac-317b4476b3aa" xlink:href="auph-20220331.xsd#auph_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_aa43a902-ff13-4d56-a231-c593378fb11e" xlink:to="loc_auph_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_b7d90a79-22f7-4dc2-8dac-317b4476b3aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_26122e70-9708-445f-97b1-0ee5024cab74" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_aa43a902-ff13-4d56-a231-c593378fb11e" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_26122e70-9708-445f-97b1-0ee5024cab74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_456924b5-815d-4814-b1e5-047045378a03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_aa43a902-ff13-4d56-a231-c593378fb11e" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_456924b5-815d-4814-b1e5-047045378a03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_44d06d59-37ae-416f-951f-412d8221f204" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_aa43a902-ff13-4d56-a231-c593378fb11e" xlink:to="loc_us-gaap_OperatingLeaseLiability_44d06d59-37ae-416f-951f-412d8221f204" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails_1" xlink:type="simple" xlink:href="auph-20220331.xsd#LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails_1"/>
  <link:presentationLink xlink:role="http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.auriniapharma.com/role/AccountsPayableandAccruedLiabilities" xlink:type="simple" xlink:href="auph-20220331.xsd#AccountsPayableandAccruedLiabilities"/>
  <link:presentationLink xlink:role="http://www.auriniapharma.com/role/AccountsPayableandAccruedLiabilities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_8688404c-7a3c-4df2-a2aa-9cb954051315" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_285235fa-ea41-4f72-ad18-9ad8a8947182" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_8688404c-7a3c-4df2-a2aa-9cb954051315" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_285235fa-ea41-4f72-ad18-9ad8a8947182" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.auriniapharma.com/role/AccountsPayableandAccruedLiabilitiesTables" xlink:type="simple" xlink:href="auph-20220331.xsd#AccountsPayableandAccruedLiabilitiesTables"/>
  <link:presentationLink xlink:role="http://www.auriniapharma.com/role/AccountsPayableandAccruedLiabilitiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_9e6f9eb4-14f4-422c-b0db-76e22edbdf99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_ab449620-f271-4f0b-b279-0b99c7a97df1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_9e6f9eb4-14f4-422c-b0db-76e22edbdf99" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_ab449620-f271-4f0b-b279-0b99c7a97df1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.auriniapharma.com/role/AccountsPayableandAccruedLiabilitiesDetails" xlink:type="simple" xlink:href="auph-20220331.xsd#AccountsPayableandAccruedLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.auriniapharma.com/role/AccountsPayableandAccruedLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_b8ab536a-8609-44b8-b10f-e1b0b84b3117" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableTradeCurrent_a95f2f3e-1186-4596-9e91-e8276b4c09d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableTradeCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_b8ab536a-8609-44b8-b10f-e1b0b84b3117" xlink:to="loc_us-gaap_AccountsPayableTradeCurrent_a95f2f3e-1186-4596-9e91-e8276b4c09d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_8366cb28-3da5-4207-8e28-d4ab57da96b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_b8ab536a-8609-44b8-b10f-e1b0b84b3117" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_8366cb28-3da5-4207-8e28-d4ab57da96b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_auph_AccruedResearchCurrent_4cab20ef-ea6c-4336-9c57-d1a88f3a7395" xlink:href="auph-20220331.xsd#auph_AccruedResearchCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_b8ab536a-8609-44b8-b10f-e1b0b84b3117" xlink:to="loc_auph_AccruedResearchCurrent_4cab20ef-ea6c-4336-9c57-d1a88f3a7395" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_9533866a-db10-4e70-9716-d07196cf9080" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_b8ab536a-8609-44b8-b10f-e1b0b84b3117" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_9533866a-db10-4e70-9716-d07196cf9080" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_auph_CommercialRelatedAccrualsCurrent_4427b728-bc27-4e5d-b333-69099b430fee" xlink:href="auph-20220331.xsd#auph_CommercialRelatedAccrualsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_b8ab536a-8609-44b8-b10f-e1b0b84b3117" xlink:to="loc_auph_CommercialRelatedAccrualsCurrent_4427b728-bc27-4e5d-b333-69099b430fee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_15ef9670-39f8-460d-a44d-1b6a7d2804c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_b8ab536a-8609-44b8-b10f-e1b0b84b3117" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_15ef9670-39f8-460d-a44d-1b6a7d2804c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.auriniapharma.com/role/DeferredCompensationandOtherNoncurrentLiabilities" xlink:type="simple" xlink:href="auph-20220331.xsd#DeferredCompensationandOtherNoncurrentLiabilities"/>
  <link:presentationLink xlink:role="http://www.auriniapharma.com/role/DeferredCompensationandOtherNoncurrentLiabilities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_23e2e4ee-23a7-4a8d-8869-c7364a2c6620" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureNoncurrentTextBlock_c3dd7746-2edc-481f-97e2-3455a0a6d561" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureNoncurrentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_23e2e4ee-23a7-4a8d-8869-c7364a2c6620" xlink:to="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureNoncurrentTextBlock_c3dd7746-2edc-481f-97e2-3455a0a6d561" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.auriniapharma.com/role/DeferredCompensationandOtherNoncurrentLiabilitiesDetails" xlink:type="simple" xlink:href="auph-20220331.xsd#DeferredCompensationandOtherNoncurrentLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.auriniapharma.com/role/DeferredCompensationandOtherNoncurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_6f7739d1-7164-45e4-9f9e-686081359a29" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_bbd114e4-ba20-4823-bbf6-d4a06a104131" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_6f7739d1-7164-45e4-9f9e-686081359a29" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_bbd114e4-ba20-4823-bbf6-d4a06a104131" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.auriniapharma.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="auph-20220331.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.auriniapharma.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_8896cf27-bdc2-4f31-bb5c-d5985396ae1d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_88c7a340-e8a8-4678-a7da-d05f93502252" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_8896cf27-bdc2-4f31-bb5c-d5985396ae1d" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_88c7a340-e8a8-4678-a7da-d05f93502252" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.auriniapharma.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="auph-20220331.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.auriniapharma.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_64d0b49f-9e66-4365-8cdf-3f7088b218cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_ededa21a-43f0-4972-b6df-9db2beac6dad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_64d0b49f-9e66-4365-8cdf-3f7088b218cb" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_ededa21a-43f0-4972-b6df-9db2beac6dad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.auriniapharma.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" xlink:type="simple" xlink:href="auph-20220331.xsd#FairValueMeasurementsAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://www.auriniapharma.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_be0da0c2-f3ec-49ef-af70-b22f3d084307" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_10daaa2e-e2b9-4ae0-acce-203dcbd6316c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_be0da0c2-f3ec-49ef-af70-b22f3d084307" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_10daaa2e-e2b9-4ae0-acce-203dcbd6316c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_307b774d-05da-462a-b210-250625755cf6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_10daaa2e-e2b9-4ae0-acce-203dcbd6316c" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_307b774d-05da-462a-b210-250625755cf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f8302e24-ba62-45a9-b04d-d35fa93a6709" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_307b774d-05da-462a-b210-250625755cf6" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f8302e24-ba62-45a9-b04d-d35fa93a6709" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_18a085fd-0179-4cbc-b92c-cb86c45ed312" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f8302e24-ba62-45a9-b04d-d35fa93a6709" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_18a085fd-0179-4cbc-b92c-cb86c45ed312" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_f2537789-14e4-4acb-9a37-604085aa6a22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f8302e24-ba62-45a9-b04d-d35fa93a6709" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_f2537789-14e4-4acb-9a37-604085aa6a22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_9a93a1d3-3a83-4aaa-9b23-d276c152ee81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f8302e24-ba62-45a9-b04d-d35fa93a6709" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_9a93a1d3-3a83-4aaa-9b23-d276c152ee81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_5e211338-e99b-4d6e-89f1-e9d27a150e05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_10daaa2e-e2b9-4ae0-acce-203dcbd6316c" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_5e211338-e99b-4d6e-89f1-e9d27a150e05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_ed632c0d-0bd3-4370-88e9-1827f9162f52" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_5e211338-e99b-4d6e-89f1-e9d27a150e05" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_ed632c0d-0bd3-4370-88e9-1827f9162f52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DemandDepositsMember_690daa18-33d3-4596-acf1-51037667921b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DemandDepositsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_ed632c0d-0bd3-4370-88e9-1827f9162f52" xlink:to="loc_us-gaap_DemandDepositsMember_690daa18-33d3-4596-acf1-51037667921b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_43c383c6-ed58-481d-ae3e-87c7573e891d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_ed632c0d-0bd3-4370-88e9-1827f9162f52" xlink:to="loc_us-gaap_MoneyMarketFundsMember_43c383c6-ed58-481d-ae3e-87c7573e891d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_79d12700-b08d-4bbe-9ae3-20eddfe0252c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_10daaa2e-e2b9-4ae0-acce-203dcbd6316c" xlink:to="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_79d12700-b08d-4bbe-9ae3-20eddfe0252c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_585eb930-f103-49de-b26f-950f53b4b902" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_79d12700-b08d-4bbe-9ae3-20eddfe0252c" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_585eb930-f103-49de-b26f-950f53b4b902" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_f74844ea-efb2-4e9f-a7af-e4ecf81871f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_585eb930-f103-49de-b26f-950f53b4b902" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_f74844ea-efb2-4e9f-a7af-e4ecf81871f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_2544b1df-2520-4888-8582-c9223dcf7c2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_585eb930-f103-49de-b26f-950f53b4b902" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_2544b1df-2520-4888-8582-c9223dcf7c2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_f8526464-1a83-4de7-958a-26291442f2ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_585eb930-f103-49de-b26f-950f53b4b902" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_f8526464-1a83-4de7-958a-26291442f2ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.auriniapharma.com/role/LicenseandCollaborationAgreement" xlink:type="simple" xlink:href="auph-20220331.xsd#LicenseandCollaborationAgreement"/>
  <link:presentationLink xlink:role="http://www.auriniapharma.com/role/LicenseandCollaborationAgreement" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_aa41438f-5839-4df1-8fa3-d47fcaf9d397" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_0d8e677b-2f1f-4cb4-8690-e13638a0733b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_aa41438f-5839-4df1-8fa3-d47fcaf9d397" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_0d8e677b-2f1f-4cb4-8690-e13638a0733b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.auriniapharma.com/role/LicenseandCollaborationAgreementDetails" xlink:type="simple" xlink:href="auph-20220331.xsd#LicenseandCollaborationAgreementDetails"/>
  <link:presentationLink xlink:role="http://www.auriniapharma.com/role/LicenseandCollaborationAgreementDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_be78e567-77da-4855-9918-1ff42d4bb9a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_d5a87416-b874-45e1-a768-bb2cf420dcd4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_be78e567-77da-4855-9918-1ff42d4bb9a1" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_d5a87416-b874-45e1-a768-bb2cf420dcd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_d99bc36f-7cc0-4d2b-8591-3a623b795131" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_d5a87416-b874-45e1-a768-bb2cf420dcd4" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_d99bc36f-7cc0-4d2b-8591-3a623b795131" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_32869e34-2a10-4e06-bf61-9e4b2ed367c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_d99bc36f-7cc0-4d2b-8591-3a623b795131" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_32869e34-2a10-4e06-bf61-9e4b2ed367c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseAgreementTermsMember_3aa790bb-8b69-4d86-8ec1-2af9c75a9624" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseAgreementTermsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_32869e34-2a10-4e06-bf61-9e4b2ed367c6" xlink:to="loc_us-gaap_LicenseAgreementTermsMember_3aa790bb-8b69-4d86-8ec1-2af9c75a9624" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_c390af95-552b-4629-b6aa-bf99ba36ed91" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_d5a87416-b874-45e1-a768-bb2cf420dcd4" xlink:to="loc_srt_CounterpartyNameAxis_c390af95-552b-4629-b6aa-bf99ba36ed91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b52ca46f-02ac-45b8-9d46-d3de21544122" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_c390af95-552b-4629-b6aa-bf99ba36ed91" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b52ca46f-02ac-45b8-9d46-d3de21544122" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_auph_OtuskaPharmaceuticalCoLtdMember_ec425b42-2236-4a5a-99b3-f2b9e66df9d0" xlink:href="auph-20220331.xsd#auph_OtuskaPharmaceuticalCoLtdMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b52ca46f-02ac-45b8-9d46-d3de21544122" xlink:to="loc_auph_OtuskaPharmaceuticalCoLtdMember_ec425b42-2236-4a5a-99b3-f2b9e66df9d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_auph_RiptideBioscienceIncMember_65b6b640-3224-414e-b627-20a51152813a" xlink:href="auph-20220331.xsd#auph_RiptideBioscienceIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b52ca46f-02ac-45b8-9d46-d3de21544122" xlink:to="loc_auph_RiptideBioscienceIncMember_65b6b640-3224-414e-b627-20a51152813a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_3e315c7f-ef00-41e2-af74-dcb4e731c1ac" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_d5a87416-b874-45e1-a768-bb2cf420dcd4" xlink:to="loc_srt_RangeAxis_3e315c7f-ef00-41e2-af74-dcb4e731c1ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_1ba18113-b457-442f-a14d-2668a000ecf2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_3e315c7f-ef00-41e2-af74-dcb4e731c1ac" xlink:to="loc_srt_RangeMember_1ba18113-b457-442f-a14d-2668a000ecf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_eb093709-1b27-4442-af7c-2883e29edefc" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1ba18113-b457-442f-a14d-2668a000ecf2" xlink:to="loc_srt_MinimumMember_eb093709-1b27-4442-af7c-2883e29edefc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_4d71087c-abe5-439e-bd1f-5ab5c6fe1509" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1ba18113-b457-442f-a14d-2668a000ecf2" xlink:to="loc_srt_MaximumMember_4d71087c-abe5-439e-bd1f-5ab5c6fe1509" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_2a015a32-b392-4d50-ae17-c0c102946797" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_d5a87416-b874-45e1-a768-bb2cf420dcd4" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_2a015a32-b392-4d50-ae17-c0c102946797" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets_84505fae-1e89-4bca-912f-aa3494a38e03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_2a015a32-b392-4d50-ae17-c0c102946797" xlink:to="loc_us-gaap_PaymentsToAcquireProductiveAssets_84505fae-1e89-4bca-912f-aa3494a38e03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_4510425a-0d84-4e03-b4da-1e174c92b072" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_2a015a32-b392-4d50-ae17-c0c102946797" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_4510425a-0d84-4e03-b4da-1e174c92b072" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_6770873f-8b3f-47e7-8ba9-b5ec827dd4c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_2a015a32-b392-4d50-ae17-c0c102946797" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_6770873f-8b3f-47e7-8ba9-b5ec827dd4c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_auph_ResearchAndDevelopmentArrangementContractToPerformForOthersPerformanceObligationPotentialRevenueAmount_4b9aabb0-742d-447b-ab9a-129b8bfe4c74" xlink:href="auph-20220331.xsd#auph_ResearchAndDevelopmentArrangementContractToPerformForOthersPerformanceObligationPotentialRevenueAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_2a015a32-b392-4d50-ae17-c0c102946797" xlink:to="loc_auph_ResearchAndDevelopmentArrangementContractToPerformForOthersPerformanceObligationPotentialRevenueAmount_4b9aabb0-742d-447b-ab9a-129b8bfe4c74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_auph_ResearchAndDevelopmentArrangementContractToPerformForOthersTieredRoyaltyPercent_0e44f509-9637-431f-8109-a072ddbc8077" xlink:href="auph-20220331.xsd#auph_ResearchAndDevelopmentArrangementContractToPerformForOthersTieredRoyaltyPercent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_2a015a32-b392-4d50-ae17-c0c102946797" xlink:to="loc_auph_ResearchAndDevelopmentArrangementContractToPerformForOthersTieredRoyaltyPercent_0e44f509-9637-431f-8109-a072ddbc8077" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_70c3711b-1e51-4fb3-bb94-7fae9e83caa0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_2a015a32-b392-4d50-ae17-c0c102946797" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_70c3711b-1e51-4fb3-bb94-7fae9e83caa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.auriniapharma.com/role/NetLossperCommonShare" xlink:type="simple" xlink:href="auph-20220331.xsd#NetLossperCommonShare"/>
  <link:presentationLink xlink:role="http://www.auriniapharma.com/role/NetLossperCommonShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_9686ffea-43af-46c4-bcec-301e3a87fde6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_db8ee3a5-a724-405e-9d13-c502561d4b29" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_9686ffea-43af-46c4-bcec-301e3a87fde6" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_db8ee3a5-a724-405e-9d13-c502561d4b29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.auriniapharma.com/role/NetLossperCommonShareTables" xlink:type="simple" xlink:href="auph-20220331.xsd#NetLossperCommonShareTables"/>
  <link:presentationLink xlink:role="http://www.auriniapharma.com/role/NetLossperCommonShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_5128a544-3611-40c3-8351-6e6559ae39e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_faa97039-d666-4747-ab60-b33095bc993a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_5128a544-3611-40c3-8351-6e6559ae39e1" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_faa97039-d666-4747-ab60-b33095bc993a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_22fc321a-7d0b-4e98-9c50-4aa7a7ff3022" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_5128a544-3611-40c3-8351-6e6559ae39e1" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_22fc321a-7d0b-4e98-9c50-4aa7a7ff3022" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.auriniapharma.com/role/NetLossperCommonShareDetails" xlink:type="simple" xlink:href="auph-20220331.xsd#NetLossperCommonShareDetails"/>
  <link:presentationLink xlink:role="http://www.auriniapharma.com/role/NetLossperCommonShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_59a21a70-8881-42f7-a345-e4671c1b99e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_0f760f9f-fda8-440c-9873-62eecd5208f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_59a21a70-8881-42f7-a345-e4671c1b99e3" xlink:to="loc_us-gaap_NetIncomeLoss_0f760f9f-fda8-440c-9873-62eecd5208f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_215d53d1-36be-4030-aabd-e23d74c38dfa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_59a21a70-8881-42f7-a345-e4671c1b99e3" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_215d53d1-36be-4030-aabd-e23d74c38dfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_602b78c3-a150-47fb-8e26-063efa056a51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_59a21a70-8881-42f7-a345-e4671c1b99e3" xlink:to="loc_us-gaap_EarningsPerShareBasic_602b78c3-a150-47fb-8e26-063efa056a51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_b74444bc-5584-48f4-ac5b-31773b53397b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_59a21a70-8881-42f7-a345-e4671c1b99e3" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_b74444bc-5584-48f4-ac5b-31773b53397b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_916225d6-bab0-4d64-8673-bb9636c960ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_59a21a70-8881-42f7-a345-e4671c1b99e3" xlink:to="loc_us-gaap_EarningsPerShareDiluted_916225d6-bab0-4d64-8673-bb9636c960ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.auriniapharma.com/role/NetLossperCommonShareAntiDilutiveSecuritiesDetails" xlink:type="simple" xlink:href="auph-20220331.xsd#NetLossperCommonShareAntiDilutiveSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.auriniapharma.com/role/NetLossperCommonShareAntiDilutiveSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_51e0ab91-14e0-4f5b-84fd-319486adb406" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_86e13817-6b79-46a7-86ca-9affdc1f7044" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_51e0ab91-14e0-4f5b-84fd-319486adb406" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_86e13817-6b79-46a7-86ca-9affdc1f7044" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_22dcd0ed-d035-4a3a-9f6c-b86e845dbedb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_86e13817-6b79-46a7-86ca-9affdc1f7044" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_22dcd0ed-d035-4a3a-9f6c-b86e845dbedb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_9d8cc07d-be6f-458c-967f-98210917ce22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_22dcd0ed-d035-4a3a-9f6c-b86e845dbedb" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_9d8cc07d-be6f-458c-967f-98210917ce22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_9cb03ee3-0e01-4bea-81ab-87defff0673e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_9d8cc07d-be6f-458c-967f-98210917ce22" xlink:to="loc_us-gaap_EmployeeStockOptionMember_9cb03ee3-0e01-4bea-81ab-87defff0673e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_d620fe00-a629-4f78-8683-28bfbfe9476c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_9d8cc07d-be6f-458c-967f-98210917ce22" xlink:to="loc_us-gaap_PerformanceSharesMember_d620fe00-a629-4f78-8683-28bfbfe9476c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_e87add96-dd13-4876-980f-0bd78b4d16ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_9d8cc07d-be6f-458c-967f-98210917ce22" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_e87add96-dd13-4876-980f-0bd78b4d16ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_cacb5027-a964-4ecf-869f-13d5976f64a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_9d8cc07d-be6f-458c-967f-98210917ce22" xlink:to="loc_us-gaap_WarrantMember_cacb5027-a964-4ecf-869f-13d5976f64a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_81d266a8-e1a8-4c0e-8864-21a433385759" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_86e13817-6b79-46a7-86ca-9affdc1f7044" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_81d266a8-e1a8-4c0e-8864-21a433385759" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_4f0f7798-1737-4dd0-81fe-9173ccb298ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_81d266a8-e1a8-4c0e-8864-21a433385759" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_4f0f7798-1737-4dd0-81fe-9173ccb298ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.auriniapharma.com/role/SharebasedCompensation" xlink:type="simple" xlink:href="auph-20220331.xsd#SharebasedCompensation"/>
  <link:presentationLink xlink:role="http://www.auriniapharma.com/role/SharebasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7ca61da4-cd09-43b7-9efc-4ef1aad28b04" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_361ad286-0400-49d3-bd38-977b889c7188" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7ca61da4-cd09-43b7-9efc-4ef1aad28b04" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_361ad286-0400-49d3-bd38-977b889c7188" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.auriniapharma.com/role/SharebasedCompensationTables" xlink:type="simple" xlink:href="auph-20220331.xsd#SharebasedCompensationTables"/>
  <link:presentationLink xlink:role="http://www.auriniapharma.com/role/SharebasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_89a47167-90b1-4e20-a277-2dd98221f7e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_84244da9-b2b1-435f-a33d-2216fe0f9821" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_89a47167-90b1-4e20-a277-2dd98221f7e1" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_84244da9-b2b1-435f-a33d-2216fe0f9821" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_aa3e6264-5686-412f-a38c-6fa9c18d60c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_89a47167-90b1-4e20-a277-2dd98221f7e1" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_aa3e6264-5686-412f-a38c-6fa9c18d60c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock_353a90c5-6a23-4526-8bbc-ca05f927b815" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_89a47167-90b1-4e20-a277-2dd98221f7e1" xlink:to="loc_us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock_353a90c5-6a23-4526-8bbc-ca05f927b815" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_8a034a36-37cb-4647-b41a-af6064db07af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_89a47167-90b1-4e20-a277-2dd98221f7e1" xlink:to="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_8a034a36-37cb-4647-b41a-af6064db07af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.auriniapharma.com/role/SharebasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="auph-20220331.xsd#SharebasedCompensationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.auriniapharma.com/role/SharebasedCompensationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e6b559d4-c3da-4646-a687-ebe2d397bac7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a0d42b69-50d0-4b5a-9416-b8f93ca678ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e6b559d4-c3da-4646-a687-ebe2d397bac7" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a0d42b69-50d0-4b5a-9416-b8f93ca678ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_ac593ad8-2ff8-406a-bd89-a4c4b8b49f23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a0d42b69-50d0-4b5a-9416-b8f93ca678ee" xlink:to="loc_us-gaap_AwardTypeAxis_ac593ad8-2ff8-406a-bd89-a4c4b8b49f23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_76654134-d2d7-452c-a1ee-12516e6d4660" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_ac593ad8-2ff8-406a-bd89-a4c4b8b49f23" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_76654134-d2d7-452c-a1ee-12516e6d4660" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_2891f358-3cae-4a77-a3e5-88c131255ca9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_76654134-d2d7-452c-a1ee-12516e6d4660" xlink:to="loc_us-gaap_PerformanceSharesMember_2891f358-3cae-4a77-a3e5-88c131255ca9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_00fa4d97-fa98-46f1-8438-e0b247650aa3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_76654134-d2d7-452c-a1ee-12516e6d4660" xlink:to="loc_us-gaap_EmployeeStockMember_00fa4d97-fa98-46f1-8438-e0b247650aa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_auph_PerformanceShareSandRestrictedStockUnitsRSUsMember_832d389d-4bac-4887-af5f-318f37284c04" xlink:href="auph-20220331.xsd#auph_PerformanceShareSandRestrictedStockUnitsRSUsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_76654134-d2d7-452c-a1ee-12516e6d4660" xlink:to="loc_auph_PerformanceShareSandRestrictedStockUnitsRSUsMember_832d389d-4bac-4887-af5f-318f37284c04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_2c59999c-e722-4e1c-bea9-3f74ddf9ee2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_76654134-d2d7-452c-a1ee-12516e6d4660" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_2c59999c-e722-4e1c-bea9-3f74ddf9ee2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_c3272c59-cb48-4965-8d87-9fd8ca93bce8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a0d42b69-50d0-4b5a-9416-b8f93ca678ee" xlink:to="loc_srt_TitleOfIndividualAxis_c3272c59-cb48-4965-8d87-9fd8ca93bce8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_d5d49d1e-f620-4335-a0f4-f9dc4fbdad11" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_c3272c59-cb48-4965-8d87-9fd8ca93bce8" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_d5d49d1e-f620-4335-a0f4-f9dc4fbdad11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OfficerMember_761cb252-7251-4e2d-81ab-6214ae234439" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OfficerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_d5d49d1e-f620-4335-a0f4-f9dc4fbdad11" xlink:to="loc_srt_OfficerMember_761cb252-7251-4e2d-81ab-6214ae234439" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_0f958d1b-92de-4d3b-b824-cf391cd2fa08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a0d42b69-50d0-4b5a-9416-b8f93ca678ee" xlink:to="loc_us-gaap_PlanNameAxis_0f958d1b-92de-4d3b-b824-cf391cd2fa08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_b2e727ef-1008-4d98-be7b-c820a4d1ae54" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_0f958d1b-92de-4d3b-b824-cf391cd2fa08" xlink:to="loc_us-gaap_PlanNameDomain_b2e727ef-1008-4d98-be7b-c820a4d1ae54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_auph_AmendedAndRestatedEquityIncentivePlanMember_adde1a23-0b87-4c0d-8f36-25899972916b" xlink:href="auph-20220331.xsd#auph_AmendedAndRestatedEquityIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_b2e727ef-1008-4d98-be7b-c820a4d1ae54" xlink:to="loc_auph_AmendedAndRestatedEquityIncentivePlanMember_adde1a23-0b87-4c0d-8f36-25899972916b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_73b37fd4-6c78-4238-9e18-14a952507971" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a0d42b69-50d0-4b5a-9416-b8f93ca678ee" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_73b37fd4-6c78-4238-9e18-14a952507971" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_9245b7e3-879e-4409-803d-9346d949194d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_73b37fd4-6c78-4238-9e18-14a952507971" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_9245b7e3-879e-4409-803d-9346d949194d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_0a9002fe-3363-4680-b919-1aa9e22f91e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_73b37fd4-6c78-4238-9e18-14a952507971" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_0a9002fe-3363-4680-b919-1aa9e22f91e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_568bc2e4-d4d9-459c-9365-89aedd3a879f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_73b37fd4-6c78-4238-9e18-14a952507971" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_568bc2e4-d4d9-459c-9365-89aedd3a879f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_83b3e036-e205-487f-957c-bab50c45bbcf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_73b37fd4-6c78-4238-9e18-14a952507971" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_83b3e036-e205-487f-957c-bab50c45bbcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_c9b1f5b7-c947-436c-ba0b-33a987e3ab0f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_73b37fd4-6c78-4238-9e18-14a952507971" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_c9b1f5b7-c947-436c-ba0b-33a987e3ab0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_b5ff2644-6d07-4d44-bc5a-4cfcd4c14366" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_73b37fd4-6c78-4238-9e18-14a952507971" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_b5ff2644-6d07-4d44-bc5a-4cfcd4c14366" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_8dbd6331-fa8c-442b-a8b9-71015a4f8a8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_73b37fd4-6c78-4238-9e18-14a952507971" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_8dbd6331-fa8c-442b-a8b9-71015a4f8a8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_d2692cfb-9bac-42ef-a394-12be67be6e43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_73b37fd4-6c78-4238-9e18-14a952507971" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_d2692cfb-9bac-42ef-a394-12be67be6e43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_760ff13e-b05d-4a80-861c-99d0c841a88d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_73b37fd4-6c78-4238-9e18-14a952507971" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_760ff13e-b05d-4a80-861c-99d0c841a88d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_8e6d3e21-609c-4b3e-916e-7db3d253e3b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_73b37fd4-6c78-4238-9e18-14a952507971" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_8e6d3e21-609c-4b3e-916e-7db3d253e3b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.auriniapharma.com/role/ShareBasedCompensationWeightedAverageAssumptionsDetails" xlink:type="simple" xlink:href="auph-20220331.xsd#ShareBasedCompensationWeightedAverageAssumptionsDetails"/>
  <link:presentationLink xlink:role="http://www.auriniapharma.com/role/ShareBasedCompensationWeightedAverageAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f125adbd-cb01-4bf5-8d29-c3d081b1a9df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_ea48d493-1311-42d5-a080-c417b75be726" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f125adbd-cb01-4bf5-8d29-c3d081b1a9df" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_ea48d493-1311-42d5-a080-c417b75be726" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_67abbb99-95cf-4a85-97fc-214034cbd435" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f125adbd-cb01-4bf5-8d29-c3d081b1a9df" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_67abbb99-95cf-4a85-97fc-214034cbd435" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_affc4df8-871a-4e39-8e8e-337a6f7346f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f125adbd-cb01-4bf5-8d29-c3d081b1a9df" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_affc4df8-871a-4e39-8e8e-337a6f7346f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_auph_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate_b4c1db3c-1b99-4a5f-8539-f21bb4f53ce5" xlink:href="auph-20220331.xsd#auph_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f125adbd-cb01-4bf5-8d29-c3d081b1a9df" xlink:to="loc_auph_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate_b4c1db3c-1b99-4a5f-8539-f21bb4f53ce5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend_798597be-bf6c-4e10-97e6-b35aa41a80f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f125adbd-cb01-4bf5-8d29-c3d081b1a9df" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend_798597be-bf6c-4e10-97e6-b35aa41a80f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7b64e48d-ea81-4026-a2e4-4a044a08b600" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f125adbd-cb01-4bf5-8d29-c3d081b1a9df" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7b64e48d-ea81-4026-a2e4-4a044a08b600" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.auriniapharma.com/role/ShareBasedCompensationStockOptionActivityDetails" xlink:type="simple" xlink:href="auph-20220331.xsd#ShareBasedCompensationStockOptionActivityDetails"/>
  <link:presentationLink xlink:role="http://www.auriniapharma.com/role/ShareBasedCompensationStockOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3acc6475-0a16-4ad2-bcba-e37bd588b8f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_e1460067-72b4-4f61-baef-b1975c6d4d2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3acc6475-0a16-4ad2-bcba-e37bd588b8f7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_e1460067-72b4-4f61-baef-b1975c6d4d2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2e950ca6-c242-4ed8-86c8-dac42951a65c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_e1460067-72b4-4f61-baef-b1975c6d4d2e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2e950ca6-c242-4ed8-86c8-dac42951a65c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_3661c480-0ca4-46bb-8b4c-f9acd934742f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_e1460067-72b4-4f61-baef-b1975c6d4d2e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_3661c480-0ca4-46bb-8b4c-f9acd934742f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_08e65715-fa6c-4920-a27d-832d937b4d6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_e1460067-72b4-4f61-baef-b1975c6d4d2e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_08e65715-fa6c-4920-a27d-832d937b4d6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_576513a8-536c-425c-88ef-9935b5d63381" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_e1460067-72b4-4f61-baef-b1975c6d4d2e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_576513a8-536c-425c-88ef-9935b5d63381" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_9a175eed-9077-480e-a249-7b660cc15c6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_e1460067-72b4-4f61-baef-b1975c6d4d2e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_9a175eed-9077-480e-a249-7b660cc15c6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_7adbd3a0-4146-4f56-b44f-866dff08507e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3acc6475-0a16-4ad2-bcba-e37bd588b8f7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_7adbd3a0-4146-4f56-b44f-866dff08507e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3bde19e5-2709-4891-b9a2-eea9b4edcf76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_7adbd3a0-4146-4f56-b44f-866dff08507e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3bde19e5-2709-4891-b9a2-eea9b4edcf76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_f9fccd45-b8cc-45cf-a3e2-b4035865d153" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_7adbd3a0-4146-4f56-b44f-866dff08507e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_f9fccd45-b8cc-45cf-a3e2-b4035865d153" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_cc42130d-7503-473b-8622-fd801a054336" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_7adbd3a0-4146-4f56-b44f-866dff08507e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_cc42130d-7503-473b-8622-fd801a054336" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_56d66585-ebb7-44d4-b735-702e9c93f288" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_7adbd3a0-4146-4f56-b44f-866dff08507e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_56d66585-ebb7-44d4-b735-702e9c93f288" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_ce853403-a340-4a05-9de6-fc4fba20054e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_7adbd3a0-4146-4f56-b44f-866dff08507e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_ce853403-a340-4a05-9de6-fc4fba20054e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.auriniapharma.com/role/ShareBasedCompensationPerformanceAwardsandRestrictedStockUnitsActivityDetails" xlink:type="simple" xlink:href="auph-20220331.xsd#ShareBasedCompensationPerformanceAwardsandRestrictedStockUnitsActivityDetails"/>
  <link:presentationLink xlink:role="http://www.auriniapharma.com/role/ShareBasedCompensationPerformanceAwardsandRestrictedStockUnitsActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d11bd524-c1a9-4ae8-ad2d-e212a7b0e908" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a4f213af-e9ce-48da-8251-400d4e7267c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d11bd524-c1a9-4ae8-ad2d-e212a7b0e908" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a4f213af-e9ce-48da-8251-400d4e7267c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_a49bb3a6-f902-4e5d-bcd5-fd381b127eb5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a4f213af-e9ce-48da-8251-400d4e7267c4" xlink:to="loc_us-gaap_AwardTypeAxis_a49bb3a6-f902-4e5d-bcd5-fd381b127eb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1bc3e917-76c5-46e6-9529-9fecac0ad064" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_a49bb3a6-f902-4e5d-bcd5-fd381b127eb5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1bc3e917-76c5-46e6-9529-9fecac0ad064" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_auph_PerformanceShareSandRestrictedStockUnitsRSUsMember_08353e3f-f847-426c-b4c5-4399095c38d9" xlink:href="auph-20220331.xsd#auph_PerformanceShareSandRestrictedStockUnitsRSUsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1bc3e917-76c5-46e6-9529-9fecac0ad064" xlink:to="loc_auph_PerformanceShareSandRestrictedStockUnitsRSUsMember_08353e3f-f847-426c-b4c5-4399095c38d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_b974942a-deca-4282-aaf6-cdb8c1f94ef8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a4f213af-e9ce-48da-8251-400d4e7267c4" xlink:to="loc_srt_TitleOfIndividualAxis_b974942a-deca-4282-aaf6-cdb8c1f94ef8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_a123bf5e-3be8-4f12-a222-6923a2d16838" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_b974942a-deca-4282-aaf6-cdb8c1f94ef8" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_a123bf5e-3be8-4f12-a222-6923a2d16838" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OfficerMember_9852309b-4dd8-46fe-b178-ebd28b52105f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OfficerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_a123bf5e-3be8-4f12-a222-6923a2d16838" xlink:to="loc_srt_OfficerMember_9852309b-4dd8-46fe-b178-ebd28b52105f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_763f838a-ce64-4d4e-b920-3fdecd175427" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a4f213af-e9ce-48da-8251-400d4e7267c4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_763f838a-ce64-4d4e-b920-3fdecd175427" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_2dcfee1e-3db4-42b4-8cf5-ca63035e30e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_763f838a-ce64-4d4e-b920-3fdecd175427" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_2dcfee1e-3db4-42b4-8cf5-ca63035e30e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_18854ead-9ceb-4375-8d4c-d6a62d0823a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_2dcfee1e-3db4-42b4-8cf5-ca63035e30e7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_18854ead-9ceb-4375-8d4c-d6a62d0823a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_73938566-9a6d-447c-b434-69435020549e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_2dcfee1e-3db4-42b4-8cf5-ca63035e30e7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_73938566-9a6d-447c-b434-69435020549e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_f616e09b-bdce-4180-8305-7bc7b6c3b933" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_2dcfee1e-3db4-42b4-8cf5-ca63035e30e7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_f616e09b-bdce-4180-8305-7bc7b6c3b933" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_de8f1e51-9427-4558-8e2e-9e32f161860f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_2dcfee1e-3db4-42b4-8cf5-ca63035e30e7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_de8f1e51-9427-4558-8e2e-9e32f161860f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_d15cb675-15ee-409a-baaf-9217de8c8342" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_2dcfee1e-3db4-42b4-8cf5-ca63035e30e7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_d15cb675-15ee-409a-baaf-9217de8c8342" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e9dc50e7-6675-4e89-a58e-e1d40aee4414" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_763f838a-ce64-4d4e-b920-3fdecd175427" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e9dc50e7-6675-4e89-a58e-e1d40aee4414" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_076bfdb5-07f1-417b-900b-c5ac6d66032e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e9dc50e7-6675-4e89-a58e-e1d40aee4414" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_076bfdb5-07f1-417b-900b-c5ac6d66032e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2a22225d-497a-48ff-b3b0-6ca788a2e4e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e9dc50e7-6675-4e89-a58e-e1d40aee4414" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2a22225d-497a-48ff-b3b0-6ca788a2e4e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_23e9e7b6-32be-4629-add4-66e74e8076cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e9dc50e7-6675-4e89-a58e-e1d40aee4414" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_23e9e7b6-32be-4629-add4-66e74e8076cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c70f56de-f59c-4821-bb1e-faf8d53f45d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e9dc50e7-6675-4e89-a58e-e1d40aee4414" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c70f56de-f59c-4821-bb1e-faf8d53f45d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_9cca6e0c-bdb8-41d6-8949-01167dcf60de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e9dc50e7-6675-4e89-a58e-e1d40aee4414" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_9cca6e0c-bdb8-41d6-8949-01167dcf60de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.auriniapharma.com/role/ShareBasedCompensationAllocatedShareBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="auph-20220331.xsd#ShareBasedCompensationAllocatedShareBasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.auriniapharma.com/role/ShareBasedCompensationAllocatedShareBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cfad342c-a787-4ec7-bbb0-9c1e0ccaf10a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_02621d7d-0365-47e4-8ba2-9ac1913e2fa2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cfad342c-a787-4ec7-bbb0-9c1e0ccaf10a" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_02621d7d-0365-47e4-8ba2-9ac1913e2fa2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_8548542c-b0dd-4d2f-812a-0e0ccefe615a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_02621d7d-0365-47e4-8ba2-9ac1913e2fa2" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_8548542c-b0dd-4d2f-812a-0e0ccefe615a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_695581a8-5a1a-4beb-aafc-6336ccddaae5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_8548542c-b0dd-4d2f-812a-0e0ccefe615a" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_695581a8-5a1a-4beb-aafc-6336ccddaae5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_fcb2f372-a407-4b69-8e50-9d64e99f8cfa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_695581a8-5a1a-4beb-aafc-6336ccddaae5" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_fcb2f372-a407-4b69-8e50-9d64e99f8cfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_0b7a3a30-01e9-4774-8c13-3d3b8f13a00f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_695581a8-5a1a-4beb-aafc-6336ccddaae5" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_0b7a3a30-01e9-4774-8c13-3d3b8f13a00f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoriesMember_1ddbc1c0-f784-4b9d-9c4c-efbf00c673cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoriesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_695581a8-5a1a-4beb-aafc-6336ccddaae5" xlink:to="loc_us-gaap_InventoriesMember_1ddbc1c0-f784-4b9d-9c4c-efbf00c673cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_114491dc-f6bf-4e24-a466-674741e1dabd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_02621d7d-0365-47e4-8ba2-9ac1913e2fa2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_114491dc-f6bf-4e24-a466-674741e1dabd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_5efb3ec0-2736-4ee6-95df-b1a1fc076767" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_114491dc-f6bf-4e24-a466-674741e1dabd" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_5efb3ec0-2736-4ee6-95df-b1a1fc076767" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.auriniapharma.com/role/IncomeTaxes" xlink:type="simple" xlink:href="auph-20220331.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.auriniapharma.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_ab350ad2-9b56-4c9e-a412-7db91373f62b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_df96eab5-9ba9-42b0-ba99-c75ddded0747" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ab350ad2-9b56-4c9e-a412-7db91373f62b" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_df96eab5-9ba9-42b0-ba99-c75ddded0747" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.auriniapharma.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="auph-20220331.xsd#IncomeTaxesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.auriniapharma.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_bd9178cd-dc43-4e7d-8d8e-9c98ccfdb4e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_92e7b2ca-a128-4c7c-8c28-be56d54d3222" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_bd9178cd-dc43-4e7d-8d8e-9c98ccfdb4e0" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_92e7b2ca-a128-4c7c-8c28-be56d54d3222" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.auriniapharma.com/role/RelatedPartyTransactions" xlink:type="simple" xlink:href="auph-20220331.xsd#RelatedPartyTransactions"/>
  <link:presentationLink xlink:role="http://www.auriniapharma.com/role/RelatedPartyTransactions" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_dc7a5d27-ab25-499e-93db-0ce2cf962e30" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_1d16d2d1-7a31-4163-b2dc-3da095a11f4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_dc7a5d27-ab25-499e-93db-0ce2cf962e30" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_1d16d2d1-7a31-4163-b2dc-3da095a11f4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.auriniapharma.com/role/RelatedPartyTransactionsDetails" xlink:type="simple" xlink:href="auph-20220331.xsd#RelatedPartyTransactionsDetails"/>
  <link:presentationLink xlink:role="http://www.auriniapharma.com/role/RelatedPartyTransactionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_eaf4d4a5-ed55-440f-b303-8bf6e2bb01b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_3bffa521-82fc-4098-90c6-4a38908b21e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_eaf4d4a5-ed55-440f-b303-8bf6e2bb01b7" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_3bffa521-82fc-4098-90c6-4a38908b21e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_9c1bcd0b-20ec-4dba-bbc7-d24643fa7782" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_3bffa521-82fc-4098-90c6-4a38908b21e8" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_9c1bcd0b-20ec-4dba-bbc7-d24643fa7782" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_e87e6523-7451-4281-89ca-73a0396b9997" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_9c1bcd0b-20ec-4dba-bbc7-d24643fa7782" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_e87e6523-7451-4281-89ca-73a0396b9997" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_auph_MilestonePaymentMember_3bf98e2f-7db2-415c-b7ec-37f71fabdc8b" xlink:href="auph-20220331.xsd#auph_MilestonePaymentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_e87e6523-7451-4281-89ca-73a0396b9997" xlink:to="loc_auph_MilestonePaymentMember_3bf98e2f-7db2-415c-b7ec-37f71fabdc8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_7db4dd8b-e7ab-421d-8fad-a6eba83c2c38" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_3bffa521-82fc-4098-90c6-4a38908b21e8" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_7db4dd8b-e7ab-421d-8fad-a6eba83c2c38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_4c92ce95-3ce1-4bd7-be50-6e5429f59006" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_7db4dd8b-e7ab-421d-8fad-a6eba83c2c38" xlink:to="loc_us-gaap_RelatedPartyDomain_4c92ce95-3ce1-4bd7-be50-6e5429f59006" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember_edbb3ab3-8aba-460d-90ce-bd443da94595" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_AffiliatedEntityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_4c92ce95-3ce1-4bd7-be50-6e5429f59006" xlink:to="loc_srt_AffiliatedEntityMember_edbb3ab3-8aba-460d-90ce-bd443da94595" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_b631caae-c520-4a72-8b22-3f3e2bbec892" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_3bffa521-82fc-4098-90c6-4a38908b21e8" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_b631caae-c520-4a72-8b22-3f3e2bbec892" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_ab0a223f-191e-4cdb-9d5d-41e762c14346" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_b631caae-c520-4a72-8b22-3f3e2bbec892" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_ab0a223f-191e-4cdb-9d5d-41e762c14346" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_60b6da3a-b524-4725-a367-6449d25e6c1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_ab0a223f-191e-4cdb-9d5d-41e762c14346" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_60b6da3a-b524-4725-a367-6449d25e6c1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_549720d2-fd9c-40ee-8ac1-eec1c004a290" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_3bffa521-82fc-4098-90c6-4a38908b21e8" xlink:to="loc_srt_CounterpartyNameAxis_549720d2-fd9c-40ee-8ac1-eec1c004a290" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_fa37543c-4ac1-44de-a3cc-3deb09f3557b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_549720d2-fd9c-40ee-8ac1-eec1c004a290" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_fa37543c-4ac1-44de-a3cc-3deb09f3557b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_auph_ILJINMember_8f62635a-75e5-42cb-ae4e-190089f15eaf" xlink:href="auph-20220331.xsd#auph_ILJINMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_fa37543c-4ac1-44de-a3cc-3deb09f3557b" xlink:to="loc_auph_ILJINMember_8f62635a-75e5-42cb-ae4e-190089f15eaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_9758139d-1367-4758-9f7b-f679685370a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_3bffa521-82fc-4098-90c6-4a38908b21e8" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_9758139d-1367-4758-9f7b-f679685370a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_77151655-8d98-4a7a-9c27-519e36f3f252" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_9758139d-1367-4758-9f7b-f679685370a8" xlink:to="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_77151655-8d98-4a7a-9c27-519e36f3f252" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_a326ccaa-e9ab-4c9b-893f-dbb3ff17dd07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_9758139d-1367-4758-9f7b-f679685370a8" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_a326ccaa-e9ab-4c9b-893f-dbb3ff17dd07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.auriniapharma.com/role/CommitmentandContingencies" xlink:type="simple" xlink:href="auph-20220331.xsd#CommitmentandContingencies"/>
  <link:presentationLink xlink:role="http://www.auriniapharma.com/role/CommitmentandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_f484f7ad-e001-43ff-8105-da80f242437f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_3230c26c-660e-48a1-93d0-6a59fa09e0e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_f484f7ad-e001-43ff-8105-da80f242437f" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_3230c26c-660e-48a1-93d0-6a59fa09e0e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140554842938904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>May 09, 2022</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36421<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Aurinia Pharmaceuticals Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">Z4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">98-1231763<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">#1203-4464 Markham Street<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Victoria<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">BC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">V8Z 7X8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(250)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">708-4272<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">141,741,580<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common shares, no par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">AUPH<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001600620<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140554847190824">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash</a></td>
<td class="nump">$ 132,542<span></span>
</td>
<td class="nump">$ 231,900<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">286,210<span></span>
</td>
<td class="nump">234,178<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsAndOtherReceivablesNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">20,401<span></span>
</td>
<td class="nump">15,414<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories, net</a></td>
<td class="nump">26,266<span></span>
</td>
<td class="nump">19,326<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">12,199<span></span>
</td>
<td class="nump">12,506<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">477,618<span></span>
</td>
<td class="nump">513,324<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>Non-current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other non-current assets</a></td>
<td class="nump">11,838<span></span>
</td>
<td class="nump">11,838<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">4,332<span></span>
</td>
<td class="nump">4,418<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Acquired intellectual property and other intangible assets, net</a></td>
<td class="nump">7,882<span></span>
</td>
<td class="nump">8,404<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="nump">5,232<span></span>
</td>
<td class="nump">5,383<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">506,902<span></span>
</td>
<td class="nump">543,367<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued liabilities</a></td>
<td class="nump">32,327<span></span>
</td>
<td class="nump">34,947<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">502<span></span>
</td>
<td class="nump">4,640<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="nump">1,009<span></span>
</td>
<td class="nump">1,059<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">33,838<span></span>
</td>
<td class="nump">40,646<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Non-current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Deferred compensation and other non-current liabilities</a></td>
<td class="nump">17,379<span></span>
</td>
<td class="nump">15,950<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities</a></td>
<td class="nump">7,562<span></span>
</td>
<td class="nump">7,680<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">58,779<span></span>
</td>
<td class="nump">64,276<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 18)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>SHAREHOLDER&#8217;S EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValueOutstanding', window );">Common shares - no par value, unlimited shares authorized, 141,742 and 141,600 shares issued and outstanding at March 31, 2022 and December 31, 2021, respectively</a></td>
<td class="nump">1,178,807<span></span>
</td>
<td class="nump">1,177,051<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">64,686<span></span>
</td>
<td class="nump">59,014<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(1,618)<span></span>
</td>
<td class="num">(852)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(793,752)<span></span>
</td>
<td class="num">(756,122)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total shareholders' equity</a></td>
<td class="nump">448,123<span></span>
</td>
<td class="nump">479,091<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and shareholders&#8217; equity</a></td>
<td class="nump">$ 506,902<span></span>
</td>
<td class="nump">$ 543,367<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsAndOtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, receivable from customers, clients, or other third-parties, and receivables classified as other due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsAndOtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of all classes of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares exclude common shares repurchased by the entity and held as treasury shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), investment in debt security measured at amortized cost (held-to-maturity), and investment in debt security measured at fair value with change in fair value recognized in net income (trading), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6787-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123349782&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140554847109016">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, issued (shares)</a></td>
<td class="nump">141,742,000<span></span>
</td>
<td class="nump">141,600,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, outstanding (shares)</a></td>
<td class="nump">141,742,000<span></span>
</td>
<td class="nump">141,600,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140554842701256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Net revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 21,625<span></span>
</td>
<td class="nump">$ 914<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of sales</a></td>
<td class="nump">256<span></span>
</td>
<td class="nump">48<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">45,197<span></span>
</td>
<td class="nump">39,805<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">12,620<span></span>
</td>
<td class="nump">9,833<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Other expense, net</a></td>
<td class="nump">1,434<span></span>
</td>
<td class="nump">1,771<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total cost of sales and operating expenses</a></td>
<td class="nump">59,507<span></span>
</td>
<td class="nump">51,457<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(37,882)<span></span>
</td>
<td class="num">(50,543)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Interest income</a></td>
<td class="nump">262<span></span>
</td>
<td class="nump">172<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Net loss before income taxes</a></td>
<td class="num">(37,620)<span></span>
</td>
<td class="num">(50,371)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(37,630)<span></span>
</td>
<td class="num">(50,379)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Unrealized (loss) gain on available-for-sale securities, net of tax of nil</a></td>
<td class="num">(766)<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (38,396)<span></span>
</td>
<td class="num">$ (50,373)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic loss per share (expressed in $ per share)</a></td>
<td class="num">$ (0.27)<span></span>
</td>
<td class="num">$ (0.40)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted loss per share (expressed in $ per share)</a></td>
<td class="num">$ (0.27)<span></span>
</td>
<td class="num">$ (0.40)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average common shares outstanding used in computation of basic loss per share</a></td>
<td class="nump">141,675<span></span>
</td>
<td class="nump">127,401<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average common shares outstanding used in computation of diluted loss per share</a></td>
<td class="nump">141,675<span></span>
</td>
<td class="nump">127,401<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product revenue, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Net revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 21,492<span></span>
</td>
<td class="nump">$ 884<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">License and collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Net revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 133<span></span>
</td>
<td class="nump">$ 30<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123384075&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNonoperatingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of nonoperating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNonoperatingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities, attributable to parent entity. Excludes amounts related to other than temporary impairment (OTTI) loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569643-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140554937777864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations and Comprehensive Loss (Parenthetical) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax', window );">Unrealized gain on available-for-sale securities, tax</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after adjustment, of tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e640-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140554840255896">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Shareholders' Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Shares</div></th>
<th class="th"><div>Additional paid in capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive (Loss) Income</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">126,725,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2020</a></td>
<td class="nump">$ 407,750<span></span>
</td>
<td class="nump">$ 944,328<span></span>
</td>
<td class="nump">$ 39,383<span></span>
</td>
<td class="num">$ (805)<span></span>
</td>
<td class="num">$ (575,156)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Shares issued on exercise of stock options and vesting of performance awards (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">877,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Shares issued on exercise of stock options and vesting of performance awards</a></td>
<td class="nump">4,999<span></span>
</td>
<td class="nump">$ 7,619<span></span>
</td>
<td class="num">(2,620)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Exercise of warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">519,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants', window );">Exercise of warrants</a></td>
<td class="nump">31<span></span>
</td>
<td class="nump">$ 726<span></span>
</td>
<td class="num">(695)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Shared-based compensation</a></td>
<td class="nump">7,821<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,821<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Unrealized gain (loss) on available-for-sale securities</a></td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(50,379)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(50,379)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">128,121,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2021</a></td>
<td class="nump">$ 370,228<span></span>
</td>
<td class="nump">$ 952,673<span></span>
</td>
<td class="nump">43,889<span></span>
</td>
<td class="num">(799)<span></span>
</td>
<td class="num">(625,535)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in shares) at Dec. 31, 2021</a></td>
<td class="nump">141,600,000<span></span>
</td>
<td class="nump">141,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2021</a></td>
<td class="nump">$ 479,091<span></span>
</td>
<td class="nump">$ 1,177,051<span></span>
</td>
<td class="nump">59,014<span></span>
</td>
<td class="num">(852)<span></span>
</td>
<td class="num">(756,122)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Shares issued on exercise of stock options and vesting of performance awards (in shares)</a></td>
<td class="nump">54,000<span></span>
</td>
<td class="nump">142,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Shares issued on exercise of stock options and vesting of performance awards</a></td>
<td class="nump">$ 405<span></span>
</td>
<td class="nump">$ 1,756<span></span>
</td>
<td class="num">(1,351)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Shared-based compensation</a></td>
<td class="nump">7,023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Unrealized gain (loss) on available-for-sale securities</a></td>
<td class="num">(766)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(766)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (37,630)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(37,630)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in shares) at Mar. 31, 2022</a></td>
<td class="nump">141,742,000<span></span>
</td>
<td class="nump">141,742,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2022</a></td>
<td class="nump">$ 448,123<span></span>
</td>
<td class="nump">$ 1,178,807<span></span>
</td>
<td class="nump">$ 64,686<span></span>
</td>
<td class="num">$ (1,618)<span></span>
</td>
<td class="num">$ (793,752)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123468992&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of preferred stock and warrants for common stock issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140554842805080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (37,630)<span></span>
</td>
<td class="num">$ (50,379)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation and amortization</a></td>
<td class="nump">687<span></span>
</td>
<td class="nump">688<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Amortization of intangible assets</a></td>
<td class="nump">151<span></span>
</td>
<td class="num">(272)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation expense</a></td>
<td class="nump">7,023<span></span>
</td>
<td class="nump">7,821<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other, net</a></td>
<td class="nump">1,514<span></span>
</td>
<td class="num">(2,111)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Net changes in operating assets and liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInReceivables', window );">Accounts receivable</a></td>
<td class="num">(4,986)<span></span>
</td>
<td class="num">(1,187)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories</a></td>
<td class="num">(6,940)<span></span>
</td>
<td class="num">(2,009)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">307<span></span>
</td>
<td class="nump">308<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Non-current assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">229<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable, accrued and other liabilities</a></td>
<td class="num">(6,704)<span></span>
</td>
<td class="num">(7,103)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Lease liabilities</a></td>
<td class="num">(168)<span></span>
</td>
<td class="nump">474<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(46,746)<span></span>
</td>
<td class="num">(53,541)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows used in investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchase of investments</a></td>
<td class="num">(163,504)<span></span>
</td>
<td class="num">(115,168)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Proceeds from investments</a></td>
<td class="nump">110,566<span></span>
</td>
<td class="nump">60,940<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireLeaseReceivables', window );">Upfront lease payment</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(11,838)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireOtherProductiveAssets', window );">Purchase of long-lived assets</a></td>
<td class="num">(79)<span></span>
</td>
<td class="num">(136)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForSoftware', window );">Additions to internal use-software implementation costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,039)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Capitalized patent costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(53,017)<span></span>
</td>
<td class="num">(67,247)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">405<span></span>
</td>
<td class="nump">4,999<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of warrants</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">30<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Cash provided by financing activities</a></td>
<td class="nump">405<span></span>
</td>
<td class="nump">5,029<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net decrease in cash, cash equivalents and restricted cash</a></td>
<td class="num">(99,358)<span></span>
</td>
<td class="num">(115,759)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, beginning of period</a></td>
<td class="nump">231,900<span></span>
</td>
<td class="nump">272,350<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, end of period</a></td>
<td class="nump">132,542<span></span>
</td>
<td class="nump">156,591<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromInterestReceived', window );">Cash received for interest</a></td>
<td class="nump">13<span></span>
</td>
<td class="nump">425<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeaseObligationsIncurred', window );">Cash paid for amounts included in the measurement of lease liabilities</a></td>
<td class="num">(281)<span></span>
</td>
<td class="num">(63)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosure of noncash transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Initial recognition of operating lease right-of-use asset</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,804<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalCashFlowElementsSummationsAbstract', window );"><strong>Reconciliation of cash, cash equivalents and restricted cash to the condensed consolidated balance sheets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash, cash equivalents</a></td>
<td class="nump">131,636<span></span>
</td>
<td class="nump">156,591<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted cash</a></td>
<td class="nump">906<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total cash, cash equivalents and restricted cash</a></td>
<td class="nump">$ 132,542<span></span>
</td>
<td class="nump">$ 156,591<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalCashFlowElementsSummationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalCashFlowElementsSummationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeaseObligationsIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in lease obligation from new lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeaseObligationsIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForSoftware">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the development, modification or acquisition of software programs or applications for internal use (that is, not to be sold, leased or otherwise marketed to others) that qualify for capitalization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForSoftware</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireLeaseReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the purchase of receivables arising from the lease of real estate, equipment or other fixed assets for a specified time in exchange for payment, usually in the form of rent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireLeaseReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireOtherProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for the purchase of or improvements to tangible or intangible assets, used to produce goods or deliver services, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireOtherProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromInterestReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest received on loans and other debt instruments during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3337-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromInterestReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140554846913992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Description of Business<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Organization and Description of Business</a></td>
<td class="text">Organization and Description of Business<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Aurinia Pharmaceuticals Inc. (Aurinia or the Company) is a fully integrated biopharmaceutical company focused on delivering therapies to treat targeted patient populations that are impacted by serious diseases with a high unmet medical need. In January 2021, the Company introduced LUPKYNIS&#8482; (voclosporin), the first U.S. Food and Drug Administration (FDA) approved oral therapy for the treatment of adult patients with active LN and continues to conduct pre-clinical, clinical, and regulatory advancement to support the voclosporin development program. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 17, 2021, the Company announced the addition of two novel assets AUR200 and AUR300. AUR200 is currently undergoing pre-clinical development with projected submission of an Investigational New Drug Application (IND) to the FDA in 2023. The Company anticipates that an IND for AUR300 will also be submitted during 2023.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Aurinia's head office is located at #1203-4464 Markham Street, Victoria, British Columbia, Canada and its registered office is located at #201, 17873-106 A Avenue, Edmonton, Alberta. Aurinia also has a U.S. commercial office located at 77 Upper Rock Circle Suite 700, Rockville, Maryland, 20850 United States.</span></div>Aurinia is incorporated pursuant to the Business Corporations Act (Alberta). The Company&#8217;s common shares are traded on the Nasdaq Global Market (Nasdaq) under the symbol AUPH<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140554846906968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccounting', window );">Basis of Presentation</a></td>
<td class="text">Basis of Presentation<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States (U.S. GAAP) for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of normal recurring adjustments considered necessary for fair presentation in accordance with U.S. GAAP. The condensed consolidated balance sheet as of December&#160;31, 2021 was derived from audited annual consolidated financial statements but does not include all annual disclosures required by U.S. GAAP. These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements included in the Company's Annual Report on Form 10-K for the year ended December&#160;31, 2021. The results of operations for the three months ended March&#160;31, 2022 are not necessarily indicative of the results to be expected for the full year or any other future periods.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, Aurinia Pharma U.S., Inc. (Delaware incorporated) and Aurinia Pharma Limited (UK incorporated). All intercompany balances and transactions have been eliminated in consolidation and operate in one segment.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These unaudited condensed consolidated financial statements are presented in U.S. dollars which is the Company's functional currency therefore there is no currency translation adjustment upon consolidation as the remeasurement of gains or losses are recorded in the condensed consolidated statements of operations. All assets and liabilities denominated in a foreign currency are remeasured into U.S. dollars at the exchange rate on the balance sheet date. Revenues and expenses are remeasured at the average exchange rate during the period. Foreign exchange gains and losses arising on translation or settlement of a foreign currency denominated monetary item are included in the condensed consolidated statements of operations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is devoting the majority of our operational efforts and financial resources towards the commercialization and post approval commitments of our approved drug, LUPKYNIS. The Company is also expending efforts towards our newly acquired assets AUR200 and AUR300. Taking into consideration the Company's cash, cash equivalents, restricted cash and investments of $418.8 million as of March&#160;31, 2022, the Company believes that it has sufficient resources to fund its operations for at least the next few years beyond the date that the unaudited condensed consolidated financial statements are issued.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccounting">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccounting</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140554846927752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">Summary of Significant Accounting PoliciesOther than as described below, the Company's significant accounting policies have not changed from those previously described in the Company's Annual Report on Form 10-K for the year ended December&#160;31, 2021.<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restricted cash</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: Restricted cash consists of the 2021 Employee Share Purchase Plan (2021 ESPP) deposits of $0.9&#160;million and $0.3&#160;million as of March&#160;31, 2022 and December&#160;31, 2021, respectively.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Major Customers:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company currently has two main customers for U.S. commercial sales of LUPKYNIS and one customer for sales of voclosporin in the European Union, Japan, as well as the United Kingdom, Russia, Switzerland, Norway, Belarus, Iceland, Liechtenstein and Ukraine. Revenues from two customers accounted for approximately 54% and 45% respectively of the Company's total revenues for the three months ended March&#160;31, 2022. The Company monitors economic conditions, the creditworthiness of customers and government regulations and funding, both domestically and abroad. The Company regularly communicates with its customers regarding the status of receivable balances, including their payment plans and obtains positive confirmation of the validity of the receivables. Global economic conditions and customer specific factors may require the Company to periodically re-evaluate the collectability of its receivables and the Company could potentially incur credit losses.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounts receivable, net:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Accounts receivable are stated at their net realizable value. As of March&#160;31, 2022 and December&#160;31, 2021, accounts receivable, net are $20.4 million and $15.4 million. We estimate the allowance for doubtful accounts using current expected credit loss model, or CECL model. Under the CECL model, the allowance for doubtful accounts reflects the net amount expected to be collected from the account receivables. We evaluate the collectability of these cash flows based on the asset&#8217;s amortized cost, the risk of loss even when that risk is remote, losses over an asset&#8217;s contractual life, and other relevant information available to us. Accounts receivable balances are written off against the allowance when it is probable that</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the receivable will not be collected. The allowance for doubtful accounts was $nil as of March&#160;31, 2022 and as of December&#160;31, 2021.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Share-Based Compensation: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company follows ASC Topic 718, Compensation - Stock Compensation (ASC 718), which requires the measurement and recognition of compensation expense, based on estimated fair values, for all share-based awards made to employees and directors. The Company records compensation expense based on the fair value on the grant date using the graded accelerated vesting method for all share-based payments related to stock options, performance awards (PAs), restricted stock units (RSUs) and purchases under the Company's 2021 ESPP. For stock options, forfeitures are estimated based on historical experience at the time of grant and revised in subsequent periods if actual forfeitures differ from those estimates. For RSUs and PAs, forfeitures are accounted for as they occur.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently adopted accounting pronouncements</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued ASU 2019-12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Topic 740): Simplifying the Accounting for Income Taxes, which clarifies and simplifies certain aspects of the accounting for income taxes. The standard is effective for years beginning after December 15, 2020, and interim periods within annual periods beginning after December 15, 2020. The Company adopted the ASU effective January 1, 2021, with no material impact on the condensed consolidated financial statements.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2021, the FASB issued ASU No. 2021-10, Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance, which requires business entities to make annual disclosures about transactions with a government (including government assistance) by analogizing to a grant or contribution accounting model. The required disclosures include the nature of the transaction, the entity's related accounting policy, the financial statement line items affected and the amounts reflected in the current period financial statements, as well as any significant terms and conditions. The guidance is effective for financial statements issued for annual periods beginning after December 15, 2021. The Company adopted the ASU effective January 1, 2022, with no material impact on the condensed consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140554846847368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Investments</a></td>
<td class="text">Investments<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March&#160;31, 2022 and December&#160;31, 2021, the Company had $286.2 million and $234.2 million of short-term investments, respectively, mainly consisting of commercial paper and bonds as summarized below. As of March&#160;31, 2022, $8.8 million are held to maturity debt securities which are carried at amortized cost and are approximately equal to fair market value. As of March&#160;31, 2022, $277.4 million are available-for-sale debt securities which are carried at fair market value. As of December&#160;31, 2021, $215.0 million were classified as available-for-sale and $19.2 million were held-to-maturity. </span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.347%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cashable Guaranteed Investment Certificate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,128</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,140&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate Bond</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">60,390</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,820&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial Paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">152,295</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206,724&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treasury Bill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">19,530</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,494&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treasury Bond</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">50,867</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">286,210</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234,178&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div>Currently, the Company does not intend to sell investments and has the ability and intent to hold these investments until maturity in order to collect interest payments over the life of the investments. As of March&#160;31, 2022 and December&#160;31, 2021, accrued interest receivable from the investments were $0.5 million and $0.1 million, respectively. During the three months ended March&#160;31, 2022 and 2021, the Company had $766 thousand and $6 thousand unrealized losses on available-for-sale securities, net of tax, respectively, which are included as a component of comprehensive loss on the consolidated statements of operations. The Company's investments as of March&#160;31, 2022 mature at various dates through January 2023.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for  investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2209399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2324412<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2176304<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1403<br> -Paragraph (b)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140554846780680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventories</a></td>
<td class="text">Inventories<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories are valued under a standard costing methodology on a first-in, first-out basis and are stated at the lower of cost or net realizable value. The Company capitalizes inventory costs related to products to be sold in the ordinary course of business. The Company makes a determination of capitalizing inventory costs for a product based on, among other factors, status of regulatory approval, information regarding safety, efficacy and expectations relating to commercial sales and recoverability of costs. Capitalized costs of inventories for LUPKYNIS mainly include third party manufacturing costs, transportation, storage, insurance, depreciation and allocated internal labor.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assesses recoverability of inventory each reporting period to determine any write down to net realizable value resulting from excess or obsolete inventories.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of inventory are as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.347%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,217</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,217&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">19,713</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,566&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,336</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,543&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventories</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">26,266</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,326&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140554846980200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCurrentAssetsTextBlock', window );">Prepaid Expenses and Other Current Assets</a></td>
<td class="text">Prepaid Expenses and Other Current Assets<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets are as follows:</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.347%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,351</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,316&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid insurance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">682</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,632&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,966</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">796&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid deposits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,200</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,762&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12,199</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,506&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCurrentAssetsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other current assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCurrentAssetsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140554846833656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">Intangible Assets</a></td>
<td class="text">Intangible Assets<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the carrying amount of intangible assets, net of accumulated amortization. </span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.584%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.424%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Carrying<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Carrying<br/>Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,471</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,200)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">271</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired intellectual property and reacquired rights</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">15,126</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(9,063)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,063</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Internal-use software implementation costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,873</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,325)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,548</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">19,470</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(11,588)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,882</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:7pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.584%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.424%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Carrying<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Carrying<br/>Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,471&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,176)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">295&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired intellectual property and reacquired rights</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,126&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,804)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,322&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Internal-use software implementation costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,873&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,086)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,787&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,470&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,066)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,404&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>Amortization expense for the three months ended March&#160;31, 2022 and 2021 was $0.5 million for both periods.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI http://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140554846834776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment, net<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property, Plant and Equipment, net</a></td>
<td class="text">Property and Equipment, net<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net are as follows: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.347%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">472</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">393&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,978</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,978&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">645</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">645&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">976</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">976&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">260</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">262&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,331</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,254</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated depreciation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(999)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(836)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,332</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,418&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140554846965064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Lease Obligations<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Lease Obligations</a></td>
<td class="text">Lease Obligations<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has the following lease obligations:</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Victoria, British Columbia</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the fourth quarter of 2020, the Company entered into facility and furniture leases for its head office located in Victoria, British Columbia for a total space of 13,206 square feet of office space for the facility lease. The lease terms commenced on January 1, 2021 for the facility and furniture leases. As of March&#160;31, 2022, the Company had $0.1 million right-of-use assets (ROU assets) and $0.1 million lease liabilities related to the leases. The Company recognized operating lease costs that are included in SG&amp;A expenses in the condensed consolidated statements of operations. The incremental borrowing rate applied to the lease liabilities on January 1, 2021 was 4.08% based on financial position of the Company, geographical region and terms of lease.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During August 2020, the Company signed a lease for commercial office space in Victoria, British Columbia. The present value of the expected minimum lease payments for this lease are $2.3&#160;million. As of March&#160;31, 2022, the lease has not commenced and as a result, there has been no accounting recognition associated with the lease.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Rockville, Maryland</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During March 2020, the Company entered into a lease for its U.S. commercial office in Rockville, Maryland for a total of 30,531 square feet of office space. The lease has a remaining term of approximately 9 years and has an option to extend for two five-year periods after the initial term of 11 years has elapsed and has an option to terminate after seven years. As of March&#160;31, 2022, the Company had a right-of-use asset of $5.1 million and lease liability of $8.5 million included in the condensed consolidated balance sheets. As of December&#160;31, 2021, the Company had a right of use asset of $5.2 million and lease liability of $8.6 million included in the condensed consolidated balance sheets. The Company recorded leasehold improvement incentives in the amount of $2.3&#160;million as additions to the lease liability. The lease term commenced on March 12, 2020. When measuring the lease liability, the Company discounted lease payments using its incremental borrowing rate at March 12, 2020. The incremental borrowing rate applied to the lease liability on March 12, 2020 was 5.2% based on the financial position of the Company, geographical region and term of lease.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Edmonton, Alberta</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized the lease premises in Edmonton, Alberta as a short-term lease in which expenses are incurred in SG&amp;A. The lease is not material to the Company's financial position.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning January 1, 2021, the Company began to incur variable lease costs under the existing Victoria and Rockville leases. These costs include operation and maintenance costs included in SG&amp;A and are expensed as incurred. The variable leases costs are not material to the Company's financial position.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The operating lease costs for the three months ended March&#160;31, 2022 and March&#160;31, 2021 are $0.3&#160;million for both periods.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides supplemental balance sheet information related to the operating lease ROU assets and lease liabilities:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.087%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.747%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.297%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.717%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance Sheet Classification</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right of-use assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,232</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,383&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,009</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,059&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,562</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,680&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,571</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,739&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents the weighted-average remaining lease term and discount rate as of March&#160;31, 2022:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.347%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of March 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Remaining Lease Term (years)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Discount Rate</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.30</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.20%</span></td></tr></table></div><div style="margin-top:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a summary of operating lease liabilities payments for the next five years and thereafter:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.346%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating Lease Payments</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">863</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,061</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,085</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,110</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,135</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,638</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total future minimum lease payments </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10,892</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: lease imputed interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2,321)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total future minimum lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,571</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 15, 2020, the Company entered into a collaborative agreement with Lonza to build a dedicated manufacturing facility within Lonza&#8217;s existing small molecule facility in Visp, Switzerland. The dedicated facility (also referred to as "monoplant") will be equipped with state-of-the-art manufacturing equipment to provide cost and production efficiency for the manufacture of voclosporin, while expanding existing capacity and providing supply security to meet future commercial demand.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following U.S. regulatory approval of LUPKYNIS in January 2021, the Company has commenced a capital expenditure payment program for the monoplant totaling approximately CHF 21.0&#160;million. The first capital expenditure payment was made in February 2021 of $11.8&#160;million and was treated as an upfront lease payment and recorded under other non-current assets on the condensed consolidated balance sheets. The second payment is not due until the facility fulfills the required operational qualifications which is estimated to be during 2023. Upon completion of the monoplant, the Company will have the right to maintain sole dedicated use of the monoplant by paying a quarterly fixed facility fee. The Company expects to account for the arrangement as a finance lease under ASC 842. The present value of the minimum lease payments total approximately $78.0&#160;million, beginning April 2023 and expiring in 2030, and are not included in the above table.</span></div>The Company has entered into an equipment and facility finance lease for a backup manufacturing encapsulation site that has not yet commenced and is therefore, not included in the above table. As part of the agreement, the Company expects to make approximately $885&#160;thousand of payments prior to lease commencement and the future value of minimum lease payments will total approximately $120&#160;thousand.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140554938004648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Payable and Accrued Liabilities<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accounts Payable and Accrued Liabilities</a></td>
<td class="text">Accounts Payable and Accrued Liabilities<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable and accrued liabilities are as follows:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.642%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.447%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,267</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,879&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,289</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,428&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued R&amp;D projects</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,409</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,383&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee accruals</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9,609</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,242&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial accruals</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,753</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,015&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accounts payable and accrued liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">32,327</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,947&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140554846849096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Deferred Compensation and Other Non-current Liabilities<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureNoncurrentTextBlock', window );">Deferred Compensation and Other Non-current Liabilities</a></td>
<td class="text">Deferred Compensation and Other Non-current LiabilitiesThe Company recorded other non-current liabilities of $17.4 million and $16.0 million as of March&#160;31, 2022 and December&#160;31, 2021, respectively. The balance as of March&#160;31, 2022 and December&#160;31, 2021 primarily included deferred compensation arrangements whereby certain executive officers as of March 8, 2012 were provided with future potential employee benefit obligations for remaining with the Company, for a certain period of time. These obligations were also contingent on the occurrence of uncertain future events. Other non-current liabilities also include milestone payments deemed probable to be paid in the future.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureNoncurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as noncurrent at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureNoncurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140554846761256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">Fair Value Measurements<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's financial instruments consist primarily of cash and cash equivalents, investments, accounts receivable, accounts payable and accrued liabilities. The carrying value of accounts receivable, accounts payable and accrued liabilities approximate their fair value because of their short-term nature. Estimated fair values of held to maturity and available-for-sale debt securities are generally based on prices obtained from commercial pricing services.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with measuring the fair value of its assets and liabilities, the Company seeks to maximize the use of observable inputs (market data obtained from sources independent from the Company) and to minimize the use of unobservable inputs (the Company&#8217;s assumptions about how market participants would price assets and liabilities). As a basis for considering such assumptions, a three-tier fair value hierarchy has been established, which prioritizes the inputs used in measuring fair value as follows:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Level 1 - Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities.</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Level 2 - Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Level 3 - Unobservable inputs that reflect the reporting entity&#8217;s own assumptions.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's Level 1 instruments include deposits held with banks and short-term investments that are valued using quoted market prices. Level 2 instruments include the Company's short-term investments that are valued through third-party pricing services that use verifiable observable market data. The Company has no Level 3 instruments as of March&#160;31, 2022 and December&#160;31, 2021.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present the financial assets measured at fair value on a recurring basis:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.777%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deposits held with banks</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">113,268</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">113,268</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term highly liquid investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">19,274</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">19,274</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">152,295</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">133,915</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">286,210</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">284,837</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">133,915</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">418,752</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:7pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.777%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deposits held with banks</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214,702&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214,702&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term highly liquid investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,198&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,198&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206,724&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,454&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234,178&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">438,624&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,454&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">466,078&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note 4, &#8220;Investments,&#8221; for the carrying amount and related unrealized gains (losses) by type of investment.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140554846805768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License and Collaboration Agreement<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">License and Collaboration Agreement</a></td>
<td class="text">License and Collaboration Agreements<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Riptide License</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 17, 2021, AUR300 (M2 macrophage modulation via CD206 binding) was secured through a global licensing and research agreement with Riptide Bioscience, Inc. (Riptide), a private company. As part of the agreement, in 2021 the Company paid Riptide an upfront license fee of $6.0&#160;million which was expensed as research and development on the condensed consolidated statements of operations. During the first quarter of 2022, Aurinia paid $4.0&#160;million for the achievement of a one-time milestone. Additional payments are due upon certain development, clinical and regulatory milestones, and royalties will be payable upon commercialization. It is anticipated that clinical development for AUR300 will commence during 2023.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Otsuka Contract</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 17, 2020, the Company entered into a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. (Otsuka) for the development and commercialization of oral LUPKYNIS in the EU, Japan, as well as the United Kingdom, Russia, Switzerland, Norway, Belarus, Iceland, Liechtenstein and Ukraine.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the agreement, Aurinia received an upfront cash payment of $50.0&#160;million for the license agreement and has the potential to receive up to $50.0&#160;million in regulatory milestones. Aurinia will receive tiered royalties on future sales ranging from 10 to 20 percent (dependent on achievement of sale thresholds) on net sales upon commercialization, along with additional milestone payments based on the attainment of certain annual sales by Otsuka. In addition, certain manufacturing services are provided to Otsuka on a cost-plus basis.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the Otsuka Agreement under ASC 606. Based on that evaluation, the license transferred was determined to be functional IP that has significant standalone functionality. That is, the treatment of LN and other diseases provides significant benefit to Otsuka at the point of transfer, and it is not expected that the utility of the IP will substantively change as a result of any remaining clinical trials or ongoing activities of Aurinia. The Company determined the upfront fee of $50.0&#160;million was fixed consideration for the transfer of the license and was recognized upon transfer of the license in December 2020.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The remaining forms of consideration are variable because they are dependent on achieving milestones or are based on aggregate future net sales for the regions. None of the regulatory milestones have been included in the transaction price, as all milestone amounts were fully constrained. As part of its evaluation of the constraint, the Company considered numerous </span></div>factors, including the magnitude of a potential reversal of revenue, uncertainty about if or when the milestone related performance obligations might be achieved, and that receipt of the milestones are outside the control of the Company since they are dependent on efforts to be undertaken by Otsuka and regulatory approval by various foreign government agencies. Any consideration related to sales-based royalties (and sales-based thresholds) will be recognized when the related sales occur.As of March&#160;31, 2022, the Company recorded $104&#160;thousand of collaboration revenue related to manufacturing services provided under the Otsuka contract<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130551-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130556-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130550-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130558-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140554846936232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Common Share<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss per Common Share</a></td>
<td class="text">Net Loss per Common Share<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted net loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding. Since the Company was in a loss position for all periods presented, diluted net loss per share is the same as basic net loss per share. The numerator and denominator used in the calculation of basic and diluted net loss per common share are as follows:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:72.135%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.388%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.694%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.388%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.695%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands, except per share data)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(37,630)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50,379)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">141,675</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127,401&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per common share (expressed in $ per share)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(0.27)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.40)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company did not include the securities in the following table in the computation of the net loss per common share because the effect would have been anti-dilutive during each period:</span></div><div><span><br/></span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.145%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14,649</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,332&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested performance awards</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">439&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested restricted units</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,952</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,014&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">16,601</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,785&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140554846817736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based Compensation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share-based Compensation</a></td>
<td class="text">Share-based Compensation<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's Amended and Restated Equity Incentive Plan (the Plan), which was adopted and approved by the Company's shareholders in June 2021, allows for an issuance of up to an aggregate of 23.8 million shares (inclusive of outstanding awards) and provides for grants of stock options, performance awards, restricted stock and restricted stock units that may be settled in cash and stock. Also in June 2021, the Company's shareholders adopted and approved the Company's 2021 ESPP, which allows for the issuance of up to 2.5 million shares. The 2021 ESPP is intended to qualify as an &#8220;employee stock purchase plan&#8221; under Section 423 of the Internal Revenue Code (the &#8220;Code&#8221;) but also permits the Company to include the employees, including non-United States employees, in offerings not intended to qualify under Section 423. The purpose of the 2021 ESPP is to provide eligible employees with opportunities to purchase the Company&#8217;s common shares at a discounted price. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Plan requires the exercise price of each option not to be less than the closing market price of the Company&#8217;s common shares on the day immediately prior to the date of grant. The board of directors approves the vesting criteria and periods at its discretion. The options issued under the plan are accounted for as equity-settled share-based payments. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company used the Black-Scholes option pricing model to estimate the fair value of the options granted. The Company considers historical volatility of its common shares in estimating its future stock price volatility. The risk-free interest rate for the expected life of the options was based on the yield available on government benchmark bonds with an approximate </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">equivalent remaining term at the time of the grant. The expected life is based upon the contractual term, taking into account expected employee exercise and expected post-vesting employment termination behavior. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following weighted average assumptions were used to estimate the fair value of the options granted during the three months ended March&#160;31, 2022 and March&#160;31, 2021:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.642%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.447%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Annualized volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">70</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.73</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life of options in years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5.0 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated forfeiture rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11.6</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.0</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value per common share option</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7.02</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the option award activity during the three months ended March&#160;31, 2022:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.642%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.447%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of shares (in thousands)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted average exercise price $</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding - Beginning of Period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12,074</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12.84</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,800</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12.00</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(54)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7.57</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(171)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">16.27</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding - End of Period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14,649</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12.66</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Performance Awards and Restricted Stock Units</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 23, 2020, the Company issued 439,000 performance awards (PAs) to executive management of the Company whose vesting is contingent upon meeting specific performance metrics based on the results for the year ended December 31, 2021. Each PA which vests entitles the participant to receive common shares on the basis of the performance metrics set. On March 18, 2021 performance metrics were set and formally communicated. Therefore, March 18, 2021 was the grant date and the fair value on the grant date was $13.56. As of March&#160;31, 2022, approximately 88,000 PAs vested based on performance metrics achieved and 351,000 were canceled as of December&#160;31, 2021 as performance metrics were not met.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 6, 2021, the Company granted approximately 619,000 PAs and restricted stock units (RSUs). The grant date for the PAs and RSUs was August 6, 2021 and the fair value on the grant date was $14.42 as this was the date performance measures were set and communicated to employees. The PAs vest on the employee's first anniversary of the grant date and the employee must achieve at least one of the performance metrics to obtain the portion of the award associated with the metric. The RSUs have no performance metrics and will vest on the one year anniversary of the grant. As of December&#160;31, 2021, approximately 375,000 PAs and RSUs were canceled or forfeited.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the quarter, the Company has granted RSUs and intends to grant RSUs throughout the year under the Plan. The RSUs are fair valued based on the market price of our common stock on the date of the grant.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the PAs and RSU activity for the three months ended March&#160;31, 2022:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.642%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.447%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of shares (in thousands)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted average exercise price $</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding - Beginning of Period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">347</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13.33</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,708</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12.01</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(88)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13.56</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(15)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13.85</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding - End of Period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,952</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12.16</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded approximately $1.9 million of share-based compensation expense related to PAs and RSUs during the three months ended March&#160;31, 2022.</span></div><div style="margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Compensation Expense</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized share-based compensation expense for the three months ended March&#160;31, 2022 and March&#160;31, 2021 as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.642%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.447%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">976</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,074&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,972</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,641&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized under inventories</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">75</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,023</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,821&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of March&#160;31, 2022, there was $48.3&#160;million of unrecognized share-based compensation expense related to unvested awards granted which is expected to be recognized over a weighted-average period of approximately 1.6 years.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140554846783800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective tax rates for the three months ended March&#160;31, 2022 and March&#160;31, 2021 differed from the federal statutory rate applied to losses before income taxes primarily as a result of the mix of income, losses and valuation allowances. The Company recognized an income tax expense of $10 thousand and $8 thousand for the three months ended March&#160;31, 2022 and 2021, respectively. The expense recognized for these periods is a result of income in certain jurisdictions. This tax expense is not offset by a tax benefit as the Company has losses which are fully offset by a valuation allowance in its significant jurisdictions.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Uncertain Tax Positions</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company was under examination by the Canadian Revenue Agency for years 2017 and 2018. In March 2022, the Company was notified by the Canadian Revenue Agency the examination is now complete and there were no findings and as a result, there is no additional tax expense or benefit recognized in regards to the audit. There are no outstanding tax audits ongoing at March 31, 2022.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140554846833096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related-Party Transactions<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related-Party Transactions</a></td>
<td class="text">Related Party TransactionsILJIN SNT Co., Ltd (ILJIN) was considered to be a related party due to their equity ownership of over 5% as per their public filing. The outstanding related party amount payable to ILJIN was the result of a settlement completed on September 20, 2013 between ILJIN and the Company. During the first quarter of 2021, Aurinia paid $4.0&#160;million upon achievement of specific milestones. The final $2.0&#160;million outstanding amount payable was paid during the fourth quarter 2021. The amount payable to ILJIN is nil as of March&#160;31, 2022 and December&#160;31, 2021.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140554846835896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitment and Contingencies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and ContingenciesThe Company may, from time to time, be subject to claims and legal proceedings brought against it in the normal course of business. Such matters are subject to many uncertainties. Management believes the ultimate resolution of such contingencies will not have a material adverse effect on the consolidated financial position of the Company. The Company's material <div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">commitments and contingencies have not changed in any material manner from those previously described in the Company's Annual Report on Form 10-K for the year ended December&#160;31, 2021 except as described below.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 15, 2022, a purported shareholder class action complaint, Ortmann v. Aurinia Pharmaceuticals, Inc. et al., case no. 1:22-cv-02185, was filed in the United States District Court for the Eastern District of New York, naming Aurinia and certain of the Company's officers as defendants. The lawsuit alleges that Aurinia made materially false and misleading statements regarding the financial guidance and commercial prospects in violation of certain federal securities laws. The plaintiff seeks unspecified monetary damages on behalf of the putative class and an award of costs and expenses, including reasonable attorneys&#8217; fees. The defendants intend to vigorously defend this lawsuit. The Company has not, however, filed a response to the complaint and does not anticipate doing so until after the court appoints a lead plaintiff and that lead plaintiff files an operative complaint.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Funding Commitments</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, the Company enters into agreements with contract research organizations, contract manufacturing organizations and other third parties for services to be provided to the Company. Generally, these agreements provide for termination upon notice, with specified amounts due upon termination based on the timing of termination and the terms of the agreement. The actual amounts and timing of payments under these agreements are uncertain and contingent upon the initiation and completion of services to be provided to the Company.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140554842790952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Restricted cash</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restricted cash</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: Restricted cash consists of the 2021 Employee Share Purchase Plan (2021 ESPP) deposits of $0.9&#160;million and $0.3&#160;million as of March&#160;31, 2022 and December&#160;31, 2021, respectively.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Major Customers</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Major Customers:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company currently has two main customers for U.S. commercial sales of LUPKYNIS and one customer for sales of voclosporin in the European Union, Japan, as well as the United Kingdom, Russia, Switzerland, Norway, Belarus, Iceland, Liechtenstein and Ukraine. Revenues from two customers accounted for approximately 54% and 45% respectively of the Company's total revenues for the three months ended March&#160;31, 2022. The Company monitors economic conditions, the creditworthiness of customers and government regulations and funding, both domestically and abroad. The Company regularly communicates with its customers regarding the status of receivable balances, including their payment plans and obtains positive confirmation of the validity of the receivables. Global economic conditions and customer specific factors may require the Company to periodically re-evaluate the collectability of its receivables and the Company could potentially incur credit losses.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Accounts receivable, net</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounts receivable, net:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Accounts receivable are stated at their net realizable value. As of March&#160;31, 2022 and December&#160;31, 2021, accounts receivable, net are $20.4 million and $15.4 million. We estimate the allowance for doubtful accounts using current expected credit loss model, or CECL model. Under the CECL model, the allowance for doubtful accounts reflects the net amount expected to be collected from the account receivables. We evaluate the collectability of these cash flows based on the asset&#8217;s amortized cost, the risk of loss even when that risk is remote, losses over an asset&#8217;s contractual life, and other relevant information available to us. Accounts receivable balances are written off against the allowance when it is probable that</span>the receivable will not be collected. The allowance for doubtful accounts was $nil as of March&#160;31, 2022 and as of December&#160;31, 2021<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-based Compensation</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Share-Based Compensation: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company follows ASC Topic 718, Compensation - Stock Compensation (ASC 718), which requires the measurement and recognition of compensation expense, based on estimated fair values, for all share-based awards made to employees and directors. The Company records compensation expense based on the fair value on the grant date using the graded accelerated vesting method for all share-based payments related to stock options, performance awards (PAs), restricted stock units (RSUs) and purchases under the Company's 2021 ESPP. For stock options, forfeitures are estimated based on historical experience at the time of grant and revised in subsequent periods if actual forfeitures differ from those estimates. For RSUs and PAs, forfeitures are accounted for as they occur.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently adopted accounting pronouncements</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently adopted accounting pronouncements</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued ASU 2019-12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Topic 740): Simplifying the Accounting for Income Taxes, which clarifies and simplifies certain aspects of the accounting for income taxes. The standard is effective for years beginning after December 15, 2020, and interim periods within annual periods beginning after December 15, 2020. The Company adopted the ASU effective January 1, 2021, with no material impact on the condensed consolidated financial statements.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2021, the FASB issued ASU No. 2021-10, Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance, which requires business entities to make annual disclosures about transactions with a government (including government assistance) by analogizing to a grant or contribution accounting model. The required disclosures include the nature of the transaction, the entity's related accounting policy, the financial statement line items affected and the amounts reflected in the current period financial statements, as well as any significant terms and conditions. The guidance is effective for financial statements issued for annual periods beginning after December 15, 2021. The Company adopted the ASU effective January 1, 2022, with no material impact on the condensed consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123345438&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e4975-111524<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5212-111524<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=SL6953423-111524<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5093-111524<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5033-111524<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10133-111534<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140554846802168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesTextBlock', window );">Investments</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.347%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cashable Guaranteed Investment Certificate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,128</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,140&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate Bond</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">60,390</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,820&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial Paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">152,295</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206,724&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treasury Bill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">19,530</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,494&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treasury Bond</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">50,867</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">286,210</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234,178&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140554846943384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventory</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of inventory are as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.347%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,217</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,217&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">19,713</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,566&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,336</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,543&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventories</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">26,266</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,326&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140554846802168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock', window );">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets are as follows:</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.347%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,351</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,316&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid insurance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">682</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,632&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,966</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">796&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid deposits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,200</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,762&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12,199</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,506&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140554846925256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Intangible Assets</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the carrying amount of intangible assets, net of accumulated amortization. </span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.584%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.424%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Carrying<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Carrying<br/>Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,471</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,200)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">271</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired intellectual property and reacquired rights</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">15,126</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(9,063)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,063</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Internal-use software implementation costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,873</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,325)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,548</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">19,470</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(11,588)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,882</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:7pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.584%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.424%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Carrying<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Carrying<br/>Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,471&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,176)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">295&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired intellectual property and reacquired rights</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,126&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,804)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,322&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Internal-use software implementation costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,873&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,086)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,787&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,470&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,066)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,404&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140554846783800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment, net (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Property, Plant and Equipment</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net are as follows: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.347%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">472</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">393&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,978</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,978&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">645</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">645&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">976</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">976&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">260</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">262&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,331</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,254</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated depreciation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(999)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(836)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,332</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,418&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140554937782488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Lease Obligations (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_auph_AssetsAndLiabilitiesLesseeTableTextBlock', window );">Supplemental Balance Sheet Information</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides supplemental balance sheet information related to the operating lease ROU assets and lease liabilities:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.087%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.747%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.297%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.717%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance Sheet Classification</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right of-use assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,232</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,383&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,009</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,059&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,562</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,680&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,571</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,739&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Lease, Cost</a></td>
<td class="text"><div style="margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents the weighted-average remaining lease term and discount rate as of March&#160;31, 2022:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.347%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of March 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Remaining Lease Term (years)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Discount Rate</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.30</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.20%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Lessee, Operating Lease, Liability, Maturity</a></td>
<td class="text"><div style="margin-top:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a summary of operating lease liabilities payments for the next five years and thereafter:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.346%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating Lease Payments</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">863</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,061</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,085</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,110</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,135</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,638</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total future minimum lease payments </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10,892</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: lease imputed interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2,321)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total future minimum lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,571</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_auph_AssetsAndLiabilitiesLesseeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Assets And Liabilities, Lessee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">auph_AssetsAndLiabilitiesLesseeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>auph_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140554842907336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Payable and Accrued Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Liabilities</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable and accrued liabilities are as follows:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.642%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.447%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,267</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,879&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,289</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,428&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued R&amp;D projects</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,409</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,383&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee accruals</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9,609</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,242&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial accruals</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,753</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,015&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accounts payable and accrued liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">32,327</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,947&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140554846740984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present the financial assets measured at fair value on a recurring basis:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.777%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deposits held with banks</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">113,268</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">113,268</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term highly liquid investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">19,274</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">19,274</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">152,295</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">133,915</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">286,210</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">284,837</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">133,915</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">418,752</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:7pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.777%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deposits held with banks</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214,702&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214,702&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term highly liquid investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,198&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,198&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206,724&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,454&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234,178&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">438,624&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,454&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">466,078&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140554847527160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Common Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Earnings Per Share, Basic and Diluted</a></td>
<td class="text">The numerator and denominator used in the calculation of basic and diluted net loss per common share are as follows:<div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:72.135%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.388%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.694%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.388%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.695%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands, except per share data)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(37,630)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50,379)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">141,675</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127,401&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per common share (expressed in $ per share)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(0.27)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.40)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company did not include the securities in the following table in the computation of the net loss per common share because the effect would have been anti-dilutive during each period:</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.145%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14,649</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,332&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested performance awards</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">439&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested restricted units</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,952</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,014&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">16,601</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,785&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140554840161480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Share-based Payment Award Valuation Assumptions</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following weighted average assumptions were used to estimate the fair value of the options granted during the three months ended March&#160;31, 2022 and March&#160;31, 2021:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.642%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.447%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Annualized volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">70</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.73</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life of options in years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5.0 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated forfeiture rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11.6</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.0</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value per common share option</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7.02</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Option Activity</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the option award activity during the three months ended March&#160;31, 2022:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.642%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.447%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of shares (in thousands)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted average exercise price $</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding - Beginning of Period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12,074</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12.84</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,800</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12.00</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(54)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7.57</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(171)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">16.27</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding - End of Period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14,649</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12.66</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock', window );">Schedule of Performance Shares Activity</a></td>
<td class="text">The following table summarizes the PAs and RSU activity for the three months ended March&#160;31, 2022:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.642%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.447%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of shares (in thousands)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted average exercise price $</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding - Beginning of Period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">347</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13.33</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,708</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12.01</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(88)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13.56</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(15)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13.85</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding - End of Period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,952</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12.16</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Allocation of Share-Based Payments</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized share-based compensation expense for the three months ended March&#160;31, 2022 and March&#160;31, 2021 as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.642%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.447%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">976</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,074&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,972</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,641&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized under inventories</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">75</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,023</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,821&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of number and weighted-average grant date fair value for nonvested performance shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140554842948856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($) </div>
<div>segment</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_auph_CashCashEquivalentsAndDebtSecuritiesCurrent', window );">Cash and cash equivalents and investments | $</a></td>
<td class="nump">$ 418.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_auph_CashCashEquivalentsAndDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents and Debt Securities, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">auph_CashCashEquivalentsAndDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>auph_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140554847216120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted Cash</a></td>
<td class="nump">$ 900<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsAndOtherReceivablesNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">20,401<span></span>
</td>
<td class="nump">15,414<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Allowance for doubtful accounts</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk | Revenue Benchmark | Specialty Pharmacy One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk</a></td>
<td class="nump">54.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk | Revenue Benchmark | Specialty Pharmacy Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk</a></td>
<td class="nump">45.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsAndOtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, receivable from customers, clients, or other third-parties, and receivables classified as other due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsAndOtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5074-111524<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=auph_SpecialtyPharmacyOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=auph_SpecialtyPharmacyOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=auph_SpecialtyPharmacyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=auph_SpecialtyPharmacyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140554839002440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">$ 286,210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 234,178<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecurities', window );">Held-to-maturity debt securities</a></td>
<td class="nump">8,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="nump">277,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">215,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestReceivable', window );">Interest receivable</a></td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss', window );">Unrealized gains on available-for-sale securities</a></td>
<td class="nump">766<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=auph_CashableGuaranteedInvestmentCertificatesMember', window );">Cashable Guaranteed Investment Certificate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">3,128<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,140<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=auph_ShortTermCorporateDebtSecuritiesMember', window );">Corporate Bond</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">60,390<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,820<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial Paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">152,295<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">206,724<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryBillSecuritiesMember', window );">Treasury Bill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">19,530<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,494<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryBondSecuritiesMember', window );">Treasury Bond</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">$ 50,867<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), investment in debt security measured at amortized cost (held-to-maturity), and investment in debt security measured at fair value with change in fair value recognized in net income (trading), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919253-210447<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7A<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=SL6953401-111524<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27232-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of interest earned but not received. Also called accrued interest or accrued interest receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=auph_CashableGuaranteedInvestmentCertificatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=auph_CashableGuaranteedInvestmentCertificatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=auph_ShortTermCorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=auph_ShortTermCorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryBillSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryBillSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140554847512104">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventories (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials</a></td>
<td class="nump">$ 2,217<span></span>
</td>
<td class="nump">$ 2,217<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work in process</a></td>
<td class="nump">19,713<span></span>
</td>
<td class="nump">12,566<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">4,336<span></span>
</td>
<td class="nump">4,543<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventories</a></td>
<td class="nump">$ 26,266<span></span>
</td>
<td class="nump">$ 19,326<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140554844971464">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_auph_PrepaidAssetsCurrent', window );">Prepaid assets</a></td>
<td class="nump">$ 6,351<span></span>
</td>
<td class="nump">$ 5,316<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidInsurance', window );">Prepaid insurance</a></td>
<td class="nump">682<span></span>
</td>
<td class="nump">1,632<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">3,966<span></span>
</td>
<td class="nump">796<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_auph_PrepaidRentAndPrepaidContinuingStudies', window );">Prepaid deposits</a></td>
<td class="nump">1,200<span></span>
</td>
<td class="nump">4,762<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">$ 12,199<span></span>
</td>
<td class="nump">$ 12,506<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_auph_PrepaidAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Prepaid Assets, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">auph_PrepaidAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>auph_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_auph_PrepaidRentAndPrepaidContinuingStudies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Prepaid Rent and Prepaid Continuing Studies</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">auph_PrepaidRentAndPrepaidContinuingStudies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>auph_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123349782&amp;loc=d3e5879-108316<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6787-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140554838957816">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Intangible Assets - Schedule of Intangible Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Value</a></td>
<td class="nump">$ 19,470<span></span>
</td>
<td class="nump">$ 19,470<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(11,588)<span></span>
</td>
<td class="num">(11,066)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">7,882<span></span>
</td>
<td class="nump">8,404<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember', window );">Patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Value</a></td>
<td class="nump">1,471<span></span>
</td>
<td class="nump">1,471<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(1,200)<span></span>
</td>
<td class="num">(1,176)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">271<span></span>
</td>
<td class="nump">295<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_IntellectualPropertyMember', window );">Acquired intellectual property and reacquired rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Value</a></td>
<td class="nump">15,126<span></span>
</td>
<td class="nump">15,126<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(9,063)<span></span>
</td>
<td class="num">(8,804)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">6,063<span></span>
</td>
<td class="nump">6,322<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember', window );">Cloud computing arrangements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Value</a></td>
<td class="nump">2,873<span></span>
</td>
<td class="nump">2,873<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(1,325)<span></span>
</td>
<td class="num">(1,086)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">$ 1,548<span></span>
</td>
<td class="nump">$ 1,787<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_IntellectualPropertyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_IntellectualPropertyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140554847527160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">$ 0.5<span></span>
</td>
<td class="nump">$ 0.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140554838934520">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property, Plant and Equipment, net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">$ 5,331<span></span>
</td>
<td class="nump">$ 5,254<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less accumulated depreciation</a></td>
<td class="num">(999)<span></span>
</td>
<td class="num">(836)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">4,332<span></span>
</td>
<td class="nump">4,418<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">472<span></span>
</td>
<td class="nump">393<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">2,978<span></span>
</td>
<td class="nump">2,978<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">976<span></span>
</td>
<td class="nump">976<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">645<span></span>
</td>
<td class="nump">645<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">$ 260<span></span>
</td>
<td class="nump">$ 262<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140554839743592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Lease Obligations - Narrative (Details)<br> $ in Thousands, SFr in Millions</strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Feb. 28, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2021 </div>
<div>CHF (SFr)</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>ft&#178; </div>
<div>extension_option</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Jan. 01, 2021</div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Aug. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Mar. 12, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,232<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,383<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,571<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,739<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Incremental borrowing rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForCapitalImprovements', window );">Payments for capital improvements | SFr</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">SFr 21.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Capital expenditure payments</a></td>
<td class="nump">$ 11,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDue', window );">Minimum finance lease liability payments due</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Minimum lease payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,892<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_auph_LesseeOperatingLeaseLeaseNotYetCommencedPaymentsPriorToCommencementOfLease', window );">Expected payments prior to commencement of lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">885<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_auph_LesseeOperatingLeaseLeaseNotYetCommencedLiabilityToBePaid', window );">Future value of minimum lease payments of leases not yet commenced</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=auph_VictoriaBritishColumbiaMember', window );">Victoria, British Columbia</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Area of property (in sqft) | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,206<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Incremental borrowing rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.08%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Minimum lease payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=auph_RockvilleMarylandMember', window );">Rockville, Maryland</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Area of property (in sqft) | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,531<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Incremental borrowing rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.20%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Remaining lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_auph_LesseeOperatingLeaseNumberOfExtensionOptions', window );">Number of extension options | extension_option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lease extension term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">11 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_auph_LesseeOperatingLeaseLeaseTerminationTerm', window );">Lease termination option term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromTenantAllowance', window );">Proceeds from tenant improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_auph_LesseeOperatingLeaseLeaseNotYetCommencedLiabilityToBePaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Lease Not yet Commenced, Liability, to be Paid</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">auph_LesseeOperatingLeaseLeaseNotYetCommencedLiabilityToBePaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>auph_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_auph_LesseeOperatingLeaseLeaseNotYetCommencedPaymentsPriorToCommencementOfLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Lease Not yet Commenced, Payments Prior To Commencement Of Lease</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">auph_LesseeOperatingLeaseLeaseNotYetCommencedPaymentsPriorToCommencementOfLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>auph_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_auph_LesseeOperatingLeaseLeaseTerminationTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Lease Termination Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">auph_LesseeOperatingLeaseLeaseTerminationTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>auph_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_auph_LesseeOperatingLeaseNumberOfExtensionOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Number of Extension Options</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">auph_LesseeOperatingLeaseNumberOfExtensionOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>auph_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfRealEstateProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area of a real estate property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfRealEstateProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRemainingLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForCapitalImprovements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for acquisition of or capital improvements to properties held for investment (operating, managed, leased) or for use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForCapitalImprovements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromTenantAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net cash outflow or inflow from monetary allowance granted by the landlord to a tenant to entice tenant to move into landlords building which will enable the tenant to prepare the leased premises for tenants occupancy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromTenantAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=auph_VictoriaBritishColumbiaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=auph_VictoriaBritishColumbiaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=auph_RockvilleMarylandMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=auph_RockvilleMarylandMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140554844971432">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Lease Obligations - Supplemental Balance Sheet Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_auph_OperatingLeaseAssetsAndLiabilitiesAssetsLesseeAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="nump">$ 5,232<span></span>
</td>
<td class="nump">$ 5,383<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_auph_OperatingLeaseAssetsAndLiabilitiesLiabilitiesCurrentLesseeAbstract', window );"><strong>Current</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current operating lease liabilities</a></td>
<td class="nump">1,009<span></span>
</td>
<td class="nump">1,059<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_auph_OperatingLeaseAssetsAndLiabilitiesLiabilitiesNoncurrentLesseeAbstract', window );"><strong>Non-current</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Non-current operating lease liabilities</a></td>
<td class="nump">7,562<span></span>
</td>
<td class="nump">7,680<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total lease liabilities</a></td>
<td class="nump">$ 8,571<span></span>
</td>
<td class="nump">$ 8,739<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_auph_OperatingLeaseAssetsAndLiabilitiesAssetsLesseeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Assets And Liabilities, Assets, Lessee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">auph_OperatingLeaseAssetsAndLiabilitiesAssetsLesseeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>auph_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_auph_OperatingLeaseAssetsAndLiabilitiesLiabilitiesCurrentLesseeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Assets And Liabilities, Liabilities, Current, Lessee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">auph_OperatingLeaseAssetsAndLiabilitiesLiabilitiesCurrentLesseeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>auph_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_auph_OperatingLeaseAssetsAndLiabilitiesLiabilitiesNoncurrentLesseeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Assets And Liabilities, Liabilities, Noncurrent, Lessee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">auph_OperatingLeaseAssetsAndLiabilitiesLiabilitiesNoncurrentLesseeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>auph_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140554846805768">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Lease Obligations - Summary of Components of Leasing Costs and Rent (Details)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term - operating leases (in years)</a></td>
<td class="text">9 years 3 months 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate - operating leases</a></td>
<td class="nump">5.20%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140554847057736">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Lease Obligations - Schedule of Maturities of Lease Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">Remainder of 2022</a></td>
<td class="nump">$ 863<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2023</a></td>
<td class="nump">1,061<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2024</a></td>
<td class="nump">1,085<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2025</a></td>
<td class="nump">1,110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2026</a></td>
<td class="nump">1,135<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_auph_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour', window );">Thereafter</a></td>
<td class="nump">5,638<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total</a></td>
<td class="nump">10,892<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: lease imputed interest</a></td>
<td class="num">(2,321)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total future minimum lease payments</a></td>
<td class="nump">$ 8,571<span></span>
</td>
<td class="nump">$ 8,739<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_auph_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Liability, to be Paid, After Year Four</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">auph_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>auph_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140554842982456">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accounts Payable and Accrued Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableTradeCurrent', window );">Accounts payable</a></td>
<td class="nump">$ 3,267<span></span>
</td>
<td class="nump">$ 3,879<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other accrued liabilities</a></td>
<td class="nump">7,289<span></span>
</td>
<td class="nump">3,428<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_auph_AccruedResearchCurrent', window );">Accrued R&amp;D projects</a></td>
<td class="nump">5,409<span></span>
</td>
<td class="nump">4,383<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Employee accruals</a></td>
<td class="nump">9,609<span></span>
</td>
<td class="nump">18,242<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_auph_CommercialRelatedAccrualsCurrent', window );">Commercial accruals</a></td>
<td class="nump">6,753<span></span>
</td>
<td class="nump">5,015<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Total accounts payable and accrued liabilities</a></td>
<td class="nump">$ 32,327<span></span>
</td>
<td class="nump">$ 34,947<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_auph_AccruedResearchCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Research, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">auph_AccruedResearchCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>auph_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_auph_CommercialRelatedAccrualsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commercial Related Accruals, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">auph_CommercialRelatedAccrualsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>auph_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableTradeCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableTradeCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140554846893608">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Deferred Compensation and Other Non-current Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other non-current liabilities</a></td>
<td class="nump">$ 17,379<span></span>
</td>
<td class="nump">$ 15,950<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140554843165784">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Assets and Liabilities Measured on a Recurring Basis (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments</a></td>
<td class="nump">$ 286,210<span></span>
</td>
<td class="nump">$ 234,178<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">418,752<span></span>
</td>
<td class="nump">466,078<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_DemandDepositsMember', window );">Deposits held with banks</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents:</a></td>
<td class="nump">113,268<span></span>
</td>
<td class="nump">214,702<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Short-term highly liquid investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents:</a></td>
<td class="nump">19,274<span></span>
</td>
<td class="nump">17,198<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments</a></td>
<td class="nump">152,295<span></span>
</td>
<td class="nump">206,724<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">284,837<span></span>
</td>
<td class="nump">438,624<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Deposits held with banks</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents:</a></td>
<td class="nump">113,268<span></span>
</td>
<td class="nump">214,702<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Short-term highly liquid investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents:</a></td>
<td class="nump">19,274<span></span>
</td>
<td class="nump">17,198<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments</a></td>
<td class="nump">133,915<span></span>
</td>
<td class="nump">27,454<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">133,915<span></span>
</td>
<td class="nump">27,454<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Deposits held with banks</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents:</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Short-term highly liquid investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents:</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Deposits held with banks</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents:</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Short-term highly liquid investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents:</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_DemandDepositsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_DemandDepositsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140554840098088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License and Collaboration Agreement (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 17, 2021</div></th>
<th class="th"><div>Dec. 17, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,620<span></span>
</td>
<td class="nump">$ 9,833<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,625<span></span>
</td>
<td class="nump">$ 914<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember', window );">License Agreement Terms | Otuska</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned', window );">Upfront payments received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_auph_ResearchAndDevelopmentArrangementContractToPerformForOthersPerformanceObligationPotentialRevenueAmount', window );">Potential regulatory milestone revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="nump">104<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember', window );">License Agreement Terms | Otuska | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_auph_ResearchAndDevelopmentArrangementContractToPerformForOthersTieredRoyaltyPercent', window );">Tiered royalty percentages on future sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember', window );">License Agreement Terms | Otuska | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_auph_ResearchAndDevelopmentArrangementContractToPerformForOthersTieredRoyaltyPercent', window );">Tiered royalty percentages on future sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember', window );">License Agreement Terms | Riptide Bioscience, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireProductiveAssets', window );">Upfront license fee</a></td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_auph_ResearchAndDevelopmentArrangementContractToPerformForOthersPerformanceObligationPotentialRevenueAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research And Development Arrangement, Contract To Perform For Others, Performance Obligation, Potential Revenue Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">auph_ResearchAndDevelopmentArrangementContractToPerformForOthersPerformanceObligationPotentialRevenueAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>auph_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_auph_ResearchAndDevelopmentArrangementContractToPerformForOthersTieredRoyaltyPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research And Development Arrangement, Contract To Perform For Others, Tiered Royalty, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">auph_ResearchAndDevelopmentArrangementContractToPerformForOthersTieredRoyaltyPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>auph_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123362884&amp;loc=d3e9212-128498<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123362884&amp;loc=d3e9215-128498<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123385561&amp;loc=d3e9135-128495<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23221-108380<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23199-108380<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=auph_OtuskaPharmaceuticalCoLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=auph_OtuskaPharmaceuticalCoLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=auph_RiptideBioscienceIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=auph_RiptideBioscienceIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140554847439000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Common Share (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (37,630)<span></span>
</td>
<td class="num">$ (50,379)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average common shares outstanding used in computation of basic loss per share</a></td>
<td class="nump">141,675<span></span>
</td>
<td class="nump">127,401<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic loss per share (expressed in $ per share)</a></td>
<td class="num">$ (0.27)<span></span>
</td>
<td class="num">$ (0.40)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average common shares outstanding used in computation of diluted loss per share</a></td>
<td class="nump">141,675<span></span>
</td>
<td class="nump">127,401<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted loss per share (expressed in $ per share)</a></td>
<td class="num">$ (0.27)<span></span>
</td>
<td class="num">$ (0.40)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140554844887480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Common Share - Anti-Dilutive Securities (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">16,601,000<span></span>
</td>
<td class="nump">15,785,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">14,649,000<span></span>
</td>
<td class="nump">14,332,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_PerformanceSharesMember', window );">Unvested performance awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">439,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Unvested restricted units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">1,952,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,014,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140554843912888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based Compensation - Narrative (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 06, 2021</div></th>
<th class="th"><div>Mar. 18, 2021</div></th>
<th class="th"><div>Oct. 23, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,023<span></span>
</td>
<td class="nump">$ 7,821<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 48,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized share-based compensation expense weighted average recognition period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=auph_AmendedAndRestatedEquityIncentivePlanMember', window );">Amended and Restated Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Number of additional shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Unvested performance awards | Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">439,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted, Weighted average exercise price (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Performance shares vested (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">88,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Shares forfeited/canceled (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">351,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">Employee Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=auph_PerformanceShareSandRestrictedStockUnitsRSUsMember', window );">Performance Share sand Restricted Stock Units (RSUs) | Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted</a></td>
<td class="nump">619,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,708,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted, Weighted average exercise price (in usd per share)</a></td>
<td class="nump">$ 14.42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Performance shares vested (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">88,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Shares forfeited/canceled (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">375,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Unvested restricted units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Unvested restricted units | Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=auph_AmendedAndRestatedEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=auph_AmendedAndRestatedEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_OfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_OfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=auph_PerformanceShareSandRestrictedStockUnitsRSUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=auph_PerformanceShareSandRestrictedStockUnitsRSUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140554842982840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Weighted Average Assumptions (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate', window );">Annualized volatility</a></td>
<td class="nump">70.00%<span></span>
</td>
<td class="nump">66.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">1.73%<span></span>
</td>
<td class="nump">0.28%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life of options in years</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">4 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_auph_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate', window );">Estimated forfeiture rate</a></td>
<td class="nump">11.60%<span></span>
</td>
<td class="nump">8.90%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend', window );">Dividend rate</a></td>
<td class="nump">$ 0.000<span></span>
</td>
<td class="nump">$ 0.000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Fair value per common share option (in usd per share)</a></td>
<td class="nump">$ 7.02<span></span>
</td>
<td class="nump">$ 6.72<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_auph_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Forfeiture Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">auph_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>auph_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of the weighted average expected dividend for an entity using a valuation technique with different dividend rates during the contractual term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Rate of weighted-average expected volatility for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140554847224312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Stock Option Activity (Details) - $ / shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Shares (in thousands)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Beginning balance (in shares)</a></td>
<td class="nump">12,074<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">2,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="num">(54)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Forfeited (in shares)</a></td>
<td class="num">(171)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Ending balance (in shares)</a></td>
<td class="nump">14,649<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted-Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Beginning balance (in usd per share)</a></td>
<td class="nump">$ 12.66<span></span>
</td>
<td class="nump">$ 12.84<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in usd per share)</a></td>
<td class="nump">12.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in usd per share)</a></td>
<td class="nump">7.57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Forfeited (in usd per share)</a></td>
<td class="nump">16.27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Ending balance (in usd per share)</a></td>
<td class="nump">$ 12.66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140554840156200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Performance Awards and Restricted Stock Units Activity (Details) - Performance Share sand Restricted Stock Units (RSUs) - Officer - $ / shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 06, 2021</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward', window );"><strong>Number of shares (in thousands)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding - Beginning of Period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">347<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">619<span></span>
</td>
<td class="nump">1,708<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Performance shares vested (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(88)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Performance shares forfeited (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(15)<span></span>
</td>
<td class="num">(375)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding - End of Period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,952<span></span>
</td>
<td class="nump">347<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted average exercise price $</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding, Weighted average exercise price - Beginning of Period (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Performance shares awards, Weighted average grant date fair value (in usd per share)</a></td>
<td class="nump">$ 14.42<span></span>
</td>
<td class="nump">12.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Performance shares vested, Weighted average grant date fair value (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Performance share forfeited, Weighted average exercise price (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding, Weighted average exercise price - End of Period (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.16<span></span>
</td>
<td class="nump">$ 13.33<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=auph_PerformanceShareSandRestrictedStockUnitsRSUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=auph_PerformanceShareSandRestrictedStockUnitsRSUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_OfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_OfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140554843887432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Allocated Share-Based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 7,023<span></span>
</td>
<td class="nump">$ 7,821<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">976<span></span>
</td>
<td class="nump">1,074<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">5,972<span></span>
</td>
<td class="nump">6,641<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_InventoriesMember', window );">Capitalized under inventories</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 75<span></span>
</td>
<td class="nump">$ 106<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_InventoriesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_InventoriesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140554846801448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax (benefit) expense</a></td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140554843150056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related-Party Transactions (Details) - ILJIN - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember', window );">Other Current Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent', window );">Due to related parties</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=auph_MilestonePaymentMember', window );">Milestone Payment | Affiliated Shareholder</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Payments to related party</a></td>
<td class="nump">$ 2.0<span></span>
</td>
<td class="nump">$ 4.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(3),(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transactions with related party during the financial reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAmountsOfTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=auph_ILJINMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=auph_ILJINMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=auph_MilestonePaymentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=auph_MilestonePaymentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>auph-20220331_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:auph="http://www.auriniapharma.com/20220331"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="auph-20220331.xsd" xlink:type="simple"/>
    <context id="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ibe0bdd3550be438099ca2e1dd9fc02ae_I20220509">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
        </entity>
        <period>
            <instant>2022-05-09</instant>
        </period>
    </context>
    <context id="id7882ae6aff54a3aacdef67ddf11a428_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i784f65549351439fa4b7bedf90ce7e3f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i34e7d6696f5d40019bbef585c942db1a_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i717bc91cf1504e20b9b5b1c709508591_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i1d6565befaf14fa4b0f390573f13f8fc_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i25e47e5aca8445b7b6e872243cf6ab56_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i56599386fa47443a8975bb3f7a6a8c57_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i61d2ecb1315b47b48046b2cc2d26a3f4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibc985adebb4d4146be71a1355b404db9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4141e328567a4e2f84032e5f733bf3a6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ieebe2ef8481d495ea52a69991654df61_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic38a142e678c4e85a1b730ee6415c5c0_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i76345d0397ef41589260147ade867835_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i33e38a2732764762b66982ec4717a1b2_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i7f565b8d63fc448ba775e2bac6da89d9_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="id1291b626776443495f8c67d0b44222b_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ie8ed19e5e01745febb700f621d5350bd_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i4bfaf26bef40473cbb8aa323aa9dbf99_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i7607dc50eb3d4d29b612005eb9d96af6_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i83ebb56fc7614da58997add4fc4d898e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i52d7b06be2c943d9943aab7a9199636b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="icd1c1d725ea74622ad8c60cbfb9c0470_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i14fc3af75b3846e58ef3a457eee1c040_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i52aa203b7e954d69b001129473620362_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id2b8ec5b433843479fee7e7d7ae9434b_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i980c28f6b4b34116a0110c4e8f58bea5_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="idf2709893482407e9aa1a24504869283_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="if37f87c2e8144a4ea775f7bcf996abdb_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ida3e66f3cb8a46fd8e7d2fa464feee4b_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="icee959888619433fa3bbb75703c9942a_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ic279a1a852fa4d1c8cfc697be1c04112_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i0bdfb000085746f589116096f0a92b19_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i0260d11b47b2403fbf3efe386b4d6b0f_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ie14c65a2be5d40e1975aef5b5c3f0072_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">auph:SpecialtyPharmacyOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i5a87beff7e574242be649c7dbc5fa755_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">auph:SpecialtyPharmacyTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ibaf8c62e96254608ab5682b00b33999f_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">auph:CashableGuaranteedInvestmentCertificatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i40b2265057054504ab60aa0aafba0f0e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">auph:CashableGuaranteedInvestmentCertificatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5235f32286c3431198c094116ea7192b_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">auph:ShortTermCorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="iea26fc49428d4511a2fb37c1bb666a8b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">auph:ShortTermCorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3dfcd77b916a46af88c7474c6cb4ec1a_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="id3450fe582114ff195b2b48f8c26afea_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iee34030c8c804c4a98def156ea552450_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i67d405ac9e79458eb8e91ab5d55e0df4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8018f58d25ea48ecbbc969caded6e2f5_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ifa7bf46cccc44c9484be6b855b0a6f1c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iafe3ea51a2814a819363caa378a6a94a_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i24997e0475c34f689abd5af9a097e9c9_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i8116ed39be8b477bb9e41a6b0e3aee53_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="idb5a73ea0d9f46779238702423cc8e54_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2473f3d624824cfa9dc37ac978052ad5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1b3926824aa84496acd5d466e41d1cb4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i24b881bff2734aaa92863336ea94e41e_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i33ea857e82c542399286eb48ddbe86ef_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i92bd80a74b4b4c98b74a56c4941dbae8_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ic252965e91864c4ca85c5288d34a489d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie8b21348dac34f0191509120fede5c4c_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i9a37e52ecdc4461f971b3b1b848318b1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8774cc7bdb954684aaebe802c8d2b5ca_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ida382f7681f54ed38ba2838dbf0642cd_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib8a4d21008a14bdda5d40b91949726ff_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ic45495e9bd3646529b0eba68d7729780_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5a90c58801134d6383b036247c03afa2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">auph:VictoriaBritishColumbiaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9d7a2759ec7d41e3937bd48023be99f9_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">auph:VictoriaBritishColumbiaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i6d2b9fee1c02434b9949db0279cfaf7f_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">auph:VictoriaBritishColumbiaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="i495ff60b2f3b469a944a5922a5e9036d_I20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">auph:VictoriaBritishColumbiaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-31</instant>
        </period>
    </context>
    <context id="ia4a97e4de8cb475abddcffdb81d0a5d1_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">auph:RockvilleMarylandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i5aa97519cf354667a42c1e73e81155c5_D20200301-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">auph:RockvilleMarylandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i0d45f33fe1934685a0328a1b8e0fb9fa_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">auph:RockvilleMarylandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="iaf32dde531a54bedaeee2771bb3cf07c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">auph:RockvilleMarylandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i26b07d59c782432196f10a8bbea26c86_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">auph:RockvilleMarylandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i32b726a815d044a59392431a6d822684_I20200312">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">auph:RockvilleMarylandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-12</instant>
        </period>
    </context>
    <context id="i46bd9d31980341bb91e4ebbab17839ed_D20210101-20210131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="ie64f915dc5df48b09796dbc7d367824b_D20210201-20210228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-02-28</endDate>
        </period>
    </context>
    <context id="ib637c27de79d47f58aea7f1e1b7c5885_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:DemandDepositsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ie1195a2d281043b09ef29f66c38b70ce_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:DemandDepositsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i9987c4f832174d15b1448eb73ba6f1e4_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:DemandDepositsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="if5d8980b569c49318287bb43ff08a07e_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:DemandDepositsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ib211792a2e6b4a88a6e391b311e94df4_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i074dc118299746aa9f97075509308a92_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i3751e29f9e2148e9be8536444f9cac26_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="icfd26c5e43f842a78369ad600a9bf8a6_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="iecaeb1e9e3bc4350b03471a79a3ee234_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="if7d17ebbb59b417ca9c046ea7c8aa94f_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="id893926028184fda8d4b75b7a5667586_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ief379dc869194260b8c12ebe6e7e061a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:DemandDepositsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4888c5f13e9e4351a811914afa543777_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:DemandDepositsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i640e6485e7c84a2ab48d83257384aea7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:DemandDepositsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6146eb45aa0d48429dc434439051e0bc_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:DemandDepositsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if383a572500e4c839c8c398879a64567_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0cb7b13b98f9423daa95abadbd4c2281_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i23085f6e6a1046b1a8320d2f389c49cd_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7d77f002b76741e8b5071bbad8036827_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i84bcadfa5a52412e91d596d25121ad94_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia35491a16c814a76bd71423d10de8bd7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib03d0da6db22482c8918b1f6ab3b5e9b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6eea8e21df8b47b4892af7d314ff753b_D20210817-20210817">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">auph:RiptideBioscienceIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-17</startDate>
            <endDate>2021-08-17</endDate>
        </period>
    </context>
    <context id="i13c8ed2824064c1abec1d76ae28d9dd8_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">auph:RiptideBioscienceIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ia4c126547bde44f3af61232c8aecf4ac_D20201217-20201217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">auph:OtuskaPharmaceuticalCoLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-17</startDate>
            <endDate>2020-12-17</endDate>
        </period>
    </context>
    <context id="ic3d998d2005a4d13bf8d4c76ad081c32_I20201217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">auph:OtuskaPharmaceuticalCoLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-17</instant>
        </period>
    </context>
    <context id="if24948855cce4a1ab004e64a606f9fda_I20201217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">auph:OtuskaPharmaceuticalCoLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-17</instant>
        </period>
    </context>
    <context id="i4263b02edbdb433b9ce6580e359a81eb_I20201217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">auph:OtuskaPharmaceuticalCoLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-17</instant>
        </period>
    </context>
    <context id="ie2ed7292d01844ac989e99b1cafc7555_D20201201-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">auph:OtuskaPharmaceuticalCoLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ibb901623e47548488a8a8d92817c020b_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">auph:OtuskaPharmaceuticalCoLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ic3ca33ca8bfb4c8aac86d02183ad2fa2_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i105a1152b5c54760ad7380e7462cbfbf_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="iae2da8378b4b45af98b0443b437184a5_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i6384fea4599b405a9d8a4d0a174ba37c_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ic530833cd3564851886dba86e0d1fbb6_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i5d28d6c0f0d940f59d45551ddc72575a_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ib81c30a26c6a41b69cf92282735549ea_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i6ee10ba4e3a1477e80be6a7ae14a5733_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ic967022eaed24a72b01d3974047a24dc_D20210601-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">auph:AmendedAndRestatedEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ib997dd537ee44595bf4b5e42a02596ac_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ib8ebe99a1b5a4e18b4d3a1b5a2e4806a_D20201023-20201023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:OfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-23</startDate>
            <endDate>2020-10-23</endDate>
        </period>
    </context>
    <context id="i6658318dd5b2443bbb61848fe5a802d9_D20210318-20210318">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:OfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-18</startDate>
            <endDate>2021-03-18</endDate>
        </period>
    </context>
    <context id="i16277210576f40e6b66abe8fff631587_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:OfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i756422f9e99948068788efa1b4d47e72_D20210806-20210806">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:OfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">auph:PerformanceShareSandRestrictedStockUnitsRSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-06</startDate>
            <endDate>2021-08-06</endDate>
        </period>
    </context>
    <context id="i262fb9bddf114af5919be54955f6f018_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i1bc38d71f54444c69c2a074dc7d8a2ce_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:OfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">auph:PerformanceShareSandRestrictedStockUnitsRSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id05699051d2448519e6e9c2935d67b1f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:OfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">auph:PerformanceShareSandRestrictedStockUnitsRSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8ae01a892dec40ae88dac42dfa1c30cb_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:OfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">auph:PerformanceShareSandRestrictedStockUnitsRSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ib9883d643a66472482b410bc95fa9f79_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:OfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">auph:PerformanceShareSandRestrictedStockUnitsRSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ie473ec9331e14abfac72e9b57746b74a_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:OfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ifd9d5feb8f3b40e69374a5807ae20c1f_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i962d1c17149f4639be473baed960c8c3_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i1b24f1f549b24893a1d6972293f410a2_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i0680c2b94da240e9969e80a91c607742_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i40ed8df1852d4048bff930cdf8525c46_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InventoriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i0424c4860c3e42b790b55eb7b0362418_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InventoriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="if708ee56f3c0413dbeaf542b7c53ca83_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">auph:ILJINMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">auph:MilestonePaymentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="if844161c2cc7421fb00cb10e05a3bda0_D20211001-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">auph:ILJINMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">auph:MilestonePaymentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i273a514c48a74a41b3aabc3abfd173d8_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">auph:ILJINMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ic0ea34cae9704c0ba2c86c1759915479_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600620</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">auph:ILJINMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="segment">
        <measure>auph:segment</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="extension_option">
        <measure>auph:extension_option</measure>
    </unit>
    <unit id="chf">
        <measure>iso4217:CHF</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl80L2ZyYWc6ZDZlZGIyMDFmMWY3NDBjM2I2ZGZiNTVlZmYwNmMyYjYvdGFibGU6YzMzMjllZDFjZjU0NDJmOGJmMDcyOTIwN2QzMDg1M2MvdGFibGVyYW5nZTpjMzMyOWVkMWNmNTQ0MmY4YmYwNzI5MjA3ZDMwODUzY18yLTEtMS0xLTQ2ODkx_99dcea64-b3ee-4ed8-8b19-d471f574c000">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl80L2ZyYWc6ZDZlZGIyMDFmMWY3NDBjM2I2ZGZiNTVlZmYwNmMyYjYvdGFibGU6YzMzMjllZDFjZjU0NDJmOGJmMDcyOTIwN2QzMDg1M2MvdGFibGVyYW5nZTpjMzMyOWVkMWNmNTQ0MmY4YmYwNzI5MjA3ZDMwODUzY18zLTEtMS0xLTQ2ODkx_791fc350-3fbb-4f28-a771-cfe5056daa60">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl80L2ZyYWc6ZDZlZGIyMDFmMWY3NDBjM2I2ZGZiNTVlZmYwNmMyYjYvdGFibGU6YzMzMjllZDFjZjU0NDJmOGJmMDcyOTIwN2QzMDg1M2MvdGFibGVyYW5nZTpjMzMyOWVkMWNmNTQ0MmY4YmYwNzI5MjA3ZDMwODUzY180LTEtMS0xLTQ2ODkx_949fddd1-86c6-4e37-a8f8-01d4b6893626">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl80L2ZyYWc6ZDZlZGIyMDFmMWY3NDBjM2I2ZGZiNTVlZmYwNmMyYjYvdGFibGU6YzMzMjllZDFjZjU0NDJmOGJmMDcyOTIwN2QzMDg1M2MvdGFibGVyYW5nZTpjMzMyOWVkMWNmNTQ0MmY4YmYwNzI5MjA3ZDMwODUzY181LTEtMS0xLTQ2ODkx_42726f00-cee0-4a11-ab06-f880a75c9836">0001600620</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl80L2ZyYWc6ZDZlZGIyMDFmMWY3NDBjM2I2ZGZiNTVlZmYwNmMyYjYvdGFibGU6YzMzMjllZDFjZjU0NDJmOGJmMDcyOTIwN2QzMDg1M2MvdGFibGVyYW5nZTpjMzMyOWVkMWNmNTQ0MmY4YmYwNzI5MjA3ZDMwODUzY182LTEtMS0xLTQ2ODkx_e9e34f7e-1c9e-4ee7-8ffb-8752e4a0771e">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentType
      contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xL2ZyYWc6N2I4NGE0Mzg1ZmRjNDY1NWI2NzI3ZDdmMTY1ZjFkMjgvdGV4dHJlZ2lvbjo3Yjg0YTQzODVmZGM0NjU1YjY3MjdkN2YxNjVmMWQyOF8yMjg4_5ed3aac5-7792-4a52-b7d5-3158a76d8df4">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xL2ZyYWc6N2I4NGE0Mzg1ZmRjNDY1NWI2NzI3ZDdmMTY1ZjFkMjgvdGFibGU6MTM1MjhiMWZmOGQ2NGFjYmJlNTQ1NTliODA1Mzk1NGUvdGFibGVyYW5nZToxMzUyOGIxZmY4ZDY0YWNiYmU1NDU1OWI4MDUzOTU0ZV8wLTAtMS0xLTQ2ODkx_75b36544-f7b9-489e-ae9d-930f8f370ec0">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xL2ZyYWc6N2I4NGE0Mzg1ZmRjNDY1NWI2NzI3ZDdmMTY1ZjFkMjgvdGV4dHJlZ2lvbjo3Yjg0YTQzODVmZGM0NjU1YjY3MjdkN2YxNjVmMWQyOF8yMTI_03470018-9452-499c-b349-67497b014b40">2022-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xL2ZyYWc6N2I4NGE0Mzg1ZmRjNDY1NWI2NzI3ZDdmMTY1ZjFkMjgvdGFibGU6ZTNhNzM5MTZlMzYyNGIwYzg0YTI3OTFkZTZlNTI1MjkvdGFibGVyYW5nZTplM2E3MzkxNmUzNjI0YjBjODRhMjc5MWRlNmU1MjUyOV8wLTAtMS0xLTQ2ODkx_5583402f-6f61-4788-98bc-7f97f3235868">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xL2ZyYWc6N2I4NGE0Mzg1ZmRjNDY1NWI2NzI3ZDdmMTY1ZjFkMjgvdGV4dHJlZ2lvbjo3Yjg0YTQzODVmZGM0NjU1YjY3MjdkN2YxNjVmMWQyOF8yMjg5_d801de8a-cf02-472c-9758-67d71403a4b9">001-36421</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xL2ZyYWc6N2I4NGE0Mzg1ZmRjNDY1NWI2NzI3ZDdmMTY1ZjFkMjgvdGV4dHJlZ2lvbjo3Yjg0YTQzODVmZGM0NjU1YjY3MjdkN2YxNjVmMWQyOF8yMjkw_aae5c906-cdc9-4c3a-98da-9521db393365">Aurinia Pharmaceuticals Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xL2ZyYWc6N2I4NGE0Mzg1ZmRjNDY1NWI2NzI3ZDdmMTY1ZjFkMjgvdGFibGU6NDVkMGEwMDk3NWEyNDE1Y2I1NjUyMzhhZmZhNjEzNTkvdGFibGVyYW5nZTo0NWQwYTAwOTc1YTI0MTVjYjU2NTIzOGFmZmE2MTM1OV8wLTAtMS0xLTQ2ODkxL3RleHRyZWdpb246NmRmOWRmZGU1ZWNjNGRjYmE4MDQ1NjNjNzczNmNhZjhfMTM_165ccc17-ae20-4d68-96b8-7dce1f57b004">Z4</dei:EntityIncorporationStateCountryCode>
    <dei:EntityAddressAddressLine1
      contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xL2ZyYWc6N2I4NGE0Mzg1ZmRjNDY1NWI2NzI3ZDdmMTY1ZjFkMjgvdGFibGU6NDVkMGEwMDk3NWEyNDE1Y2I1NjUyMzhhZmZhNjEzNTkvdGFibGVyYW5nZTo0NWQwYTAwOTc1YTI0MTVjYjU2NTIzOGFmZmE2MTM1OV8yLTAtMS0xLTQ2ODkxL3RleHRyZWdpb246YzExMjlkNjUwMDQ0NDkxNWE4YjIxYjQ2ZTZlZjFjNjFfNA_86aacf91-5e5a-41d8-950c-cfcfafd58d99">#1203-4464 Markham Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xL2ZyYWc6N2I4NGE0Mzg1ZmRjNDY1NWI2NzI3ZDdmMTY1ZjFkMjgvdGFibGU6NDVkMGEwMDk3NWEyNDE1Y2I1NjUyMzhhZmZhNjEzNTkvdGFibGVyYW5nZTo0NWQwYTAwOTc1YTI0MTVjYjU2NTIzOGFmZmE2MTM1OV8yLTAtMS0xLTQ2ODkxL3RleHRyZWdpb246YzExMjlkNjUwMDQ0NDkxNWE4YjIxYjQ2ZTZlZjFjNjFfNw_296ecdc2-41b8-4906-9031-9998671a26a5">Victoria</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xL2ZyYWc6N2I4NGE0Mzg1ZmRjNDY1NWI2NzI3ZDdmMTY1ZjFkMjgvdGFibGU6NDVkMGEwMDk3NWEyNDE1Y2I1NjUyMzhhZmZhNjEzNTkvdGFibGVyYW5nZTo0NWQwYTAwOTc1YTI0MTVjYjU2NTIzOGFmZmE2MTM1OV8yLTAtMS0xLTQ2ODkxL3RleHRyZWdpb246YzExMjlkNjUwMDQ0NDkxNWE4YjIxYjQ2ZTZlZjFjNjFfMTE_ca88ed60-86b3-4457-97d8-67be89277a58">BC</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xL2ZyYWc6N2I4NGE0Mzg1ZmRjNDY1NWI2NzI3ZDdmMTY1ZjFkMjgvdGFibGU6NDVkMGEwMDk3NWEyNDE1Y2I1NjUyMzhhZmZhNjEzNTkvdGFibGVyYW5nZTo0NWQwYTAwOTc1YTI0MTVjYjU2NTIzOGFmZmE2MTM1OV8yLTAtMS0xLTQ2ODkxL3RleHRyZWdpb246YzExMjlkNjUwMDQ0NDkxNWE4YjIxYjQ2ZTZlZjFjNjFfMTQ_b8334960-1069-4ce3-9a8b-79559ac1a7c0">V8Z 7X8</dei:EntityAddressPostalZipCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xL2ZyYWc6N2I4NGE0Mzg1ZmRjNDY1NWI2NzI3ZDdmMTY1ZjFkMjgvdGFibGU6NDVkMGEwMDk3NWEyNDE1Y2I1NjUyMzhhZmZhNjEzNTkvdGFibGVyYW5nZTo0NWQwYTAwOTc1YTI0MTVjYjU2NTIzOGFmZmE2MTM1OV8yLTEtMS0xLTQ2ODkxL3RleHRyZWdpb246NzM4ZTg4YThkMzdiNDU4ZmFhZmQwNDc1NWMwYzczYWRfNA_2209c04d-df4e-4efb-ab72-d615daa7e1c2">98-1231763</dei:EntityTaxIdentificationNumber>
    <dei:CityAreaCode
      contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xL2ZyYWc6N2I4NGE0Mzg1ZmRjNDY1NWI2NzI3ZDdmMTY1ZjFkMjgvdGV4dHJlZ2lvbjo3Yjg0YTQzODVmZGM0NjU1YjY3MjdkN2YxNjVmMWQyOF8yMjkx_9de8421f-e4d3-4b74-9a3b-76d83a9a6441">(250)</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xL2ZyYWc6N2I4NGE0Mzg1ZmRjNDY1NWI2NzI3ZDdmMTY1ZjFkMjgvdGV4dHJlZ2lvbjo3Yjg0YTQzODVmZGM0NjU1YjY3MjdkN2YxNjVmMWQyOF8yMjg0_a9b48124-c7a4-4c51-85fd-871eb36cbfbb">708-4272</dei:LocalPhoneNumber>
    <dei:EntityCurrentReportingStatus
      contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xL2ZyYWc6N2I4NGE0Mzg1ZmRjNDY1NWI2NzI3ZDdmMTY1ZjFkMjgvdGV4dHJlZ2lvbjo3Yjg0YTQzODVmZGM0NjU1YjY3MjdkN2YxNjVmMWQyOF8yMjg1_af642d76-b161-4cdc-8366-18d59e3aa994">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xL2ZyYWc6N2I4NGE0Mzg1ZmRjNDY1NWI2NzI3ZDdmMTY1ZjFkMjgvdGV4dHJlZ2lvbjo3Yjg0YTQzODVmZGM0NjU1YjY3MjdkN2YxNjVmMWQyOF8yMjg2_f573ef0e-e43e-492e-85f6-bccb4dc2110e">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xL2ZyYWc6N2I4NGE0Mzg1ZmRjNDY1NWI2NzI3ZDdmMTY1ZjFkMjgvdGFibGU6ODVlNWY5YTA5NjJhNDI4ZjhlZTA2M2MxNGEyOTMzODYvdGFibGVyYW5nZTo4NWU1ZjlhMDk2MmE0MjhmOGVlMDYzYzE0YTI5MzM4Nl8wLTAtMS0xLTQ2ODkx_5e2d0bdf-5e86-4d8f-a805-a8610f8fb97e">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xL2ZyYWc6N2I4NGE0Mzg1ZmRjNDY1NWI2NzI3ZDdmMTY1ZjFkMjgvdGFibGU6ODVlNWY5YTA5NjJhNDI4ZjhlZTA2M2MxNGEyOTMzODYvdGFibGVyYW5nZTo4NWU1ZjlhMDk2MmE0MjhmOGVlMDYzYzE0YTI5MzM4Nl8yLTQtMS0xLTQ2ODkx_089e2492-ef54-4970-9632-4b1b79cfdb34">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xL2ZyYWc6N2I4NGE0Mzg1ZmRjNDY1NWI2NzI3ZDdmMTY1ZjFkMjgvdGFibGU6ODVlNWY5YTA5NjJhNDI4ZjhlZTA2M2MxNGEyOTMzODYvdGFibGVyYW5nZTo4NWU1ZjlhMDk2MmE0MjhmOGVlMDYzYzE0YTI5MzM4Nl80LTEtMS0xLTQ2ODkx_33c563a1-da88-4946-9df0-3d3c8fa35791">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xL2ZyYWc6N2I4NGE0Mzg1ZmRjNDY1NWI2NzI3ZDdmMTY1ZjFkMjgvdGV4dHJlZ2lvbjo3Yjg0YTQzODVmZGM0NjU1YjY3MjdkN2YxNjVmMWQyOF8yMjg3_ffac4596-3302-4221-a90d-43a93a2fbde6">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="ibe0bdd3550be438099ca2e1dd9fc02ae_I20220509"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xL2ZyYWc6N2I4NGE0Mzg1ZmRjNDY1NWI2NzI3ZDdmMTY1ZjFkMjgvdGV4dHJlZ2lvbjo3Yjg0YTQzODVmZGM0NjU1YjY3MjdkN2YxNjVmMWQyOF8yMTg5_105f8330-c940-444b-86f0-cdd3cdf570cb"
      unitRef="shares">141741580</dei:EntityCommonStockSharesOutstanding>
    <dei:Security12bTitle
      contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xL2ZyYWc6N2I4NGE0Mzg1ZmRjNDY1NWI2NzI3ZDdmMTY1ZjFkMjgvdGFibGU6OGQwZTJjMjk1OWEyNDBkNGI3MTQ5OWQ2ZjFmZDk3OGIvdGFibGVyYW5nZTo4ZDBlMmMyOTU5YTI0MGQ0YjcxNDk5ZDZmMWZkOTc4Yl8xLTAtMS0xLTQ2ODkx_35f8bbfc-93c8-4ae8-bf44-f8250bb87fa4">Common shares, no par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xL2ZyYWc6N2I4NGE0Mzg1ZmRjNDY1NWI2NzI3ZDdmMTY1ZjFkMjgvdGFibGU6OGQwZTJjMjk1OWEyNDBkNGI3MTQ5OWQ2ZjFmZDk3OGIvdGFibGVyYW5nZTo4ZDBlMmMyOTU5YTI0MGQ0YjcxNDk5ZDZmMWZkOTc4Yl8xLTEtMS0xLTQ2ODkx_64bfa2bc-1aef-4547-8273-083752bb72f3">AUPH</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xL2ZyYWc6N2I4NGE0Mzg1ZmRjNDY1NWI2NzI3ZDdmMTY1ZjFkMjgvdGFibGU6OGQwZTJjMjk1OWEyNDBkNGI3MTQ5OWQ2ZjFmZDk3OGIvdGFibGVyYW5nZTo4ZDBlMmMyOTU5YTI0MGQ0YjcxNDk5ZDZmMWZkOTc4Yl8xLTItMS0xLTQ2ODkx_4823a0d6-a518-4b28-aa6d-503781298f5e">NASDAQ</dei:SecurityExchangeName>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="id7882ae6aff54a3aacdef67ddf11a428_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xNi9mcmFnOjljZDUxYTE0NzJmODQ5ZWViZmI0YzllYmNiOGRjNzdiL3RhYmxlOjBjZDY0ODYwODI3MzRmYTJhZDJiNWNiNDQzZGZhMDhjL3RhYmxlcmFuZ2U6MGNkNjQ4NjA4MjczNGZhMmFkMmI1Y2I0NDNkZmEwOGNfNC0yLTEtMS00Njg5MQ_8930a944-bcd1-47bd-a3a9-5fe3bae6e44c"
      unitRef="usd">132542000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i784f65549351439fa4b7bedf90ce7e3f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xNi9mcmFnOjljZDUxYTE0NzJmODQ5ZWViZmI0YzllYmNiOGRjNzdiL3RhYmxlOjBjZDY0ODYwODI3MzRmYTJhZDJiNWNiNDQzZGZhMDhjL3RhYmxlcmFuZ2U6MGNkNjQ4NjA4MjczNGZhMmFkMmI1Y2I0NDNkZmEwOGNfNC00LTEtMS00Njg5MQ_f022cd0a-8041-4871-88bc-ef2d96a21f6a"
      unitRef="usd">231900000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:DebtSecuritiesCurrent
      contextRef="id7882ae6aff54a3aacdef67ddf11a428_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xNi9mcmFnOjljZDUxYTE0NzJmODQ5ZWViZmI0YzllYmNiOGRjNzdiL3RhYmxlOjBjZDY0ODYwODI3MzRmYTJhZDJiNWNiNDQzZGZhMDhjL3RhYmxlcmFuZ2U6MGNkNjQ4NjA4MjczNGZhMmFkMmI1Y2I0NDNkZmEwOGNfNS0yLTEtMS00Njg5MQ_1f119417-74f0-46a6-ada9-a6887a7dc948"
      unitRef="usd">286210000</us-gaap:DebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesCurrent
      contextRef="i784f65549351439fa4b7bedf90ce7e3f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xNi9mcmFnOjljZDUxYTE0NzJmODQ5ZWViZmI0YzllYmNiOGRjNzdiL3RhYmxlOjBjZDY0ODYwODI3MzRmYTJhZDJiNWNiNDQzZGZhMDhjL3RhYmxlcmFuZ2U6MGNkNjQ4NjA4MjczNGZhMmFkMmI1Y2I0NDNkZmEwOGNfNS00LTEtMS00Njg5MQ_1b341612-041b-476c-a249-41cd97edc662"
      unitRef="usd">234178000</us-gaap:DebtSecuritiesCurrent>
    <us-gaap:AccountsAndOtherReceivablesNetCurrent
      contextRef="id7882ae6aff54a3aacdef67ddf11a428_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xNi9mcmFnOjljZDUxYTE0NzJmODQ5ZWViZmI0YzllYmNiOGRjNzdiL3RhYmxlOjBjZDY0ODYwODI3MzRmYTJhZDJiNWNiNDQzZGZhMDhjL3RhYmxlcmFuZ2U6MGNkNjQ4NjA4MjczNGZhMmFkMmI1Y2I0NDNkZmEwOGNfNi0yLTEtMS00Njg5MQ_e54664c5-2407-4b11-b6e7-2fae43735277"
      unitRef="usd">20401000</us-gaap:AccountsAndOtherReceivablesNetCurrent>
    <us-gaap:AccountsAndOtherReceivablesNetCurrent
      contextRef="i784f65549351439fa4b7bedf90ce7e3f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xNi9mcmFnOjljZDUxYTE0NzJmODQ5ZWViZmI0YzllYmNiOGRjNzdiL3RhYmxlOjBjZDY0ODYwODI3MzRmYTJhZDJiNWNiNDQzZGZhMDhjL3RhYmxlcmFuZ2U6MGNkNjQ4NjA4MjczNGZhMmFkMmI1Y2I0NDNkZmEwOGNfNi00LTEtMS00Njg5MQ_e2f076b2-65ca-4cde-bd80-4c1b368a14b0"
      unitRef="usd">15414000</us-gaap:AccountsAndOtherReceivablesNetCurrent>
    <us-gaap:InventoryNet
      contextRef="id7882ae6aff54a3aacdef67ddf11a428_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xNi9mcmFnOjljZDUxYTE0NzJmODQ5ZWViZmI0YzllYmNiOGRjNzdiL3RhYmxlOjBjZDY0ODYwODI3MzRmYTJhZDJiNWNiNDQzZGZhMDhjL3RhYmxlcmFuZ2U6MGNkNjQ4NjA4MjczNGZhMmFkMmI1Y2I0NDNkZmEwOGNfNy0yLTEtMS00Njg5MQ_e161541b-8bd3-481f-8cd7-30be3a3bd074"
      unitRef="usd">26266000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i784f65549351439fa4b7bedf90ce7e3f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xNi9mcmFnOjljZDUxYTE0NzJmODQ5ZWViZmI0YzllYmNiOGRjNzdiL3RhYmxlOjBjZDY0ODYwODI3MzRmYTJhZDJiNWNiNDQzZGZhMDhjL3RhYmxlcmFuZ2U6MGNkNjQ4NjA4MjczNGZhMmFkMmI1Y2I0NDNkZmEwOGNfNy00LTEtMS00Njg5MQ_960a5424-f637-4a41-8ed7-2647361bdcba"
      unitRef="usd">19326000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="id7882ae6aff54a3aacdef67ddf11a428_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xNi9mcmFnOjljZDUxYTE0NzJmODQ5ZWViZmI0YzllYmNiOGRjNzdiL3RhYmxlOjBjZDY0ODYwODI3MzRmYTJhZDJiNWNiNDQzZGZhMDhjL3RhYmxlcmFuZ2U6MGNkNjQ4NjA4MjczNGZhMmFkMmI1Y2I0NDNkZmEwOGNfOC0yLTEtMS00Njg5MQ_29681420-c706-46c7-82d4-8d2d3a7219c2"
      unitRef="usd">12199000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="i784f65549351439fa4b7bedf90ce7e3f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xNi9mcmFnOjljZDUxYTE0NzJmODQ5ZWViZmI0YzllYmNiOGRjNzdiL3RhYmxlOjBjZDY0ODYwODI3MzRmYTJhZDJiNWNiNDQzZGZhMDhjL3RhYmxlcmFuZ2U6MGNkNjQ4NjA4MjczNGZhMmFkMmI1Y2I0NDNkZmEwOGNfOC00LTEtMS00Njg5MQ_2731f796-3831-4487-863b-c6d07398bccf"
      unitRef="usd">12506000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:AssetsCurrent
      contextRef="id7882ae6aff54a3aacdef67ddf11a428_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xNi9mcmFnOjljZDUxYTE0NzJmODQ5ZWViZmI0YzllYmNiOGRjNzdiL3RhYmxlOjBjZDY0ODYwODI3MzRmYTJhZDJiNWNiNDQzZGZhMDhjL3RhYmxlcmFuZ2U6MGNkNjQ4NjA4MjczNGZhMmFkMmI1Y2I0NDNkZmEwOGNfOS0yLTEtMS00Njg5MQ_754e5f2f-23db-412c-b918-98617cf7e453"
      unitRef="usd">477618000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i784f65549351439fa4b7bedf90ce7e3f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xNi9mcmFnOjljZDUxYTE0NzJmODQ5ZWViZmI0YzllYmNiOGRjNzdiL3RhYmxlOjBjZDY0ODYwODI3MzRmYTJhZDJiNWNiNDQzZGZhMDhjL3RhYmxlcmFuZ2U6MGNkNjQ4NjA4MjczNGZhMmFkMmI1Y2I0NDNkZmEwOGNfOS00LTEtMS00Njg5MQ_1b9a2bd2-0b5a-400a-b080-86792e3e6852"
      unitRef="usd">513324000</us-gaap:AssetsCurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="id7882ae6aff54a3aacdef67ddf11a428_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xNi9mcmFnOjljZDUxYTE0NzJmODQ5ZWViZmI0YzllYmNiOGRjNzdiL3RhYmxlOjBjZDY0ODYwODI3MzRmYTJhZDJiNWNiNDQzZGZhMDhjL3RhYmxlcmFuZ2U6MGNkNjQ4NjA4MjczNGZhMmFkMmI1Y2I0NDNkZmEwOGNfMTMtMi0xLTEtNDY4OTE_c9eb3abd-8fb9-49b3-9ebf-397b0a4cee22"
      unitRef="usd">11838000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i784f65549351439fa4b7bedf90ce7e3f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xNi9mcmFnOjljZDUxYTE0NzJmODQ5ZWViZmI0YzllYmNiOGRjNzdiL3RhYmxlOjBjZDY0ODYwODI3MzRmYTJhZDJiNWNiNDQzZGZhMDhjL3RhYmxlcmFuZ2U6MGNkNjQ4NjA4MjczNGZhMmFkMmI1Y2I0NDNkZmEwOGNfMTMtNC0xLTEtNDY4OTE_7a9770a4-0550-4bc8-8fbc-bf9b37c0d2f8"
      unitRef="usd">11838000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="id7882ae6aff54a3aacdef67ddf11a428_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xNi9mcmFnOjljZDUxYTE0NzJmODQ5ZWViZmI0YzllYmNiOGRjNzdiL3RhYmxlOjBjZDY0ODYwODI3MzRmYTJhZDJiNWNiNDQzZGZhMDhjL3RhYmxlcmFuZ2U6MGNkNjQ4NjA4MjczNGZhMmFkMmI1Y2I0NDNkZmEwOGNfMTQtMi0xLTEtNDY4OTE_b6486062-4cc1-400a-9f60-0137d27f41e7"
      unitRef="usd">4332000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i784f65549351439fa4b7bedf90ce7e3f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xNi9mcmFnOjljZDUxYTE0NzJmODQ5ZWViZmI0YzllYmNiOGRjNzdiL3RhYmxlOjBjZDY0ODYwODI3MzRmYTJhZDJiNWNiNDQzZGZhMDhjL3RhYmxlcmFuZ2U6MGNkNjQ4NjA4MjczNGZhMmFkMmI1Y2I0NDNkZmEwOGNfMTQtNC0xLTEtNDY4OTE_bc8de736-a591-4fa8-a86d-6cf1a9029c56"
      unitRef="usd">4418000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="id7882ae6aff54a3aacdef67ddf11a428_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xNi9mcmFnOjljZDUxYTE0NzJmODQ5ZWViZmI0YzllYmNiOGRjNzdiL3RhYmxlOjBjZDY0ODYwODI3MzRmYTJhZDJiNWNiNDQzZGZhMDhjL3RhYmxlcmFuZ2U6MGNkNjQ4NjA4MjczNGZhMmFkMmI1Y2I0NDNkZmEwOGNfMTUtMi0xLTEtNDY4OTE_91a836d0-6824-411d-840a-e9c63bb45be8"
      unitRef="usd">7882000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i784f65549351439fa4b7bedf90ce7e3f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xNi9mcmFnOjljZDUxYTE0NzJmODQ5ZWViZmI0YzllYmNiOGRjNzdiL3RhYmxlOjBjZDY0ODYwODI3MzRmYTJhZDJiNWNiNDQzZGZhMDhjL3RhYmxlcmFuZ2U6MGNkNjQ4NjA4MjczNGZhMmFkMmI1Y2I0NDNkZmEwOGNfMTUtNC0xLTEtNDY4OTE_995e007c-87fa-46b5-bc1c-c651c01988b3"
      unitRef="usd">8404000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="id7882ae6aff54a3aacdef67ddf11a428_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xNi9mcmFnOjljZDUxYTE0NzJmODQ5ZWViZmI0YzllYmNiOGRjNzdiL3RhYmxlOjBjZDY0ODYwODI3MzRmYTJhZDJiNWNiNDQzZGZhMDhjL3RhYmxlcmFuZ2U6MGNkNjQ4NjA4MjczNGZhMmFkMmI1Y2I0NDNkZmEwOGNfMTYtMi0xLTEtNDY4OTE_891acbd1-3620-4313-9cb6-2b80dfbea883"
      unitRef="usd">5232000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i784f65549351439fa4b7bedf90ce7e3f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xNi9mcmFnOjljZDUxYTE0NzJmODQ5ZWViZmI0YzllYmNiOGRjNzdiL3RhYmxlOjBjZDY0ODYwODI3MzRmYTJhZDJiNWNiNDQzZGZhMDhjL3RhYmxlcmFuZ2U6MGNkNjQ4NjA4MjczNGZhMmFkMmI1Y2I0NDNkZmEwOGNfMTYtNC0xLTEtNDY4OTE_421b0fe2-020e-428e-a6e2-16b21529c5c8"
      unitRef="usd">5383000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:Assets
      contextRef="id7882ae6aff54a3aacdef67ddf11a428_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xNi9mcmFnOjljZDUxYTE0NzJmODQ5ZWViZmI0YzllYmNiOGRjNzdiL3RhYmxlOjBjZDY0ODYwODI3MzRmYTJhZDJiNWNiNDQzZGZhMDhjL3RhYmxlcmFuZ2U6MGNkNjQ4NjA4MjczNGZhMmFkMmI1Y2I0NDNkZmEwOGNfMTctMi0xLTEtNDY4OTE_caa856d4-c6b6-4cf7-accb-c1e2e4c61927"
      unitRef="usd">506902000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i784f65549351439fa4b7bedf90ce7e3f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xNi9mcmFnOjljZDUxYTE0NzJmODQ5ZWViZmI0YzllYmNiOGRjNzdiL3RhYmxlOjBjZDY0ODYwODI3MzRmYTJhZDJiNWNiNDQzZGZhMDhjL3RhYmxlcmFuZ2U6MGNkNjQ4NjA4MjczNGZhMmFkMmI1Y2I0NDNkZmEwOGNfMTctNC0xLTEtNDY4OTE_99a65914-7693-4e5a-a1d1-1c9b609404f9"
      unitRef="usd">543367000</us-gaap:Assets>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="id7882ae6aff54a3aacdef67ddf11a428_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xNi9mcmFnOjljZDUxYTE0NzJmODQ5ZWViZmI0YzllYmNiOGRjNzdiL3RhYmxlOjBjZDY0ODYwODI3MzRmYTJhZDJiNWNiNDQzZGZhMDhjL3RhYmxlcmFuZ2U6MGNkNjQ4NjA4MjczNGZhMmFkMmI1Y2I0NDNkZmEwOGNfMjEtMi0xLTEtNDY4OTE_cdd3de98-2939-4691-81f0-b660ee2809b8"
      unitRef="usd">32327000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="i784f65549351439fa4b7bedf90ce7e3f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xNi9mcmFnOjljZDUxYTE0NzJmODQ5ZWViZmI0YzllYmNiOGRjNzdiL3RhYmxlOjBjZDY0ODYwODI3MzRmYTJhZDJiNWNiNDQzZGZhMDhjL3RhYmxlcmFuZ2U6MGNkNjQ4NjA4MjczNGZhMmFkMmI1Y2I0NDNkZmEwOGNfMjEtNC0xLTEtNDY4OTE_e017904a-9877-4965-8b9a-78ffd72d082b"
      unitRef="usd">34947000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="id7882ae6aff54a3aacdef67ddf11a428_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xNi9mcmFnOjljZDUxYTE0NzJmODQ5ZWViZmI0YzllYmNiOGRjNzdiL3RhYmxlOjBjZDY0ODYwODI3MzRmYTJhZDJiNWNiNDQzZGZhMDhjL3RhYmxlcmFuZ2U6MGNkNjQ4NjA4MjczNGZhMmFkMmI1Y2I0NDNkZmEwOGNfMjItMi0xLTEtNDY4OTE_88ede420-6590-43de-ab14-386d5e681b5f"
      unitRef="usd">502000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i784f65549351439fa4b7bedf90ce7e3f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xNi9mcmFnOjljZDUxYTE0NzJmODQ5ZWViZmI0YzllYmNiOGRjNzdiL3RhYmxlOjBjZDY0ODYwODI3MzRmYTJhZDJiNWNiNDQzZGZhMDhjL3RhYmxlcmFuZ2U6MGNkNjQ4NjA4MjczNGZhMmFkMmI1Y2I0NDNkZmEwOGNfMjItNC0xLTEtNDY4OTE_95fa483c-1382-48e5-b19f-45a2628158f4"
      unitRef="usd">4640000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="id7882ae6aff54a3aacdef67ddf11a428_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xNi9mcmFnOjljZDUxYTE0NzJmODQ5ZWViZmI0YzllYmNiOGRjNzdiL3RhYmxlOjBjZDY0ODYwODI3MzRmYTJhZDJiNWNiNDQzZGZhMDhjL3RhYmxlcmFuZ2U6MGNkNjQ4NjA4MjczNGZhMmFkMmI1Y2I0NDNkZmEwOGNfMjMtMi0xLTEtNDY4OTE_f7c9defa-1e47-45ce-bb64-0155deb67c7a"
      unitRef="usd">1009000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i784f65549351439fa4b7bedf90ce7e3f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xNi9mcmFnOjljZDUxYTE0NzJmODQ5ZWViZmI0YzllYmNiOGRjNzdiL3RhYmxlOjBjZDY0ODYwODI3MzRmYTJhZDJiNWNiNDQzZGZhMDhjL3RhYmxlcmFuZ2U6MGNkNjQ4NjA4MjczNGZhMmFkMmI1Y2I0NDNkZmEwOGNfMjMtNC0xLTEtNDY4OTE_fe059d7c-43df-4973-8cf3-b530d60a1893"
      unitRef="usd">1059000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="id7882ae6aff54a3aacdef67ddf11a428_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xNi9mcmFnOjljZDUxYTE0NzJmODQ5ZWViZmI0YzllYmNiOGRjNzdiL3RhYmxlOjBjZDY0ODYwODI3MzRmYTJhZDJiNWNiNDQzZGZhMDhjL3RhYmxlcmFuZ2U6MGNkNjQ4NjA4MjczNGZhMmFkMmI1Y2I0NDNkZmEwOGNfMjQtMi0xLTEtNDY4OTE_9fe2ecfc-2061-4975-a051-fadf7fddfbd9"
      unitRef="usd">33838000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i784f65549351439fa4b7bedf90ce7e3f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xNi9mcmFnOjljZDUxYTE0NzJmODQ5ZWViZmI0YzllYmNiOGRjNzdiL3RhYmxlOjBjZDY0ODYwODI3MzRmYTJhZDJiNWNiNDQzZGZhMDhjL3RhYmxlcmFuZ2U6MGNkNjQ4NjA4MjczNGZhMmFkMmI1Y2I0NDNkZmEwOGNfMjQtNC0xLTEtNDY4OTE_666119e9-bc76-4b34-976e-499cfc1822ae"
      unitRef="usd">40646000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="id7882ae6aff54a3aacdef67ddf11a428_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xNi9mcmFnOjljZDUxYTE0NzJmODQ5ZWViZmI0YzllYmNiOGRjNzdiL3RhYmxlOjBjZDY0ODYwODI3MzRmYTJhZDJiNWNiNDQzZGZhMDhjL3RhYmxlcmFuZ2U6MGNkNjQ4NjA4MjczNGZhMmFkMmI1Y2I0NDNkZmEwOGNfMjctMi0xLTEtNDY4OTE_41e7a447-47a3-4409-87de-b880e94ca448"
      unitRef="usd">17379000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i784f65549351439fa4b7bedf90ce7e3f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xNi9mcmFnOjljZDUxYTE0NzJmODQ5ZWViZmI0YzllYmNiOGRjNzdiL3RhYmxlOjBjZDY0ODYwODI3MzRmYTJhZDJiNWNiNDQzZGZhMDhjL3RhYmxlcmFuZ2U6MGNkNjQ4NjA4MjczNGZhMmFkMmI1Y2I0NDNkZmEwOGNfMjctNC0xLTEtNDY4OTE_a99416c5-aa0a-4acd-a348-bf995070f79c"
      unitRef="usd">15950000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="id7882ae6aff54a3aacdef67ddf11a428_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xNi9mcmFnOjljZDUxYTE0NzJmODQ5ZWViZmI0YzllYmNiOGRjNzdiL3RhYmxlOjBjZDY0ODYwODI3MzRmYTJhZDJiNWNiNDQzZGZhMDhjL3RhYmxlcmFuZ2U6MGNkNjQ4NjA4MjczNGZhMmFkMmI1Y2I0NDNkZmEwOGNfMjgtMi0xLTEtNDY4OTE_514bb88a-afd6-4e83-9efd-9243da723574"
      unitRef="usd">7562000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i784f65549351439fa4b7bedf90ce7e3f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xNi9mcmFnOjljZDUxYTE0NzJmODQ5ZWViZmI0YzllYmNiOGRjNzdiL3RhYmxlOjBjZDY0ODYwODI3MzRmYTJhZDJiNWNiNDQzZGZhMDhjL3RhYmxlcmFuZ2U6MGNkNjQ4NjA4MjczNGZhMmFkMmI1Y2I0NDNkZmEwOGNfMjgtNC0xLTEtNDY4OTE_1e0d38e6-eddb-40cc-b95c-c72186630479"
      unitRef="usd">7680000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities
      contextRef="id7882ae6aff54a3aacdef67ddf11a428_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xNi9mcmFnOjljZDUxYTE0NzJmODQ5ZWViZmI0YzllYmNiOGRjNzdiL3RhYmxlOjBjZDY0ODYwODI3MzRmYTJhZDJiNWNiNDQzZGZhMDhjL3RhYmxlcmFuZ2U6MGNkNjQ4NjA4MjczNGZhMmFkMmI1Y2I0NDNkZmEwOGNfMjktMi0xLTEtNDY4OTE_c30057a6-2b04-4414-89d3-85d1b4615dad"
      unitRef="usd">58779000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i784f65549351439fa4b7bedf90ce7e3f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xNi9mcmFnOjljZDUxYTE0NzJmODQ5ZWViZmI0YzllYmNiOGRjNzdiL3RhYmxlOjBjZDY0ODYwODI3MzRmYTJhZDJiNWNiNDQzZGZhMDhjL3RhYmxlcmFuZ2U6MGNkNjQ4NjA4MjczNGZhMmFkMmI1Y2I0NDNkZmEwOGNfMjktNC0xLTEtNDY4OTE_6bd54b0f-685e-4550-b03b-6c855029eb3e"
      unitRef="usd">64276000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="id7882ae6aff54a3aacdef67ddf11a428_I20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xNi9mcmFnOjljZDUxYTE0NzJmODQ5ZWViZmI0YzllYmNiOGRjNzdiL3RhYmxlOjBjZDY0ODYwODI3MzRmYTJhZDJiNWNiNDQzZGZhMDhjL3RhYmxlcmFuZ2U6MGNkNjQ4NjA4MjczNGZhMmFkMmI1Y2I0NDNkZmEwOGNfMzAtMi0xLTEtNDY4OTE_264b2948-41a7-4ff1-9b4c-11aaf45ee63d"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i784f65549351439fa4b7bedf90ce7e3f_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xNi9mcmFnOjljZDUxYTE0NzJmODQ5ZWViZmI0YzllYmNiOGRjNzdiL3RhYmxlOjBjZDY0ODYwODI3MzRmYTJhZDJiNWNiNDQzZGZhMDhjL3RhYmxlcmFuZ2U6MGNkNjQ4NjA4MjczNGZhMmFkMmI1Y2I0NDNkZmEwOGNfMzAtNC0xLTEtNDY4OTE_a4c77908-6f11-4eda-a79f-c0089d7918df"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="id7882ae6aff54a3aacdef67ddf11a428_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xNi9mcmFnOjljZDUxYTE0NzJmODQ5ZWViZmI0YzllYmNiOGRjNzdiL3RhYmxlOjBjZDY0ODYwODI3MzRmYTJhZDJiNWNiNDQzZGZhMDhjL3RhYmxlcmFuZ2U6MGNkNjQ4NjA4MjczNGZhMmFkMmI1Y2I0NDNkZmEwOGNfMzItMC0xLTEtNDY4OTEvdGV4dHJlZ2lvbjphOTA1NmUzYTA5ZTE0NGE2ODI0YzVkMzcwMDUzMDJhZV82Mw_7c03301b-bd7a-45cd-929c-646116f22f96"
      unitRef="shares">141742000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="id7882ae6aff54a3aacdef67ddf11a428_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xNi9mcmFnOjljZDUxYTE0NzJmODQ5ZWViZmI0YzllYmNiOGRjNzdiL3RhYmxlOjBjZDY0ODYwODI3MzRmYTJhZDJiNWNiNDQzZGZhMDhjL3RhYmxlcmFuZ2U6MGNkNjQ4NjA4MjczNGZhMmFkMmI1Y2I0NDNkZmEwOGNfMzItMC0xLTEtNDY4OTEvdGV4dHJlZ2lvbjphOTA1NmUzYTA5ZTE0NGE2ODI0YzVkMzcwMDUzMDJhZV82Mw_af017bc0-a057-4396-8eb4-cad062249461"
      unitRef="shares">141742000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i784f65549351439fa4b7bedf90ce7e3f_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xNi9mcmFnOjljZDUxYTE0NzJmODQ5ZWViZmI0YzllYmNiOGRjNzdiL3RhYmxlOjBjZDY0ODYwODI3MzRmYTJhZDJiNWNiNDQzZGZhMDhjL3RhYmxlcmFuZ2U6MGNkNjQ4NjA4MjczNGZhMmFkMmI1Y2I0NDNkZmEwOGNfMzItMC0xLTEtNDY4OTEvdGV4dHJlZ2lvbjphOTA1NmUzYTA5ZTE0NGE2ODI0YzVkMzcwMDUzMDJhZV83MA_7141f9a4-296a-4ba3-a091-af1dc46ed667"
      unitRef="shares">141600000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i784f65549351439fa4b7bedf90ce7e3f_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xNi9mcmFnOjljZDUxYTE0NzJmODQ5ZWViZmI0YzllYmNiOGRjNzdiL3RhYmxlOjBjZDY0ODYwODI3MzRmYTJhZDJiNWNiNDQzZGZhMDhjL3RhYmxlcmFuZ2U6MGNkNjQ4NjA4MjczNGZhMmFkMmI1Y2I0NDNkZmEwOGNfMzItMC0xLTEtNDY4OTEvdGV4dHJlZ2lvbjphOTA1NmUzYTA5ZTE0NGE2ODI0YzVkMzcwMDUzMDJhZV83MA_bf7f1f85-74ff-4824-bed0-4b64a739fca7"
      unitRef="shares">141600000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValueOutstanding
      contextRef="id7882ae6aff54a3aacdef67ddf11a428_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xNi9mcmFnOjljZDUxYTE0NzJmODQ5ZWViZmI0YzllYmNiOGRjNzdiL3RhYmxlOjBjZDY0ODYwODI3MzRmYTJhZDJiNWNiNDQzZGZhMDhjL3RhYmxlcmFuZ2U6MGNkNjQ4NjA4MjczNGZhMmFkMmI1Y2I0NDNkZmEwOGNfMzItMi0xLTEtNDY4OTE_a887c287-2465-4c73-b331-221d2a4beaf3"
      unitRef="usd">1178807000</us-gaap:CommonStockValueOutstanding>
    <us-gaap:CommonStockValueOutstanding
      contextRef="i784f65549351439fa4b7bedf90ce7e3f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xNi9mcmFnOjljZDUxYTE0NzJmODQ5ZWViZmI0YzllYmNiOGRjNzdiL3RhYmxlOjBjZDY0ODYwODI3MzRmYTJhZDJiNWNiNDQzZGZhMDhjL3RhYmxlcmFuZ2U6MGNkNjQ4NjA4MjczNGZhMmFkMmI1Y2I0NDNkZmEwOGNfMzItNC0xLTEtNDY4OTE_a7418a4f-86bc-4163-a596-ddb0a6e72f3a"
      unitRef="usd">1177051000</us-gaap:CommonStockValueOutstanding>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="id7882ae6aff54a3aacdef67ddf11a428_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xNi9mcmFnOjljZDUxYTE0NzJmODQ5ZWViZmI0YzllYmNiOGRjNzdiL3RhYmxlOjBjZDY0ODYwODI3MzRmYTJhZDJiNWNiNDQzZGZhMDhjL3RhYmxlcmFuZ2U6MGNkNjQ4NjA4MjczNGZhMmFkMmI1Y2I0NDNkZmEwOGNfMzMtMi0xLTEtNDY4OTE_547f4476-81e5-4b3b-bf88-d7eb3d4d30c0"
      unitRef="usd">64686000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i784f65549351439fa4b7bedf90ce7e3f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xNi9mcmFnOjljZDUxYTE0NzJmODQ5ZWViZmI0YzllYmNiOGRjNzdiL3RhYmxlOjBjZDY0ODYwODI3MzRmYTJhZDJiNWNiNDQzZGZhMDhjL3RhYmxlcmFuZ2U6MGNkNjQ4NjA4MjczNGZhMmFkMmI1Y2I0NDNkZmEwOGNfMzMtNC0xLTEtNDY4OTE_9aaa2942-cbb3-4a65-a83d-1b86aceac49c"
      unitRef="usd">59014000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="id7882ae6aff54a3aacdef67ddf11a428_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xNi9mcmFnOjljZDUxYTE0NzJmODQ5ZWViZmI0YzllYmNiOGRjNzdiL3RhYmxlOjBjZDY0ODYwODI3MzRmYTJhZDJiNWNiNDQzZGZhMDhjL3RhYmxlcmFuZ2U6MGNkNjQ4NjA4MjczNGZhMmFkMmI1Y2I0NDNkZmEwOGNfMzQtMi0xLTEtNDY4OTE_12b5dfc9-35a1-4101-9e63-0152e58bbf6c"
      unitRef="usd">-1618000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i784f65549351439fa4b7bedf90ce7e3f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xNi9mcmFnOjljZDUxYTE0NzJmODQ5ZWViZmI0YzllYmNiOGRjNzdiL3RhYmxlOjBjZDY0ODYwODI3MzRmYTJhZDJiNWNiNDQzZGZhMDhjL3RhYmxlcmFuZ2U6MGNkNjQ4NjA4MjczNGZhMmFkMmI1Y2I0NDNkZmEwOGNfMzQtNC0xLTEtNDY4OTE_ba2af9c9-1b73-46ce-9973-24d60d252c4a"
      unitRef="usd">-852000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="id7882ae6aff54a3aacdef67ddf11a428_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xNi9mcmFnOjljZDUxYTE0NzJmODQ5ZWViZmI0YzllYmNiOGRjNzdiL3RhYmxlOjBjZDY0ODYwODI3MzRmYTJhZDJiNWNiNDQzZGZhMDhjL3RhYmxlcmFuZ2U6MGNkNjQ4NjA4MjczNGZhMmFkMmI1Y2I0NDNkZmEwOGNfMzUtMi0xLTEtNDY4OTE_0858511f-8d99-49df-9c0a-91ddf7b581a4"
      unitRef="usd">-793752000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i784f65549351439fa4b7bedf90ce7e3f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xNi9mcmFnOjljZDUxYTE0NzJmODQ5ZWViZmI0YzllYmNiOGRjNzdiL3RhYmxlOjBjZDY0ODYwODI3MzRmYTJhZDJiNWNiNDQzZGZhMDhjL3RhYmxlcmFuZ2U6MGNkNjQ4NjA4MjczNGZhMmFkMmI1Y2I0NDNkZmEwOGNfMzUtNC0xLTEtNDY4OTE_7a56e2f7-841c-43c5-93eb-49c7b672662b"
      unitRef="usd">-756122000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="id7882ae6aff54a3aacdef67ddf11a428_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xNi9mcmFnOjljZDUxYTE0NzJmODQ5ZWViZmI0YzllYmNiOGRjNzdiL3RhYmxlOjBjZDY0ODYwODI3MzRmYTJhZDJiNWNiNDQzZGZhMDhjL3RhYmxlcmFuZ2U6MGNkNjQ4NjA4MjczNGZhMmFkMmI1Y2I0NDNkZmEwOGNfMzYtMi0xLTEtNDY4OTE_35adae84-cfea-4c61-8efd-fe211c87725d"
      unitRef="usd">448123000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i784f65549351439fa4b7bedf90ce7e3f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xNi9mcmFnOjljZDUxYTE0NzJmODQ5ZWViZmI0YzllYmNiOGRjNzdiL3RhYmxlOjBjZDY0ODYwODI3MzRmYTJhZDJiNWNiNDQzZGZhMDhjL3RhYmxlcmFuZ2U6MGNkNjQ4NjA4MjczNGZhMmFkMmI1Y2I0NDNkZmEwOGNfMzYtNC0xLTEtNDY4OTE_0aa8425b-f2be-4a08-a0c5-01d1b3e46669"
      unitRef="usd">479091000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="id7882ae6aff54a3aacdef67ddf11a428_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xNi9mcmFnOjljZDUxYTE0NzJmODQ5ZWViZmI0YzllYmNiOGRjNzdiL3RhYmxlOjBjZDY0ODYwODI3MzRmYTJhZDJiNWNiNDQzZGZhMDhjL3RhYmxlcmFuZ2U6MGNkNjQ4NjA4MjczNGZhMmFkMmI1Y2I0NDNkZmEwOGNfMzctMi0xLTEtNDY4OTE_a99d6340-d02c-4605-86a4-aabcf351429d"
      unitRef="usd">506902000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i784f65549351439fa4b7bedf90ce7e3f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xNi9mcmFnOjljZDUxYTE0NzJmODQ5ZWViZmI0YzllYmNiOGRjNzdiL3RhYmxlOjBjZDY0ODYwODI3MzRmYTJhZDJiNWNiNDQzZGZhMDhjL3RhYmxlcmFuZ2U6MGNkNjQ4NjA4MjczNGZhMmFkMmI1Y2I0NDNkZmEwOGNfMzctNC0xLTEtNDY4OTE_38a6c4f8-6d68-4a2e-aee9-c89d3fce0bd7"
      unitRef="usd">543367000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i34e7d6696f5d40019bbef585c942db1a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xOS9mcmFnOjA2ZWYwNzk4YTBlODRlMjRhODJiNTcxNWU1YmRmMjU1L3RhYmxlOmE4MWYwMGM4NmI2NDQyZTNiNGVlZDU5YjUyOWY2ODBlL3RhYmxlcmFuZ2U6YTgxZjAwYzg2YjY0NDJlM2I0ZWVkNTliNTI5ZjY4MGVfNS0yLTEtMS00Njg5MQ_32856bdd-a3a8-4f1e-b853-a24778262576"
      unitRef="usd">21492000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i717bc91cf1504e20b9b5b1c709508591_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xOS9mcmFnOjA2ZWYwNzk4YTBlODRlMjRhODJiNTcxNWU1YmRmMjU1L3RhYmxlOmE4MWYwMGM4NmI2NDQyZTNiNGVlZDU5YjUyOWY2ODBlL3RhYmxlcmFuZ2U6YTgxZjAwYzg2YjY0NDJlM2I0ZWVkNTliNTI5ZjY4MGVfNS00LTEtMS00Njg5MQ_4c9c5cc2-3cf9-41a4-80eb-4c75874c850e"
      unitRef="usd">884000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1d6565befaf14fa4b0f390573f13f8fc_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xOS9mcmFnOjA2ZWYwNzk4YTBlODRlMjRhODJiNTcxNWU1YmRmMjU1L3RhYmxlOmE4MWYwMGM4NmI2NDQyZTNiNGVlZDU5YjUyOWY2ODBlL3RhYmxlcmFuZ2U6YTgxZjAwYzg2YjY0NDJlM2I0ZWVkNTliNTI5ZjY4MGVfNi0yLTEtMS00Njg5MQ_acdb18d5-e1fc-486a-94f6-1721d209a1a0"
      unitRef="usd">133000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i25e47e5aca8445b7b6e872243cf6ab56_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xOS9mcmFnOjA2ZWYwNzk4YTBlODRlMjRhODJiNTcxNWU1YmRmMjU1L3RhYmxlOmE4MWYwMGM4NmI2NDQyZTNiNGVlZDU5YjUyOWY2ODBlL3RhYmxlcmFuZ2U6YTgxZjAwYzg2YjY0NDJlM2I0ZWVkNTliNTI5ZjY4MGVfNi00LTEtMS00Njg5MQ_74da76bb-9d14-49c6-8883-a4baa9338e7f"
      unitRef="usd">30000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xOS9mcmFnOjA2ZWYwNzk4YTBlODRlMjRhODJiNTcxNWU1YmRmMjU1L3RhYmxlOmE4MWYwMGM4NmI2NDQyZTNiNGVlZDU5YjUyOWY2ODBlL3RhYmxlcmFuZ2U6YTgxZjAwYzg2YjY0NDJlM2I0ZWVkNTliNTI5ZjY4MGVfNy0yLTEtMS00Njg5MQ_2aa366e2-71d2-4463-b824-fbdf410cafd5"
      unitRef="usd">21625000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i56599386fa47443a8975bb3f7a6a8c57_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xOS9mcmFnOjA2ZWYwNzk4YTBlODRlMjRhODJiNTcxNWU1YmRmMjU1L3RhYmxlOmE4MWYwMGM4NmI2NDQyZTNiNGVlZDU5YjUyOWY2ODBlL3RhYmxlcmFuZ2U6YTgxZjAwYzg2YjY0NDJlM2I0ZWVkNTliNTI5ZjY4MGVfNy00LTEtMS00Njg5MQ_204187e2-8742-4409-8d9b-71743d0aa110"
      unitRef="usd">914000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfRevenue
      contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xOS9mcmFnOjA2ZWYwNzk4YTBlODRlMjRhODJiNTcxNWU1YmRmMjU1L3RhYmxlOmE4MWYwMGM4NmI2NDQyZTNiNGVlZDU5YjUyOWY2ODBlL3RhYmxlcmFuZ2U6YTgxZjAwYzg2YjY0NDJlM2I0ZWVkNTliNTI5ZjY4MGVfOS0yLTEtMS00Njg5MQ_17954d37-3abc-4a7c-9741-f9af54255ef6"
      unitRef="usd">256000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="i56599386fa47443a8975bb3f7a6a8c57_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xOS9mcmFnOjA2ZWYwNzk4YTBlODRlMjRhODJiNTcxNWU1YmRmMjU1L3RhYmxlOmE4MWYwMGM4NmI2NDQyZTNiNGVlZDU5YjUyOWY2ODBlL3RhYmxlcmFuZ2U6YTgxZjAwYzg2YjY0NDJlM2I0ZWVkNTliNTI5ZjY4MGVfOS00LTEtMS00Njg5MQ_c61a2e02-d411-4604-8999-428b806a82ad"
      unitRef="usd">48000</us-gaap:CostOfRevenue>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xOS9mcmFnOjA2ZWYwNzk4YTBlODRlMjRhODJiNTcxNWU1YmRmMjU1L3RhYmxlOmE4MWYwMGM4NmI2NDQyZTNiNGVlZDU5YjUyOWY2ODBlL3RhYmxlcmFuZ2U6YTgxZjAwYzg2YjY0NDJlM2I0ZWVkNTliNTI5ZjY4MGVfMTAtMi0xLTEtNDY4OTE_7c363fef-e153-461c-90ab-6d185908f38f"
      unitRef="usd">45197000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i56599386fa47443a8975bb3f7a6a8c57_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xOS9mcmFnOjA2ZWYwNzk4YTBlODRlMjRhODJiNTcxNWU1YmRmMjU1L3RhYmxlOmE4MWYwMGM4NmI2NDQyZTNiNGVlZDU5YjUyOWY2ODBlL3RhYmxlcmFuZ2U6YTgxZjAwYzg2YjY0NDJlM2I0ZWVkNTliNTI5ZjY4MGVfMTAtNC0xLTEtNDY4OTE_eebff4e8-cf1f-48a5-976a-e7860432a3d0"
      unitRef="usd">39805000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xOS9mcmFnOjA2ZWYwNzk4YTBlODRlMjRhODJiNTcxNWU1YmRmMjU1L3RhYmxlOmE4MWYwMGM4NmI2NDQyZTNiNGVlZDU5YjUyOWY2ODBlL3RhYmxlcmFuZ2U6YTgxZjAwYzg2YjY0NDJlM2I0ZWVkNTliNTI5ZjY4MGVfMTEtMi0xLTEtNDY4OTE_cf9e60c4-5385-4e5c-8380-bbaa79c16e8c"
      unitRef="usd">12620000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i56599386fa47443a8975bb3f7a6a8c57_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xOS9mcmFnOjA2ZWYwNzk4YTBlODRlMjRhODJiNTcxNWU1YmRmMjU1L3RhYmxlOmE4MWYwMGM4NmI2NDQyZTNiNGVlZDU5YjUyOWY2ODBlL3RhYmxlcmFuZ2U6YTgxZjAwYzg2YjY0NDJlM2I0ZWVkNTliNTI5ZjY4MGVfMTEtNC0xLTEtNDY4OTE_a07a4a03-8b1b-42d5-a1c9-e68717ad169c"
      unitRef="usd">9833000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xOS9mcmFnOjA2ZWYwNzk4YTBlODRlMjRhODJiNTcxNWU1YmRmMjU1L3RhYmxlOmE4MWYwMGM4NmI2NDQyZTNiNGVlZDU5YjUyOWY2ODBlL3RhYmxlcmFuZ2U6YTgxZjAwYzg2YjY0NDJlM2I0ZWVkNTliNTI5ZjY4MGVfMTMtMi0xLTEtNDY4OTE_115e8791-5b2b-4f17-af04-af6ab0e4471a"
      unitRef="usd">-1434000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="i56599386fa47443a8975bb3f7a6a8c57_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xOS9mcmFnOjA2ZWYwNzk4YTBlODRlMjRhODJiNTcxNWU1YmRmMjU1L3RhYmxlOmE4MWYwMGM4NmI2NDQyZTNiNGVlZDU5YjUyOWY2ODBlL3RhYmxlcmFuZ2U6YTgxZjAwYzg2YjY0NDJlM2I0ZWVkNTliNTI5ZjY4MGVfMTMtNC0xLTEtNDY4OTE_347c7b23-851a-45bf-95f6-ca8b44687deb"
      unitRef="usd">-1771000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:CostsAndExpenses
      contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xOS9mcmFnOjA2ZWYwNzk4YTBlODRlMjRhODJiNTcxNWU1YmRmMjU1L3RhYmxlOmE4MWYwMGM4NmI2NDQyZTNiNGVlZDU5YjUyOWY2ODBlL3RhYmxlcmFuZ2U6YTgxZjAwYzg2YjY0NDJlM2I0ZWVkNTliNTI5ZjY4MGVfMTQtMi0xLTEtNDY4OTE_bc2f471e-5369-44c7-b6e5-c1ae35c972df"
      unitRef="usd">59507000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i56599386fa47443a8975bb3f7a6a8c57_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xOS9mcmFnOjA2ZWYwNzk4YTBlODRlMjRhODJiNTcxNWU1YmRmMjU1L3RhYmxlOmE4MWYwMGM4NmI2NDQyZTNiNGVlZDU5YjUyOWY2ODBlL3RhYmxlcmFuZ2U6YTgxZjAwYzg2YjY0NDJlM2I0ZWVkNTliNTI5ZjY4MGVfMTQtNC0xLTEtNDY4OTE_dc5fa5f5-6b4b-4687-aa9c-fece878d22cb"
      unitRef="usd">51457000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xOS9mcmFnOjA2ZWYwNzk4YTBlODRlMjRhODJiNTcxNWU1YmRmMjU1L3RhYmxlOmE4MWYwMGM4NmI2NDQyZTNiNGVlZDU5YjUyOWY2ODBlL3RhYmxlcmFuZ2U6YTgxZjAwYzg2YjY0NDJlM2I0ZWVkNTliNTI5ZjY4MGVfMTUtMi0xLTEtNDY4OTE_bdc20dce-d9c5-4c6c-a3ba-8c6b5de69b4e"
      unitRef="usd">-37882000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i56599386fa47443a8975bb3f7a6a8c57_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xOS9mcmFnOjA2ZWYwNzk4YTBlODRlMjRhODJiNTcxNWU1YmRmMjU1L3RhYmxlOmE4MWYwMGM4NmI2NDQyZTNiNGVlZDU5YjUyOWY2ODBlL3RhYmxlcmFuZ2U6YTgxZjAwYzg2YjY0NDJlM2I0ZWVkNTliNTI5ZjY4MGVfMTUtNC0xLTEtNDY4OTE_860fa46a-e426-4f94-b1ef-ce39dd5c53ec"
      unitRef="usd">-50543000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xOS9mcmFnOjA2ZWYwNzk4YTBlODRlMjRhODJiNTcxNWU1YmRmMjU1L3RhYmxlOmE4MWYwMGM4NmI2NDQyZTNiNGVlZDU5YjUyOWY2ODBlL3RhYmxlcmFuZ2U6YTgxZjAwYzg2YjY0NDJlM2I0ZWVkNTliNTI5ZjY4MGVfMTYtMi0xLTEtNDY4OTE_c5aa731f-4b02-46a2-83e8-7ed9f81f1b16"
      unitRef="usd">262000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="i56599386fa47443a8975bb3f7a6a8c57_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xOS9mcmFnOjA2ZWYwNzk4YTBlODRlMjRhODJiNTcxNWU1YmRmMjU1L3RhYmxlOmE4MWYwMGM4NmI2NDQyZTNiNGVlZDU5YjUyOWY2ODBlL3RhYmxlcmFuZ2U6YTgxZjAwYzg2YjY0NDJlM2I0ZWVkNTliNTI5ZjY4MGVfMTYtNC0xLTEtNDY4OTE_17a761eb-18c0-40a6-9f57-ce6ebb5175b0"
      unitRef="usd">172000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xOS9mcmFnOjA2ZWYwNzk4YTBlODRlMjRhODJiNTcxNWU1YmRmMjU1L3RhYmxlOmE4MWYwMGM4NmI2NDQyZTNiNGVlZDU5YjUyOWY2ODBlL3RhYmxlcmFuZ2U6YTgxZjAwYzg2YjY0NDJlM2I0ZWVkNTliNTI5ZjY4MGVfMTctMi0xLTEtNDY4OTE_d18c6200-3c45-4b11-8b4e-51ea3bce60c8"
      unitRef="usd">-37620000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i56599386fa47443a8975bb3f7a6a8c57_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xOS9mcmFnOjA2ZWYwNzk4YTBlODRlMjRhODJiNTcxNWU1YmRmMjU1L3RhYmxlOmE4MWYwMGM4NmI2NDQyZTNiNGVlZDU5YjUyOWY2ODBlL3RhYmxlcmFuZ2U6YTgxZjAwYzg2YjY0NDJlM2I0ZWVkNTliNTI5ZjY4MGVfMTctNC0xLTEtNDY4OTE_ce4af9c0-20a8-42e9-a5e8-a8f983917a69"
      unitRef="usd">-50371000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xOS9mcmFnOjA2ZWYwNzk4YTBlODRlMjRhODJiNTcxNWU1YmRmMjU1L3RhYmxlOmE4MWYwMGM4NmI2NDQyZTNiNGVlZDU5YjUyOWY2ODBlL3RhYmxlcmFuZ2U6YTgxZjAwYzg2YjY0NDJlM2I0ZWVkNTliNTI5ZjY4MGVfMTgtMi0xLTEtNDY4OTE_f39e9a53-8400-4ffc-8374-4994149debfc"
      unitRef="usd">10000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i56599386fa47443a8975bb3f7a6a8c57_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xOS9mcmFnOjA2ZWYwNzk4YTBlODRlMjRhODJiNTcxNWU1YmRmMjU1L3RhYmxlOmE4MWYwMGM4NmI2NDQyZTNiNGVlZDU5YjUyOWY2ODBlL3RhYmxlcmFuZ2U6YTgxZjAwYzg2YjY0NDJlM2I0ZWVkNTliNTI5ZjY4MGVfMTgtNC0xLTEtNDY4OTE_c7ffd45b-972c-42e0-923c-a5ef9a7da933"
      unitRef="usd">8000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xOS9mcmFnOjA2ZWYwNzk4YTBlODRlMjRhODJiNTcxNWU1YmRmMjU1L3RhYmxlOmE4MWYwMGM4NmI2NDQyZTNiNGVlZDU5YjUyOWY2ODBlL3RhYmxlcmFuZ2U6YTgxZjAwYzg2YjY0NDJlM2I0ZWVkNTliNTI5ZjY4MGVfMTktMi0xLTEtNDY4OTE_6ac9ab29-7f15-4343-8494-ecfbaffe82b1"
      unitRef="usd">-37630000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i56599386fa47443a8975bb3f7a6a8c57_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xOS9mcmFnOjA2ZWYwNzk4YTBlODRlMjRhODJiNTcxNWU1YmRmMjU1L3RhYmxlOmE4MWYwMGM4NmI2NDQyZTNiNGVlZDU5YjUyOWY2ODBlL3RhYmxlcmFuZ2U6YTgxZjAwYzg2YjY0NDJlM2I0ZWVkNTliNTI5ZjY4MGVfMTktNC0xLTEtNDY4OTE_0d63b369-faef-472b-80a7-2b877d7d527e"
      unitRef="usd">-50379000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax
      contextRef="i56599386fa47443a8975bb3f7a6a8c57_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xOS9mcmFnOjA2ZWYwNzk4YTBlODRlMjRhODJiNTcxNWU1YmRmMjU1L3RhYmxlOmE4MWYwMGM4NmI2NDQyZTNiNGVlZDU5YjUyOWY2ODBlL3RhYmxlcmFuZ2U6YTgxZjAwYzg2YjY0NDJlM2I0ZWVkNTliNTI5ZjY4MGVfMjEtMC0xLTEtNDY4OTEvdGV4dHJlZ2lvbjoxN2M4OTQzMjJmZjg0Mjc0OTNhYWQzZmQxOGU0MjJlN183NQ_1e3f377e-175e-4fcf-a1e9-e1052ec7698b"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax
      contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xOS9mcmFnOjA2ZWYwNzk4YTBlODRlMjRhODJiNTcxNWU1YmRmMjU1L3RhYmxlOmE4MWYwMGM4NmI2NDQyZTNiNGVlZDU5YjUyOWY2ODBlL3RhYmxlcmFuZ2U6YTgxZjAwYzg2YjY0NDJlM2I0ZWVkNTliNTI5ZjY4MGVfMjEtMC0xLTEtNDY4OTEvdGV4dHJlZ2lvbjoxN2M4OTQzMjJmZjg0Mjc0OTNhYWQzZmQxOGU0MjJlN183NQ_d4682284-a245-41cd-9277-4d50df7fb4be"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xOS9mcmFnOjA2ZWYwNzk4YTBlODRlMjRhODJiNTcxNWU1YmRmMjU1L3RhYmxlOmE4MWYwMGM4NmI2NDQyZTNiNGVlZDU5YjUyOWY2ODBlL3RhYmxlcmFuZ2U6YTgxZjAwYzg2YjY0NDJlM2I0ZWVkNTliNTI5ZjY4MGVfMjEtMi0xLTEtNDY4OTE_a78c72f4-16d8-470e-ad9a-0a1a3ff3e2bc"
      unitRef="usd">-766000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i56599386fa47443a8975bb3f7a6a8c57_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xOS9mcmFnOjA2ZWYwNzk4YTBlODRlMjRhODJiNTcxNWU1YmRmMjU1L3RhYmxlOmE4MWYwMGM4NmI2NDQyZTNiNGVlZDU5YjUyOWY2ODBlL3RhYmxlcmFuZ2U6YTgxZjAwYzg2YjY0NDJlM2I0ZWVkNTliNTI5ZjY4MGVfMjEtNC0xLTEtNDY4OTE_db2bc88f-fe82-4db7-b6b9-fb9a1f76579d"
      unitRef="usd">6000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xOS9mcmFnOjA2ZWYwNzk4YTBlODRlMjRhODJiNTcxNWU1YmRmMjU1L3RhYmxlOmE4MWYwMGM4NmI2NDQyZTNiNGVlZDU5YjUyOWY2ODBlL3RhYmxlcmFuZ2U6YTgxZjAwYzg2YjY0NDJlM2I0ZWVkNTliNTI5ZjY4MGVfMjItMi0xLTEtNDY4OTE_b8df8f16-00ec-4a31-b05d-d539fb46fe7f"
      unitRef="usd">-38396000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i56599386fa47443a8975bb3f7a6a8c57_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xOS9mcmFnOjA2ZWYwNzk4YTBlODRlMjRhODJiNTcxNWU1YmRmMjU1L3RhYmxlOmE4MWYwMGM4NmI2NDQyZTNiNGVlZDU5YjUyOWY2ODBlL3RhYmxlcmFuZ2U6YTgxZjAwYzg2YjY0NDJlM2I0ZWVkNTliNTI5ZjY4MGVfMjItNC0xLTEtNDY4OTE_5c6e3640-7e08-43fe-bccb-964847e12150"
      unitRef="usd">-50373000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareBasic
      contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xOS9mcmFnOjA2ZWYwNzk4YTBlODRlMjRhODJiNTcxNWU1YmRmMjU1L3RhYmxlOmE4MWYwMGM4NmI2NDQyZTNiNGVlZDU5YjUyOWY2ODBlL3RhYmxlcmFuZ2U6YTgxZjAwYzg2YjY0NDJlM2I0ZWVkNTliNTI5ZjY4MGVfMjMtMi0xLTEtNDY4OTE_26db01ce-09b9-4be6-b2bb-72394cd25e91"
      unitRef="usdPerShare">-0.27</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xOS9mcmFnOjA2ZWYwNzk4YTBlODRlMjRhODJiNTcxNWU1YmRmMjU1L3RhYmxlOmE4MWYwMGM4NmI2NDQyZTNiNGVlZDU5YjUyOWY2ODBlL3RhYmxlcmFuZ2U6YTgxZjAwYzg2YjY0NDJlM2I0ZWVkNTliNTI5ZjY4MGVfMjMtMi0xLTEtNDY4OTE_ee9c1b3b-7795-487a-ac85-fc59066ce615"
      unitRef="usdPerShare">-0.27</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i56599386fa47443a8975bb3f7a6a8c57_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xOS9mcmFnOjA2ZWYwNzk4YTBlODRlMjRhODJiNTcxNWU1YmRmMjU1L3RhYmxlOmE4MWYwMGM4NmI2NDQyZTNiNGVlZDU5YjUyOWY2ODBlL3RhYmxlcmFuZ2U6YTgxZjAwYzg2YjY0NDJlM2I0ZWVkNTliNTI5ZjY4MGVfMjMtNC0xLTEtNDY4OTE_6a5c9688-627f-450e-b9dd-161ad682d9a8"
      unitRef="usdPerShare">-0.40</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i56599386fa47443a8975bb3f7a6a8c57_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xOS9mcmFnOjA2ZWYwNzk4YTBlODRlMjRhODJiNTcxNWU1YmRmMjU1L3RhYmxlOmE4MWYwMGM4NmI2NDQyZTNiNGVlZDU5YjUyOWY2ODBlL3RhYmxlcmFuZ2U6YTgxZjAwYzg2YjY0NDJlM2I0ZWVkNTliNTI5ZjY4MGVfMjMtNC0xLTEtNDY4OTE_e012714c-63bc-4814-872b-7e1def5e0d90"
      unitRef="usdPerShare">-0.40</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xOS9mcmFnOjA2ZWYwNzk4YTBlODRlMjRhODJiNTcxNWU1YmRmMjU1L3RhYmxlOmE4MWYwMGM4NmI2NDQyZTNiNGVlZDU5YjUyOWY2ODBlL3RhYmxlcmFuZ2U6YTgxZjAwYzg2YjY0NDJlM2I0ZWVkNTliNTI5ZjY4MGVfMjQtMi0xLTEtNDY4OTE_342538a5-4abe-486e-97b8-17d9cf1d2bab"
      unitRef="shares">141675000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xOS9mcmFnOjA2ZWYwNzk4YTBlODRlMjRhODJiNTcxNWU1YmRmMjU1L3RhYmxlOmE4MWYwMGM4NmI2NDQyZTNiNGVlZDU5YjUyOWY2ODBlL3RhYmxlcmFuZ2U6YTgxZjAwYzg2YjY0NDJlM2I0ZWVkNTliNTI5ZjY4MGVfMjQtMi0xLTEtNDY4OTE_6147aa37-f6b8-4a0d-aaea-2ec3d8b80492"
      unitRef="shares">141675000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i56599386fa47443a8975bb3f7a6a8c57_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xOS9mcmFnOjA2ZWYwNzk4YTBlODRlMjRhODJiNTcxNWU1YmRmMjU1L3RhYmxlOmE4MWYwMGM4NmI2NDQyZTNiNGVlZDU5YjUyOWY2ODBlL3RhYmxlcmFuZ2U6YTgxZjAwYzg2YjY0NDJlM2I0ZWVkNTliNTI5ZjY4MGVfMjQtNC0xLTEtNDY4OTE_608cff76-b0d9-4ef1-846a-ac66460ee841"
      unitRef="shares">127401000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i56599386fa47443a8975bb3f7a6a8c57_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8xOS9mcmFnOjA2ZWYwNzk4YTBlODRlMjRhODJiNTcxNWU1YmRmMjU1L3RhYmxlOmE4MWYwMGM4NmI2NDQyZTNiNGVlZDU5YjUyOWY2ODBlL3RhYmxlcmFuZ2U6YTgxZjAwYzg2YjY0NDJlM2I0ZWVkNTliNTI5ZjY4MGVfMjQtNC0xLTEtNDY4OTE_80803525-c7ec-4166-b3aa-da0462874adf"
      unitRef="shares">127401000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i61d2ecb1315b47b48046b2cc2d26a3f4_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yMi9mcmFnOjYxMTdlMmQxMDAwYTQyNjRiZDM4ODA2OTRlY2IwNzJmL3RhYmxlOmYyNGY0YzM1ZjI4MDRjZWI4YWEwOTkxYjFlM2E3YWNmL3RhYmxlcmFuZ2U6ZjI0ZjRjMzVmMjgwNGNlYjhhYTA5OTFiMWUzYTdhY2ZfMi0yLTEtMS00Njg5MQ_72d88b53-9236-434b-b6a0-52b015c3a6ff"
      unitRef="shares">141600000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i61d2ecb1315b47b48046b2cc2d26a3f4_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yMi9mcmFnOjYxMTdlMmQxMDAwYTQyNjRiZDM4ODA2OTRlY2IwNzJmL3RhYmxlOmYyNGY0YzM1ZjI4MDRjZWI4YWEwOTkxYjFlM2E3YWNmL3RhYmxlcmFuZ2U6ZjI0ZjRjMzVmMjgwNGNlYjhhYTA5OTFiMWUzYTdhY2ZfMi00LTEtMS00Njg5MQ_5aef5401-dca4-496d-98e6-90ec1fdfc611"
      unitRef="usd">1177051000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ibc985adebb4d4146be71a1355b404db9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yMi9mcmFnOjYxMTdlMmQxMDAwYTQyNjRiZDM4ODA2OTRlY2IwNzJmL3RhYmxlOmYyNGY0YzM1ZjI4MDRjZWI4YWEwOTkxYjFlM2E3YWNmL3RhYmxlcmFuZ2U6ZjI0ZjRjMzVmMjgwNGNlYjhhYTA5OTFiMWUzYTdhY2ZfMi02LTEtMS00Njg5MQ_aaf2c995-24b6-456b-a8ba-32edbda8f6e8"
      unitRef="usd">59014000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4141e328567a4e2f84032e5f733bf3a6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yMi9mcmFnOjYxMTdlMmQxMDAwYTQyNjRiZDM4ODA2OTRlY2IwNzJmL3RhYmxlOmYyNGY0YzM1ZjI4MDRjZWI4YWEwOTkxYjFlM2E3YWNmL3RhYmxlcmFuZ2U6ZjI0ZjRjMzVmMjgwNGNlYjhhYTA5OTFiMWUzYTdhY2ZfMi04LTEtMS00Njg5MQ_2db4faf3-9dfe-4b67-b7aa-13a00b8023b9"
      unitRef="usd">-852000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ieebe2ef8481d495ea52a69991654df61_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yMi9mcmFnOjYxMTdlMmQxMDAwYTQyNjRiZDM4ODA2OTRlY2IwNzJmL3RhYmxlOmYyNGY0YzM1ZjI4MDRjZWI4YWEwOTkxYjFlM2E3YWNmL3RhYmxlcmFuZ2U6ZjI0ZjRjMzVmMjgwNGNlYjhhYTA5OTFiMWUzYTdhY2ZfMi0xMC0xLTEtNDY4OTE_426cf8c1-1998-4413-9fd1-05961d69c5e9"
      unitRef="usd">-756122000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i784f65549351439fa4b7bedf90ce7e3f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yMi9mcmFnOjYxMTdlMmQxMDAwYTQyNjRiZDM4ODA2OTRlY2IwNzJmL3RhYmxlOmYyNGY0YzM1ZjI4MDRjZWI4YWEwOTkxYjFlM2E3YWNmL3RhYmxlcmFuZ2U6ZjI0ZjRjMzVmMjgwNGNlYjhhYTA5OTFiMWUzYTdhY2ZfMi0xMi0xLTEtNDY4OTE_91aa15f8-8576-46d1-898b-e233ccce3ed5"
      unitRef="usd">479091000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ic38a142e678c4e85a1b730ee6415c5c0_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yMi9mcmFnOjYxMTdlMmQxMDAwYTQyNjRiZDM4ODA2OTRlY2IwNzJmL3RhYmxlOmYyNGY0YzM1ZjI4MDRjZWI4YWEwOTkxYjFlM2E3YWNmL3RhYmxlcmFuZ2U6ZjI0ZjRjMzVmMjgwNGNlYjhhYTA5OTFiMWUzYTdhY2ZfMy0yLTEtMS00Njg5MQ_ebf8f39c-1ce9-45d9-bdc2-00d998198a0b"
      unitRef="shares">142000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ic38a142e678c4e85a1b730ee6415c5c0_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yMi9mcmFnOjYxMTdlMmQxMDAwYTQyNjRiZDM4ODA2OTRlY2IwNzJmL3RhYmxlOmYyNGY0YzM1ZjI4MDRjZWI4YWEwOTkxYjFlM2E3YWNmL3RhYmxlcmFuZ2U6ZjI0ZjRjMzVmMjgwNGNlYjhhYTA5OTFiMWUzYTdhY2ZfMy00LTEtMS00Njg5MQ_6025514e-56bd-4b0c-af63-c2867b2ca6e4"
      unitRef="usd">1756000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i76345d0397ef41589260147ade867835_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yMi9mcmFnOjYxMTdlMmQxMDAwYTQyNjRiZDM4ODA2OTRlY2IwNzJmL3RhYmxlOmYyNGY0YzM1ZjI4MDRjZWI4YWEwOTkxYjFlM2E3YWNmL3RhYmxlcmFuZ2U6ZjI0ZjRjMzVmMjgwNGNlYjhhYTA5OTFiMWUzYTdhY2ZfMy02LTEtMS00Njg5MQ_21cc72d0-09b3-4274-a42b-70468eea031f"
      unitRef="usd">-1351000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yMi9mcmFnOjYxMTdlMmQxMDAwYTQyNjRiZDM4ODA2OTRlY2IwNzJmL3RhYmxlOmYyNGY0YzM1ZjI4MDRjZWI4YWEwOTkxYjFlM2E3YWNmL3RhYmxlcmFuZ2U6ZjI0ZjRjMzVmMjgwNGNlYjhhYTA5OTFiMWUzYTdhY2ZfMy0xMi0xLTEtNDY4OTE_2095025c-236e-4f61-87fa-19e1b87d2de4"
      unitRef="usd">405000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i76345d0397ef41589260147ade867835_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yMi9mcmFnOjYxMTdlMmQxMDAwYTQyNjRiZDM4ODA2OTRlY2IwNzJmL3RhYmxlOmYyNGY0YzM1ZjI4MDRjZWI4YWEwOTkxYjFlM2E3YWNmL3RhYmxlcmFuZ2U6ZjI0ZjRjMzVmMjgwNGNlYjhhYTA5OTFiMWUzYTdhY2ZfNC02LTEtMS00Njg5MQ_04c121f0-51b2-4bff-8d5a-71c362a16342"
      unitRef="usd">7023000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yMi9mcmFnOjYxMTdlMmQxMDAwYTQyNjRiZDM4ODA2OTRlY2IwNzJmL3RhYmxlOmYyNGY0YzM1ZjI4MDRjZWI4YWEwOTkxYjFlM2E3YWNmL3RhYmxlcmFuZ2U6ZjI0ZjRjMzVmMjgwNGNlYjhhYTA5OTFiMWUzYTdhY2ZfNC0xMi0xLTEtNDY4OTE_ae94930f-279f-4eeb-8883-f8d6d57fe867"
      unitRef="usd">7023000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i33e38a2732764762b66982ec4717a1b2_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yMi9mcmFnOjYxMTdlMmQxMDAwYTQyNjRiZDM4ODA2OTRlY2IwNzJmL3RhYmxlOmYyNGY0YzM1ZjI4MDRjZWI4YWEwOTkxYjFlM2E3YWNmL3RhYmxlcmFuZ2U6ZjI0ZjRjMzVmMjgwNGNlYjhhYTA5OTFiMWUzYTdhY2ZfNS04LTEtMS00Njg5MQ_c7f2d4a0-aa8a-40cd-84b6-68ed96f34944"
      unitRef="usd">-766000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yMi9mcmFnOjYxMTdlMmQxMDAwYTQyNjRiZDM4ODA2OTRlY2IwNzJmL3RhYmxlOmYyNGY0YzM1ZjI4MDRjZWI4YWEwOTkxYjFlM2E3YWNmL3RhYmxlcmFuZ2U6ZjI0ZjRjMzVmMjgwNGNlYjhhYTA5OTFiMWUzYTdhY2ZfNS0xMi0xLTEtNDY4OTE_1fc2e9b5-5020-4e5c-a3ad-01e818384d71"
      unitRef="usd">-766000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="i7f565b8d63fc448ba775e2bac6da89d9_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yMi9mcmFnOjYxMTdlMmQxMDAwYTQyNjRiZDM4ODA2OTRlY2IwNzJmL3RhYmxlOmYyNGY0YzM1ZjI4MDRjZWI4YWEwOTkxYjFlM2E3YWNmL3RhYmxlcmFuZ2U6ZjI0ZjRjMzVmMjgwNGNlYjhhYTA5OTFiMWUzYTdhY2ZfNy0xMC0xLTEtNDY4OTE_4530f302-ea4f-43f1-ae58-d7e727c8879f"
      unitRef="usd">-37630000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yMi9mcmFnOjYxMTdlMmQxMDAwYTQyNjRiZDM4ODA2OTRlY2IwNzJmL3RhYmxlOmYyNGY0YzM1ZjI4MDRjZWI4YWEwOTkxYjFlM2E3YWNmL3RhYmxlcmFuZ2U6ZjI0ZjRjMzVmMjgwNGNlYjhhYTA5OTFiMWUzYTdhY2ZfNy0xMi0xLTEtNDY4OTE_30fbe2af-1fc0-4c62-9dc6-c5887dd0dfae"
      unitRef="usd">-37630000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="id1291b626776443495f8c67d0b44222b_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yMi9mcmFnOjYxMTdlMmQxMDAwYTQyNjRiZDM4ODA2OTRlY2IwNzJmL3RhYmxlOmYyNGY0YzM1ZjI4MDRjZWI4YWEwOTkxYjFlM2E3YWNmL3RhYmxlcmFuZ2U6ZjI0ZjRjMzVmMjgwNGNlYjhhYTA5OTFiMWUzYTdhY2ZfOC0yLTEtMS00Njg5MQ_54e91b3b-d336-4c75-b7ae-5e6f737a76db"
      unitRef="shares">141742000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="id1291b626776443495f8c67d0b44222b_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yMi9mcmFnOjYxMTdlMmQxMDAwYTQyNjRiZDM4ODA2OTRlY2IwNzJmL3RhYmxlOmYyNGY0YzM1ZjI4MDRjZWI4YWEwOTkxYjFlM2E3YWNmL3RhYmxlcmFuZ2U6ZjI0ZjRjMzVmMjgwNGNlYjhhYTA5OTFiMWUzYTdhY2ZfOC00LTEtMS00Njg5MQ_5e01fde3-6829-46f1-bde1-cbb1dbf7d939"
      unitRef="usd">1178807000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie8ed19e5e01745febb700f621d5350bd_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yMi9mcmFnOjYxMTdlMmQxMDAwYTQyNjRiZDM4ODA2OTRlY2IwNzJmL3RhYmxlOmYyNGY0YzM1ZjI4MDRjZWI4YWEwOTkxYjFlM2E3YWNmL3RhYmxlcmFuZ2U6ZjI0ZjRjMzVmMjgwNGNlYjhhYTA5OTFiMWUzYTdhY2ZfOC02LTEtMS00Njg5MQ_592264d0-a6ca-4b1f-a149-d4803efe930f"
      unitRef="usd">64686000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4bfaf26bef40473cbb8aa323aa9dbf99_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yMi9mcmFnOjYxMTdlMmQxMDAwYTQyNjRiZDM4ODA2OTRlY2IwNzJmL3RhYmxlOmYyNGY0YzM1ZjI4MDRjZWI4YWEwOTkxYjFlM2E3YWNmL3RhYmxlcmFuZ2U6ZjI0ZjRjMzVmMjgwNGNlYjhhYTA5OTFiMWUzYTdhY2ZfOC04LTEtMS00Njg5MQ_f12590cb-e3ea-41d1-b00b-6511b41461b2"
      unitRef="usd">-1618000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7607dc50eb3d4d29b612005eb9d96af6_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yMi9mcmFnOjYxMTdlMmQxMDAwYTQyNjRiZDM4ODA2OTRlY2IwNzJmL3RhYmxlOmYyNGY0YzM1ZjI4MDRjZWI4YWEwOTkxYjFlM2E3YWNmL3RhYmxlcmFuZ2U6ZjI0ZjRjMzVmMjgwNGNlYjhhYTA5OTFiMWUzYTdhY2ZfOC0xMC0xLTEtNDY4OTE_4b576531-aae3-4580-836a-64da13ba8d67"
      unitRef="usd">-793752000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id7882ae6aff54a3aacdef67ddf11a428_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yMi9mcmFnOjYxMTdlMmQxMDAwYTQyNjRiZDM4ODA2OTRlY2IwNzJmL3RhYmxlOmYyNGY0YzM1ZjI4MDRjZWI4YWEwOTkxYjFlM2E3YWNmL3RhYmxlcmFuZ2U6ZjI0ZjRjMzVmMjgwNGNlYjhhYTA5OTFiMWUzYTdhY2ZfOC0xMi0xLTEtNDY4OTE_2b0c817c-0b14-441c-bd71-467d9f8bd8f8"
      unitRef="usd">448123000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i83ebb56fc7614da58997add4fc4d898e_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yMi9mcmFnOjYxMTdlMmQxMDAwYTQyNjRiZDM4ODA2OTRlY2IwNzJmL3RhYmxlOmYyNGY0YzM1ZjI4MDRjZWI4YWEwOTkxYjFlM2E3YWNmL3RhYmxlcmFuZ2U6ZjI0ZjRjMzVmMjgwNGNlYjhhYTA5OTFiMWUzYTdhY2ZfMTItMi0xLTEtNDY4OTE_d9002037-d7f0-4e61-88dc-28a0a7421e29"
      unitRef="shares">126725000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i83ebb56fc7614da58997add4fc4d898e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yMi9mcmFnOjYxMTdlMmQxMDAwYTQyNjRiZDM4ODA2OTRlY2IwNzJmL3RhYmxlOmYyNGY0YzM1ZjI4MDRjZWI4YWEwOTkxYjFlM2E3YWNmL3RhYmxlcmFuZ2U6ZjI0ZjRjMzVmMjgwNGNlYjhhYTA5OTFiMWUzYTdhY2ZfMTItNC0xLTEtNDY4OTE_ca19b015-759b-45e8-b1f1-af1a5c095072"
      unitRef="usd">944328000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i52d7b06be2c943d9943aab7a9199636b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yMi9mcmFnOjYxMTdlMmQxMDAwYTQyNjRiZDM4ODA2OTRlY2IwNzJmL3RhYmxlOmYyNGY0YzM1ZjI4MDRjZWI4YWEwOTkxYjFlM2E3YWNmL3RhYmxlcmFuZ2U6ZjI0ZjRjMzVmMjgwNGNlYjhhYTA5OTFiMWUzYTdhY2ZfMTItNi0xLTEtNDY4OTE_a2526309-ff28-4fda-9678-b94304b455c5"
      unitRef="usd">39383000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="icd1c1d725ea74622ad8c60cbfb9c0470_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yMi9mcmFnOjYxMTdlMmQxMDAwYTQyNjRiZDM4ODA2OTRlY2IwNzJmL3RhYmxlOmYyNGY0YzM1ZjI4MDRjZWI4YWEwOTkxYjFlM2E3YWNmL3RhYmxlcmFuZ2U6ZjI0ZjRjMzVmMjgwNGNlYjhhYTA5OTFiMWUzYTdhY2ZfMTItOC0xLTEtNDY4OTE_90e91ca5-ba58-4e7b-a04e-f4c21dc1d422"
      unitRef="usd">-805000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i14fc3af75b3846e58ef3a457eee1c040_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yMi9mcmFnOjYxMTdlMmQxMDAwYTQyNjRiZDM4ODA2OTRlY2IwNzJmL3RhYmxlOmYyNGY0YzM1ZjI4MDRjZWI4YWEwOTkxYjFlM2E3YWNmL3RhYmxlcmFuZ2U6ZjI0ZjRjMzVmMjgwNGNlYjhhYTA5OTFiMWUzYTdhY2ZfMTItMTAtMS0xLTQ2ODkx_bdd1cbf7-992f-477d-babe-ae55d4590a95"
      unitRef="usd">-575156000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i52aa203b7e954d69b001129473620362_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yMi9mcmFnOjYxMTdlMmQxMDAwYTQyNjRiZDM4ODA2OTRlY2IwNzJmL3RhYmxlOmYyNGY0YzM1ZjI4MDRjZWI4YWEwOTkxYjFlM2E3YWNmL3RhYmxlcmFuZ2U6ZjI0ZjRjMzVmMjgwNGNlYjhhYTA5OTFiMWUzYTdhY2ZfMTItMTItMS0xLTQ2ODkx_01cbfeaa-a733-4e41-b07b-469735a50fcc"
      unitRef="usd">407750000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="id2b8ec5b433843479fee7e7d7ae9434b_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yMi9mcmFnOjYxMTdlMmQxMDAwYTQyNjRiZDM4ODA2OTRlY2IwNzJmL3RhYmxlOmYyNGY0YzM1ZjI4MDRjZWI4YWEwOTkxYjFlM2E3YWNmL3RhYmxlcmFuZ2U6ZjI0ZjRjMzVmMjgwNGNlYjhhYTA5OTFiMWUzYTdhY2ZfMTMtMi0xLTEtNDY4OTE_106b2396-3b9c-45e6-87f4-6b51c2da6d57"
      unitRef="shares">877000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="id2b8ec5b433843479fee7e7d7ae9434b_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yMi9mcmFnOjYxMTdlMmQxMDAwYTQyNjRiZDM4ODA2OTRlY2IwNzJmL3RhYmxlOmYyNGY0YzM1ZjI4MDRjZWI4YWEwOTkxYjFlM2E3YWNmL3RhYmxlcmFuZ2U6ZjI0ZjRjMzVmMjgwNGNlYjhhYTA5OTFiMWUzYTdhY2ZfMTMtNC0xLTEtNDY4OTE_afc2d889-c02d-42b9-9da6-f63e8ae25155"
      unitRef="usd">7619000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i980c28f6b4b34116a0110c4e8f58bea5_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yMi9mcmFnOjYxMTdlMmQxMDAwYTQyNjRiZDM4ODA2OTRlY2IwNzJmL3RhYmxlOmYyNGY0YzM1ZjI4MDRjZWI4YWEwOTkxYjFlM2E3YWNmL3RhYmxlcmFuZ2U6ZjI0ZjRjMzVmMjgwNGNlYjhhYTA5OTFiMWUzYTdhY2ZfMTMtNi0xLTEtNDY4OTE_222cbe33-5615-4eec-bf4c-344fe79732d9"
      unitRef="usd">-2620000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i56599386fa47443a8975bb3f7a6a8c57_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yMi9mcmFnOjYxMTdlMmQxMDAwYTQyNjRiZDM4ODA2OTRlY2IwNzJmL3RhYmxlOmYyNGY0YzM1ZjI4MDRjZWI4YWEwOTkxYjFlM2E3YWNmL3RhYmxlcmFuZ2U6ZjI0ZjRjMzVmMjgwNGNlYjhhYTA5OTFiMWUzYTdhY2ZfMTMtMTItMS0xLTQ2ODkx_e51bf58e-5034-49ef-96f4-a5171ecf9795"
      unitRef="usd">4999000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="id2b8ec5b433843479fee7e7d7ae9434b_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yMi9mcmFnOjYxMTdlMmQxMDAwYTQyNjRiZDM4ODA2OTRlY2IwNzJmL3RhYmxlOmYyNGY0YzM1ZjI4MDRjZWI4YWEwOTkxYjFlM2E3YWNmL3RhYmxlcmFuZ2U6ZjI0ZjRjMzVmMjgwNGNlYjhhYTA5OTFiMWUzYTdhY2ZfMTQtMi0xLTEtNDY4OTE_18895764-6130-409b-8fb4-80a0824ff7cc"
      unitRef="shares">519000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants
      contextRef="id2b8ec5b433843479fee7e7d7ae9434b_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yMi9mcmFnOjYxMTdlMmQxMDAwYTQyNjRiZDM4ODA2OTRlY2IwNzJmL3RhYmxlOmYyNGY0YzM1ZjI4MDRjZWI4YWEwOTkxYjFlM2E3YWNmL3RhYmxlcmFuZ2U6ZjI0ZjRjMzVmMjgwNGNlYjhhYTA5OTFiMWUzYTdhY2ZfMTQtNC0xLTEtNDY4OTE_f7aca47c-edd7-41ca-b18f-fca5605178c8"
      unitRef="usd">726000</us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants>
    <us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants
      contextRef="i980c28f6b4b34116a0110c4e8f58bea5_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yMi9mcmFnOjYxMTdlMmQxMDAwYTQyNjRiZDM4ODA2OTRlY2IwNzJmL3RhYmxlOmYyNGY0YzM1ZjI4MDRjZWI4YWEwOTkxYjFlM2E3YWNmL3RhYmxlcmFuZ2U6ZjI0ZjRjMzVmMjgwNGNlYjhhYTA5OTFiMWUzYTdhY2ZfMTQtNi0xLTEtNDY4OTE_6094795b-fae5-4e7b-9100-add4eb5a3442"
      unitRef="usd">-695000</us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants>
    <us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants
      contextRef="i56599386fa47443a8975bb3f7a6a8c57_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yMi9mcmFnOjYxMTdlMmQxMDAwYTQyNjRiZDM4ODA2OTRlY2IwNzJmL3RhYmxlOmYyNGY0YzM1ZjI4MDRjZWI4YWEwOTkxYjFlM2E3YWNmL3RhYmxlcmFuZ2U6ZjI0ZjRjMzVmMjgwNGNlYjhhYTA5OTFiMWUzYTdhY2ZfMTQtMTItMS0xLTQ2ODkx_5899b5d5-2eff-4632-beb2-fa88caf81838"
      unitRef="usd">31000</us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i980c28f6b4b34116a0110c4e8f58bea5_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yMi9mcmFnOjYxMTdlMmQxMDAwYTQyNjRiZDM4ODA2OTRlY2IwNzJmL3RhYmxlOmYyNGY0YzM1ZjI4MDRjZWI4YWEwOTkxYjFlM2E3YWNmL3RhYmxlcmFuZ2U6ZjI0ZjRjMzVmMjgwNGNlYjhhYTA5OTFiMWUzYTdhY2ZfMTUtNi0xLTEtNDY4OTE_dfc95d69-e0bf-4d07-9106-b194acf646f9"
      unitRef="usd">7821000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i56599386fa47443a8975bb3f7a6a8c57_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yMi9mcmFnOjYxMTdlMmQxMDAwYTQyNjRiZDM4ODA2OTRlY2IwNzJmL3RhYmxlOmYyNGY0YzM1ZjI4MDRjZWI4YWEwOTkxYjFlM2E3YWNmL3RhYmxlcmFuZ2U6ZjI0ZjRjMzVmMjgwNGNlYjhhYTA5OTFiMWUzYTdhY2ZfMTUtMTItMS0xLTQ2ODkx_4e892362-8e66-4946-930c-a1a24d0050de"
      unitRef="usd">7821000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="idf2709893482407e9aa1a24504869283_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yMi9mcmFnOjYxMTdlMmQxMDAwYTQyNjRiZDM4ODA2OTRlY2IwNzJmL3RhYmxlOmYyNGY0YzM1ZjI4MDRjZWI4YWEwOTkxYjFlM2E3YWNmL3RhYmxlcmFuZ2U6ZjI0ZjRjMzVmMjgwNGNlYjhhYTA5OTFiMWUzYTdhY2ZfMTYtOC0xLTEtNDY4OTE_58c9d5f4-da81-4697-9fb3-8859a80023df"
      unitRef="usd">6000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i56599386fa47443a8975bb3f7a6a8c57_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yMi9mcmFnOjYxMTdlMmQxMDAwYTQyNjRiZDM4ODA2OTRlY2IwNzJmL3RhYmxlOmYyNGY0YzM1ZjI4MDRjZWI4YWEwOTkxYjFlM2E3YWNmL3RhYmxlcmFuZ2U6ZjI0ZjRjMzVmMjgwNGNlYjhhYTA5OTFiMWUzYTdhY2ZfMTYtMTItMS0xLTQ2ODkx_552698c4-eaad-495d-8a36-1992951b8d43"
      unitRef="usd">6000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="if37f87c2e8144a4ea775f7bcf996abdb_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yMi9mcmFnOjYxMTdlMmQxMDAwYTQyNjRiZDM4ODA2OTRlY2IwNzJmL3RhYmxlOmYyNGY0YzM1ZjI4MDRjZWI4YWEwOTkxYjFlM2E3YWNmL3RhYmxlcmFuZ2U6ZjI0ZjRjMzVmMjgwNGNlYjhhYTA5OTFiMWUzYTdhY2ZfMTctMTAtMS0xLTQ2ODkx_d3ee49b8-5d8e-4d60-bfcb-cae6eb334117"
      unitRef="usd">-50379000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i56599386fa47443a8975bb3f7a6a8c57_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yMi9mcmFnOjYxMTdlMmQxMDAwYTQyNjRiZDM4ODA2OTRlY2IwNzJmL3RhYmxlOmYyNGY0YzM1ZjI4MDRjZWI4YWEwOTkxYjFlM2E3YWNmL3RhYmxlcmFuZ2U6ZjI0ZjRjMzVmMjgwNGNlYjhhYTA5OTFiMWUzYTdhY2ZfMTctMTItMS0xLTQ2ODkx_e9ed88ec-956e-4f0c-b55f-e35942cba274"
      unitRef="usd">-50379000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ida3e66f3cb8a46fd8e7d2fa464feee4b_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yMi9mcmFnOjYxMTdlMmQxMDAwYTQyNjRiZDM4ODA2OTRlY2IwNzJmL3RhYmxlOmYyNGY0YzM1ZjI4MDRjZWI4YWEwOTkxYjFlM2E3YWNmL3RhYmxlcmFuZ2U6ZjI0ZjRjMzVmMjgwNGNlYjhhYTA5OTFiMWUzYTdhY2ZfMTgtMi0xLTEtNDY4OTE_2d7f5bd6-8215-478a-af9a-11d53161c867"
      unitRef="shares">128121000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ida3e66f3cb8a46fd8e7d2fa464feee4b_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yMi9mcmFnOjYxMTdlMmQxMDAwYTQyNjRiZDM4ODA2OTRlY2IwNzJmL3RhYmxlOmYyNGY0YzM1ZjI4MDRjZWI4YWEwOTkxYjFlM2E3YWNmL3RhYmxlcmFuZ2U6ZjI0ZjRjMzVmMjgwNGNlYjhhYTA5OTFiMWUzYTdhY2ZfMTgtNC0xLTEtNDY4OTE_172eff61-cb29-46d6-bb41-48ddf3087aac"
      unitRef="usd">952673000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="icee959888619433fa3bbb75703c9942a_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yMi9mcmFnOjYxMTdlMmQxMDAwYTQyNjRiZDM4ODA2OTRlY2IwNzJmL3RhYmxlOmYyNGY0YzM1ZjI4MDRjZWI4YWEwOTkxYjFlM2E3YWNmL3RhYmxlcmFuZ2U6ZjI0ZjRjMzVmMjgwNGNlYjhhYTA5OTFiMWUzYTdhY2ZfMTgtNi0xLTEtNDY4OTE_f2b94762-61b6-4a0e-bd32-0a64b84be78b"
      unitRef="usd">43889000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic279a1a852fa4d1c8cfc697be1c04112_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yMi9mcmFnOjYxMTdlMmQxMDAwYTQyNjRiZDM4ODA2OTRlY2IwNzJmL3RhYmxlOmYyNGY0YzM1ZjI4MDRjZWI4YWEwOTkxYjFlM2E3YWNmL3RhYmxlcmFuZ2U6ZjI0ZjRjMzVmMjgwNGNlYjhhYTA5OTFiMWUzYTdhY2ZfMTgtOC0xLTEtNDY4OTE_f60a28c6-b5c9-47d8-8530-c250a86d4693"
      unitRef="usd">-799000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i0bdfb000085746f589116096f0a92b19_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yMi9mcmFnOjYxMTdlMmQxMDAwYTQyNjRiZDM4ODA2OTRlY2IwNzJmL3RhYmxlOmYyNGY0YzM1ZjI4MDRjZWI4YWEwOTkxYjFlM2E3YWNmL3RhYmxlcmFuZ2U6ZjI0ZjRjMzVmMjgwNGNlYjhhYTA5OTFiMWUzYTdhY2ZfMTgtMTAtMS0xLTQ2ODkx_2888690c-d357-42cc-8fe3-899559df6a67"
      unitRef="usd">-625535000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i0260d11b47b2403fbf3efe386b4d6b0f_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yMi9mcmFnOjYxMTdlMmQxMDAwYTQyNjRiZDM4ODA2OTRlY2IwNzJmL3RhYmxlOmYyNGY0YzM1ZjI4MDRjZWI4YWEwOTkxYjFlM2E3YWNmL3RhYmxlcmFuZ2U6ZjI0ZjRjMzVmMjgwNGNlYjhhYTA5OTFiMWUzYTdhY2ZfMTgtMTItMS0xLTQ2ODkx_8824b434-2ec7-4b8b-a375-2611849d28cb"
      unitRef="usd">370228000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yNS9mcmFnOmZjZmRhMmQ4NmM2NTRiNjA5OTNkM2UxN2YzN2I0ZWE1L3RhYmxlOjlkMWYxMzljZjdjMzRiOGI5YzY3ODFmNWVmY2NhYmJjL3RhYmxlcmFuZ2U6OWQxZjEzOWNmN2MzNGI4YjljNjc4MWY1ZWZjY2FiYmNfNS0yLTEtMS00Njg5MQ_2c29e920-4e2a-4c45-a9eb-e8e17930730c"
      unitRef="usd">-37630000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i56599386fa47443a8975bb3f7a6a8c57_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yNS9mcmFnOmZjZmRhMmQ4NmM2NTRiNjA5OTNkM2UxN2YzN2I0ZWE1L3RhYmxlOjlkMWYxMzljZjdjMzRiOGI5YzY3ODFmNWVmY2NhYmJjL3RhYmxlcmFuZ2U6OWQxZjEzOWNmN2MzNGI4YjljNjc4MWY1ZWZjY2FiYmNfNS00LTEtMS00Njg5MQ_77ddcc9d-0356-442b-9b57-5c72891a16c8"
      unitRef="usd">-50379000</us-gaap:NetIncomeLoss>
    <us-gaap:Depreciation
      contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yNS9mcmFnOmZjZmRhMmQ4NmM2NTRiNjA5OTNkM2UxN2YzN2I0ZWE1L3RhYmxlOjlkMWYxMzljZjdjMzRiOGI5YzY3ODFmNWVmY2NhYmJjL3RhYmxlcmFuZ2U6OWQxZjEzOWNmN2MzNGI4YjljNjc4MWY1ZWZjY2FiYmNfNy0yLTEtMS00Njg5MQ_221d84ea-7c0e-4638-a5fd-e5bcfbc6862d"
      unitRef="usd">687000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i56599386fa47443a8975bb3f7a6a8c57_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yNS9mcmFnOmZjZmRhMmQ4NmM2NTRiNjA5OTNkM2UxN2YzN2I0ZWE1L3RhYmxlOjlkMWYxMzljZjdjMzRiOGI5YzY3ODFmNWVmY2NhYmJjL3RhYmxlcmFuZ2U6OWQxZjEzOWNmN2MzNGI4YjljNjc4MWY1ZWZjY2FiYmNfNy00LTEtMS00Njg5MQ_59d77926-760c-4d7e-adce-b7f092bace8c"
      unitRef="usd">688000</us-gaap:Depreciation>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yNS9mcmFnOmZjZmRhMmQ4NmM2NTRiNjA5OTNkM2UxN2YzN2I0ZWE1L3RhYmxlOjlkMWYxMzljZjdjMzRiOGI5YzY3ODFmNWVmY2NhYmJjL3RhYmxlcmFuZ2U6OWQxZjEzOWNmN2MzNGI4YjljNjc4MWY1ZWZjY2FiYmNfOC0yLTEtMS00Njg5MQ_444ac5e0-0255-4eba-9093-c01b6222186a"
      unitRef="usd">151000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="i56599386fa47443a8975bb3f7a6a8c57_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yNS9mcmFnOmZjZmRhMmQ4NmM2NTRiNjA5OTNkM2UxN2YzN2I0ZWE1L3RhYmxlOjlkMWYxMzljZjdjMzRiOGI5YzY3ODFmNWVmY2NhYmJjL3RhYmxlcmFuZ2U6OWQxZjEzOWNmN2MzNGI4YjljNjc4MWY1ZWZjY2FiYmNfOC00LTEtMS00Njg5MQ_56658e62-b3f6-4b39-926e-e66d13185c2f"
      unitRef="usd">-272000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:ShareBasedCompensation
      contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yNS9mcmFnOmZjZmRhMmQ4NmM2NTRiNjA5OTNkM2UxN2YzN2I0ZWE1L3RhYmxlOjlkMWYxMzljZjdjMzRiOGI5YzY3ODFmNWVmY2NhYmJjL3RhYmxlcmFuZ2U6OWQxZjEzOWNmN2MzNGI4YjljNjc4MWY1ZWZjY2FiYmNfMTAtMi0xLTEtNDY4OTE_550a4c95-9cac-4388-89e3-81da6cd43d33"
      unitRef="usd">7023000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i56599386fa47443a8975bb3f7a6a8c57_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yNS9mcmFnOmZjZmRhMmQ4NmM2NTRiNjA5OTNkM2UxN2YzN2I0ZWE1L3RhYmxlOjlkMWYxMzljZjdjMzRiOGI5YzY3ODFmNWVmY2NhYmJjL3RhYmxlcmFuZ2U6OWQxZjEzOWNmN2MzNGI4YjljNjc4MWY1ZWZjY2FiYmNfMTAtNC0xLTEtNDY4OTE_972a4c5a-7582-4298-b6e1-9560ac5e64b8"
      unitRef="usd">7821000</us-gaap:ShareBasedCompensation>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yNS9mcmFnOmZjZmRhMmQ4NmM2NTRiNjA5OTNkM2UxN2YzN2I0ZWE1L3RhYmxlOjlkMWYxMzljZjdjMzRiOGI5YzY3ODFmNWVmY2NhYmJjL3RhYmxlcmFuZ2U6OWQxZjEzOWNmN2MzNGI4YjljNjc4MWY1ZWZjY2FiYmNfMTEtMi0xLTEtNDY4OTE_55961320-4f81-495c-8c03-fc5dab3e8d37"
      unitRef="usd">-1514000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="i56599386fa47443a8975bb3f7a6a8c57_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yNS9mcmFnOmZjZmRhMmQ4NmM2NTRiNjA5OTNkM2UxN2YzN2I0ZWE1L3RhYmxlOjlkMWYxMzljZjdjMzRiOGI5YzY3ODFmNWVmY2NhYmJjL3RhYmxlcmFuZ2U6OWQxZjEzOWNmN2MzNGI4YjljNjc4MWY1ZWZjY2FiYmNfMTEtNC0xLTEtNDY4OTE_e9f55c72-7fbf-4e41-8d81-8e4b6ff52271"
      unitRef="usd">2111000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInReceivables
      contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yNS9mcmFnOmZjZmRhMmQ4NmM2NTRiNjA5OTNkM2UxN2YzN2I0ZWE1L3RhYmxlOjlkMWYxMzljZjdjMzRiOGI5YzY3ODFmNWVmY2NhYmJjL3RhYmxlcmFuZ2U6OWQxZjEzOWNmN2MzNGI4YjljNjc4MWY1ZWZjY2FiYmNfMTMtMi0xLTEtNDY4OTE_4d7f9b71-d7bc-4aa5-a29f-b5c728b9666c"
      unitRef="usd">4986000</us-gaap:IncreaseDecreaseInReceivables>
    <us-gaap:IncreaseDecreaseInReceivables
      contextRef="i56599386fa47443a8975bb3f7a6a8c57_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yNS9mcmFnOmZjZmRhMmQ4NmM2NTRiNjA5OTNkM2UxN2YzN2I0ZWE1L3RhYmxlOjlkMWYxMzljZjdjMzRiOGI5YzY3ODFmNWVmY2NhYmJjL3RhYmxlcmFuZ2U6OWQxZjEzOWNmN2MzNGI4YjljNjc4MWY1ZWZjY2FiYmNfMTMtNC0xLTEtNDY4OTE_3446d8a4-ab91-4775-b352-a450a56e47ff"
      unitRef="usd">1187000</us-gaap:IncreaseDecreaseInReceivables>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yNS9mcmFnOmZjZmRhMmQ4NmM2NTRiNjA5OTNkM2UxN2YzN2I0ZWE1L3RhYmxlOjlkMWYxMzljZjdjMzRiOGI5YzY3ODFmNWVmY2NhYmJjL3RhYmxlcmFuZ2U6OWQxZjEzOWNmN2MzNGI4YjljNjc4MWY1ZWZjY2FiYmNfMTQtMi0xLTEtNDY4OTE_8c2545a1-86d8-447f-a5e4-a91aec70041d"
      unitRef="usd">6940000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i56599386fa47443a8975bb3f7a6a8c57_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yNS9mcmFnOmZjZmRhMmQ4NmM2NTRiNjA5OTNkM2UxN2YzN2I0ZWE1L3RhYmxlOjlkMWYxMzljZjdjMzRiOGI5YzY3ODFmNWVmY2NhYmJjL3RhYmxlcmFuZ2U6OWQxZjEzOWNmN2MzNGI4YjljNjc4MWY1ZWZjY2FiYmNfMTQtNC0xLTEtNDY4OTE_bcbdcb84-e9a2-4883-8b89-75a4e10afc1a"
      unitRef="usd">2009000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yNS9mcmFnOmZjZmRhMmQ4NmM2NTRiNjA5OTNkM2UxN2YzN2I0ZWE1L3RhYmxlOjlkMWYxMzljZjdjMzRiOGI5YzY3ODFmNWVmY2NhYmJjL3RhYmxlcmFuZ2U6OWQxZjEzOWNmN2MzNGI4YjljNjc4MWY1ZWZjY2FiYmNfMTUtMi0xLTEtNDY4OTE_8ba3b8c8-9d55-4396-999c-61acd7688322"
      unitRef="usd">-307000</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="i56599386fa47443a8975bb3f7a6a8c57_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yNS9mcmFnOmZjZmRhMmQ4NmM2NTRiNjA5OTNkM2UxN2YzN2I0ZWE1L3RhYmxlOjlkMWYxMzljZjdjMzRiOGI5YzY3ODFmNWVmY2NhYmJjL3RhYmxlcmFuZ2U6OWQxZjEzOWNmN2MzNGI4YjljNjc4MWY1ZWZjY2FiYmNfMTUtNC0xLTEtNDY4OTE_1a9f1bc0-1cf0-435b-bd83-2f0aa19dc2f4"
      unitRef="usd">-308000</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yNS9mcmFnOmZjZmRhMmQ4NmM2NTRiNjA5OTNkM2UxN2YzN2I0ZWE1L3RhYmxlOjlkMWYxMzljZjdjMzRiOGI5YzY3ODFmNWVmY2NhYmJjL3RhYmxlcmFuZ2U6OWQxZjEzOWNmN2MzNGI4YjljNjc4MWY1ZWZjY2FiYmNfMTYtMi0xLTEtNDY4OTE_239b7a88-c57b-4c37-956d-a1ad4dac3438"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="i56599386fa47443a8975bb3f7a6a8c57_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yNS9mcmFnOmZjZmRhMmQ4NmM2NTRiNjA5OTNkM2UxN2YzN2I0ZWE1L3RhYmxlOjlkMWYxMzljZjdjMzRiOGI5YzY3ODFmNWVmY2NhYmJjL3RhYmxlcmFuZ2U6OWQxZjEzOWNmN2MzNGI4YjljNjc4MWY1ZWZjY2FiYmNfMTYtNC0xLTEtNDY4OTE_332da4be-0002-48d0-a0e2-be18c8e0462a"
      unitRef="usd">-229000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yNS9mcmFnOmZjZmRhMmQ4NmM2NTRiNjA5OTNkM2UxN2YzN2I0ZWE1L3RhYmxlOjlkMWYxMzljZjdjMzRiOGI5YzY3ODFmNWVmY2NhYmJjL3RhYmxlcmFuZ2U6OWQxZjEzOWNmN2MzNGI4YjljNjc4MWY1ZWZjY2FiYmNfMTgtMi0xLTEtNDY4OTE_0ccd2e30-c093-4d82-a476-7e8311dbd800"
      unitRef="usd">-6704000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="i56599386fa47443a8975bb3f7a6a8c57_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yNS9mcmFnOmZjZmRhMmQ4NmM2NTRiNjA5OTNkM2UxN2YzN2I0ZWE1L3RhYmxlOjlkMWYxMzljZjdjMzRiOGI5YzY3ODFmNWVmY2NhYmJjL3RhYmxlcmFuZ2U6OWQxZjEzOWNmN2MzNGI4YjljNjc4MWY1ZWZjY2FiYmNfMTgtNC0xLTEtNDY4OTE_502aa765-4da8-4937-9bfd-54da3c377982"
      unitRef="usd">-7103000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yNS9mcmFnOmZjZmRhMmQ4NmM2NTRiNjA5OTNkM2UxN2YzN2I0ZWE1L3RhYmxlOjlkMWYxMzljZjdjMzRiOGI5YzY3ODFmNWVmY2NhYmJjL3RhYmxlcmFuZ2U6OWQxZjEzOWNmN2MzNGI4YjljNjc4MWY1ZWZjY2FiYmNfMTktMi0xLTEtNDY4OTE_a303a984-9070-459d-93d6-e27f9aaf088d"
      unitRef="usd">-168000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="i56599386fa47443a8975bb3f7a6a8c57_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yNS9mcmFnOmZjZmRhMmQ4NmM2NTRiNjA5OTNkM2UxN2YzN2I0ZWE1L3RhYmxlOjlkMWYxMzljZjdjMzRiOGI5YzY3ODFmNWVmY2NhYmJjL3RhYmxlcmFuZ2U6OWQxZjEzOWNmN2MzNGI4YjljNjc4MWY1ZWZjY2FiYmNfMTktNC0xLTEtNDY4OTE_929d7042-77d7-48d2-98e5-c834352a096c"
      unitRef="usd">474000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yNS9mcmFnOmZjZmRhMmQ4NmM2NTRiNjA5OTNkM2UxN2YzN2I0ZWE1L3RhYmxlOjlkMWYxMzljZjdjMzRiOGI5YzY3ODFmNWVmY2NhYmJjL3RhYmxlcmFuZ2U6OWQxZjEzOWNmN2MzNGI4YjljNjc4MWY1ZWZjY2FiYmNfMjAtMi0xLTEtNDY4OTE_0e1bff7f-9673-45b4-bc18-6817cc4a2f84"
      unitRef="usd">-46746000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i56599386fa47443a8975bb3f7a6a8c57_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yNS9mcmFnOmZjZmRhMmQ4NmM2NTRiNjA5OTNkM2UxN2YzN2I0ZWE1L3RhYmxlOjlkMWYxMzljZjdjMzRiOGI5YzY3ODFmNWVmY2NhYmJjL3RhYmxlcmFuZ2U6OWQxZjEzOWNmN2MzNGI4YjljNjc4MWY1ZWZjY2FiYmNfMjAtNC0xLTEtNDY4OTE_afd3f199-588a-4587-8b7b-828ddfbf859d"
      unitRef="usd">-53541000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yNS9mcmFnOmZjZmRhMmQ4NmM2NTRiNjA5OTNkM2UxN2YzN2I0ZWE1L3RhYmxlOjlkMWYxMzljZjdjMzRiOGI5YzY3ODFmNWVmY2NhYmJjL3RhYmxlcmFuZ2U6OWQxZjEzOWNmN2MzNGI4YjljNjc4MWY1ZWZjY2FiYmNfMjItMi0xLTEtNDY4OTE_72962182-0dc3-458d-8846-013b8fa15cc7"
      unitRef="usd">163504000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="i56599386fa47443a8975bb3f7a6a8c57_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yNS9mcmFnOmZjZmRhMmQ4NmM2NTRiNjA5OTNkM2UxN2YzN2I0ZWE1L3RhYmxlOjlkMWYxMzljZjdjMzRiOGI5YzY3ODFmNWVmY2NhYmJjL3RhYmxlcmFuZ2U6OWQxZjEzOWNmN2MzNGI4YjljNjc4MWY1ZWZjY2FiYmNfMjItNC0xLTEtNDY4OTE_ba226cef-56b3-483b-8e3c-a0e276976734"
      unitRef="usd">115168000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yNS9mcmFnOmZjZmRhMmQ4NmM2NTRiNjA5OTNkM2UxN2YzN2I0ZWE1L3RhYmxlOjlkMWYxMzljZjdjMzRiOGI5YzY3ODFmNWVmY2NhYmJjL3RhYmxlcmFuZ2U6OWQxZjEzOWNmN2MzNGI4YjljNjc4MWY1ZWZjY2FiYmNfMjMtMi0xLTEtNDY4OTE_67478d3a-fc9f-49db-af00-5efa90c82116"
      unitRef="usd">110566000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="i56599386fa47443a8975bb3f7a6a8c57_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yNS9mcmFnOmZjZmRhMmQ4NmM2NTRiNjA5OTNkM2UxN2YzN2I0ZWE1L3RhYmxlOjlkMWYxMzljZjdjMzRiOGI5YzY3ODFmNWVmY2NhYmJjL3RhYmxlcmFuZ2U6OWQxZjEzOWNmN2MzNGI4YjljNjc4MWY1ZWZjY2FiYmNfMjMtNC0xLTEtNDY4OTE_dba1f52e-af0a-40ca-a01f-28943124420c"
      unitRef="usd">60940000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:PaymentsToAcquireLeaseReceivables
      contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yNS9mcmFnOmZjZmRhMmQ4NmM2NTRiNjA5OTNkM2UxN2YzN2I0ZWE1L3RhYmxlOjlkMWYxMzljZjdjMzRiOGI5YzY3ODFmNWVmY2NhYmJjL3RhYmxlcmFuZ2U6OWQxZjEzOWNmN2MzNGI4YjljNjc4MWY1ZWZjY2FiYmNfMjQtMi0xLTEtNDY4OTE_1584a79c-b214-4a1d-9493-3dd5680d4dfa"
      unitRef="usd">0</us-gaap:PaymentsToAcquireLeaseReceivables>
    <us-gaap:PaymentsToAcquireLeaseReceivables
      contextRef="i56599386fa47443a8975bb3f7a6a8c57_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yNS9mcmFnOmZjZmRhMmQ4NmM2NTRiNjA5OTNkM2UxN2YzN2I0ZWE1L3RhYmxlOjlkMWYxMzljZjdjMzRiOGI5YzY3ODFmNWVmY2NhYmJjL3RhYmxlcmFuZ2U6OWQxZjEzOWNmN2MzNGI4YjljNjc4MWY1ZWZjY2FiYmNfMjQtNC0xLTEtNDY4OTE_68c594ed-41b8-4b7c-9915-36f10ddd967d"
      unitRef="usd">11838000</us-gaap:PaymentsToAcquireLeaseReceivables>
    <us-gaap:PaymentsToAcquireOtherProductiveAssets
      contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yNS9mcmFnOmZjZmRhMmQ4NmM2NTRiNjA5OTNkM2UxN2YzN2I0ZWE1L3RhYmxlOjlkMWYxMzljZjdjMzRiOGI5YzY3ODFmNWVmY2NhYmJjL3RhYmxlcmFuZ2U6OWQxZjEzOWNmN2MzNGI4YjljNjc4MWY1ZWZjY2FiYmNfMjYtMi0xLTEtNDY4OTE_ded4ce73-9912-49e6-81ef-3d8a572f469c"
      unitRef="usd">79000</us-gaap:PaymentsToAcquireOtherProductiveAssets>
    <us-gaap:PaymentsToAcquireOtherProductiveAssets
      contextRef="i56599386fa47443a8975bb3f7a6a8c57_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yNS9mcmFnOmZjZmRhMmQ4NmM2NTRiNjA5OTNkM2UxN2YzN2I0ZWE1L3RhYmxlOjlkMWYxMzljZjdjMzRiOGI5YzY3ODFmNWVmY2NhYmJjL3RhYmxlcmFuZ2U6OWQxZjEzOWNmN2MzNGI4YjljNjc4MWY1ZWZjY2FiYmNfMjYtNC0xLTEtNDY4OTE_93ef979a-3589-434f-9932-e1e921b0c17e"
      unitRef="usd">136000</us-gaap:PaymentsToAcquireOtherProductiveAssets>
    <us-gaap:PaymentsForSoftware
      contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yNS9mcmFnOmZjZmRhMmQ4NmM2NTRiNjA5OTNkM2UxN2YzN2I0ZWE1L3RhYmxlOjlkMWYxMzljZjdjMzRiOGI5YzY3ODFmNWVmY2NhYmJjL3RhYmxlcmFuZ2U6OWQxZjEzOWNmN2MzNGI4YjljNjc4MWY1ZWZjY2FiYmNfMjctMi0xLTEtNDY4OTE_582ac4b1-d8ac-4851-8c6a-c001f0cb9543"
      unitRef="usd">0</us-gaap:PaymentsForSoftware>
    <us-gaap:PaymentsForSoftware
      contextRef="i56599386fa47443a8975bb3f7a6a8c57_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yNS9mcmFnOmZjZmRhMmQ4NmM2NTRiNjA5OTNkM2UxN2YzN2I0ZWE1L3RhYmxlOjlkMWYxMzljZjdjMzRiOGI5YzY3ODFmNWVmY2NhYmJjL3RhYmxlcmFuZ2U6OWQxZjEzOWNmN2MzNGI4YjljNjc4MWY1ZWZjY2FiYmNfMjctNC0xLTEtNDY4OTE_06d86959-7feb-476f-9028-4a43aaabf33c"
      unitRef="usd">1039000</us-gaap:PaymentsForSoftware>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yNS9mcmFnOmZjZmRhMmQ4NmM2NTRiNjA5OTNkM2UxN2YzN2I0ZWE1L3RhYmxlOjlkMWYxMzljZjdjMzRiOGI5YzY3ODFmNWVmY2NhYmJjL3RhYmxlcmFuZ2U6OWQxZjEzOWNmN2MzNGI4YjljNjc4MWY1ZWZjY2FiYmNfMjgtMi0xLTEtNDY4OTE_47a237b6-ee31-4048-afeb-4436f61b53ee"
      unitRef="usd">0</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="i56599386fa47443a8975bb3f7a6a8c57_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yNS9mcmFnOmZjZmRhMmQ4NmM2NTRiNjA5OTNkM2UxN2YzN2I0ZWE1L3RhYmxlOjlkMWYxMzljZjdjMzRiOGI5YzY3ODFmNWVmY2NhYmJjL3RhYmxlcmFuZ2U6OWQxZjEzOWNmN2MzNGI4YjljNjc4MWY1ZWZjY2FiYmNfMjgtNC0xLTEtNDY4OTE_9b28044a-3c48-442e-bbee-454ef9903b61"
      unitRef="usd">6000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yNS9mcmFnOmZjZmRhMmQ4NmM2NTRiNjA5OTNkM2UxN2YzN2I0ZWE1L3RhYmxlOjlkMWYxMzljZjdjMzRiOGI5YzY3ODFmNWVmY2NhYmJjL3RhYmxlcmFuZ2U6OWQxZjEzOWNmN2MzNGI4YjljNjc4MWY1ZWZjY2FiYmNfMjktMi0xLTEtNDY4OTE_e09acc9a-6ddd-4ce1-8fc3-be376a06624e"
      unitRef="usd">-53017000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i56599386fa47443a8975bb3f7a6a8c57_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yNS9mcmFnOmZjZmRhMmQ4NmM2NTRiNjA5OTNkM2UxN2YzN2I0ZWE1L3RhYmxlOjlkMWYxMzljZjdjMzRiOGI5YzY3ODFmNWVmY2NhYmJjL3RhYmxlcmFuZ2U6OWQxZjEzOWNmN2MzNGI4YjljNjc4MWY1ZWZjY2FiYmNfMjktNC0xLTEtNDY4OTE_a690bca7-cbf1-43a9-a3e4-0d84b0b26f9e"
      unitRef="usd">-67247000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yNS9mcmFnOmZjZmRhMmQ4NmM2NTRiNjA5OTNkM2UxN2YzN2I0ZWE1L3RhYmxlOjlkMWYxMzljZjdjMzRiOGI5YzY3ODFmNWVmY2NhYmJjL3RhYmxlcmFuZ2U6OWQxZjEzOWNmN2MzNGI4YjljNjc4MWY1ZWZjY2FiYmNfMzEtMi0xLTEtNDY4OTE_7e5cacd2-bd54-4f35-ae02-728f9c0e3310"
      unitRef="usd">405000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i56599386fa47443a8975bb3f7a6a8c57_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yNS9mcmFnOmZjZmRhMmQ4NmM2NTRiNjA5OTNkM2UxN2YzN2I0ZWE1L3RhYmxlOjlkMWYxMzljZjdjMzRiOGI5YzY3ODFmNWVmY2NhYmJjL3RhYmxlcmFuZ2U6OWQxZjEzOWNmN2MzNGI4YjljNjc4MWY1ZWZjY2FiYmNfMzEtNC0xLTEtNDY4OTE_0ca0d223-29bb-45ad-b375-970e17daf043"
      unitRef="usd">4999000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yNS9mcmFnOmZjZmRhMmQ4NmM2NTRiNjA5OTNkM2UxN2YzN2I0ZWE1L3RhYmxlOjlkMWYxMzljZjdjMzRiOGI5YzY3ODFmNWVmY2NhYmJjL3RhYmxlcmFuZ2U6OWQxZjEzOWNmN2MzNGI4YjljNjc4MWY1ZWZjY2FiYmNfMzItMi0xLTEtNDY4OTE_aa86ef09-151c-438d-9239-3575a9d79f4c"
      unitRef="usd">0</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="i56599386fa47443a8975bb3f7a6a8c57_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yNS9mcmFnOmZjZmRhMmQ4NmM2NTRiNjA5OTNkM2UxN2YzN2I0ZWE1L3RhYmxlOjlkMWYxMzljZjdjMzRiOGI5YzY3ODFmNWVmY2NhYmJjL3RhYmxlcmFuZ2U6OWQxZjEzOWNmN2MzNGI4YjljNjc4MWY1ZWZjY2FiYmNfMzItNC0xLTEtNDY4OTE_ba2f777a-9840-40c0-a478-894a3004fa5a"
      unitRef="usd">30000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yNS9mcmFnOmZjZmRhMmQ4NmM2NTRiNjA5OTNkM2UxN2YzN2I0ZWE1L3RhYmxlOjlkMWYxMzljZjdjMzRiOGI5YzY3ODFmNWVmY2NhYmJjL3RhYmxlcmFuZ2U6OWQxZjEzOWNmN2MzNGI4YjljNjc4MWY1ZWZjY2FiYmNfMzQtMi0xLTEtNDY4OTE_6626e449-c13e-49c1-b8ce-b482e297d620"
      unitRef="usd">405000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i56599386fa47443a8975bb3f7a6a8c57_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yNS9mcmFnOmZjZmRhMmQ4NmM2NTRiNjA5OTNkM2UxN2YzN2I0ZWE1L3RhYmxlOjlkMWYxMzljZjdjMzRiOGI5YzY3ODFmNWVmY2NhYmJjL3RhYmxlcmFuZ2U6OWQxZjEzOWNmN2MzNGI4YjljNjc4MWY1ZWZjY2FiYmNfMzQtNC0xLTEtNDY4OTE_b0b632b3-e878-4194-b8df-ad2f6c0969c6"
      unitRef="usd">5029000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yNS9mcmFnOmZjZmRhMmQ4NmM2NTRiNjA5OTNkM2UxN2YzN2I0ZWE1L3RhYmxlOjlkMWYxMzljZjdjMzRiOGI5YzY3ODFmNWVmY2NhYmJjL3RhYmxlcmFuZ2U6OWQxZjEzOWNmN2MzNGI4YjljNjc4MWY1ZWZjY2FiYmNfMzUtMi0xLTEtNDY4OTE_3d400d43-12fc-49e1-bd34-2d9419099659"
      unitRef="usd">-99358000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i56599386fa47443a8975bb3f7a6a8c57_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yNS9mcmFnOmZjZmRhMmQ4NmM2NTRiNjA5OTNkM2UxN2YzN2I0ZWE1L3RhYmxlOjlkMWYxMzljZjdjMzRiOGI5YzY3ODFmNWVmY2NhYmJjL3RhYmxlcmFuZ2U6OWQxZjEzOWNmN2MzNGI4YjljNjc4MWY1ZWZjY2FiYmNfMzUtNC0xLTEtNDY4OTE_ea7ce96d-bf34-487d-947b-3f0e33c403ba"
      unitRef="usd">-115759000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i784f65549351439fa4b7bedf90ce7e3f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yNS9mcmFnOmZjZmRhMmQ4NmM2NTRiNjA5OTNkM2UxN2YzN2I0ZWE1L3RhYmxlOjlkMWYxMzljZjdjMzRiOGI5YzY3ODFmNWVmY2NhYmJjL3RhYmxlcmFuZ2U6OWQxZjEzOWNmN2MzNGI4YjljNjc4MWY1ZWZjY2FiYmNfMzYtMi0xLTEtNDY4OTE_94b2659f-a7a3-4143-a824-301adc511e36"
      unitRef="usd">231900000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i52aa203b7e954d69b001129473620362_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yNS9mcmFnOmZjZmRhMmQ4NmM2NTRiNjA5OTNkM2UxN2YzN2I0ZWE1L3RhYmxlOjlkMWYxMzljZjdjMzRiOGI5YzY3ODFmNWVmY2NhYmJjL3RhYmxlcmFuZ2U6OWQxZjEzOWNmN2MzNGI4YjljNjc4MWY1ZWZjY2FiYmNfMzYtNC0xLTEtNDY4OTE_880f27a6-1ccc-401c-acfd-3499e3f95df7"
      unitRef="usd">272350000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="id7882ae6aff54a3aacdef67ddf11a428_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yNS9mcmFnOmZjZmRhMmQ4NmM2NTRiNjA5OTNkM2UxN2YzN2I0ZWE1L3RhYmxlOjlkMWYxMzljZjdjMzRiOGI5YzY3ODFmNWVmY2NhYmJjL3RhYmxlcmFuZ2U6OWQxZjEzOWNmN2MzNGI4YjljNjc4MWY1ZWZjY2FiYmNfMzctMi0xLTEtNDY4OTE_c4f851be-8f63-4b51-98fb-b457a637dc3b"
      unitRef="usd">132542000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i0260d11b47b2403fbf3efe386b4d6b0f_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yNS9mcmFnOmZjZmRhMmQ4NmM2NTRiNjA5OTNkM2UxN2YzN2I0ZWE1L3RhYmxlOjlkMWYxMzljZjdjMzRiOGI5YzY3ODFmNWVmY2NhYmJjL3RhYmxlcmFuZ2U6OWQxZjEzOWNmN2MzNGI4YjljNjc4MWY1ZWZjY2FiYmNfMzctNC0xLTEtNDY4OTE_b70dbe69-ef20-4648-8e58-1ca76161ca95"
      unitRef="usd">156591000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:ProceedsFromInterestReceived
      contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yNS9mcmFnOmZjZmRhMmQ4NmM2NTRiNjA5OTNkM2UxN2YzN2I0ZWE1L3RhYmxlOjlkMWYxMzljZjdjMzRiOGI5YzY3ODFmNWVmY2NhYmJjL3RhYmxlcmFuZ2U6OWQxZjEzOWNmN2MzNGI4YjljNjc4MWY1ZWZjY2FiYmNfNDAtMi0xLTEtNDY4OTE_909cabab-3be1-45bf-83b8-06dcba65b6e5"
      unitRef="usd">13000</us-gaap:ProceedsFromInterestReceived>
    <us-gaap:ProceedsFromInterestReceived
      contextRef="i56599386fa47443a8975bb3f7a6a8c57_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yNS9mcmFnOmZjZmRhMmQ4NmM2NTRiNjA5OTNkM2UxN2YzN2I0ZWE1L3RhYmxlOjlkMWYxMzljZjdjMzRiOGI5YzY3ODFmNWVmY2NhYmJjL3RhYmxlcmFuZ2U6OWQxZjEzOWNmN2MzNGI4YjljNjc4MWY1ZWZjY2FiYmNfNDAtNC0xLTEtNDY4OTE_8fcb95de-6d5b-4157-99e5-7a826d2ae314"
      unitRef="usd">425000</us-gaap:ProceedsFromInterestReceived>
    <us-gaap:CapitalLeaseObligationsIncurred
      contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yNS9mcmFnOmZjZmRhMmQ4NmM2NTRiNjA5OTNkM2UxN2YzN2I0ZWE1L3RhYmxlOjlkMWYxMzljZjdjMzRiOGI5YzY3ODFmNWVmY2NhYmJjL3RhYmxlcmFuZ2U6OWQxZjEzOWNmN2MzNGI4YjljNjc4MWY1ZWZjY2FiYmNfNDItMi0xLTEtNDY4OTE_0dba29aa-d8a4-4980-996b-720c5882e6a4"
      unitRef="usd">281000</us-gaap:CapitalLeaseObligationsIncurred>
    <us-gaap:CapitalLeaseObligationsIncurred
      contextRef="i56599386fa47443a8975bb3f7a6a8c57_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yNS9mcmFnOmZjZmRhMmQ4NmM2NTRiNjA5OTNkM2UxN2YzN2I0ZWE1L3RhYmxlOjlkMWYxMzljZjdjMzRiOGI5YzY3ODFmNWVmY2NhYmJjL3RhYmxlcmFuZ2U6OWQxZjEzOWNmN2MzNGI4YjljNjc4MWY1ZWZjY2FiYmNfNDItNC0xLTEtNDY4OTE_135c41ec-ab3b-4629-9663-afdc61975d0f"
      unitRef="usd">63000</us-gaap:CapitalLeaseObligationsIncurred>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yNS9mcmFnOmZjZmRhMmQ4NmM2NTRiNjA5OTNkM2UxN2YzN2I0ZWE1L3RhYmxlOjlkMWYxMzljZjdjMzRiOGI5YzY3ODFmNWVmY2NhYmJjL3RhYmxlcmFuZ2U6OWQxZjEzOWNmN2MzNGI4YjljNjc4MWY1ZWZjY2FiYmNfNDQtMi0xLTEtNDY4OTE_3e14d862-7286-4b2c-bd96-4c231dfae361"
      unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i56599386fa47443a8975bb3f7a6a8c57_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yNS9mcmFnOmZjZmRhMmQ4NmM2NTRiNjA5OTNkM2UxN2YzN2I0ZWE1L3RhYmxlOjlkMWYxMzljZjdjMzRiOGI5YzY3ODFmNWVmY2NhYmJjL3RhYmxlcmFuZ2U6OWQxZjEzOWNmN2MzNGI4YjljNjc4MWY1ZWZjY2FiYmNfNDQtNC0xLTEtNDY4OTE_3629d87e-2861-4ecd-8912-42d68416881e"
      unitRef="usd">5804000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="id7882ae6aff54a3aacdef67ddf11a428_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yNS9mcmFnOmZjZmRhMmQ4NmM2NTRiNjA5OTNkM2UxN2YzN2I0ZWE1L3RhYmxlOjlkMWYxMzljZjdjMzRiOGI5YzY3ODFmNWVmY2NhYmJjL3RhYmxlcmFuZ2U6OWQxZjEzOWNmN2MzNGI4YjljNjc4MWY1ZWZjY2FiYmNfNDctMi0xLTEtNTQ3OTQ_0d252311-fd4f-4800-9940-df0c7daf4e23"
      unitRef="usd">131636000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i0260d11b47b2403fbf3efe386b4d6b0f_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yNS9mcmFnOmZjZmRhMmQ4NmM2NTRiNjA5OTNkM2UxN2YzN2I0ZWE1L3RhYmxlOjlkMWYxMzljZjdjMzRiOGI5YzY3ODFmNWVmY2NhYmJjL3RhYmxlcmFuZ2U6OWQxZjEzOWNmN2MzNGI4YjljNjc4MWY1ZWZjY2FiYmNfNDctNC0xLTEtNTQ3OTQ_50591c50-94eb-4817-9cf6-81d382e1275e"
      unitRef="usd">156591000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="id7882ae6aff54a3aacdef67ddf11a428_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yNS9mcmFnOmZjZmRhMmQ4NmM2NTRiNjA5OTNkM2UxN2YzN2I0ZWE1L3RhYmxlOjlkMWYxMzljZjdjMzRiOGI5YzY3ODFmNWVmY2NhYmJjL3RhYmxlcmFuZ2U6OWQxZjEzOWNmN2MzNGI4YjljNjc4MWY1ZWZjY2FiYmNfNDgtMi0xLTEtNTQ3OTQ_a5ab9125-7b37-4922-8ad8-c17093086b42"
      unitRef="usd">906000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="i0260d11b47b2403fbf3efe386b4d6b0f_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yNS9mcmFnOmZjZmRhMmQ4NmM2NTRiNjA5OTNkM2UxN2YzN2I0ZWE1L3RhYmxlOjlkMWYxMzljZjdjMzRiOGI5YzY3ODFmNWVmY2NhYmJjL3RhYmxlcmFuZ2U6OWQxZjEzOWNmN2MzNGI4YjljNjc4MWY1ZWZjY2FiYmNfNDgtNC0xLTEtNTQ3OTQ_ac9ba817-684f-4762-b10f-7a68d2c42752"
      unitRef="usd">0</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="id7882ae6aff54a3aacdef67ddf11a428_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yNS9mcmFnOmZjZmRhMmQ4NmM2NTRiNjA5OTNkM2UxN2YzN2I0ZWE1L3RhYmxlOjlkMWYxMzljZjdjMzRiOGI5YzY3ODFmNWVmY2NhYmJjL3RhYmxlcmFuZ2U6OWQxZjEzOWNmN2MzNGI4YjljNjc4MWY1ZWZjY2FiYmNfNDktMi0xLTEtNTQ3OTQ_a0ebb017-2866-4949-bc76-506c4cfe0aad"
      unitRef="usd">132542000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i0260d11b47b2403fbf3efe386b4d6b0f_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8yNS9mcmFnOmZjZmRhMmQ4NmM2NTRiNjA5OTNkM2UxN2YzN2I0ZWE1L3RhYmxlOjlkMWYxMzljZjdjMzRiOGI5YzY3ODFmNWVmY2NhYmJjL3RhYmxlcmFuZ2U6OWQxZjEzOWNmN2MzNGI4YjljNjc4MWY1ZWZjY2FiYmNfNDktNC0xLTEtNTQ3OTQ_9dcb81d6-b69d-4c0a-a1b2-2c2897aa8abb"
      unitRef="usd">156591000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8zMS9mcmFnOjI5NDExMmFjODQ1NzQ2OTk4MThjMTI5ZWIyNTZkNTI3L3RleHRyZWdpb246Mjk0MTEyYWM4NDU3NDY5OTgxOGMxMjllYjI1NmQ1MjdfMTc2MA_f76d1406-c51e-4fbd-8d9d-a12555b17025">Organization and Description of Business&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Aurinia Pharmaceuticals Inc. (Aurinia or the Company) is a fully integrated biopharmaceutical company focused on delivering therapies to treat targeted patient populations that are impacted by serious diseases with a high unmet medical need. In January 2021, the Company introduced LUPKYNIS&#x2122; (voclosporin), the first U.S. Food and Drug Administration (FDA) approved oral therapy for the treatment of adult patients with active LN and continues to conduct pre-clinical, clinical, and regulatory advancement to support the voclosporin development program. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 17, 2021, the Company announced the addition of two novel assets AUR200 and AUR300. AUR200 is currently undergoing pre-clinical development with projected submission of an Investigational New Drug Application (IND) to the FDA in 2023. The Company anticipates that an IND for AUR300 will also be submitted during 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Aurinia's head office is located at #1203-4464 Markham Street, Victoria, British Columbia, Canada and its registered office is located at #201, 17873-106 A Avenue, Edmonton, Alberta. Aurinia also has a U.S. commercial office located at 77 Upper Rock Circle Suite 700, Rockville, Maryland, 20850 United States.&lt;/span&gt;&lt;/div&gt;Aurinia is incorporated pursuant to the Business Corporations Act (Alberta). The Company&#x2019;s common shares are traded on the Nasdaq Global Market (Nasdaq) under the symbol AUPH</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:BasisOfAccounting
      contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8zNC9mcmFnOmQwODBmYjU4YjRmNDQwMTRhYjFmN2Q4ZGJkNjRjODYwL3RleHRyZWdpb246ZDA4MGZiNThiNGY0NDAxNGFiMWY3ZDhkYmQ2NGM4NjBfMzIzNw_b28cea4c-e25a-44b5-9190-09112ceec5db">Basis of Presentation&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States (U.S. GAAP) for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of normal recurring adjustments considered necessary for fair presentation in accordance with U.S. GAAP. The condensed consolidated balance sheet as of December&#160;31, 2021 was derived from audited annual consolidated financial statements but does not include all annual disclosures required by U.S. GAAP. These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements included in the Company's Annual Report on Form 10-K for the year ended December&#160;31, 2021. The results of operations for the three months ended March&#160;31, 2022 are not necessarily indicative of the results to be expected for the full year or any other future periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, Aurinia Pharma U.S., Inc. (Delaware incorporated) and Aurinia Pharma Limited (UK incorporated). All intercompany balances and transactions have been eliminated in consolidation and operate in one segment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These unaudited condensed consolidated financial statements are presented in U.S. dollars which is the Company's functional currency therefore there is no currency translation adjustment upon consolidation as the remeasurement of gains or losses are recorded in the condensed consolidated statements of operations. All assets and liabilities denominated in a foreign currency are remeasured into U.S. dollars at the exchange rate on the balance sheet date. Revenues and expenses are remeasured at the average exchange rate during the period. Foreign exchange gains and losses arising on translation or settlement of a foreign currency denominated monetary item are included in the condensed consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is devoting the majority of our operational efforts and financial resources towards the commercialization and post approval commitments of our approved drug, LUPKYNIS. The Company is also expending efforts towards our newly acquired assets AUR200 and AUR300. Taking into consideration the Company's cash, cash equivalents, restricted cash and investments of $418.8 million as of March&#160;31, 2022, the Company believes that it has sufficient resources to fund its operations for at least the next few years beyond the date that the unaudited condensed consolidated financial statements are issued.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccounting>
    <us-gaap:NumberOfOperatingSegments
      contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8zNC9mcmFnOmQwODBmYjU4YjRmNDQwMTRhYjFmN2Q4ZGJkNjRjODYwL3RleHRyZWdpb246ZDA4MGZiNThiNGY0NDAxNGFiMWY3ZDhkYmQ2NGM4NjBfMTY0OTI2NzQ0NTI3OA_6ae86e88-2a47-427e-8c29-1855d6f56c7d"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <auph:CashCashEquivalentsAndDebtSecuritiesCurrent
      contextRef="id7882ae6aff54a3aacdef67ddf11a428_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8zNC9mcmFnOmQwODBmYjU4YjRmNDQwMTRhYjFmN2Q4ZGJkNjRjODYwL3RleHRyZWdpb246ZDA4MGZiNThiNGY0NDAxNGFiMWY3ZDhkYmQ2NGM4NjBfMzA0MA_8e61c9d1-3e70-49a6-b31b-db77ac4de434"
      unitRef="usd">418800000</auph:CashCashEquivalentsAndDebtSecuritiesCurrent>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8zNy9mcmFnOmNjZmQ3NmIxZTk2MDQ0ODBiYjcyOTBjYjUzMjdlYmQ0L3RleHRyZWdpb246Y2NmZDc2YjFlOTYwNDQ4MGJiNzI5MGNiNTMyN2ViZDRfMjA0MjU_ae2a0e2a-a3c2-41ac-a4a7-a9b846fb0c05">Summary of Significant Accounting PoliciesOther than as described below, the Company's significant accounting policies have not changed from those previously described in the Company's Annual Report on Form 10-K for the year ended December&#160;31, 2021.&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Restricted cash&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;: Restricted cash consists of the 2021 Employee Share Purchase Plan (2021 ESPP) deposits of $0.9&#160;million and $0.3&#160;million as of March&#160;31, 2022 and December&#160;31, 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Major Customers:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company currently has two main customers for U.S. commercial sales of LUPKYNIS and one customer for sales of voclosporin in the European Union, Japan, as well as the United Kingdom, Russia, Switzerland, Norway, Belarus, Iceland, Liechtenstein and Ukraine. Revenues from two customers accounted for approximately 54% and 45% respectively of the Company's total revenues for the three months ended March&#160;31, 2022. The Company monitors economic conditions, the creditworthiness of customers and government regulations and funding, both domestically and abroad. The Company regularly communicates with its customers regarding the status of receivable balances, including their payment plans and obtains positive confirmation of the validity of the receivables. Global economic conditions and customer specific factors may require the Company to periodically re-evaluate the collectability of its receivables and the Company could potentially incur credit losses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Accounts receivable, net:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Accounts receivable are stated at their net realizable value. As of March&#160;31, 2022 and December&#160;31, 2021, accounts receivable, net are $20.4 million and $15.4 million. We estimate the allowance for doubtful accounts using current expected credit loss model, or CECL model. Under the CECL model, the allowance for doubtful accounts reflects the net amount expected to be collected from the account receivables. We evaluate the collectability of these cash flows based on the asset&#x2019;s amortized cost, the risk of loss even when that risk is remote, losses over an asset&#x2019;s contractual life, and other relevant information available to us. Accounts receivable balances are written off against the allowance when it is probable that&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;the receivable will not be collected. The allowance for doubtful accounts was $nil as of March&#160;31, 2022 and as of December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Share-Based Compensation: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company follows ASC Topic 718, Compensation - Stock Compensation (ASC 718), which requires the measurement and recognition of compensation expense, based on estimated fair values, for all share-based awards made to employees and directors. The Company records compensation expense based on the fair value on the grant date using the graded accelerated vesting method for all share-based payments related to stock options, performance awards (PAs), restricted stock units (RSUs) and purchases under the Company's 2021 ESPP. For stock options, forfeitures are estimated based on historical experience at the time of grant and revised in subsequent periods if actual forfeitures differ from those estimates. For RSUs and PAs, forfeitures are accounted for as they occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently adopted accounting pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, the FASB issued ASU 2019-12, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (Topic 740): Simplifying the Accounting for Income Taxes, which clarifies and simplifies certain aspects of the accounting for income taxes. The standard is effective for years beginning after December 15, 2020, and interim periods within annual periods beginning after December 15, 2020. The Company adopted the ASU effective January 1, 2021, with no material impact on the condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2021, the FASB issued ASU No. 2021-10, Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance, which requires business entities to make annual disclosures about transactions with a government (including government assistance) by analogizing to a grant or contribution accounting model. The required disclosures include the nature of the transaction, the entity's related accounting policy, the financial statement line items affected and the amounts reflected in the current period financial statements, as well as any significant terms and conditions. The guidance is effective for financial statements issued for annual periods beginning after December 15, 2021. The Company adopted the ASU effective January 1, 2022, with no material impact on the condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy
      contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8zNy9mcmFnOmNjZmQ3NmIxZTk2MDQ0ODBiYjcyOTBjYjUzMjdlYmQ0L3RleHRyZWdpb246Y2NmZDc2YjFlOTYwNDQ4MGJiNzI5MGNiNTMyN2ViZDRfMzI5ODUzNDk2MTA3MQ_14cd3394-592d-49f4-972b-28dff8024c03">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Restricted cash&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;: Restricted cash consists of the 2021 Employee Share Purchase Plan (2021 ESPP) deposits of $0.9&#160;million and $0.3&#160;million as of March&#160;31, 2022 and December&#160;31, 2021, respectively.&lt;/span&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:RestrictedCash
      contextRef="id7882ae6aff54a3aacdef67ddf11a428_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8zNy9mcmFnOmNjZmQ3NmIxZTk2MDQ0ODBiYjcyOTBjYjUzMjdlYmQ0L3RleHRyZWdpb246Y2NmZDc2YjFlOTYwNDQ4MGJiNzI5MGNiNTMyN2ViZDRfMzI5ODUzNDk2MTA0NA_1c4c033c-3864-47f8-8a76-96be045c517d"
      unitRef="usd">900000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="i784f65549351439fa4b7bedf90ce7e3f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8zNy9mcmFnOmNjZmQ3NmIxZTk2MDQ0ODBiYjcyOTBjYjUzMjdlYmQ0L3RleHRyZWdpb246Y2NmZDc2YjFlOTYwNDQ4MGJiNzI5MGNiNTMyN2ViZDRfMzI5ODUzNDk2MTA1OA_0a5f2576-a87b-4d48-aa2d-57f0c055551f"
      unitRef="usd">300000</us-gaap:RestrictedCash>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8zNy9mcmFnOmNjZmQ3NmIxZTk2MDQ0ODBiYjcyOTBjYjUzMjdlYmQ0L3RleHRyZWdpb246Y2NmZDc2YjFlOTYwNDQ4MGJiNzI5MGNiNTMyN2ViZDRfMjA0MjE_6cd516f7-249c-4f9b-988c-e1396ce0152e">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Major Customers:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company currently has two main customers for U.S. commercial sales of LUPKYNIS and one customer for sales of voclosporin in the European Union, Japan, as well as the United Kingdom, Russia, Switzerland, Norway, Belarus, Iceland, Liechtenstein and Ukraine. Revenues from two customers accounted for approximately 54% and 45% respectively of the Company's total revenues for the three months ended March&#160;31, 2022. The Company monitors economic conditions, the creditworthiness of customers and government regulations and funding, both domestically and abroad. The Company regularly communicates with its customers regarding the status of receivable balances, including their payment plans and obtains positive confirmation of the validity of the receivables. Global economic conditions and customer specific factors may require the Company to periodically re-evaluate the collectability of its receivables and the Company could potentially incur credit losses.&lt;/span&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ie14c65a2be5d40e1975aef5b5c3f0072_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8zNy9mcmFnOmNjZmQ3NmIxZTk2MDQ0ODBiYjcyOTBjYjUzMjdlYmQ0L3RleHRyZWdpb246Y2NmZDc2YjFlOTYwNDQ4MGJiNzI5MGNiNTMyN2ViZDRfNDA3Mw_9a4af87a-0e2d-4835-be58-3687000e604f"
      unitRef="number">0.54</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i5a87beff7e574242be649c7dbc5fa755_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8zNy9mcmFnOmNjZmQ3NmIxZTk2MDQ0ODBiYjcyOTBjYjUzMjdlYmQ0L3RleHRyZWdpb246Y2NmZDc2YjFlOTYwNDQ4MGJiNzI5MGNiNTMyN2ViZDRfNDA4MA_c9035910-95d0-41ee-9b0a-a4901af6e02e"
      unitRef="number">0.45</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:TradeAndOtherAccountsReceivablePolicy
      contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8zNy9mcmFnOmNjZmQ3NmIxZTk2MDQ0ODBiYjcyOTBjYjUzMjdlYmQ0L3RleHRyZWdpb246Y2NmZDc2YjFlOTYwNDQ4MGJiNzI5MGNiNTMyN2ViZDRfMjA0MTk_d8ad4885-14ab-4665-8e5d-8a04a0463471">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Accounts receivable, net:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Accounts receivable are stated at their net realizable value. As of March&#160;31, 2022 and December&#160;31, 2021, accounts receivable, net are $20.4 million and $15.4 million. We estimate the allowance for doubtful accounts using current expected credit loss model, or CECL model. Under the CECL model, the allowance for doubtful accounts reflects the net amount expected to be collected from the account receivables. We evaluate the collectability of these cash flows based on the asset&#x2019;s amortized cost, the risk of loss even when that risk is remote, losses over an asset&#x2019;s contractual life, and other relevant information available to us. Accounts receivable balances are written off against the allowance when it is probable that&lt;/span&gt;the receivable will not be collected. The allowance for doubtful accounts was $nil as of March&#160;31, 2022 and as of December&#160;31, 2021</us-gaap:TradeAndOtherAccountsReceivablePolicy>
    <us-gaap:AccountsAndOtherReceivablesNetCurrent
      contextRef="id7882ae6aff54a3aacdef67ddf11a428_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8zNy9mcmFnOmNjZmQ3NmIxZTk2MDQ0ODBiYjcyOTBjYjUzMjdlYmQ0L3RleHRyZWdpb246Y2NmZDc2YjFlOTYwNDQ4MGJiNzI5MGNiNTMyN2ViZDRfMTk2MzA_0262a4d8-8c9c-452d-9162-9d05fd5c5b5c"
      unitRef="usd">20400000</us-gaap:AccountsAndOtherReceivablesNetCurrent>
    <us-gaap:AccountsAndOtherReceivablesNetCurrent
      contextRef="i784f65549351439fa4b7bedf90ce7e3f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8zNy9mcmFnOmNjZmQ3NmIxZTk2MDQ0ODBiYjcyOTBjYjUzMjdlYmQ0L3RleHRyZWdpb246Y2NmZDc2YjFlOTYwNDQ4MGJiNzI5MGNiNTMyN2ViZDRfMTA5OTUxMTcwNTU0OQ_76fb857b-0038-435d-b680-5fa86959bf58"
      unitRef="usd">15400000</us-gaap:AccountsAndOtherReceivablesNetCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="id7882ae6aff54a3aacdef67ddf11a428_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8zNy9mcmFnOmNjZmQ3NmIxZTk2MDQ0ODBiYjcyOTBjYjUzMjdlYmQ0L3RleHRyZWdpb246Y2NmZDc2YjFlOTYwNDQ4MGJiNzI5MGNiNTMyN2ViZDRfMTk4Nzg_2c9863bd-741b-4c7e-bd0e-920d266243d2"
      unitRef="usd">0</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="i784f65549351439fa4b7bedf90ce7e3f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8zNy9mcmFnOmNjZmQ3NmIxZTk2MDQ0ODBiYjcyOTBjYjUzMjdlYmQ0L3RleHRyZWdpb246Y2NmZDc2YjFlOTYwNDQ4MGJiNzI5MGNiNTMyN2ViZDRfMTk4Nzg_64150c8b-0ab4-43bd-853c-a2f244064536"
      unitRef="usd">0</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl8zNy9mcmFnOmNjZmQ3NmIxZTk2MDQ0ODBiYjcyOTBjYjUzMjdlYmQ0L3RleHRyZWdpb246Y2NmZDc2YjFlOTYwNDQ4MGJiNzI5MGNiNTMyN2ViZDRfMzI5ODUzNDkxODU5NQ_43ba0ab7-2115-49ae-a794-627e44f909b7">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Share-Based Compensation: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company follows ASC Topic 718, Compensation - Stock Compensation (ASC 718), which requires the measurement and recognition of compensation expense, based on estimated fair values, for all share-based awards made to employees and directors. The Company records compensation expense based on the fair value on the grant date using the graded accelerated vesting method for all share-based payments related to stock options, performance awards (PAs), restricted stock units (RSUs) and purchases under the Company's 2021 ESPP. For stock options, forfeitures are estimated based on historical experience at the time of grant and revised in subsequent periods if actual forfeitures differ from those estimates. For RSUs and PAs, forfeitures are accounted for as they occur.&lt;/span&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl80MC9mcmFnOjE5Y2RlOTg2NGRmYzQwZmRiYWM4MzU3ZjhhZTM5OTllL3RleHRyZWdpb246MTljZGU5ODY0ZGZjNDBmZGJhYzgzNTdmOGFlMzk5OWVfNDkyMA_1a778848-d3a3-4b3e-9671-3d5fae08ce00">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently adopted accounting pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, the FASB issued ASU 2019-12, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (Topic 740): Simplifying the Accounting for Income Taxes, which clarifies and simplifies certain aspects of the accounting for income taxes. The standard is effective for years beginning after December 15, 2020, and interim periods within annual periods beginning after December 15, 2020. The Company adopted the ASU effective January 1, 2021, with no material impact on the condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2021, the FASB issued ASU No. 2021-10, Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance, which requires business entities to make annual disclosures about transactions with a government (including government assistance) by analogizing to a grant or contribution accounting model. The required disclosures include the nature of the transaction, the entity's related accounting policy, the financial statement line items affected and the amounts reflected in the current period financial statements, as well as any significant terms and conditions. The guidance is effective for financial statements issued for annual periods beginning after December 15, 2021. The Company adopted the ASU effective January 1, 2022, with no material impact on the condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock
      contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl80My9mcmFnOjQ3ZjgwM2VmY2QyNTRiNjFiNzI0MGU2ZDk1M2IxODllL3RleHRyZWdpb246NDdmODAzZWZjZDI1NGI2MWI3MjQwZTZkOTUzYjE4OWVfMTMwMw_fe4305a8-91db-4d2e-928b-272fd7bf68bd">Investments&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At March&#160;31, 2022 and December&#160;31, 2021, the Company had $286.2 million and $234.2 million of short-term investments, respectively, mainly consisting of commercial paper and bonds as summarized below. As of March&#160;31, 2022, $8.8 million are held to maturity debt securities which are carried at amortized cost and are approximately equal to fair market value. As of March&#160;31, 2022, $277.4 million are available-for-sale debt securities which are carried at fair market value. As of December&#160;31, 2021, $215.0 million were classified as available-for-sale and $19.2 million were held-to-maturity. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cashable Guaranteed Investment Certificate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,128&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate Bond&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;60,390&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,820&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial Paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;152,295&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;206,724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Treasury Bill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;19,530&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Treasury Bond&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;50,867&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;286,210&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;234,178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;Currently, the Company does not intend to sell investments and has the ability and intent to hold these investments until maturity in order to collect interest payments over the life of the investments. As of March&#160;31, 2022 and December&#160;31, 2021, accrued interest receivable from the investments were $0.5 million and $0.1 million, respectively. During the three months ended March&#160;31, 2022 and 2021, the Company had $766 thousand and $6 thousand unrealized losses on available-for-sale securities, net of tax, respectively, which are included as a component of comprehensive loss on the consolidated statements of operations. The Company's investments as of March&#160;31, 2022 mature at various dates through January 2023.</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:DebtSecuritiesCurrent
      contextRef="id7882ae6aff54a3aacdef67ddf11a428_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl80My9mcmFnOjQ3ZjgwM2VmY2QyNTRiNjFiNzI0MGU2ZDk1M2IxODllL3RleHRyZWdpb246NDdmODAzZWZjZDI1NGI2MWI3MjQwZTZkOTUzYjE4OWVfNTM_f4188e32-f751-491a-b3b6-6b8005803173"
      unitRef="usd">286200000</us-gaap:DebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesCurrent
      contextRef="i784f65549351439fa4b7bedf90ce7e3f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl80My9mcmFnOjQ3ZjgwM2VmY2QyNTRiNjFiNzI0MGU2ZDk1M2IxODllL3RleHRyZWdpb246NDdmODAzZWZjZDI1NGI2MWI3MjQwZTZkOTUzYjE4OWVfNjg_8ef9c19a-79ec-45ba-a8a0-b89fdb5ca98e"
      unitRef="usd">234200000</us-gaap:DebtSecuritiesCurrent>
    <us-gaap:HeldToMaturitySecurities
      contextRef="id7882ae6aff54a3aacdef67ddf11a428_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl80My9mcmFnOjQ3ZjgwM2VmY2QyNTRiNjFiNzI0MGU2ZDk1M2IxODllL3RleHRyZWdpb246NDdmODAzZWZjZDI1NGI2MWI3MjQwZTZkOTUzYjE4OWVfMjc0_ace439e1-84af-40b2-9e83-45fac4e2bfce"
      unitRef="usd">8800000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id7882ae6aff54a3aacdef67ddf11a428_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl80My9mcmFnOjQ3ZjgwM2VmY2QyNTRiNjFiNzI0MGU2ZDk1M2IxODllL3RleHRyZWdpb246NDdmODAzZWZjZDI1NGI2MWI3MjQwZTZkOTUzYjE4OWVfNDEw_ea18a798-7ba4-4831-8ea6-7b827e96b602"
      unitRef="usd">277400000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i784f65549351439fa4b7bedf90ce7e3f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl80My9mcmFnOjQ3ZjgwM2VmY2QyNTRiNjFiNzI0MGU2ZDk1M2IxODllL3RleHRyZWdpb246NDdmODAzZWZjZDI1NGI2MWI3MjQwZTZkOTUzYjE4OWVfMTA5OTUxMTYyOTM4Ng_f0be5335-c6b5-4bb6-9b73-88e497db7609"
      unitRef="usd">215000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:HeldToMaturitySecurities
      contextRef="i784f65549351439fa4b7bedf90ce7e3f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl80My9mcmFnOjQ3ZjgwM2VmY2QyNTRiNjFiNzI0MGU2ZDk1M2IxODllL3RleHRyZWdpb246NDdmODAzZWZjZDI1NGI2MWI3MjQwZTZkOTUzYjE4OWVfMTA5OTUxMTYyOTM3MA_168f33f8-39e3-4a50-90f6-3d8e4a074cb5"
      unitRef="usd">19200000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:MarketableSecuritiesTextBlock
      contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl80My9mcmFnOjQ3ZjgwM2VmY2QyNTRiNjFiNzI0MGU2ZDk1M2IxODllL3RleHRyZWdpb246NDdmODAzZWZjZDI1NGI2MWI3MjQwZTZkOTUzYjE4OWVfMTMwNA_6e45e5cc-c7c7-43cc-96b5-fbc6efaeffd1">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cashable Guaranteed Investment Certificate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,128&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate Bond&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;60,390&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,820&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial Paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;152,295&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;206,724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Treasury Bill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;19,530&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Treasury Bond&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;50,867&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;286,210&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;234,178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:MarketableSecuritiesTextBlock>
    <us-gaap:DebtSecuritiesCurrent
      contextRef="ibaf8c62e96254608ab5682b00b33999f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl80My9mcmFnOjQ3ZjgwM2VmY2QyNTRiNjFiNzI0MGU2ZDk1M2IxODllL3RhYmxlOmI0NGZiZWQ5NDBhNDQ2MWM5OGY2NTA1YTVmNDM2NjE5L3RhYmxlcmFuZ2U6YjQ0ZmJlZDk0MGE0NDYxYzk4ZjY1MDVhNWY0MzY2MTlfMS0yLTEtMS00Njg5MQ_6dac04f5-2aaf-4727-ae54-0792b50eb658"
      unitRef="usd">3128000</us-gaap:DebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesCurrent
      contextRef="i40b2265057054504ab60aa0aafba0f0e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl80My9mcmFnOjQ3ZjgwM2VmY2QyNTRiNjFiNzI0MGU2ZDk1M2IxODllL3RhYmxlOmI0NGZiZWQ5NDBhNDQ2MWM5OGY2NTA1YTVmNDM2NjE5L3RhYmxlcmFuZ2U6YjQ0ZmJlZDk0MGE0NDYxYzk4ZjY1MDVhNWY0MzY2MTlfMS00LTEtMS00Njg5MQ_df36d4a8-3b6f-4751-b96d-dfd7a31cf730"
      unitRef="usd">3140000</us-gaap:DebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesCurrent
      contextRef="i5235f32286c3431198c094116ea7192b_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl80My9mcmFnOjQ3ZjgwM2VmY2QyNTRiNjFiNzI0MGU2ZDk1M2IxODllL3RhYmxlOmI0NGZiZWQ5NDBhNDQ2MWM5OGY2NTA1YTVmNDM2NjE5L3RhYmxlcmFuZ2U6YjQ0ZmJlZDk0MGE0NDYxYzk4ZjY1MDVhNWY0MzY2MTlfMi0yLTEtMS00Njg5MQ_f3e7463a-351a-45e3-8a36-5bf7092650b5"
      unitRef="usd">60390000</us-gaap:DebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesCurrent
      contextRef="iea26fc49428d4511a2fb37c1bb666a8b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl80My9mcmFnOjQ3ZjgwM2VmY2QyNTRiNjFiNzI0MGU2ZDk1M2IxODllL3RhYmxlOmI0NGZiZWQ5NDBhNDQ2MWM5OGY2NTA1YTVmNDM2NjE5L3RhYmxlcmFuZ2U6YjQ0ZmJlZDk0MGE0NDYxYzk4ZjY1MDVhNWY0MzY2MTlfMi00LTEtMS00Njg5MQ_73a73b1f-bd9d-4cc6-ad13-9911995563a9"
      unitRef="usd">21820000</us-gaap:DebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesCurrent
      contextRef="i3dfcd77b916a46af88c7474c6cb4ec1a_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl80My9mcmFnOjQ3ZjgwM2VmY2QyNTRiNjFiNzI0MGU2ZDk1M2IxODllL3RhYmxlOmI0NGZiZWQ5NDBhNDQ2MWM5OGY2NTA1YTVmNDM2NjE5L3RhYmxlcmFuZ2U6YjQ0ZmJlZDk0MGE0NDYxYzk4ZjY1MDVhNWY0MzY2MTlfMy0yLTEtMS00Njg5MQ_de6f521d-a4f2-4f0c-8990-e646ab3d5d7d"
      unitRef="usd">152295000</us-gaap:DebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesCurrent
      contextRef="id3450fe582114ff195b2b48f8c26afea_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl80My9mcmFnOjQ3ZjgwM2VmY2QyNTRiNjFiNzI0MGU2ZDk1M2IxODllL3RhYmxlOmI0NGZiZWQ5NDBhNDQ2MWM5OGY2NTA1YTVmNDM2NjE5L3RhYmxlcmFuZ2U6YjQ0ZmJlZDk0MGE0NDYxYzk4ZjY1MDVhNWY0MzY2MTlfMy00LTEtMS00Njg5MQ_9eeb33a1-8a19-4005-8521-a2819ce1ba59"
      unitRef="usd">206724000</us-gaap:DebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesCurrent
      contextRef="iee34030c8c804c4a98def156ea552450_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl80My9mcmFnOjQ3ZjgwM2VmY2QyNTRiNjFiNzI0MGU2ZDk1M2IxODllL3RhYmxlOmI0NGZiZWQ5NDBhNDQ2MWM5OGY2NTA1YTVmNDM2NjE5L3RhYmxlcmFuZ2U6YjQ0ZmJlZDk0MGE0NDYxYzk4ZjY1MDVhNWY0MzY2MTlfNC0yLTEtMS00Njg5MQ_2042a4cc-a033-4ac4-8028-4c056de98211"
      unitRef="usd">19530000</us-gaap:DebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesCurrent
      contextRef="i67d405ac9e79458eb8e91ab5d55e0df4_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl80My9mcmFnOjQ3ZjgwM2VmY2QyNTRiNjFiNzI0MGU2ZDk1M2IxODllL3RhYmxlOmI0NGZiZWQ5NDBhNDQ2MWM5OGY2NTA1YTVmNDM2NjE5L3RhYmxlcmFuZ2U6YjQ0ZmJlZDk0MGE0NDYxYzk4ZjY1MDVhNWY0MzY2MTlfNC00LTEtMS00Njg5MQ_e8d081e7-4701-4f4d-bfaf-80e9b5eb10c6"
      unitRef="usd">2494000</us-gaap:DebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesCurrent
      contextRef="i8018f58d25ea48ecbbc969caded6e2f5_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl80My9mcmFnOjQ3ZjgwM2VmY2QyNTRiNjFiNzI0MGU2ZDk1M2IxODllL3RhYmxlOmI0NGZiZWQ5NDBhNDQ2MWM5OGY2NTA1YTVmNDM2NjE5L3RhYmxlcmFuZ2U6YjQ0ZmJlZDk0MGE0NDYxYzk4ZjY1MDVhNWY0MzY2MTlfNS0yLTEtMS00Njg5MQ_56ab8fb4-ea3e-4baf-9f31-64706d7afcac"
      unitRef="usd">50867000</us-gaap:DebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesCurrent
      contextRef="ifa7bf46cccc44c9484be6b855b0a6f1c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl80My9mcmFnOjQ3ZjgwM2VmY2QyNTRiNjFiNzI0MGU2ZDk1M2IxODllL3RhYmxlOmI0NGZiZWQ5NDBhNDQ2MWM5OGY2NTA1YTVmNDM2NjE5L3RhYmxlcmFuZ2U6YjQ0ZmJlZDk0MGE0NDYxYzk4ZjY1MDVhNWY0MzY2MTlfNS00LTEtMS00Njg5MQ_e507cd23-e306-465a-8e6b-900a41a6ec4e"
      unitRef="usd">0</us-gaap:DebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesCurrent
      contextRef="id7882ae6aff54a3aacdef67ddf11a428_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl80My9mcmFnOjQ3ZjgwM2VmY2QyNTRiNjFiNzI0MGU2ZDk1M2IxODllL3RhYmxlOmI0NGZiZWQ5NDBhNDQ2MWM5OGY2NTA1YTVmNDM2NjE5L3RhYmxlcmFuZ2U6YjQ0ZmJlZDk0MGE0NDYxYzk4ZjY1MDVhNWY0MzY2MTlfNy0yLTEtMS00Njg5MQ_9bad803c-0f6a-4e03-800f-2eedf8cb7053"
      unitRef="usd">286210000</us-gaap:DebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesCurrent
      contextRef="i784f65549351439fa4b7bedf90ce7e3f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl80My9mcmFnOjQ3ZjgwM2VmY2QyNTRiNjFiNzI0MGU2ZDk1M2IxODllL3RhYmxlOmI0NGZiZWQ5NDBhNDQ2MWM5OGY2NTA1YTVmNDM2NjE5L3RhYmxlcmFuZ2U6YjQ0ZmJlZDk0MGE0NDYxYzk4ZjY1MDVhNWY0MzY2MTlfNy00LTEtMS00Njg5MQ_45f446ee-fc1e-4da1-9331-88fd3bd8ff06"
      unitRef="usd">234178000</us-gaap:DebtSecuritiesCurrent>
    <us-gaap:InterestReceivable
      contextRef="id7882ae6aff54a3aacdef67ddf11a428_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl80My9mcmFnOjQ3ZjgwM2VmY2QyNTRiNjFiNzI0MGU2ZDk1M2IxODllL3RleHRyZWdpb246NDdmODAzZWZjZDI1NGI2MWI3MjQwZTZkOTUzYjE4OWVfOTM4_e0ec7b50-2292-4c34-a3c2-23979428fde9"
      unitRef="usd">500000</us-gaap:InterestReceivable>
    <us-gaap:InterestReceivable
      contextRef="i784f65549351439fa4b7bedf90ce7e3f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl80My9mcmFnOjQ3ZjgwM2VmY2QyNTRiNjFiNzI0MGU2ZDk1M2IxODllL3RleHRyZWdpb246NDdmODAzZWZjZDI1NGI2MWI3MjQwZTZkOTUzYjE4OWVfOTQ1_339378a8-e1dc-4718-b1c8-5f7d451d4de5"
      unitRef="usd">100000</us-gaap:InterestReceivable>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss
      contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl80My9mcmFnOjQ3ZjgwM2VmY2QyNTRiNjFiNzI0MGU2ZDk1M2IxODllL3RleHRyZWdpb246NDdmODAzZWZjZDI1NGI2MWI3MjQwZTZkOTUzYjE4OWVfMTAyNw_ec5d6ef2-4527-4d30-bc5c-410700e82378"
      unitRef="usd">766000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss
      contextRef="i56599386fa47443a8975bb3f7a6a8c57_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl80My9mcmFnOjQ3ZjgwM2VmY2QyNTRiNjFiNzI0MGU2ZDk1M2IxODllL3RleHRyZWdpb246NDdmODAzZWZjZDI1NGI2MWI3MjQwZTZkOTUzYjE4OWVfMTA5OTUxMTYyOTU2Ng_58238264-c0c6-4a68-8277-3831bcf829d3"
      unitRef="usd">6000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl80OS9mcmFnOjc3NzgxNmZhNmQ0ZDQwYmRhYmQ0YzNjZTZiOThiYTk1L3RleHRyZWdpb246Nzc3ODE2ZmE2ZDRkNDBiZGFiZDRjM2NlNmI5OGJhOTVfOTQy_2357ab93-c982-4df9-b785-7f1c5f38b32f">Inventories&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories are valued under a standard costing methodology on a first-in, first-out basis and are stated at the lower of cost or net realizable value. The Company capitalizes inventory costs related to products to be sold in the ordinary course of business. The Company makes a determination of capitalizing inventory costs for a product based on, among other factors, status of regulatory approval, information regarding safety, efficacy and expectations relating to commercial sales and recoverability of costs. Capitalized costs of inventories for LUPKYNIS mainly include third party manufacturing costs, transportation, storage, insurance, depreciation and allocated internal labor.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company assesses recoverability of inventory each reporting period to determine any write down to net realizable value resulting from excess or obsolete inventories.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of inventory are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,217&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;19,713&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4,336&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,543&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inventories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;26,266&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl80OS9mcmFnOjc3NzgxNmZhNmQ0ZDQwYmRhYmQ0YzNjZTZiOThiYTk1L3RleHRyZWdpb246Nzc3ODE2ZmE2ZDRkNDBiZGFiZDRjM2NlNmI5OGJhOTVfOTQz_09cdd4e7-e2c5-4ebd-8444-f0baccf8fcce">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of inventory are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,217&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;19,713&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4,336&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,543&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inventories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;26,266&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="id7882ae6aff54a3aacdef67ddf11a428_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl80OS9mcmFnOjc3NzgxNmZhNmQ0ZDQwYmRhYmQ0YzNjZTZiOThiYTk1L3RhYmxlOjgxOGE2MGM0MTVhNzQzYmViMGQwNGJkODhjZTFlN2MyL3RhYmxlcmFuZ2U6ODE4YTYwYzQxNWE3NDNiZWIwZDA0YmQ4OGNlMWU3YzJfMS0yLTEtMS00Njg5MQ_128b742b-562c-47fd-a5ca-cc93a5824e32"
      unitRef="usd">2217000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="i784f65549351439fa4b7bedf90ce7e3f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl80OS9mcmFnOjc3NzgxNmZhNmQ0ZDQwYmRhYmQ0YzNjZTZiOThiYTk1L3RhYmxlOjgxOGE2MGM0MTVhNzQzYmViMGQwNGJkODhjZTFlN2MyL3RhYmxlcmFuZ2U6ODE4YTYwYzQxNWE3NDNiZWIwZDA0YmQ4OGNlMWU3YzJfMS00LTEtMS00Njg5MQ_a33fed47-7863-4ea1-8e6f-b868c926dc23"
      unitRef="usd">2217000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="id7882ae6aff54a3aacdef67ddf11a428_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl80OS9mcmFnOjc3NzgxNmZhNmQ0ZDQwYmRhYmQ0YzNjZTZiOThiYTk1L3RhYmxlOjgxOGE2MGM0MTVhNzQzYmViMGQwNGJkODhjZTFlN2MyL3RhYmxlcmFuZ2U6ODE4YTYwYzQxNWE3NDNiZWIwZDA0YmQ4OGNlMWU3YzJfMi0yLTEtMS00Njg5MQ_d8b7b0c9-8330-4638-bbe2-8e9190591701"
      unitRef="usd">19713000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="i784f65549351439fa4b7bedf90ce7e3f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl80OS9mcmFnOjc3NzgxNmZhNmQ0ZDQwYmRhYmQ0YzNjZTZiOThiYTk1L3RhYmxlOjgxOGE2MGM0MTVhNzQzYmViMGQwNGJkODhjZTFlN2MyL3RhYmxlcmFuZ2U6ODE4YTYwYzQxNWE3NDNiZWIwZDA0YmQ4OGNlMWU3YzJfMi00LTEtMS00Njg5MQ_23612fe1-1584-42a5-b020-bbea8ebf207a"
      unitRef="usd">12566000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="id7882ae6aff54a3aacdef67ddf11a428_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl80OS9mcmFnOjc3NzgxNmZhNmQ0ZDQwYmRhYmQ0YzNjZTZiOThiYTk1L3RhYmxlOjgxOGE2MGM0MTVhNzQzYmViMGQwNGJkODhjZTFlN2MyL3RhYmxlcmFuZ2U6ODE4YTYwYzQxNWE3NDNiZWIwZDA0YmQ4OGNlMWU3YzJfMy0yLTEtMS00Njg5MQ_52d3826b-6d1b-42c6-9326-a7429568d9fb"
      unitRef="usd">4336000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="i784f65549351439fa4b7bedf90ce7e3f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl80OS9mcmFnOjc3NzgxNmZhNmQ0ZDQwYmRhYmQ0YzNjZTZiOThiYTk1L3RhYmxlOjgxOGE2MGM0MTVhNzQzYmViMGQwNGJkODhjZTFlN2MyL3RhYmxlcmFuZ2U6ODE4YTYwYzQxNWE3NDNiZWIwZDA0YmQ4OGNlMWU3YzJfMy00LTEtMS00Njg5MQ_9cd7d049-b1e8-4525-9e3e-daf3dbb8d8bd"
      unitRef="usd">4543000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryNet
      contextRef="id7882ae6aff54a3aacdef67ddf11a428_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl80OS9mcmFnOjc3NzgxNmZhNmQ0ZDQwYmRhYmQ0YzNjZTZiOThiYTk1L3RhYmxlOjgxOGE2MGM0MTVhNzQzYmViMGQwNGJkODhjZTFlN2MyL3RhYmxlcmFuZ2U6ODE4YTYwYzQxNWE3NDNiZWIwZDA0YmQ4OGNlMWU3YzJfNC0yLTEtMS00Njg5MQ_cedc5c58-2671-4e89-950d-84a6b3a6e450"
      unitRef="usd">26266000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i784f65549351439fa4b7bedf90ce7e3f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl80OS9mcmFnOjc3NzgxNmZhNmQ0ZDQwYmRhYmQ0YzNjZTZiOThiYTk1L3RhYmxlOjgxOGE2MGM0MTVhNzQzYmViMGQwNGJkODhjZTFlN2MyL3RhYmxlcmFuZ2U6ODE4YTYwYzQxNWE3NDNiZWIwZDA0YmQ4OGNlMWU3YzJfNC00LTEtMS00Njg5MQ_3659594e-20cc-4cf8-ad80-c9c6dacc603f"
      unitRef="usd">19326000</us-gaap:InventoryNet>
    <us-gaap:OtherCurrentAssetsTextBlock
      contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl81Mi9mcmFnOjQ4NTI5N2U4ZWNiMzRlZGM4ZWVhNzU5MWUyZWE4ZTRhL3RleHRyZWdpb246NDg1Mjk3ZThlY2IzNGVkYzhlZWE3NTkxZTJlYThlNGFfMTI0_3c5bd595-9ca2-471f-ab8f-780a93b1dfe3">Prepaid Expenses and Other Current Assets&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid expenses and other current assets are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6,351&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid insurance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;682&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,632&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,966&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;796&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid deposits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,200&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,762&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;12,199&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:OtherCurrentAssetsTextBlock>
    <us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock
      contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl81Mi9mcmFnOjQ4NTI5N2U4ZWNiMzRlZGM4ZWVhNzU5MWUyZWE4ZTRhL3RleHRyZWdpb246NDg1Mjk3ZThlY2IzNGVkYzhlZWE3NTkxZTJlYThlNGFfMTI1_6ce74ef0-aa94-4bbc-aa87-4930a2c35d85">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid expenses and other current assets are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6,351&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid insurance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;682&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,632&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,966&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;796&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid deposits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,200&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,762&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;12,199&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock>
    <auph:PrepaidAssetsCurrent
      contextRef="id7882ae6aff54a3aacdef67ddf11a428_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl81Mi9mcmFnOjQ4NTI5N2U4ZWNiMzRlZGM4ZWVhNzU5MWUyZWE4ZTRhL3RhYmxlOmE5YTY3OWJkMWExYjQ4MjJiZTk2M2M2NjZmZmI1MWEwL3RhYmxlcmFuZ2U6YTlhNjc5YmQxYTFiNDgyMmJlOTYzYzY2NmZmYjUxYTBfMS0yLTEtMS00Njg5MQ_699d61ec-1e81-47e0-aae8-914f5732401a"
      unitRef="usd">6351000</auph:PrepaidAssetsCurrent>
    <auph:PrepaidAssetsCurrent
      contextRef="i784f65549351439fa4b7bedf90ce7e3f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl81Mi9mcmFnOjQ4NTI5N2U4ZWNiMzRlZGM4ZWVhNzU5MWUyZWE4ZTRhL3RhYmxlOmE5YTY3OWJkMWExYjQ4MjJiZTk2M2M2NjZmZmI1MWEwL3RhYmxlcmFuZ2U6YTlhNjc5YmQxYTFiNDgyMmJlOTYzYzY2NmZmYjUxYTBfMS00LTEtMS00Njg5MQ_1e592ca8-40ef-45dc-8db9-209d52b86d2a"
      unitRef="usd">5316000</auph:PrepaidAssetsCurrent>
    <us-gaap:PrepaidInsurance
      contextRef="id7882ae6aff54a3aacdef67ddf11a428_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl81Mi9mcmFnOjQ4NTI5N2U4ZWNiMzRlZGM4ZWVhNzU5MWUyZWE4ZTRhL3RhYmxlOmE5YTY3OWJkMWExYjQ4MjJiZTk2M2M2NjZmZmI1MWEwL3RhYmxlcmFuZ2U6YTlhNjc5YmQxYTFiNDgyMmJlOTYzYzY2NmZmYjUxYTBfMi0yLTEtMS00Njg5MQ_089c1f72-bf49-4e8e-ab6d-421a6c253ecd"
      unitRef="usd">682000</us-gaap:PrepaidInsurance>
    <us-gaap:PrepaidInsurance
      contextRef="i784f65549351439fa4b7bedf90ce7e3f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl81Mi9mcmFnOjQ4NTI5N2U4ZWNiMzRlZGM4ZWVhNzU5MWUyZWE4ZTRhL3RhYmxlOmE5YTY3OWJkMWExYjQ4MjJiZTk2M2M2NjZmZmI1MWEwL3RhYmxlcmFuZ2U6YTlhNjc5YmQxYTFiNDgyMmJlOTYzYzY2NmZmYjUxYTBfMi00LTEtMS00Njg5MQ_4a865a83-26d3-4a80-8ada-0ccebe18e1bf"
      unitRef="usd">1632000</us-gaap:PrepaidInsurance>
    <us-gaap:OtherAssetsCurrent
      contextRef="id7882ae6aff54a3aacdef67ddf11a428_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl81Mi9mcmFnOjQ4NTI5N2U4ZWNiMzRlZGM4ZWVhNzU5MWUyZWE4ZTRhL3RhYmxlOmE5YTY3OWJkMWExYjQ4MjJiZTk2M2M2NjZmZmI1MWEwL3RhYmxlcmFuZ2U6YTlhNjc5YmQxYTFiNDgyMmJlOTYzYzY2NmZmYjUxYTBfMy0yLTEtMS00Njg5MQ_1cf3cdc1-cfa1-494c-adfb-dc11f7311175"
      unitRef="usd">3966000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="i784f65549351439fa4b7bedf90ce7e3f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl81Mi9mcmFnOjQ4NTI5N2U4ZWNiMzRlZGM4ZWVhNzU5MWUyZWE4ZTRhL3RhYmxlOmE5YTY3OWJkMWExYjQ4MjJiZTk2M2M2NjZmZmI1MWEwL3RhYmxlcmFuZ2U6YTlhNjc5YmQxYTFiNDgyMmJlOTYzYzY2NmZmYjUxYTBfMy00LTEtMS00Njg5MQ_2bcffd19-de4a-462f-a745-9ddb4cf6732a"
      unitRef="usd">796000</us-gaap:OtherAssetsCurrent>
    <auph:PrepaidRentAndPrepaidContinuingStudies
      contextRef="id7882ae6aff54a3aacdef67ddf11a428_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl81Mi9mcmFnOjQ4NTI5N2U4ZWNiMzRlZGM4ZWVhNzU5MWUyZWE4ZTRhL3RhYmxlOmE5YTY3OWJkMWExYjQ4MjJiZTk2M2M2NjZmZmI1MWEwL3RhYmxlcmFuZ2U6YTlhNjc5YmQxYTFiNDgyMmJlOTYzYzY2NmZmYjUxYTBfNC0yLTEtMS00Njg5MQ_991c899d-66c0-4168-9681-d06fca0e45a8"
      unitRef="usd">1200000</auph:PrepaidRentAndPrepaidContinuingStudies>
    <auph:PrepaidRentAndPrepaidContinuingStudies
      contextRef="i784f65549351439fa4b7bedf90ce7e3f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl81Mi9mcmFnOjQ4NTI5N2U4ZWNiMzRlZGM4ZWVhNzU5MWUyZWE4ZTRhL3RhYmxlOmE5YTY3OWJkMWExYjQ4MjJiZTk2M2M2NjZmZmI1MWEwL3RhYmxlcmFuZ2U6YTlhNjc5YmQxYTFiNDgyMmJlOTYzYzY2NmZmYjUxYTBfNC00LTEtMS00Njg5MQ_306337f1-0add-456b-a5fd-349456d748f2"
      unitRef="usd">4762000</auph:PrepaidRentAndPrepaidContinuingStudies>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="id7882ae6aff54a3aacdef67ddf11a428_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl81Mi9mcmFnOjQ4NTI5N2U4ZWNiMzRlZGM4ZWVhNzU5MWUyZWE4ZTRhL3RhYmxlOmE5YTY3OWJkMWExYjQ4MjJiZTk2M2M2NjZmZmI1MWEwL3RhYmxlcmFuZ2U6YTlhNjc5YmQxYTFiNDgyMmJlOTYzYzY2NmZmYjUxYTBfNS0yLTEtMS00Njg5MQ_a1194edf-da66-425c-a1a7-28ed38ef54ec"
      unitRef="usd">12199000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i784f65549351439fa4b7bedf90ce7e3f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl81Mi9mcmFnOjQ4NTI5N2U4ZWNiMzRlZGM4ZWVhNzU5MWUyZWE4ZTRhL3RhYmxlOmE5YTY3OWJkMWExYjQ4MjJiZTk2M2M2NjZmZmI1MWEwL3RhYmxlcmFuZ2U6YTlhNjc5YmQxYTFiNDgyMmJlOTYzYzY2NmZmYjUxYTBfNS00LTEtMS00Njg5MQ_be266423-6202-4aed-86d0-8f8c8016beb4"
      unitRef="usd">12506000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:IntangibleAssetsDisclosureTextBlock
      contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl81NS9mcmFnOmYxNjVmMjIyM2VmNzRkMTdhY2Q0MGJmMGU5ZTJlMzNiL3RleHRyZWdpb246ZjE2NWYyMjIzZWY3NGQxN2FjZDQwYmYwZTllMmUzM2JfMjg3_9ab06955-ae2e-4922-8cb6-e4ccf734f099">Intangible Assets&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the carrying amount of intangible assets, net of accumulated amortization. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.584%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.424%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross Carrying&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Patents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,471&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(1,200)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;271&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired intellectual property and reacquired rights&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;15,126&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(9,063)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6,063&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Internal-use software implementation costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,873&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(1,325)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,548&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;19,470&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(11,588)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;7,882&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.584%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.424%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross Carrying&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Patents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,471&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,176)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired intellectual property and reacquired rights&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,804)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Internal-use software implementation costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,873&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,086)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,066)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;Amortization expense for the three months ended March&#160;31, 2022 and 2021 was $0.5 million for both periods.</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock
      contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl81NS9mcmFnOmYxNjVmMjIyM2VmNzRkMTdhY2Q0MGJmMGU5ZTJlMzNiL3RleHRyZWdpb246ZjE2NWYyMjIzZWY3NGQxN2FjZDQwYmYwZTllMmUzM2JfMjg4_dc4d6a40-820d-4866-95a5-b10bf44c83e8">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the carrying amount of intangible assets, net of accumulated amortization. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.584%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.424%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross Carrying&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Patents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,471&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(1,200)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;271&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired intellectual property and reacquired rights&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;15,126&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(9,063)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6,063&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Internal-use software implementation costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,873&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(1,325)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,548&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;19,470&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(11,588)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;7,882&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.584%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.424%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross Carrying&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Patents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,471&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,176)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired intellectual property and reacquired rights&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,804)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Internal-use software implementation costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,873&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,086)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,066)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="iafe3ea51a2814a819363caa378a6a94a_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl81NS9mcmFnOmYxNjVmMjIyM2VmNzRkMTdhY2Q0MGJmMGU5ZTJlMzNiL3RhYmxlOjY2Zjg4N2I0Njc5ZDQzNDdhMWIyODliNzc0ZDE3OGY0L3RhYmxlcmFuZ2U6NjZmODg3YjQ2NzlkNDM0N2ExYjI4OWI3NzRkMTc4ZjRfMi0yLTEtMS00Njg5MQ_e7f3fe2c-ed51-4b2b-b95d-4f49a3b20fa1"
      unitRef="usd">1471000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="iafe3ea51a2814a819363caa378a6a94a_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl81NS9mcmFnOmYxNjVmMjIyM2VmNzRkMTdhY2Q0MGJmMGU5ZTJlMzNiL3RhYmxlOjY2Zjg4N2I0Njc5ZDQzNDdhMWIyODliNzc0ZDE3OGY0L3RhYmxlcmFuZ2U6NjZmODg3YjQ2NzlkNDM0N2ExYjI4OWI3NzRkMTc4ZjRfMi00LTEtMS00Njg5MQ_d0b10162-272a-4aac-93ae-d547738e2acc"
      unitRef="usd">1200000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="iafe3ea51a2814a819363caa378a6a94a_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl81NS9mcmFnOmYxNjVmMjIyM2VmNzRkMTdhY2Q0MGJmMGU5ZTJlMzNiL3RhYmxlOjY2Zjg4N2I0Njc5ZDQzNDdhMWIyODliNzc0ZDE3OGY0L3RhYmxlcmFuZ2U6NjZmODg3YjQ2NzlkNDM0N2ExYjI4OWI3NzRkMTc4ZjRfMi02LTEtMS00Njg5MQ_d50e2f08-5b21-4a48-8396-10de49ef0c3a"
      unitRef="usd">271000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i24997e0475c34f689abd5af9a097e9c9_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl81NS9mcmFnOmYxNjVmMjIyM2VmNzRkMTdhY2Q0MGJmMGU5ZTJlMzNiL3RhYmxlOjY2Zjg4N2I0Njc5ZDQzNDdhMWIyODliNzc0ZDE3OGY0L3RhYmxlcmFuZ2U6NjZmODg3YjQ2NzlkNDM0N2ExYjI4OWI3NzRkMTc4ZjRfMy0yLTEtMS00Njg5MQ_cf14ecb4-b476-4b10-ae86-6b5dece898c2"
      unitRef="usd">15126000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i24997e0475c34f689abd5af9a097e9c9_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl81NS9mcmFnOmYxNjVmMjIyM2VmNzRkMTdhY2Q0MGJmMGU5ZTJlMzNiL3RhYmxlOjY2Zjg4N2I0Njc5ZDQzNDdhMWIyODliNzc0ZDE3OGY0L3RhYmxlcmFuZ2U6NjZmODg3YjQ2NzlkNDM0N2ExYjI4OWI3NzRkMTc4ZjRfMy00LTEtMS00Njg5MQ_7ec1e670-e807-479f-b5b0-bf92e390cb25"
      unitRef="usd">9063000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i24997e0475c34f689abd5af9a097e9c9_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl81NS9mcmFnOmYxNjVmMjIyM2VmNzRkMTdhY2Q0MGJmMGU5ZTJlMzNiL3RhYmxlOjY2Zjg4N2I0Njc5ZDQzNDdhMWIyODliNzc0ZDE3OGY0L3RhYmxlcmFuZ2U6NjZmODg3YjQ2NzlkNDM0N2ExYjI4OWI3NzRkMTc4ZjRfMy02LTEtMS00Njg5MQ_484f16d7-9e3f-41d2-a1bc-fbea6c0b677f"
      unitRef="usd">6063000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i8116ed39be8b477bb9e41a6b0e3aee53_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl81NS9mcmFnOmYxNjVmMjIyM2VmNzRkMTdhY2Q0MGJmMGU5ZTJlMzNiL3RhYmxlOjY2Zjg4N2I0Njc5ZDQzNDdhMWIyODliNzc0ZDE3OGY0L3RhYmxlcmFuZ2U6NjZmODg3YjQ2NzlkNDM0N2ExYjI4OWI3NzRkMTc4ZjRfNC0yLTEtMS00Njg5MQ_285ade06-e556-471f-a7ff-2c1e3e8ff662"
      unitRef="usd">2873000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i8116ed39be8b477bb9e41a6b0e3aee53_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl81NS9mcmFnOmYxNjVmMjIyM2VmNzRkMTdhY2Q0MGJmMGU5ZTJlMzNiL3RhYmxlOjY2Zjg4N2I0Njc5ZDQzNDdhMWIyODliNzc0ZDE3OGY0L3RhYmxlcmFuZ2U6NjZmODg3YjQ2NzlkNDM0N2ExYjI4OWI3NzRkMTc4ZjRfNC00LTEtMS00Njg5MQ_b4066554-1bb5-4bb6-b060-caa4e79df78e"
      unitRef="usd">1325000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i8116ed39be8b477bb9e41a6b0e3aee53_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl81NS9mcmFnOmYxNjVmMjIyM2VmNzRkMTdhY2Q0MGJmMGU5ZTJlMzNiL3RhYmxlOjY2Zjg4N2I0Njc5ZDQzNDdhMWIyODliNzc0ZDE3OGY0L3RhYmxlcmFuZ2U6NjZmODg3YjQ2NzlkNDM0N2ExYjI4OWI3NzRkMTc4ZjRfNC02LTEtMS00Njg5MQ_64981f8a-cefb-4942-bfa6-a2097d7d38db"
      unitRef="usd">1548000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="id7882ae6aff54a3aacdef67ddf11a428_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl81NS9mcmFnOmYxNjVmMjIyM2VmNzRkMTdhY2Q0MGJmMGU5ZTJlMzNiL3RhYmxlOjY2Zjg4N2I0Njc5ZDQzNDdhMWIyODliNzc0ZDE3OGY0L3RhYmxlcmFuZ2U6NjZmODg3YjQ2NzlkNDM0N2ExYjI4OWI3NzRkMTc4ZjRfNS0yLTEtMS00Njg5MQ_4934b60a-ddea-40af-b24f-7094ea6add75"
      unitRef="usd">19470000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="id7882ae6aff54a3aacdef67ddf11a428_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl81NS9mcmFnOmYxNjVmMjIyM2VmNzRkMTdhY2Q0MGJmMGU5ZTJlMzNiL3RhYmxlOjY2Zjg4N2I0Njc5ZDQzNDdhMWIyODliNzc0ZDE3OGY0L3RhYmxlcmFuZ2U6NjZmODg3YjQ2NzlkNDM0N2ExYjI4OWI3NzRkMTc4ZjRfNS00LTEtMS00Njg5MQ_ba6511ec-41f1-4bd3-aea2-9024a44b26ec"
      unitRef="usd">11588000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="id7882ae6aff54a3aacdef67ddf11a428_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl81NS9mcmFnOmYxNjVmMjIyM2VmNzRkMTdhY2Q0MGJmMGU5ZTJlMzNiL3RhYmxlOjY2Zjg4N2I0Njc5ZDQzNDdhMWIyODliNzc0ZDE3OGY0L3RhYmxlcmFuZ2U6NjZmODg3YjQ2NzlkNDM0N2ExYjI4OWI3NzRkMTc4ZjRfNS02LTEtMS00Njg5MQ_831c25d9-2035-489d-84bb-c584b8d63015"
      unitRef="usd">7882000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="idb5a73ea0d9f46779238702423cc8e54_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl81NS9mcmFnOmYxNjVmMjIyM2VmNzRkMTdhY2Q0MGJmMGU5ZTJlMzNiL3RhYmxlOjE0YWM4NmU1OWM3MDQ5ZjdiZDA0YTMzZmY5OTdmZmRlL3RhYmxlcmFuZ2U6MTRhYzg2ZTU5YzcwNDlmN2JkMDRhMzNmZjk5N2ZmZGVfMi0yLTEtMS00Njg5MQ_0f45958a-59e0-4091-9a42-410c2328aa94"
      unitRef="usd">1471000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="idb5a73ea0d9f46779238702423cc8e54_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl81NS9mcmFnOmYxNjVmMjIyM2VmNzRkMTdhY2Q0MGJmMGU5ZTJlMzNiL3RhYmxlOjE0YWM4NmU1OWM3MDQ5ZjdiZDA0YTMzZmY5OTdmZmRlL3RhYmxlcmFuZ2U6MTRhYzg2ZTU5YzcwNDlmN2JkMDRhMzNmZjk5N2ZmZGVfMi00LTEtMS00Njg5MQ_987e879a-8961-4692-b22a-8ac3b4b90c43"
      unitRef="usd">1176000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="idb5a73ea0d9f46779238702423cc8e54_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl81NS9mcmFnOmYxNjVmMjIyM2VmNzRkMTdhY2Q0MGJmMGU5ZTJlMzNiL3RhYmxlOjE0YWM4NmU1OWM3MDQ5ZjdiZDA0YTMzZmY5OTdmZmRlL3RhYmxlcmFuZ2U6MTRhYzg2ZTU5YzcwNDlmN2JkMDRhMzNmZjk5N2ZmZGVfMi02LTEtMS00Njg5MQ_d65f4900-79ce-4f00-bfd6-7bbcb6f66295"
      unitRef="usd">295000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i2473f3d624824cfa9dc37ac978052ad5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl81NS9mcmFnOmYxNjVmMjIyM2VmNzRkMTdhY2Q0MGJmMGU5ZTJlMzNiL3RhYmxlOjE0YWM4NmU1OWM3MDQ5ZjdiZDA0YTMzZmY5OTdmZmRlL3RhYmxlcmFuZ2U6MTRhYzg2ZTU5YzcwNDlmN2JkMDRhMzNmZjk5N2ZmZGVfMy0yLTEtMS00Njg5MQ_57ac1b7f-2ee4-4480-acfd-d9730baf70bc"
      unitRef="usd">15126000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i2473f3d624824cfa9dc37ac978052ad5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl81NS9mcmFnOmYxNjVmMjIyM2VmNzRkMTdhY2Q0MGJmMGU5ZTJlMzNiL3RhYmxlOjE0YWM4NmU1OWM3MDQ5ZjdiZDA0YTMzZmY5OTdmZmRlL3RhYmxlcmFuZ2U6MTRhYzg2ZTU5YzcwNDlmN2JkMDRhMzNmZjk5N2ZmZGVfMy00LTEtMS00Njg5MQ_1e74cc1e-426e-41a2-9430-69b1b2fcb079"
      unitRef="usd">8804000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i2473f3d624824cfa9dc37ac978052ad5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl81NS9mcmFnOmYxNjVmMjIyM2VmNzRkMTdhY2Q0MGJmMGU5ZTJlMzNiL3RhYmxlOjE0YWM4NmU1OWM3MDQ5ZjdiZDA0YTMzZmY5OTdmZmRlL3RhYmxlcmFuZ2U6MTRhYzg2ZTU5YzcwNDlmN2JkMDRhMzNmZjk5N2ZmZGVfMy02LTEtMS00Njg5MQ_d66c17f5-d632-4e2f-b1f8-5a5b6890eb5d"
      unitRef="usd">6322000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i1b3926824aa84496acd5d466e41d1cb4_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl81NS9mcmFnOmYxNjVmMjIyM2VmNzRkMTdhY2Q0MGJmMGU5ZTJlMzNiL3RhYmxlOjE0YWM4NmU1OWM3MDQ5ZjdiZDA0YTMzZmY5OTdmZmRlL3RhYmxlcmFuZ2U6MTRhYzg2ZTU5YzcwNDlmN2JkMDRhMzNmZjk5N2ZmZGVfNC0yLTEtMS00Njg5MQ_27688142-e91a-4587-9751-f0343b947ae9"
      unitRef="usd">2873000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i1b3926824aa84496acd5d466e41d1cb4_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl81NS9mcmFnOmYxNjVmMjIyM2VmNzRkMTdhY2Q0MGJmMGU5ZTJlMzNiL3RhYmxlOjE0YWM4NmU1OWM3MDQ5ZjdiZDA0YTMzZmY5OTdmZmRlL3RhYmxlcmFuZ2U6MTRhYzg2ZTU5YzcwNDlmN2JkMDRhMzNmZjk5N2ZmZGVfNC00LTEtMS00Njg5MQ_c9a60279-e1f3-426f-924c-290f7ef7ce53"
      unitRef="usd">1086000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i1b3926824aa84496acd5d466e41d1cb4_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl81NS9mcmFnOmYxNjVmMjIyM2VmNzRkMTdhY2Q0MGJmMGU5ZTJlMzNiL3RhYmxlOjE0YWM4NmU1OWM3MDQ5ZjdiZDA0YTMzZmY5OTdmZmRlL3RhYmxlcmFuZ2U6MTRhYzg2ZTU5YzcwNDlmN2JkMDRhMzNmZjk5N2ZmZGVfNC02LTEtMS00Njg5MQ_8869a134-cb30-407a-897a-a9c65c463f89"
      unitRef="usd">1787000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i784f65549351439fa4b7bedf90ce7e3f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl81NS9mcmFnOmYxNjVmMjIyM2VmNzRkMTdhY2Q0MGJmMGU5ZTJlMzNiL3RhYmxlOjE0YWM4NmU1OWM3MDQ5ZjdiZDA0YTMzZmY5OTdmZmRlL3RhYmxlcmFuZ2U6MTRhYzg2ZTU5YzcwNDlmN2JkMDRhMzNmZjk5N2ZmZGVfNS0yLTEtMS00Njg5MQ_1d54d1e1-0966-49b8-9eed-30dfcadd930d"
      unitRef="usd">19470000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i784f65549351439fa4b7bedf90ce7e3f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl81NS9mcmFnOmYxNjVmMjIyM2VmNzRkMTdhY2Q0MGJmMGU5ZTJlMzNiL3RhYmxlOjE0YWM4NmU1OWM3MDQ5ZjdiZDA0YTMzZmY5OTdmZmRlL3RhYmxlcmFuZ2U6MTRhYzg2ZTU5YzcwNDlmN2JkMDRhMzNmZjk5N2ZmZGVfNS00LTEtMS00Njg5MQ_bdec8dec-8550-4b83-a4c9-b2d05edcd0e0"
      unitRef="usd">11066000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i784f65549351439fa4b7bedf90ce7e3f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl81NS9mcmFnOmYxNjVmMjIyM2VmNzRkMTdhY2Q0MGJmMGU5ZTJlMzNiL3RhYmxlOjE0YWM4NmU1OWM3MDQ5ZjdiZDA0YTMzZmY5OTdmZmRlL3RhYmxlcmFuZ2U6MTRhYzg2ZTU5YzcwNDlmN2JkMDRhMzNmZjk5N2ZmZGVfNS02LTEtMS00Njg5MQ_e4b0c3d5-ea67-499c-88b5-ec74edeb710d"
      unitRef="usd">8404000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i56599386fa47443a8975bb3f7a6a8c57_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl81NS9mcmFnOmYxNjVmMjIyM2VmNzRkMTdhY2Q0MGJmMGU5ZTJlMzNiL3RleHRyZWdpb246ZjE2NWYyMjIzZWY3NGQxN2FjZDQwYmYwZTllMmUzM2JfMTk2_08c9e462-5bc8-49d4-9408-971fc001b56b"
      unitRef="usd">500000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl81NS9mcmFnOmYxNjVmMjIyM2VmNzRkMTdhY2Q0MGJmMGU5ZTJlMzNiL3RleHRyZWdpb246ZjE2NWYyMjIzZWY3NGQxN2FjZDQwYmYwZTllMmUzM2JfMTk2_74d839ed-76d4-4785-bbff-b8d9d557397f"
      unitRef="usd">500000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl81OC9mcmFnOmJhZmFkMmZjZGQ5OTRkMmE4ZmQxMTg4M2Y0NjcxMjNmL3RleHRyZWdpb246YmFmYWQyZmNkZDk5NGQyYThmZDExODgzZjQ2NzEyM2ZfMzMx_5f216d3d-af9d-446c-887c-f09893b38b7a">Property and Equipment, net&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, net are as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;472&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,978&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,978&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Office equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;645&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;645&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;976&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;260&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;5,331&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,254&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(999)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(836)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4,332&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl81OC9mcmFnOmJhZmFkMmZjZGQ5OTRkMmE4ZmQxMTg4M2Y0NjcxMjNmL3RleHRyZWdpb246YmFmYWQyZmNkZDk5NGQyYThmZDExODgzZjQ2NzEyM2ZfMzMy_3c6c8a7f-5ec9-490c-880f-f09b7e34d518">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, net are as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;472&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,978&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,978&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Office equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;645&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;645&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;976&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;260&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;5,331&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,254&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(999)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(836)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4,332&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i24b881bff2734aaa92863336ea94e41e_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl81OC9mcmFnOmJhZmFkMmZjZGQ5OTRkMmE4ZmQxMTg4M2Y0NjcxMjNmL3RhYmxlOmJiYWM2MmRmZTQwMzQ5ZDI5MDJhYzNjOWVlZTA4YmRjL3RhYmxlcmFuZ2U6YmJhYzYyZGZlNDAzNDlkMjkwMmFjM2M5ZWVlMDhiZGNfMS0yLTEtMS00Njg5MQ_1678b718-440b-426f-9518-2225de11f32c"
      unitRef="usd">472000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i33ea857e82c542399286eb48ddbe86ef_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl81OC9mcmFnOmJhZmFkMmZjZGQ5OTRkMmE4ZmQxMTg4M2Y0NjcxMjNmL3RhYmxlOmJiYWM2MmRmZTQwMzQ5ZDI5MDJhYzNjOWVlZTA4YmRjL3RhYmxlcmFuZ2U6YmJhYzYyZGZlNDAzNDlkMjkwMmFjM2M5ZWVlMDhiZGNfMS00LTEtMS00Njg5MQ_60e1ccea-46de-49a1-af8b-3b364382cdc7"
      unitRef="usd">393000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i92bd80a74b4b4c98b74a56c4941dbae8_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl81OC9mcmFnOmJhZmFkMmZjZGQ5OTRkMmE4ZmQxMTg4M2Y0NjcxMjNmL3RhYmxlOmJiYWM2MmRmZTQwMzQ5ZDI5MDJhYzNjOWVlZTA4YmRjL3RhYmxlcmFuZ2U6YmJhYzYyZGZlNDAzNDlkMjkwMmFjM2M5ZWVlMDhiZGNfMi0yLTEtMS00Njg5MQ_cf03e423-c6f0-46da-9206-74b842c66a88"
      unitRef="usd">2978000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ic252965e91864c4ca85c5288d34a489d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl81OC9mcmFnOmJhZmFkMmZjZGQ5OTRkMmE4ZmQxMTg4M2Y0NjcxMjNmL3RhYmxlOmJiYWM2MmRmZTQwMzQ5ZDI5MDJhYzNjOWVlZTA4YmRjL3RhYmxlcmFuZ2U6YmJhYzYyZGZlNDAzNDlkMjkwMmFjM2M5ZWVlMDhiZGNfMi00LTEtMS00Njg5MQ_c465fdd1-e066-404f-bcbd-578c7be17907"
      unitRef="usd">2978000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ie8b21348dac34f0191509120fede5c4c_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl81OC9mcmFnOmJhZmFkMmZjZGQ5OTRkMmE4ZmQxMTg4M2Y0NjcxMjNmL3RhYmxlOmJiYWM2MmRmZTQwMzQ5ZDI5MDJhYzNjOWVlZTA4YmRjL3RhYmxlcmFuZ2U6YmJhYzYyZGZlNDAzNDlkMjkwMmFjM2M5ZWVlMDhiZGNfMy0yLTEtMS00Njg5MQ_c63dd669-fa7e-4115-9532-454d41d560ec"
      unitRef="usd">645000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i9a37e52ecdc4461f971b3b1b848318b1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl81OC9mcmFnOmJhZmFkMmZjZGQ5OTRkMmE4ZmQxMTg4M2Y0NjcxMjNmL3RhYmxlOmJiYWM2MmRmZTQwMzQ5ZDI5MDJhYzNjOWVlZTA4YmRjL3RhYmxlcmFuZ2U6YmJhYzYyZGZlNDAzNDlkMjkwMmFjM2M5ZWVlMDhiZGNfMy00LTEtMS00Njg5MQ_04ae6f9c-8716-4c40-a4e1-6399f27ecbb8"
      unitRef="usd">645000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i8774cc7bdb954684aaebe802c8d2b5ca_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl81OC9mcmFnOmJhZmFkMmZjZGQ5OTRkMmE4ZmQxMTg4M2Y0NjcxMjNmL3RhYmxlOmJiYWM2MmRmZTQwMzQ5ZDI5MDJhYzNjOWVlZTA4YmRjL3RhYmxlcmFuZ2U6YmJhYzYyZGZlNDAzNDlkMjkwMmFjM2M5ZWVlMDhiZGNfNC0yLTEtMS01MTI2NQ_370a8a2e-1586-4e99-92b0-266dff6820de"
      unitRef="usd">976000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ida382f7681f54ed38ba2838dbf0642cd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl81OC9mcmFnOmJhZmFkMmZjZGQ5OTRkMmE4ZmQxMTg4M2Y0NjcxMjNmL3RhYmxlOmJiYWM2MmRmZTQwMzQ5ZDI5MDJhYzNjOWVlZTA4YmRjL3RhYmxlcmFuZ2U6YmJhYzYyZGZlNDAzNDlkMjkwMmFjM2M5ZWVlMDhiZGNfNC00LTEtMS01MTI2NQ_d7cb67db-3e79-45bb-bb83-90237570289f"
      unitRef="usd">976000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ib8a4d21008a14bdda5d40b91949726ff_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl81OC9mcmFnOmJhZmFkMmZjZGQ5OTRkMmE4ZmQxMTg4M2Y0NjcxMjNmL3RhYmxlOmJiYWM2MmRmZTQwMzQ5ZDI5MDJhYzNjOWVlZTA4YmRjL3RhYmxlcmFuZ2U6YmJhYzYyZGZlNDAzNDlkMjkwMmFjM2M5ZWVlMDhiZGNfNC0yLTEtMS00Njg5MQ_5c91b82e-5382-4d24-9afd-c6209cd746d1"
      unitRef="usd">260000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ic45495e9bd3646529b0eba68d7729780_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl81OC9mcmFnOmJhZmFkMmZjZGQ5OTRkMmE4ZmQxMTg4M2Y0NjcxMjNmL3RhYmxlOmJiYWM2MmRmZTQwMzQ5ZDI5MDJhYzNjOWVlZTA4YmRjL3RhYmxlcmFuZ2U6YmJhYzYyZGZlNDAzNDlkMjkwMmFjM2M5ZWVlMDhiZGNfNC00LTEtMS00Njg5MQ_ec45be7e-963d-49e9-8522-b65d3aab8d6d"
      unitRef="usd">262000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="id7882ae6aff54a3aacdef67ddf11a428_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl81OC9mcmFnOmJhZmFkMmZjZGQ5OTRkMmE4ZmQxMTg4M2Y0NjcxMjNmL3RhYmxlOmJiYWM2MmRmZTQwMzQ5ZDI5MDJhYzNjOWVlZTA4YmRjL3RhYmxlcmFuZ2U6YmJhYzYyZGZlNDAzNDlkMjkwMmFjM2M5ZWVlMDhiZGNfNS0yLTEtMS00Njg5MQ_4aa40ac3-0bb2-4905-8f01-120d758218b4"
      unitRef="usd">5331000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i784f65549351439fa4b7bedf90ce7e3f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl81OC9mcmFnOmJhZmFkMmZjZGQ5OTRkMmE4ZmQxMTg4M2Y0NjcxMjNmL3RhYmxlOmJiYWM2MmRmZTQwMzQ5ZDI5MDJhYzNjOWVlZTA4YmRjL3RhYmxlcmFuZ2U6YmJhYzYyZGZlNDAzNDlkMjkwMmFjM2M5ZWVlMDhiZGNfNS00LTEtMS00Njg5MQ_61a3a265-ee2b-4718-a676-3ad579131915"
      unitRef="usd">5254000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="id7882ae6aff54a3aacdef67ddf11a428_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl81OC9mcmFnOmJhZmFkMmZjZGQ5OTRkMmE4ZmQxMTg4M2Y0NjcxMjNmL3RhYmxlOmJiYWM2MmRmZTQwMzQ5ZDI5MDJhYzNjOWVlZTA4YmRjL3RhYmxlcmFuZ2U6YmJhYzYyZGZlNDAzNDlkMjkwMmFjM2M5ZWVlMDhiZGNfNi0yLTEtMS00Njg5MQ_e5f32d74-f30e-43b2-b857-9879ec05d607"
      unitRef="usd">999000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i784f65549351439fa4b7bedf90ce7e3f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl81OC9mcmFnOmJhZmFkMmZjZGQ5OTRkMmE4ZmQxMTg4M2Y0NjcxMjNmL3RhYmxlOmJiYWM2MmRmZTQwMzQ5ZDI5MDJhYzNjOWVlZTA4YmRjL3RhYmxlcmFuZ2U6YmJhYzYyZGZlNDAzNDlkMjkwMmFjM2M5ZWVlMDhiZGNfNi00LTEtMS00Njg5MQ_ac024879-d553-4aac-8cb7-d49c92dd5e62"
      unitRef="usd">836000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="id7882ae6aff54a3aacdef67ddf11a428_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl81OC9mcmFnOmJhZmFkMmZjZGQ5OTRkMmE4ZmQxMTg4M2Y0NjcxMjNmL3RhYmxlOmJiYWM2MmRmZTQwMzQ5ZDI5MDJhYzNjOWVlZTA4YmRjL3RhYmxlcmFuZ2U6YmJhYzYyZGZlNDAzNDlkMjkwMmFjM2M5ZWVlMDhiZGNfNy0yLTEtMS00Njg5MQ_981bf617-2e87-4115-ad11-4cf98a8a9f32"
      unitRef="usd">4332000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i784f65549351439fa4b7bedf90ce7e3f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl81OC9mcmFnOmJhZmFkMmZjZGQ5OTRkMmE4ZmQxMTg4M2Y0NjcxMjNmL3RhYmxlOmJiYWM2MmRmZTQwMzQ5ZDI5MDJhYzNjOWVlZTA4YmRjL3RhYmxlcmFuZ2U6YmJhYzYyZGZlNDAzNDlkMjkwMmFjM2M5ZWVlMDhiZGNfNy00LTEtMS00Njg5MQ_09096ec0-532b-471e-976f-3b1741a7b96a"
      unitRef="usd">4418000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl82MS9mcmFnOjhhNTE5MDJjNjUzMDQ2NWQ5MWE2MWM4NGJmMTVjYjJiL3RleHRyZWdpb246OGE1MTkwMmM2NTMwNDY1ZDkxYTYxYzg0YmYxNWNiMmJfNDgwNQ_368b1db0-9676-4b8d-99b4-21bd70d9eb91">Lease Obligations&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has the following lease obligations:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Victoria, British Columbia&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the fourth quarter of 2020, the Company entered into facility and furniture leases for its head office located in Victoria, British Columbia for a total space of 13,206 square feet of office space for the facility lease. The lease terms commenced on January 1, 2021 for the facility and furniture leases. As of March&#160;31, 2022, the Company had $0.1 million right-of-use assets (ROU assets) and $0.1 million lease liabilities related to the leases. The Company recognized operating lease costs that are included in SG&amp;amp;A expenses in the condensed consolidated statements of operations. The incremental borrowing rate applied to the lease liabilities on January 1, 2021 was 4.08% based on financial position of the Company, geographical region and terms of lease.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During August 2020, the Company signed a lease for commercial office space in Victoria, British Columbia. The present value of the expected minimum lease payments for this lease are $2.3&#160;million. As of March&#160;31, 2022, the lease has not commenced and as a result, there has been no accounting recognition associated with the lease.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Rockville, Maryland&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During March 2020, the Company entered into a lease for its U.S. commercial office in Rockville, Maryland for a total of 30,531 square feet of office space. The lease has a remaining term of approximately 9 years and has an option to extend for two five-year periods after the initial term of 11 years has elapsed and has an option to terminate after seven years. As of March&#160;31, 2022, the Company had a right-of-use asset of $5.1 million and lease liability of $8.5 million included in the condensed consolidated balance sheets. As of December&#160;31, 2021, the Company had a right of use asset of $5.2 million and lease liability of $8.6 million included in the condensed consolidated balance sheets. The Company recorded leasehold improvement incentives in the amount of $2.3&#160;million as additions to the lease liability. The lease term commenced on March 12, 2020. When measuring the lease liability, the Company discounted lease payments using its incremental borrowing rate at March 12, 2020. The incremental borrowing rate applied to the lease liability on March 12, 2020 was 5.2% based on the financial position of the Company, geographical region and term of lease.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Edmonton, Alberta&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognized the lease premises in Edmonton, Alberta as a short-term lease in which expenses are incurred in SG&amp;amp;A. The lease is not material to the Company's financial position.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Beginning January 1, 2021, the Company began to incur variable lease costs under the existing Victoria and Rockville leases. These costs include operation and maintenance costs included in SG&amp;amp;A and are expensed as incurred. The variable leases costs are not material to the Company's financial position.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The operating lease costs for the three months ended March&#160;31, 2022 and March&#160;31, 2021 are $0.3&#160;million for both periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides supplemental balance sheet information related to the operating lease ROU assets and lease liabilities:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.087%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.747%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.297%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.717%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance Sheet Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease right of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;5,232&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,383&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,009&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,059&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;7,562&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;8,571&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,739&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table represents the weighted-average remaining lease term and discount rate as of March&#160;31, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Remaining Lease Term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Discount Rate&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.30&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.20%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:7pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a summary of operating lease liabilities payments for the next five years and thereafter:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.346%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Operating Lease Payments&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Remainder of 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;863&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,061&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,085&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,110&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,135&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;5,638&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total future minimum lease payments &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;10,892&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: lease imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(2,321)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total future minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;8,571&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 15, 2020, the Company entered into a collaborative agreement with Lonza to build a dedicated manufacturing facility within Lonza&#x2019;s existing small molecule facility in Visp, Switzerland. The dedicated facility (also referred to as "monoplant") will be equipped with state-of-the-art manufacturing equipment to provide cost and production efficiency for the manufacture of voclosporin, while expanding existing capacity and providing supply security to meet future commercial demand.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Following U.S. regulatory approval of LUPKYNIS in January 2021, the Company has commenced a capital expenditure payment program for the monoplant totaling approximately CHF 21.0&#160;million. The first capital expenditure payment was made in February 2021 of $11.8&#160;million and was treated as an upfront lease payment and recorded under other non-current assets on the condensed consolidated balance sheets. The second payment is not due until the facility fulfills the required operational qualifications which is estimated to be during 2023. Upon completion of the monoplant, the Company will have the right to maintain sole dedicated use of the monoplant by paying a quarterly fixed facility fee. The Company expects to account for the arrangement as a finance lease under ASC 842. The present value of the minimum lease payments total approximately $78.0&#160;million, beginning April 2023 and expiring in 2030, and are not included in the above table.&lt;/span&gt;&lt;/div&gt;The Company has entered into an equipment and facility finance lease for a backup manufacturing encapsulation site that has not yet commenced and is therefore, not included in the above table. As part of the agreement, the Company expects to make approximately $885&#160;thousand of payments prior to lease commencement and the future value of minimum lease payments will total approximately $120&#160;thousand.</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="i5a90c58801134d6383b036247c03afa2_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl82MS9mcmFnOjhhNTE5MDJjNjUzMDQ2NWQ5MWE2MWM4NGJmMTVjYjJiL3RleHRyZWdpb246OGE1MTkwMmM2NTMwNDY1ZDkxYTYxYzg0YmYxNWNiMmJfNDgwOA_64a89957-8178-4a78-a9f5-56fc81472874"
      unitRef="sqft">13206</us-gaap:AreaOfRealEstateProperty>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i9d7a2759ec7d41e3937bd48023be99f9_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl82MS9mcmFnOjhhNTE5MDJjNjUzMDQ2NWQ5MWE2MWM4NGJmMTVjYjJiL3RleHRyZWdpb246OGE1MTkwMmM2NTMwNDY1ZDkxYTYxYzg0YmYxNWNiMmJfNDM2_f1da340e-f7a7-48f7-981b-952c8c162292"
      unitRef="usd">100000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="i9d7a2759ec7d41e3937bd48023be99f9_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl82MS9mcmFnOjhhNTE5MDJjNjUzMDQ2NWQ5MWE2MWM4NGJmMTVjYjJiL3RleHRyZWdpb246OGE1MTkwMmM2NTMwNDY1ZDkxYTYxYzg0YmYxNWNiMmJfNDgwMQ_926baa62-2c82-4fbe-b338-96b4acd0ca3d"
      unitRef="usd">100000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i6d2b9fee1c02434b9949db0279cfaf7f_I20210101"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl82MS9mcmFnOjhhNTE5MDJjNjUzMDQ2NWQ5MWE2MWM4NGJmMTVjYjJiL3RleHRyZWdpb246OGE1MTkwMmM2NTMwNDY1ZDkxYTYxYzg0YmYxNWNiMmJfNzIy_909de453-1e79-49f3-a0c9-ee936f4628ef"
      unitRef="number">0.0408</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i495ff60b2f3b469a944a5922a5e9036d_I20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl82MS9mcmFnOjhhNTE5MDJjNjUzMDQ2NWQ5MWE2MWM4NGJmMTVjYjJiL3RleHRyZWdpb246OGE1MTkwMmM2NTMwNDY1ZDkxYTYxYzg0YmYxNWNiMmJfMTAxMw_54c338b3-b17a-458e-874b-0e34156fc7fd"
      unitRef="usd">2300000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="ia4a97e4de8cb475abddcffdb81d0a5d1_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl82MS9mcmFnOjhhNTE5MDJjNjUzMDQ2NWQ5MWE2MWM4NGJmMTVjYjJiL3RleHRyZWdpb246OGE1MTkwMmM2NTMwNDY1ZDkxYTYxYzg0YmYxNWNiMmJfMzI5ODUzNDg4OTQ1MA_b24e4d09-5002-408f-bb86-da1447ec221e"
      unitRef="sqft">30531</us-gaap:AreaOfRealEstateProperty>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm
      contextRef="ia4a97e4de8cb475abddcffdb81d0a5d1_I20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl82MS9mcmFnOjhhNTE5MDJjNjUzMDQ2NWQ5MWE2MWM4NGJmMTVjYjJiL3RleHRyZWdpb246OGE1MTkwMmM2NTMwNDY1ZDkxYTYxYzg0YmYxNWNiMmJfMTMwOQ_2bd19f30-e2f6-416d-b445-36e4ce07ad4e">P9Y</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <auph:LesseeOperatingLeaseNumberOfExtensionOptions
      contextRef="ia4a97e4de8cb475abddcffdb81d0a5d1_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl82MS9mcmFnOjhhNTE5MDJjNjUzMDQ2NWQ5MWE2MWM4NGJmMTVjYjJiL3RleHRyZWdpb246OGE1MTkwMmM2NTMwNDY1ZDkxYTYxYzg0YmYxNWNiMmJfMTM0NA_f516fb95-b270-4ed7-b751-356ba856ba2a"
      unitRef="extension_option">2</auph:LesseeOperatingLeaseNumberOfExtensionOptions>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="ia4a97e4de8cb475abddcffdb81d0a5d1_I20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl82MS9mcmFnOjhhNTE5MDJjNjUzMDQ2NWQ5MWE2MWM4NGJmMTVjYjJiL3RleHRyZWdpb246OGE1MTkwMmM2NTMwNDY1ZDkxYTYxYzg0YmYxNWNiMmJfNDgwMw_3d985f07-0690-41ad-9d3b-17d6a45afe2a">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="ia4a97e4de8cb475abddcffdb81d0a5d1_I20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl82MS9mcmFnOjhhNTE5MDJjNjUzMDQ2NWQ5MWE2MWM4NGJmMTVjYjJiL3RleHRyZWdpb246OGE1MTkwMmM2NTMwNDY1ZDkxYTYxYzg0YmYxNWNiMmJfMTM3Mw_455fafcc-b2cb-471a-878c-705eea37b5b3">P11Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <auph:LesseeOperatingLeaseLeaseTerminationTerm
      contextRef="i5aa97519cf354667a42c1e73e81155c5_D20200301-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl82MS9mcmFnOjhhNTE5MDJjNjUzMDQ2NWQ5MWE2MWM4NGJmMTVjYjJiL3RleHRyZWdpb246OGE1MTkwMmM2NTMwNDY1ZDkxYTYxYzg0YmYxNWNiMmJfMTQyNQ_e3c1d73a-934f-4c4b-adda-119a009956d5">P7Y</auph:LesseeOperatingLeaseLeaseTerminationTerm>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i0d45f33fe1934685a0328a1b8e0fb9fa_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl82MS9mcmFnOjhhNTE5MDJjNjUzMDQ2NWQ5MWE2MWM4NGJmMTVjYjJiL3RleHRyZWdpb246OGE1MTkwMmM2NTMwNDY1ZDkxYTYxYzg0YmYxNWNiMmJfMTQ3OQ_b1fa2da1-0e77-448b-a1f2-43aa5897be48"
      unitRef="usd">5100000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="i0d45f33fe1934685a0328a1b8e0fb9fa_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl82MS9mcmFnOjhhNTE5MDJjNjUzMDQ2NWQ5MWE2MWM4NGJmMTVjYjJiL3RleHRyZWdpb246OGE1MTkwMmM2NTMwNDY1ZDkxYTYxYzg0YmYxNWNiMmJfMTUwNQ_1a7b9ac4-d7fe-40f0-bf89-2f7ba2319398"
      unitRef="usd">8500000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="iaf32dde531a54bedaeee2771bb3cf07c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl82MS9mcmFnOjhhNTE5MDJjNjUzMDQ2NWQ5MWE2MWM4NGJmMTVjYjJiL3RleHRyZWdpb246OGE1MTkwMmM2NTMwNDY1ZDkxYTYxYzg0YmYxNWNiMmJfMTYxMw_49955f62-bd5c-4ee1-bfd6-79d26d2261c9"
      unitRef="usd">5200000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="iaf32dde531a54bedaeee2771bb3cf07c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl82MS9mcmFnOjhhNTE5MDJjNjUzMDQ2NWQ5MWE2MWM4NGJmMTVjYjJiL3RleHRyZWdpb246OGE1MTkwMmM2NTMwNDY1ZDkxYTYxYzg0YmYxNWNiMmJfMTYzOQ_1d535375-13dd-405b-acf5-b478d17f3c60"
      unitRef="usd">8600000</us-gaap:OperatingLeaseLiability>
    <us-gaap:PaymentsForProceedsFromTenantAllowance
      contextRef="i26b07d59c782432196f10a8bbea26c86_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl82MS9mcmFnOjhhNTE5MDJjNjUzMDQ2NWQ5MWE2MWM4NGJmMTVjYjJiL3RleHRyZWdpb246OGE1MTkwMmM2NTMwNDY1ZDkxYTYxYzg0YmYxNWNiMmJfMzI5ODUzNDg5NTA5NA_a557682c-3ade-477e-8874-7c6de4bc75e4"
      unitRef="usd">-2300000</us-gaap:PaymentsForProceedsFromTenantAllowance>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i32b726a815d044a59392431a6d822684_I20200312"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl82MS9mcmFnOjhhNTE5MDJjNjUzMDQ2NWQ5MWE2MWM4NGJmMTVjYjJiL3RleHRyZWdpb246OGE1MTkwMmM2NTMwNDY1ZDkxYTYxYzg0YmYxNWNiMmJfMjE5NQ_7cab6834-b849-476e-b828-955c33f4c8a7"
      unitRef="number">0.052</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseCost
      contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl82MS9mcmFnOjhhNTE5MDJjNjUzMDQ2NWQ5MWE2MWM4NGJmMTVjYjJiL3RleHRyZWdpb246OGE1MTkwMmM2NTMwNDY1ZDkxYTYxYzg0YmYxNWNiMmJfMzI5ODUzNDg5NTEwOA_0826e651-a62d-49ff-9b53-9dea7002994f"
      unitRef="usd">300000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i56599386fa47443a8975bb3f7a6a8c57_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl82MS9mcmFnOjhhNTE5MDJjNjUzMDQ2NWQ5MWE2MWM4NGJmMTVjYjJiL3RleHRyZWdpb246OGE1MTkwMmM2NTMwNDY1ZDkxYTYxYzg0YmYxNWNiMmJfMzI5ODUzNDg5NTEwOA_ba81a244-a17d-4bf9-bea5-da2e56a5067c"
      unitRef="usd">300000</us-gaap:OperatingLeaseCost>
    <auph:AssetsAndLiabilitiesLesseeTableTextBlock
      contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl82MS9mcmFnOjhhNTE5MDJjNjUzMDQ2NWQ5MWE2MWM4NGJmMTVjYjJiL3RleHRyZWdpb246OGE1MTkwMmM2NTMwNDY1ZDkxYTYxYzg0YmYxNWNiMmJfNDc5OA_5c9b716f-6669-40d9-a944-3b0a71c293d6">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides supplemental balance sheet information related to the operating lease ROU assets and lease liabilities:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.087%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.747%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.297%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.717%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance Sheet Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease right of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;5,232&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,383&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,009&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,059&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;7,562&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;8,571&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,739&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</auph:AssetsAndLiabilitiesLesseeTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="id7882ae6aff54a3aacdef67ddf11a428_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl82MS9mcmFnOjhhNTE5MDJjNjUzMDQ2NWQ5MWE2MWM4NGJmMTVjYjJiL3RhYmxlOmRmODBmMzRmZGYyMTRiZmRhNDU0YTQ2ZjQ0ODVkZTQyL3RhYmxlcmFuZ2U6ZGY4MGYzNGZkZjIxNGJmZGE0NTRhNDZmNDQ4NWRlNDJfMi00LTEtMS00Njg5MQ_be7e4dc2-461d-4405-875f-4e141a65d2c1"
      unitRef="usd">5232000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i784f65549351439fa4b7bedf90ce7e3f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl82MS9mcmFnOjhhNTE5MDJjNjUzMDQ2NWQ5MWE2MWM4NGJmMTVjYjJiL3RhYmxlOmRmODBmMzRmZGYyMTRiZmRhNDU0YTQ2ZjQ0ODVkZTQyL3RhYmxlcmFuZ2U6ZGY4MGYzNGZkZjIxNGJmZGE0NTRhNDZmNDQ4NWRlNDJfMi02LTEtMS00Njg5MQ_b905961e-621b-46c6-ab3d-b3db6662f58b"
      unitRef="usd">5383000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="id7882ae6aff54a3aacdef67ddf11a428_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl82MS9mcmFnOjhhNTE5MDJjNjUzMDQ2NWQ5MWE2MWM4NGJmMTVjYjJiL3RhYmxlOmRmODBmMzRmZGYyMTRiZmRhNDU0YTQ2ZjQ0ODVkZTQyL3RhYmxlcmFuZ2U6ZGY4MGYzNGZkZjIxNGJmZGE0NTRhNDZmNDQ4NWRlNDJfNS00LTEtMS00Njg5MQ_4782767e-6791-4668-b3da-179f41e5ac7f"
      unitRef="usd">1009000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i784f65549351439fa4b7bedf90ce7e3f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl82MS9mcmFnOjhhNTE5MDJjNjUzMDQ2NWQ5MWE2MWM4NGJmMTVjYjJiL3RhYmxlOmRmODBmMzRmZGYyMTRiZmRhNDU0YTQ2ZjQ0ODVkZTQyL3RhYmxlcmFuZ2U6ZGY4MGYzNGZkZjIxNGJmZGE0NTRhNDZmNDQ4NWRlNDJfNS02LTEtMS00Njg5MQ_ef4bd689-2dd0-449e-b3ae-99fe697051e9"
      unitRef="usd">1059000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="id7882ae6aff54a3aacdef67ddf11a428_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl82MS9mcmFnOjhhNTE5MDJjNjUzMDQ2NWQ5MWE2MWM4NGJmMTVjYjJiL3RhYmxlOmRmODBmMzRmZGYyMTRiZmRhNDU0YTQ2ZjQ0ODVkZTQyL3RhYmxlcmFuZ2U6ZGY4MGYzNGZkZjIxNGJmZGE0NTRhNDZmNDQ4NWRlNDJfNi00LTEtMS00Njg5MQ_76dbbd9c-fc2c-410d-8997-437074a6f77e"
      unitRef="usd">7562000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i784f65549351439fa4b7bedf90ce7e3f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl82MS9mcmFnOjhhNTE5MDJjNjUzMDQ2NWQ5MWE2MWM4NGJmMTVjYjJiL3RhYmxlOmRmODBmMzRmZGYyMTRiZmRhNDU0YTQ2ZjQ0ODVkZTQyL3RhYmxlcmFuZ2U6ZGY4MGYzNGZkZjIxNGJmZGE0NTRhNDZmNDQ4NWRlNDJfNi02LTEtMS00Njg5MQ_e281467a-cf43-4012-8b25-b9fe174a62f7"
      unitRef="usd">7680000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="id7882ae6aff54a3aacdef67ddf11a428_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl82MS9mcmFnOjhhNTE5MDJjNjUzMDQ2NWQ5MWE2MWM4NGJmMTVjYjJiL3RhYmxlOmRmODBmMzRmZGYyMTRiZmRhNDU0YTQ2ZjQ0ODVkZTQyL3RhYmxlcmFuZ2U6ZGY4MGYzNGZkZjIxNGJmZGE0NTRhNDZmNDQ4NWRlNDJfNy00LTEtMS00Njg5MQ_1eabbfe2-e0e4-4ceb-972f-f41e19493f50"
      unitRef="usd">8571000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="i784f65549351439fa4b7bedf90ce7e3f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl82MS9mcmFnOjhhNTE5MDJjNjUzMDQ2NWQ5MWE2MWM4NGJmMTVjYjJiL3RhYmxlOmRmODBmMzRmZGYyMTRiZmRhNDU0YTQ2ZjQ0ODVkZTQyL3RhYmxlcmFuZ2U6ZGY4MGYzNGZkZjIxNGJmZGE0NTRhNDZmNDQ4NWRlNDJfNy02LTEtMS00Njg5MQ_3d87a440-61b4-42a8-afcc-b16c61dc57b9"
      unitRef="usd">8739000</us-gaap:OperatingLeaseLiability>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl82MS9mcmFnOjhhNTE5MDJjNjUzMDQ2NWQ5MWE2MWM4NGJmMTVjYjJiL3RleHRyZWdpb246OGE1MTkwMmM2NTMwNDY1ZDkxYTYxYzg0YmYxNWNiMmJfNDgwMg_6dce3039-5cc5-4f50-8f0f-93c89e584cca">&lt;div style="margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table represents the weighted-average remaining lease term and discount rate as of March&#160;31, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Remaining Lease Term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Discount Rate&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.30&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.20%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="id7882ae6aff54a3aacdef67ddf11a428_I20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl82MS9mcmFnOjhhNTE5MDJjNjUzMDQ2NWQ5MWE2MWM4NGJmMTVjYjJiL3RhYmxlOjdhMmJiNmYxNWNjYzRjNGY5NzA4YjA1YjdiOTBlYTZjL3RhYmxlcmFuZ2U6N2EyYmI2ZjE1Y2NjNGM0Zjk3MDhiMDViN2I5MGVhNmNfMi0yLTEtMS00Njg5MQ_b7204339-fd43-44c7-b060-c49fa1a42ef4">P9Y3M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="id7882ae6aff54a3aacdef67ddf11a428_I20220331"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl82MS9mcmFnOjhhNTE5MDJjNjUzMDQ2NWQ5MWE2MWM4NGJmMTVjYjJiL3RhYmxlOjdhMmJiNmYxNWNjYzRjNGY5NzA4YjA1YjdiOTBlYTZjL3RhYmxlcmFuZ2U6N2EyYmI2ZjE1Y2NjNGM0Zjk3MDhiMDViN2I5MGVhNmNfMi00LTEtMS00Njg5MQ_9e4fcc56-f665-4030-a14d-3f0720157b58"
      unitRef="number">0.0520</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl82MS9mcmFnOjhhNTE5MDJjNjUzMDQ2NWQ5MWE2MWM4NGJmMTVjYjJiL3RleHRyZWdpb246OGE1MTkwMmM2NTMwNDY1ZDkxYTYxYzg0YmYxNWNiMmJfNDgwNA_12e3a2f8-4d20-4f69-806f-5041db38558a">&lt;div style="margin-top:7pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a summary of operating lease liabilities payments for the next five years and thereafter:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.346%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Operating Lease Payments&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Remainder of 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;863&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,061&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,085&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,110&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,135&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;5,638&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total future minimum lease payments &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;10,892&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: lease imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(2,321)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total future minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;8,571&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="id7882ae6aff54a3aacdef67ddf11a428_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl82MS9mcmFnOjhhNTE5MDJjNjUzMDQ2NWQ5MWE2MWM4NGJmMTVjYjJiL3RhYmxlOjFlODcxN2VhYzJjMzRlOWViZmIyZGY3MjI2MjIzNDc5L3RhYmxlcmFuZ2U6MWU4NzE3ZWFjMmMzNGU5ZWJmYjJkZjcyMjYyMjM0NzlfMS0yLTEtMS00Njg5MQ_655aa437-a854-463e-9278-29ee92ffa4aa"
      unitRef="usd">863000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="id7882ae6aff54a3aacdef67ddf11a428_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl82MS9mcmFnOjhhNTE5MDJjNjUzMDQ2NWQ5MWE2MWM4NGJmMTVjYjJiL3RhYmxlOjFlODcxN2VhYzJjMzRlOWViZmIyZGY3MjI2MjIzNDc5L3RhYmxlcmFuZ2U6MWU4NzE3ZWFjMmMzNGU5ZWJmYjJkZjcyMjYyMjM0NzlfMi0yLTEtMS00Njg5MQ_17f81313-0ba6-4521-8df7-e4e4533a69c3"
      unitRef="usd">1061000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="id7882ae6aff54a3aacdef67ddf11a428_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl82MS9mcmFnOjhhNTE5MDJjNjUzMDQ2NWQ5MWE2MWM4NGJmMTVjYjJiL3RhYmxlOjFlODcxN2VhYzJjMzRlOWViZmIyZGY3MjI2MjIzNDc5L3RhYmxlcmFuZ2U6MWU4NzE3ZWFjMmMzNGU5ZWJmYjJkZjcyMjYyMjM0NzlfMy0yLTEtMS00Njg5MQ_720af77d-ba55-4d7f-9668-3f5b0df339b6"
      unitRef="usd">1085000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="id7882ae6aff54a3aacdef67ddf11a428_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl82MS9mcmFnOjhhNTE5MDJjNjUzMDQ2NWQ5MWE2MWM4NGJmMTVjYjJiL3RhYmxlOjFlODcxN2VhYzJjMzRlOWViZmIyZGY3MjI2MjIzNDc5L3RhYmxlcmFuZ2U6MWU4NzE3ZWFjMmMzNGU5ZWJmYjJkZjcyMjYyMjM0NzlfNC0yLTEtMS00Njg5MQ_70300c78-6327-40eb-bf37-e4e1a2a08188"
      unitRef="usd">1110000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="id7882ae6aff54a3aacdef67ddf11a428_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl82MS9mcmFnOjhhNTE5MDJjNjUzMDQ2NWQ5MWE2MWM4NGJmMTVjYjJiL3RhYmxlOjFlODcxN2VhYzJjMzRlOWViZmIyZGY3MjI2MjIzNDc5L3RhYmxlcmFuZ2U6MWU4NzE3ZWFjMmMzNGU5ZWJmYjJkZjcyMjYyMjM0NzlfNS0yLTEtMS00Njg5MQ_b86ba297-b3fc-4ac2-978b-d6cc581e47e7"
      unitRef="usd">1135000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <auph:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour
      contextRef="id7882ae6aff54a3aacdef67ddf11a428_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl82MS9mcmFnOjhhNTE5MDJjNjUzMDQ2NWQ5MWE2MWM4NGJmMTVjYjJiL3RhYmxlOjFlODcxN2VhYzJjMzRlOWViZmIyZGY3MjI2MjIzNDc5L3RhYmxlcmFuZ2U6MWU4NzE3ZWFjMmMzNGU5ZWJmYjJkZjcyMjYyMjM0NzlfNi0yLTEtMS00Njg5MQ_b95b4ba0-51b4-439e-9330-6ebb1a1a69d9"
      unitRef="usd">5638000</auph:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="id7882ae6aff54a3aacdef67ddf11a428_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl82MS9mcmFnOjhhNTE5MDJjNjUzMDQ2NWQ5MWE2MWM4NGJmMTVjYjJiL3RhYmxlOjFlODcxN2VhYzJjMzRlOWViZmIyZGY3MjI2MjIzNDc5L3RhYmxlcmFuZ2U6MWU4NzE3ZWFjMmMzNGU5ZWJmYjJkZjcyMjYyMjM0NzlfNy0yLTEtMS00Njg5MQ_616a26b5-b112-4b59-b14b-56e470b8343f"
      unitRef="usd">10892000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="id7882ae6aff54a3aacdef67ddf11a428_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl82MS9mcmFnOjhhNTE5MDJjNjUzMDQ2NWQ5MWE2MWM4NGJmMTVjYjJiL3RhYmxlOjFlODcxN2VhYzJjMzRlOWViZmIyZGY3MjI2MjIzNDc5L3RhYmxlcmFuZ2U6MWU4NzE3ZWFjMmMzNGU5ZWJmYjJkZjcyMjYyMjM0NzlfOC0yLTEtMS00Njg5MQ_1b179c12-843d-4f85-8a31-5e3d1833b9ff"
      unitRef="usd">2321000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="id7882ae6aff54a3aacdef67ddf11a428_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl82MS9mcmFnOjhhNTE5MDJjNjUzMDQ2NWQ5MWE2MWM4NGJmMTVjYjJiL3RhYmxlOjFlODcxN2VhYzJjMzRlOWViZmIyZGY3MjI2MjIzNDc5L3RhYmxlcmFuZ2U6MWU4NzE3ZWFjMmMzNGU5ZWJmYjJkZjcyMjYyMjM0NzlfOS0yLTEtMS00Njg5MQ_26e13d47-096d-4e0f-a34c-918fd71341b5"
      unitRef="usd">8571000</us-gaap:OperatingLeaseLiability>
    <us-gaap:PaymentsForCapitalImprovements
      contextRef="i46bd9d31980341bb91e4ebbab17839ed_D20210101-20210131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl82MS9mcmFnOjhhNTE5MDJjNjUzMDQ2NWQ5MWE2MWM4NGJmMTVjYjJiL3RleHRyZWdpb246OGE1MTkwMmM2NTMwNDY1ZDkxYTYxYzg0YmYxNWNiMmJfMzI5ODUzNDg4OTQzNg_52ce8015-c879-48b0-b908-c106082464df"
      unitRef="chf">21000000</us-gaap:PaymentsForCapitalImprovements>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="ie64f915dc5df48b09796dbc7d367824b_D20210201-20210228"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl82MS9mcmFnOjhhNTE5MDJjNjUzMDQ2NWQ5MWE2MWM4NGJmMTVjYjJiL3RleHRyZWdpb246OGE1MTkwMmM2NTMwNDY1ZDkxYTYxYzg0YmYxNWNiMmJfMTA5OTUxMTYzMzk3NQ_bfd4f149-9ec9-434c-bfed-5aeacf30990a"
      unitRef="usd">11800000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeaseLiabilityPaymentsDue
      contextRef="id7882ae6aff54a3aacdef67ddf11a428_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl82MS9mcmFnOjhhNTE5MDJjNjUzMDQ2NWQ5MWE2MWM4NGJmMTVjYjJiL3RleHRyZWdpb246OGE1MTkwMmM2NTMwNDY1ZDkxYTYxYzg0YmYxNWNiMmJfNDcxMg_773d3793-b5e6-4b6a-9527-01994944846c"
      unitRef="usd">78000000</us-gaap:FinanceLeaseLiabilityPaymentsDue>
    <auph:LesseeOperatingLeaseLeaseNotYetCommencedPaymentsPriorToCommencementOfLease
      contextRef="id7882ae6aff54a3aacdef67ddf11a428_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl82MS9mcmFnOjhhNTE5MDJjNjUzMDQ2NWQ5MWE2MWM4NGJmMTVjYjJiL3RleHRyZWdpb246OGE1MTkwMmM2NTMwNDY1ZDkxYTYxYzg0YmYxNWNiMmJfMTA5OTUxMTYzNzQ0OQ_7c3a1dfb-2534-49d0-a000-065dbb9b7f6a"
      unitRef="usd">885000</auph:LesseeOperatingLeaseLeaseNotYetCommencedPaymentsPriorToCommencementOfLease>
    <auph:LesseeOperatingLeaseLeaseNotYetCommencedLiabilityToBePaid
      contextRef="id7882ae6aff54a3aacdef67ddf11a428_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl82MS9mcmFnOjhhNTE5MDJjNjUzMDQ2NWQ5MWE2MWM4NGJmMTVjYjJiL3RleHRyZWdpb246OGE1MTkwMmM2NTMwNDY1ZDkxYTYxYzg0YmYxNWNiMmJfMTA5OTUxMTYzNzQ2NA_c79e5a10-92ce-4fd2-b983-570c9e91ff13"
      unitRef="usd">120000</auph:LesseeOperatingLeaseLeaseNotYetCommencedLiabilityToBePaid>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
      contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl82NC9mcmFnOmZjMjUxNmJhNDU3ZTQzM2VhY2U4NTFkODVhYTU2Yjc2L3RleHRyZWdpb246ZmMyNTE2YmE0NTdlNDMzZWFjZTg1MWQ4NWFhNTZiNzZfMTM2_3403c3bb-80e5-461d-ae73-e8659786d9a5">Accounts Payable and Accrued Liabilities&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts payable and accrued liabilities are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.642%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.447%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,267&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,879&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;7,289&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued R&amp;amp;D projects&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;5,409&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,383&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employee accruals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;9,609&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial accruals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6,753&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,015&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total accounts payable and accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;32,327&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl82NC9mcmFnOmZjMjUxNmJhNDU3ZTQzM2VhY2U4NTFkODVhYTU2Yjc2L3RleHRyZWdpb246ZmMyNTE2YmE0NTdlNDMzZWFjZTg1MWQ4NWFhNTZiNzZfMTM3_c1583cf5-b2ca-4b2a-93f3-9a70edb8ec19">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts payable and accrued liabilities are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.642%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.447%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,267&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,879&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;7,289&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued R&amp;amp;D projects&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;5,409&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,383&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employee accruals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;9,609&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial accruals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6,753&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,015&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total accounts payable and accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;32,327&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccountsPayableTradeCurrent
      contextRef="id7882ae6aff54a3aacdef67ddf11a428_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl82NC9mcmFnOmZjMjUxNmJhNDU3ZTQzM2VhY2U4NTFkODVhYTU2Yjc2L3RhYmxlOjA0OWQ0OTU3YzJkYTQ0NzM4MTA0YzhiMzdiNjFiMjBjL3RhYmxlcmFuZ2U6MDQ5ZDQ5NTdjMmRhNDQ3MzgxMDRjOGIzN2I2MWIyMGNfMS0yLTEtMS00Njg5MQ_a2e5b14b-b616-4569-bb5b-73c0967b5f08"
      unitRef="usd">3267000</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:AccountsPayableTradeCurrent
      contextRef="i784f65549351439fa4b7bedf90ce7e3f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl82NC9mcmFnOmZjMjUxNmJhNDU3ZTQzM2VhY2U4NTFkODVhYTU2Yjc2L3RhYmxlOjA0OWQ0OTU3YzJkYTQ0NzM4MTA0YzhiMzdiNjFiMjBjL3RhYmxlcmFuZ2U6MDQ5ZDQ5NTdjMmRhNDQ3MzgxMDRjOGIzN2I2MWIyMGNfMS00LTEtMS00Njg5MQ_59861f6f-223c-45ae-ac56-dbbaf4b37a77"
      unitRef="usd">3879000</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="id7882ae6aff54a3aacdef67ddf11a428_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl82NC9mcmFnOmZjMjUxNmJhNDU3ZTQzM2VhY2U4NTFkODVhYTU2Yjc2L3RhYmxlOjA0OWQ0OTU3YzJkYTQ0NzM4MTA0YzhiMzdiNjFiMjBjL3RhYmxlcmFuZ2U6MDQ5ZDQ5NTdjMmRhNDQ3MzgxMDRjOGIzN2I2MWIyMGNfMi0yLTEtMS00Njg5MQ_9bdc8115-50b8-422d-92c5-d40fa94c165e"
      unitRef="usd">7289000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i784f65549351439fa4b7bedf90ce7e3f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl82NC9mcmFnOmZjMjUxNmJhNDU3ZTQzM2VhY2U4NTFkODVhYTU2Yjc2L3RhYmxlOjA0OWQ0OTU3YzJkYTQ0NzM4MTA0YzhiMzdiNjFiMjBjL3RhYmxlcmFuZ2U6MDQ5ZDQ5NTdjMmRhNDQ3MzgxMDRjOGIzN2I2MWIyMGNfMi00LTEtMS00Njg5MQ_dedf610a-89d1-4d79-a96f-bfb5d0e83d8e"
      unitRef="usd">3428000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <auph:AccruedResearchCurrent
      contextRef="id7882ae6aff54a3aacdef67ddf11a428_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl82NC9mcmFnOmZjMjUxNmJhNDU3ZTQzM2VhY2U4NTFkODVhYTU2Yjc2L3RhYmxlOjA0OWQ0OTU3YzJkYTQ0NzM4MTA0YzhiMzdiNjFiMjBjL3RhYmxlcmFuZ2U6MDQ5ZDQ5NTdjMmRhNDQ3MzgxMDRjOGIzN2I2MWIyMGNfMy0yLTEtMS00Njg5MQ_1af6dc62-8da5-4b9f-8ce0-b2815fd4ef30"
      unitRef="usd">5409000</auph:AccruedResearchCurrent>
    <auph:AccruedResearchCurrent
      contextRef="i784f65549351439fa4b7bedf90ce7e3f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl82NC9mcmFnOmZjMjUxNmJhNDU3ZTQzM2VhY2U4NTFkODVhYTU2Yjc2L3RhYmxlOjA0OWQ0OTU3YzJkYTQ0NzM4MTA0YzhiMzdiNjFiMjBjL3RhYmxlcmFuZ2U6MDQ5ZDQ5NTdjMmRhNDQ3MzgxMDRjOGIzN2I2MWIyMGNfMy00LTEtMS00Njg5MQ_5e074b03-c5f4-44c5-b60e-ae30d9144cd0"
      unitRef="usd">4383000</auph:AccruedResearchCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="id7882ae6aff54a3aacdef67ddf11a428_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl82NC9mcmFnOmZjMjUxNmJhNDU3ZTQzM2VhY2U4NTFkODVhYTU2Yjc2L3RhYmxlOjA0OWQ0OTU3YzJkYTQ0NzM4MTA0YzhiMzdiNjFiMjBjL3RhYmxlcmFuZ2U6MDQ5ZDQ5NTdjMmRhNDQ3MzgxMDRjOGIzN2I2MWIyMGNfNC0yLTEtMS00Njg5MQ_70bc6692-01fd-49b2-86d7-e856eb8d5d25"
      unitRef="usd">9609000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i784f65549351439fa4b7bedf90ce7e3f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl82NC9mcmFnOmZjMjUxNmJhNDU3ZTQzM2VhY2U4NTFkODVhYTU2Yjc2L3RhYmxlOjA0OWQ0OTU3YzJkYTQ0NzM4MTA0YzhiMzdiNjFiMjBjL3RhYmxlcmFuZ2U6MDQ5ZDQ5NTdjMmRhNDQ3MzgxMDRjOGIzN2I2MWIyMGNfNC00LTEtMS00Njg5MQ_46e7ad5f-89bb-4952-9f7f-bb858dafdc5e"
      unitRef="usd">18242000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <auph:CommercialRelatedAccrualsCurrent
      contextRef="id7882ae6aff54a3aacdef67ddf11a428_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl82NC9mcmFnOmZjMjUxNmJhNDU3ZTQzM2VhY2U4NTFkODVhYTU2Yjc2L3RhYmxlOjA0OWQ0OTU3YzJkYTQ0NzM4MTA0YzhiMzdiNjFiMjBjL3RhYmxlcmFuZ2U6MDQ5ZDQ5NTdjMmRhNDQ3MzgxMDRjOGIzN2I2MWIyMGNfNS0yLTEtMS01NTc1MA_a7f860d7-dbca-4794-98b6-fbce5cce5a77"
      unitRef="usd">6753000</auph:CommercialRelatedAccrualsCurrent>
    <auph:CommercialRelatedAccrualsCurrent
      contextRef="i784f65549351439fa4b7bedf90ce7e3f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl82NC9mcmFnOmZjMjUxNmJhNDU3ZTQzM2VhY2U4NTFkODVhYTU2Yjc2L3RhYmxlOjA0OWQ0OTU3YzJkYTQ0NzM4MTA0YzhiMzdiNjFiMjBjL3RhYmxlcmFuZ2U6MDQ5ZDQ5NTdjMmRhNDQ3MzgxMDRjOGIzN2I2MWIyMGNfNS00LTEtMS01NTc1MA_34e5a14b-7427-47a8-b9bf-2ecd62f5716b"
      unitRef="usd">5015000</auph:CommercialRelatedAccrualsCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="id7882ae6aff54a3aacdef67ddf11a428_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl82NC9mcmFnOmZjMjUxNmJhNDU3ZTQzM2VhY2U4NTFkODVhYTU2Yjc2L3RhYmxlOjA0OWQ0OTU3YzJkYTQ0NzM4MTA0YzhiMzdiNjFiMjBjL3RhYmxlcmFuZ2U6MDQ5ZDQ5NTdjMmRhNDQ3MzgxMDRjOGIzN2I2MWIyMGNfNS0yLTEtMS00Njg5MQ_9969d3f2-92ae-4944-a6d7-7b1f00b222de"
      unitRef="usd">32327000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="i784f65549351439fa4b7bedf90ce7e3f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl82NC9mcmFnOmZjMjUxNmJhNDU3ZTQzM2VhY2U4NTFkODVhYTU2Yjc2L3RhYmxlOjA0OWQ0OTU3YzJkYTQ0NzM4MTA0YzhiMzdiNjFiMjBjL3RhYmxlcmFuZ2U6MDQ5ZDQ5NTdjMmRhNDQ3MzgxMDRjOGIzN2I2MWIyMGNfNS00LTEtMS00Njg5MQ_36703dbe-549a-4724-b7ac-f62b5375a928"
      unitRef="usd">34947000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureNoncurrentTextBlock
      contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl82Ny9mcmFnOjZjZjc3NGY1MjJhMTQ2ZTRhYTRhYmI0N2FkOGMxYWIzL3RleHRyZWdpb246NmNmNzc0ZjUyMmExNDZlNGFhNGFiYjQ3YWQ4YzFhYjNfNTM5_5560bdfa-2e42-4e8c-9e86-5abaea322af5">Deferred Compensation and Other Non-current LiabilitiesThe Company recorded other non-current liabilities of $17.4 million and $16.0 million as of March&#160;31, 2022 and December&#160;31, 2021, respectively. The balance as of March&#160;31, 2022 and December&#160;31, 2021 primarily included deferred compensation arrangements whereby certain executive officers as of March 8, 2012 were provided with future potential employee benefit obligations for remaining with the Company, for a certain period of time. These obligations were also contingent on the occurrence of uncertain future events. Other non-current liabilities also include milestone payments deemed probable to be paid in the future.</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureNoncurrentTextBlock>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="id7882ae6aff54a3aacdef67ddf11a428_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl82Ny9mcmFnOjZjZjc3NGY1MjJhMTQ2ZTRhYTRhYmI0N2FkOGMxYWIzL3RleHRyZWdpb246NmNmNzc0ZjUyMmExNDZlNGFhNGFiYjQ3YWQ4YzFhYjNfODQ_ae94998f-b69f-462a-9ced-b95b719fd667"
      unitRef="usd">17400000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i784f65549351439fa4b7bedf90ce7e3f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl82Ny9mcmFnOjZjZjc3NGY1MjJhMTQ2ZTRhYTRhYmI0N2FkOGMxYWIzL3RleHRyZWdpb246NmNmNzc0ZjUyMmExNDZlNGFhNGFiYjQ3YWQ4YzFhYjNfOTE_7ada42b0-46a5-4863-b5c4-c7647ab6e071"
      unitRef="usd">16000000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83MC9mcmFnOjZiNDI0YTgyMzM0NzQzOWFhNmU4NjZiZmNmMGVjMDAxL3RleHRyZWdpb246NmI0MjRhODIzMzQ3NDM5YWE2ZTg2NmJmY2YwZWMwMDFfMjE4MQ_1c440ff5-9e62-430c-a00f-25d925e23c12">Fair Value Measurements&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's financial instruments consist primarily of cash and cash equivalents, investments, accounts receivable, accounts payable and accrued liabilities. The carrying value of accounts receivable, accounts payable and accrued liabilities approximate their fair value because of their short-term nature. Estimated fair values of held to maturity and available-for-sale debt securities are generally based on prices obtained from commercial pricing services.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with measuring the fair value of its assets and liabilities, the Company seeks to maximize the use of observable inputs (market data obtained from sources independent from the Company) and to minimize the use of unobservable inputs (the Company&#x2019;s assumptions about how market participants would price assets and liabilities). As a basis for considering such assumptions, a three-tier fair value hierarchy has been established, which prioritizes the inputs used in measuring fair value as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt"&gt;Level 1 - Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt"&gt;Level 2 - Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt"&gt;Level 3 - Unobservable inputs that reflect the reporting entity&#x2019;s own assumptions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's Level 1 instruments include deposits held with banks and short-term investments that are valued using quoted market prices. Level 2 instruments include the Company's short-term investments that are valued through third-party pricing services that use verifiable observable market data. The Company has no Level 3 instruments as of March&#160;31, 2022 and December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables present the financial assets measured at fair value on a recurring basis:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deposits held with banks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;113,268&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;113,268&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term highly liquid investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;19,274&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;19,274&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;152,295&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;133,915&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;286,210&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;284,837&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;133,915&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;418,752&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:7pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deposits held with banks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;214,702&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;214,702&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term highly liquid investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;206,724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,454&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;234,178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;438,624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,454&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;466,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Refer to Note 4, &#x201c;Investments,&#x201d; for the carrying amount and related unrealized gains (losses) by type of investment.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83MC9mcmFnOjZiNDI0YTgyMzM0NzQzOWFhNmU4NjZiZmNmMGVjMDAxL3RleHRyZWdpb246NmI0MjRhODIzMzQ3NDM5YWE2ZTg2NmJmY2YwZWMwMDFfMjE4MA_9d461440-02dd-47be-a785-d6d8d5bbd802">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables present the financial assets measured at fair value on a recurring basis:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deposits held with banks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;113,268&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;113,268&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term highly liquid investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;19,274&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;19,274&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;152,295&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;133,915&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;286,210&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;284,837&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;133,915&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;418,752&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:7pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deposits held with banks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;214,702&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;214,702&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term highly liquid investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;206,724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,454&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;234,178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;438,624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,454&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;466,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ib637c27de79d47f58aea7f1e1b7c5885_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83MC9mcmFnOjZiNDI0YTgyMzM0NzQzOWFhNmU4NjZiZmNmMGVjMDAxL3RhYmxlOjNiYzg4Mjg2NDAyZTQ2NTU4Mzk5NzQ0OWI0NGU3ZmEzL3RhYmxlcmFuZ2U6M2JjODgyODY0MDJlNDY1NTgzOTk3NDQ5YjQ0ZTdmYTNfNC0yLTEtMS00Njg5MQ_b730d006-d5d0-4624-9fa0-4bb1298ec6d1"
      unitRef="usd">113268000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ie1195a2d281043b09ef29f66c38b70ce_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83MC9mcmFnOjZiNDI0YTgyMzM0NzQzOWFhNmU4NjZiZmNmMGVjMDAxL3RhYmxlOjNiYzg4Mjg2NDAyZTQ2NTU4Mzk5NzQ0OWI0NGU3ZmEzL3RhYmxlcmFuZ2U6M2JjODgyODY0MDJlNDY1NTgzOTk3NDQ5YjQ0ZTdmYTNfNC00LTEtMS00Njg5MQ_798b8c8b-cf3d-4360-8a40-c4c7d27a3a40"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i9987c4f832174d15b1448eb73ba6f1e4_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83MC9mcmFnOjZiNDI0YTgyMzM0NzQzOWFhNmU4NjZiZmNmMGVjMDAxL3RhYmxlOjNiYzg4Mjg2NDAyZTQ2NTU4Mzk5NzQ0OWI0NGU3ZmEzL3RhYmxlcmFuZ2U6M2JjODgyODY0MDJlNDY1NTgzOTk3NDQ5YjQ0ZTdmYTNfNC02LTEtMS00Njg5MQ_23c57b18-9340-4bd6-84cd-4e03ea555f47"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="if5d8980b569c49318287bb43ff08a07e_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83MC9mcmFnOjZiNDI0YTgyMzM0NzQzOWFhNmU4NjZiZmNmMGVjMDAxL3RhYmxlOjNiYzg4Mjg2NDAyZTQ2NTU4Mzk5NzQ0OWI0NGU3ZmEzL3RhYmxlcmFuZ2U6M2JjODgyODY0MDJlNDY1NTgzOTk3NDQ5YjQ0ZTdmYTNfNC04LTEtMS00Njg5MQ_e20e6aaf-7f0f-49b4-a4ef-85129704a5cf"
      unitRef="usd">113268000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ib211792a2e6b4a88a6e391b311e94df4_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83MC9mcmFnOjZiNDI0YTgyMzM0NzQzOWFhNmU4NjZiZmNmMGVjMDAxL3RhYmxlOjNiYzg4Mjg2NDAyZTQ2NTU4Mzk5NzQ0OWI0NGU3ZmEzL3RhYmxlcmFuZ2U6M2JjODgyODY0MDJlNDY1NTgzOTk3NDQ5YjQ0ZTdmYTNfNS0yLTEtMS00Njg5MQ_d73fc93e-aa82-494f-b423-99f824dc5ed6"
      unitRef="usd">19274000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i074dc118299746aa9f97075509308a92_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83MC9mcmFnOjZiNDI0YTgyMzM0NzQzOWFhNmU4NjZiZmNmMGVjMDAxL3RhYmxlOjNiYzg4Mjg2NDAyZTQ2NTU4Mzk5NzQ0OWI0NGU3ZmEzL3RhYmxlcmFuZ2U6M2JjODgyODY0MDJlNDY1NTgzOTk3NDQ5YjQ0ZTdmYTNfNS00LTEtMS00Njg5MQ_53f2dd4d-7a9d-4c6b-b402-03a17c2c2813"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i3751e29f9e2148e9be8536444f9cac26_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83MC9mcmFnOjZiNDI0YTgyMzM0NzQzOWFhNmU4NjZiZmNmMGVjMDAxL3RhYmxlOjNiYzg4Mjg2NDAyZTQ2NTU4Mzk5NzQ0OWI0NGU3ZmEzL3RhYmxlcmFuZ2U6M2JjODgyODY0MDJlNDY1NTgzOTk3NDQ5YjQ0ZTdmYTNfNS02LTEtMS00Njg5MQ_3b35e00b-6a6b-48b1-9b93-061784d5f7f6"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="icfd26c5e43f842a78369ad600a9bf8a6_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83MC9mcmFnOjZiNDI0YTgyMzM0NzQzOWFhNmU4NjZiZmNmMGVjMDAxL3RhYmxlOjNiYzg4Mjg2NDAyZTQ2NTU4Mzk5NzQ0OWI0NGU3ZmEzL3RhYmxlcmFuZ2U6M2JjODgyODY0MDJlNDY1NTgzOTk3NDQ5YjQ0ZTdmYTNfNS04LTEtMS00Njg5MQ_6c35eb69-556b-4721-855d-95eb77c61558"
      unitRef="usd">19274000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="iecaeb1e9e3bc4350b03471a79a3ee234_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83MC9mcmFnOjZiNDI0YTgyMzM0NzQzOWFhNmU4NjZiZmNmMGVjMDAxL3RhYmxlOjNiYzg4Mjg2NDAyZTQ2NTU4Mzk5NzQ0OWI0NGU3ZmEzL3RhYmxlcmFuZ2U6M2JjODgyODY0MDJlNDY1NTgzOTk3NDQ5YjQ0ZTdmYTNfNi0yLTEtMS00Njg5MQ_e8430eb0-57ad-48e3-9357-e44fa0c743c2"
      unitRef="usd">152295000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="if7d17ebbb59b417ca9c046ea7c8aa94f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83MC9mcmFnOjZiNDI0YTgyMzM0NzQzOWFhNmU4NjZiZmNmMGVjMDAxL3RhYmxlOjNiYzg4Mjg2NDAyZTQ2NTU4Mzk5NzQ0OWI0NGU3ZmEzL3RhYmxlcmFuZ2U6M2JjODgyODY0MDJlNDY1NTgzOTk3NDQ5YjQ0ZTdmYTNfNi00LTEtMS00Njg5MQ_4a39445c-a419-478a-8a6a-1cd4cc3ff623"
      unitRef="usd">133915000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="id893926028184fda8d4b75b7a5667586_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83MC9mcmFnOjZiNDI0YTgyMzM0NzQzOWFhNmU4NjZiZmNmMGVjMDAxL3RhYmxlOjNiYzg4Mjg2NDAyZTQ2NTU4Mzk5NzQ0OWI0NGU3ZmEzL3RhYmxlcmFuZ2U6M2JjODgyODY0MDJlNDY1NTgzOTk3NDQ5YjQ0ZTdmYTNfNi02LTEtMS00Njg5MQ_4cde465c-763e-42c6-b152-f6a50c9e6856"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="id7882ae6aff54a3aacdef67ddf11a428_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83MC9mcmFnOjZiNDI0YTgyMzM0NzQzOWFhNmU4NjZiZmNmMGVjMDAxL3RhYmxlOjNiYzg4Mjg2NDAyZTQ2NTU4Mzk5NzQ0OWI0NGU3ZmEzL3RhYmxlcmFuZ2U6M2JjODgyODY0MDJlNDY1NTgzOTk3NDQ5YjQ0ZTdmYTNfNi04LTEtMS00Njg5MQ_95cb4821-34ac-4550-899a-00b90486b455"
      unitRef="usd">286210000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="iecaeb1e9e3bc4350b03471a79a3ee234_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83MC9mcmFnOjZiNDI0YTgyMzM0NzQzOWFhNmU4NjZiZmNmMGVjMDAxL3RhYmxlOjNiYzg4Mjg2NDAyZTQ2NTU4Mzk5NzQ0OWI0NGU3ZmEzL3RhYmxlcmFuZ2U6M2JjODgyODY0MDJlNDY1NTgzOTk3NDQ5YjQ0ZTdmYTNfNy0yLTEtMS00Njg5MQ_97e033d2-a53b-46b9-97c7-054ced005212"
      unitRef="usd">284837000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="if7d17ebbb59b417ca9c046ea7c8aa94f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83MC9mcmFnOjZiNDI0YTgyMzM0NzQzOWFhNmU4NjZiZmNmMGVjMDAxL3RhYmxlOjNiYzg4Mjg2NDAyZTQ2NTU4Mzk5NzQ0OWI0NGU3ZmEzL3RhYmxlcmFuZ2U6M2JjODgyODY0MDJlNDY1NTgzOTk3NDQ5YjQ0ZTdmYTNfNy00LTEtMS00Njg5MQ_cf8d4de0-a6c2-4108-901c-4386bca146a1"
      unitRef="usd">133915000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="id893926028184fda8d4b75b7a5667586_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83MC9mcmFnOjZiNDI0YTgyMzM0NzQzOWFhNmU4NjZiZmNmMGVjMDAxL3RhYmxlOjNiYzg4Mjg2NDAyZTQ2NTU4Mzk5NzQ0OWI0NGU3ZmEzL3RhYmxlcmFuZ2U6M2JjODgyODY0MDJlNDY1NTgzOTk3NDQ5YjQ0ZTdmYTNfNy02LTEtMS00Njg5MQ_b64cf1d8-b9e9-4472-8223-6c0dbbef7168"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="id7882ae6aff54a3aacdef67ddf11a428_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83MC9mcmFnOjZiNDI0YTgyMzM0NzQzOWFhNmU4NjZiZmNmMGVjMDAxL3RhYmxlOjNiYzg4Mjg2NDAyZTQ2NTU4Mzk5NzQ0OWI0NGU3ZmEzL3RhYmxlcmFuZ2U6M2JjODgyODY0MDJlNDY1NTgzOTk3NDQ5YjQ0ZTdmYTNfNy04LTEtMS00Njg5MQ_6cc5ca04-88ad-4cce-8013-e2605a072495"
      unitRef="usd">418752000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ief379dc869194260b8c12ebe6e7e061a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83MC9mcmFnOjZiNDI0YTgyMzM0NzQzOWFhNmU4NjZiZmNmMGVjMDAxL3RhYmxlOmNlNTBjY2Q4ZjEzYTQwOWFiNTU3ZGUwOWQ2NWFhNmIzL3RhYmxlcmFuZ2U6Y2U1MGNjZDhmMTNhNDA5YWI1NTdkZTA5ZDY1YWE2YjNfNC0yLTEtMS00Njg5MQ_c6a5bad8-8044-493c-85b5-23534fde5c36"
      unitRef="usd">214702000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i4888c5f13e9e4351a811914afa543777_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83MC9mcmFnOjZiNDI0YTgyMzM0NzQzOWFhNmU4NjZiZmNmMGVjMDAxL3RhYmxlOmNlNTBjY2Q4ZjEzYTQwOWFiNTU3ZGUwOWQ2NWFhNmIzL3RhYmxlcmFuZ2U6Y2U1MGNjZDhmMTNhNDA5YWI1NTdkZTA5ZDY1YWE2YjNfNC00LTEtMS00Njg5MQ_75eb7b0b-f156-44aa-8a61-6b1bea9c91c3"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i640e6485e7c84a2ab48d83257384aea7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83MC9mcmFnOjZiNDI0YTgyMzM0NzQzOWFhNmU4NjZiZmNmMGVjMDAxL3RhYmxlOmNlNTBjY2Q4ZjEzYTQwOWFiNTU3ZGUwOWQ2NWFhNmIzL3RhYmxlcmFuZ2U6Y2U1MGNjZDhmMTNhNDA5YWI1NTdkZTA5ZDY1YWE2YjNfNC02LTEtMS00Njg5MQ_13bdfdcc-7f21-4979-8640-cd7a0f3cc919"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i6146eb45aa0d48429dc434439051e0bc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83MC9mcmFnOjZiNDI0YTgyMzM0NzQzOWFhNmU4NjZiZmNmMGVjMDAxL3RhYmxlOmNlNTBjY2Q4ZjEzYTQwOWFiNTU3ZGUwOWQ2NWFhNmIzL3RhYmxlcmFuZ2U6Y2U1MGNjZDhmMTNhNDA5YWI1NTdkZTA5ZDY1YWE2YjNfNC04LTEtMS00Njg5MQ_5574db62-6d7b-48bc-ad63-223712bef7a5"
      unitRef="usd">214702000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="if383a572500e4c839c8c398879a64567_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83MC9mcmFnOjZiNDI0YTgyMzM0NzQzOWFhNmU4NjZiZmNmMGVjMDAxL3RhYmxlOmNlNTBjY2Q4ZjEzYTQwOWFiNTU3ZGUwOWQ2NWFhNmIzL3RhYmxlcmFuZ2U6Y2U1MGNjZDhmMTNhNDA5YWI1NTdkZTA5ZDY1YWE2YjNfNS0yLTEtMS00Njg5MQ_9e47bc73-a1cc-41cc-af15-9faa9017617b"
      unitRef="usd">17198000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i0cb7b13b98f9423daa95abadbd4c2281_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83MC9mcmFnOjZiNDI0YTgyMzM0NzQzOWFhNmU4NjZiZmNmMGVjMDAxL3RhYmxlOmNlNTBjY2Q4ZjEzYTQwOWFiNTU3ZGUwOWQ2NWFhNmIzL3RhYmxlcmFuZ2U6Y2U1MGNjZDhmMTNhNDA5YWI1NTdkZTA5ZDY1YWE2YjNfNS00LTEtMS00Njg5MQ_99bcd4d4-589e-466b-98a4-a3c9ee758838"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i23085f6e6a1046b1a8320d2f389c49cd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83MC9mcmFnOjZiNDI0YTgyMzM0NzQzOWFhNmU4NjZiZmNmMGVjMDAxL3RhYmxlOmNlNTBjY2Q4ZjEzYTQwOWFiNTU3ZGUwOWQ2NWFhNmIzL3RhYmxlcmFuZ2U6Y2U1MGNjZDhmMTNhNDA5YWI1NTdkZTA5ZDY1YWE2YjNfNS02LTEtMS00Njg5MQ_b93a0643-ea94-4367-836c-94aea0a608b6"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i7d77f002b76741e8b5071bbad8036827_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83MC9mcmFnOjZiNDI0YTgyMzM0NzQzOWFhNmU4NjZiZmNmMGVjMDAxL3RhYmxlOmNlNTBjY2Q4ZjEzYTQwOWFiNTU3ZGUwOWQ2NWFhNmIzL3RhYmxlcmFuZ2U6Y2U1MGNjZDhmMTNhNDA5YWI1NTdkZTA5ZDY1YWE2YjNfNS04LTEtMS00Njg5MQ_897af133-4c72-4585-9531-414c784a4153"
      unitRef="usd">17198000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i84bcadfa5a52412e91d596d25121ad94_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83MC9mcmFnOjZiNDI0YTgyMzM0NzQzOWFhNmU4NjZiZmNmMGVjMDAxL3RhYmxlOmNlNTBjY2Q4ZjEzYTQwOWFiNTU3ZGUwOWQ2NWFhNmIzL3RhYmxlcmFuZ2U6Y2U1MGNjZDhmMTNhNDA5YWI1NTdkZTA5ZDY1YWE2YjNfNi0yLTEtMS00Njg5MQ_46486d7b-93d8-49b7-a2aa-a1d5e069f4ef"
      unitRef="usd">206724000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="ia35491a16c814a76bd71423d10de8bd7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83MC9mcmFnOjZiNDI0YTgyMzM0NzQzOWFhNmU4NjZiZmNmMGVjMDAxL3RhYmxlOmNlNTBjY2Q4ZjEzYTQwOWFiNTU3ZGUwOWQ2NWFhNmIzL3RhYmxlcmFuZ2U6Y2U1MGNjZDhmMTNhNDA5YWI1NTdkZTA5ZDY1YWE2YjNfNi00LTEtMS00Njg5MQ_32452a7d-c740-4775-afa3-2faa8790461b"
      unitRef="usd">27454000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="ib03d0da6db22482c8918b1f6ab3b5e9b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83MC9mcmFnOjZiNDI0YTgyMzM0NzQzOWFhNmU4NjZiZmNmMGVjMDAxL3RhYmxlOmNlNTBjY2Q4ZjEzYTQwOWFiNTU3ZGUwOWQ2NWFhNmIzL3RhYmxlcmFuZ2U6Y2U1MGNjZDhmMTNhNDA5YWI1NTdkZTA5ZDY1YWE2YjNfNi02LTEtMS00Njg5MQ_d7e0d35b-2f4d-4938-b62c-9fb59078d173"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i784f65549351439fa4b7bedf90ce7e3f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83MC9mcmFnOjZiNDI0YTgyMzM0NzQzOWFhNmU4NjZiZmNmMGVjMDAxL3RhYmxlOmNlNTBjY2Q4ZjEzYTQwOWFiNTU3ZGUwOWQ2NWFhNmIzL3RhYmxlcmFuZ2U6Y2U1MGNjZDhmMTNhNDA5YWI1NTdkZTA5ZDY1YWE2YjNfNi04LTEtMS00Njg5MQ_59d02411-5197-45bc-b484-20bb6b403c9a"
      unitRef="usd">234178000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i84bcadfa5a52412e91d596d25121ad94_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83MC9mcmFnOjZiNDI0YTgyMzM0NzQzOWFhNmU4NjZiZmNmMGVjMDAxL3RhYmxlOmNlNTBjY2Q4ZjEzYTQwOWFiNTU3ZGUwOWQ2NWFhNmIzL3RhYmxlcmFuZ2U6Y2U1MGNjZDhmMTNhNDA5YWI1NTdkZTA5ZDY1YWE2YjNfNy0yLTEtMS00Njg5MQ_9fa98d29-3376-4133-b070-4a9bb8ea2844"
      unitRef="usd">438624000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ia35491a16c814a76bd71423d10de8bd7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83MC9mcmFnOjZiNDI0YTgyMzM0NzQzOWFhNmU4NjZiZmNmMGVjMDAxL3RhYmxlOmNlNTBjY2Q4ZjEzYTQwOWFiNTU3ZGUwOWQ2NWFhNmIzL3RhYmxlcmFuZ2U6Y2U1MGNjZDhmMTNhNDA5YWI1NTdkZTA5ZDY1YWE2YjNfNy00LTEtMS00Njg5MQ_0bf292c2-5d05-42cc-976c-69500d8c0d1d"
      unitRef="usd">27454000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ib03d0da6db22482c8918b1f6ab3b5e9b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83MC9mcmFnOjZiNDI0YTgyMzM0NzQzOWFhNmU4NjZiZmNmMGVjMDAxL3RhYmxlOmNlNTBjY2Q4ZjEzYTQwOWFiNTU3ZGUwOWQ2NWFhNmIzL3RhYmxlcmFuZ2U6Y2U1MGNjZDhmMTNhNDA5YWI1NTdkZTA5ZDY1YWE2YjNfNy02LTEtMS00Njg5MQ_8571c14b-f28e-45eb-ac0f-e70dccbf3a3b"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i784f65549351439fa4b7bedf90ce7e3f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83MC9mcmFnOjZiNDI0YTgyMzM0NzQzOWFhNmU4NjZiZmNmMGVjMDAxL3RhYmxlOmNlNTBjY2Q4ZjEzYTQwOWFiNTU3ZGUwOWQ2NWFhNmIzL3RhYmxlcmFuZ2U6Y2U1MGNjZDhmMTNhNDA5YWI1NTdkZTA5ZDY1YWE2YjNfNy04LTEtMS00Njg5MQ_6e4df82f-2e06-4f2a-b1fd-9481bc6f892c"
      unitRef="usd">466078000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:RevenueFromContractWithCustomerTextBlock
      contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83My9mcmFnOjBmMDFlMDBlNmZmZDRjZmQ5ZjlmZWVlNzM3NmVlODFmL3RleHRyZWdpb246MGYwMWUwMGU2ZmZkNGNmZDlmOWZlZWU3Mzc2ZWU4MWZfMzIwMA_f5447370-a5de-4c60-bb8d-d5898bea2373">License and Collaboration Agreements&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Riptide License&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 17, 2021, AUR300 (M2 macrophage modulation via CD206 binding) was secured through a global licensing and research agreement with Riptide Bioscience, Inc. (Riptide), a private company. As part of the agreement, in 2021 the Company paid Riptide an upfront license fee of $6.0&#160;million which was expensed as research and development on the condensed consolidated statements of operations. During the first quarter of 2022, Aurinia paid $4.0&#160;million for the achievement of a one-time milestone. Additional payments are due upon certain development, clinical and regulatory milestones, and royalties will be payable upon commercialization. It is anticipated that clinical development for AUR300 will commence during 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Otsuka Contract&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 17, 2020, the Company entered into a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. (Otsuka) for the development and commercialization of oral LUPKYNIS in the EU, Japan, as well as the United Kingdom, Russia, Switzerland, Norway, Belarus, Iceland, Liechtenstein and Ukraine.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As part of the agreement, Aurinia received an upfront cash payment of $50.0&#160;million for the license agreement and has the potential to receive up to $50.0&#160;million in regulatory milestones. Aurinia will receive tiered royalties on future sales ranging from 10 to 20 percent (dependent on achievement of sale thresholds) on net sales upon commercialization, along with additional milestone payments based on the attainment of certain annual sales by Otsuka. In addition, certain manufacturing services are provided to Otsuka on a cost-plus basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluated the Otsuka Agreement under ASC 606. Based on that evaluation, the license transferred was determined to be functional IP that has significant standalone functionality. That is, the treatment of LN and other diseases provides significant benefit to Otsuka at the point of transfer, and it is not expected that the utility of the IP will substantively change as a result of any remaining clinical trials or ongoing activities of Aurinia. The Company determined the upfront fee of $50.0&#160;million was fixed consideration for the transfer of the license and was recognized upon transfer of the license in December 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The remaining forms of consideration are variable because they are dependent on achieving milestones or are based on aggregate future net sales for the regions. None of the regulatory milestones have been included in the transaction price, as all milestone amounts were fully constrained. As part of its evaluation of the constraint, the Company considered numerous &lt;/span&gt;&lt;/div&gt;factors, including the magnitude of a potential reversal of revenue, uncertainty about if or when the milestone related performance obligations might be achieved, and that receipt of the milestones are outside the control of the Company since they are dependent on efforts to be undertaken by Otsuka and regulatory approval by various foreign government agencies. Any consideration related to sales-based royalties (and sales-based thresholds) will be recognized when the related sales occur.As of March&#160;31, 2022, the Company recorded $104&#160;thousand of collaboration revenue related to manufacturing services provided under the Otsuka contract</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="i6eea8e21df8b47b4892af7d314ff753b_D20210817-20210817"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83My9mcmFnOjBmMDFlMDBlNmZmZDRjZmQ5ZjlmZWVlNzM3NmVlODFmL3RleHRyZWdpb246MGYwMWUwMGU2ZmZkNGNmZDlmOWZlZWU3Mzc2ZWU4MWZfMzI5_fc1c625d-e0d6-43e6-9481-cddae7aad6bb"
      unitRef="usd">6000000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i13c8ed2824064c1abec1d76ae28d9dd8_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83My9mcmFnOjBmMDFlMDBlNmZmZDRjZmQ5ZjlmZWVlNzM3NmVlODFmL3RleHRyZWdpb246MGYwMWUwMGU2ZmZkNGNmZDlmOWZlZWU3Mzc2ZWU4MWZfMTA5OTUxMTYzMTg2OQ_7912c7a1-c464-46f1-a1b4-cf46ac2f7576"
      unitRef="usd">4000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="ia4c126547bde44f3af61232c8aecf4ac_D20201217-20201217"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83My9mcmFnOjBmMDFlMDBlNmZmZDRjZmQ5ZjlmZWVlNzM3NmVlODFmL3RleHRyZWdpb246MGYwMWUwMGU2ZmZkNGNmZDlmOWZlZWU3Mzc2ZWU4MWZfMTEzNA_df50944d-c4f9-4004-87ce-71d1ca181fe9"
      unitRef="usd">50000000</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <auph:ResearchAndDevelopmentArrangementContractToPerformForOthersPerformanceObligationPotentialRevenueAmount
      contextRef="ic3d998d2005a4d13bf8d4c76ad081c32_I20201217"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83My9mcmFnOjBmMDFlMDBlNmZmZDRjZmQ5ZjlmZWVlNzM3NmVlODFmL3RleHRyZWdpb246MGYwMWUwMGU2ZmZkNGNmZDlmOWZlZWU3Mzc2ZWU4MWZfMTIwMg_3f8aafdf-38cd-4f39-ad9a-b5aec6287167"
      unitRef="usd">50000000</auph:ResearchAndDevelopmentArrangementContractToPerformForOthersPerformanceObligationPotentialRevenueAmount>
    <auph:ResearchAndDevelopmentArrangementContractToPerformForOthersTieredRoyaltyPercent
      contextRef="if24948855cce4a1ab004e64a606f9fda_I20201217"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83My9mcmFnOjBmMDFlMDBlNmZmZDRjZmQ5ZjlmZWVlNzM3NmVlODFmL3RleHRyZWdpb246MGYwMWUwMGU2ZmZkNGNmZDlmOWZlZWU3Mzc2ZWU4MWZfMTI5OA_933661f6-e355-4182-8162-53f69f79569f"
      unitRef="number">0.10</auph:ResearchAndDevelopmentArrangementContractToPerformForOthersTieredRoyaltyPercent>
    <auph:ResearchAndDevelopmentArrangementContractToPerformForOthersTieredRoyaltyPercent
      contextRef="i4263b02edbdb433b9ce6580e359a81eb_I20201217"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83My9mcmFnOjBmMDFlMDBlNmZmZDRjZmQ5ZjlmZWVlNzM3NmVlODFmL3RleHRyZWdpb246MGYwMWUwMGU2ZmZkNGNmZDlmOWZlZWU3Mzc2ZWU4MWZfMTMwNA_f7646f86-9c95-4648-8a36-caddffa4d31f"
      unitRef="number">0.20</auph:ResearchAndDevelopmentArrangementContractToPerformForOthersTieredRoyaltyPercent>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie2ed7292d01844ac989e99b1cafc7555_D20201201-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83My9mcmFnOjBmMDFlMDBlNmZmZDRjZmQ5ZjlmZWVlNzM3NmVlODFmL3RleHRyZWdpb246MGYwMWUwMGU2ZmZkNGNmZDlmOWZlZWU3Mzc2ZWU4MWZfMjA3OQ_ceae9ddc-aa48-444c-a42c-06dd44e262cb"
      unitRef="usd">50000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibb901623e47548488a8a8d92817c020b_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83My9mcmFnOjBmMDFlMDBlNmZmZDRjZmQ5ZjlmZWVlNzM3NmVlODFmL3RleHRyZWdpb246MGYwMWUwMGU2ZmZkNGNmZDlmOWZlZWU3Mzc2ZWU4MWZfMTA5OTUxMTYzMTg5OA_03ed36e1-ebef-414f-9351-853947670c73"
      unitRef="usd">104000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83Ni9mcmFnOjU1YjBkMDU4NTU2MDRhNjE4NGI4ZTgyYjNmMjQxMjM0L3RleHRyZWdpb246NTViMGQwNTg1NTYwNGE2MTg0YjhlODJiM2YyNDEyMzRfNDc5_1a9359e8-4af3-46cf-a90d-3264b3549689">Net Loss per Common Share&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic and diluted net loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding. Since the Company was in a loss position for all periods presented, diluted net loss per share is the same as basic net loss per share. The numerator and denominator used in the calculation of basic and diluted net loss per common share are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.135%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.388%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.694%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.388%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three months ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in thousands, except per share data)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(37,630)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(50,379)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average common shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;141,675&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127,401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss per common share (expressed in $ per share)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(0.27)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.40)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company did not include the securities in the following table in the computation of the net loss per common share because the effect would have been anti-dilutive during each period:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.145%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three months ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;14,649&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested performance awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;439&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested restricted units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,952&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,014&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;16,601&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,785&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83Ni9mcmFnOjU1YjBkMDU4NTU2MDRhNjE4NGI4ZTgyYjNmMjQxMjM0L3RleHRyZWdpb246NTViMGQwNTg1NTYwNGE2MTg0YjhlODJiM2YyNDEyMzRfNDgw_5de1f9a7-d558-47dd-9fe7-907055a89007">The numerator and denominator used in the calculation of basic and diluted net loss per common share are as follows:&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.135%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.388%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.694%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.388%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three months ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in thousands, except per share data)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(37,630)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(50,379)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average common shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;141,675&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127,401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss per common share (expressed in $ per share)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(0.27)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.40)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company did not include the securities in the following table in the computation of the net loss per common share because the effect would have been anti-dilutive during each period:&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83Ni9mcmFnOjU1YjBkMDU4NTU2MDRhNjE4NGI4ZTgyYjNmMjQxMjM0L3RhYmxlOjI4YmEwZmI0OTNlMDQxZjk5MTU5MWM5ZWFmNzlmNTRjL3RhYmxlcmFuZ2U6MjhiYTBmYjQ5M2UwNDFmOTkxNTkxYzllYWY3OWY1NGNfMi0yLTEtMS00Njg5MQ_6ac9ab29-7f15-4343-8494-ecfbaffe82b1"
      unitRef="usd">-37630000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i56599386fa47443a8975bb3f7a6a8c57_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83Ni9mcmFnOjU1YjBkMDU4NTU2MDRhNjE4NGI4ZTgyYjNmMjQxMjM0L3RhYmxlOjI4YmEwZmI0OTNlMDQxZjk5MTU5MWM5ZWFmNzlmNTRjL3RhYmxlcmFuZ2U6MjhiYTBmYjQ5M2UwNDFmOTkxNTkxYzllYWY3OWY1NGNfMi00LTEtMS00Njg5MQ_0d63b369-faef-472b-80a7-2b877d7d527e"
      unitRef="usd">-50379000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83Ni9mcmFnOjU1YjBkMDU4NTU2MDRhNjE4NGI4ZTgyYjNmMjQxMjM0L3RhYmxlOjI4YmEwZmI0OTNlMDQxZjk5MTU5MWM5ZWFmNzlmNTRjL3RhYmxlcmFuZ2U6MjhiYTBmYjQ5M2UwNDFmOTkxNTkxYzllYWY3OWY1NGNfMy0yLTEtMS00Njg5MQ_342538a5-4abe-486e-97b8-17d9cf1d2bab"
      unitRef="shares">141675000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83Ni9mcmFnOjU1YjBkMDU4NTU2MDRhNjE4NGI4ZTgyYjNmMjQxMjM0L3RhYmxlOjI4YmEwZmI0OTNlMDQxZjk5MTU5MWM5ZWFmNzlmNTRjL3RhYmxlcmFuZ2U6MjhiYTBmYjQ5M2UwNDFmOTkxNTkxYzllYWY3OWY1NGNfMy0yLTEtMS00Njg5MQ_6147aa37-f6b8-4a0d-aaea-2ec3d8b80492"
      unitRef="shares">141675000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i56599386fa47443a8975bb3f7a6a8c57_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83Ni9mcmFnOjU1YjBkMDU4NTU2MDRhNjE4NGI4ZTgyYjNmMjQxMjM0L3RhYmxlOjI4YmEwZmI0OTNlMDQxZjk5MTU5MWM5ZWFmNzlmNTRjL3RhYmxlcmFuZ2U6MjhiYTBmYjQ5M2UwNDFmOTkxNTkxYzllYWY3OWY1NGNfMy00LTEtMS00Njg5MQ_608cff76-b0d9-4ef1-846a-ac66460ee841"
      unitRef="shares">127401000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i56599386fa47443a8975bb3f7a6a8c57_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83Ni9mcmFnOjU1YjBkMDU4NTU2MDRhNjE4NGI4ZTgyYjNmMjQxMjM0L3RhYmxlOjI4YmEwZmI0OTNlMDQxZjk5MTU5MWM5ZWFmNzlmNTRjL3RhYmxlcmFuZ2U6MjhiYTBmYjQ5M2UwNDFmOTkxNTkxYzllYWY3OWY1NGNfMy00LTEtMS00Njg5MQ_80803525-c7ec-4166-b3aa-da0462874adf"
      unitRef="shares">127401000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83Ni9mcmFnOjU1YjBkMDU4NTU2MDRhNjE4NGI4ZTgyYjNmMjQxMjM0L3RhYmxlOjI4YmEwZmI0OTNlMDQxZjk5MTU5MWM5ZWFmNzlmNTRjL3RhYmxlcmFuZ2U6MjhiYTBmYjQ5M2UwNDFmOTkxNTkxYzllYWY3OWY1NGNfNC0yLTEtMS00Njg5MQ_26db01ce-09b9-4be6-b2bb-72394cd25e91"
      unitRef="usdPerShare">-0.27</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83Ni9mcmFnOjU1YjBkMDU4NTU2MDRhNjE4NGI4ZTgyYjNmMjQxMjM0L3RhYmxlOjI4YmEwZmI0OTNlMDQxZjk5MTU5MWM5ZWFmNzlmNTRjL3RhYmxlcmFuZ2U6MjhiYTBmYjQ5M2UwNDFmOTkxNTkxYzllYWY3OWY1NGNfNC0yLTEtMS00Njg5MQ_ee9c1b3b-7795-487a-ac85-fc59066ce615"
      unitRef="usdPerShare">-0.27</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i56599386fa47443a8975bb3f7a6a8c57_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83Ni9mcmFnOjU1YjBkMDU4NTU2MDRhNjE4NGI4ZTgyYjNmMjQxMjM0L3RhYmxlOjI4YmEwZmI0OTNlMDQxZjk5MTU5MWM5ZWFmNzlmNTRjL3RhYmxlcmFuZ2U6MjhiYTBmYjQ5M2UwNDFmOTkxNTkxYzllYWY3OWY1NGNfNC00LTEtMS00Njg5MQ_6a5c9688-627f-450e-b9dd-161ad682d9a8"
      unitRef="usdPerShare">-0.40</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i56599386fa47443a8975bb3f7a6a8c57_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83Ni9mcmFnOjU1YjBkMDU4NTU2MDRhNjE4NGI4ZTgyYjNmMjQxMjM0L3RhYmxlOjI4YmEwZmI0OTNlMDQxZjk5MTU5MWM5ZWFmNzlmNTRjL3RhYmxlcmFuZ2U6MjhiYTBmYjQ5M2UwNDFmOTkxNTkxYzllYWY3OWY1NGNfNC00LTEtMS00Njg5MQ_e012714c-63bc-4814-872b-7e1def5e0d90"
      unitRef="usdPerShare">-0.40</us-gaap:EarningsPerShareBasic>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83Ni9mcmFnOjU1YjBkMDU4NTU2MDRhNjE4NGI4ZTgyYjNmMjQxMjM0L3RleHRyZWdpb246NTViMGQwNTg1NTYwNGE2MTg0YjhlODJiM2YyNDEyMzRfNDgx_3c997a36-8c8b-4b7b-8bb0-7e1064210164">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.145%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three months ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;14,649&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested performance awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;439&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested restricted units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,952&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,014&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;16,601&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,785&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ic3ca33ca8bfb4c8aac86d02183ad2fa2_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83Ni9mcmFnOjU1YjBkMDU4NTU2MDRhNjE4NGI4ZTgyYjNmMjQxMjM0L3RhYmxlOjcyZjMwYThiNzE3NzRiMGNiYzJiODU1NGI0MmRkOGQ4L3RhYmxlcmFuZ2U6NzJmMzBhOGI3MTc3NGIwY2JjMmI4NTU0YjQyZGQ4ZDhfMi0yLTEtMS00Njg5MQ_28366fd9-30e8-47eb-b26b-c5980a9cd7c1"
      unitRef="shares">14649000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i105a1152b5c54760ad7380e7462cbfbf_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83Ni9mcmFnOjU1YjBkMDU4NTU2MDRhNjE4NGI4ZTgyYjNmMjQxMjM0L3RhYmxlOjcyZjMwYThiNzE3NzRiMGNiYzJiODU1NGI0MmRkOGQ4L3RhYmxlcmFuZ2U6NzJmMzBhOGI3MTc3NGIwY2JjMmI4NTU0YjQyZGQ4ZDhfMi00LTEtMS00Njg5MQ_1ce5f89a-a9a2-4ee1-abab-0d9c23fe3300"
      unitRef="shares">14332000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="iae2da8378b4b45af98b0443b437184a5_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83Ni9mcmFnOjU1YjBkMDU4NTU2MDRhNjE4NGI4ZTgyYjNmMjQxMjM0L3RhYmxlOjcyZjMwYThiNzE3NzRiMGNiYzJiODU1NGI0MmRkOGQ4L3RhYmxlcmFuZ2U6NzJmMzBhOGI3MTc3NGIwY2JjMmI4NTU0YjQyZGQ4ZDhfMy0yLTEtMS00Njg5MQ_bc86eb90-9e7a-4521-aec2-83d8e87120e9"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i6384fea4599b405a9d8a4d0a174ba37c_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83Ni9mcmFnOjU1YjBkMDU4NTU2MDRhNjE4NGI4ZTgyYjNmMjQxMjM0L3RhYmxlOjcyZjMwYThiNzE3NzRiMGNiYzJiODU1NGI0MmRkOGQ4L3RhYmxlcmFuZ2U6NzJmMzBhOGI3MTc3NGIwY2JjMmI4NTU0YjQyZGQ4ZDhfMy00LTEtMS00Njg5MQ_28e6c093-a99b-44c7-bb42-1a0e6c2954c1"
      unitRef="shares">439000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ic530833cd3564851886dba86e0d1fbb6_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83Ni9mcmFnOjU1YjBkMDU4NTU2MDRhNjE4NGI4ZTgyYjNmMjQxMjM0L3RhYmxlOjcyZjMwYThiNzE3NzRiMGNiYzJiODU1NGI0MmRkOGQ4L3RhYmxlcmFuZ2U6NzJmMzBhOGI3MTc3NGIwY2JjMmI4NTU0YjQyZGQ4ZDhfNC0yLTEtMS00Njg5MQ_2cfdc8b9-462a-4aac-8266-8a14107b3857"
      unitRef="shares">1952000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i5d28d6c0f0d940f59d45551ddc72575a_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83Ni9mcmFnOjU1YjBkMDU4NTU2MDRhNjE4NGI4ZTgyYjNmMjQxMjM0L3RhYmxlOjcyZjMwYThiNzE3NzRiMGNiYzJiODU1NGI0MmRkOGQ4L3RhYmxlcmFuZ2U6NzJmMzBhOGI3MTc3NGIwY2JjMmI4NTU0YjQyZGQ4ZDhfNC00LTEtMS00Njg5MQ_f68bb30c-b094-46da-abd2-7db5b27e6145"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ib81c30a26c6a41b69cf92282735549ea_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83Ni9mcmFnOjU1YjBkMDU4NTU2MDRhNjE4NGI4ZTgyYjNmMjQxMjM0L3RhYmxlOjcyZjMwYThiNzE3NzRiMGNiYzJiODU1NGI0MmRkOGQ4L3RhYmxlcmFuZ2U6NzJmMzBhOGI3MTc3NGIwY2JjMmI4NTU0YjQyZGQ4ZDhfNS0yLTEtMS00Njg5MQ_bc356448-8c38-47b1-8dad-f58c08b686e7"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i6ee10ba4e3a1477e80be6a7ae14a5733_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83Ni9mcmFnOjU1YjBkMDU4NTU2MDRhNjE4NGI4ZTgyYjNmMjQxMjM0L3RhYmxlOjcyZjMwYThiNzE3NzRiMGNiYzJiODU1NGI0MmRkOGQ4L3RhYmxlcmFuZ2U6NzJmMzBhOGI3MTc3NGIwY2JjMmI4NTU0YjQyZGQ4ZDhfNS00LTEtMS00Njg5MQ_858d1896-ea8f-4690-bc85-6aa7bf2cbe8b"
      unitRef="shares">1014000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83Ni9mcmFnOjU1YjBkMDU4NTU2MDRhNjE4NGI4ZTgyYjNmMjQxMjM0L3RhYmxlOjcyZjMwYThiNzE3NzRiMGNiYzJiODU1NGI0MmRkOGQ4L3RhYmxlcmFuZ2U6NzJmMzBhOGI3MTc3NGIwY2JjMmI4NTU0YjQyZGQ4ZDhfNi0yLTEtMS00Njg5MQ_6f7c433a-fe91-4570-91e7-4e38f05b34f7"
      unitRef="shares">16601000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i56599386fa47443a8975bb3f7a6a8c57_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83Ni9mcmFnOjU1YjBkMDU4NTU2MDRhNjE4NGI4ZTgyYjNmMjQxMjM0L3RhYmxlOjcyZjMwYThiNzE3NzRiMGNiYzJiODU1NGI0MmRkOGQ4L3RhYmxlcmFuZ2U6NzJmMzBhOGI3MTc3NGIwY2JjMmI4NTU0YjQyZGQ4ZDhfNi00LTEtMS00Njg5MQ_e2696b1d-c3de-4145-a674-7f2259449e35"
      unitRef="shares">15785000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83OS9mcmFnOmJmMGVkNmYyMzkyYzQyZDJiNWQxNjkzN2ZmMjQzOTU5L3RleHRyZWdpb246YmYwZWQ2ZjIzOTJjNDJkMmI1ZDE2OTM3ZmYyNDM5NTlfMzc1Mg_b96726ef-f30c-447c-988d-a762c8e64f34">Share-based Compensation&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's Amended and Restated Equity Incentive Plan (the Plan), which was adopted and approved by the Company's shareholders in June 2021, allows for an issuance of up to an aggregate of 23.8 million shares (inclusive of outstanding awards) and provides for grants of stock options, performance awards, restricted stock and restricted stock units that may be settled in cash and stock. Also in June 2021, the Company's shareholders adopted and approved the Company's 2021 ESPP, which allows for the issuance of up to 2.5 million shares. The 2021 ESPP is intended to qualify as an &#x201c;employee stock purchase plan&#x201d; under Section 423 of the Internal Revenue Code (the &#x201c;Code&#x201d;) but also permits the Company to include the employees, including non-United States employees, in offerings not intended to qualify under Section 423. The purpose of the 2021 ESPP is to provide eligible employees with opportunities to purchase the Company&#x2019;s common shares at a discounted price. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock Options&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Plan requires the exercise price of each option not to be less than the closing market price of the Company&#x2019;s common shares on the day immediately prior to the date of grant. The board of directors approves the vesting criteria and periods at its discretion. The options issued under the plan are accounted for as equity-settled share-based payments. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company used the Black-Scholes option pricing model to estimate the fair value of the options granted. The Company considers historical volatility of its common shares in estimating its future stock price volatility. The risk-free interest rate for the expected life of the options was based on the yield available on government benchmark bonds with an approximate &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;equivalent remaining term at the time of the grant. The expected life is based upon the contractual term, taking into account expected employee exercise and expected post-vesting employment termination behavior. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following weighted average assumptions were used to estimate the fair value of the options granted during the three months ended March&#160;31, 2022 and March&#160;31, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.642%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.447%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Annualized volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;70&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1.73&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected life of options in years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;5.0 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.0 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Estimated forfeiture rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;11.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;0.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.0%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value per common share option&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;7.02&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the option award activity during the three months ended March&#160;31, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.642%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.447%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number of shares (in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted average exercise price $&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding - Beginning of Period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;12,074&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;12.84&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,800&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;12.00&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(54)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;7.57&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(171)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;16.27&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding - End of Period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;14,649&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;12.66&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Performance Awards and Restricted Stock Units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 23, 2020, the Company issued 439,000 performance awards (PAs) to executive management of the Company whose vesting is contingent upon meeting specific performance metrics based on the results for the year ended December 31, 2021. Each PA which vests entitles the participant to receive common shares on the basis of the performance metrics set. On March 18, 2021 performance metrics were set and formally communicated. Therefore, March 18, 2021 was the grant date and the fair value on the grant date was $13.56. As of March&#160;31, 2022, approximately 88,000 PAs vested based on performance metrics achieved and 351,000 were canceled as of December&#160;31, 2021 as performance metrics were not met.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 6, 2021, the Company granted approximately 619,000 PAs and restricted stock units (RSUs). The grant date for the PAs and RSUs was August 6, 2021 and the fair value on the grant date was $14.42 as this was the date performance measures were set and communicated to employees. The PAs vest on the employee's first anniversary of the grant date and the employee must achieve at least one of the performance metrics to obtain the portion of the award associated with the metric. The RSUs have no performance metrics and will vest on the one year anniversary of the grant. As of December&#160;31, 2021, approximately 375,000 PAs and RSUs were canceled or forfeited.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the quarter, the Company has granted RSUs and intends to grant RSUs throughout the year under the Plan. The RSUs are fair valued based on the market price of our common stock on the date of the grant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the PAs and RSU activity for the three months ended March&#160;31, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.642%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.447%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number of shares (in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted average exercise price $&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding - Beginning of Period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;347&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;13.33&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,708&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;12.01&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(88)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;13.56&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(15)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;13.85&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding - End of Period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,952&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;12.16&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recorded approximately $1.9 million of share-based compensation expense related to PAs and RSUs during the three months ended March&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Compensation Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognized share-based compensation expense for the three months ended March&#160;31, 2022 and March&#160;31, 2021 as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.642%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.447%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;976&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,074&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;5,972&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,641&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Capitalized under inventories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;75&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;7,023&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As of March&#160;31, 2022, there was $48.3&#160;million of unrecognized share-based compensation expense related to unvested awards granted which is expected to be recognized over a weighted-average period of approximately 1.6 years.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="ic967022eaed24a72b01d3974047a24dc_D20210601-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83OS9mcmFnOmJmMGVkNmYyMzkyYzQyZDJiNWQxNjkzN2ZmMjQzOTU5L3RleHRyZWdpb246YmYwZWQ2ZjIzOTJjNDJkMmI1ZDE2OTM3ZmYyNDM5NTlfMjIy_2ad29544-571b-4c92-a108-9ca2acc1330d"
      unitRef="shares">23800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="ib997dd537ee44595bf4b5e42a02596ac_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83OS9mcmFnOmJmMGVkNmYyMzkyYzQyZDJiNWQxNjkzN2ZmMjQzOTU5L3RleHRyZWdpb246YmYwZWQ2ZjIzOTJjNDJkMmI1ZDE2OTM3ZmYyNDM5NTlfNDI5_728391be-2859-4ddc-8d14-0a89e143db2d"
      unitRef="shares">2500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83OS9mcmFnOmJmMGVkNmYyMzkyYzQyZDJiNWQxNjkzN2ZmMjQzOTU5L3RleHRyZWdpb246YmYwZWQ2ZjIzOTJjNDJkMmI1ZDE2OTM3ZmYyNDM5NTlfMzc1Mw_e5748198-907d-4522-80df-cd29edda5be1">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following weighted average assumptions were used to estimate the fair value of the options granted during the three months ended March&#160;31, 2022 and March&#160;31, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.642%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.447%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Annualized volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;70&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1.73&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected life of options in years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;5.0 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.0 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Estimated forfeiture rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;11.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;0.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.0%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value per common share option&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;7.02&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83OS9mcmFnOmJmMGVkNmYyMzkyYzQyZDJiNWQxNjkzN2ZmMjQzOTU5L3RhYmxlOjA0OTJiZjU1NzZiNDRlNTFiYjU1MzZkYTZhODIyN2I2L3RhYmxlcmFuZ2U6MDQ5MmJmNTU3NmI0NGU1MWJiNTUzNmRhNmE4MjI3YjZfMS0yLTEtMS00Njg5MQ_51dc1472-ace3-48a0-9936-fc0d228bd517"
      unitRef="number">0.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="i56599386fa47443a8975bb3f7a6a8c57_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83OS9mcmFnOmJmMGVkNmYyMzkyYzQyZDJiNWQxNjkzN2ZmMjQzOTU5L3RhYmxlOjA0OTJiZjU1NzZiNDRlNTFiYjU1MzZkYTZhODIyN2I2L3RhYmxlcmFuZ2U6MDQ5MmJmNTU3NmI0NGU1MWJiNTUzNmRhNmE4MjI3YjZfMS00LTEtMS00Njg5MQ_202fb2f9-113b-462e-98d7-a67d78502fa9"
      unitRef="number">0.66</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83OS9mcmFnOmJmMGVkNmYyMzkyYzQyZDJiNWQxNjkzN2ZmMjQzOTU5L3RhYmxlOjA0OTJiZjU1NzZiNDRlNTFiYjU1MzZkYTZhODIyN2I2L3RhYmxlcmFuZ2U6MDQ5MmJmNTU3NmI0NGU1MWJiNTUzNmRhNmE4MjI3YjZfMi0yLTEtMS00Njg5MQ_c95384f0-4f44-4f36-a9d9-8188adc3d0ee"
      unitRef="number">0.0173</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i56599386fa47443a8975bb3f7a6a8c57_D20210101-20210331"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83OS9mcmFnOmJmMGVkNmYyMzkyYzQyZDJiNWQxNjkzN2ZmMjQzOTU5L3RhYmxlOjA0OTJiZjU1NzZiNDRlNTFiYjU1MzZkYTZhODIyN2I2L3RhYmxlcmFuZ2U6MDQ5MmJmNTU3NmI0NGU1MWJiNTUzNmRhNmE4MjI3YjZfMi00LTEtMS00Njg5MQ_8bef1eae-651e-4b9c-b4b2-e77a6d803924"
      unitRef="number">0.0028</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83OS9mcmFnOmJmMGVkNmYyMzkyYzQyZDJiNWQxNjkzN2ZmMjQzOTU5L3RhYmxlOjA0OTJiZjU1NzZiNDRlNTFiYjU1MzZkYTZhODIyN2I2L3RhYmxlcmFuZ2U6MDQ5MmJmNTU3NmI0NGU1MWJiNTUzNmRhNmE4MjI3YjZfMy0yLTEtMS00Njg5MQ_78993305-acc4-4fe9-91c2-0378b84878f2">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i56599386fa47443a8975bb3f7a6a8c57_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83OS9mcmFnOmJmMGVkNmYyMzkyYzQyZDJiNWQxNjkzN2ZmMjQzOTU5L3RhYmxlOjA0OTJiZjU1NzZiNDRlNTFiYjU1MzZkYTZhODIyN2I2L3RhYmxlcmFuZ2U6MDQ5MmJmNTU3NmI0NGU1MWJiNTUzNmRhNmE4MjI3YjZfMy00LTEtMS00Njg5MQ_4aed2215-21cb-4a9b-8bff-932de444596c">P4Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <auph:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate
      contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83OS9mcmFnOmJmMGVkNmYyMzkyYzQyZDJiNWQxNjkzN2ZmMjQzOTU5L3RhYmxlOjA0OTJiZjU1NzZiNDRlNTFiYjU1MzZkYTZhODIyN2I2L3RhYmxlcmFuZ2U6MDQ5MmJmNTU3NmI0NGU1MWJiNTUzNmRhNmE4MjI3YjZfNC0yLTEtMS00Njg5MQ_b7227811-78f8-4258-870d-227a27c417ee"
      unitRef="number">0.116</auph:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate>
    <auph:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate
      contextRef="i56599386fa47443a8975bb3f7a6a8c57_D20210101-20210331"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83OS9mcmFnOmJmMGVkNmYyMzkyYzQyZDJiNWQxNjkzN2ZmMjQzOTU5L3RhYmxlOjA0OTJiZjU1NzZiNDRlNTFiYjU1MzZkYTZhODIyN2I2L3RhYmxlcmFuZ2U6MDQ5MmJmNTU3NmI0NGU1MWJiNTUzNmRhNmE4MjI3YjZfNC00LTEtMS00Njg5MQ_61662d0f-8761-4d11-a3b2-5d30ac2027d3"
      unitRef="number">0.089</auph:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend
      contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83OS9mcmFnOmJmMGVkNmYyMzkyYzQyZDJiNWQxNjkzN2ZmMjQzOTU5L3RhYmxlOjA0OTJiZjU1NzZiNDRlNTFiYjU1MzZkYTZhODIyN2I2L3RhYmxlcmFuZ2U6MDQ5MmJmNTU3NmI0NGU1MWJiNTUzNmRhNmE4MjI3YjZfNS0yLTEtMS00Njg5MQ_f3836eb0-c10e-4efc-ae7a-ed37c586ec13"
      unitRef="usd">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend
      contextRef="i56599386fa47443a8975bb3f7a6a8c57_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83OS9mcmFnOmJmMGVkNmYyMzkyYzQyZDJiNWQxNjkzN2ZmMjQzOTU5L3RhYmxlOjA0OTJiZjU1NzZiNDRlNTFiYjU1MzZkYTZhODIyN2I2L3RhYmxlcmFuZ2U6MDQ5MmJmNTU3NmI0NGU1MWJiNTUzNmRhNmE4MjI3YjZfNS00LTEtMS00Njg5MQ_d92e28c5-3a01-409b-9635-25333c99ff60"
      unitRef="usd">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83OS9mcmFnOmJmMGVkNmYyMzkyYzQyZDJiNWQxNjkzN2ZmMjQzOTU5L3RhYmxlOjA0OTJiZjU1NzZiNDRlNTFiYjU1MzZkYTZhODIyN2I2L3RhYmxlcmFuZ2U6MDQ5MmJmNTU3NmI0NGU1MWJiNTUzNmRhNmE4MjI3YjZfNi0yLTEtMS00Njg5MQ_bd5578f6-55f3-4e2a-954c-2aba40e71e91"
      unitRef="usdPerShare">7.02</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i56599386fa47443a8975bb3f7a6a8c57_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83OS9mcmFnOmJmMGVkNmYyMzkyYzQyZDJiNWQxNjkzN2ZmMjQzOTU5L3RhYmxlOjA0OTJiZjU1NzZiNDRlNTFiYjU1MzZkYTZhODIyN2I2L3RhYmxlcmFuZ2U6MDQ5MmJmNTU3NmI0NGU1MWJiNTUzNmRhNmE4MjI3YjZfNi00LTEtMS00Njg5MQ_8bac8f52-0342-45d1-8255-bbe2e041e2e4"
      unitRef="usdPerShare">6.72</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83OS9mcmFnOmJmMGVkNmYyMzkyYzQyZDJiNWQxNjkzN2ZmMjQzOTU5L3RleHRyZWdpb246YmYwZWQ2ZjIzOTJjNDJkMmI1ZDE2OTM3ZmYyNDM5NTlfMzI5ODUzNDg4NzU1MA_1a03b8d3-c6e7-441e-9a0c-96af39bdf1af">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the option award activity during the three months ended March&#160;31, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.642%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.447%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number of shares (in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted average exercise price $&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding - Beginning of Period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;12,074&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;12.84&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,800&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;12.00&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(54)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;7.57&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(171)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;16.27&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding - End of Period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;14,649&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;12.66&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i784f65549351439fa4b7bedf90ce7e3f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83OS9mcmFnOmJmMGVkNmYyMzkyYzQyZDJiNWQxNjkzN2ZmMjQzOTU5L3RhYmxlOjQ0NjcxM2RjYzhiZjQ5MjNiMWI1NWNhMDZiZjYzMWUwL3RhYmxlcmFuZ2U6NDQ2NzEzZGNjOGJmNDkyM2IxYjU1Y2EwNmJmNjMxZTBfMi0yLTEtMS00Njg5MQ_dcdb1193-f0ff-45e4-9f02-9284dc172754"
      unitRef="shares">12074000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i784f65549351439fa4b7bedf90ce7e3f_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83OS9mcmFnOmJmMGVkNmYyMzkyYzQyZDJiNWQxNjkzN2ZmMjQzOTU5L3RhYmxlOjQ0NjcxM2RjYzhiZjQ5MjNiMWI1NWNhMDZiZjYzMWUwL3RhYmxlcmFuZ2U6NDQ2NzEzZGNjOGJmNDkyM2IxYjU1Y2EwNmJmNjMxZTBfMi00LTEtMS00Njg5MQ_e93eeee4-e785-4b90-bd5c-adeb74751961"
      unitRef="usdPerShare">12.84</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83OS9mcmFnOmJmMGVkNmYyMzkyYzQyZDJiNWQxNjkzN2ZmMjQzOTU5L3RhYmxlOjQ0NjcxM2RjYzhiZjQ5MjNiMWI1NWNhMDZiZjYzMWUwL3RhYmxlcmFuZ2U6NDQ2NzEzZGNjOGJmNDkyM2IxYjU1Y2EwNmJmNjMxZTBfMy0yLTEtMS00Njg5MQ_5f2af206-a86d-4821-9133-7062d4c05fc6"
      unitRef="shares">2800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83OS9mcmFnOmJmMGVkNmYyMzkyYzQyZDJiNWQxNjkzN2ZmMjQzOTU5L3RhYmxlOjQ0NjcxM2RjYzhiZjQ5MjNiMWI1NWNhMDZiZjYzMWUwL3RhYmxlcmFuZ2U6NDQ2NzEzZGNjOGJmNDkyM2IxYjU1Y2EwNmJmNjMxZTBfMy00LTEtMS00Njg5MQ_e102a642-ba2e-4d22-9d33-969f5b36c766"
      unitRef="usdPerShare">12.00</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83OS9mcmFnOmJmMGVkNmYyMzkyYzQyZDJiNWQxNjkzN2ZmMjQzOTU5L3RhYmxlOjQ0NjcxM2RjYzhiZjQ5MjNiMWI1NWNhMDZiZjYzMWUwL3RhYmxlcmFuZ2U6NDQ2NzEzZGNjOGJmNDkyM2IxYjU1Y2EwNmJmNjMxZTBfNC0yLTEtMS00Njg5MQ_2e398c43-450c-4c96-85d6-b6c7e4a3e241"
      unitRef="shares">54000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83OS9mcmFnOmJmMGVkNmYyMzkyYzQyZDJiNWQxNjkzN2ZmMjQzOTU5L3RhYmxlOjQ0NjcxM2RjYzhiZjQ5MjNiMWI1NWNhMDZiZjYzMWUwL3RhYmxlcmFuZ2U6NDQ2NzEzZGNjOGJmNDkyM2IxYjU1Y2EwNmJmNjMxZTBfNC00LTEtMS00Njg5MQ_0446072f-92af-48ff-9974-ad60a2b35fad"
      unitRef="usdPerShare">7.57</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83OS9mcmFnOmJmMGVkNmYyMzkyYzQyZDJiNWQxNjkzN2ZmMjQzOTU5L3RhYmxlOjQ0NjcxM2RjYzhiZjQ5MjNiMWI1NWNhMDZiZjYzMWUwL3RhYmxlcmFuZ2U6NDQ2NzEzZGNjOGJmNDkyM2IxYjU1Y2EwNmJmNjMxZTBfNS0yLTEtMS00Njg5MQ_b8a4b60d-9f9e-483e-8380-d2f52c17c880"
      unitRef="shares">171000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83OS9mcmFnOmJmMGVkNmYyMzkyYzQyZDJiNWQxNjkzN2ZmMjQzOTU5L3RhYmxlOjQ0NjcxM2RjYzhiZjQ5MjNiMWI1NWNhMDZiZjYzMWUwL3RhYmxlcmFuZ2U6NDQ2NzEzZGNjOGJmNDkyM2IxYjU1Y2EwNmJmNjMxZTBfNS00LTEtMS00Njg5MQ_87312974-f14f-47b5-a1ec-ef56b3228771"
      unitRef="usdPerShare">16.27</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="id7882ae6aff54a3aacdef67ddf11a428_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83OS9mcmFnOmJmMGVkNmYyMzkyYzQyZDJiNWQxNjkzN2ZmMjQzOTU5L3RhYmxlOjQ0NjcxM2RjYzhiZjQ5MjNiMWI1NWNhMDZiZjYzMWUwL3RhYmxlcmFuZ2U6NDQ2NzEzZGNjOGJmNDkyM2IxYjU1Y2EwNmJmNjMxZTBfNi0yLTEtMS00Njg5MQ_af564570-38a3-4f90-bfc7-5b4a4b196edb"
      unitRef="shares">14649000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="id7882ae6aff54a3aacdef67ddf11a428_I20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83OS9mcmFnOmJmMGVkNmYyMzkyYzQyZDJiNWQxNjkzN2ZmMjQzOTU5L3RhYmxlOjQ0NjcxM2RjYzhiZjQ5MjNiMWI1NWNhMDZiZjYzMWUwL3RhYmxlcmFuZ2U6NDQ2NzEzZGNjOGJmNDkyM2IxYjU1Y2EwNmJmNjMxZTBfNi00LTEtMS00Njg5MQ_68002c04-0e98-4608-9699-e4df4aa95a8d"
      unitRef="usdPerShare">12.66</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="ib8ebe99a1b5a4e18b4d3a1b5a2e4806a_D20201023-20201023"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83OS9mcmFnOmJmMGVkNmYyMzkyYzQyZDJiNWQxNjkzN2ZmMjQzOTU5L3RleHRyZWdpb246YmYwZWQ2ZjIzOTJjNDJkMmI1ZDE2OTM3ZmYyNDM5NTlfMjIyNQ_dc1f2919-9ee3-43ff-b720-f7e35692e858"
      unitRef="shares">439000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i6658318dd5b2443bbb61848fe5a802d9_D20210318-20210318"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83OS9mcmFnOmJmMGVkNmYyMzkyYzQyZDJiNWQxNjkzN2ZmMjQzOTU5L3RleHRyZWdpb246YmYwZWQ2ZjIzOTJjNDJkMmI1ZDE2OTM3ZmYyNDM5NTlfMjY4MQ_3df76d40-78dd-4794-80bb-9fdbd2843901"
      unitRef="usdPerShare">13.56</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i16277210576f40e6b66abe8fff631587_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83OS9mcmFnOmJmMGVkNmYyMzkyYzQyZDJiNWQxNjkzN2ZmMjQzOTU5L3RleHRyZWdpb246YmYwZWQ2ZjIzOTJjNDJkMmI1ZDE2OTM3ZmYyNDM5NTlfMTA5OTUxMTYzMzM0OA_06ed27ec-d09d-439c-aa2e-4a07cc29ee2c"
      unitRef="shares">88000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i16277210576f40e6b66abe8fff631587_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83OS9mcmFnOmJmMGVkNmYyMzkyYzQyZDJiNWQxNjkzN2ZmMjQzOTU5L3RleHRyZWdpb246YmYwZWQ2ZjIzOTJjNDJkMmI1ZDE2OTM3ZmYyNDM5NTlfMTA5OTUxMTYzMzMzOQ_296fb877-afaf-48cb-89bb-e150a611273f"
      unitRef="shares">351000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i756422f9e99948068788efa1b4d47e72_D20210806-20210806"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83OS9mcmFnOmJmMGVkNmYyMzkyYzQyZDJiNWQxNjkzN2ZmMjQzOTU5L3RleHRyZWdpb246YmYwZWQ2ZjIzOTJjNDJkMmI1ZDE2OTM3ZmYyNDM5NTlfMjczOA_0accfc5f-e824-48f6-9f93-4f1f02792109"
      unitRef="shares">619000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i756422f9e99948068788efa1b4d47e72_D20210806-20210806"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83OS9mcmFnOmJmMGVkNmYyMzkyYzQyZDJiNWQxNjkzN2ZmMjQzOTU5L3RleHRyZWdpb246YmYwZWQ2ZjIzOTJjNDJkMmI1ZDE2OTM3ZmYyNDM5NTlfMjg3Ng_4336137a-588e-4456-9e77-cb6c69b6f5ba"
      unitRef="usdPerShare">14.42</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i262fb9bddf114af5919be54955f6f018_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83OS9mcmFnOmJmMGVkNmYyMzkyYzQyZDJiNWQxNjkzN2ZmMjQzOTU5L3RleHRyZWdpb246YmYwZWQ2ZjIzOTJjNDJkMmI1ZDE2OTM3ZmYyNDM5NTlfMzI5ODUzNDg4OTU2Nw_9578cedb-4cde-4d5c-97cb-4f3f8b26f320">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i1bc38d71f54444c69c2a074dc7d8a2ce_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83OS9mcmFnOmJmMGVkNmYyMzkyYzQyZDJiNWQxNjkzN2ZmMjQzOTU5L3RleHRyZWdpb246YmYwZWQ2ZjIzOTJjNDJkMmI1ZDE2OTM3ZmYyNDM5NTlfMTA5OTUxMTYzMzM1Ng_6d56c6f9-7bd2-4aa2-9199-c5d48e4fb385"
      unitRef="shares">375000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock
      contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83OS9mcmFnOmJmMGVkNmYyMzkyYzQyZDJiNWQxNjkzN2ZmMjQzOTU5L3RleHRyZWdpb246YmYwZWQ2ZjIzOTJjNDJkMmI1ZDE2OTM3ZmYyNDM5NTlfMzc1NA_49b204e5-f162-4dc7-8bdf-075200508e05">The following table summarizes the PAs and RSU activity for the three months ended March&#160;31, 2022:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.642%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.447%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number of shares (in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted average exercise price $&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding - Beginning of Period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;347&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;13.33&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,708&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;12.01&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(88)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;13.56&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(15)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;13.85&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding - End of Period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,952&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;12.16&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="id05699051d2448519e6e9c2935d67b1f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83OS9mcmFnOmJmMGVkNmYyMzkyYzQyZDJiNWQxNjkzN2ZmMjQzOTU5L3RhYmxlOmNiZTA5ZDUzNzIyNDRiOWNhMjc0NWYwYjNiMzNmNmEzL3RhYmxlcmFuZ2U6Y2JlMDlkNTM3MjI0NGI5Y2EyNzQ1ZjBiM2IzM2Y2YTNfMi0yLTEtMS01MzQ3Ng_3380a24c-a159-47b5-8ce8-3fc26f8076c8"
      unitRef="shares">347000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="id05699051d2448519e6e9c2935d67b1f_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83OS9mcmFnOmJmMGVkNmYyMzkyYzQyZDJiNWQxNjkzN2ZmMjQzOTU5L3RhYmxlOmNiZTA5ZDUzNzIyNDRiOWNhMjc0NWYwYjNiMzNmNmEzL3RhYmxlcmFuZ2U6Y2JlMDlkNTM3MjI0NGI5Y2EyNzQ1ZjBiM2IzM2Y2YTNfMi00LTEtMS01MzQ3Ng_a51f6fc9-1b95-4d1c-8e6c-627d3c2d8391"
      unitRef="usdPerShare">13.33</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i8ae01a892dec40ae88dac42dfa1c30cb_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83OS9mcmFnOmJmMGVkNmYyMzkyYzQyZDJiNWQxNjkzN2ZmMjQzOTU5L3RhYmxlOmNiZTA5ZDUzNzIyNDRiOWNhMjc0NWYwYjNiMzNmNmEzL3RhYmxlcmFuZ2U6Y2JlMDlkNTM3MjI0NGI5Y2EyNzQ1ZjBiM2IzM2Y2YTNfMy0yLTEtMS01MzQ3Ng_f40f25c6-3796-4184-8fb5-fcab97799656"
      unitRef="shares">1708000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i8ae01a892dec40ae88dac42dfa1c30cb_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83OS9mcmFnOmJmMGVkNmYyMzkyYzQyZDJiNWQxNjkzN2ZmMjQzOTU5L3RhYmxlOmNiZTA5ZDUzNzIyNDRiOWNhMjc0NWYwYjNiMzNmNmEzL3RhYmxlcmFuZ2U6Y2JlMDlkNTM3MjI0NGI5Y2EyNzQ1ZjBiM2IzM2Y2YTNfMy00LTEtMS01MzQ3Ng_a5566e4a-36d8-46e8-8073-cbea0569c692"
      unitRef="usdPerShare">12.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i8ae01a892dec40ae88dac42dfa1c30cb_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83OS9mcmFnOmJmMGVkNmYyMzkyYzQyZDJiNWQxNjkzN2ZmMjQzOTU5L3RhYmxlOmNiZTA5ZDUzNzIyNDRiOWNhMjc0NWYwYjNiMzNmNmEzL3RhYmxlcmFuZ2U6Y2JlMDlkNTM3MjI0NGI5Y2EyNzQ1ZjBiM2IzM2Y2YTNfNC0yLTEtMS01MzQ3Ng_a0c4b9ab-feac-488f-8e4b-5fe0e0d2e064"
      unitRef="shares">88000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="i8ae01a892dec40ae88dac42dfa1c30cb_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83OS9mcmFnOmJmMGVkNmYyMzkyYzQyZDJiNWQxNjkzN2ZmMjQzOTU5L3RhYmxlOmNiZTA5ZDUzNzIyNDRiOWNhMjc0NWYwYjNiMzNmNmEzL3RhYmxlcmFuZ2U6Y2JlMDlkNTM3MjI0NGI5Y2EyNzQ1ZjBiM2IzM2Y2YTNfNC00LTEtMS01MzQ3Ng_58445c16-aef0-4c4b-afe4-fd02486bb52b"
      unitRef="usdPerShare">13.56</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i8ae01a892dec40ae88dac42dfa1c30cb_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83OS9mcmFnOmJmMGVkNmYyMzkyYzQyZDJiNWQxNjkzN2ZmMjQzOTU5L3RhYmxlOmNiZTA5ZDUzNzIyNDRiOWNhMjc0NWYwYjNiMzNmNmEzL3RhYmxlcmFuZ2U6Y2JlMDlkNTM3MjI0NGI5Y2EyNzQ1ZjBiM2IzM2Y2YTNfNS0yLTEtMS01MzQ3Ng_c34c02f1-ee4c-43d6-ae03-23ef96f53be3"
      unitRef="shares">15000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="i8ae01a892dec40ae88dac42dfa1c30cb_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83OS9mcmFnOmJmMGVkNmYyMzkyYzQyZDJiNWQxNjkzN2ZmMjQzOTU5L3RhYmxlOmNiZTA5ZDUzNzIyNDRiOWNhMjc0NWYwYjNiMzNmNmEzL3RhYmxlcmFuZ2U6Y2JlMDlkNTM3MjI0NGI5Y2EyNzQ1ZjBiM2IzM2Y2YTNfNS00LTEtMS01MzQ3Ng_73cfaded-9fce-43ab-9f47-5150ea34de03"
      unitRef="usdPerShare">13.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="ib9883d643a66472482b410bc95fa9f79_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83OS9mcmFnOmJmMGVkNmYyMzkyYzQyZDJiNWQxNjkzN2ZmMjQzOTU5L3RhYmxlOmNiZTA5ZDUzNzIyNDRiOWNhMjc0NWYwYjNiMzNmNmEzL3RhYmxlcmFuZ2U6Y2JlMDlkNTM3MjI0NGI5Y2EyNzQ1ZjBiM2IzM2Y2YTNfNi0yLTEtMS01MzQ3Ng_eeedf98f-40d0-4b42-a52c-14eafff8fd1f"
      unitRef="shares">1952000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="ib9883d643a66472482b410bc95fa9f79_I20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83OS9mcmFnOmJmMGVkNmYyMzkyYzQyZDJiNWQxNjkzN2ZmMjQzOTU5L3RhYmxlOmNiZTA5ZDUzNzIyNDRiOWNhMjc0NWYwYjNiMzNmNmEzL3RhYmxlcmFuZ2U6Y2JlMDlkNTM3MjI0NGI5Y2EyNzQ1ZjBiM2IzM2Y2YTNfNi00LTEtMS01MzQ3Ng_188c59be-594d-4d9d-b884-f40c8c2bf85c"
      unitRef="usdPerShare">12.16</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ie473ec9331e14abfac72e9b57746b74a_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83OS9mcmFnOmJmMGVkNmYyMzkyYzQyZDJiNWQxNjkzN2ZmMjQzOTU5L3RleHRyZWdpb246YmYwZWQ2ZjIzOTJjNDJkMmI1ZDE2OTM3ZmYyNDM5NTlfMzI5Ng_6756f7e9-79a0-46b1-9898-9c0ef9d4241c"
      unitRef="usd">1900000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock
      contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83OS9mcmFnOmJmMGVkNmYyMzkyYzQyZDJiNWQxNjkzN2ZmMjQzOTU5L3RleHRyZWdpb246YmYwZWQ2ZjIzOTJjNDJkMmI1ZDE2OTM3ZmYyNDM5NTlfMzc1NQ_f1077dca-b5fc-47de-b472-2539a6e99d5e">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognized share-based compensation expense for the three months ended March&#160;31, 2022 and March&#160;31, 2021 as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.642%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.447%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;976&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,074&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;5,972&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,641&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Capitalized under inventories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;75&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;7,023&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ifd9d5feb8f3b40e69374a5807ae20c1f_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83OS9mcmFnOmJmMGVkNmYyMzkyYzQyZDJiNWQxNjkzN2ZmMjQzOTU5L3RhYmxlOjg2NGYxZTIxY2NkMzRlYTI4Mjc3MWJmYTk5MGU3Y2E0L3RhYmxlcmFuZ2U6ODY0ZjFlMjFjY2QzNGVhMjgyNzcxYmZhOTkwZTdjYTRfMi0yLTEtMS00Njg5MQ_b4561f0b-7037-414c-8cb9-5868a25f2479"
      unitRef="usd">976000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i962d1c17149f4639be473baed960c8c3_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83OS9mcmFnOmJmMGVkNmYyMzkyYzQyZDJiNWQxNjkzN2ZmMjQzOTU5L3RhYmxlOjg2NGYxZTIxY2NkMzRlYTI4Mjc3MWJmYTk5MGU3Y2E0L3RhYmxlcmFuZ2U6ODY0ZjFlMjFjY2QzNGVhMjgyNzcxYmZhOTkwZTdjYTRfMi00LTEtMS00Njg5MQ_8c1b061d-11f5-4fad-9013-165b3f5c9e20"
      unitRef="usd">1074000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i1b24f1f549b24893a1d6972293f410a2_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83OS9mcmFnOmJmMGVkNmYyMzkyYzQyZDJiNWQxNjkzN2ZmMjQzOTU5L3RhYmxlOjg2NGYxZTIxY2NkMzRlYTI4Mjc3MWJmYTk5MGU3Y2E0L3RhYmxlcmFuZ2U6ODY0ZjFlMjFjY2QzNGVhMjgyNzcxYmZhOTkwZTdjYTRfMy0yLTEtMS00Njg5MQ_bbfde43c-7c46-48f6-b1a9-a221b72cad6e"
      unitRef="usd">5972000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i0680c2b94da240e9969e80a91c607742_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83OS9mcmFnOmJmMGVkNmYyMzkyYzQyZDJiNWQxNjkzN2ZmMjQzOTU5L3RhYmxlOjg2NGYxZTIxY2NkMzRlYTI4Mjc3MWJmYTk5MGU3Y2E0L3RhYmxlcmFuZ2U6ODY0ZjFlMjFjY2QzNGVhMjgyNzcxYmZhOTkwZTdjYTRfMy00LTEtMS00Njg5MQ_d7a10594-1550-4d86-870f-5379dd385993"
      unitRef="usd">6641000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i40ed8df1852d4048bff930cdf8525c46_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83OS9mcmFnOmJmMGVkNmYyMzkyYzQyZDJiNWQxNjkzN2ZmMjQzOTU5L3RhYmxlOjg2NGYxZTIxY2NkMzRlYTI4Mjc3MWJmYTk5MGU3Y2E0L3RhYmxlcmFuZ2U6ODY0ZjFlMjFjY2QzNGVhMjgyNzcxYmZhOTkwZTdjYTRfNC0yLTEtMS00Njg5MQ_8f30d175-76d8-4076-a3fc-3f9f972f20bb"
      unitRef="usd">75000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i0424c4860c3e42b790b55eb7b0362418_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83OS9mcmFnOmJmMGVkNmYyMzkyYzQyZDJiNWQxNjkzN2ZmMjQzOTU5L3RhYmxlOjg2NGYxZTIxY2NkMzRlYTI4Mjc3MWJmYTk5MGU3Y2E0L3RhYmxlcmFuZ2U6ODY0ZjFlMjFjY2QzNGVhMjgyNzcxYmZhOTkwZTdjYTRfNC00LTEtMS00Njg5MQ_35a295e7-6857-49db-9335-d28bbd74bd5a"
      unitRef="usd">106000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83OS9mcmFnOmJmMGVkNmYyMzkyYzQyZDJiNWQxNjkzN2ZmMjQzOTU5L3RhYmxlOjg2NGYxZTIxY2NkMzRlYTI4Mjc3MWJmYTk5MGU3Y2E0L3RhYmxlcmFuZ2U6ODY0ZjFlMjFjY2QzNGVhMjgyNzcxYmZhOTkwZTdjYTRfNS0yLTEtMS00Njg5MQ_46cec457-be66-4037-9776-de2ab182385e"
      unitRef="usd">7023000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i56599386fa47443a8975bb3f7a6a8c57_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83OS9mcmFnOmJmMGVkNmYyMzkyYzQyZDJiNWQxNjkzN2ZmMjQzOTU5L3RhYmxlOjg2NGYxZTIxY2NkMzRlYTI4Mjc3MWJmYTk5MGU3Y2E0L3RhYmxlcmFuZ2U6ODY0ZjFlMjFjY2QzNGVhMjgyNzcxYmZhOTkwZTdjYTRfNS00LTEtMS00Njg5MQ_7c046dd0-a887-44f1-8d86-f1812befeb5c"
      unitRef="usd">7821000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="id7882ae6aff54a3aacdef67ddf11a428_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83OS9mcmFnOmJmMGVkNmYyMzkyYzQyZDJiNWQxNjkzN2ZmMjQzOTU5L3RleHRyZWdpb246YmYwZWQ2ZjIzOTJjNDJkMmI1ZDE2OTM3ZmYyNDM5NTlfMzU3Mw_99749182-36f3-4db8-a196-8e7b7076cada"
      unitRef="usd">48300000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl83OS9mcmFnOmJmMGVkNmYyMzkyYzQyZDJiNWQxNjkzN2ZmMjQzOTU5L3RleHRyZWdpb246YmYwZWQ2ZjIzOTJjNDJkMmI1ZDE2OTM3ZmYyNDM5NTlfMzc0Mw_5bb3f9b9-3982-4667-b1ec-095a06b4f455">P1Y7M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl84Mi9mcmFnOjU2MjBkYjlmMzJhMzQzNjg5ODU1ZTM4M2JjYmI4MWYyL3RleHRyZWdpb246NTYyMGRiOWYzMmEzNDM2ODk4NTVlMzgzYmNiYjgxZjJfMTE4NA_4d7921f2-8c85-4094-8c6b-2c9a07fb9edb">Income Taxes&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The effective tax rates for the three months ended March&#160;31, 2022 and March&#160;31, 2021 differed from the federal statutory rate applied to losses before income taxes primarily as a result of the mix of income, losses and valuation allowances. The Company recognized an income tax expense of $10 thousand and $8 thousand for the three months ended March&#160;31, 2022 and 2021, respectively. The expense recognized for these periods is a result of income in certain jurisdictions. This tax expense is not offset by a tax benefit as the Company has losses which are fully offset by a valuation allowance in its significant jurisdictions.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Uncertain Tax Positions&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company was under examination by the Canadian Revenue Agency for years 2017 and 2018. In March 2022, the Company was notified by the Canadian Revenue Agency the examination is now complete and there were no findings and as a result, there is no additional tax expense or benefit recognized in regards to the audit. There are no outstanding tax audits ongoing at March 31, 2022.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl84Mi9mcmFnOjU2MjBkYjlmMzJhMzQzNjg5ODU1ZTM4M2JjYmI4MWYyL3RleHRyZWdpb246NTYyMGRiOWYzMmEzNDM2ODk4NTVlMzgzYmNiYjgxZjJfMjgx_f39e9a53-8400-4ffc-8374-4994149debfc"
      unitRef="usd">10000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i56599386fa47443a8975bb3f7a6a8c57_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl84Mi9mcmFnOjU2MjBkYjlmMzJhMzQzNjg5ODU1ZTM4M2JjYmI4MWYyL3RleHRyZWdpb246NTYyMGRiOWYzMmEzNDM2ODk4NTVlMzgzYmNiYjgxZjJfMTA5OTUxMTYyOTMwMA_c7ffd45b-972c-42e0-923c-a5ef9a7da933"
      unitRef="usd">8000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl84NS9mcmFnOjFhZGE0M2I2MTIxMDQ3ZDk4N2JjNWVmODY2N2M0OTA3L3RleHRyZWdpb246MWFkYTQzYjYxMjEwNDdkOTg3YmM1ZWY4NjY3YzQ5MDdfMTIwNA_a205a278-2dfd-4156-ad78-78b52fb8aae1">Related Party TransactionsILJIN SNT Co., Ltd (ILJIN) was considered to be a related party due to their equity ownership of over 5% as per their public filing. The outstanding related party amount payable to ILJIN was the result of a settlement completed on September 20, 2013 between ILJIN and the Company. During the first quarter of 2021, Aurinia paid $4.0&#160;million upon achievement of specific milestones. The final $2.0&#160;million outstanding amount payable was paid during the fourth quarter 2021. The amount payable to ILJIN is nil as of March&#160;31, 2022 and December&#160;31, 2021.</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="if708ee56f3c0413dbeaf542b7c53ca83_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl84NS9mcmFnOjFhZGE0M2I2MTIxMDQ3ZDk4N2JjNWVmODY2N2M0OTA3L3RleHRyZWdpb246MWFkYTQzYjYxMjEwNDdkOTg3YmM1ZWY4NjY3YzQ5MDdfMzEw_5b712aab-53dc-48ee-8b10-83817f618b53"
      unitRef="usd">4000000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="if844161c2cc7421fb00cb10e05a3bda0_D20211001-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl84NS9mcmFnOjFhZGE0M2I2MTIxMDQ3ZDk4N2JjNWVmODY2N2M0OTA3L3RleHRyZWdpb246MWFkYTQzYjYxMjEwNDdkOTg3YmM1ZWY4NjY3YzQ5MDdfMTA5OTUxMTYzMDMxMw_dbcb8283-8a38-444e-8908-efde14dedcb0"
      unitRef="usd">2000000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:DueToRelatedPartiesCurrentAndNoncurrent
      contextRef="i273a514c48a74a41b3aabc3abfd173d8_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl84NS9mcmFnOjFhZGE0M2I2MTIxMDQ3ZDk4N2JjNWVmODY2N2M0OTA3L3RleHRyZWdpb246MWFkYTQzYjYxMjEwNDdkOTg3YmM1ZWY4NjY3YzQ5MDdfMzg1_0e93d6e9-2c12-422e-bbc1-4eb7a018a4d9"
      unitRef="usd">0</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>
    <us-gaap:DueToRelatedPartiesCurrentAndNoncurrent
      contextRef="ic0ea34cae9704c0ba2c86c1759915479_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl84NS9mcmFnOjFhZGE0M2I2MTIxMDQ3ZDk4N2JjNWVmODY2N2M0OTA3L3RleHRyZWdpb246MWFkYTQzYjYxMjEwNDdkOTg3YmM1ZWY4NjY3YzQ5MDdfMzg1_708ad859-55f4-4175-aa49-9b5cbc18f970"
      unitRef="usd">0</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJkM2E4ZjdlNTJlODRkY2ViZmE5MzViZWM1Y2E5ZWI2L3NlYzoyZDNhOGY3ZTUyZTg0ZGNlYmZhOTM1YmVjNWNhOWViNl84OC9mcmFnOjhiOWJiOTYyMzFmNzRjOWE4MzUyOTM5ZTc3YjhmNzE2L3RleHRyZWdpb246OGI5YmI5NjIzMWY3NGM5YTgzNTI5MzllNzdiOGY3MTZfMTE3Ng_1e76a4a6-e400-4cfa-8665-4308ee388683">Commitments and ContingenciesThe Company may, from time to time, be subject to claims and legal proceedings brought against it in the normal course of business. Such matters are subject to many uncertainties. Management believes the ultimate resolution of such contingencies will not have a material adverse effect on the consolidated financial position of the Company. The Company's material &lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;commitments and contingencies have not changed in any material manner from those previously described in the Company's Annual Report on Form 10-K for the year ended December&#160;31, 2021 except as described below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 15, 2022, a purported shareholder class action complaint, Ortmann v. Aurinia Pharmaceuticals, Inc. et al., case no. 1:22-cv-02185, was filed in the United States District Court for the Eastern District of New York, naming Aurinia and certain of the Company's officers as defendants. The lawsuit alleges that Aurinia made materially false and misleading statements regarding the financial guidance and commercial prospects in violation of certain federal securities laws. The plaintiff seeks unspecified monetary damages on behalf of the putative class and an award of costs and expenses, including reasonable attorneys&#x2019; fees. The defendants intend to vigorously defend this lawsuit. The Company has not, however, filed a response to the complaint and does not anticipate doing so until after the court appoints a lead plaintiff and that lead plaintiff files an operative complaint.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other Funding Commitments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the normal course of business, the Company enters into agreements with contract research organizations, contract manufacturing organizations and other third parties for services to be provided to the Company. Generally, these agreements provide for termination upon notice, with specified amounts due upon termination based on the timing of termination and the terms of the agreement. The actual amounts and timing of payments under these agreements are uncertain and contingent upon the initiation and completion of services to be provided to the Company.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>73
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M6)8N]O6*$Z/6^=;87!FCDOQPQ5G$M7T [B^4,OL3^P_*W=71?U!+ P04
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M!-Y,\N&)@K";@[JSV%)LEFW#7!GBF\E/S)A;I/S$G\$X<0UVDTU?QPYP)GE
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M@.\; <0PO.B;TO%F?/T?4$L#!!0    ( %8QJE3ZY1_P+ (  #L%   8
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MDK4HGY6LQ<Y%MA5)XA;))\'3;=+L?2R]W&G@5LQ(\#LV5*35'^+6G_>W5'6
MTSU5,#GO-BQF<=RW0%H%(NX=T)<LT8IMNLR$YR *O&K=#I!=26B5B$2_):NM
M!!"W!'P@J]VRCH_V#W5.NT9'XE]A&QV=D11,K,S1D81D;4M5G1LT;YOCJ4_F
M4.;L_3V^G5>'3&V8ZLSKD8I55DJ4LR6$]&XB&&I1'2-5#XIOS$G,@BO%"W.[
M9C1E0AO _TO.U>%!?Z YS)O]#U!+ P04    " !6,:I40<MPRV8"  !9!0
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M)IW1>8ML<\LW+]Y4\69=&8][.CZ&[K$-&_!];8S?OX0$AY]:DW\!4$L#!!0
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M U%$'VS=*@-!K4S^ES=M'#Y'8=HJ3!/NO%%"^5P&>7KL[%HXEH8U?DBN)FV
M4X:3<AD<OBKHA=,SZ947=BGFCCR9(#E6Q^, TRPP+EHS9]G,]!XSA^*--:'R
MXGM34KFO/P:D'M>TPW4V_:3!-]*-Q.'!4$PGT^DG[!WV?AXF>X?WV/O9K:11
M?R?WAN+<&F^U*F5FABGWW.=PO%!&FD))+2ZQ2*!A\.+/V<('!R+]]0E$1SVB
MHX3HZ&LC_P5FQ-N*0/C"UHTT&V56(AH92Q6H%(5%BHS/3VT4\++L'?9;ARMY
M36)!9 0JOI$.<LHDPZZ$-(&LH1(K,N2DUAO^0@U;8Y%H N_<. 6[C2;/N@'
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M6I<#4+.?'D:+$0S-L1!I^-/)3+$Z'Q_N/OSCT_L%*V(*U?(Q6TNV-E%F'&(
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MV]+ A[K XB4^(B&]&G96LV;O$G[B>@BC) 06,_8.WZB/;N3Y1O\>70BWN+'
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M   9    >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;)U6;6_;-A#^*P>A'SI
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M((%_U3\X:<L2S;X9/@2IKI5M.[2_[>?;LFWK9_-V.'+B]APT%+ACZ.!R//+
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MMOUCQV6XX]^0A[^4H-?#9+HS6H!U/#J=#L)I-E^\*?G&'].I-SD_TF6MLD2
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M@-H)T/N-4O:P<0;&SXK5WU!+ P04    " !6,:I46(HYZY4)  !T&0  &0
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M-)D> )DP.SI)V ,50V0(-GRM9:%76T%N-^+/?UJDZ?!G55:%W2K5@%#5+MN
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M&L9"VRF[!4^V4ZJ]:RE"2!1=^IU2P1!A\0>$(6NE4;K-G@ROE*'.NY*Y@LM
MA7<]>$UJ!8&'2!K_+$4$L2(*0Z7K?6!R-15] - 09O30EPV"Q\@>?OU1M%:
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M\;.$.7T*] I\17]I%UY2KG\!2&.3]\5]Y9R6?3%?:?]%620T[HM/QJ[DNB_
MM])6KB_>1RJ\^:!5E'KPJ5<Z9/7AT<(]-0"2GE11P;S$FIS]WK@L0V5 ,7DA
MR]*:9PTZ1$+%Z<GW+.CD]/NM3#<(K./Z#]AO/$)E6ST011M\:@'-/'"#(FYX
M@:O!5GZP47L#HQ2P;G(=$>9C3?P.3TE@9!6>T0E\"L\<![SC"VQ=FB=E"_05
M#W.652;Y-+]**@@KEGVQ,#X5B#$*#'R8P2%Z+1?6R'C;HB#"8@<AHBJPW<,_
M9"055$P;W=@I+8EG.YV7OF+K+(I&/\E%IM!>D*E(P15=1%G5;-96E'+-%I?8
M$&PU"X_<.<%%BZ!3)!)-?8I*M([_D\PTPM'F8Z/+#<2/F8'"7:%D!2UX*:W4
M%T0"*J3@YY+\_JW25G6SC!R+4EEMXCIF5ATI6% A(B$W)J-F+!<ZJVVB"'5L
M8KU=B4!>%L-%H-9KEHG 5+;.LD 9.7BRAU;>M+3R9B\KU/3?M:8O"N5W\<N?
MDW0A=KP11,D$!>!>^CK7V(PMR-P7WD(11(E.OX%TY2LVL+KO)J/!R3:YCT\W
M*P/QJQ*$^[Q)&^)N5H1+KMK85 N?5-E&2>4(IS5U"O5,+$ M:9,CU&VLLKX@
MXKV[_1 >!^"S6 4:V*SV_Y!*3&Z$I$"+[%A.+S;* <5%"SBB+N8UDAQ$;%<"
M>;P?J%A%S^0NF\ TQY,@D7P0"ACZO__M?#(^^Z<C6ZS77R@$QOG@D-7ND>1P
M-(@$Q2I5=!A9YW>:G,H!]'Z-:D$TA?2\$(XBY9&D0N5F.L%V)@/HL!"0P0TX
MIXLPK7."GZ3.&$B(205G=\&P(1X&R,IJCX*#N8F02R(9_R(I;#MR"Z/1#19!
M.ES94XAG;2&>[2T?GE*.0G2)!="NV(]=A?A')-U\)6F[XR<FXWQ.Y[?BLRG!
M<F?C\_[6 7$DYMY$C]N+!W0">P_["(=&4=:,&#"9*^DJ))0J@A*$6!M,UPTW
M1UU)!-K"(9,MIIKR VXE"($9 $V!^R_& =>)D5RAJ1 EQYQ@54][@4ICV,.4
M_;)G188.[;)B&]@;]<W*TA+ 8JJ44/?U(G5NU!80:-GP)_(!KW/E4Q/O-+WN
M:03$3-9%ZSC0IJP[.MH)(YE 5WMZ,)NZ0YXKF]DWG$'KA:B#^_F#.V3GRWK2
M!4%M>*:=1]K!=R#>T7"VK1=*$Z5]9>N2V"2D#4^*21LC7$0=])G:GF(C0ZE@
MMZ(\AV@% #QI.HG)RU4+!ZQP.^=VZ81.1%W37<VQ3A(:'@-W&;>QPP6KR5F6
MCIA\;?2+P8V!"3*+P-3[6N9Y6ZGGOW,?B<*H+&/$+:2_N4*!%0K\CK@ =@[I
M?Y5L\;[8=,#):/Q#X-MWT_D-Z,E5.#N=/_";H_$$TW !U"OQ63[3C;:N^)/1
MX06NOZ@=G:P;4'=NA!2_[L&FY"-,?IB,ZFIS00 ]1LK2=(:@E]RFZO%+;HO4
M0:0GD:%",0H4,6!.S*J0?!ZG>>]:24Q>"[7414'G9>+A<.OY^)1[_RBT XVL
M6YVW\*)IE$?^@B#6K/ZNL&W6:%+!L4%(-_;]+"'7KD4[?_#T6]#EB>R 2D0&
M^&XXA 9-XIJ8;ZRX;<>!ZW2!0N<;%4U$G-X!Y?<36F&=7Y*^*[^?S(#?'HT1
M@A\W$_[4T8V8^:-.]OGQ!,E^JQU=PKA6%FMQ0UQ&MX4[9,=S0A>F\KLE?47X
MB^:T:DY[\OU1-1&/.]J"8/1P$&\4IFT.E^Q>3 XV\W]G5;8F')+1LI"96>HO
M#%A# IAM !8>$O2BJK][M:"KYZ[/?!-@X^,MVX+6, ,5DIBD06['WI  =I6(
MM"'O;H72!Y1UV+<CJ8*J'>.#RA$-!A$=KR?_,,BU$UY@3 9-/5\&].X$R]:%
MF2#K.E^T@,2\OMBT]YP0BF4% !)"OBJZ74H:U#&G?EM!C?]<04W^TH+:Q?S#
MSO=#W/B6_)64Y@.D(GQ*;%?;#['3\/UQLSU\Q<4%94G7TDPE.#H:G)WV,.#R
ME]'PX$W)7R-QQ<;UDG^F"N.#I0UXGQ@,P?4#*6@_3U__'U!+ P04    " !6
M,:I4$\4C+Z,"  !Y!0  &0   'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6R%
M5%%/VS 0_BNG#$T@921QTC:PMA(M;.,!J0*V/4Q[<)-K8Y'8P;Y0^/>SDS9T
M$I27V.>[[[OOSCF/-TH_F *1X+DJI9EX!5%]'@0F*[#BYE35**UGI73%R9IZ
M'9A:(\];4%4&+ R'0<6%]*;C]FRAIV/54"DD+C28IJJX?IEAJ383+_)V![=B
M79 ["*;CFJ_Q#NEGO=#6"GJ67%0HC5 2-*XFWD5T/DM<?!OP2^#&[.W!5;)4
MZL$9U_G$"YT@+#$CQ\#M\H1S+$M'9&4\;CF]/J4#[N]W[-_:VFTM2VYPKLK?
M(J=BXJ4>Y+CB34FW:O,#M_4,'%^F2M-^8=/%#FS&K#&DJBW8VI60W<J?MWW8
M Z3A.P"V!;!6=Y>H57G)B4_'6FU NVC+YC9MJ2W:BA/27<H=:>L5%D?3:_F$
MAFR7R<#Q/5^6:$[& 5EFYP^R+<NL8V'OL,1PHR05!JYDCOG_^, JZF6QG:P9
M.TAXP_4IQ)$/+&3L %_<EQFW?/''9?IPB4L"+G.X>FP$O< =9HT6)-# GXNE
M(6U_E;\'DB9]TJ1-FGR<]*V6'@2[83PW-<]PXMEI,ZB?T)L>"PE4J,98]>8$
M;)>RHF^3K2O#:HEZ=Q+!G)O"W2E\;[CFDA!S>%4%<]0D5B+CA' $L1^QM%N3
M$.9*UTH[STS95@U#/SX+@45^RIRSJE!G@I>PX+7-& V8S\X&-NO0'[$$[NT#
M81K] C-1EA"=^8/8@OWD;-_E> >AGPY'\/E3RB+V%>X564Y3*$U?"'4%8N__
M/ *6#GT6A6X7)WXT2N&M:PKVQL'*7+=#;R!3C:1N,OK3_EVYZ,;I-;Q[E&R'
MUT(:*'%EH>'I:."![@:],TC5[7 M%=E1;;>%?1M1NP#K7RE%.\,EZ%_;Z3]0
M2P,$%     @ 5C&J5/OH[=Q\ @  -04  !D   !X;"]W;W)K<VAE971S+W-H
M965T,C@N>&ULA5113]LP$/XKIX@'D"K2.&UA51N)PM!X0*J C8=I#VYR;2P<
M._,Y%/[]SDF;=1)T+['O?-]W]SEWGFVM>Z$2T<-;I0W-H]+[>AK'E)=823JW
M-1H^65M72<^FV\14.Y1%"ZIT+(;#25Q)9:)LUOJ6+IO9QFME<.F FJJ2[GV!
MVF[G41+M'0]J4_K@B+-9+3?XB/Y[O71LQ3U+H2HTI*P!A^MY=)5,%Z,0WP;\
M4+BE@ST$)2MK7X)Q5\RC82@(->8^,$A>7O$:M0Y$7,;O'6?4IPS P_V>_;;5
MSEI6DO#:ZF=5^'(>7490X%HVVC_8[3?<Z1D'OMQJ:K^P[6)3$4'>D+?5#LP5
M5,ITJWS;W<,!X'+X"4#L **MNTO45GDCO<QFSF[!A6AF"YM6:HOFXI0)/^71
M.SY5C//9G7E%XZU32'#Z)%<:Z6P6>V8.YW&^8UET+.(3EA3NK?$EP5=38/$O
M/N:*^K+$OJR%.$IX+]TYI,D Q%"((WQI+S-M^=+_R'R'&T6YMM0XA)]7*_*.
M^^+7D0RC/L.HS3#Z),,CCTO1: 2[AC[;1S=YE";,X)1JF>,\XB$C=*\894\E
M0FZKVAJFI9!!]7HD"Y$$:ZMYOF@*I\J +VU#TA1T!GR1>=G?)-Q@CM4*W=Z3
MP(/<<C]Y=$IJ@A,0 Y%<].LSCQ0G@]K9'(D@^3*X2%)(Q& \F<"M,HI;KX"-
MM07!:)"F$_Z.1RD\62]U7V;H+J:<# 2C3@)+*B;PT:W'!ZU<H=NT TNLOC&^
MZ^K>V[\)5]TH_ WO'A26OE&&0..:H</SBW$$KAO2SO"V;@=C93V/6;LM^5U#
M%P+X?&VMWQLA0?]29G\ 4$L#!!0    ( %8QJE1NX3\CI (  /@%   9
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M( GS<4+K21+2)!G0+B5Y7G[KN"8OHD@M2SW<,0&MIFFD[8._0)I!>R/M>L]
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M:0R?GOV$JW;K<8#B/^X)1T%P:;_)Y0\N#.G\[+Z+43*)Z#N9!K"1MFZO]WR
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M4=D \F^D-/N+%>CV^?P/4$L#!!0    ( %8QJE2E%;2N0P,  'L'   9
M>&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;+U5VV[;.!#]E8$V6+2 -I(HV5:\
MMH$XV:(%&B!(LMV'H@^T-+:(4*1+4G;[]SO4+0ZV2?NT+^)MYLR90\YH<=3F
MT5:(#K[54MEE4#FWGT>1+2JLN3W7>U1TLM6FYHZ69A?9O4%>MDZUC%@<3Z.:
M"Q6L%NW>K5DM=..D4'AKP#9US<WW-4I]7 9),&S<B5WE_$:T6NSY#N_1_;V_
M-;2*1I12U*BLT H,;I?!93)?9]Z^-?@D\&A/YN SV6C]Z!<?RF40>T(HL7 >
M@=-PP"N4T@,1C:\]9C"&](ZG\P']79L[Y;+A%J^T_$>4KEH&>0 E;GDCW9T^
MOL<^GXG'*[2T[1>.G>UL$D#16*?KWID8U$)U(__6ZW#BD,<O.+#>@;6\NT M
MRVON^&IA]!&,MR8T/VE3;;V)G%#^4NZ=H5-!?F[UC@L#G[AL$&Z0V\8@*>XL
MO'G@&XGV[2)R%,7;1D6/N.X0V0N(*=QHY2H+?ZD2R^?^$;$;*;*!XIJ]"GC#
MS3FD20@L9NP5O'1,.6WQTI^G?"UL(;7/VL+GRXUUAE[)EU=B9&.,K(V1O1#C
MGHJG;"2"WL)3O! NK452EZL2/@J^$5(X0;%[Z4N@=WJ'16.,4#M8<ROLCR[@
MU=B^C.=VSPM<!E2G%LT!@]5#A;#5DFK0([OV<J$]5@Z</Q2*JT)P";SC6 ^<
MN(.M3^'02N8KB:IQX+CQ'.= =U14XR7!&Z$(5#>6$K5OX2,>4$+2CZP?4WC0
MCN)UFLSABMNJ5:;P$_S:"(KH'^,<KG&OK2!2%<J2*L15%%@]6CB#)$E#-LUI
M]OMO.4O8G\]FP^E]I8W[PZ&IH:(ZE=]!"@I0@E 'M*Y[\\E%R&;9Z#V,_?:'
M4\L)"]G%!)(T#2^2R6C*\FG(DKA/[(S669BG,T^DMSPEER5Y.)LPRJ[ >H-F
MT"_Y/_5C21;.8O:"?L/IK^DW"Y.+_+_Z==NG^K%X&LY8!FP69I,GQ5F:A<DL
M'^7+TCR<DMG98/A,O>DTC,GX1]4:G33$&LVN;?L6"MTHU_7&<7?\LUQV#?7)
MO/LMT<O>"65!XI9<XW/?R$W7ZKN%T_NVO6ZTHV;=3BOZ.Z+Q!G2^U=H-"Q]@
M_-^N_@502P,$%     @ 5C&J5.U<Z->< P  '@@  !D   !X;"]W;W)K<VAE
M971S+W-H965T,S4N>&ULC59M;]LV$/XK!ZT8$D"+WOR2>+:!.$VQ 6L1U.GR
M8=@'6CI91"A2(ZG8_?<[4K+L+HW7#[%(Z>ZYYYX['C/?*?UL*D0+^UI(LP@J
M:YM9%)F\PIJ9*]6@I"^ETC6SM-7;R#0:6>&=:A&E<3R):L9EL)S[=P]Z.5>M
M%5SB@P;3UC737U<HU&X1),'AQ6>^K:Q[$2WG#=OB&NV7YD'3+AI0"EZC-%Q)
MT%@N@MMDMAH[>V_P)\>=.5F#RV2CU+/;_%XL@M@10H&Y=0B,'B]XAT(X(*+Q
M3X\9#"&=X^GZ@/[!YTZY;)C!.R6>>&&K17 =0($E:X7]K':_89^/)Y@K8?PO
M['K;.("\-5;5O3,QJ+GLGFS?Z_ C#FGOD'K>72#/\CVS;#G7:@?:61.:6_A4
MO3>1X](596TU?>7D9Y>?J.Y_*&.@00UWJJY)J77%-,+%(]L(-)?SR%(<9QWE
M/>:JPTS?P,S@HY*V,G O"RR^]8^(WT R/9!<I6<!/S)]!5D20AJGZ1F\;$@Z
M\WC9&WCW3$LNMP8>*.DNV[]N-\9JZI&_S^"/!OR1QQ^]@;^FHU.T D&5\#I6
M""MF> Y,%O">B];^5Z-.DO,A'BL$V=:HF57:0Q4H%36(W[<&"^ 2+%GE3.2M
M8/X,$)_-$+OH8H.D%A"'%LB[%C!>%/]GH%2"SJZ9P6.E$:'NBHNNN'#AHZC6
M$*() ?<Y-M8C=1 %->6EKYO[2>#3(=@[N,BFX22++]UR'(?9].82GOPI(ESV
M0JEM\1L^!FBJ&$N12%!(1DDXF8XA2:?A*#Y!?I7&!>YI8)E>DW='=CYT?)5.
M^\6(R#AAZ1PT3'XEA4@=9<DK%VV!7DZ#>:NYY<2F%[B3QU&R[L0,NA-(:P?=
MW:NWE=Y@SJAHW@K+DD863;-6%%"1$/05:7Y)RW_Q-:,Q!@61H(C(\LJA<57,
MSC3N>&C<\0\W[BW%&\*MCUG?[[T8!91:U5ZJDRQ?=_OW6OLL"7<-S4S#<EP$
MKFRH7S!8_E_KG?;8VJK\&53C2!GJDW RNG&/+$OABWQ!XQJ,1/-7FLRIQW=,
M%P9^_NDZ3=)?893='.V(@=4\=\M6<DMXX<TX'6R?F-94F:-S$L;)"))).*&>
M3,;A]'H,WZM,=#*SZ1AO_<UDJ"M::;OQ/;P=+K_;;N8?S;N;D\;CEE.F DMR
MC:^FI*_N;J-N8U7C;X"-LG2?^&5%%SAJ9T#?2Z7L8>,"#/\2+/\%4$L#!!0
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M&<=+0\I:2UKE)*<7ZXQ)O#!^I7 M"N):,1NNL^]LDZ,ZGPTUJ3&;ATD+>=5
M!N] CN"K*'6FX*9,,7TM/R3S.AN#9QNO@E[ KTRZ,/('$'A!T(,WZGP>6;S1
M!WQ>L2=*,0U+*5FY0SO^8[E16E*^_-FC;-PI&UMEX_>4T3%*ZQQ!;.&DX@.3
M*=RSO&[BOE1T/BHS5*="WZO,G."IJEB"<X>.J$*Y1V?Q/4/8BIR.'R]W<+!Y
M2@:P/4HZ=L!>%-*B1*B->5H *LTI[1&T 6!<PIZLM(Z8&='*["AP!B^MI<$W
M2SJ3B% T68 F"X X3+*.1&#EFRE_VBR8(2S+LF8Y_YOD]B*GN.1</T'LP6>(
M(GK<<?5PL34Z.*DF1S5(8ZCOQB-:]MQ@0J^;QXJ./F'D?&NM?K:8E_"$3"H(
M7:\=C;O13>MU2C&36^2ZII TZ+YKE$_<2WI^X7N>DFO-DN=Z5J_W&6Y? E6A
MA$04% =0AOG6 /@$L>L%](K<.(">' N[' L_G&/?&AU+<]M1U$[E4"_81W)(
MFZNAO<>))764#\!L/K-6_;_*BNG;+/F]+C840_+*QD_!&5&G,U$KRA]U#C_?
MYC(^HDRXHM!+GB!%^%NME:;-QH8+N,(=+TLS)L@52BY2\(.!%X_IY4[&\$N;
MR\%@XGEFCIXW+68*9^'XG*@+8[AM4L/,^;%_#G[D!O$;973[':L9#Z+QI8&D
M#.ZA/.HHCSY,.:FPU;DDE]=-H/KH[P7^S_2OELJ>ZKOUCQ?VR:S_,?6C<0S^
MR!V-.M[]0>Q-+.\^W-.U8@B>3,[-KC!ZQ7IH)R=A/^F#RS P<'XOYW''>=S+
M^9((2)HJT163J^-B<K)B]&*^3[=I!ECY1(U7(G:EO8O54?E*CGL%?#1C_#C=
M)^Y_JD-MBJGI6[)?*L,=F6C%#$"*>VHJ*UM&/\%E'-'3MZ=Y35T>$3* '9:4
M'KG=SE+JG[BI[*81A'!P2;=O1,?2AVM6<=U6G)KLE50C]@0K)*?4BT/PO>A5
M]3[I/MWK R\8V?>$C#U%^?"H52M0[FQ#J@BO+G73M76S7<^[;%J]E^U-PTSQ
MHYQ6D..61#TWIGM=-DUH\Z%%91N_C=#41MIA1GT[2K.!UK="Z.</HZ#[$UC\
M U!+ P04    " !6,:I4;LP=FF "   W!0  &0   'AL+W=O<FMS:&5E=',O
M<VAE970S-RYX;6Q]E-]OVC 0Q_^54\1#*U4$ FRH"I'XL6I[8$-%W1ZF/9CD
M2*PZ-K4=:*?]\3L[(:,3\$+L\]WW/G?X'!^4?C8%HH774D@S"0IK=_=A:-("
M2V:Z:H>23K9*E\S25N>AV6EDF0\J11CU>A_"DG$9)+&WK702J\H*+G&EP51E
MR?3;#(4Z3()^<#0\\KRPSA F\8[EN$;[M%MIVH6M2L9+E(8K"1JWDV#:OY^-
MG+]W^,[Q8$[6X"K9*/7L-E^R2=!S0"@PM4Z!T6>/<Q3""1'&2Z,9M"E=X.GZ
MJ/[@:Z=:-LS@7(D?/+/%)!@'D.&65<(^JL-G;.KQ@*D2QO_"H?'M!9!6QJJR
M"2:"DLOZRUZ;/IP$1.,+ 5$3$'GN.I&G7##+DEBK VCG36INX4OUT03'I?M3
MUE;3*:<XF\R8X0;4%E8:#4K+?*]N%F@9%^86.L E++D09#9Q:"FE"PS31GY6
MRT<7Y >P5-(6!C[)#+/W\2&AMKS1D7<6715<,MV%0?\.HEX4/:T7<-.Y-9C3
M-;%7U =M-P9>?7!!_9O.F>2_?1/N8$XE*\&SNB=,9N^;1$U[X)+)E#,!:S*B
MHS#P<[HQ5M-U^W6%:-@2#3W1\ +1UZK<H':Y: XU)98Y-/4:^ -G2Z_[6.N.
MO*X;S7W2C\/]&911BS*ZBC)GIO!=2-T"7RJ^9\)S.".7>S3VR-4Y1U3+CT^(
MAOUQ=_P?57ARF4O4N1]9 ZFJI*WO=6MM7X5I/0S_W.LGA2Y+SJ4!@5L*[74_
M$H&NQ[3>6+7SH[%1E@;-+PMZV5 [!SK?*F6/&Y>@?2N3OU!+ P04    " !6
M,:I44QSN\B$#  !X"0  &0   'AL+W=O<FMS:&5E=',O<VAE970S."YX;6RU
M5MMNVS ,_17"V( -Z.I+G/2")$";;MB 78)DW1Z&/2@V$PN5I4R2DQ78QX^2
M73=M$^]E?;$EF>?PD+0H#;=*WY@"T<+O4D@S"@IKU^=A:+("2V:.U1HE?5DJ
M73)+4[T*S5HCRSVH%&$218.P9%P&XZ%?F^KQ4%56<(E3#:8J2Z9O+U&H[2B(
M@[N%&5\5UBV$X^&:K7".]GH]U30+6Y:<ER@-5Q(T+D?!17P^B1,'\!;?.&[-
MSAA<* NE;MSD0SX*(J<(!6;643!Z;7""0C@FTO&K(0U:GPZX.[YC?^>#IV 6
MS.!$B>\\M\4H. T@QR6KA)VI[7ML NH[ODP)XY^P;6RC ++*6%4V8%)0<EF_
MV>\F$3L XMD/2!I \AB0'@#T&D#/!UHK\V%=,<O&0ZVVH)TUL;F!SXU'4S1<
MNC+.K::OG'!V/*_+!VH)<[Z2?,DS)BU<9)FJI.5R!5,E>,;1P!OXS+1F+NWP
MZ@HMX\*\IM7K^16\>O$:7@"7\+50E6$R-\/0DCSG),P:*9>UE.2 E!Y\4M(6
M!M[*'/.'^)#":F-+[F*[3#H)/S%]#+WX")(H2?;HF73#KS!KX7&'G%Z;ZI[G
MZQW@FVK:?-K>'L%4N!Q3EN#MKXJO:5=8^/&1S.&#Q=+\['"6MLY2[RP]X&R&
MQFJ>6<QAPDRQKQHUP< 3N-V^&9]%T3#<[&;HJ4UOQ^:!LGZKK-^IK/FU##6!
M#/F&+00>@42[3V+-U-]QGT1I%#\2^=0J[J=QNE_FH)4YZ)8IJ,,QF2%0KX1<
M50N[K 2UG5K]/K6#)\EZG,XNBP<J3UJ5)YTJ)[Y#H(:)(JG2NNU)S7'&S0W\
M@1EN4%8(ERBS@K:Y6YNO,>-,V%N8%HSZ8'8+7R1V_'&GK933Y_^]SUIG9]UQ
M/PA74[C["M+-T4^/H^AEAY@XNF^BT?.7X>M6=8G9Z>CQ\Q<B3N[=)?^A%/\@
M2?N':A'NG&V4X94_\@WX75@?<^UJ>ZVX\(=I>&]>WTGH/%AQ:4#@DJ#1\0FU
M#%T?\_7$JK4_*1?*4CG]L*"K$6IG0-^72MF[B7/07K;&?P%02P,$%     @
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M\=W<\9S7%_=T4RCSPDUF-=G@ ZK'>BGTS.VRY+3$2E)>@<#UW+GQKM/8Q-N
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MLN)7#:UWX/.5,;3;>('^G<Q_ U!+ P04    " !6,:I4MI_Q&#P#   W#0
M&0   'AL+W=O<FMS:&5E=',O<VAE970T-"YX;6R]EV]/HS <Q]]*0WR@B2>T
M,!AF6W)N9\[$RRUZWCVXW(,*W6@$BFW9]-U?"PB,(1J3^62C\/OS[8?VFS+9
M,OX@(D(D>$KB5$R-2,KLW#1%$)$$BS.6D50]63&>8*F&?&V*C!,<%DE);"++
M<LT$T]2838I[2SZ;L%S&-"5+#D2>))@_7Y"8;:<&-%YNW-!U)/4-<S;)\)K<
M$GF7+;D:F765D"8D%92E@)/5U/@*S^?(T@E%Q&]*MJ)U#?14[AE[T(.K<&I8
M6A&)22!U":S^-F1.XEA74CH>JZ)&W5,GMJ]?JE\6DU>3N<>"S%G\AX8RFAIC
M X1DA?-8WK#M=U)-:*3K!2P6Q2_8EK&>98 @%Y(E5;)2D-"T_,=/%8A6 G1>
M24!5 GIO@ETEV,5$2V7%M!98XMF$LRW@.EI5TQ<%FR);S8:F^C7>2JZ>4I4G
M9TNN5@27SZ=@&>-4 IR&X-MC3C/UJN0I2-5".EX0B6DL3L 7<'>[ ,=')^ (
MT!3\BE@N5(*8F%))T07-H&I[4;9%K[3]@?D9L.$I0!9"/>GSX?0%">ITN)MN
M*@ U!5130$4]^R,4P-]K%0ZN)$G$OX%F=MW,+IHY;S;+ZF:D0;[F3/02+:NZ
M156].S>SD6VKV6_:W'J"T,BI@W8$.[5@9U#P-1%"[;<@3_(82Q*J;:(L(Z!8
M;\0^I66Y44O$%]_W.TI[@L:VVZ]T5"L=O0MMEZE:QGTZ1WL2'-M&'9T]00X<
M]^MT:YWNH,XY2X7D>>ED:B=EG*TYZ;[VG=)>7=H[_%(>U\W&!UG*XWVF7I?[
M?HSMV_W8_5JN_\9"5H8?L3@$-%'(-T3+'((.K<9&K<-CARW7A@<!7Y5M4T6^
M-^Z@?RMJ5W1CLA -BK[,>4IESLD0@L9%H?T)Q!L/A,,F^&'B^S[G>VX7^'#0
MKN3&#.&P&_Y<K6A &I5#'!KG@NXG8&_<#'J'P>[M$76=41?[<-"NY,83X; I
MSEF2Y9+P]X%OO OZAP>/&D-#UD' 5V7;)Q#D6AWPO4&H ]YLG6KU)X4Z,ZYI
M*D!,5BK+.O/4>^/E*;T<2)85!]U[)M6QN;B,U)<-X3I /5\Q)E\&^NQ<?RO-
M_@-02P,$%     @ 5C&J5,U[BQ_$!0  [A@  !D   !X;"]W;W)K<VAE971S
M+W-H965T-#4N>&ULM5EK;]LV%/TKA-<-*9#&(F79<N882.*X2=NT0=-V'X9A
MH&7:)BJ)+DGE ?3'[U)21,>6:'5HOR1Z\!P>75X>7M*C>R&_JA5C&CTD<:I.
M.BNMU\?=KHI6+*'J2*Q9"F\60B94PZU<=M5:,CK/04G<)9[7[R:4IYWQ*']V
M(\<CD>F8I^Q&(I4E"96/9RP6]R<=W'EZ\)$O5]H\Z(Y':[IDMTQ_7M](N.M6
M+'.>L%1QD2+)%B>=4WS\UB<&D+?XPMF]VKA&YE-F0GPU-U?SDXYG%+&81=I0
M4/AWQ\Y9'!LFT/&M).U4?1K@YO43^S3_>/B8&57L7,1_\;E>G73"#IJS!<UB
M_5'<7[+R@P+#%XE8Y7_1?=%V0#HHRI0620D&!0E/B__TH0S$!H#@!@ I 60;
MX#< _!+@;P'\)D"O!/3:2@I*0- 6T"\!_;: 00D8; %PKP$0EH!P&S!H  Q+
MP+"M).P]C9S75A2N!KM(NB)+\A2;4$W'(RGND33M@<]<Y'F:XR&S>&JFU*V6
M\)8#3H_?,<A']&$6\R4U.:[0*_2>2DE-IJ.#"=.4Q^HE>H%XBCZM1*9H.E>'
MZ'8JS9-K'L<&->IJ$&,HNU'9\5G1,6GH&*-KD>J50A?IG,UK\!=NO+\/_WI/
M_\1!T(4H5J$D3Z$\(T[&*9L=(1(>(N(1_/EV@@Y>O*S1=>YF>4/3(^3C@N7\
M<HH.(-1U/!,WSS65%8^WT'_\A@?AG^Q!%V[XKUB;T:X+>WM:TOR1T_8LCE"]
M=K-,6-2&Y;)%P+V2I09^U5Y$%><:FC=NFM-L:6F:O^5MB[AB4K X4MJOW,'/
M^?Q&=U"*L4.4N\0AFC 529YG#OK[';1%5YHEZA]'3[VJIU[>4Z^AIWPM?R46
MKS*P(PJ]ZCI/N2A(^CF)J1;NQ@'QR:A[MYDU-8W\T*\:/=,75/H"I[Y/0M,8
MQ;E;QIS.>,PU9[4:@YWNPV" MS06C8+-1@-_6*^Q7VGL.S5>I9%D4.X8I3,A
M <W3)0(K9W4RW5S!$?%^=XSKH-(T</)\6#.SEH".(G:14/4C.]B)FN]YSX,V
M=;=YIB^L](5.?3?TT41,(:A.4437W 2/)VLI[ECQXKM9Z^I\O" >;J@AN%[,
ML!(S=(HY+_MG#U QS[G.)$/K4F#="CO<B0?&85-$L&=+ L\IXYJG/,D2M. I
M32.VE?6/E20TSVHSJZ3?3.X!R&K2M5&JX%:Z"CV.P%R41)L*L!<.28,"8A40
MIX(+&)A(L[D-P5IR2!PM(+$3>!+E28/$HA!9JXWL3OTP:%!FC1K[3F73+,^6
M.QIGS'2?U,:J$J90*C1ZA"W;D^[Z$LS?C2-I&D=K]=CM]5]XI(7D]!"=27!1
MM4*P(<J2&:<.P\'6J7'PBQ<M;!T7NVWR%+:Q)JC@%V!T,#<.H"A6WQ;Z)?B&
MHQJX*GF?1=8G7K\AMM9NL=MO6ZZC)<OS"=(TL-9+L=M,?V"1+)G:";#^B=T&
M^D,KX.4>LMZ1%[J60&(-E;0SU+W&]:8DVK1TTKC&$>N<Q.V<'T7T]0ZV:C =
MH$1\C&$/Y_HPZX>$_.*I1JS#$;?#_=^I-B&[)N9[@=^P5A-K8^2GE*PERV;W
M =XN;5[7M2*- V^]D/RTLI74U:V[.FL*UWZC3NNCY">6KF_WD.VK78EU4[+'
M39DYE;35JV8RJ4TQ-\T05EHJE4N2]5CB]MCWL% R:29"M9E'Q6;>E*HM-O@3
MLFN]#841L<9+W%Y9'"-918V!<M,$>P/E6]/UW:;[SCEB>\ 8[U=BW==WNZ]5
M @6UM@/6+,[--]BOS3JX[ZYH;Z2(&)O#_D>*! 1!Q:^?[7_JCF5*SCVK5'?C
M5#)A<ID?G"LH.+-4%T<0U=/J</XT/Y+>>GZ&CR>XYOD%/IX6IZ"6OO@E !:Y
M)8<)$;,%=.4=#2#997&X7MQHL<[/1&=":Y'DERM&YTR:!O!^(81^NC$=5#]Q
MC/\#4$L#!!0    ( %8QJE3><',[B@(  !,'   9    >&PO=V]R:W-H965T
M<R]S:&5E=#0V+GAM;)5576^;,!3]*Q;J0RLMY2L$6B5(;:)IE?81->WV[)";
MQ*K!S#9-]^]W;2BB*6'="]APS^&<8_LR/0CYI/8 FKSDO% S9Z]U>>VZ*MM#
M3M6E**' -ULA<ZIQ*G>N*B70C07EW T\;^+FE!5..K7/EC*=BDIS5L!2$E7E
M.95_;H&+P\SQG=<']VRWU^:!FTY+NH,5Z,=R*7'FMBP;ED.AF"B(A.W,N?&O
MYXFIMP4_&1Q49TR,D[403V9RMYDYGA$$'#)M&"C>GF$.G!LBE/&[X73:3QI@
M=_S*_MEZ1R]KJF N^"^VT?N9DSAD UM:<7TO#E^@\1,9ODQP9:_DT-1Z#LDJ
MI47>@%%!SHKZ3E^:'#H ?WP"$#2 X*. L &$UFBMS-I:4$W3J10'(DTULIF!
MS<:BT0TKS"JNM,2W#'$Z_0J8 ?FQYFQ'3:Z*C,BJ*DL.N%2:<G)+.2TR("N[
MI^Z*>N.8%3A?@*:,JPN$/*X6Y/SL@IP15I"'O:@4+39JZFJ4:#[D9HV<VUI.
M<$+.-RHO2>A_(H$7!#WP^3!\ 5D+]]_"70RF32=HTPDL7WB"[T8IT&J *&R)
M0DLT/D%D3\=(;$<5IDU[6.MP:I*))3'G[SF-@A!S>.Y&T%,4)F%;]$;?N-4W
M'C0ZKZ3$]1YP&K5,T:#3AHE@GY&X3XH=X7:+<4;7C#/-H-=Y31IU3/F>=W7D
MO*\HNNIW/FGU3@:=?Q?%*/NG^[AEBP?==]C^-X'XG;DXFARO?4_1)/'Z$TA:
MS<F@Y@=ASOF'-";OMEX2Q?Z1QIZB.#Q>);?3LLSO @_^CF'WX;!%F'<9HT=9
MM^!ZHD5IN]A::.R)=KC'OQ9(4X#OMT+HUXEIC.U_,/T+4$L#!!0    ( %8Q
MJE2P0$OE)@(  -D$   9    >&PO=V]R:W-H965T<R]S:&5E=#0W+GAM;)54
M;6O;,!#^*X=AT,$6.TZR=L4Q-"EC@XV%A*T?QCXH]MD6U8LG*4WS[W>2'9-!
M$M@76W>Z>^Z>>U&VU^;9-H@.7J50=AXUSK7W<6R+!B6S(]VBHIM*&\D<B::.
M;6N0E<%)BCA-D@^Q9%Q%>19T*Y-G>N<$5[@R8'=2,G-8H-#[>32.CHHUKQOG
M%7&>M:S&#;H?[<J0% \H)9>H+-<*#%;SZ&%\OYAZ^V#PD^/>GIS!,]EJ_>R%
M+^4\2GQ"*+!P'H'1[P67*(0'HC3^])C1$-([GIZ/Z)\"=^*R91:76CSQTC7S
MZ"Z"$BNV$VZM]Y^QYS/S>(46-GQAW]G>DG&QLT[+WIDRD%QU?_;:U^'$(9U=
M<$A[AS3DW04*63XRQ_+,Z#T8;TUH_A"H!F]*CBO?E(TS=,O)S^5?D2C!]ZW@
M-?-ELO >-EV#0%>PU++5"I6S7O+&7-6DM:1@JH0U7<'-(SK&A7V;Q8Y2\L!Q
MT8=?=.'3"^&_,3."R?@=I$F:_NL>$Y.!3CK020/>Y!H="[\>MM89ZOCO*YB3
M 7,2,*<7,)]"9[$$]H*&!I5FT4^[+X0(U7-H))6-%L50#8]J"S=<P0&9.5^8
MZT$_=IXP :F5:RR,[Z!D!WN%SW3@,_T_/B6WA=Y1(RE]/$/D7/;70\Q&:?+F
M7*KQR:3ZI:?^UYR&3F!%0,GHEJ;>=(O4"4ZW87BWVM$JA&-#;P\:;T#WE=;N
M*/A]&%ZS_"]02P,$%     @ 5C&J5!D!(B;( @  * @  !D   !X;"]W;W)K
M<VAE971S+W-H965T-#@N>&ULC99=3]LP%(;_BA5Q =(@7TW:HK82M)HV"31$
M8;N8=N$V)XV%$V>V0^'?[]@)H5O=LIO&=OR^SSDGR7$G6R&?5 &@R4O)*S7U
M"JWK2]]7ZP)*JBY$#17>R84LJ<:IW/BJED S*RJY'P5!ZI>45=YL8M?NY&PB
M&LU9!7>2J*8LJ7R]!BZV4R_TWA;NV:;09L&?36JZ@27HQ_I.XLSO73)60J68
MJ(B$?.I=A9?ST KLCN\,MFIG3$PJ*R&>S.1K-O4"$Q%P6&MC0?'R#'/@W#AA
M'+\[4Z]G&N'N^,W]LTT>DUE1!7/!?[!,%U-OY)$,<MIP?2^V7Z!+*#%^:\&5
M_27;;F_@D76CM"@[,490LJJ]TI>N$#N"<'! $'6"Z'\%<2>(;:)M9#:M!=5T
M-I%B2Z39C6YF8&MCU9@-J\QC7&J)=QGJ].P&L ;DVXJS#35U5>2<+/%=R1H.
M1.3DENI&,LU F5F[^X;1%>/MXND"-&5<G:'N<;D@IR=GY(2PBCP4HE&TRM3$
MUQBGH?GK+J;K-J;H0$RW5%Z0./Q$HB"*'/+Y<?D"UKT\_%ON8W7Z$D5]B2+K
M%Q\KD2(_KU9*2WSM?AWQC'O/V'H.#GC>@_G$,I"FJ@?2O&XM4FMA/L?GV2B-
M)_ZS@SOHN8.C7$3%+E2K2G9089"&;E;2LY*/6 ,7*W&P1HF;E?:L]"-6XF*E
M^ZPP#-RL8<\:?L1*7:RA@Q4?R&O4LT9'60\%8'/.-4@7<;1'3-)XY":.>^+X
M.%%HREVPL>NQC2,W+0S>^T]PE'<#2ET2;AL+*^M&0X;M Q,&I9VM(]B+XSR*
MHP/O:KC3!\./\R9Y@^T.3*-E95-V8=7T%0\N[>YDX?Y'F@S?H^D:EF/7,![_
M$[._T\;-&8I]<,.P(W/(419<##%IV1Y+[42+VG;VE=!X3MAA@4<Y2+,![^="
MZ+>).2SZ/P>S/U!+ P04    " !6,:I42*ZO5;L"  "_!P  &0   'AL+W=O
M<FMS:&5E=',O<VAE970T.2YX;6R-E5UOFS 4AO^*A:JIE;:2F,]T)%*;;-JD
M38OZL5U,NW#@)'@UF-FF:?_];$-I&FC:F\0VYWW/<P[83K9<W,H<0*'[@I5R
MZN1*56>N*],<"B)/>06E?K+FHB!*3\7&E94 DEE1P5P\&H5N06CIS!*[MA2S
MA->*T1*6 LFZ*(AXN #&MU-G[#PN7-)-KLR".TLJLH$K4#?54NB9V[EDM(!2
M4EXB >NI<SX^F\<FW@;\I+"5.V-D*EEQ?FLF7[.I,S) P"!5QH'HOSN8 V/&
M2&/\:SV=+J41[HX?W3_;VG4M*R)ASMDOFJE\ZL0.RF!-:J8N^?8+M/4$QB_E
M3-I?M&UBH]!!:2T5+UJQ)BAHV?R3^[8/.X*Q_X( MP+\5H'7"CQ;:$-FRUH0
M16:)X%LD3+1V,P/;&ZO6U=#2O,4K)?13JG5J=IZFO"Z51$OR0%8,$"DSI!=%
M#1GZ1LF*,JHH2'2\ $4HDR?H [JY6J#CHQ-TA&B)KG->2ZV2B:LTD+%UTS;Y
M19,<OY#\.Q&GR!N_1WB$\8!\?EB^@+23CY_+7=V&KA>XZP6V?MX+?FT+Y%,/
M")/H]_E**J$_MS\'4GA="L^F\%]K=]7D&NI9XQ!:![,)[V8>#J/$O=OMS$!0
M'$VZH&=P?@?G'X3[H7(0>F,U+Y\]O?PARL8JV &(<#S9H^P'>3Z.ARF#CC)X
MK866[_(=*:J/"U0)_E>?"8.002]_X(_V(?M!OA=[PY!A!QD>A/Q45(P_ #3=
MU)_1$%W82SP)>W3]H'&,?3R,%W5XT4&\.2\*$"DE["!@U,L=1H&W!]@/"D;C
M8)@O[OCB@WS77#5HSS:+W9=O_#SC@4WDX?U=-!#E3_QH#][=.5[-U::/K0TM
M)6*PUKK1::2+%\UUT4P4K^R)N^)*G]]VF.L;%H0)T,_7G*O'B3G$NSM[]A]0
M2P,$%     @ 5C&J5.Q0@*LB @  E@0  !D   !X;"]W;W)K<VAE971S+W-H
M965T-3 N>&ULC51=;YLP%/TK5Z@/K;3&?#3-6A&D-M&T2>L6->OV,.W!@4NP
M:FQFF]#^^]F&L$Q*JKV KWW/N><>KDD[J9YUA6C@I>9"SX/*F.:6$)U76%,]
MD0T*>U)*55-C0[4ENE%("P^J.8G#\)K4E(D@2_W>2F6I; UG E<*=%O75+W>
M(Y?=/(B"_<8CVU;&;9 L;>@6UVB>FI6R$1E9"E:CT$P*4%C.@[OH=I&X?)_P
MG6&G#];@.ME(^>R"3\4\")T@Y)@;QT#M:X<+Y-P161F_!\Y@+.F A^L]^P??
MN^UE0S4N)/_!"E/-@_<!%%C2EIM'V7W$H9^IX\LEU_X)W9 ;!I"WVLAZ %L%
M-1/]F[X,/AP HJL3@'@ Q/\+2 : =X[TRGQ;2VIHEBK9@7+9ELTMO#<>;;MA
MPGW%M5'VE%F<R998HE)8P$+6=C(T[<T5!7PU%2KX(L5EWMH,8> SHQO&F6&H
MX7R)AC*N+^ 2GM9+.#^[@#-@ KY5LM46KU-BK#Y7A>2#EOM>2WQ"RP-5$TBB
M=Q"'<7P$OG@;OL1\A$?_PHEU9;0F'JV)/5]R@F]%7^F&VUZ=&W=YKEK*-?R\
MVVBC[/3]>J-$,I9(?(FK$R5ZC\6!Q_ROQ\<,[.FN/9V[H+LLFB6SFY3L#GTZ
MDC6]F89C5J^5'$R-N['6_BT3&CB6%A=.9M, 5'\+^L#(Q@_21AH[EGY9V1\'
M*I=@STLIS3YPLSG^BK(_4$L#!!0    ( %8QJE0'XM5X* 0  &\5   9
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M.*3@[GVCVST;?@2N>*J)@"7"O-X0VTR5VZ#RPLBL^&Q_D@8W <7I&K>.H.P
M?+Z4N%Q5%W8G4&]&9_\!4$L#!!0    ( %8QJE30KRI!Z0(  'P(   9
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M&<P%DD66$?%W"BG?CAWL[!:>Z&JMS(([&>5D!0M0S_E<Z)E;HR0T R8I9TC
M<NS<XIL9CDR"C?A)82M;8V2DO'+^9B8/R=CQ#"-((58&@NB_#<P@30V2YO&G
M G7J/4UB>[Q#_VK%:S&O1,*,IR\T4>NQ,W!0 DM2I.J);[]!)2@T>#%/I?U%
MVRK6<U!<2,6S*EDSR"@K_\E[58A6@L8YGN!7"?['A-Z)A*!*"*S0DIF5=4<4
MF8P$WR)AHC6:&=C:V&RMAC)CXT()?97J/#7YH>^4[UQ*E(- ,YYENK2+-1&
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M ,1DB8M4W-+=-3$)!2I>1%.NO\'.]'4'("JXH)D!2P99DI>_^-%,1 , _0X
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MTF!#=,,M_K* L@:X7TAI7B?60?<3-/L+4$L#!!0    ( %8QJE31">U ' ,
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MYC-5#1UPO4#]7S,F#P--4+>(D[]02P,$%     @ 5C&J5-W3%&.$ P  3 P
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M6R)\+Y14Z(SE:ZS&'-8LS_480V)M&8]-R#+Z=9.>I?N!<:_WH-TL"$<39]?
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M?R!- '[/A-"[B4G0WJC17U!+ P04    " !6,:I4SRTH5A\#   J$@  #0
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MMFJ4.H>R:STSO-Q^2;?]"O#+OU!+ P04    " !6,:I4]4F2S $"  !>)
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M4635*+)J%%DUBJPS%%EG_RGKH[6K/XX?GT5GFOXSGXW_[;EZ!U!+ 0(4 Q0
M   ( %8QJE0'04UB@0   +$    0              "  0    !D;V-0<F]P
M<R]A<' N>&UL4$L! A0#%     @ 5C&J5,2\T*GN    *P(  !$
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M970R+GAM;%!+ 0(4 Q0    ( %8QJE3ZY1_P+ (  #L%   8
M  " @;\3  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4    " !6
M,:I4*[POK2@%  #8$P  &               @($A%@  >&PO=V]R:W-H965T
M<R]S:&5E=#0N>&UL4$L! A0#%     @ 5C&J5$'+<,MF @  604  !@
M         ("!?QL  'AL+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0
M   ( %8QJE0S<\S'-P4  !46   8              " @1L>  !X;"]W;W)K
M<VAE971S+W-H965T-BYX;6Q02P$"% ,4    " !6,:I4&;K:!R4'  !_'0
M&               @(&((P  >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L!
M A0#%     @ 5C&J5%KRE26$!   =@D  !@              ("!XRH  'AL
M+W=O<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    ( %8QJE3H[*YJ& 8
M (X/   8              " @9TO  !X;"]W;W)K<VAE971S+W-H965T.2YX
M;6Q02P$"% ,4    " !6,:I4>1)I!=,(    %@  &0              @('K
M-0  >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    ( %8QJE0!
M7Z@,B ,  ,X'   9              " @?4^  !X;"]W;W)K<VAE971S+W-H
M965T,3$N>&UL4$L! A0#%     @ 5C&J5(K7=N@+!   B @  !D
M     ("!M$(  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( %8QJE3U^O5'F (   0&   9              "
M@899  !X;"]W;W)K<VAE971S+W-H965T,3<N>&UL4$L! A0#%     @ 5C&J
M5%0!&&X8 P  20<  !D              ("!55P  'AL+W=O<FMS:&5E=',O
M<VAE970Q."YX;6Q02P$"% ,4    " !6,:I4XS3,F?,%   F#P  &0
M        @(&D7P  >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0
M   ( %8QJE0GNM]#>P8  .D.   9              " @<YE  !X;"]W;W)K
M<VAE971S+W-H965T,C N>&UL4$L! A0#%     @ 5C&J5)MK/V>L P  8@@
M !D              ("!@&P  'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q0
M2P$"% ,4    " !6,:I46(HYZY4)  !T&0  &0              @(%C<
M>&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    ( %8QJE3"^UQ^
MDP,  % (   9              " @2]Z  !X;"]W;W)K<VAE971S+W-H965T
M,C,N>&UL4$L! A0#%     @ 5C&J5*1Q*_W^ @  KP8  !D
M ("!^7T  'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"% ,4    " !6
M,:I4SKJ-FYH%  "2#   &0              @($N@0  >&PO=V]R:W-H965T
M<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    ( %8QJE1Y.#)MM@@  *H6   9
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M970S,"YX;6Q02P$"% ,4    " !6,:I4T9X[OJ<"  #2!0  &0
M    @(&?FP  >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0    (
M %8QJE1FXC5OY0,  /\)   9              " @7V>  !X;"]W;W)K<VAE
M971S+W-H965T,S(N>&UL4$L! A0#%     @ 5C&J5 WZXIBH @  VP4  !D
M             ("!F:(  'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6Q02P$"
M% ,4    " !6,:I4I16TKD,#  ![!P  &0              @(%XI0  >&PO
M=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    ( %8QJE3M7.C7G ,
M !X(   9              " @?*H  !X;"]W;W)K<VAE971S+W-H965T,S4N
M>&UL4$L! A0#%     @ 5C&J5*V^(F>/!   %0P  !D              ("!
MQ:P  'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q02P$"% ,4    " !6,:I4
M;LP=FF "   W!0  &0              @(&+L0  >&PO=V]R:W-H965T<R]S
M:&5E=#,W+GAM;%!+ 0(4 Q0    ( %8QJE13'.[R(0,  '@)   9
M      " @2*T  !X;"]W;W)K<VAE971S+W-H965T,S@N>&UL4$L! A0#%
M  @ 5C&J5.-A\57F P  .0\  !D              ("!>K<  'AL+W=O<FMS
M:&5E=',O<VAE970S.2YX;6Q02P$"% ,4    " !6,:I4Y;\7Y5\"   P!@
M&0              @(&7NP  >&PO=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+
M 0(4 Q0    ( %8QJE1+L?,AG (  #4'   9              " @2V^  !X
M;"]W;W)K<VAE971S+W-H965T-#$N>&UL4$L! A0#%     @ 5C&J5-A D)F)
M P  (@X  !D              ("! ,$  'AL+W=O<FMS:&5E=',O<VAE970T
M,BYX;6Q02P$"% ,4    " !6,:I4':7L#D4"   S!0  &0
M@(' Q   >&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+ 0(4 Q0    ( %8Q
MJE2VG_$8/ ,  #<-   9              " @3S'  !X;"]W;W)K<VAE971S
M+W-H965T-#0N>&UL4$L! A0#%     @ 5C&J5,U[BQ_$!0  [A@  !D
M         ("!K\H  'AL+W=O<FMS:&5E=',O<VAE970T-2YX;6Q02P$"% ,4
M    " !6,:I4WG!S.XH"   3!P  &0              @(&JT   >&PO=V]R
M:W-H965T<R]S:&5E=#0V+GAM;%!+ 0(4 Q0    ( %8QJE2P0$OE)@(  -D$
M   9              " @6O3  !X;"]W;W)K<VAE971S+W-H965T-#<N>&UL
M4$L! A0#%     @ 5C&J5!D!(B;( @  * @  !D              ("!R-4
M 'AL+W=O<FMS:&5E=',O<VAE970T."YX;6Q02P$"% ,4    " !6,:I42*ZO
M5;L"  "_!P  &0              @(''V   >&PO=V]R:W-H965T<R]S:&5E
M=#0Y+GAM;%!+ 0(4 Q0    ( %8QJE3L4("K(@(  )8$   9
M  " @;G;  !X;"]W;W)K<VAE971S+W-H965T-3 N>&UL4$L! A0#%     @
M5C&J5 ?BU7@H!   ;Q4  !D              ("!$MX  'AL+W=O<FMS:&5E
M=',O<VAE970U,2YX;6Q02P$"% ,4    " !6,:I4*1,W[*T#  "8#@  &0
M            @(%QX@  >&PO=V]R:W-H965T<R]S:&5E=#4R+GAM;%!+ 0(4
M Q0    ( %8QJE30KRI!Z0(  'P(   9              " @57F  !X;"]W
M;W)K<VAE971S+W-H965T-3,N>&UL4$L! A0#%     @ 5C&J5*3RD<PE P
MY P  !D              ("!=>D  'AL+W=O<FMS:&5E=',O<VAE970U-"YX
M;6Q02P$"% ,4    " !6,:I4KS#(@<\$  !V%0  &0              @('1
M[   >&PO=V]R:W-H965T<R]S:&5E=#4U+GAM;%!+ 0(4 Q0    ( %8QJE1.
M;B$H% ,  ! )   9              " @=?Q  !X;"]W;W)K<VAE971S+W-H
M965T-38N>&UL4$L! A0#%     @ 5C&J5-$)[4 < P  +@H  !D
M     ("!(O4  'AL+W=O<FMS:&5E=',O<VAE970U-RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( %8QJE3/+2A6'P,  "H2   -              "
M ;\$ 0!X;"]S='EL97,N>&UL4$L! A0#%     @ 5C&J5)>*NQS     $P(
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9>&UL4$L%!@    !% $4 VA(  %T2 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>135</ContextCount>
  <ElementCount>234</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>52</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>8</UnitCount>
  <MyReports>
    <Report instance="auph-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.auriniapharma.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="auph-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.auriniapharma.com/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="auph-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.auriniapharma.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="auph-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss</Role>
      <ShortName>Condensed Consolidated Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="auph-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossParenthetical</Role>
      <ShortName>Condensed Consolidated Statements of Operations and Comprehensive Loss (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="auph-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - Condensed Consolidated Statements of Shareholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofShareholdersEquity</Role>
      <ShortName>Condensed Consolidated Statements of Shareholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="auph-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1006007 - Statement - Condensed Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="auph-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Organization and Description of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.auriniapharma.com/role/OrganizationandDescriptionofBusiness</Role>
      <ShortName>Organization and Description of Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="auph-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2102102 - Disclosure - Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.auriniapharma.com/role/BasisofPresentation</Role>
      <ShortName>Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="auph-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2104103 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.auriniapharma.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="auph-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2107104 - Disclosure - Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.auriniapharma.com/role/Investments</Role>
      <ShortName>Investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="auph-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2110105 - Disclosure - Inventories</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.auriniapharma.com/role/Inventories</Role>
      <ShortName>Inventories</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="auph-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2113106 - Disclosure - Prepaid Expenses and Other Current Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.auriniapharma.com/role/PrepaidExpensesandOtherCurrentAssets</Role>
      <ShortName>Prepaid Expenses and Other Current Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="auph-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2116107 - Disclosure - Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.auriniapharma.com/role/IntangibleAssets</Role>
      <ShortName>Intangible Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="auph-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2120108 - Disclosure - Property, Plant and Equipment, net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.auriniapharma.com/role/PropertyPlantandEquipmentnet</Role>
      <ShortName>Property, Plant and Equipment, net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="auph-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2123109 - Disclosure - Lease Obligations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.auriniapharma.com/role/LeaseObligations</Role>
      <ShortName>Lease Obligations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="auph-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2129110 - Disclosure - Accounts Payable and Accrued Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.auriniapharma.com/role/AccountsPayableandAccruedLiabilities</Role>
      <ShortName>Accounts Payable and Accrued Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="auph-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2132111 - Disclosure - Deferred Compensation and Other Non-current Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.auriniapharma.com/role/DeferredCompensationandOtherNoncurrentLiabilities</Role>
      <ShortName>Deferred Compensation and Other Non-current Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="auph-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2134112 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.auriniapharma.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="auph-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2137113 - Disclosure - License and Collaboration Agreement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.auriniapharma.com/role/LicenseandCollaborationAgreement</Role>
      <ShortName>License and Collaboration Agreement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="auph-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2139114 - Disclosure - Net Loss per Common Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.auriniapharma.com/role/NetLossperCommonShare</Role>
      <ShortName>Net Loss per Common Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="auph-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2143115 - Disclosure - Share-based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.auriniapharma.com/role/SharebasedCompensation</Role>
      <ShortName>Share-based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="auph-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2150116 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.auriniapharma.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="auph-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2152117 - Disclosure - Related-Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.auriniapharma.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related-Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="auph-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2154118 - Disclosure - Commitment and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.auriniapharma.com/role/CommitmentandContingencies</Role>
      <ShortName>Commitment and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="auph-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2205201 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.auriniapharma.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="auph-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2308301 - Disclosure - Investments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.auriniapharma.com/role/InvestmentsTables</Role>
      <ShortName>Investments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.auriniapharma.com/role/Investments</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="auph-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2311302 - Disclosure - Inventories (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.auriniapharma.com/role/InventoriesTables</Role>
      <ShortName>Inventories (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.auriniapharma.com/role/Inventories</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="auph-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2314303 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.auriniapharma.com/role/PrepaidExpensesandOtherCurrentAssetsTables</Role>
      <ShortName>Prepaid Expenses and Other Current Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.auriniapharma.com/role/PrepaidExpensesandOtherCurrentAssets</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="auph-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2317304 - Disclosure - Intangible Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.auriniapharma.com/role/IntangibleAssetsTables</Role>
      <ShortName>Intangible Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.auriniapharma.com/role/IntangibleAssets</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="auph-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2321305 - Disclosure - Property, Plant and Equipment, net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.auriniapharma.com/role/PropertyPlantandEquipmentnetTables</Role>
      <ShortName>Property, Plant and Equipment, net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.auriniapharma.com/role/PropertyPlantandEquipmentnet</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="auph-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2324306 - Disclosure - Lease Obligations (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.auriniapharma.com/role/LeaseObligationsTables</Role>
      <ShortName>Lease Obligations (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.auriniapharma.com/role/LeaseObligations</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="auph-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2330307 - Disclosure - Accounts Payable and Accrued Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.auriniapharma.com/role/AccountsPayableandAccruedLiabilitiesTables</Role>
      <ShortName>Accounts Payable and Accrued Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.auriniapharma.com/role/AccountsPayableandAccruedLiabilities</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="auph-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2335308 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.auriniapharma.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.auriniapharma.com/role/FairValueMeasurements</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="auph-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2340309 - Disclosure - Net Loss per Common Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.auriniapharma.com/role/NetLossperCommonShareTables</Role>
      <ShortName>Net Loss per Common Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.auriniapharma.com/role/NetLossperCommonShare</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="auph-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2344310 - Disclosure - Share-based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.auriniapharma.com/role/SharebasedCompensationTables</Role>
      <ShortName>Share-based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.auriniapharma.com/role/SharebasedCompensation</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="auph-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2403401 - Disclosure - Basis of Presentation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.auriniapharma.com/role/BasisofPresentationDetails</Role>
      <ShortName>Basis of Presentation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.auriniapharma.com/role/BasisofPresentation</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="auph-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="auph-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2409403 - Disclosure - Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.auriniapharma.com/role/InvestmentsDetails</Role>
      <ShortName>Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.auriniapharma.com/role/InvestmentsTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="auph-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2412404 - Disclosure - Inventories (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.auriniapharma.com/role/InventoriesDetails</Role>
      <ShortName>Inventories (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.auriniapharma.com/role/InventoriesTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="auph-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2415405 - Disclosure - Prepaid Expenses and Other Current Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.auriniapharma.com/role/PrepaidExpensesandOtherCurrentAssetsDetails</Role>
      <ShortName>Prepaid Expenses and Other Current Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.auriniapharma.com/role/PrepaidExpensesandOtherCurrentAssetsTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="auph-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2418406 - Disclosure - Intangible Assets - Schedule of Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.auriniapharma.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails</Role>
      <ShortName>Intangible Assets - Schedule of Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="auph-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2419407 - Disclosure - Intangible Assets - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.auriniapharma.com/role/IntangibleAssetsNarrativeDetails</Role>
      <ShortName>Intangible Assets - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="auph-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2422408 - Disclosure - Property, Plant and Equipment, net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.auriniapharma.com/role/PropertyPlantandEquipmentnetDetails</Role>
      <ShortName>Property, Plant and Equipment, net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.auriniapharma.com/role/PropertyPlantandEquipmentnetTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="auph-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2425409 - Disclosure - Lease Obligations - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.auriniapharma.com/role/LeaseObligationsNarrativeDetails</Role>
      <ShortName>Lease Obligations - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="auph-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2426410 - Disclosure - Lease Obligations - Supplemental Balance Sheet Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.auriniapharma.com/role/LeaseObligationsSupplementalBalanceSheetInformationDetails</Role>
      <ShortName>Lease Obligations - Supplemental Balance Sheet Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="auph-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2427411 - Disclosure - Lease Obligations - Summary of Components of Leasing Costs and Rent (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.auriniapharma.com/role/LeaseObligationsSummaryofComponentsofLeasingCostsandRentDetails</Role>
      <ShortName>Lease Obligations - Summary of Components of Leasing Costs and Rent (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="auph-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2428412 - Disclosure - Lease Obligations - Schedule of Maturities of Lease Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails</Role>
      <ShortName>Lease Obligations - Schedule of Maturities of Lease Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="auph-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2431413 - Disclosure - Accounts Payable and Accrued Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.auriniapharma.com/role/AccountsPayableandAccruedLiabilitiesDetails</Role>
      <ShortName>Accounts Payable and Accrued Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.auriniapharma.com/role/AccountsPayableandAccruedLiabilitiesTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="auph-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2433414 - Disclosure - Deferred Compensation and Other Non-current Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.auriniapharma.com/role/DeferredCompensationandOtherNoncurrentLiabilitiesDetails</Role>
      <ShortName>Deferred Compensation and Other Non-current Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.auriniapharma.com/role/DeferredCompensationandOtherNoncurrentLiabilities</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="auph-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2436415 - Disclosure - Fair Value Measurements - Assets and Liabilities Measured on a Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.auriniapharma.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonaRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurements - Assets and Liabilities Measured on a Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="auph-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2438416 - Disclosure - License and Collaboration Agreement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.auriniapharma.com/role/LicenseandCollaborationAgreementDetails</Role>
      <ShortName>License and Collaboration Agreement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.auriniapharma.com/role/LicenseandCollaborationAgreement</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="auph-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2441417 - Disclosure - Net Loss per Common Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.auriniapharma.com/role/NetLossperCommonShareDetails</Role>
      <ShortName>Net Loss per Common Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.auriniapharma.com/role/NetLossperCommonShareTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="auph-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2442418 - Disclosure - Net Loss per Common Share - Anti-Dilutive Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.auriniapharma.com/role/NetLossperCommonShareAntiDilutiveSecuritiesDetails</Role>
      <ShortName>Net Loss per Common Share - Anti-Dilutive Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="auph-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2445419 - Disclosure - Share-based Compensation - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.auriniapharma.com/role/SharebasedCompensationNarrativeDetails</Role>
      <ShortName>Share-based Compensation - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="auph-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2446420 - Disclosure - Share-Based Compensation - Weighted Average Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.auriniapharma.com/role/ShareBasedCompensationWeightedAverageAssumptionsDetails</Role>
      <ShortName>Share-Based Compensation - Weighted Average Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="auph-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>2447421 - Disclosure - Share-Based Compensation - Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.auriniapharma.com/role/ShareBasedCompensationStockOptionActivityDetails</Role>
      <ShortName>Share-Based Compensation - Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="auph-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>2448422 - Disclosure - Share-Based Compensation - Performance Awards and Restricted Stock Units Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.auriniapharma.com/role/ShareBasedCompensationPerformanceAwardsandRestrictedStockUnitsActivityDetails</Role>
      <ShortName>Share-Based Compensation - Performance Awards and Restricted Stock Units Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="auph-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>2449423 - Disclosure - Share-Based Compensation - Allocated Share-Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.auriniapharma.com/role/ShareBasedCompensationAllocatedShareBasedCompensationExpenseDetails</Role>
      <ShortName>Share-Based Compensation - Allocated Share-Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="auph-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>2451424 - Disclosure - Income Taxes - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.auriniapharma.com/role/IncomeTaxesNarrativeDetails</Role>
      <ShortName>Income Taxes - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="auph-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>2453425 - Disclosure - Related-Party Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.auriniapharma.com/role/RelatedPartyTransactionsDetails</Role>
      <ShortName>Related-Party Transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.auriniapharma.com/role/RelatedPartyTransactions</ParentRole>
      <Position>61</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="auph-20220331.htm">auph-20220331.htm</File>
    <File>auph-20220331.xsd</File>
    <File>auph-20220331_cal.xml</File>
    <File>auph-20220331_def.xml</File>
    <File>auph-20220331_lab.xml</File>
    <File>auph-20220331_pre.xml</File>
    <File>auph-2022q1exx311.htm</File>
    <File>auph-2022q1exx312.htm</File>
    <File>auph-2022q1exx321.htm</File>
    <File>auph-2022q1exx322.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="491">http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy items="29">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>79
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "auph-20220331.htm": {
   "axisCustom": 0,
   "axisStandard": 22,
   "contextCount": 135,
   "dts": {
    "calculationLink": {
     "local": [
      "auph-20220331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "auph-20220331_def.xml"
     ]
    },
    "inline": {
     "local": [
      "auph-20220331.htm"
     ]
    },
    "labelLink": {
     "local": [
      "auph-20220331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "auph-20220331_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "auph-20220331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"
     ]
    }
   },
   "elementCount": 396,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021q4": 5,
    "total": 5
   },
   "keyCustom": 14,
   "keyStandard": 220,
   "memberCustom": 12,
   "memberStandard": 38,
   "nsprefix": "auph",
   "nsuri": "http://www.auriniapharma.com/20220331",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "auph-20220331.htm",
      "contextRef": "iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover Page",
     "role": "http://www.auriniapharma.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "auph-20220331.htm",
      "contextRef": "iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "auph-20220331.htm",
      "contextRef": "iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2104103 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "auph-20220331.htm",
      "contextRef": "iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "auph-20220331.htm",
      "contextRef": "iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2107104 - Disclosure - Investments",
     "role": "http://www.auriniapharma.com/role/Investments",
     "shortName": "Investments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "auph-20220331.htm",
      "contextRef": "iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "auph-20220331.htm",
      "contextRef": "iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2110105 - Disclosure - Inventories",
     "role": "http://www.auriniapharma.com/role/Inventories",
     "shortName": "Inventories",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "auph-20220331.htm",
      "contextRef": "iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "auph-20220331.htm",
      "contextRef": "iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherCurrentAssetsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2113106 - Disclosure - Prepaid Expenses and Other Current Assets",
     "role": "http://www.auriniapharma.com/role/PrepaidExpensesandOtherCurrentAssets",
     "shortName": "Prepaid Expenses and Other Current Assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "auph-20220331.htm",
      "contextRef": "iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherCurrentAssetsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "auph-20220331.htm",
      "contextRef": "iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2116107 - Disclosure - Intangible Assets",
     "role": "http://www.auriniapharma.com/role/IntangibleAssets",
     "shortName": "Intangible Assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "auph-20220331.htm",
      "contextRef": "iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "auph-20220331.htm",
      "contextRef": "iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2120108 - Disclosure - Property, Plant and Equipment, net",
     "role": "http://www.auriniapharma.com/role/PropertyPlantandEquipmentnet",
     "shortName": "Property, Plant and Equipment, net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "auph-20220331.htm",
      "contextRef": "iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "auph-20220331.htm",
      "contextRef": "iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2123109 - Disclosure - Lease Obligations",
     "role": "http://www.auriniapharma.com/role/LeaseObligations",
     "shortName": "Lease Obligations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "auph-20220331.htm",
      "contextRef": "iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "auph-20220331.htm",
      "contextRef": "iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2129110 - Disclosure - Accounts Payable and Accrued Liabilities",
     "role": "http://www.auriniapharma.com/role/AccountsPayableandAccruedLiabilities",
     "shortName": "Accounts Payable and Accrued Liabilities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "auph-20220331.htm",
      "contextRef": "iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "auph-20220331.htm",
      "contextRef": "iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureNoncurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2132111 - Disclosure - Deferred Compensation and Other Non-current Liabilities",
     "role": "http://www.auriniapharma.com/role/DeferredCompensationandOtherNoncurrentLiabilities",
     "shortName": "Deferred Compensation and Other Non-current Liabilities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "auph-20220331.htm",
      "contextRef": "iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureNoncurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "auph-20220331.htm",
      "contextRef": "iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2134112 - Disclosure - Fair Value Measurements",
     "role": "http://www.auriniapharma.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "auph-20220331.htm",
      "contextRef": "iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "auph-20220331.htm",
      "contextRef": "id7882ae6aff54a3aacdef67ddf11a428_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - Condensed Consolidated Balance Sheets",
     "role": "http://www.auriniapharma.com/role/CondensedConsolidatedBalanceSheets",
     "shortName": "Condensed Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "auph-20220331.htm",
      "contextRef": "id7882ae6aff54a3aacdef67ddf11a428_I20220331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:PrepaidExpenseCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "auph-20220331.htm",
      "contextRef": "iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2137113 - Disclosure - License and Collaboration Agreement",
     "role": "http://www.auriniapharma.com/role/LicenseandCollaborationAgreement",
     "shortName": "License and Collaboration Agreement",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "auph-20220331.htm",
      "contextRef": "iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "auph-20220331.htm",
      "contextRef": "iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2139114 - Disclosure - Net Loss per Common Share",
     "role": "http://www.auriniapharma.com/role/NetLossperCommonShare",
     "shortName": "Net Loss per Common Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "auph-20220331.htm",
      "contextRef": "iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "auph-20220331.htm",
      "contextRef": "iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2143115 - Disclosure - Share-based Compensation",
     "role": "http://www.auriniapharma.com/role/SharebasedCompensation",
     "shortName": "Share-based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "auph-20220331.htm",
      "contextRef": "iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "auph-20220331.htm",
      "contextRef": "iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2150116 - Disclosure - Income Taxes",
     "role": "http://www.auriniapharma.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "auph-20220331.htm",
      "contextRef": "iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "auph-20220331.htm",
      "contextRef": "iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2152117 - Disclosure - Related-Party Transactions",
     "role": "http://www.auriniapharma.com/role/RelatedPartyTransactions",
     "shortName": "Related-Party Transactions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "auph-20220331.htm",
      "contextRef": "iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "auph-20220331.htm",
      "contextRef": "iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2154118 - Disclosure - Commitment and Contingencies",
     "role": "http://www.auriniapharma.com/role/CommitmentandContingencies",
     "shortName": "Commitment and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "auph-20220331.htm",
      "contextRef": "iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "auph-20220331.htm",
      "contextRef": "iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2205201 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "auph-20220331.htm",
      "contextRef": "iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "auph-20220331.htm",
      "contextRef": "iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MarketableSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2308301 - Disclosure - Investments (Tables)",
     "role": "http://www.auriniapharma.com/role/InvestmentsTables",
     "shortName": "Investments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "auph-20220331.htm",
      "contextRef": "iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MarketableSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "auph-20220331.htm",
      "contextRef": "iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2311302 - Disclosure - Inventories (Tables)",
     "role": "http://www.auriniapharma.com/role/InventoriesTables",
     "shortName": "Inventories (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "auph-20220331.htm",
      "contextRef": "iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "auph-20220331.htm",
      "contextRef": "iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2314303 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)",
     "role": "http://www.auriniapharma.com/role/PrepaidExpensesandOtherCurrentAssetsTables",
     "shortName": "Prepaid Expenses and Other Current Assets (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "auph-20220331.htm",
      "contextRef": "iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockSharesOutstanding",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "auph-20220331.htm",
      "contextRef": "id7882ae6aff54a3aacdef67ddf11a428_I20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "role": "http://www.auriniapharma.com/role/ConsolidatedBalanceSheetsParenthetical",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CommonStockSharesOutstanding",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "auph-20220331.htm",
      "contextRef": "id7882ae6aff54a3aacdef67ddf11a428_I20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "auph-20220331.htm",
      "contextRef": "iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2317304 - Disclosure - Intangible Assets (Tables)",
     "role": "http://www.auriniapharma.com/role/IntangibleAssetsTables",
     "shortName": "Intangible Assets (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "auph-20220331.htm",
      "contextRef": "iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "auph-20220331.htm",
      "contextRef": "iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2321305 - Disclosure - Property, Plant and Equipment, net (Tables)",
     "role": "http://www.auriniapharma.com/role/PropertyPlantandEquipmentnetTables",
     "shortName": "Property, Plant and Equipment, net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "auph-20220331.htm",
      "contextRef": "iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "auph-20220331.htm",
      "contextRef": "iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "auph:AssetsAndLiabilitiesLesseeTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2324306 - Disclosure - Lease Obligations (Tables)",
     "role": "http://www.auriniapharma.com/role/LeaseObligationsTables",
     "shortName": "Lease Obligations (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "auph-20220331.htm",
      "contextRef": "iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "auph:AssetsAndLiabilitiesLesseeTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "auph-20220331.htm",
      "contextRef": "iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2330307 - Disclosure - Accounts Payable and Accrued Liabilities (Tables)",
     "role": "http://www.auriniapharma.com/role/AccountsPayableandAccruedLiabilitiesTables",
     "shortName": "Accounts Payable and Accrued Liabilities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "auph-20220331.htm",
      "contextRef": "iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "auph-20220331.htm",
      "contextRef": "iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2335308 - Disclosure - Fair Value Measurements (Tables)",
     "role": "http://www.auriniapharma.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "auph-20220331.htm",
      "contextRef": "iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "auph-20220331.htm",
      "contextRef": "iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2340309 - Disclosure - Net Loss per Common Share (Tables)",
     "role": "http://www.auriniapharma.com/role/NetLossperCommonShareTables",
     "shortName": "Net Loss per Common Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "auph-20220331.htm",
      "contextRef": "iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "auph-20220331.htm",
      "contextRef": "iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2344310 - Disclosure - Share-based Compensation (Tables)",
     "role": "http://www.auriniapharma.com/role/SharebasedCompensationTables",
     "shortName": "Share-based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "auph-20220331.htm",
      "contextRef": "iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "auph-20220331.htm",
      "contextRef": "iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2403401 - Disclosure - Basis of Presentation (Details)",
     "role": "http://www.auriniapharma.com/role/BasisofPresentationDetails",
     "shortName": "Basis of Presentation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "auph-20220331.htm",
      "contextRef": "iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "auph-20220331.htm",
      "contextRef": "id7882ae6aff54a3aacdef67ddf11a428_I20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestrictedCash",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406402 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)",
     "role": "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails",
     "shortName": "Summary of Significant Accounting Policies - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "auph-20220331.htm",
      "contextRef": "id7882ae6aff54a3aacdef67ddf11a428_I20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestrictedCash",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "auph-20220331.htm",
      "contextRef": "id7882ae6aff54a3aacdef67ddf11a428_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409403 - Disclosure - Investments (Details)",
     "role": "http://www.auriniapharma.com/role/InvestmentsDetails",
     "shortName": "Investments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "auph-20220331.htm",
      "contextRef": "id7882ae6aff54a3aacdef67ddf11a428_I20220331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:HeldToMaturitySecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "auph-20220331.htm",
      "contextRef": "iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss",
     "role": "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss",
     "shortName": "Condensed Consolidated Statements of Operations and Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "auph-20220331.htm",
      "contextRef": "iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:CostOfRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "auph-20220331.htm",
      "contextRef": "id7882ae6aff54a3aacdef67ddf11a428_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412404 - Disclosure - Inventories (Details)",
     "role": "http://www.auriniapharma.com/role/InventoriesDetails",
     "shortName": "Inventories (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "auph-20220331.htm",
      "contextRef": "id7882ae6aff54a3aacdef67ddf11a428_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "auph-20220331.htm",
      "contextRef": "id7882ae6aff54a3aacdef67ddf11a428_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "auph:PrepaidAssetsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2415405 - Disclosure - Prepaid Expenses and Other Current Assets (Details)",
     "role": "http://www.auriniapharma.com/role/PrepaidExpensesandOtherCurrentAssetsDetails",
     "shortName": "Prepaid Expenses and Other Current Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "auph-20220331.htm",
      "contextRef": "id7882ae6aff54a3aacdef67ddf11a428_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "auph:PrepaidAssetsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "auph-20220331.htm",
      "contextRef": "id7882ae6aff54a3aacdef67ddf11a428_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418406 - Disclosure - Intangible Assets - Schedule of Intangible Assets (Details)",
     "role": "http://www.auriniapharma.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails",
     "shortName": "Intangible Assets - Schedule of Intangible Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "auph-20220331.htm",
      "contextRef": "id7882ae6aff54a3aacdef67ddf11a428_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:AmortizationOfIntangibleAssets",
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "auph-20220331.htm",
      "contextRef": "iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2419407 - Disclosure - Intangible Assets - Narrative (Details)",
     "role": "http://www.auriniapharma.com/role/IntangibleAssetsNarrativeDetails",
     "shortName": "Intangible Assets - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:AmortizationOfIntangibleAssets",
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "auph-20220331.htm",
      "contextRef": "iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "auph-20220331.htm",
      "contextRef": "id7882ae6aff54a3aacdef67ddf11a428_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2422408 - Disclosure - Property, Plant and Equipment, net (Details)",
     "role": "http://www.auriniapharma.com/role/PropertyPlantandEquipmentnetDetails",
     "shortName": "Property, Plant and Equipment, net (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "auph-20220331.htm",
      "contextRef": "id7882ae6aff54a3aacdef67ddf11a428_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "auph:AssetsAndLiabilitiesLesseeTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "auph-20220331.htm",
      "contextRef": "id7882ae6aff54a3aacdef67ddf11a428_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2425409 - Disclosure - Lease Obligations - Narrative (Details)",
     "role": "http://www.auriniapharma.com/role/LeaseObligationsNarrativeDetails",
     "shortName": "Lease Obligations - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "auph-20220331.htm",
      "contextRef": "iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "auph:AssetsAndLiabilitiesLesseeTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "auph-20220331.htm",
      "contextRef": "id7882ae6aff54a3aacdef67ddf11a428_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2426410 - Disclosure - Lease Obligations - Supplemental Balance Sheet Information (Details)",
     "role": "http://www.auriniapharma.com/role/LeaseObligationsSupplementalBalanceSheetInformationDetails",
     "shortName": "Lease Obligations - Supplemental Balance Sheet Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "auph-20220331.htm",
      "contextRef": "id7882ae6aff54a3aacdef67ddf11a428_I20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2427411 - Disclosure - Lease Obligations - Summary of Components of Leasing Costs and Rent (Details)",
     "role": "http://www.auriniapharma.com/role/LeaseObligationsSummaryofComponentsofLeasingCostsandRentDetails",
     "shortName": "Lease Obligations - Summary of Components of Leasing Costs and Rent (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "auph-20220331.htm",
      "contextRef": "id7882ae6aff54a3aacdef67ddf11a428_I20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "auph-20220331.htm",
      "contextRef": "id7882ae6aff54a3aacdef67ddf11a428_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2428412 - Disclosure - Lease Obligations - Schedule of Maturities of Lease Liabilities (Details)",
     "role": "http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails",
     "shortName": "Lease Obligations - Schedule of Maturities of Lease Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "auph-20220331.htm",
      "contextRef": "id7882ae6aff54a3aacdef67ddf11a428_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "auph-20220331.htm",
      "contextRef": "id7882ae6aff54a3aacdef67ddf11a428_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableTradeCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2431413 - Disclosure - Accounts Payable and Accrued Liabilities (Details)",
     "role": "http://www.auriniapharma.com/role/AccountsPayableandAccruedLiabilitiesDetails",
     "shortName": "Accounts Payable and Accrued Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "auph-20220331.htm",
      "contextRef": "id7882ae6aff54a3aacdef67ddf11a428_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableTradeCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "auph-20220331.htm",
      "contextRef": "iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Parenthetical)",
     "role": "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossParenthetical",
     "shortName": "Condensed Consolidated Statements of Operations and Comprehensive Loss (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "auph-20220331.htm",
      "contextRef": "iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "auph-20220331.htm",
      "contextRef": "id7882ae6aff54a3aacdef67ddf11a428_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherLiabilitiesNoncurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2433414 - Disclosure - Deferred Compensation and Other Non-current Liabilities (Details)",
     "role": "http://www.auriniapharma.com/role/DeferredCompensationandOtherNoncurrentLiabilitiesDetails",
     "shortName": "Deferred Compensation and Other Non-current Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "auph-20220331.htm",
      "contextRef": "id7882ae6aff54a3aacdef67ddf11a428_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2436415 - Disclosure - Fair Value Measurements - Assets and Liabilities Measured on a Recurring Basis (Details)",
     "role": "http://www.auriniapharma.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonaRecurringBasisDetails",
     "shortName": "Fair Value Measurements - Assets and Liabilities Measured on a Recurring Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "auph-20220331.htm",
      "contextRef": "id7882ae6aff54a3aacdef67ddf11a428_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "auph-20220331.htm",
      "contextRef": "iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2438416 - Disclosure - License and Collaboration Agreement (Details)",
     "role": "http://www.auriniapharma.com/role/LicenseandCollaborationAgreementDetails",
     "shortName": "License and Collaboration Agreement (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "auph-20220331.htm",
      "contextRef": "ia4c126547bde44f3af61232c8aecf4ac_D20201217-20201217",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "auph-20220331.htm",
      "contextRef": "iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2441417 - Disclosure - Net Loss per Common Share (Details)",
     "role": "http://www.auriniapharma.com/role/NetLossperCommonShareDetails",
     "shortName": "Net Loss per Common Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "auph-20220331.htm",
      "contextRef": "iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2442418 - Disclosure - Net Loss per Common Share - Anti-Dilutive Securities (Details)",
     "role": "http://www.auriniapharma.com/role/NetLossperCommonShareAntiDilutiveSecuritiesDetails",
     "shortName": "Net Loss per Common Share - Anti-Dilutive Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "auph-20220331.htm",
      "contextRef": "iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "auph-20220331.htm",
      "contextRef": "iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2445419 - Disclosure - Share-based Compensation - Narrative (Details)",
     "role": "http://www.auriniapharma.com/role/SharebasedCompensationNarrativeDetails",
     "shortName": "Share-based Compensation - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "auph-20220331.htm",
      "contextRef": "id7882ae6aff54a3aacdef67ddf11a428_I20220331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "auph-20220331.htm",
      "contextRef": "iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2446420 - Disclosure - Share-Based Compensation - Weighted Average Assumptions (Details)",
     "role": "http://www.auriniapharma.com/role/ShareBasedCompensationWeightedAverageAssumptionsDetails",
     "shortName": "Share-Based Compensation - Weighted Average Assumptions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "auph-20220331.htm",
      "contextRef": "iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "auph-20220331.htm",
      "contextRef": "i784f65549351439fa4b7bedf90ce7e3f_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2447421 - Disclosure - Share-Based Compensation - Stock Option Activity (Details)",
     "role": "http://www.auriniapharma.com/role/ShareBasedCompensationStockOptionActivityDetails",
     "shortName": "Share-Based Compensation - Stock Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "auph-20220331.htm",
      "contextRef": "i784f65549351439fa4b7bedf90ce7e3f_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "auph-20220331.htm",
      "contextRef": "id05699051d2448519e6e9c2935d67b1f_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2448422 - Disclosure - Share-Based Compensation - Performance Awards and Restricted Stock Units Activity (Details)",
     "role": "http://www.auriniapharma.com/role/ShareBasedCompensationPerformanceAwardsandRestrictedStockUnitsActivityDetails",
     "shortName": "Share-Based Compensation - Performance Awards and Restricted Stock Units Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "auph-20220331.htm",
      "contextRef": "ib9883d643a66472482b410bc95fa9f79_I20220331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "auph-20220331.htm",
      "contextRef": "iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2449423 - Disclosure - Share-Based Compensation - Allocated Share-Based Compensation Expense (Details)",
     "role": "http://www.auriniapharma.com/role/ShareBasedCompensationAllocatedShareBasedCompensationExpenseDetails",
     "shortName": "Share-Based Compensation - Allocated Share-Based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "auph-20220331.htm",
      "contextRef": "ifd9d5feb8f3b40e69374a5807ae20c1f_D20220101-20220331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "auph-20220331.htm",
      "contextRef": "i83ebb56fc7614da58997add4fc4d898e_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - Condensed Consolidated Statements of Shareholders' Equity",
     "role": "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofShareholdersEquity",
     "shortName": "Condensed Consolidated Statements of Shareholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "auph-20220331.htm",
      "contextRef": "i83ebb56fc7614da58997add4fc4d898e_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "auph-20220331.htm",
      "contextRef": "iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2451424 - Disclosure - Income Taxes - Narrative (Details)",
     "role": "http://www.auriniapharma.com/role/IncomeTaxesNarrativeDetails",
     "shortName": "Income Taxes - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:DueToRelatedPartiesCurrentAndNoncurrent",
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "auph-20220331.htm",
      "contextRef": "ic0ea34cae9704c0ba2c86c1759915479_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DueToRelatedPartiesCurrentAndNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2453425 - Disclosure - Related-Party Transactions (Details)",
     "role": "http://www.auriniapharma.com/role/RelatedPartyTransactionsDetails",
     "shortName": "Related-Party Transactions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:DueToRelatedPartiesCurrentAndNoncurrent",
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "auph-20220331.htm",
      "contextRef": "ic0ea34cae9704c0ba2c86c1759915479_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DueToRelatedPartiesCurrentAndNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "auph-20220331.htm",
      "contextRef": "iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006007 - Statement - Condensed Consolidated Statements of Cash Flows",
     "role": "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows",
     "shortName": "Condensed Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "auph-20220331.htm",
      "contextRef": "iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "auph-20220331.htm",
      "contextRef": "iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Organization and Description of Business",
     "role": "http://www.auriniapharma.com/role/OrganizationandDescriptionofBusiness",
     "shortName": "Organization and Description of Business",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "auph-20220331.htm",
      "contextRef": "iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "auph-20220331.htm",
      "contextRef": "iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccounting",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2102102 - Disclosure - Basis of Presentation",
     "role": "http://www.auriniapharma.com/role/BasisofPresentation",
     "shortName": "Basis of Presentation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "auph-20220331.htm",
      "contextRef": "iff299a8da43f48caa3ae58a0d558bd37_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccounting",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 52,
   "tag": {
    "auph_AccruedResearchCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.auriniapharma.com/role/AccountsPayableandAccruedLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Research, Current",
        "label": "Accrued Research, Current",
        "terseLabel": "Accrued R&amp;D projects"
       }
      }
     },
     "localname": "AccruedResearchCurrent",
     "nsuri": "http://www.auriniapharma.com/20220331",
     "presentation": [
      "http://www.auriniapharma.com/role/AccountsPayableandAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "auph_AmendedAndRestatedEquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amended and Restated Equity Incentive Plan",
        "label": "Amended and Restated Equity Incentive Plan [Member]",
        "terseLabel": "Amended and Restated Equity Incentive Plan"
       }
      }
     },
     "localname": "AmendedAndRestatedEquityIncentivePlanMember",
     "nsuri": "http://www.auriniapharma.com/20220331",
     "presentation": [
      "http://www.auriniapharma.com/role/SharebasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "auph_AssetsAndLiabilitiesLesseeTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assets And Liabilities, Lessee",
        "label": "Assets And Liabilities, Lessee [Table Text Block]",
        "terseLabel": "Supplemental Balance Sheet Information"
       }
      }
     },
     "localname": "AssetsAndLiabilitiesLesseeTableTextBlock",
     "nsuri": "http://www.auriniapharma.com/20220331",
     "presentation": [
      "http://www.auriniapharma.com/role/LeaseObligationsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "auph_CashCashEquivalentsAndDebtSecuritiesCurrent": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash, Cash Equivalents and Debt Securities, Current",
        "label": "Cash, Cash Equivalents and Debt Securities, Current",
        "terseLabel": "Cash and cash equivalents and investments"
       }
      }
     },
     "localname": "CashCashEquivalentsAndDebtSecuritiesCurrent",
     "nsuri": "http://www.auriniapharma.com/20220331",
     "presentation": [
      "http://www.auriniapharma.com/role/BasisofPresentationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "auph_CashableGuaranteedInvestmentCertificatesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cashable Guaranteed Investment Certificates",
        "label": "Cashable Guaranteed Investment Certificates [Member]",
        "terseLabel": "Cashable Guaranteed Investment Certificate"
       }
      }
     },
     "localname": "CashableGuaranteedInvestmentCertificatesMember",
     "nsuri": "http://www.auriniapharma.com/20220331",
     "presentation": [
      "http://www.auriniapharma.com/role/InvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "auph_CommercialRelatedAccrualsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.auriniapharma.com/role/AccountsPayableandAccruedLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commercial Related Accruals, Current",
        "label": "Commercial Related Accruals, Current",
        "terseLabel": "Commercial accruals"
       }
      }
     },
     "localname": "CommercialRelatedAccrualsCurrent",
     "nsuri": "http://www.auriniapharma.com/20220331",
     "presentation": [
      "http://www.auriniapharma.com/role/AccountsPayableandAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "auph_ILJINMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ILJIN",
        "label": "ILJIN [Member]",
        "terseLabel": "ILJIN"
       }
      }
     },
     "localname": "ILJINMember",
     "nsuri": "http://www.auriniapharma.com/20220331",
     "presentation": [
      "http://www.auriniapharma.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "auph_LesseeOperatingLeaseLeaseNotYetCommencedLiabilityToBePaid": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Lease Not yet Commenced, Liability, to be Paid",
        "label": "Lessee, Operating Lease, Lease Not yet Commenced, Liability, to be Paid",
        "terseLabel": "Future value of minimum lease payments of leases not yet commenced"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLeaseNotYetCommencedLiabilityToBePaid",
     "nsuri": "http://www.auriniapharma.com/20220331",
     "presentation": [
      "http://www.auriniapharma.com/role/LeaseObligationsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "auph_LesseeOperatingLeaseLeaseNotYetCommencedPaymentsPriorToCommencementOfLease": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Lease Not yet Commenced, Payments Prior To Commencement Of Lease",
        "label": "Lessee, Operating Lease, Lease Not yet Commenced, Payments Prior To Commencement Of Lease",
        "terseLabel": "Expected payments prior to commencement of lease"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLeaseNotYetCommencedPaymentsPriorToCommencementOfLease",
     "nsuri": "http://www.auriniapharma.com/20220331",
     "presentation": [
      "http://www.auriniapharma.com/role/LeaseObligationsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "auph_LesseeOperatingLeaseLeaseTerminationTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Lease Termination Term",
        "label": "Lessee, Operating Lease, Lease Termination Term",
        "terseLabel": "Lease termination option term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLeaseTerminationTerm",
     "nsuri": "http://www.auriniapharma.com/20220331",
     "presentation": [
      "http://www.auriniapharma.com/role/LeaseObligationsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "auph_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Liability, to be Paid, After Year Four",
        "label": "Lessee, Operating Lease, Liability, to be Paid, After Year Four",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityToBePaidAfterYearFour",
     "nsuri": "http://www.auriniapharma.com/20220331",
     "presentation": [
      "http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "auph_LesseeOperatingLeaseNumberOfExtensionOptions": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Number of Extension Options",
        "label": "Lessee, Operating Lease, Number of Extension Options",
        "terseLabel": "Number of extension options"
       }
      }
     },
     "localname": "LesseeOperatingLeaseNumberOfExtensionOptions",
     "nsuri": "http://www.auriniapharma.com/20220331",
     "presentation": [
      "http://www.auriniapharma.com/role/LeaseObligationsNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "auph_MilestonePaymentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Payment",
        "label": "Milestone Payment [Member]",
        "terseLabel": "Milestone Payment"
       }
      }
     },
     "localname": "MilestonePaymentMember",
     "nsuri": "http://www.auriniapharma.com/20220331",
     "presentation": [
      "http://www.auriniapharma.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "auph_OperatingLeaseAssetsAndLiabilitiesAssetsLesseeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Lease, Assets And Liabilities, Assets, Lessee",
        "label": "Operating Lease, Assets And Liabilities, Assets, Lessee [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "OperatingLeaseAssetsAndLiabilitiesAssetsLesseeAbstract",
     "nsuri": "http://www.auriniapharma.com/20220331",
     "presentation": [
      "http://www.auriniapharma.com/role/LeaseObligationsSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "auph_OperatingLeaseAssetsAndLiabilitiesLiabilitiesCurrentLesseeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Lease, Assets And Liabilities, Liabilities, Current, Lessee",
        "label": "Operating Lease, Assets And Liabilities, Liabilities, Current, Lessee [Abstract]",
        "terseLabel": "Current"
       }
      }
     },
     "localname": "OperatingLeaseAssetsAndLiabilitiesLiabilitiesCurrentLesseeAbstract",
     "nsuri": "http://www.auriniapharma.com/20220331",
     "presentation": [
      "http://www.auriniapharma.com/role/LeaseObligationsSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "auph_OperatingLeaseAssetsAndLiabilitiesLiabilitiesNoncurrentLesseeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Lease, Assets And Liabilities, Liabilities, Noncurrent, Lessee",
        "label": "Operating Lease, Assets And Liabilities, Liabilities, Noncurrent, Lessee [Abstract]",
        "terseLabel": "Non-current"
       }
      }
     },
     "localname": "OperatingLeaseAssetsAndLiabilitiesLiabilitiesNoncurrentLesseeAbstract",
     "nsuri": "http://www.auriniapharma.com/20220331",
     "presentation": [
      "http://www.auriniapharma.com/role/LeaseObligationsSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "auph_OtuskaPharmaceuticalCoLtdMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Otuska Pharmaceutical Co., Ltd.",
        "label": "Otuska Pharmaceutical Co., Ltd. [Member]",
        "terseLabel": "Otuska"
       }
      }
     },
     "localname": "OtuskaPharmaceuticalCoLtdMember",
     "nsuri": "http://www.auriniapharma.com/20220331",
     "presentation": [
      "http://www.auriniapharma.com/role/LicenseandCollaborationAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "auph_PerformanceShareSandRestrictedStockUnitsRSUsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Performance Share sand Restricted Stock Units (RSUs)",
        "label": "Performance Share sand Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Performance Share sand Restricted Stock Units (RSUs)"
       }
      }
     },
     "localname": "PerformanceShareSandRestrictedStockUnitsRSUsMember",
     "nsuri": "http://www.auriniapharma.com/20220331",
     "presentation": [
      "http://www.auriniapharma.com/role/ShareBasedCompensationPerformanceAwardsandRestrictedStockUnitsActivityDetails",
      "http://www.auriniapharma.com/role/SharebasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "auph_PrepaidAssetsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.auriniapharma.com/role/PrepaidExpensesandOtherCurrentAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid Assets, Current",
        "label": "Prepaid Assets, Current",
        "terseLabel": "Prepaid assets"
       }
      }
     },
     "localname": "PrepaidAssetsCurrent",
     "nsuri": "http://www.auriniapharma.com/20220331",
     "presentation": [
      "http://www.auriniapharma.com/role/PrepaidExpensesandOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "auph_PrepaidRentAndPrepaidContinuingStudies": {
     "auth_ref": [],
     "calculation": {
      "http://www.auriniapharma.com/role/PrepaidExpensesandOtherCurrentAssetsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid Rent and Prepaid Continuing Studies",
        "label": "Prepaid Rent and Prepaid Continuing Studies",
        "terseLabel": "Prepaid deposits"
       }
      }
     },
     "localname": "PrepaidRentAndPrepaidContinuingStudies",
     "nsuri": "http://www.auriniapharma.com/20220331",
     "presentation": [
      "http://www.auriniapharma.com/role/PrepaidExpensesandOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "auph_ResearchAndDevelopmentArrangementContractToPerformForOthersPerformanceObligationPotentialRevenueAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research And Development Arrangement, Contract To Perform For Others, Performance Obligation, Potential Revenue Amount",
        "label": "Research And Development Arrangement, Contract To Perform For Others, Performance Obligation, Potential Revenue Amount",
        "terseLabel": "Potential regulatory milestone revenue"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersPerformanceObligationPotentialRevenueAmount",
     "nsuri": "http://www.auriniapharma.com/20220331",
     "presentation": [
      "http://www.auriniapharma.com/role/LicenseandCollaborationAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "auph_ResearchAndDevelopmentArrangementContractToPerformForOthersTieredRoyaltyPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research And Development Arrangement, Contract To Perform For Others, Tiered Royalty, Percent",
        "label": "Research And Development Arrangement, Contract To Perform For Others, Tiered Royalty, Percent",
        "terseLabel": "Tiered royalty percentages on future sales"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTieredRoyaltyPercent",
     "nsuri": "http://www.auriniapharma.com/20220331",
     "presentation": [
      "http://www.auriniapharma.com/role/LicenseandCollaborationAgreementDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "auph_RiptideBioscienceIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Riptide Bioscience, Inc.",
        "label": "Riptide Bioscience, Inc. [Member]",
        "terseLabel": "Riptide Bioscience, Inc."
       }
      }
     },
     "localname": "RiptideBioscienceIncMember",
     "nsuri": "http://www.auriniapharma.com/20220331",
     "presentation": [
      "http://www.auriniapharma.com/role/LicenseandCollaborationAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "auph_RockvilleMarylandMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rockville, Maryland",
        "label": "Rockville, Maryland [Member]",
        "terseLabel": "Rockville, Maryland"
       }
      }
     },
     "localname": "RockvilleMarylandMember",
     "nsuri": "http://www.auriniapharma.com/20220331",
     "presentation": [
      "http://www.auriniapharma.com/role/LeaseObligationsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "auph_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Forfeiture Rate",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Forfeiture Rate",
        "terseLabel": "Estimated forfeiture rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate",
     "nsuri": "http://www.auriniapharma.com/20220331",
     "presentation": [
      "http://www.auriniapharma.com/role/ShareBasedCompensationWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "auph_ShortTermCorporateDebtSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short-Term Corporate Debt Securities",
        "label": "Short-Term Corporate Debt Securities [Member]",
        "terseLabel": "Corporate Bond"
       }
      }
     },
     "localname": "ShortTermCorporateDebtSecuritiesMember",
     "nsuri": "http://www.auriniapharma.com/20220331",
     "presentation": [
      "http://www.auriniapharma.com/role/InvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "auph_SpecialtyPharmacyOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Specialty Pharmacy One",
        "label": "Specialty Pharmacy One [Member]",
        "terseLabel": "Specialty Pharmacy One"
       }
      }
     },
     "localname": "SpecialtyPharmacyOneMember",
     "nsuri": "http://www.auriniapharma.com/20220331",
     "presentation": [
      "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "auph_SpecialtyPharmacyTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Specialty Pharmacy Two",
        "label": "Specialty Pharmacy Two [Member]",
        "terseLabel": "Specialty Pharmacy Two"
       }
      }
     },
     "localname": "SpecialtyPharmacyTwoMember",
     "nsuri": "http://www.auriniapharma.com/20220331",
     "presentation": [
      "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "auph_VictoriaBritishColumbiaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Victoria, British Columbia",
        "label": "Victoria, British Columbia [Member]",
        "terseLabel": "Victoria, British Columbia"
       }
      }
     },
     "localname": "VictoriaBritishColumbiaMember",
     "nsuri": "http://www.auriniapharma.com/20220331",
     "presentation": [
      "http://www.auriniapharma.com/role/LeaseObligationsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.auriniapharma.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.auriniapharma.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.auriniapharma.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.auriniapharma.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.auriniapharma.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.auriniapharma.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r505"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.auriniapharma.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r506"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.auriniapharma.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.auriniapharma.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.auriniapharma.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.auriniapharma.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.auriniapharma.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.auriniapharma.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r503"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.auriniapharma.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.auriniapharma.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.auriniapharma.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r503"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.auriniapharma.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.auriniapharma.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r503"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.auriniapharma.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.auriniapharma.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r515"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.auriniapharma.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r503"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.auriniapharma.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r503"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.auriniapharma.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r503"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.auriniapharma.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r503"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.auriniapharma.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.auriniapharma.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r502"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.auriniapharma.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r504"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.auriniapharma.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.auriniapharma.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_AffiliatedEntityMember": {
     "auth_ref": [
      "r263",
      "r380",
      "r381",
      "r384",
      "r498"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Affiliated Entity [Member]",
        "terseLabel": "Affiliated Shareholder"
       }
      }
     },
     "localname": "AffiliatedEntityMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r51",
      "r53",
      "r100",
      "r101",
      "r228",
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/LicenseandCollaborationAgreementDetails",
      "http://www.auriniapharma.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r152",
      "r249",
      "r253",
      "r473"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r227",
      "r234",
      "r265",
      "r266",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r420",
      "r470",
      "r474",
      "r499",
      "r500"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/LicenseandCollaborationAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r227",
      "r234",
      "r265",
      "r266",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r420",
      "r470",
      "r474",
      "r499",
      "r500"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/LicenseandCollaborationAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r152",
      "r249",
      "r253",
      "r473"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_OfficerMember": {
     "auth_ref": [
      "r153"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Officer [Member]",
        "terseLabel": "Officer"
       }
      }
     },
     "localname": "OfficerMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/ShareBasedCompensationPerformanceAwardsandRestrictedStockUnitsActivityDetails",
      "http://www.auriniapharma.com/role/SharebasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r149",
      "r249",
      "r251",
      "r422",
      "r469",
      "r471"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r149",
      "r249",
      "r251",
      "r422",
      "r469",
      "r471"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r227",
      "r234",
      "r255",
      "r265",
      "r266",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r420",
      "r470",
      "r474",
      "r499",
      "r500"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/LicenseandCollaborationAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r227",
      "r234",
      "r255",
      "r265",
      "r266",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r420",
      "r470",
      "r474",
      "r499",
      "r500"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/LicenseandCollaborationAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r52",
      "r53",
      "r100",
      "r101",
      "r228",
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/LicenseandCollaborationAgreementDetails",
      "http://www.auriniapharma.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r150",
      "r151",
      "r249",
      "r252",
      "r472",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/LeaseObligationsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r150",
      "r151",
      "r249",
      "r252",
      "r472",
      "r483",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/LeaseObligationsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r153",
      "r383"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]",
        "terseLabel": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/ShareBasedCompensationPerformanceAwardsandRestrictedStockUnitsActivityDetails",
      "http://www.auriniapharma.com/role/SharebasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]",
        "terseLabel": "Title of Individual [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/ShareBasedCompensationPerformanceAwardsandRestrictedStockUnitsActivityDetails",
      "http://www.auriniapharma.com/role/SharebasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsAndOtherReceivablesNetCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.auriniapharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance, receivable from customers, clients, or other third-parties, and receivables classified as other due within one year or the normal operating cycle, if longer.",
        "label": "Accounts and Other Receivables, Net, Current",
        "terseLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "AccountsAndOtherReceivablesNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureNoncurrentTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as noncurrent at the end of the reporting period.",
        "label": "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Noncurrent [Text Block]",
        "terseLabel": "Deferred Compensation and Other Non-current Liabilities"
       }
      }
     },
     "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureNoncurrentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/DeferredCompensationandOtherNoncurrentLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r40"
     ],
     "calculation": {
      "http://www.auriniapharma.com/role/AccountsPayableandAccruedLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.auriniapharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Accounts Payable and Accrued Liabilities, Current",
        "terseLabel": "Accounts payable and accrued liabilities",
        "totalLabel": "Total accounts payable and accrued liabilities"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/AccountsPayableandAccruedLiabilitiesDetails",
      "http://www.auriniapharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r39"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "Accounts Payable and Accrued Liabilities"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/AccountsPayableandAccruedLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableTradeCurrent": {
     "auth_ref": [
      "r12",
      "r38"
     ],
     "calculation": {
      "http://www.auriniapharma.com/role/AccountsPayableandAccruedLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Trade, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableTradeCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/AccountsPayableandAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r36",
      "r203"
     ],
     "calculation": {
      "http://www.auriniapharma.com/role/PropertyPlantandEquipmentnetDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedTerseLabel": "Less accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/PropertyPlantandEquipmentnetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r22",
      "r57",
      "r59",
      "r60",
      "r457",
      "r479",
      "r480"
     ],
     "calculation": {
      "http://www.auriniapharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r56",
      "r60",
      "r67",
      "r68",
      "r69",
      "r103",
      "r104",
      "r105",
      "r337",
      "r475",
      "r476",
      "r516"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive (Loss) Income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalCashFlowElementsSummationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Cash Flow Elements, Summations [Abstract]",
        "terseLabel": "Reconciliation of cash, cash equivalents and restricted cash to the condensed consolidated balance sheets"
       }
      }
     },
     "localname": "AdditionalCashFlowElementsSummationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r20"
     ],
     "calculation": {
      "http://www.auriniapharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r103",
      "r104",
      "r105",
      "r300",
      "r301",
      "r302",
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional paid in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r267",
      "r269",
      "r306",
      "r307"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Shared-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "verboseLabel": "Adjustments to reconcile net loss to net cash used in operating activities"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r269",
      "r296",
      "r305"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Share-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/ShareBasedCompensationAllocatedShareBasedCompensationExpenseDetails",
      "http://www.auriniapharma.com/role/SharebasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivable": {
     "auth_ref": [
      "r158",
      "r175",
      "r177",
      "r178"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on accounts receivable.",
        "label": "Accounts Receivable, Allowance for Credit Loss",
        "terseLabel": "Allowance for doubtful accounts"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r88",
      "r193",
      "r198"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "terseLabel": "Amortization of intangible assets"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/IntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r123"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive securities excluded from computation of earnings per share (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/NetLossperCommonShareAntiDilutiveSecuritiesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r123"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/NetLossperCommonShareAntiDilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/NetLossperCommonShareAntiDilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r123"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/NetLossperCommonShareAntiDilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AreaOfRealEstateProperty": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area of a real estate property.",
        "label": "Area of Real Estate Property",
        "terseLabel": "Area of property (in sqft)"
       }
      }
     },
     "localname": "AreaOfRealEstateProperty",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/LeaseObligationsNarrativeDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r96",
      "r138",
      "r141",
      "r147",
      "r173",
      "r214",
      "r215",
      "r216",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r225",
      "r226",
      "r334",
      "r338",
      "r354",
      "r387",
      "r389",
      "r440",
      "r455"
     ],
     "calculation": {
      "http://www.auriniapharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r7",
      "r9",
      "r50",
      "r96",
      "r173",
      "r214",
      "r215",
      "r216",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r225",
      "r226",
      "r334",
      "r338",
      "r354",
      "r387",
      "r389"
     ],
     "calculation": {
      "http://www.auriniapharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r347"
     ],
     "calculation": {
      "http://www.auriniapharma.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonaRecurringBasisDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "terseLabel": "Assets:"
       }
      }
     },
     "localname": "AssetsFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Noncurrent [Abstract]",
        "terseLabel": "Non-current assets:"
       }
      }
     },
     "localname": "AssetsNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r163",
      "r165",
      "r183",
      "r442"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale",
        "terseLabel": "Available-for-sale debt securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/InvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r270",
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/ShareBasedCompensationPerformanceAwardsandRestrictedStockUnitsActivityDetails",
      "http://www.auriniapharma.com/role/SharebasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r341",
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccounting": {
     "auth_ref": [
      "r102"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting [Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccounting",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/BasisofPresentation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalLeaseObligationsIncurred": {
     "auth_ref": [
      "r92",
      "r93"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in lease obligation from new lease.",
        "label": "Lease Obligation Incurred",
        "negatedTerseLabel": "Cash paid for amounts included in the measurement of lease liabilities"
       }
      }
     },
     "localname": "CapitalLeaseObligationsIncurred",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r3",
      "r34",
      "r90"
     ],
     "calculation": {
      "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash, cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of cash and cash equivalent balance.",
        "label": "Cash and Cash Equivalents [Axis]",
        "terseLabel": "Cash and Cash Equivalents [Axis]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.auriniapharma.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonaRecurringBasisDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash and cash equivalents:"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "auth_ref": [
      "r15",
      "r91",
      "r439"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.",
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r85",
      "r90",
      "r94"
     ],
     "calculation": {
      "http://www.auriniapharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash, end of period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash, beginning of period",
        "terseLabel": "Cash, cash equivalents and restricted cash",
        "totalLabel": "Total cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r85",
      "r355"
     ],
     "calculation": {
      "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net decrease in cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "Supplemental disclosure of noncash transactions"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r213"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial Paper"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/InvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r45",
      "r211",
      "r444",
      "r461"
     ],
     "calculation": {
      "http://www.auriniapharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Note 18)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r208",
      "r209",
      "r210",
      "r212",
      "r485"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/CommitmentandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r103",
      "r104",
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Shares"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, issued (shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r19",
      "r237"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Balance (in shares)",
        "periodStartLabel": "Balance (in shares)",
        "terseLabel": "Common stock, outstanding (shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofShareholdersEquity",
      "http://www.auriniapharma.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValueOutstanding": {
     "auth_ref": [
      "r19"
     ],
     "calculation": {
      "http://www.auriniapharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of all classes of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares exclude common shares repurchased by the entity and held as treasury shares.",
        "label": "Common Stock, Value, Outstanding",
        "terseLabel": "Common shares - no par value, unlimited shares authorized, 141,742 and 141,600 shares issued and outstanding at March 31, 2022 and December 31, 2021, respectively"
       }
      }
     },
     "localname": "CommonStockValueOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r63",
      "r65",
      "r66",
      "r74",
      "r448",
      "r465"
     ],
     "calculation": {
      "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComputerEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.",
        "label": "Computer Equipment [Member]",
        "terseLabel": "Computer equipment"
       }
      }
     },
     "localname": "ComputerEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/PropertyPlantandEquipmentnetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ComputerSoftwareIntangibleAssetMember": {
     "auth_ref": [
      "r194",
      "r196",
      "r326"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collection of computer programs and related data that provide instructions to a computer, for example, but not limited to, application program, control module or operating system, that perform one or more particular functions or tasks.",
        "label": "Computer Software, Intangible Asset [Member]",
        "terseLabel": "Cloud computing arrangements"
       }
      }
     },
     "localname": "ComputerSoftwareIntangibleAssetMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r132",
      "r133",
      "r152",
      "r352",
      "r353",
      "r484"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r132",
      "r133",
      "r152",
      "r352",
      "r353",
      "r481",
      "r484"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r132",
      "r133",
      "r152",
      "r352",
      "r353",
      "r481",
      "r484"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r130",
      "r454"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Major Customers"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r132",
      "r133",
      "r152",
      "r352",
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Concentration risk"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r132",
      "r133",
      "r152",
      "r352",
      "r353",
      "r484"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConstructionInProgressMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Progress [Member]",
        "terseLabel": "Construction in progress"
       }
      }
     },
     "localname": "ConstructionInProgressMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/PropertyPlantandEquipmentnetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfRevenue": {
     "auth_ref": [
      "r78",
      "r96",
      "r173",
      "r214",
      "r215",
      "r216",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r225",
      "r226",
      "r354"
     ],
     "calculation": {
      "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 4.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period.",
        "label": "Cost of Revenue",
        "terseLabel": "Cost of sales"
       }
      }
     },
     "localname": "CostOfRevenue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "totalLabel": "Total cost of sales and operating expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r131",
      "r152"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Customer Concentration Risk"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Unrealized Gain (Loss)",
        "terseLabel": "Unrealized gains on available-for-sale securities"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/InvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.auriniapharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), investment in debt security measured at amortized cost (held-to-maturity), and investment in debt security measured at fair value with change in fair value recognized in net income (trading), classified as current.",
        "label": "Debt Securities, Current",
        "terseLabel": "Short-term investments"
       }
      }
     },
     "localname": "DebtSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.auriniapharma.com/role/InvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r37"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.",
        "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]",
        "terseLabel": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure"
       }
      }
     },
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/PrepaidExpensesandOtherCurrentAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DemandDepositsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounts that may or may not bear interest and that depositor is entitled to withdraw at anytime without prior notice. Checking and negotiable order of withdrawal (NOW) accounts are the most common forms of demand deposits.",
        "label": "Demand Deposits [Member]",
        "terseLabel": "Deposits held with banks"
       }
      }
     },
     "localname": "DemandDepositsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r88",
      "r201"
     ],
     "calculation": {
      "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r308"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "Share-based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/SharebasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DueToRelatedPartiesCurrentAndNoncurrent": {
     "auth_ref": [
      "r99",
      "r217",
      "r219",
      "r220",
      "r224",
      "r225",
      "r226",
      "r381",
      "r443",
      "r462"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties.",
        "label": "Due to Related Parties",
        "terseLabel": "Due to related parties"
       }
      }
     },
     "localname": "DueToRelatedPartiesCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r75",
      "r108",
      "r109",
      "r110",
      "r111",
      "r112",
      "r116",
      "r118",
      "r120",
      "r121",
      "r122",
      "r126",
      "r127",
      "r345",
      "r346",
      "r449",
      "r466"
     ],
     "calculation": {
      "http://www.auriniapharma.com/role/NetLossperCommonShareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Basic loss per share (expressed in $ per share)",
        "totalLabel": "Basic loss per share (expressed in $ per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.auriniapharma.com/role/NetLossperCommonShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r75",
      "r108",
      "r109",
      "r110",
      "r111",
      "r112",
      "r118",
      "r120",
      "r121",
      "r122",
      "r126",
      "r127",
      "r345",
      "r346",
      "r449",
      "r466"
     ],
     "calculation": {
      "http://www.auriniapharma.com/role/NetLossperCommonShareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Diluted loss per share (expressed in $ per share)",
        "totalLabel": "Diluted loss per share (expressed in $ per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.auriniapharma.com/role/NetLossperCommonShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r123",
      "r124",
      "r125",
      "r128"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Loss per Common Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/NetLossperCommonShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://www.auriniapharma.com/role/AccountsPayableandAccruedLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Employee accruals"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/AccountsPayableandAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r297"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Unrecognized share-based compensation expense weighted average recognition period"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/SharebasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r297"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized share-based compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/SharebasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.",
        "label": "Employee Stock [Member]",
        "terseLabel": "Employee Stock"
       }
      }
     },
     "localname": "EmployeeStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/SharebasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/NetLossperCommonShareAntiDilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r67",
      "r68",
      "r69",
      "r103",
      "r104",
      "r105",
      "r107",
      "r113",
      "r115",
      "r129",
      "r174",
      "r237",
      "r239",
      "r300",
      "r301",
      "r302",
      "r317",
      "r318",
      "r344",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r362",
      "r475",
      "r476",
      "r477",
      "r516"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]",
        "terseLabel": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]"
       }
      }
     },
     "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByBalanceSheetGroupingTable": {
     "auth_ref": [
      "r347",
      "r350",
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.",
        "label": "Fair Value, by Balance Sheet Grouping [Table]",
        "terseLabel": "Fair Value, by Balance Sheet Grouping [Table]"
       }
      }
     },
     "localname": "FairValueByBalanceSheetGroupingTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r229",
      "r232",
      "r233",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r264",
      "r348",
      "r393",
      "r394",
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r349"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r229",
      "r256",
      "r257",
      "r262",
      "r264",
      "r348",
      "r393"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r229",
      "r232",
      "r233",
      "r256",
      "r257",
      "r262",
      "r264",
      "r348",
      "r394"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r229",
      "r232",
      "r233",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r264",
      "r348",
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r229",
      "r232",
      "r233",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r264",
      "r393",
      "r394",
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r375"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease.",
        "label": "Finance Lease, Liability, Payment, Due",
        "terseLabel": "Minimum finance lease liability payments due"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/LeaseObligationsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "auth_ref": [
      "r365",
      "r370"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for principal payment on finance lease.",
        "label": "Finance Lease, Principal Payments",
        "terseLabel": "Capital expenditure payments"
       }
      }
     },
     "localname": "FinanceLeasePrincipalPayments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/LeaseObligationsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r167",
      "r168",
      "r170",
      "r171",
      "r172",
      "r176",
      "r179",
      "r180",
      "r181",
      "r182",
      "r184",
      "r185",
      "r186",
      "r187",
      "r231",
      "r236",
      "r343",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/InvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r197"
     ],
     "calculation": {
      "http://www.auriniapharma.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "negatedTerseLabel": "Accumulated Amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r194",
      "r195",
      "r197",
      "r199",
      "r423",
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r197",
      "r424"
     ],
     "calculation": {
      "http://www.auriniapharma.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "terseLabel": "Gross Carrying Value"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r194",
      "r196"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r197",
      "r423"
     ],
     "calculation": {
      "http://www.auriniapharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.auriniapharma.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "terseLabel": "Acquired intellectual property and other intangible assets, net",
        "totalLabel": "Net Carrying Amount"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.auriniapharma.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/PropertyPlantandEquipmentnetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r76"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/ShareBasedCompensationAllocatedShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_HeldToMaturitySecurities": {
     "auth_ref": [
      "r160",
      "r166",
      "r175",
      "r180"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity).",
        "label": "Debt Securities, Held-to-Maturity, Amortized Cost, before Allowance for Credit Loss",
        "terseLabel": "Held-to-maturity debt securities"
       }
      }
     },
     "localname": "HeldToMaturitySecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/InvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r71",
      "r138",
      "r140",
      "r143",
      "r146",
      "r148",
      "r437",
      "r445",
      "r450",
      "r467"
     ],
     "calculation": {
      "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Net loss before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r205",
      "r207"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/ShareBasedCompensationAllocatedShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r207"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/ShareBasedCompensationAllocatedShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r97",
      "r314",
      "r315",
      "r316",
      "r319",
      "r321",
      "r323",
      "r324",
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r98",
      "r114",
      "r115",
      "r137",
      "r313",
      "r320",
      "r322",
      "r468"
     ],
     "calculation": {
      "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Income tax (benefit) expense",
        "verboseLabel": "Income tax expense"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.auriniapharma.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "terseLabel": "Accounts payable, accrued and other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedTerseLabel": "Inventories"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "verboseLabel": "Net changes in operating assets and liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "auth_ref": [
      "r87",
      "r370"
     ],
     "calculation": {
      "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation for operating lease.",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "terseLabel": "Lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent assets classified as other.",
        "label": "Increase (Decrease) in Other Noncurrent Assets",
        "negatedTerseLabel": "Non-current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidExpense": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.",
        "label": "Increase (Decrease) in Prepaid Expense",
        "negatedTerseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInReceivables": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Receivables",
        "negatedTerseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInReceivables",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r200"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all or part of the information related to intangible assets.",
        "label": "Intangible Assets Disclosure [Text Block]",
        "terseLabel": "Intangible Assets"
       }
      }
     },
     "localname": "IntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/IntangibleAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IntellectualPropertyMember": {
     "auth_ref": [
      "r328"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intangible asset arising from original creative thought. Include, but is not limited to, trademarks, patents, and copyrights.",
        "label": "Intellectual Property [Member]",
        "terseLabel": "Acquired intellectual property and reacquired rights"
       }
      }
     },
     "localname": "IntellectualPropertyMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InterestIncomeExpenseNonoperatingNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of nonoperating interest income (expense).",
        "label": "Interest Income (Expense), Nonoperating, Net",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InterestIncomeExpenseNonoperatingNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestReceivable": {
     "auth_ref": [
      "r49"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of interest earned but not received. Also called accrued interest or accrued interest receivable.",
        "label": "Interest Receivable",
        "terseLabel": "Interest receivable"
       }
      }
     },
     "localname": "InterestReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/InvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoriesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property held for sale in the ordinary course of business, or in process of, or to be consumed in, production for sale.",
        "label": "Inventories [Member]",
        "terseLabel": "Capitalized under inventories"
       }
      }
     },
     "localname": "InventoriesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/ShareBasedCompensationAllocatedShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r189"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "terseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/Inventories"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "auth_ref": [
      "r26",
      "r188"
     ],
     "calculation": {
      "http://www.auriniapharma.com/role/InventoriesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.",
        "label": "Inventory, Finished Goods, Net of Reserves",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/InventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r4",
      "r48",
      "r389"
     ],
     "calculation": {
      "http://www.auriniapharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.auriniapharma.com/role/InventoriesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventories, net",
        "totalLabel": "Total inventories"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.auriniapharma.com/role/InventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryRawMaterialsNetOfReserves": {
     "auth_ref": [
      "r28",
      "r188"
     ],
     "calculation": {
      "http://www.auriniapharma.com/role/InventoriesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.",
        "label": "Inventory, Raw Materials, Net of Reserves",
        "terseLabel": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterialsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/InventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcessNetOfReserves": {
     "auth_ref": [
      "r27",
      "r188"
     ],
     "calculation": {
      "http://www.auriniapharma.com/role/InventoriesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.",
        "label": "Inventory, Work in Process, Net of Reserves",
        "terseLabel": "Work in process"
       }
      }
     },
     "localname": "InventoryWorkInProcessNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/InventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsFairValueDisclosure": {
     "auth_ref": [
      "r347"
     ],
     "calculation": {
      "http://www.auriniapharma.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonaRecurringBasisDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.",
        "label": "Investments, Fair Value Disclosure",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "InvestmentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r169",
      "r438",
      "r452",
      "r482",
      "r514"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for  investments in certain debt and equity securities.",
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/Investments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r374"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Lease, Cost"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/LeaseObligationsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r202"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/PropertyPlantandEquipmentnetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee, Lease, Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/LeaseObligationsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/LeaseObligationsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Lessee, Operating Lease, Liability, Maturity"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/LeaseObligationsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r375"
     ],
     "calculation": {
      "http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "terseLabel": "Minimum lease payments",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/LeaseObligationsNarrativeDetails",
      "http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r375"
     ],
     "calculation": {
      "http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails_1": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r375"
     ],
     "calculation": {
      "http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails_1": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r375"
     ],
     "calculation": {
      "http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails_1": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r375"
     ],
     "calculation": {
      "http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r375"
     ],
     "calculation": {
      "http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails_1": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "terseLabel": "Remainder of 2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r375"
     ],
     "calculation": {
      "http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less: lease imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": {
     "auth_ref": [
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Remaining Lease Term",
        "terseLabel": "Remaining lease term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRemainingLeaseTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/LeaseObligationsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Lease extension term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/LeaseObligationsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Lease term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/LeaseObligationsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Lease Obligations"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/LeaseObligations"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r41",
      "r96",
      "r142",
      "r173",
      "r214",
      "r215",
      "r216",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r225",
      "r226",
      "r335",
      "r338",
      "r339",
      "r354",
      "r387",
      "r388"
     ],
     "calculation": {
      "http://www.auriniapharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r25",
      "r96",
      "r173",
      "r354",
      "r389",
      "r441",
      "r459"
     ],
     "calculation": {
      "http://www.auriniapharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and shareholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and Shareholders' Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r43",
      "r96",
      "r173",
      "r214",
      "r215",
      "r216",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r225",
      "r226",
      "r335",
      "r338",
      "r339",
      "r354",
      "r387",
      "r388",
      "r389"
     ],
     "calculation": {
      "http://www.auriniapharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Noncurrent [Abstract]",
        "terseLabel": "Non-current liabilities"
       }
      }
     },
     "localname": "LiabilitiesNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LicenseAgreementTermsMember": {
     "auth_ref": [
      "r311",
      "r312"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Terms of the license agreements under research and development arrangements accounted for as a contract to perform research and development for others.",
        "label": "License Agreement Terms [Member]",
        "terseLabel": "License Agreement Terms"
       }
      }
     },
     "localname": "LicenseAgreementTermsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/LicenseandCollaborationAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LicenseMember": {
     "auth_ref": [
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark.",
        "label": "License [Member]",
        "terseLabel": "License and collaboration revenue"
       }
      }
     },
     "localname": "LicenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MarketableSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Marketable Securities [Line Items]",
        "terseLabel": "Marketable Securities [Line Items]"
       }
      }
     },
     "localname": "MarketableSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/InvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MarketableSecuritiesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about investment in marketable security.",
        "label": "Marketable Securities [Table]",
        "terseLabel": "Marketable Securities [Table]"
       }
      }
     },
     "localname": "MarketableSecuritiesTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/InvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MarketableSecuritiesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.",
        "label": "Marketable Securities [Table Text Block]",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "MarketableSecuritiesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/InvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Short-term highly liquid investments"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r85"
     ],
     "calculation": {
      "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]",
        "terseLabel": "Cash flows from financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r85"
     ],
     "calculation": {
      "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]",
        "terseLabel": "Cash flows used in investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r85",
      "r86",
      "r89"
     ],
     "calculation": {
      "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]",
        "terseLabel": "Cash flows used in operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r1",
      "r61",
      "r64",
      "r69",
      "r72",
      "r89",
      "r96",
      "r106",
      "r108",
      "r109",
      "r110",
      "r111",
      "r114",
      "r115",
      "r119",
      "r138",
      "r140",
      "r143",
      "r146",
      "r148",
      "r173",
      "r214",
      "r215",
      "r216",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r225",
      "r226",
      "r346",
      "r354",
      "r446",
      "r463"
     ],
     "calculation": {
      "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://www.auriniapharma.com/role/NetLossperCommonShareDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_EarningsPerShareBasic",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofShareholdersEquity",
      "http://www.auriniapharma.com/role/NetLossperCommonShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently adopted accounting pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r134"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/BasisofPresentationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OfficeEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine.",
        "label": "Office Equipment [Member]",
        "terseLabel": "Office equipment"
       }
      }
     },
     "localname": "OfficeEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/PropertyPlantandEquipmentnetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r138",
      "r140",
      "r143",
      "r146",
      "r148"
     ],
     "calculation": {
      "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r369",
      "r376"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease costs"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/LeaseObligationsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r364"
     ],
     "calculation": {
      "http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      },
      "http://www.auriniapharma.com/role/LeaseObligationsSupplementalBalanceSheetInformationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Total lease liabilities",
        "totalLabel": "Total lease liabilities",
        "verboseLabel": "Total future minimum lease payments"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/LeaseObligationsNarrativeDetails",
      "http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails",
      "http://www.auriniapharma.com/role/LeaseObligationsSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r364"
     ],
     "calculation": {
      "http://www.auriniapharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.auriniapharma.com/role/LeaseObligationsSupplementalBalanceSheetInformationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease liabilities",
        "verboseLabel": "Current operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.auriniapharma.com/role/LeaseObligationsSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r364"
     ],
     "calculation": {
      "http://www.auriniapharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://www.auriniapharma.com/role/LeaseObligationsSupplementalBalanceSheetInformationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liabilities",
        "verboseLabel": "Non-current operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.auriniapharma.com/role/LeaseObligationsSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r363"
     ],
     "calculation": {
      "http://www.auriniapharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.auriniapharma.com/role/LeaseObligationsNarrativeDetails",
      "http://www.auriniapharma.com/role/LeaseObligationsSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "auth_ref": [
      "r88"
     ],
     "calculation": {
      "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for right-of-use asset from operating lease.",
        "label": "Operating Lease, Right-of-Use Asset, Amortization Expense",
        "terseLabel": "Amortization of intangible assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r373",
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted average discount rate - operating leases",
        "verboseLabel": "Incremental borrowing rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/LeaseObligationsNarrativeDetails",
      "http://www.auriniapharma.com/role/LeaseObligationsSummaryofComponentsofLeasingCostsandRentDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r372",
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted average remaining lease term - operating leases (in years)"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/LeaseObligationsSummaryofComponentsofLeasingCostsandRentDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r2",
      "r340"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "Organization and Description of Business"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/OrganizationandDescriptionofBusiness"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r11",
      "r12",
      "r13",
      "r42"
     ],
     "calculation": {
      "http://www.auriniapharma.com/role/AccountsPayableandAccruedLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other accrued liabilities"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/AccountsPayableandAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r49",
      "r389"
     ],
     "calculation": {
      "http://www.auriniapharma.com/role/PrepaidExpensesandOtherCurrentAssetsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "terseLabel": "Other current assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/PrepaidExpensesandOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://www.auriniapharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other non-current assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r332",
      "r333",
      "r336"
     ],
     "calculation": {
      "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities, attributable to parent entity. Excludes amounts related to other than temporary impairment (OTTI) loss.",
        "label": "Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Unrealized (loss) gain on available-for-sale securities, net of tax of nil"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax": {
     "auth_ref": [
      "r54",
      "r55",
      "r58"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after adjustment, of tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, Tax",
        "terseLabel": "Unrealized gain on available-for-sale securities, tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r62",
      "r65",
      "r67",
      "r68",
      "r70",
      "r73",
      "r237",
      "r356",
      "r361",
      "r362",
      "r447",
      "r464"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Unrealized gain (loss) on available-for-sale securities"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]",
        "terseLabel": "Other comprehensive loss:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherCurrentAssetsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for other current assets.",
        "label": "Other Current Assets [Text Block]",
        "terseLabel": "Prepaid Expenses and Other Current Assets"
       }
      }
     },
     "localname": "OtherCurrentAssetsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/PrepaidExpensesandOtherCurrentAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherCurrentLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other current liabilities.",
        "label": "Other Current Liabilities [Member]",
        "terseLabel": "Other Current Liabilities"
       }
      }
     },
     "localname": "OtherCurrentLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r10",
      "r11",
      "r42",
      "r389"
     ],
     "calculation": {
      "http://www.auriniapharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "terseLabel": "Other current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://www.auriniapharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Deferred compensation and other non-current liabilities",
        "verboseLabel": "Other non-current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.auriniapharma.com/role/DeferredCompensationandOtherNoncurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.",
        "label": "Other Noncash Income (Expense)",
        "negatedTerseLabel": "Other, net"
       }
      }
     },
     "localname": "OtherNoncashIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherOperatingIncomeExpenseNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.",
        "label": "Other Operating Income (Expense), Net",
        "negatedLabel": "Other expense, net"
       }
      }
     },
     "localname": "OtherOperatingIncomeExpenseNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PatentsMember": {
     "auth_ref": [
      "r327"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law.",
        "label": "Patents [Member]",
        "terseLabel": "Patents"
       }
      }
     },
     "localname": "PatentsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsForCapitalImprovements": {
     "auth_ref": [
      "r81"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for acquisition of or capital improvements to properties held for investment (operating, managed, leased) or for use.",
        "label": "Payments for Capital Improvements",
        "terseLabel": "Payments for capital improvements"
       }
      }
     },
     "localname": "PaymentsForCapitalImprovements",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/LeaseObligationsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForProceedsFromTenantAllowance": {
     "auth_ref": [
      "r80",
      "r82"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net cash outflow or inflow from monetary allowance granted by the landlord to a tenant to entice tenant to move into landlords building which will enable the tenant to prepare the leased premises for tenants occupancy.",
        "label": "Payments for (Proceeds from) Tenant Allowance",
        "negatedTerseLabel": "Proceeds from tenant improvements"
       }
      }
     },
     "localname": "PaymentsForProceedsFromTenantAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/LeaseObligationsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForSoftware": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the development, modification or acquisition of software programs or applications for internal use (that is, not to be sold, leased or otherwise marketed to others) that qualify for capitalization.",
        "label": "Payments for Software",
        "negatedTerseLabel": "Additions to internal use-software implementation costs"
       }
      }
     },
     "localname": "PaymentsForSoftware",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireIntangibleAssets": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.",
        "label": "Payments to Acquire Intangible Assets",
        "negatedTerseLabel": "Capitalized patent costs"
       }
      }
     },
     "localname": "PaymentsToAcquireIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireLeaseReceivables": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for the purchase of receivables arising from the lease of real estate, equipment or other fixed assets for a specified time in exchange for payment, usually in the form of rent.",
        "label": "Payments to Acquire Lease Receivables",
        "negatedTerseLabel": "Upfront lease payment"
       }
      }
     },
     "localname": "PaymentsToAcquireLeaseReceivables",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "auth_ref": [
      "r164"
     ],
     "calculation": {
      "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for purchase of marketable security.",
        "label": "Payments to Acquire Marketable Securities",
        "negatedTerseLabel": "Purchase of investments"
       }
      }
     },
     "localname": "PaymentsToAcquireMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireOtherProductiveAssets": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for the purchase of or improvements to tangible or intangible assets, used to produce goods or deliver services, classified as other.",
        "label": "Payments to Acquire Other Productive Assets",
        "negatedLabel": "Purchase of long-lived assets"
       }
      }
     },
     "localname": "PaymentsToAcquireOtherProductiveAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireProductiveAssets": {
     "auth_ref": [
      "r81",
      "r329",
      "r330",
      "r331"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.",
        "label": "Payments to Acquire Productive Assets",
        "terseLabel": "Upfront license fee"
       }
      }
     },
     "localname": "PaymentsToAcquireProductiveAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/LicenseandCollaborationAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PerformanceSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement awarded for meeting performance target.",
        "label": "Performance Shares [Member]",
        "terseLabel": "Unvested performance awards"
       }
      }
     },
     "localname": "PerformanceSharesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/NetLossperCommonShareAntiDilutiveSecuritiesDetails",
      "http://www.auriniapharma.com/role/SharebasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r270",
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/SharebasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/SharebasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r7",
      "r32",
      "r33"
     ],
     "calculation": {
      "http://www.auriniapharma.com/role/PrepaidExpensesandOtherCurrentAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "totalLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/PrepaidExpensesandOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "auth_ref": [
      "r5",
      "r8",
      "r191",
      "r192"
     ],
     "calculation": {
      "http://www.auriniapharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidInsurance": {
     "auth_ref": [
      "r6",
      "r8",
      "r190",
      "r192"
     ],
     "calculation": {
      "http://www.auriniapharma.com/role/PrepaidExpensesandOtherCurrentAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Insurance",
        "terseLabel": "Prepaid insurance"
       }
      }
     },
     "localname": "PrepaidInsurance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/PrepaidExpensesandOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromInterestReceived": {
     "auth_ref": [
      "r84"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest received on loans and other debt instruments during the current period.",
        "label": "Proceeds from Interest Received",
        "terseLabel": "Cash received for interest"
       }
      }
     },
     "localname": "ProceedsFromInterestReceived",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.",
        "label": "Proceeds from Sale and Maturity of Marketable Securities",
        "terseLabel": "Proceeds from investments"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r83",
      "r299"
     ],
     "calculation": {
      "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from exercise of stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "auth_ref": [
      "r83"
     ],
     "calculation": {
      "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants.",
        "label": "Proceeds from Warrant Exercises",
        "terseLabel": "Proceeds from exercise of warrants"
       }
      }
     },
     "localname": "ProceedsFromWarrantExercises",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Product [Member]",
        "terseLabel": "Product revenue, net"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r36",
      "r204"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Long-Lived Tangible Asset [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/PropertyPlantandEquipmentnetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r206",
      "r486",
      "r487",
      "r488"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property, Plant and Equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/PropertyPlantandEquipmentnet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r35",
      "r202"
     ],
     "calculation": {
      "http://www.auriniapharma.com/role/PropertyPlantandEquipmentnetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property, plant and equipment, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/PropertyPlantandEquipmentnetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/PropertyPlantandEquipmentnetDetails",
      "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r16",
      "r17",
      "r204",
      "r389",
      "r453",
      "r460"
     ],
     "calculation": {
      "http://www.auriniapharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.auriniapharma.com/role/PropertyPlantandEquipmentnetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.auriniapharma.com/role/PropertyPlantandEquipmentnetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r16",
      "r204"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Property, Plant and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/PropertyPlantandEquipmentnetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r16",
      "r202"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Long-Lived Tangible Asset [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/PropertyPlantandEquipmentnetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r263",
      "r380",
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionAmountsOfTransaction": {
     "auth_ref": [
      "r380",
      "r384"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transactions with related party during the financial reporting period.",
        "label": "Related Party Transaction, Amounts of Transaction",
        "terseLabel": "Payments to related party"
       }
      }
     },
     "localname": "RelatedPartyTransactionAmountsOfTransaction",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "auth_ref": [
      "r263",
      "r380",
      "r381",
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party transaction.",
        "label": "Related Party Transaction [Axis]",
        "terseLabel": "Related Party Transaction [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "auth_ref": [
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction between related party.",
        "label": "Related Party Transaction [Domain]",
        "terseLabel": "Related Party Transaction [Domain]"
       }
      }
     },
     "localname": "RelatedPartyTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r263",
      "r380",
      "r384",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]",
        "terseLabel": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r378",
      "r379",
      "r381",
      "r385",
      "r386"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "Related-Party Transactions"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/RelatedPartyTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": {
     "auth_ref": [
      "r311",
      "r312"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by form of arrangement related to research and development.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/LicenseandCollaborationAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned": {
     "auth_ref": [
      "r310",
      "r312"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Compensation Earned",
        "terseLabel": "Upfront payments received"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/LicenseandCollaborationAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Research and Development Arrangement, Contract to Perform for Others [Line Items]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others [Line Items]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/LicenseandCollaborationAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": {
     "auth_ref": [
      "r311",
      "r312"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/LicenseandCollaborationAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r309",
      "r421",
      "r501"
     ],
     "calculation": {
      "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.auriniapharma.com/role/LicenseandCollaborationAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/ShareBasedCompensationAllocatedShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCash": {
     "auth_ref": [
      "r94",
      "r439",
      "r456"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash",
        "terseLabel": "Restricted Cash"
       }
      }
     },
     "localname": "RestrictedCash",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalents": {
     "auth_ref": [
      "r15",
      "r90",
      "r94",
      "r439",
      "r456"
     ],
     "calculation": {
      "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash and Cash Equivalents",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Domain]",
        "terseLabel": "Cash and Cash Equivalents [Domain]"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Unvested restricted units"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/NetLossperCommonShareAntiDilutiveSecuritiesDetails",
      "http://www.auriniapharma.com/role/SharebasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r21",
      "r239",
      "r303",
      "r389",
      "r458",
      "r478",
      "r480"
     ],
     "calculation": {
      "http://www.auriniapharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r103",
      "r104",
      "r105",
      "r107",
      "r113",
      "r115",
      "r174",
      "r300",
      "r301",
      "r302",
      "r317",
      "r318",
      "r344",
      "r475",
      "r477"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "verboseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r135",
      "r136",
      "r139",
      "r144",
      "r145",
      "r149",
      "r150",
      "r152",
      "r248",
      "r249",
      "r422"
     ],
     "calculation": {
      "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Revenues",
        "verboseLabel": "Total revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.auriniapharma.com/role/LicenseandCollaborationAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "auth_ref": [
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r250",
      "r254"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
        "label": "Revenue from Contract with Customer [Text Block]",
        "terseLabel": "License and Collaboration Agreement"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/LicenseandCollaborationAgreement"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Net revenue:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r371",
      "r376"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Initial recognition of operating lease right-of-use asset"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SalesRevenueNetMember": {
     "auth_ref": [
      "r132",
      "r152"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue Benchmark [Member]",
        "terseLabel": "Revenue Benchmark"
       }
      }
     },
     "localname": "SalesRevenueNetMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accrued Liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/AccountsPayableandAccruedLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r123"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/NetLossperCommonShareAntiDilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r123"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/NetLossperCommonShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": {
     "auth_ref": [
      "r295"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.",
        "label": "Share-based Payment Arrangement, Cost by Plan [Table Text Block]",
        "terseLabel": "Allocation of Share-Based Payments"
       }
      }
     },
     "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/SharebasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r122"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of Earnings Per Share, Basic and Diluted"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/NetLossperCommonShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r347",
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r194",
      "r196",
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r194",
      "r196"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Schedule of Intangible Assets"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/IntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r14",
      "r29",
      "r30",
      "r31"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Schedule of Inventory"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/InventoriesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r36",
      "r204"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/PropertyPlantandEquipmentnetDetails",
      "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r382",
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable": {
     "auth_ref": [
      "r311",
      "r312"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A schedule reflecting the terms of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others (including royalty arrangements, purchase provisions, license agreements, and commitments to provide additional funding), aggregated by similar arrangements or individually if necessary to understand the effects on the financial statements.",
        "label": "Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]",
        "terseLabel": "Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]"
       }
      }
     },
     "localname": "ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/LicenseandCollaborationAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r270",
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/ShareBasedCompensationAllocatedShareBasedCompensationExpenseDetails",
      "http://www.auriniapharma.com/role/ShareBasedCompensationPerformanceAwardsandRestrictedStockUnitsActivityDetails",
      "http://www.auriniapharma.com/role/SharebasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r276",
      "r286",
      "r288"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Schedule of Option Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/SharebasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Share-based Payment Award Valuation Assumptions"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/SharebasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Share-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Award vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/SharebasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "Performance shares forfeited (in shares)",
        "terseLabel": "Shares forfeited/canceled (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/ShareBasedCompensationPerformanceAwardsandRestrictedStockUnitsActivityDetails",
      "http://www.auriniapharma.com/role/SharebasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r285"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "verboseLabel": "Performance share forfeited, Weighted average exercise price (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/ShareBasedCompensationPerformanceAwardsandRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r283"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Granted",
        "verboseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/ShareBasedCompensationPerformanceAwardsandRestrictedStockUnitsActivityDetails",
      "http://www.auriniapharma.com/role/SharebasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r283"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Granted, Weighted average exercise price (in usd per share)",
        "verboseLabel": "Performance shares awards, Weighted average grant date fair value (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/ShareBasedCompensationPerformanceAwardsandRestrictedStockUnitsActivityDetails",
      "http://www.auriniapharma.com/role/SharebasedCompensationNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r282"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Outstanding - End of Period (in shares)",
        "periodStartLabel": "Outstanding - Beginning of Period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/ShareBasedCompensationPerformanceAwardsandRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r282"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Outstanding, Weighted average exercise price - End of Period (in usd per share)",
        "periodStartLabel": "Outstanding, Weighted average exercise price - Beginning of Period (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/ShareBasedCompensationPerformanceAwardsandRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted average exercise price $"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/ShareBasedCompensationPerformanceAwardsandRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "Performance shares vested (in shares)",
        "terseLabel": "Performance shares vested (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/ShareBasedCompensationPerformanceAwardsandRestrictedStockUnitsActivityDetails",
      "http://www.auriniapharma.com/role/SharebasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "verboseLabel": "Performance shares vested, Weighted average grant date fair value (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/ShareBasedCompensationPerformanceAwardsandRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r293"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/ShareBasedCompensationWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend": {
     "auth_ref": [
      "r292"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of the weighted average expected dividend for an entity using a valuation technique with different dividend rates during the contractual term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Expected Dividend",
        "terseLabel": "Dividend rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/ShareBasedCompensationWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate": {
     "auth_ref": [
      "r291"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rate of weighted-average expected volatility for award under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate",
        "terseLabel": "Annualized volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/ShareBasedCompensationWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/ShareBasedCompensationAllocatedShareBasedCompensationExpenseDetails",
      "http://www.auriniapharma.com/role/ShareBasedCompensationPerformanceAwardsandRestrictedStockUnitsActivityDetails",
      "http://www.auriniapharma.com/role/SharebasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]",
        "terseLabel": "Number of shares (in thousands)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/ShareBasedCompensationPerformanceAwardsandRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized",
        "terseLabel": "Number of additional shares authorized"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/SharebasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized",
        "terseLabel": "Number of shares authorized"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/SharebasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "auth_ref": [
      "r281"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period",
        "negatedTerseLabel": "Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/ShareBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r281"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price of options that were either forfeited or expired.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Forfeited (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/ShareBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/ShareBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r287"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "verboseLabel": "Fair value per common share option (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/ShareBasedCompensationWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r278",
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/ShareBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Number of Shares (in thousands)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/ShareBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r277"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Ending balance (in usd per share)",
        "terseLabel": "Beginning balance (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/ShareBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted-Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/ShareBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r268",
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/ShareBasedCompensationPerformanceAwardsandRestrictedStockUnitsActivityDetails",
      "http://www.auriniapharma.com/role/SharebasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/ShareBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/ShareBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r270",
      "r274"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Share-based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock": {
     "auth_ref": [
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of number and weighted-average grant date fair value for nonvested performance shares.",
        "label": "Share-based Payment Arrangement, Performance Shares, Activity [Table Text Block]",
        "terseLabel": "Schedule of Performance Shares Activity"
       }
      }
     },
     "localname": "ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/SharebasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r290",
      "r304"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected life of options in years"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/ShareBasedCompensationWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r95",
      "r102"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r47",
      "r67",
      "r68",
      "r69",
      "r103",
      "r104",
      "r105",
      "r107",
      "r113",
      "r115",
      "r129",
      "r174",
      "r237",
      "r239",
      "r300",
      "r301",
      "r302",
      "r317",
      "r318",
      "r344",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r362",
      "r475",
      "r476",
      "r477",
      "r516"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r103",
      "r104",
      "r105",
      "r129",
      "r422"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of preferred stock and warrants for common stock issued.",
        "label": "Stock and Warrants Issued During Period, Value, Preferred Stock and Warrants",
        "terseLabel": "Exercise of warrants"
       }
      }
     },
     "localname": "StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r46",
      "r230",
      "r237",
      "r238",
      "r239"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "terseLabel": "Exercise of warrants (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r18",
      "r19",
      "r237",
      "r239",
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Exercised (in shares)",
        "terseLabel": "Shares issued on exercise of stock options and vesting of performance awards (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofShareholdersEquity",
      "http://www.auriniapharma.com/role/ShareBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r47",
      "r237",
      "r239"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "verboseLabel": "Shares issued on exercise of stock options and vesting of performance awards"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r19",
      "r23",
      "r24",
      "r96",
      "r161",
      "r173",
      "r354",
      "r389"
     ],
     "calculation": {
      "http://www.auriniapharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "totalLabel": "Total shareholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]",
        "terseLabel": "SHAREHOLDER\u2019S EQUITY"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental cash flow information:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TradeAndOtherAccountsReceivablePolicy": {
     "auth_ref": [
      "r154",
      "r155",
      "r156",
      "r157",
      "r159",
      "r162"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for accounts receivable.",
        "label": "Accounts Receivable [Policy Text Block]",
        "terseLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "TradeAndOtherAccountsReceivablePolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r167",
      "r168",
      "r170",
      "r171",
      "r172",
      "r231",
      "r236",
      "r343",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/InvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USTreasuryBillSecuritiesMember": {
     "auth_ref": [
      "r451"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about negotiable debt securities issued by the United States Department of the Treasury which generally have maturities of one year or less, are interest bearing, and are backed by the full faith and credit of the United States government.",
        "label": "US Treasury Bill Securities [Member]",
        "terseLabel": "Treasury Bill"
       }
      }
     },
     "localname": "USTreasuryBillSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/InvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USTreasuryBondSecuritiesMember": {
     "auth_ref": [
      "r451"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about negotiable debt securities issued by the United States Department of the Treasury which generally have maturities greater than ten and as long as thirty years, are interest bearing, and are backed by the full faith and credit of the United States government.",
        "label": "US Treasury Bond Securities [Member]",
        "terseLabel": "Treasury Bond"
       }
      }
     },
     "localname": "USTreasuryBondSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/InvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]",
        "terseLabel": "Warrants"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/NetLossperCommonShareAntiDilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r117",
      "r122"
     ],
     "calculation": {
      "http://www.auriniapharma.com/role/NetLossperCommonShareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_EarningsPerShareBasic",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted-average common shares outstanding used in computation of diluted loss per share"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.auriniapharma.com/role/NetLossperCommonShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r116",
      "r122"
     ],
     "calculation": {
      "http://www.auriniapharma.com/role/NetLossperCommonShareDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_EarningsPerShareBasic",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "verboseLabel": "Weighted-average common shares outstanding used in computation of basic loss per share"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.auriniapharma.com/role/NetLossperCommonShareDetails"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 8
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8672-108599"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e4975-111524"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=SL6953423-111524"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5212-111524"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5033-111524"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5093-111524"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=SL6953401-111524"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL120269820-111563"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "http://asc.fasb.org/topic&trid=2126998"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=123349782&loc=d3e5879-108316"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=123349782&loc=d3e5879-108316"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "http://asc.fasb.org/topic&trid=2144416"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130551-203045"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130558-203045"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130550-203045"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)-(4)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "38",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "38",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "44",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5558-128473"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123385561&loc=d3e9135-128495"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123362884&loc=d3e9212-128498"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123362884&loc=d3e9215-128498"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569643-111683"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13467-108611"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13476-108611"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/subtopic&trid=77888251"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "http://asc.fasb.org/topic&trid=2122745"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "940",
   "URI": "http://asc.fasb.org/subtopic&trid=2176304"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(3),(4))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62557-112803"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/subtopic&trid=2209399"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123345438&loc=d3e61044-112788"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.17)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "946",
   "URI": "http://asc.fasb.org/subtopic&trid=2324412"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=123364037&loc=d3e3115-115594"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 4))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r502": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r503": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r504": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r505": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r506": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r507": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r508": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)"
  },
  "r509": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r510": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)"
  },
  "r511": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)"
  },
  "r512": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)"
  },
  "r513": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)"
  },
  "r514": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1403"
  },
  "r515": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e640-108580"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)(1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6787-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3337-108585"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>80
<FILENAME>0001628280-22-013439-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-22-013439-xbrl.zip
M4$L#!!0    ( %8QJE0).OM)%$P! $2I#@ 1    875P:"TR,#(R,#,S,2YH
M=&WL?6E7&\G2YO?W5VBX,_?M/H>R<U_<W<S!@-WT(&&#L%_XXI,K%&CA:L'@
M7S^1)0D#PC88 2JY>K$EU9:5$?'D$Y&1D7_^W_-VJW86>OV\V_EK";] 2[7_
MN_+G_\JR_WF]LU5;[[IA.W0&M;5>,(/@:Y_SP5'MHP_]DUKL==NUC]W>27YF
MLJRX9JU[>M'+#X\&-8((N7&P]TI*%9'R/K.:F(R1B#++K,T,1\%%*PRG<OGP
ME1$H.N%5%@F'TZR$,Z(P<)5W3MB ?63+_A7QU*@H R=!,>^"C493;H/CSNA@
M17KLT0#>#MZPTW]UWLH[)W\M'0T&IZ]>OOS\^?.+S_1%MW?X$FNM7Q9'ER:G
MVEXKOW9J^J4XF2!$7^:=_L!T7)B<GY\/LGYPUZZ [R\.NV=P+MPYI,Y\.>B9
M3C]V>VTS@,Z&6V&>(951/+F/#U^?6CQQ<A,X *<3_!\V.77J9:ZW,!VVIG_9
MPN&@]\VS]4LX>ODJ_2XC6'[OY4=G7-ZYGQT:<WIY031]6YP\/E"T.T/XRFM"
M=]U^_^_U%4$9(ADFES+JY[<)$YJ(7_Y/?6O7'86VR6Y**CW*W^CD\67BY>C@
MY-1^;S#]4O#CK2_TK?["],I+C4__M@XF;9W<TPQ/CZZ=:8:]O).;TR,#G?+"
M==NI(031<3->M4SG\*^ET,GV=I= \8/Q*W^VP\#4TCVR\)]A?O;7TEJW,P!S
MSIH7I] G;O3MKZ5!.!^\+)[^<N6__NN__ASD@U9824W()@_Y\^7HQS]?CFYM
MN_YBY4^?G]7Z@XM6^&O)Y_W3EKEXU>EV C0@/W^53@R]T<?<^] I/L+Q!F!*
M+W>CYY\/=D+\:RF/D6AME#>,1J:<,=0$K@SRG"OKJ?RT7C0%0\]_??&.::='
MA_S5*L"43U#UIF4.EVJYAUMZ^N'"KG?/MLC.V3ZM#_WQQMG!6WV\??S/29UL
ML(-CWVHT_VEMK^^<[),/^4%[@]>_P-\?ZWB?;/"#CYMDBS9:^U^Z%P?KC:/M
MM_OTH+EW<= \1 =OX??VP=%V$\YM?SAN?(3C'S_DC99"6^3@8O^C$P?K!ZV#
MMYL7]?4W[?K'?=I8?WU<)YODX.U!WFA^:!VT]S\WVO6+_>/],__V36[?[HG]
M+_4O]>-6ZV#]S?'!\1YJK/_3WG[[3[N^[BZVFYN?&^3]E_KZ(:Z3^OB:#_ L
MWCEHGA[#E1?0AI/ZQT:[T7R/ZNU]MI^>\663UX]7Z<%Z_?/V^MZ7?:PNMIH;
M@_HN.M]JOB?;ZR?GGS2@:S""99:&D+$ ^*LLUIEG$D<NF4,(+:U$T^J'/U]>
MD^-CBG4R +W)^\ZT]H/IO8%?^I6 ?R3@+U,"EAI'1SG*:(0QET6B,B,ESEP,
M'''A#8R[2RM)",\FWW=P_ZZO)'PG":-I$V8Z>N]QIH038,)49L"0% Q6GEFA
M-!5$+*V\QT\HWXT.#!L7:R#AGFEM=GPX_W_AHI+MCV2+IV3+B"0B(I2Y$%#&
M#,:9L4AD42ED)'=:49 M8#06P&4(>D(9KPU[O6L0O='QZ^ M+-5&! Z><#YX
MY>&7K V//<J\J53@ARI IE0@Z$ 9.#P9=CJ-T$%F*D:;*0DN$#,(P!R8%R89
MG;;PE]=)6"_$ #)SH7\+=TS.PZM^0:!!/VJ%:_1J (SQKZ5^WCYM)39=_';4
M2^ISC2:^..][N,7+Z_<8/?_K0\=MZ'>'O>);X7"]&NOD2#-^1B<G-PH%Z$R^
MY3Y]CWGHU8H&A5O]M+7-_W?=?&Y>O#+YZ?K=3XLA:_(-O(W>(.E^,8XF+P'A
MR75?CUTVTU\YE19BNWYD\GWRD)?7.NK6?K,!6>\IY\@&1A72VAD"+K/7T2%B
MPJ?-HKLXTG/072/W;##N ?"&]>6-QD?NU@/#3CYZ_3YX1Z%_^6;M8/K#7E@9
M"Z X.+G%Y-CD>[K'K3WJI5+0<<+$R!FHH7$^1"&]CQ@;1M2X1^=# :_WZ%6=
M^LD>'1;V?+W+QB& 5WN[Z_?N3:E8%)PS33EF5$>3XCO!1XU<D('&HC<Q)O/6
MFS@; ^O/].:U'J L2"^$%I%[!BW4UH;(%0SAC'B+S3,@V]@^PF&BXJ.O'AYV
M?MK*73ZHA[:%1_@<CH["A/W>X-6[7M</W6"[MQMZ9[D+J^<Y&-XXZC,Y.KKT
MSY>WWO&RMRX?7 J$E5A:I[&+F",6"++:<HN=1)HCQ34NY(<G\L.5_+XM/WQW
M^>&9R0][P04'FS,1LX0_*%*-N*01TZBB6PC[VX)?.OVPB/9'>& R<..,8HS#
MZ"&"DH0PZJ(PEHN%L+^GD=^SV!\8G]94"3 ]R1@U2DMN+8W2"*,<E\\@OWGM
MMZLL[%WH[28">]D7/C^#=[AZ:N'MF4'W4B/O2=BFKD\_KH=.MYUW;KOM76GU
MM5N\O-[Z'_%%@3T)SF**N672,H68L,0YXHDPX!H^'5^\KY%/3'EW  )/UVS\
M9YAB8=WV:;<#7_O7+1Y^;W<[NX.N.YF]U3\*D046I+CQP5KF&0:Q!(D-!M?3
M,L2\U0LCFE7O\S0-:5KO3.XW.VOF-!^85DG$!*+!@1+%A33 5Z-BB)+ HZ34
M1FK$XHC)N6%[V$IY"MN#H]!+Y_7"4;K;6=CLN&[[$<;31Q%9"#:0 ))2V#/-
M@^'$"*TU%ISY*/#"B&PG#$S>"7[#]#IYY[!?$ODXJ@QF) BI' L @MA*BD(0
M#'/''2J!"S%/H]/S^Q124,8]HEJ&"#)4F@B$F83!38&,*5\\@3[9F/;\PJ4T
M@+T228D43 IBA= *2"636(+ED@44[G.,A,\O:!E38$=Y0:-C3%DC)0_$&B<\
M>)E>+YZ@'W_\?'ZI>DPTMH((">;+*/"AJ)R0'EG&""'VZ>9?RCS&SFIBZ#I/
M5<%C'7A 6#(>P1.4"$5!L.>4(^L71C3/X0'.3DS,1A,)^.<1''-)G;7*&$JH
M,=K;J/7BB.F9/<#9B4P*)+WC*%CJF2?:"DP0XL'","9,% LCLB?U &<G'T4!
M[+B(3@K,O &/08.WX!D0#Z^T&J59H 7PT)]J4$(S<\XY\=(B0#OB-*->PQ_&
M6&DTUEI081=&-,\Q*,U.3,YCA[TD/!C)!"'& ZM#SD:K'8Q2:''$],R#TNQ$
MA@'>J(F26ZJ8"%R%2 WC,H2 06:+([(G'91FB7S& ">P,FC.O- 6^A"<)Z!\
MT(WP_]/)Y[EZP!.K@N.64=!0RJ2.(<@@O30!A@%F2Y ;,$_C\_,G"VB%'%%1
M6&8IPU@8T&B48NZ1*QL,7SR!/D]@]EF$ZR.12"M-F2(, 6H9@PUA'#$E-%%T
M 87[[('99Q%TI#(JZ4A0F#'#0@K,1FE=!$9NK%] 6'[BP.SSF*^A08A(G56&
MB>@5#+0DPD<&HVY@(T=K$83Y=*DYLPI/N  44"NE! ;>0Z.AUEK)):(._&%B
M%D8TSY.:,S,Q$:EAR%,\F0WXP\I%)[2TA3L%U'UQQ/3LJ3FS$AFR/H)?A9#B
M$D"/*PVL%&D1D='$8KTP(GOBU)R9R8<(Y#%.N:+ *6FTD888J (/P@N+XM/)
MYPE[X.OZMU'W3ZW82FLT)[*9W./.2[8"9DYP0VQ("Y8"UI*;$+GECD:$9)GR
M)]:Z'1?26O0T9NSD_9/7%Z]#QQVU3>_DNOKOFE;H[X2ST!F&1OC10IB'-"#5
M8KG!-X;] 2!B;^KDA[8BK3NHF^-N;_*$L<T7ZK%[&EQN6H.+=T6)&7>QW5F4
M+)%+^^@,4\._L3[T%#[>VSBX43!>QU2'2C+"P$@$TTYZZW@TDI<A<^Q^6M'\
MW'U$8U@@:RR+<5S/Z3<IN88$+0AG JFTH$H1(#R64JUUG/]YYS=YQW22RF["
M$-HKBLM<4><UTS\RMA7>#DT/QM<0P&<X"_U!.FTM]-+#'71=6::A&;*$"([
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M G\H+=5$1&'%HC?*,RNYE88+(;DJ ?#]2OYKB%1J[Y1(&<0@-:L<)L$&$61
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M*M+^FG9I12)PU(C\J?2\)YF;O=O"E*^S9O_^ER)8_M&O#4(KG"85&"<V+-<
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MC$>"$*9!L996,,/+DMTV,WGCA\(UNY_Z_5SLI *UQ=!!6E_])$&]HC8L(UH
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M!6)MA,%V;)KS"@%GAX#3A>$PL=Q'IS/*#0:/$>%,!W ;$>8D<&5M%&D]\K+
MTW7AIG(0JZ#/O'"9^QCXSY.961EX9</WLN&;+,8:8J(&&\96 HL1+F0Z5; E
MS OD"2>.F:45Q:>GM9_%@G^A4,\5]@*#9N[R017C*1=9V0D# RWR&Z;7@7[K
M7Q'I^DBB%3^9';;M3?$3I+CB&,=,>:TSIGW,M$,FTQAD*BU7(-:E%:GILGP0
MOE71EE^)H516_;16?9.Q2,-%(%%FBN%4<]_Q3--@P;Z=M$(2(=)&C)*+94SF
MQ*H7?MW9:#%_D0%TU&WYT.O_=RW\9Y@/+IX[P/+-M3QSO]YV;B:MBECR6*P;
MA5 K@)L=P.U/T1;*C3=!L<S%8#+F!,Y4JH(4 XQ33DE)N%]:84P!P-$RSU+=
MUT1+%/8I+^S,S?Q6!3N/"SLW>14R1C'";1:)#1DS2&4& ;E"V&-+ Q-":( =
MJ9>1GE7VSZ.;_@(MS[QC&:4BK_HJ$QNOVGP('_N!MWG'H@XCR;RB($K?'=I6
MN)3TP]#R-H$\*T?[WS]9]6(6'30OP\C<L-<KU6)6.[X:5!YS4)DN>VZT]H(R
ME'E$P%D7B&=*&)898UU,!('H5*L*B65=[AW(9V[)SQQ!_'4Q_79UJ#!]CER#
M"M.?$M-O.@I4&>%85)GP0H&C0$)F0M"92U4(HPO(>@F8SN@R%=/+C<J*JX4G
M\7)@X*&3!8E7RFZT3>\P[Q2/E]>1S 4P@-[CV69QQU<I\S-WW[=64O@+1Z%F
M7$J$,YV+M#"STQTDIZ$'/W=J.;3UL%>L+N@-:MU8&QR%?DA&[$.G7VP)U"FZ
MMIB6CGG'=%R>(K\#^*&H2?3B^IK-*UTT;@8CH\*TI]U^D;[ZJA=:)BWW_.-S
M[@='$U"Y<N%8Z.CK)<9"(X:#;U_RA/W_W=[&-U:P7ODSM;: '^*I45$&3H)B
MW@4;#>"C#8X[HX,5G[!>FEQT=+F)W*DY#)GM!7.2F0@O^,JT/IN+_M++ZVH)
M.GFCWV]VV:AC5OZTO9<KM[7V=B7'Y&FU_%M>A60I56)O9[.QN5I[]_?J3GUU
M;6.ON;FVNK5;VVRLO:BM-M9KNWNO=S?7-U=W-C=VOZF?\_(V:]N-]8W&[L9Z
M#3[M;F]MKJ\VX<MN$_ZJ;S2:N[7M-[7M=QL[J\U-.*%XP;7M^KN=C;_ALLT/
M&[6M[=VY?LW"-'[+.X NW2'<P_>7:^'<!4#FT] ;!2]J #'F]WN]18'-7T&C
M& _@;5KFM!]>33[\X?/^:<M<O,H[19N*B_X8:_88:9*9W SPI.>-#G^UH!=H
M9$7C^-+XR>/#+XI#-\:WT3%)7A"-OWD8O?C98U2QG[KR>XW%^(7 ND2-)>2N
MM[W%3YIH!S"6,!]G_B"">8\"9C\\54^=>HMG-C*WN8HJ-8]Z(=3:<-Y1OQ:
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MZ\/>_S:VWG_<WC^H_)O]TNX"H/1&<(\P^+7ZPQUU[2BT >GN-M;"1ER!5V%
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M>IGJ9:J7J5ZF924P):JPT89Q33E6T=B"%@C,M314LSN3Q:(*\[4"S&71Y5R
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M/G^^SO"I@,)78@>M5OC**OPL&Q*86JND %VW&G&3G2J7 A+P;P8NEC*:YL.
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M+6.P<5P4J%'@S#@T<)VGY'&^ CM;1)'*L63#U;UZT<O'C&\*^-8'CC=S\W&
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M9;>3R1NE["96]23IGK6@/<BUF61\'IS#>'CK\'/"+@K&!/+2"<0=4"SC%$-
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MRN2YX50'+@BQ-#FF/'%.2FFUJZE15=!CEAHI9A5S)"$73$#<>XEL( P9 S;
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MCSWW 8 1]!O)%MURF\5TC IH[\?#$8P^WZ<HT0ZOWH1[EW0A/Q<NL/VBH=G
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M+/T$"8('$@G"1DK$C=/(Q!@0PR%Y$%L#7]Q*/W$WZ"U=77*%;Q6^/216>P:
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M6?J<MUCO]6?L]VOVFL .Y/JL!Z)8U+I7&8&'%Y:^@'V?X!_<GE@]^+H5\Q>
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M;P5IK;6*6>Q>S^*O]Z5T?5;"VN*.OS8'\#A_CW?^I^D'W5[3KM=^[X%MZ)_
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M4_>[:2K#:/-\+-K7^XO#?KY!W@2XZQ3!8&8$CSEW<#'[2C]QZ(!1IZBTFHB
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MG;3(" IQ'LFTO)QK+OW:IM(_,D;KH#_@WA6,>UMG/=#1K$4%3(" -@N] C6
MY80 (/_4@H7*2@VHWQJ&(@(H9=9ULQ+ER&?*E[R3%7IIO<OY;,D_9C_>G_(J
M;P9*G8D (<_F-3S<T/ ,!+:6X]SAV72 T0&?H9\]W3RH?G.0D<L.BF?E=;D
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MW$TE.&<3=TQ9I3+0:K7@!LY5&>&C&K(5!Y;F)'.J&L)5<"N+Y9M-QE: MVC
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M:2V\UKW5("1^;LW<W=X[LM%P8W1"3IJ$N,PT4CX&E-OT*F)2D-GJ$+7!9]R
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MP]0T$X1H\.#^ 'RN+#Z35S<'%QNU_7QYLU\^<M"+=C"6E#\;A:/6S0A2"TT
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M>',?']CM2]1MP*OWE=E0ER";*Q?[RTL\+#]NU(17E=\8B&E>!1'(5!A;3WV
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M3BS#XR$KCZ#*=8%V#P?ABX%V!*#:LEU--3UBJE:$H2L1=54[L$#ATWV'A0%
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M(*]F,P(#2PUR1BY4$L%DWY+DBDR*5[_.H@] S]P:SK_^ZJ+,=6WRYO9(9K3
M*@\LG9B46E'H>=30F!.!,1I%D47\5YMCX-+GW$K17=7HKFIT5S6ZK15QNZK1
MK=^BKFIT5S6Z[4DN7=7H5B6S:+;C^YJMAX8%FIGN,X?YU/!-.W3<0'_XJM&W
MNJN.,FE05DDNSR&/97@4?S_9L[^CW_/Z ,S%+_$Q1H.?4^WH[].K4XP0OSX:
M'@T_7L]'A9\:?R2'^\G%$9B:A^?8K>G AO>8'%W_I7\__RT^- ZN#XU3X_3D
MJ%DP6C^\_@M/+4S3TXAA497HMB]2$3W*/-6,J.%$GN8ZU'OUWK1V.A&QJQ:]
MRT!U0P++G=!J>PDLZX/5LS\]?6P<T^9PC-AZY$345_7 MU4KU*GJ,8>JCN&&
M)C5"S_1%**-I=DC6U;WI2DD_GD[I$:;IQ/,-@&!+(\SS0D(M(XR(3DV-!H]7
M].9!8K@ZQ7,-P)XL*)Z1I46&31W5='U'M73/4KT(M,^(DL!W7=]W;*SLVG,U
M;Y<!NZO-TQ9L6JU&WA.@'E&??&$A>8^-48M*I>TXS"*JZ828,@UV,5C$IDH#
M1M#TH(YOB.K3B^6[7B9&O1 7ILC[>6H_Y0ZB\X;U$G=(=9Q/!>NTP[61MU&P
MND9>C5J!3P(U8H2JEN=%8,Y;@6I'3&-::##-L3!#K"M8O3N\_ZPULUGV[S2S
M+>/#O&9F>Y9E4]U1"8LTU0*P4$G$+#4*-</RG""PC6!5YO(.:69=,>NNF'6G
MG#U(CD.GGZV/OU\7]#-J6E0S(EUES +]S P1B353-4P6^4YDFP$S 7_MKJKU
M[K#_L];/&O6N.^5LR^ PKYRY)HU(R+#F/64 #@0KREBN:NNVQHAIA8 47#GS
M%O%AAY2SSFWV4LI;:S?5N'UNX3;+*P3ZG@="'GC9<2P73"PCL'0MH+X=$3]R
M_0<O<KUY7&!W=KLE@%\,&F2,A9'O1:JEA6!]!Y:A$MN@JFXQ I#H1:$>X=FM
M;R^6.M@A@-\Z-'3^Q9;IKW>#M2Z \!E@VKS2JGL>M?V J;9OA:H5^J$:>)ZE
M1I9&/6H$D6=3?M:K=Q[%936D%S)]=R=;_J11FB!G%-%\OFK9C;6>YD"%6:[)
MJ ^@P72+!!&AKL'\P'9=RPE<B]SF%[/GX64O23)>XF<YSGS\B;^R]30>9S?1
MX5[E9+!4AVL[D<M\U?4):"Q.H*N^YWNJ3S46^:%E6#IR=W^Q5X<"!)?(BD5<
M-59%50G:V &%B2U0>.JZ*,4T4]TCG!;$6"^O?JV:$VZ[2[$W:5211#K[6@]<
MI8(.6#A.V''4G,F'K"@_9?FB/&YTK94,!U<?1\MY#D<I?IM@_9&NH,5?/R)=
M<]V0$C6P(ZI:;@A< OJ4:MBF3QSF^Z'-Y@M4[*1H.$OAYO!V(-BLB@8'BL7/
M>=U04<.C>+MN$9JN:D)7-6&CJ@D[U;+D&7=C6?UJ-WAY$Q:URPC?N,+ !N4"
M=BOW?Z$JQLM[?WV-]]\Y;KS+8<P3LNERK\$75C!>OP4UCY!=LB0;H>K[$,<P
M#YC%W#KX^^5A,CDW<,VTS?,ZWP<[!%L@8H$7F0%V5O!-UR*VI[F$&1K5HXV#
MAM9UCCR'$Y_S,^/H]].?WT\.?IX:1Q>'UU^2TY,#Z_"<FH=__S$\/;FP#W__
M9L+\M'GOZ/'^J?;]_%-R>/[I_-3XZ_KH]_\,#L_/)D?7]*>8Z\75]Y/P_/3D
M2[-,1-W&WK(=/=("U=5,5[5TBZH>#7S5]AR/&'9D6*[_ZKWO/@??Z$Z4B7B>
MH+I\&Y\[J"Y_ZPU U7>,4*>ZJUM^9#FF'Z +.B L]!T\O##GJDUO#U2?_1G[
MXR'N?+M6C^J!YNBAJNN1K5H1"55?TTU5=^S C&SJ,RQZKO<TUUK W-W!O6>@
M_=\>)]\Z0/W*$OCPK*><L93E).%6  F'<1H79<Z+[W;A\P^I!>N!@;UN;"P$
M;7F^2?30\5W#\,W(TC5B/)@6W 'VE@![LJ@B!U'(+).J+K4<T=0HT(FO$L/0
M ]>@)'0 9.P>[/,N*\E=6'Y[]4#-\31J!+X5$@.,:]]W?.9IQ->IH[FN971Z
M8/MA95X/#%VB:[9OJ;IM:ZH5>H[JN5JDVJ;KAZ'IV;YOOGKO]!QKL09%VUC[
M&6A[.^CK_4!&/&8##ZY%ZY0XO61IF>4Q*YXZ[K[5@'QO/0] ./3"2/=L([0T
MRPNBR#<U&D;P@0UJ0N?M?'K,;52?J&WOR-1"W;55E]?]T5Q')69$53/R(U#?
M(D,+@E?OW9W.7NK*7[18C[,,BUJ>HU&364;@^EI@VRQP \UT#$MV)WP(/:Z#
MC4U@8UY5,VUB^#9S5<>S7=7RPT#U3=-60\,+@M"U@M#&#J#:XB%)VWCW&2AJ
MN^B6NR6J\"%\<K?==V/RTXZ>,MWWZ'Z;2],6F77_@_V[!&QWOH<6";2O"WJP
MY5!&+9!E 7,<T(--5_5=4(9#9I! ]PS3LP&@W9YF['11]2WR\Q.[0E\BFM\W
M9N YHOF]+1#;0;^BYT3$<BW+))[OVD%@1BYQB$=MM_,DMQ_-Y\T3EVJ6$X::
M2CP/S!,KTE4/W<F1[NE&P"(68(:KV_.,;7F2VX>H+35LZBS:NFMNLZ5N.[+_
M5D&+;@.T[!68'[DDM8DW_LZ9<D6*C9)H0]?S#,(<$D6V!;HDH2&+'#<,(UTG
MEN&M*#BRD#O[<3A*L@EC7UE^&<O&U OH4V?9\Z3\XB0K23*?[7>4E:<,)E?E
M@'W%GN$R2[]+O5V>&_C-/+SZX?NNY8.RJ)I.9*I6&'@JT7U']9@;N-A?C(3D
MU7O+ZR_JD(*4&@FXXW23)+Q&-NY8;K!"^ [7W>>O!C$=*''![Z'RXH U<_TR
M@!F%*%>R (-:M7(<\;I%.*O95/$'SFI],((6=9@^9;G\"*_39R@;P(&^#<?Y
MA)'\Q=$RU8"6N0[D![YJ^D#0EN. ::0SJFJ^330GL"++MC&-W)G'< 77K)C+
MZKZQ._JZ2+^LN3<.P[?'"$%UBUQF&\RS0LJ"B/BF'3!J4^*SP/GA&:\:-SVZ
MDT'T1'?ZCV,L+GM\I6NH:,&\-<R^S0VJA^7A@Q3PBIV0G_MQ09.L&.=M22"W
M#F/)6.??C,/SWRY.SY/AX?4?@\-KT#=!CSS>_Z9_/SFT#HT_SD^'H+?^?3J9
M9ZRC$V#&W[%RR^GUX?#C-3"1<;Q_81V=_"<YO#Z[/AT>Q:?G9S^_G_\1'9Y\
MM([V?EBAZQMZ9*@>]6S5TGP+?G,"U: ^T=PH\%D8" T!F 5@K>3=_W17#VU"
M-8-:OD=(H&N^1VD$@E<WF3.?<"Y678%EQV/O.1UKGG]6,]?27O:WSF6&M]N@
MMM7I[2R*0/+%ETPIR4\E!R%6;"M]/01F >4O5*(\&_(!(Q;R@-.B).6XS/()
M?R!*T"06PA?8H8 9@#V2@=H8BSTK<<^P9S*@(JP"YL43D-'%."E1 ./(P_@G
M_BINZ%7#X,PN22*WBF J/4DI*_K*BLQ^V(/I,VM- @;>1'G=NB^T!@QI)__&
M4A;%Y4Z8RX\/*?#OC\CTF4]L4_6 \E4KBJCJF:ZE6KYOZ98?@BC$@B_:8KV7
M*GN9T\XFN[YUGTFWZQL)DCT;M+R?AW /S.?J<.\'=:,HM.Q ]5V#JI;!--4W
M3*H2FT4^<4/0A<Q7[Q=[B$Q)X XXB%O;0VP:"51-)@)KID9)C35R]**R)0HT
M1)JX)I$H3A7*\I+ O^?C/"["F,^3@QC<T00J^#/-\-ZH8*42 %+RKP-!.8B;
M90/W!O"W!$IA"($MH43C!!"V.<(2 ,4YQ66A%"##XBBF8$W-S6UEO9*--=DG
M$)HK*QTM%Z/?TFI_@%F5SUG!C:=BIY=@[;(XZ-D1887L)SPK%90"A,,IC:0D
MC&&"7]@E \U-V3MC*9UPTN<F$?"+[DK&T;V^<I *SIHZCV8>!,0-Y :\<\OX
M)>>XZ70X7UQQ-T'"4.& !TK'%/Y(,R6*>5UBH3(T](O*@<5'4-!8P %!A9G1
M#_*:Q1K\#?20LS/N;P#%!J=$QG [QP,8D8@'9XVBR#@FOZ90LO0LPX](*1=D
M16FPY4;DFM:?_6H)E;6@&-,*0]%]:8;B%^'!^DSR<G*2P]R%A"K:9S<>50Z9
M\T^#[[]_U Z- ^/PY.#GX?Y?YG<4V2#FC_[^S_!X_]0X,@ZUXY,]<U[<'_[]
MZ>+TY*_KT_/3GX?G'Z^.]L.+XY,S\W1XJ'__^]0Z.C\U3Z__L@_W0Q#W!U=@
M-Q)#LXGA>JH11J%JZ;:CDA#^=+W -J( ##&FS]N-@1Y$OF.Y.K-MBWFA%P:^
M;ENNH7EF9#)OWFZ4FZ#P75":VW"K%=DBEEH.Y,NMV5M7Z/W!GW\<'"E?CTX
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M+;/!#*)YHVOTW>JCN82ZW8.3OQE?6!"%65E)FR$YSW*$3$FC&:@:G(I12D9
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M]4/ VA=!O<L$MZ7@B582W(J 0]OLV9;^) 2WS2CKUN/]0>VFNB?>OY0 V14
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M??NF4P"D6>9VO<.K3+NE3$$&IZ<[\S XY5SX?C8QHN*G7W1=:W2 @>L 14!
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MF9YD?"Y.JTM#6:2C%#"/)T=:XU@.U/CQD$\)1#JO6U_K[,CO0Z%@X1$?Z#Z
M3'OR%O@0)W0%AC3CJO/M,\+J4NBB06V*%^W+1EQIJ4S BFK(4,!F,>"U_((,
M'=Q2/ GYMWJNC9D*1RE7IP!;Q>4+%-B@T$)@[/R$I][5&,B/EHMV*JW]F$"H
MR^%Y99VD%X66![4G[7G#Y/0]AV!T@=[,72.3"@K&G LE?U;U=RB&S*#>"_2>
M]YK%?V3$QGPU(>Z'K-IGEIQ 934PK!%4X.E^-8L!D)\X1)JA9\EUDIZK0X%>
M1]F;4_8'8?\];[)&\[6V<-$C,O6"-XA<1H-PLE@9K]Y3YF,@R*(&S=7@44(H
MFU8X6EJ5CDOK*P[>C:)S&2K  Y@_QKQQK61*V&A\ I],C[G$=.3!.G<1\:>
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M4JI.WT&6TVC&SC:#9JM:):)<@SC,4^I")=/2%?6)@PC771J4\_^W=S:K$<)
M''^5''M8%)JTU!X*J5VVEBJBZP-8S*)@M737@V]?XV3KUH]BW063XLF#&LB
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M0>(OC:SJ]F7D3<@4?WCW/U!+ P04    " !6,:I4AW-U=C\:   L_0  %0
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MB+F"_XRCV73YDTH"#HPO-H%_7XWE0L./']T[_(SC<YR>Q.EL$M)L4*1%:9P
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M_ @V>W >:^$LLI)<48&GM0BTWON^5^(TT$:CYE_U!HS:DXB,WV5+D9 2NAA
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MZJFP-F5Q]^/ZOJBSJ2(:.(N754#WX+PX-XN"V<@LK\W<"*E3 9PC!]?$R(Q
MU"FW.5E<'^.N#JF;DZ:16@[H\'K5H)Y_O<AV'X7I14E*D=FCT06TC)XF2*KI
M@MR E<@$C9!IW2;8M0'(_=?P]4N3]9>PK=2UVVWO$FBMJE@>A*X!M^EA]X:
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M,=$7"/4R9J0-K#CN+"]M8GUK0]P]MWI6[\T"VB:Z:5"9='EU]YWHA%8J\ER
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MU,*,X&4PME&_S0-@V$-WE1T:P3;154MBO1J?G<^F<PGPY9TV+C"G"PF!6UK
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M*8\?R>+[&M"\O%GD;4?&V&P81N_H:>-S/#FM[;$'*OH08F1@U;R-F(T0Z$?
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M"AA+,AB&@ C*S597IIW"F $9\A1E29P(GKF0ZGC 9J!1'X#94>5H&"8F1X-
MHUCP@U'MC\&+[;;,V6Y+V5H&VT(OT4O];?ICR9-(>.7%QQ)F9<*3QCWEOM,7
MC6.[Q_ONGTQ6Q ?U<[L#OX(P%%"$*<"IT!\SIQ&@"=-K/1QF$4-<9BQQ^9@'
MI2WMXZ[5 X4"NTH&U.$@U0Y;N^_>&V)S'X[NT=/*-B=O_BC "A2OE# L<5:*
ML#+^*678W33R%&U;\%]?;$0;E5J]K:J=%*]VI1;7;$W5Z[J/>CQD64KQ]/H5
M3[27D*$8\ 0*O0[3?$,X(T 2%2DN("<0.9V.7:G0THCH]=7AZU</D>6AQ8S
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MA0H#1ID 4B"]$L,R)3A9Z;M9\?RE(5P,<_G(^^9-]ZT?E0P(5&./%#=!9T]
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MY>/!ZZPRIP_-(<9-T%CFD5)] NV7>;UH-B]!^P3SB,>]/GR"PAJO\HH;&2:
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M\V^FFF]Q)]\55?7B&\W7AAG?%.5GNNZ%S-[2[RN5152(+-6LA1F ,52 ($:
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MX59/YI5^I-D%<WP9+SUF0:]G5Y:RUC7H*SO)*VN+C.=D@PM"9\XTL(/@.,W
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M2[A6R29>H9)-_'%1DTE77:].$7,\>CR-L-VD<#5N$Q-X!UFKX$W0JN@S>V$
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M[]WKY<CNKJE@]7=I>GY+\>*;+.D7V45WO\J_Y4)NQ$I@)5/%E:F8J&=XJB#
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MEL,"?]Y1FVDSP,OH>=I \ ?PX&:#!S'S;4SXP^31)H;'QXXLT],IT+;J/"R
M]:PE,X0Y4#'5<QH7"< RS0"*L@3A"'+)G2ILGY6TM-GJ\"G*5E/'JCQG(;7S
MB[T -=MDTRDYR7+_(A1^*_"<E39O\9U+1A_5W;EX@Y^X@J-3)<U4=7Y2[U>'
M(LBF$7!#6(>%81J'$4]2!F1$(8 QE( HEH!0, *Y675+I\!+[QHNC8M>226U
MAD]20LRY[;[U-6AMZ'L&UYV/7S_.XT[19QV]F<_:;TX?M!]&LA_I=3#R)CB8
M.='.PV2C,.D!_O5:/NLQOS>0+P4#^!,TMH;]VXTFROHT1[ZB6[HO )DD/$LA
M!I)C!2#&$2!AB(!BB&)%H6*Q50'L2X*6QNB-KD%/V<!H>S'DQ@W=80+VB=G4
M&[ CX1I1^WX8BRN+X)]Y^,S5\(=-/"Z+?^%Z'\ETQUW=3_^V#02)8QI&C#(@
M4-T#(TD!59" B&0998ID*'6JFW^-,DNCEOK<UG@4]0\]=8-?7A5W--\XYO9<
M-5!V+N!<\$_,4E<@?V6JX#C()DPL=%3H&=,0QT$WG+0X\IDCZWB8A(*W5:4=
MO%>[4J__FSSHNHA:_6]/,J7%"I,LEBS20QC&(8 T2DSB8P*TSY42I6*80+CZ
M)DM66!?C<-7!Y:OM:S+=QUN?)%9!7AL1Z.6U[.HB%"JHC U!T1A1?^*F5JO9
M^-+_>"]+591W5+]\ 36IZ8X+;_<!M&/520=E8BJM]0L:Y8-&^WT%B[:O7W-)
M:\.^BH7/$I=C\?-;@\)9BWG+2(P%Z:@2Q.@'N=%F56Y7?\TW^=WNKO51],I3
M,HXY$!$B9@V* 6,P!1)AKJ*$$H:L(H".GKPTS[!5SHZ=CG$:9IVKK)^835J]
M/+;^/&OMT+>O;^I]]_IO3[_YXZ?.\BV?-:;[1L]?,/*XL?Q"-_E_U=O8+_4W
M7:QST11^V8B/>N"[@_8/ZDV^T?-J3M>?]6^:@C"'?:K>B4+*I$(4 A6'"$"I
M/1H"32D'Q'B&](\D="K%XEO!I3%!W[[:G>E7,M NC5N?Q<F&U?*D]!D':^H#
MUIYI=8#UP;AZV/KFF7';&Q@<+'S4)7:2LX.I!L#OL:YO)><]#9X(XJ-#Y*GD
MC(C(U&MJJ>\PZ^97IDUT<5\7_SK4!C/QXF9?\K;XV"S!WA1E?:I1?3PLR3ZP
M=?ZEUOECL=4W:8T_Z:=M=O+%G3DC62&2I0C'VOT3+ 909!+@2 @ B<)9C)",
M8JNY8T:=ES:=[+4,2OEEMS9T\1#<[1/;RD9WAU#"F89^>'Y9Z(!./.5T!M<Q
MASV3^Q4HFUP?8W5P6P2MG8$VO#G%KFZ"GNW!P7C]^_V;TMH?-  L[]UP"$5=
MWCLR4[CJPMX5M_C6>4=M, 9V)E7FBY.=%]M'L;0SBW;??'JA5+[.34']YG2U
MW5U)0H03(4R*<"P!A-H-82BB(.$,*I9 E4BK0-OS(I;F-1RT[!<)L]^=.@/D
MY6VJZ^&9> [N(=-&/OC=N1H&X.HMK#./GVTO:]B\_J;6A2NOJ3GZ.*:_B[-Z
MZ$K[O]K)_] \=?M;L1*$9ADB&*B0<KWLP"$@IN%0A#EG(<4Q8U9I8R/E+XT6
M] L%QU0?M0?<;EMI0A@GIH^N2NE1-M%>_1O3&X29DB.YN F,!8$VP7?M4F?L
M)JAG:J_#,]0X=0;H=-U3]\>,([:?Z-KX1I^_2KE]9]X![1XU@2VK)"8BAB("
M2B89@!FD@,8D!2)-5 031&3F%-)_7M32Z*K5-*A5#3I=1\9:#2!L1UI^<)N8
MG\9"YDQ#E]'PRC@#XF8EE\MF/^41BSMF[C7<GO;KM9F2^797UB'KK[_?YVU=
M$*MF,TQ*),.$@12E"8 L-=V'$@J$S#B3 @K"K:K2+<*:I1%?:\P<+8@F?4GL
MB/5W,_03<[>']L7[_D0]3)JRU@=4EMFQ:(XQ7D:38R\6+:N?T1R#YZT-LE>E
M1@;IF#U1HW8IOVK-\V_R[887=]+4C'HOMQ_4+?W^L2AK@[;;,F>[K<DUNRT^
M4I,>LD]W#[FD,$(82$CTT@!3!;" &>!(2LPP8E'J%IOC1Z^E3:=-_B?OVQ6L
MM4F.=0]]C9IEZ,W\8S%UQ$T]#(],"AJ;@A^,57^\"4SAM$(%VC1S1E4VLU_/
M.K.WTM@W334$OYC[#;+QI-N\L35^ 3T*J?'\^)D78F]H7M9!V"^J:G?73$M/
M9IV_%6O]-+/E](ENY4HR&K$DT\NL!)JRMR0") DE@$)%$4U"%2&G_>SY5%_:
MG/!BL]G1=?Y?VO?]ME=TIK65^[A/O)":=#27OVHRYC>I+T$/@!.KHP,(@4%A
M <NCT2.WC+60N_J_CX7/Z&'QMLH9K\'8,A1-G=LZGZA)^/NPVU9;NA'YYLM*
M"D%A1@1(90A-(A '.#9UB3B'821@Q++(K1C%D+BE339MI$%7"=CH?!.T69$]
MM5U+4PPB/CQE^,=Q8IJ_%L(1Y2ILD+FR:,6@B)E+5]B8>US PNJNL93R0@C]
MQ*H.@_]0UF7.M3$K*;6C&PH!J,($0*H@P*%*M5.<4!AQ)$B*W,CDM*"%TDBK
M[$V3B*(A#3J%70GD#+ZVU'$]:O.0Q@C 1M#%,!I7$L69A\],$<,F'I/#A>O'
M+;?U8[B4HGJC%:S+Y\AJ^TERJ5?_8A5%4<@Q%8!#F0(8*M,XGB< 1EE*,P19
MFECY&3;"ED8/=6F4LE4N4/HUSUN-W=:U@P#;K41]P38Q/W1J!N9E#SI%@TY3
M?^L[&SR\KL@&!<ZZAK(Q_>FJQ^J>JYM.M\6V#CT&*(VHB&/ B8JU6T$(H(03
M@#+.HPA%,;<K5G!9U.*8HZU_.;H!Z "J=H3A!ZN)Z>)49?BI.T6?06.JWM!/
MQ3U7-^@S9@_T?SYWQSB:>+OA9=/ROOFSUU3I<23H*@PSEJ@( 9(H:IH<18!$
M+ ,AC3.>:OY@U"D0REKRTDBDUFX\A=@C;L<HD^ X,<%T.@<_=%K_T43K/ DV
M/\2:^V,<9[2\$I"]]%GYR!F4I_3D_H"12Z(V'/VV>,'_L<M+63^]\9C,@6>U
MBD5,N!0A$(I% $+. 8TU50FHA) A1S3CJXW\8O)U;AV61Y<$6WU<I/FXCL1/
M]Z']?*]'VS@\]?=T[])DV!YSRZ62%PAG6B^UNIHPC%;;EI)Z^GI<-=E"XW?I
M=%'JO.LG6Q".%E'6-XXCG;_(C>:RM>F&+N[R36[\+E/'N.V1L4IP&N$8(T!Q
ME $H$0$,<0E@D@F9IEG$&75QC"[(6YH[]%FN]9._W 1?&KWK,%SZ2',WPKF$
MMQW=>$1Q8K+Y2P^WQ[IV+7'\,8TE*EYYYI+,65G&$H"G'&-[VSB&.10]^J#Z
MQ]^?Y-HX"B^+:EL=G7Y7AQIG29;%2-$,H)0R "E. 882FI[A&<R(BA%VBI:Z
M4I_%,=29R!DW6KIVD.QH:T;H)Z:UDW%(O5"E:>K(><+/*P%>J].L!.D)P*<$
MZNNQXPAV'R3T=G._VU;O3%&7I*WUP5@"&:$QX S'VGU+"""$$6#*I3!)E$BX
M4]KQ@*RE$6.M6Y"X\> 0EG8<YPFAB?GK$"QY$S2*FN:H-6 >2ZDX8.*5DX;D
MS<HW%H8_Y1*;6\;NAG_3M%.4#Z<JR=;KO"3A(&4( Q@C!H@B')@X]2B%.".A
MTSIO2-C2F*+3=<1N]P"BMAO<?G":?$^[57/Z8KDVB'C>MQX0./-6]673CW>G
M+>X945SV\[TTQ6NW#Q^UXW)'^<.'C6PG0BA#B(TK@;!F"!C!## D,4!AIC(6
M);&@5EQQ0<[2:&*O:="I&FA='0IS#D Z3!8>@9IZ7702H\LNA1-8#I5'_8 V
M4[50QQ?,K9KG920&*W .W#Y?U<S+-CRJ=&EQ^54=GTT/EF*=\]RY=_GY!RSH
M6SXH&71:3A(G<QF,*5KDGA+W'+UN!\P^T[1VZ(X1$_W;=__K[?N662,*$4*0
M@)3&J2GPG@%JVH2D808A%L34!;*>V7L/7MI47JOF,!GU,;*8JD=:/K4/;[0:
M,Q7WK7>8>T>B,--D._P*N,VM)RP=G$S[U\\W>Y[0\M%T>>K?1U9&.1/SQ4@&
M>0I-2T4H <P2"EB:A8"S+,(R2A,9)DZ53GX?,76WQ9:NVRB5T9%UYS!-<402
MI(E:FKYL,-:\302,@:(Q2R -*4)JM34:S(?I7MKO%--(Z;DNBQC !$4F-2T"
M-)(4X(REC$>80H;=^G]Z0'6>+I\-KFIG2BH%=VU;N$<!5IXPMG.4EQ_M>;Z&
ML,>*-C-&<2XB9M,Q0M-O/*;)?'O5.B&W)=U4>7.6=U^4VY6 &48XB@$6D:;;
MA$0 IXP!%I,X(SR!C%EYR$-"EC9_=7H&!T6#1E/[5-6S@ [S@"^8)B:!$0@Y
MY:9>@F!T7NK9!\^6DWK)M'X^ZL5KQ[FKK^_NU\6#E)]E^2TW17Y/5>MX7VQ,
M2VLIZL(<53U/]O_='/*_+[;_(4V.6_%E8XH2-24(WQ1E^RMS7;2241+QF!"0
MT;J[.$& Q%0[&Q%/M+>6,,R=O.!YU5\:.?V\*?<*-\5UV[ <WB\C))M0MN"W
MKA@0;8L!E0?33'E>;:^;>S/SNV/G-2WWC9CZ^&$X+.LFV!O=58TR5NK?;H,'
M6:<,MX;>M,5UZP3LGK'^?+KG&2.OKN+,)LSJ@3[/\#QU;)])BYDK*+[^QTY[
MZV\WU;:LI_>JK@AY^Y5NVBJ_>PN?U+[ZBW[T]A7=RGW0S(K)-(X8"@'!1 #(
M%0(T4Q1DF,<L#$66*KIJB/[SEI9;NREV"::YT.Q3 R=<_AX*!?5*[76SJ^P*
MD=^;>LL!"'Z27_+-QJR6"]51[+-5Q_?YWH5)2EA&$0@A2TUV# 28A2;:$E((
M4Q5EC+3OW>N-^&=^ZSKS%O/.:87^V=XV.S=P":HNU#D<66.T 2;H(=,T:0VV
M&IM#WX8]/">JC]80!0:C7L72!=0@G6#,EU&=U*=AOX^ZI1,,I;>*IE/H-LY=
M?;FKML6=J3RN1V.S;?I&?,JK7]N3;DDI95S$@$D* 90R RSB'""LHH0B+D*.
M7;9I+LA;VKY*IV[P2-_ *.PV85["V6XN\XC>Q-/, ' 3I%98XN*5BB_)G)4E
M+0%X2F"VMXTLY7%HE-W44VW?]5!*S(E* :=* A@S!%C,"% BXF&L<*R4<BIL
M>%K.TKCDYV[3[;[7R9[6NQ6.Y3K.X&K'(1[0FI@[>AIV99']4\8%&/R6X3@C
M:][B&\,&'Y7<N'#Y2'>CN+O+M[7+\V*CO:8ZCE-N3!3GBJ44BI1D@&+& $0$
MF=;V'%#*0QI'24HBI^IC [*61@T]5>L:$;RO;/##^T*ODR+LN$8?PMK2W?"#
MX-2NQA/P'NGIT<>X#(9?_V) WKR^Q67#C_P*BUM&UCP]T<JZ5X&!I5Q"AA1@
MBF( PP@#$J$,)(J*C"@<<I$YU3T=%+<T&FGJ5WU@Z_Q+T__/L?+I,+9VG.$/
ML8EIHU'TYFE%PFJBA$X[7"9O;?]<-2?LS+=I7.^M8L0+SG=WN[HVA4WSM54(
M!<E"!@&7(M7+%A4"DB (,J2XJ<J3$K<J$H[RET8V/?6#XDQ72C?^<1T0.T*:
M$.:)&:J/L%/#2:]9:6/ \YVJYJ3#W/EK8P ZD=0VZC%CN]&\OI/E%\VH?RF+
MW[9?C32Z>5C)##$LX@1$L8G)$YK<F/Y1K\6R5,5"1 *&;LUH3LI9&I.UK54Z
M78-&V:#5UK41S6EHA[G*(V 3<])(K$;TH!E$XLH6-*>?/7,'FD$#CQO0#%_N
M;S6U3QSH*G1]DG<TW^B'?E!O\HK3]7](6JY$B*5*. 0111S A&EO*$U3D&!*
MXXB(E&=.!0G'J[(T.MDK:69CD_9X_2K,<DS&K]#\(_T\J[=>XM&-J>S,9/"1
MYN(F>#0HC46!,6G:!9X;K),O_BS5>?:%H1ML-HM&QR>.#/WD7Z78K>4'=?K4
MO^XLV![PF[/[)EK@T-/TMF[HO=]O(31-$102* D%@!@AP#C2?EF"B224D"AU
MZN'C5[VEL6YGG?F^S\8N!7N[^MV1'4/?_(ZR'6<_W]A-S.-6PW;3-$D]A):=
M',;@E]K*8)+MNVD&P&]LF%\5YXWRF@3>HWBM::2,W'[47KW(USM38_RSY+NR
M3MU_K[^55X69FU8Q3[)(:>JG46;.,E0*"*,QD*F,(A@QFA"G#+E+ I?&Z'U]
M@X/"-X%1.?BE4=JR@HLUZ)9[BAZAG'H3\3H4W7<,+:'QNT5X2>B\>X*6$!QM
M MK>-[[R;=4<RK[=O))L^V(C_DK+7^76T%H3DGH0:\YM9;G58F]+:I(,- _*
M;76R:BZ/$R0Y U"$*8 TT9,XC/1_$ABK#(6<<\>V<=,HNC2"Z]GI7G%WDI&T
M8[\EC,_$K-DST72M,T;6L24',[LLB(.AP0]U]$EC:] :&S36_G&>BL%3CHKW
M:L.3*#M[I>(I(3]5Y7A2>>['22^+;[*TK/MY=/V"/OA:+Z^%/<]:._KLXO'3
M9CNM.&E$_WSB] 7CG)2?/]^:]I*[\N&G8B,.+W,;XFPVOG J%. 840 )2P'#
M% .$B,0DCD-&K H/V8E;FL/0Z1H89=U<A@NXVDW\_M":^&O^^7/P"*O^+.T_
ME-P.%J_SYP61L\Z"=N8_G<LL[QH;9E[5D:=M[[9JE2&8\80RH*CD &:0 !+"
M!"1I&!,N!),B=*D/^52 $U/,5AB2F[(NA0HJNI9-;'2Q/RYK:P$YKCR.@+4C
MCFO@FGSBK]JX\=>7$!D1,G[:;,]QXD^$S!P<?MK$XXCP,]=-$+CP\T9H']<4
M"9=:'M>7OK@S?UNE28)2I6) L8P C$,.<,:Q=B8BI$(JH"2PZQSM(6KAG!Y6
M;__C1M(3TX4QX\]M@=/\[GYG(@YSK;:6X=A*>MS > A<N KLY<0L],T(&CN"
MQI"9(A4NX3A?D,)93983GW )+*?0A(L/N[+AV=^+\M>WFX]E81Y=1Y)^DI4L
MO^E9'&&1L#25("$J!!!'FA@CE !,44)I"+&":%3?L_,RE[:V,IJ:K;[[1M>1
M+= &,+;?6_6(W S;I+6V-T&'7ZOQ/AR]TWJ"UFB7(9JF0]J W.=IE'89B+/]
MTBQN'9G\W_5W+5[P?^SR4FH98L?-V5:S#[E*M.L5\1@!214&,&*AYANB !.0
M*44%HLHJVMQ:XM(HY^=[/::;;;#.>5V654G+/FKV&-N1CE?D)J:<3E<3W=EJ
M&QS4;8];/)8)L(7&;\& BU+G+1U@"\)1$0'K&T>23"GO:=XM*O7RLDZ>:1[]
M<E>66O8*QPJ%*L,@47$"8)JE@"4T!AE/4AXF<<C<MGXL9"YM-ZA5>;_GTVP%
M-3E[C<8!'?YN1J-O24!^,9V:@EHX6W5K-)O\O$;CFZ#5V2,-V0/DEX@LY,Y+
M1?9 ')&1PZTC>]#G&[HQS18/E=U>?,^K%559*!%) !>*: J"$<")@B!4(2%1
M7)<W<>H_?UK.TOR;O9J]4I'!+T93QZB]<[C:D8L'M"8FE#% N;>?'X;!;^OY
M,[+F;3L_;/!1R_D+EX^CA$]2+[1V\HW6SI1!,2?D?\^W7[O":Z^_\_6NB\W0
M_Q,FKUU0$H:A0B",D0!0869*(L6&/1@E4,A8.#;>&J&%R^<Q9U.NLC'%T549
M,PPP2:104@$*A3+QUW5$(P-Q(A*H74H])$YEZB8>A'E2&^<"WX[:)X9T8MIO
MM0\,=06=_L%ON<FG;BVX"?8V!)T1?BL\7 &AURECC!ZS3B=7 /5TJKGF42-Z
M&W_8[JI?:=O^6^ZV.3>M,=YM1=?-5N$T3O6H\%B:%;+BIGR6 #1+"&.$T]"N
MFYN-L*4Q6J.N0QO@2V .$Y=OB"9FJ$;3X+&JFJK^=!-H=?\TIHWRQ9?1OK6R
M1QQG:K=\ 4]/C9@M<1ELSGSI&?,U;+:TYE$39]M[1C9V5BKG=;CUO7EGVA=7
M4:DB@D/ :9("B)(,8 RU$\^@C#G.H$JA4UOG4U(61Y^UDH'LM'3LBGL22#O7
M[VIXIJ;.!IF]@A/$G0Y"X+<=[DE)\S;#'3+VJ!7NX,4C7*AV[_"3V138B/9O
M35W3G7;4/F^UOR:K59PF3*DD!-IETIX4#RD@$54@E5#_FL>49M3:D[*3N31&
MZ#;'A;POJMSV2,$%9 L/RS]T,QTI?*K/8C8BZ'YQ4#IHM?8/J(/+Y1_8F3PO
M'P"[>6%N4 TZ8Y:/FL\G<[/MD6OF>.N5,6]O\DU>?97B+T4AGL1CT5!!*!@&
M+$4*0*4G/LS3$"10Q Q'(2+8Z5#&0N;2N+K3-/AB5!T9\C8 L9TGYQFXB9FZ
M%_*VAZ]6>(Z(M\L(31/Q-B#W>2+>+@-Q-N+-XM8K&Z@?JLBT*YJ,"T8PA8"Q
M-#%5$@1@"B8@BSD4"8]"E3@M#<]*6AK!-&6;BC%EMLZC:<<J7C":F$LN-NIN
M])Y@Z7@1G6E:9!])>YYNUN>,/MMX^NP-8]T3;G(?Y2O9_&D"</NQ*:N8I1%!
M&LLH,:7F*28 $XF!5 IRE2 11:I+5+IU<5&&Y5I]&H\3DVYG7%)Z#E^[. JV
M[HL'4.?R71H5@Q\Z9?_8A.P_BF?SZ;?80>/9:;D@=&:/Q0Z"8W?%\KZ1D6I=
M^]"?'O8__L]<EOI!7Q_>R6\:$Q-@I7B"&=/L$R;2K)%8"%B<92"EBG(<4^W
M.+6\L!.[-"_FT*$XV"M;<]#[%W\;%\]FA[X=__C'=&(6N@9.]Z@W)W3\!L'9
MB9XW)LX)CJ,0.;>[W:L)O6HW _^?'2WUE[U^^"3OBW*[2BF&BF(&" ^QV5=7
M@/&0 "(I206/.296^^H#,I9&.IV:P5[/H%'4OA_%.32'><431A.3B#L\3H6;
M+@ PNH33N>?.5LSI@F']LDZ7+AW? ;38U"NJ;G<D9)!P*@!+!0(PC"$@42B
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M.4*/>0]'QP-U=(AZQ:-&+AZ.JE*N.)),"LR 2)3V\95>]1/,,) 9(TD8AI&
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MRCO6]XT(''U)JZ\F;.DO.UH7A)/"5#VOMO7.O2RWN<KUR,JJ30PE(J*:=S)
M.>$ QC$%+(DD0!QAG$1<,&55AGR$[*614:=]<% _..@?] QPB'9T'(YA5IH8
MY*EWR*SQK<:D0SLB[1!=.AWB,\68.B#O*>!T'&2#8:>.CYPO^'2<K8]"4$<^
M8F0YYOKTY.#D[F-.$6&,9PB#E)EBK$A%@"B4@#33_X()XR1T:DEQ3M#2B+^_
M^J6USG]V+--\#E$[)],'3A-S=Z-B?PT[263N)23\UG0^)VS>\LX73#ZJ]'SI
M^A$^XZ?\?IL+^5->5#R76NVW&]Y.DW&2*9BDD?8/(Z+7I5(!G D&8DH9QCS%
M";,ZLK@@9VF4T&H:'%2],>5#_N3@CPR :N'E^8%J8E8XA](8]VT +@=7S0]L
M,[EESB^9FP]V&8M!?VO@]OE\J\LV//*C+"X?08\?2WE/<]$P;]? 73*<QCS,
M0$)D#& :$\!DQD&<*":CC*<PM*\>=DK"TBBQU;'UD!R^[)/P65#@M:!,3'X=
M'IUK=*GMO24P#F1W+4 ST9PK4&XL-P3"(+^=O'$^9AO2^Q&G#5XX-IMB2_.-
M%*]IN<DW7ZH77+\(N[I'\BNIEYKY=@43GLDLS0#%D=)K01X"2I$$L8IB J-4
M(.G4I>>RR*7Q74_#0#0JNF8R7$39;GWH%[NI?<)6V:#3-OBACV2K\/G28R,R
M"VS1\9PV<%'LS#D!MC <!_Q;W^FO=\*M+.],D_8FE6"5)5@3=(I!!LTR,PL3
M33PP!K&@''%)<*:<(EXNBUP:W=0J!EK2W?5]#YZ :\<R?B&;F&7.=C4P&INN
MIYW.T_8O.(W/Y.T*GHA]]NX$IV&P:49PYL[12:+;,N>:M^KR@3]O\FWUZ?//
M[2Y"JJA*PRP$&"-STHDP()PG@&.101/!'^'$,?GSO+2EL<O/]7&"GG_+O=;!
MSFCLG)PY@+"M-^,)M\D=F3U2M:)!K6GP@]:U^N/E':XQ&9*7<?&=^3@@<>Z,
MQLO&G\A4M+AI')?\_/G65/K:E0\_Y>OU9\E-JY1\?WJ,(J*71"D%R,2*PI28
ML D$ <J@]E9DPE4(7<AD6-S2V*33-3#*NC'(!5SM*,0?6A-SR,^?@T=8!0==
M)V 0.UB\4L@%D;-RB)WY3TG$\JZQW9#T*LILL7U0QWTN'$^)K9ZUH'=_KZ]Q
MQT_V6IGB!-D))<\M5VPDS]R%Q0&,X\8L+C>/K=WT)E_+\J66]*4H'U:*Q$I!
MI4"69)'IRV22,4AF*O4G8:R2E"ON5K?IT?.7-H^V%8EJ'8-.2==B38\1'.82
M#[A,S!IND(RHSG32\"LK,SU^YLQ5F4X:=%R1Z?1E_C;T/LD[FF_ZZ_H5PERH
M#$E )%8 <H@ $2$#(I:QS#A%F71:<=N)7=I'OM>PS6[PL\5W N[QVWS7@?A<
M6WT'8)N]T]LA8+UL]YW':?(MOQ.BGWW;[SP<-EM_ W>/=+8O-9,^UTOZ#<W+
MO]'USM05V=TUC:5-&8 WI91O-_I[E=7VDV;.%:0)IY!Q0!"4AM!B@(4>/U-5
M4LD($>760VARC1?'A5I'H+220=YJ&936^13SC;/E@FQ)HS?U8LX8 IBQ).A;
MVZ\L%["'H']=:W)0VWP3&*N#VNR@9_=-71TE,*8'G>W!IZ%WPGU).-<X^5U.
M3J[UO$O1N0;A:!D[F^#1C7**.[E?;#MN"IVY>T',T6@8'':#IMCUN0"#[^XG
M)V7-W=YDR. 3_4L&+Q^[>_-)?LG-HS;;]_H5, N^*%-* 4%P!*"*$* FL3U*
MXX@P%"4D%F[;-X\%+,V=:3<K#DH&1DO7#9PG(-KNX(R'9IXM'%M41NSAG#;]
MRDV<)P^=>1?GM$G'VSAGKAL[]WS3;%"4#Z,;4 P\84%OY%[+J3M+6,#A>2XZ
M+V_F^>BBX<=STN5;QKW6'\N"2RFJ-UK-^NCB0^.]O?XN2YYK-V_%2(AA1D(0
M(=/Z/4TIH#3E(*112$(11:G=.8.UQ*7-7)W"@1G*0+9JFI.ZNE-P4#3ZNRW,
M+^-N1RI>T9R86AX#V00*M>H&>WW]$8PU-%YIYK+46<G&&H2GE&-_X]@ Q#IJ
M^B,MMP^W>HZN-)=U]2G35$8BRP2 B,0 1E@ &K(4<(:%")/_K[HW:XX<Y[($
MW_M7T&S:>C+-A"Z2 $&@VZS-%%M6V$1&Q$0HJZPF']RPAKS2Y:[/%WVA^O4#
M</%%[DX'Z #%?,A,I402]QZ0!]N]YQ)&B-/<V*&ML9%-8VI2V9KL&=NS0,1Y
MD-WX)1!TD9FE-VH](@\OXA$X[O!\>P-''5YT_#CF\/(MO<7BIFOU:?JDCFIF
MO7FN)+C?SMAJ5;WGK!0E(K0 )5'8,(JA%5IB!##CJ2PP48AZ%;+Q:'MLY%*;
M#BK;3Y22X\])(U]N'>A%.#X=XT9 D>".3$A!D>XC-^>+66CE.>?VAQ:A\P7F
MA!Z=]R.NV>V^8S_?_[1[\>J-FBL]74_,="@5)"4 HJ($B,$4\!0* "DM"VJU
MAW+NI\)[IB6?[VD8[=UF@WS-?IIU6&6J=_WVDY!"2*@N= D$Y1J8U2X!!$,-
MF!D<-$MQ2C/E5Q_G:D"'J8FSA?,77IOX:UA@?4YFKH)KF),98V+2V)C\TE@9
M,#WW @X1CF:.VWJ%HYFS#I\^FCE_N?_1S.V#FDM[S/-AQGY,K+YPJE4)5(K,
MNE,A,U7DJ0!"8Y*F@C%>.&6J'#UY;!_^UKC$6N=^"',(U^73E]X@1/Z<'?WW
M.FXYZ6OO<Y;#IPUVP'+2B?V3E=,77)GQ4<?)VYB#Q=S*^E;+ ZA1GHH2 TS-
M7 <AB &C" +S#4K"2YZFF=<F4&=K8_M FZR/G9&]5F/= +N-S<%@BWV2ZHM8
M_W29+B3BI,F<;/%UTF.ZG#^;%M-Y4]^ "C,/^"C-TVK!U^EB_GE3Y46B5&1(
ME1E ,)4 Y8@"BH@&9:K2,I4YI,IY%.]L:72D40<3V$GJH;E);:]OL,4Y@"^/
M^\%@BTT:?1'K$8AQ 8TK(S+./7W@T(P+3A[':%RZH>?^<!N/N#LO7WE&:W0]
M8D1O\%ZD\)ZA40(V7! )NXW8U>"P^X8.KA]M%+K<TU.5W'PO<CK;K*=/:I>%
M_?ZGF&VDDO;$U@ZUFUJL\(MNQ:J^JF4=OOM\^@'5K%!(##&K\DBIK=VJ)2"L
M*$&*M2P@893[J4M%M'5LX^^^I0?J!3VF[C&[V(T 1])QL7<"^O69OUI[?#3#
M"KY'M'=8S?CXP!_)S@_0I/^BZ5VC8/O!#$=L9AJ;+N0'\[O5I( H5P6$ )?,
M4#[)"D#37(""L[*4Q'Q#I5.J7F<K8R/KUM"DMC2I34TJ6]T72N=!O;Q("@)5
M9'KLA9+7XN@B"KT71N>?/-BBZ*)S^PNBRQ=?4\.FU<S&2@HHD 2*"JO&11!@
M$I6 Y+ H,<KRG)N/?;%F,\?Y76\=]FT;\5[?.]M&<EBOID^Y&C<E]JLAB3W7
M"2TJWNEPA/HS@RJ/=SIWNM),&,5QFS YFRFQWA@66-H2P^OG1O(-,4*PA KD
MG$B TI0#(B4"'*9,*;-BH]I+2N]\4V,;KF_%/S;3I9)5,GQK<O+8V)RPN97K
M9.U%R^F/>]\OO0-VM\\^#)B1.6#?R*2U,H*^WF4P D<SG&UNX("&2VX?QS1<
MO".<\-#)ZKXE*5DA)0$BEZF=_F> J)0 61!<0*53F7N5LG-M>&P4TQ98KJ6'
MVG+*U\L/G02=X5Q*7A2 8UC8:9@ IAM2(*32&&L*(<M\IF%10!]JAA8)8S?:
MCH%<9!(_*_.T5\AZO4BX2KZR:<",*E^HHBL]O7Y9:U](7-2> I:Y;IMY:[VQ
MPO%VR\DJ<]R9Y[Q;6%6I2<K-@E"* N10*JO/7 "2$C,(Y%20%&(N=>K#_QUM
MC8WR#TRMU76LL<F?M;F>>_9=(+MQ42#H(M-/;]2\"<<!CZ <T]7>H+3BX/A+
M)G&Y96"QN#KLY^-\M5Y6.UNK+^M[M;R[9_,FF?3#8JG5=&U3*>K]KHG.-$<4
M:Z RC0"2+ .,<VCK!5*::\(T]8K$']#VL9%;Y=<JT:V=_R*8>4-F9GG\RW2>
MK*J_G@]>?_4WH<2808)*4!2$ Z21K:^F<B!Y2:%F>5X6=#)7/VR*X=_S7:#U
MN[#O0[RWP=AEWH0'^PHT?;][,_X>+X3;$#JV3O[;: XV ;1[ "05 LG:0-#J
M--PD6Q02\\[4.(Q ?K!_YXU#B+"'_7\/2<+^'1-,G/ *$ZZ4BOJLUA.9942E
MA0"82&&&,6@F-,B6TBHT3'&FM,9>PM[[#Q_;C*.U;:H,4<R59PW0 ]A$7N8H
MSQ&@C)I%*5$:4"Q+4)8ILXK"E$GALS_6&[;!3BFG._"NP,WUJ*(?&M$/)QJS
M;I+/'6]/?ZFQ/7?C:(O9!EY'3&S/M;/J8?O7A%P*UCQZ.S<$:I>@TR?UU?3K
MZNMB-A7/$T(RDBHI@7&O- R8<T HE4"DN2I+F%(!O00X>M@P-J(\-UT+,?GN
M[HQK)M'!(!YP,KR=Y.[-@_^L+4[NU,]U\L9\37^%S!+K#]T 4]%N.T8PI70"
MRFUJZ/:HJXN5?9C.S:)ZRF9?%ZMIU6+O6F5G'S6FCVN_5-G6X*2U.':ALHL0
MQ:I3=K[AURI3=A&*CBIEE^_M]UV\?WB<+9Z5^JZ63U.A3G^8GQ=-A=UJ>;:J
MIK_[?W^[6*T_+];_H=;?E%C\F$__JZE:VJS7)JKD#,*R $5N<U1(:D^L6 EH
MP1 M.=(%RGQF%(-8/;8YR!_SY=;.>O.O&3+%_OY1+S688=X"-WH=7=^^[N3'
MK*Q:7]N-O]J'F\0Z:?ZZ3I[5.MGY>9/</BPV(<-%!^V2H./!,)8/.J ,VADO
M1Z1A&_<;TE;+M17!E1NQ_K)L#*S2YRC.848S#@2"-D,RA8!E' &H"\AQF19,
M<I?1YUP#8QLH&ANK&-O&3*^4QK- =A-X"'@B<VT/9)S)\I+[7;QF[MWC-/-_
M+_GL[,,'H9Y+KK4L<?&ZWI+W592M70VNS?+0G@\\VK%Q+UQ'(LE5FG.0,U[:
M+&@SPR125;OV7&K&4K^86(<VQ_;9?UK,?S0"IG<'\J4]HZ-<8'>;T@4&,S))
M7(%C'\E[5V1"B]Y?;'=HV7M7($X(WSO?>J4ZR9OG-VQF(S*^WRNU_FVYV#Q.
MYS_NF'E%)B7,B.2V8*9DVJQQ<6I3?5)0:*8,.2'#1H67;+5#HV.CH)VXR8T-
M7FCL3BK#D];RY,_*=E^A:I<^<*.CT,A&YJ,PH/97CW% *8Z*3%?#KZ,FXP#%
M6549EWO[T=-GM7[+5O>&!Y^F4LDWSW^L;&A$LV4X_W$KUM.G2I'@[6*^GLXW
MYG=- +M9;6UWO['(&".E!$1Q6^".,,!U@0&BC,N"*"BDU[%?&+/&1G'6I43/
M%O]LJN+HUIV$;?WQ8[9 W>?&?<-W2F1V- XE59^T+EF._,5ZE4SGOR9;QY*=
M9W;GK/4MV3D7Y20D+-Y!>3:0:8,R<5@X7W)UX*?W8_,W;#5=?=&W0MA-7-/"
M)"N10@)E ,N"VR1R"7B)"-!:*<YH*C3#/L1\U,+8.+8RT!Y7?C5/-1/Y'J$6
MQRBZ\>-5V$2FNBTL.^O,M"]&3,19%((2T'$K@W+)62=?TL+Y"WO&(K"96GU3
M3VJ^489R&LT"!2&5&<6 :&6F7PAS0#7!0&5I21%*=:J<=JD[6QG;E][8E[Q1
M<W'_P)9_>094G432,8SC6GPB?^U'T$00?>C$(&Q@QLF6AHW$Z'+V*/2B\^*!
MT_*:<['?;&7D51OS_N_*:J8H>?MD)B _5/7'=VRMM@O.B2JP5,*LY5)<4H R
MR0%)"V5F$.8O&<E$5N9^=8<&]L#G:QRFGE&U%_-4J?>:>9^-O'A8-)E835G9
M*C5KLY+5WZL_#)6AU?,M<63+\?;\@/$9/3.UMKE8-0J[1*R;I$4B::"H+TDL
M&,ENXV\$"5O7]>,XDK9Z^C""*-OH'10L>>M*,WI&,1Z6J]CJ9#!.J"S->Z3-
MC#HG9D:MN  ,(DPEHPKSW"OJ\%0K8YM1ORRKTO/P]S2B;F/%U3A%9G1_B/PC
MYKH@"!OA=K*E82/2NIP]BB#KO+C?Y_].\?6>[/(3F\[LL<J'Q=).XVW<+)O9
M(+/?3%.?%JO5!,J<L2*#(..9JN.1&<F5^1<KS1^*5&&OHPY? \9&&CL+DQ_&
MQ%5BIC>L]0+HQ1*LC!_):NNB'YEX]X\;S\1$/3(%6=/WU.MODMLCM&^2O5ZQ
M+B2_6"<"5J_LBU]0_O(V8E!JZPO12];K_9RX4I*?U<_UW3_5[$G]OIBO[U<3
MP141A.= $$H!*A4V4R8F0586FM$<0^2F+'^M(6,C2//RPCBBAT==X,9]0P ;
MF0/]1!%ODO]0;)E\F0=<#%\+XJO()1X9,TKYQ'.0]953//N\?@3Y3:W,VR3N
M;^?RG7I2LT45,+BWO+4'O/8P]V[1Z# 9JJYD2%9[T:\909J72 $%.:JV50&S
M1S8:<\TR)?,B]UI@!K%J;-39.E4%W>^Y=9CDU'IFO_C&-RMW52L:F?G1%2J/
M8?K:C98'[\'HAU##=9XW?0<%.RB7A[%L4&(/"N9+E@_[\)ZG;^)>R<U,?='7
M6%.%&6N68J1I!K("%0#I,@64X1)@*G51LE25?I&2X4P;&_FWGMFHE1!<TB]V
M/&#7.YZ6O4J'QCX(&[HO_0^W@L,>]MPJG'G#'DD%A_7HM"E\"U?*Q'R:SM5'
M\^-JDF-6\A1)0(BR:NM" *9*#K360N!"0X:H%]D?-3$ZTMXJQOQI;4PJ(WTI
M]QA(1^J\"I[8%.B'3'_=G"/GXZCD[)IY'4V<(S?/*N <7WEM*M^)9)RMR,ZV
MV;>L/L[>O<5,0,@(S(%@I00H(U9,@!9F[J<SC*C*L?"2LKG6H+&1QWZVVNE4
MM9L]%:K=!]4Z=@7G7-VW;@PU9(]%YK-A.NN*U,/K$(Z4EMC3J%=*6;P.PO/I
MC%<^]W5":+]LUJNU6;,88U_$)+W_J99BNE)?EU.AOBUF,S.WM#=.($$,,2U
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M4\L;Z6E"1<&(SH%&BMC**1HPI"7(8%JDN,@U*;U$O#O:&ML"OK(MR7NF;)S
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M],#!L.F>]:.'3>8\<.<H5?/PKSV#'TQ_[*7_294K1'("A&8%0&E9 (XS!(3
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MM34HA5]P^"597[J\'RV_B+RUX\$7_<=*53(XMP^+Y7KZ7]7L:IO,)SE5*I<
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M"OQAEZ%!+1QV51H#W*-%:I1&^HT9MT)L'C;5\?.7];U:G@BV;;-C8&[KU3-
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M0*#<OLX, 9;1%"C*4UC"4ND2-RB_G\O7P+AM]N^*L.M!4QC,HI\T50SPO6:
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M6VM!"UU]G#=%!'9%:,QZQ_QB8T.]ZFA<8](V=JA@)<F%,"\*$AP@2"F@K!1
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MU5FL]>4F:;S9.X.UIPQ;A_9.9/>X,,K$,!2^8</HKS5JV##[0! >A>&'>N[
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MO*C471OIG7!S!*0;/5P'3V12\$2F1T;+.><#YZ<<-3-PMLDY-X]S1\Y>>6W
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MV2:,6FFG"ZG8979.MOW:-7:Z '$HL--YNQ]5V<KIW^ST\?;G=#5!@A>95A!
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M.$=L^[W]R?ST?_Y;^QOS+RNM^G_^V_\/4$L#!!0    ( %8QJE3-I4;;FFD
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M(F=2P>K\/V^F<^23D*-2] >X$LA:IJ @.F/!,*-BX3:)@@.!Y)[7;P40WSM
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M9H9#*X[&C14:H?:V!>P"#L_%9F[B_$,MY_E#FMC/^P@\OA6UP6<A5  NPZ9
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M,5%@R*M9"%)Y%:1#UF9PR9.D/=N4]9YH6;1470=8O%^BOWRKW>9QHC1G2N@
M+#M5D_MUC\J!>.-6)2\BL\WN2S],UNB7"<?%X' JZQ9_6TGS^DR$7\)RCGEB
MK"472!9PD?Y0%BW]5/MO:$Q.V)Q) KWY W?9&#>3T2F^CP&)T7.L^W-^_GN]
MF_<VSJ;_?WM7UMM6LJ/?Y[\0J'UY&<#I3E]DD$D:2?H.YLFHA946KB-E+#G3
MF5\_+%F.;=FRM9S2*3F=#7$4GU,D/[)(%HO\O&3![[,%?=-R]-NRVNSL2\U<
MGJOH0XB1@54B4[QA(\4,GDR$\-'%@BK9M:/P3?G:HZQW7#]Y-'7H%1$GK"2?
M)DB+_3#['BX6W^G#1/_[G*%2A6)C\$92]"TI9':<O@RT4>8<DV/6MM:&QQ8V
M[BS*DX7]P3+NPBEZLCCX]5_IXBI/II]KR$&_\J?PU[EE25K.(SEZFH,JL4[#
M\0HLQ2(>G4PAM)E\M\=BQYUYV8&#TU:\7=]J>8>+M[/Y_"M>ULFTL^E'^GSM
MIN%V=U@>?]!P-U:V6.A ]U.JITKBKCOV\B4_BO^]<:84K/,4 OFN)BF("1-(
MQE$&9TO&-B6XFU9T\"3QM>?>WMK*T2'1I"'8>M#--(+/7$+23&C#LXJ-YL=M
M7-*XF:Y!,/%@;/@@[#\]\[+_2*.G'M?8U#0<:;017)H+%[12( VG78;V''"2
M]AN#1NO:K\5CFQLOK0S.[2G'^AOJ4))478#)Q=6B[K'W)MF4$+QETD,V=::.
M598"(L/J9'3F=4S>KY<T#7Z_;:<%=VJL=L'3YMMK[437@:]_2^89!>:YDC3Y
MAA_K[)SE0)UK;Q#SM;?XY>O5M5@?<N66 T*4).L8)IM9K,UH''@RY+5EL VV
M%,D:]0@?GI9Q4_V-<3V*P$]O]S[@GON3SVN\?[>\T;X9F+[.7UNVJ'0$3%'(
M^$FE 2D@Y8E'[['-P7&K#9Q8^V9*C,;*X'-6K&'%%RBY3MXDQ0/OK 0C$%/6
M@KE&(X;N+:/7S78'V:\;I?W9W,$6^E\X^?PG.0)GW_ R?,9W5[4>ZGU9<F?^
M_FHQ7X1I7LVA2^>"ZZQE)A&;B&2[)8,08@84,EN5I,NEC6NWTS)[W?@.P%@[
M,0TXW7LXFWQ-AF$B6D?^0>V'3MYHB>!0&&!&8@E,FZ"/$U%MCZIF)\M-4'4X
MVP=K;S:X!5L%. \TY#Q:13]B JUKD8<K"D+2D3!@K8Q:2F_;]*/:<:'C'MT>
MTXH-(JH.]M)UGJWH.J^-SH7.!F*(M1>!J5VU[/(0PDB3O&';W>DYV(ZM%C3N
MZ>A1+-D^K.^Z5>.C85(-@G]]$ 0/'?,]_9;&D> .)+9/\"(+T?,ZIHRP5,@0
M.54R*9U7SH0<%3NM$Z7ALBG+4G9GD$O'+9A8)P6:8$G7:@EO*"4G7BQ3K?N:
M#4%'KQ'J#NAKES;;6= =;,L'TOSJ^^,/6%X]%"*GS#!#9E*#"I*X4$R"2#QR
M2N>(N8TSV9"H7IJ?'1^KZQV@.P%.MSITYP*_SRXE9C-$- 64=@F\L06\$YQY
M;A,V.C=Y;F4CSUCH!4);07M/>7: S]?DW<Z^(WY<S-*_WB\'J-Q,_DR1240)
M# D\*F( QP-MGC9C*851--"F:?[&)?6(R'TEOQZ&#2*&#O!TIP#\.BVQ(B,;
MP0HR!J'V0%+%.MI.G 3A8HD%O;*F32B_84$CC_5HB:4A1- !DF[GYRV5XH_I
M9#'_\/&/F[X#SH:<O8%<*\:4LX9XPTJ=EV==5)F;1JFA)Y<U\EB/EJ@:3AP=
M8.N_0BV\7JP6GT**F@D+P9MZ>S&5VKR_ )=9>VN*48U:L-];QKAIZZ;8V9_=
M'6#E0$_T[8_J?<>S,"8X0%X/N!-#<(XX('A04DJGK6Y3;3P4!;TT]SSU^'8_
M2)R^*MS<^RNL6.L=<%OO1>7,R*,M"&1$9$I1>-=J&M<0R^\Q"&F-O&'AOP<,
MNJX?7!(5PQSSW9O@^YPB;7C2<"=%VRQUH-.@V[%O[\O=EWW BU!G8L_FB_GM
M<FY:G/S(VML4#,]!0<J,S+.,%CR61.Y"X2%DBEE8FS.1P]9]J(7=^NVO[K[]
MMBA7&EZ98X"IVM'/9PDQ2P?>VNB<3Y8[-R[;'E_XN%;UB%A=MZ7'%/@)6M']
M+U$]^;S6%K7A-:H#L>I\4)8;0BB+G! J& 1A+0B*WIT0Y/<VNFPUKEV]#1X>
M*-/9_X;+?"?O.J]32Z]-SWQ^]>7ZW]:N^S@EE,JUH8NH7)2Z0) R S'0%&2E
M!L6-3^R'H..DK>XN2-Y\KG]T.'00QCU&_5T!W*7^K+:9FRR^KU$<@D0C*%[0
MAO8>M>PU)UT"4X)/W&7#4NO;7ONN?=PL1F>@;RCV'H#^*)T/SD>6*O_'<A8Z
MY@V42RV#9TF#"4*"TL* BS%!"DP7+\C9XKH-X >C8=S#B3&!/PX,>E" 'RI_
ME_+*Z]]FEP^WOMMN-/.SB^73EPF<Q_FWE-BK[[]?A.GZ=AB85$$:D#;5H3?*
M0E0\0"B&&94CLZ$TWAR.2.ZXYS9=[">]@NL$ ]YW]:BL)E8/*$;?\LFM@^"G
M2>DC'$83M?9909)UTK%1!H)Q%C"BJ(/A8TAM>KGW%P[?7<5=97WU_?$8Z?H8
M+;"L1!V6J%EFH&*=)G7=E;UXF8*QK0YS!B/AI(/@7?"[:SS0!@0=>$77*[\9
M>!N2]C)D!Z(4!XJ9 #$[#T$E%5U4OH@VW0ON+:.7VO&C0F']7'%ON70 JOT9
M=TOV-%>'YT[1C35&*RX59)%M#3<2!(X(7&ANT&1E3)O^FBVH&?GD?']P;15.
M'E'2':!]4XVI<)X7J1V0KB.H8.M55-3@7.*2:-$IM*EQ.J3,MYU9'1TI6Y8&
M[R*V#M!WKUI^10)C):CL+93@2:--X>"4=( L"F6-9B$T:D+T<#$C%\KUAKI#
MQ35V\_=UK?D8IGE#.?2-0CE)[K?SF3R@.I;5D4L>BBZ$'5>D%4ZE]?*5#?W=
M=W_WR"-)>P'?,237@2E\NBQ?D)M#/Q*@%0(4\@01@P=9K,JY>*0HL=-;$NUF
MT/6"T.%%./* S4^310TAWTSSY-LD7X6+I:N=I+"5"$A1D:7WAMR*3%KE2W;D
M5LB8<*N2M*T&;3ZZA%[JUL>(K8>12V_ JI,+EAFR>E;]Y^3KI]GKZ6*R^+[2
MQJRS\IDC%".(45)J"*PH*#XG56(.F6]5GK,?Y)Y>W'C#?P> P5.@&E F(\/M
M?2F3A)<K VP-3U%H 5;HY1%9OKZ :P17 8542@XW*/C>JSN"RI#"G0W!Z0Y<
MKQL78*E&K'CM,H_@1:8(.LM(9EDH2$5ZGK(H@;4IO+Z[BI%=_RZ2R'M+I2-$
MK;0J"O+Y+!;@C)%ISA0H1[01DA.,@F<>4+>Y ]%3WG9_>6X QA[,'3L!<?9E
M>51^=AV\UG/!U_]S1=;WS;0.&IM\PTK;RHB&G)'7XB06:1>G:)6,:)$&A'84
M1ECAN5EKK+0A\[##2_M R#Z"G1V!RQT8EF<-\B9[_/;'A4$KH[0E*S#)$EM%
MO6."W %MS5X+S:RWC4K>#UY[+S/OQ]P6CXR 4\;\37?=LYPG]5O"Q:H^]&KQ
MY^QR\G^U.ZI0.EJ4X*S'VJO>@V,R@Y?*9*\\]ZI-7JTA49T?E0V,SZ'48V"P
MO 2]><  %CQCHB!(:20HXQA$HAIX"!Z%*)YCFT/AP4GI_&"O<QTY"!BGK!DW
M?N1\<7FUW.>7@UT__1FFJ^LV_ZCM<>9OZIV$R2R?:^-B$J@@D_L*2OM$QJ(F
MYGS G.O 1=^H@/Y(%'9^1MFI'K6$T4^D7FO#%)8?_DKAWF]A<EDO>^*Y(^DB
MHW .!=.UFUD!KVVJO? U2[2;QW3:^O<L"SH_HGT9"CHL$%^T!O]S>2GOAV5+
M/O)"3C4DKRPH69OW!A;)CPC>D:L=(CLU!;U/X;B31EZL_AT HQ>M7K_-+@M.
M[K(FZE*$422_S&IW+E4G?NL *I645>+$K#8S.XY(Y%9*9OY6LJ."Z93U;/E'
MM3&3Z>=KTOFYRS$;*3F4X!(H)2($%SU8SK@.JCCZJB]%>H2*K33%_JTIP\*A
M U58W=1>S9A[P(37?]6_XGD6QHM4(OAET:S VA?$*^ BHK'T&U6C.W1;K6\K
M^+H7"M\&(NP F#_N%.#EM\FJNOL!;>]F-]T\*COGG^JXN?4N ^]FB__&Q0=,
ML\_3FI2\VP7GO$XD+EPB1*8SJ. 8.,,3>)]9<HH'Y]J<\QR%O*W4PK]0M>@/
M0"]9JZZW/_(,5_]4_Q]MAFBR1%( PSS9G"AK]U^#8'.466B),K9IJG1<.K<[
M665_*]JQ,=5_?Y@'C%K+&=[I27AHPY@]7C5P!YE#B>VCI4SA0@?R\B'%Y<"F
M4@OJA:\=.ICCD0>?V^0F1VXILZ^5^9'MOB/>-<'_<U8KSR\FB^\?B))S#,IE
MY25PR>N\XURKS6EG38K;:'5$*SK+3>U,XTDWI=E% P8+MMO"J /?;%#.?)C,
M__7;)>*;*2V0-MXE0XP-,4;OP>M4JK.JP=N20'#%I$HQ*WG,'I<#DG;2/5^[
M4:>#0=.+%CUH5?>0(7$;AM3<2;VW^PDOO_#S4$I2N3APE@=0*#TX=+6XR093
MK%2F--R6FM!TTBUC#]:;\6$R]L630<W'ZER(Q+DT'%$E3C%9 EZMAPJZ@-/$
MC")XC*IHF5 _%[BT7N1)]W;=!_]=2;V7[:*1.WIC%GZM=VPI<#VWWFEO(T*L
MTZ@5<D9;*1J(4H=0<X6L=%8GO0>5XU:VC+VE] BE4U:S/>OJ;#0**?H##([D
MR(2!4 ME56"*?KMHV$A]%8<E=-P*EU-4MB, :F]]H[?'V4AYYSNG6C>C$09/
M.#_QCM:9YFW)ZR/%+$-*1ED-+'!#&,L"8HH!4-J8M7/1E1?9M?Q I7Y_M9@O
MPC1/II\_S"XNR#.M'YXC5Z2=QH(5D32V& XQ8('(O=7)9)5%HQ;F3>@YZ=3Q
M+L@>VN8/ (\7X$K=X<+UO;US@5ZS% PDH6H'NNSJI&P'.20EO.;!Z-2[?ER3
M<J)7G ?$9SN5V0,L>VO+UZ57]G$1+A==Z,Q];_$?E[/Y_%P:PY-R#(@;)!83
M([BH$A0?4O92624ZNZ*RF9@3O?;<K]X<"I@>]IGJ,;^9SZ\P_UH][56%\Y+L
M^=T:N-=_X66:S.MU;X=&6ZZAA)J4\-?#IC+4EKN>-GB5UUL3#:42.Z_U1"\H
M-T1\6W'O#FA_#>@I?JY^91?;P&VJ>WXVS:__^CJY7#[ASHUL:S27P8&N=\V4
MT F<(PEX+W74]6* ZZR)TK:DG>B%X7ZWB&'!=*A^?>HX/O&!6XV8P3-K@790
M)#NC/-AH#$N)5TEUJ53[Q2?]W?KM5XD. \N!\<GK:1_;TATF/#@VNMZK?[^<
M)*PR*RN9V9IWEX&!(N&1S+2!J%2A4,[D4IC3S':?$MN2UI,N#>LD7=8"5CV$
M.,?AT+F,&;E'#<(R3S;)DX7T00!B\%%A3L5V5L^\&X$O)NW6!.?CJ.5.H#L%
M7=S8.W6;$]W[K"F^I)25AN@2.=:UKC5()-.JF-3.Z,QUF]O,1R3RQ:3TNM#)
MD<#W$O3RAOKMN).2$ERR#%8S"<K*2 (4 DIVC >FE90C;96#TOEBTH\GH9WM
M('@*"GIH'NI)9FF3C=%. \9(X;;*"J*5&BP3Z).71;@V8U%&)?O%)$.[4-]N
M /H"M'G;Z""ATY(\#O(]%*M5C!I\1@.ECG,*1)E6)YT >C&9UE/0T!:@&S0W
M>[PRVCL#::\[76P82-NLQG;?!;0NP!V$,7U4YV;.8]9U*A4/]8H3.@A99$#!
M1;"1H6\T"F[DZMSAYMRH0AYV*$ [,()R.8!;3@1D+*MZ*]^F-G//!B/AI&MP
M=\'O@ZUB%!!TX)C=SH:N<^J"\C'*0%N79[4*4F>(*6N*$66]N2(L-FIL=6\9
M(^?=QX'">O?#O>72 :CV9]P3H\IY3!(]MV!-TJ ,.5A>"P^^8 J)A<Q,(^O:
M@)IQ(7X N ;+80TDZ;$[#=SQ_Y9T?MS@_WWX^,=\-8.1.5G;N14HKG9O%[5[
MNZJ$2N^9UTFZ[)]SDO=\=^<GFLW!,CN>Y'H;/;]4]>BM\DH$R,0<(L )"*$8
M2#FZQ(M76+9R\?<;,+_UWM[N_&[4O7T8N?0&K&=&K <N9"P:049RR%7A1)H0
M HP7,HC,C9,-(??TXCH:5+\[#)X"U8 R&1EN[TN9)+Q<&6#OM)#,1U YT\)-
M08C<.L"8A8M:<*:WNIRT%9CNO;HCJ PIW-D0G#Z%B&.+7L%&%F)-@(1&U6$?
M1'&]^R$+:6/F5BO1YG+ZX6L?^=B]BX#YR @X9<R_FZU&WCP<B?-X*;S(J2!R
M,BFYEL+7>GB7BH84C&12HV38F6KL2F+G@=' V!UL0&Y+()VRACT[:^I'W_C5
M]0[NG%88,I#AHSU7VMHS2"7()AB1F:M;=U\:MBN))ZIA;2%^M-EFA^#M]-L=
M[#J V$HOG38&?# 9E*J32Y54Y$(KJ9E@6OG.JDA:S+'NKXKZA2CC 6@;L =;
MCWJX-N>T&&ZP!J$QUWB URE$DFFP,=EHDHQ>CG2AX9CC<ONKEWXA>G@ VDZ[
M[\,>HU SNL*18G%/@00HK1TX% @>I2C<<&=.;G+U?G-U^RM_?B':>!CF7KA"
MKOOOF>L4#7GM7"/9*N8#Q! *>,$ML2TYJ7Z&>+&_2N<7HHR'X.W4VT]LSYQG
M^RO?ZR?B<](D3#"5CPJ=AZ = O*L6$!4BH]4OW1<1IQH[#ERJK4#4/X<"=GG
M>Z8S:V+)40.SA4,=N@:>L0A)AU1O93'96]_E :D_T31N#^K3H2G8"<L_71[X
M>?:)6EDAZH1L;P,H5PI$&1F8%*QS=9("GEJ"JL6DCOYV\Y_*'K1$]4^5D-Z"
M=1(]VFA BDAQDA$$@%SGCQNT! <RMZFSGO-#L^!$4]H_E4%HB>H7;A#N=&UX
MGF_)LJ)-1BC:)S*DI+DQ<OHR%)>U+$KGS@83#TK_B>;3?RI3T S/+]P.[!!C
M^92"098@YN@HQLH&G%>>U)8;FU,Q+/_D^8+^TO@_E0UHA.43;75R=K&T*Y@?
M_[B.+)W.<? &)[N]MG5;DP.8T$<SDU1"EDHDH)#5DJ8E2UL5Q; ^<8)O"H6S
M\'<SDR?N8C!A!,\V Y.&3)5%!2X& 3XD[KE$45I5)/_=S&1'_+9K9K(+"#HX
M'GHS);.&'TG(2^+>UF^H]-:[E4XK^D4,C2QG4%D4<%P$8)6=M%S#=1N#\,2B
M7DJCDYU@,FLCLW[AM[J7:;S6CM>Q-X$'4!%CO=R;P$AI4LHY!&R3#'AR6>-"
M<##A;P>J/231 :P^D$QH 7^>3?.O^ TO9E\K32L7;'5=MZ0HBK0"@F*T743C
MP:&F[2(;A=X71_M)$W!ML;@N(;8/%&9MY=(!U/Z!4XK\+HBBL_R%HH7JC"PF
MW_ ^42S:((-D! ?T9.YM+5GC$F26T14N VM4"[S5\L8]D6P'M^%ETP'@WDR_
M$9=FEQ.\Z;'#<XZ))P;%.D4L\O6.FDJ )1;&DK$RM0'7@Z6,>Y+5#DB'\;P#
MT Q0P\>Y4I[G!,7$0N&54&2AC0%CE54<>0ZQL]E[;W=J]G "'90."1J.C( .
M,+]=0NY<D\I*)$T65AJB:MD-+=>AA8&7Q*RAGTUPO=WZ3K1Z<$_4K+?T'%Z$
M@P&S17K]>@?[%/["O=+D=[]]N'3WQD4-E+;^\?S;_-^/G%Z(4K,ZZ]!'39)-
M'@D\7(#-D0R>E<6(-G/$GUC4,#F/>X_^1*Q\1?_G7^>Y>(,A:B*X=F06D0']
MQ4.R.F?B-2.M.1;!/U;50SAZ.#X>SW@,((=3,2GOPN5U_'/ 2=Q3CVMB<IY>
M]!%,4,R>6Y<RY*0D;2YUK'UV2.Z^=RF5'!6RDS5!JQWT%07*9;(X]P)M%"E
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M=2/74'KM;=WJ@_I';6[V[__V_U!+ P04    " !6,:I4.7Q[JF8(  !B*@
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M=_G"?<?BT]^^=/= 3_\'4$L#!!0    ( %8QJE0^S>*X8 @  / J   5
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MZW2G.R1=GB0]"W?%#L8?23Q!:Y1!1\,?6.T)C!8Z%8P!;B GR[[R&RC[)D\
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M:"TR,#(R,#,S,2YX<V102P$"% ,4    " !6,:I4AW-U=C\:   L_0  %0
M            @ %:6@$ 875P:"TR,#(R,#,S,5]C86PN>&UL4$L! A0#%
M  @ 5C&J5/GK3LER-@  95H" !4              ( !S'0! &%U<&@M,C R
M,C S,S%?9&5F+GAM;%!+ 0(4 Q0    ( %8QJE0U5K_3][   ,&2!P 5
M          "  7&K 0!A=7!H+3(P,C(P,S,Q7VQA8BYX;6Q02P$"% ,4
M" !6,:I4S:5&VYII  "FX 0 %0              @ &;7 ( 875P:"TR,#(R
M,#,S,5]P<F4N>&UL4$L! A0#%     @ 5C&J5#E\>ZIF"   8BH  !4
M         ( !:,8" &%U<&@M,C R,G$Q97AX,S$Q+FAT;5!+ 0(4 Q0    (
M %8QJE0^S>*X8 @  / J   5              "  0'/ @!A=7!H+3(P,C)Q
M,65X>#,Q,BYH=&U02P$"% ,4    " !6,:I4F.- .Z@$  #&%   %0
M        @ &4UP( 875P:"TR,#(R<3%E>'@S,C$N:'1M4$L! A0#%     @
M5C&J5-3C7UFO!   SA0  !4              ( !;]P" &%U<&@M,C R,G$Q
@97AX,S(R+FAT;5!+!08     "@ * )8"  !1X0(    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
